data_1eo1_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1eo1 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.271 0.558 . . . . 0.0 109.513 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.468 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 23.2 mttp -110.91 128.27 55.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.232 -0.917 . . . . 0.0 109.501 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.633 ' CD1' ' CD2' ' A' ' 104' ' ' PHE . 3.9 mt -95.51 128.05 47.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.301 -0.875 . . . . 0.0 109.57 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.448 ' HB3' ' CG1' ' A' ' 66' ' ' VAL . . . -116.33 122.55 45.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.205 -0.934 . . . . 0.0 109.451 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.514 ' N ' ' CD1' ' A' ' 5' ' ' ILE . 1.2 mm -97.24 115.53 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.196 -0.94 . . . . 0.0 109.485 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.557 ' HB3' ' CE1' ' A' ' 26' ' ' PHE . . . -59.01 146.58 37.73 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.297 -0.877 . . . . 0.0 109.626 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 2.4 m 52.73 -98.09 0.07 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -0.851 . . . . 0.0 109.611 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.454 ' OG ' HG13 ' A' ' 97' ' ' VAL . 75.4 m 59.05 15.36 3.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.078 -1.014 . . . . 0.0 109.448 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.536 ' N ' ' HB3' ' A' ' 14' ' ' SER . . . 52.69 -150.96 8.78 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.3 m -129.5 -8.38 4.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.243 -1.151 . . . . 0.0 110.092 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.19 -89.17 0.46 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.965 -1.084 . . . . 0.0 109.873 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -158.99 26.33 0.21 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.167 -0.958 . . . . 0.0 109.669 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.86 -41.17 1.47 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.536 ' HB3' ' N ' ' A' ' 9' ' ' GLY . 0.7 OUTLIER -77.34 84.17 3.77 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.251 -1.146 . . . . 0.0 109.48 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.473 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER -72.44 83.31 1.08 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.441 -0.787 . . . . 0.0 109.556 179.982 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.473 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 14.2 t 70.23 5.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.383 -0.823 . . . . 0.0 109.769 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 51.6 -95.91 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.286 -0.884 . . . . 0.0 109.682 179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.408 ' N ' ' O ' ' A' ' 16' ' ' VAL . 2.2 mtt180 -158.35 -77.93 0.07 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.029 -1.044 . . . . 0.0 109.707 -179.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.421 ' CD2' ' O ' ' A' ' 72' ' ' SER . 22.4 m-85 -117.17 174.3 6.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.221 -0.924 . . . . 0.0 109.632 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.513 ' CB ' ' HB2' ' A' ' 71' ' ' ALA . 2.9 t80 -117.04 104.72 11.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.254 -0.903 . . . . 0.0 109.402 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.45 ' HA2' ' CD1' ' A' ' 55' ' ' ILE . . . -143.01 -57.94 0.03 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.456 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.6 mtp85 -128.75 17.2 6.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.307 -1.114 . . . . 0.0 109.24 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -48.16 106.63 0.63 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.337 -0.852 . . . . 0.0 109.776 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.503 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 37.0 Cg_endo -80.74 42.23 1.29 Allowed 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.609 2.206 . . . . 0.0 110.477 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.503 ' CD2' ' O ' ' A' ' 24' ' ' PRO . 5.7 m-85 -159.83 69.53 0.42 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.09 -1.007 . . . . 0.0 109.584 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.571 ' CE2' HD13 ' A' ' 61' ' ' ILE . 0.1 OUTLIER -84.61 112.86 20.82 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.214 -0.929 . . . . 0.0 109.215 179.865 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -79.74 135.39 36.5 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.291 -0.88 . . . . 0.0 109.77 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 14.3 mm -108.25 138.47 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.209 -0.932 . . . . 0.0 109.323 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 75.8 t -131.92 103.83 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.385 -0.822 . . . . 0.0 109.459 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -85.43 88.65 7.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.183 -0.948 . . . . 0.0 109.539 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -82.83 141.73 32.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.316 -0.865 . . . . 0.0 109.386 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 4.9 tptt -117.58 -72.08 0.71 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.127 -0.983 . . . . 0.0 109.463 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 23.3 mttm -110.58 58.84 0.61 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.206 -0.934 . . . . 0.0 109.395 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 65.0 13.5 57.47 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 36' ' ' ILE . 25.0 t30 -132.74 105.87 7.42 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.293 -1.122 . . . . 0.0 109.403 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.406 ' C ' ' O ' ' A' ' 35' ' ' ASN . 3.3 mp -42.97 114.25 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.311 -0.868 . . . . 0.0 109.577 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -96.76 -9.52 28.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 109.492 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -159.62 119.23 2.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.27 -0.894 . . . . 0.0 109.513 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.6 p -120.83 102.89 8.67 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.229 -0.919 . . . . 0.0 108.906 179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -121.7 -176.45 3.32 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.371 -0.831 . . . . 0.0 109.859 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.8 p -151.98 130.4 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.408 -0.808 . . . . 0.0 109.309 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.403 ' O ' HG13 ' A' ' 42' ' ' ILE . 12.2 pt -114.12 131.22 66.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.189 -0.944 . . . . 0.0 109.671 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -97.73 150.42 21.23 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.285 -0.884 . . . . 0.0 109.429 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.437 ' HB2' ' HB3' ' A' ' 24' ' ' PRO . 55.6 m-20 . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.319 -0.863 . . . . 0.0 109.404 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.45 ' CD1' ' HA2' ' A' ' 21' ' ' GLY . 7.1 mm -74.82 -7.32 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.268 -1.136 . . . . 0.0 109.516 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.33 -23.07 60.2 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.237 -0.914 . . . . 0.0 109.23 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 6.1 t -57.47 -22.77 45.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.39 -0.819 . . . . 0.0 109.468 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.453 ' HA ' HD11 ' A' ' 61' ' ' ILE . . . -53.71 -50.0 66.88 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.306 -0.871 . . . . 0.0 109.624 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -46.41 -41.24 13.41 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.91 . . . . 0.0 109.625 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 50.4 mt -71.51 -39.97 71.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.237 -0.914 . . . . 0.0 109.703 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.571 HD13 ' CE2' ' A' ' 26' ' ' PHE . 63.4 mt -56.11 -32.82 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.226 -0.922 . . . . 0.0 109.473 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.443 ' HB2' ' CD1' ' A' ' 87' ' ' ILE . . . -76.67 -31.19 57.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.285 -0.884 . . . . 0.0 109.477 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 27.7 t30 -72.71 -14.38 61.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -0.876 . . . . 0.0 109.639 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -90.08 -1.22 57.92 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.206 -0.934 . . . . 0.0 109.649 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.52 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 87.4 -6.37 83.49 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.468 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 96.0 t -48.09 92.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -1.103 . . . . 0.0 109.662 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.52 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.6 OUTLIER -79.5 -2.09 40.54 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.371 -0.83 . . . . 0.0 108.813 179.38 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.438 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -134.79 129.52 34.7 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.861 . . . . 0.0 109.373 179.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.4 t -130.46 96.84 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.163 -0.96 . . . . 0.0 109.613 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.452 ' HA ' ' HB3' ' A' ' 90' ' ' TYR . 7.0 mt -91.22 109.73 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.213 -0.929 . . . . 0.0 109.288 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.513 ' HB2' ' CB ' ' A' ' 20' ' ' PHE . . . -144.08 176.94 8.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.248 -0.908 . . . . 0.0 109.778 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.421 ' O ' ' CD2' ' A' ' 19' ' ' PHE . 75.1 m -133.38 41.6 3.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.527 -0.733 . . . . 0.0 109.435 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -53.64 143.12 39.91 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.307 -0.871 . . . . 0.0 109.459 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -79.03 88.04 1.5 Allowed 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 122.639 2.226 . . . . 0.0 110.601 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 122.5 162.6 11.6 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.84 7.88 4.05 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 C-N-CA 122.75 2.3 . . . . 0.0 110.591 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.453 ' O ' ' HB3' ' A' ' 80' ' ' GLU . 1.5 m120 -55.25 -65.66 0.55 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.226 -0.921 . . . . 0.0 109.583 -179.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.8 -51.93 67.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.906 . . . . 0.0 109.675 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.8 m-30 -57.76 -15.97 9.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.223 -0.923 . . . . 0.0 109.754 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.453 ' HB3' ' O ' ' A' ' 77' ' ' ASN . 54.0 tt0 -72.82 -50.34 24.77 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.197 -0.939 . . . . 0.0 109.302 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 82' ' ' LEU . 2.4 t -71.3 -53.16 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 O-C-N 121.289 -0.882 . . . . 0.0 109.258 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.51 HD21 ' N ' ' A' ' 82' ' ' LEU . 4.4 mm? -45.75 -30.09 1.51 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.14 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -77.06 -47.75 19.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.336 -0.853 . . . . 0.0 109.346 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -68.02 -8.63 39.18 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.244 -0.91 . . . . 0.0 109.59 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.6 mp -86.48 -48.4 8.43 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.22 -0.925 . . . . 0.0 109.539 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.35 11.1 9.96 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.443 ' CD1' ' HB2' ' A' ' 62' ' ' ALA . 1.6 mt -91.69 172.37 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.24 -1.153 . . . . 0.0 109.419 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.463 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 0.1 OUTLIER -90.35 114.66 26.8 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.269 -0.894 . . . . 0.0 109.669 -179.926 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.494 ' CG1' ' HB3' ' A' ' 82' ' ' LEU . 5.9 mt -82.77 150.37 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.294 -0.879 . . . . 0.0 108.939 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.541 ' CE2' ' HB3' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -139.68 148.17 42.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.625 -179.95 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.42 140.2 39.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.315 -0.866 . . . . 0.0 109.614 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.32 88.04 2.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.936 . . . . 0.0 109.677 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.92 -40.32 42.98 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -0.901 . . . . 0.0 109.29 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 128.3 116.43 1.95 Allowed Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -164.38 -67.3 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.198 -1.178 . . . . 0.0 109.471 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.462 ' O ' ' HB2' ' A' ' 100' ' ' ASN . 0.1 OUTLIER 171.71 157.21 0.09 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.244 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.454 HG13 ' OG ' ' A' ' 8' ' ' SER . 1.8 t -74.28 -48.07 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.278 -0.889 . . . . 0.0 109.651 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -50.93 -50.16 58.29 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.276 -0.89 . . . . 0.0 109.846 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 31.0 mm-40 -70.55 -35.58 73.18 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.224 -0.923 . . . . 0.0 109.893 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.462 ' HB2' ' O ' ' A' ' 96' ' ' SER . 7.4 t30 -56.23 -39.08 71.96 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.165 -0.96 . . . . 0.0 109.735 -179.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 75.7 mt -57.77 -62.92 1.45 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.233 -0.917 . . . . 0.0 109.558 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 5.7 ttpt -62.52 -15.11 48.77 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.212 -0.93 . . . . 0.0 109.575 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -77.09 -33.55 56.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.224 -0.922 . . . . 0.0 109.799 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.633 ' CD2' ' CD1' ' A' ' 3' ' ' ILE . 79.3 t80 -74.2 -24.78 59.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.163 -0.961 . . . . 0.0 109.765 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 61.3 m -72.24 -22.91 61.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.227 -0.92 . . . . 0.0 109.674 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -103.79 4.95 35.67 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 109.597 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 55.95 40.54 82.17 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 -79.96 -51.45 9.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.192 -1.181 . . . . 0.0 109.558 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 13.8 mt -56.34 176.8 0.08 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 109.497 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.425 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 8.7 pt-20 -109.65 148.4 31.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.286 -0.884 . . . . 0.0 109.42 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.541 ' HB3' ' CE2' ' A' ' 90' ' ' TYR . 6.1 pt-20 -134.25 155.68 49.75 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.232 -0.917 . . . . 0.0 109.656 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 67.5 mt -135.36 143.44 36.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.321 -0.862 . . . . 0.0 109.047 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.54 0 O-C-N 121.112 -0.992 . . . . 0.0 109.909 -179.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.447 ' HA ' ' CB ' ' A' ' 67' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.432 ' HD2' ' O ' ' A' ' 65' ' ' GLY . 0.5 OUTLIER -89.29 147.4 24.13 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.223 -0.923 . . . . 0.0 109.474 -179.926 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.464 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 5.3 mt -115.08 119.86 62.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.212 -0.93 . . . . 0.0 109.701 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.463 ' CB ' HG12 ' A' ' 66' ' ' VAL . . . -112.87 111.45 22.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.279 -0.888 . . . . 0.0 109.073 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.51 HG23 ' CG2' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -98.41 126.19 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.228 -0.92 . . . . 0.0 109.8 -179.487 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.49 134.27 42.28 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.302 -0.874 . . . . 0.0 109.153 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.411 ' OG ' ' HG3' ' A' ' 27' ' ' MET . 0.0 OUTLIER -144.45 156.08 44.03 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.067 -1.02 . . . . 0.0 109.768 -179.814 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.42 -26.56 11.4 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.345 -0.847 . . . . 0.0 109.427 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -87.63 -105.62 0.9 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -148.73 -45.05 0.15 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.155 -1.203 . . . . 0.0 109.407 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' A' ' 11' ' ' ASP . 2.3 t70 -154.47 -55.29 0.1 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 109.367 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.2 tt -105.62 -37.69 6.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.18 -0.95 . . . . 0.0 109.337 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -57.71 -26.47 57.5 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.413 ' O ' ' OG ' ' A' ' 14' ' ' SER . 54.4 p -76.92 80.14 3.48 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.271 -1.135 . . . . 0.0 109.439 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.458 ' O ' ' CB ' ' A' ' 16' ' ' VAL . 0.3 OUTLIER -76.88 82.0 3.45 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.261 -0.899 . . . . 0.0 109.575 -179.88 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 95' ' ' THR . 3.0 t 73.16 19.64 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.255 -0.903 . . . . 0.0 109.651 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 44.36 -163.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.209 -0.932 . . . . 0.0 109.422 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.32 -32.71 2.67 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -0.902 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -150.12 -179.83 7.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.141 -0.974 . . . . 0.0 109.666 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -121.77 83.78 2.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.356 -0.84 . . . . 0.0 109.404 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 147.1 -18.64 1.56 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.458 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 1.6 mtp180 -110.55 -29.41 8.07 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.257 -1.143 . . . . 0.0 109.373 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.37 110.61 2.47 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.917 . . . . 0.0 109.399 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.458 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.5 46.65 2.31 Favored 'Trans proline' 0 C--N 1.312 -1.369 0 C-N-CA 122.692 2.261 . . . . 0.0 110.948 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.472 ' CE2' ' OE2' ' A' ' 43' ' ' GLU . 11.3 m-85 -158.51 70.01 0.51 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.99 -1.068 . . . . 0.0 109.417 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.495 ' CD1' ' HB2' ' A' ' 44' ' ' ASN . 46.1 m-85 -81.4 153.53 26.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.2 -0.937 . . . . 0.0 109.737 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' MET . . . . . 0.441 ' O ' ' HA ' ' A' ' 4' ' ' ALA . 37.9 mtp -120.3 114.16 21.47 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.34 -0.85 . . . . 0.0 109.041 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.439 ' O ' ' HA ' ' A' ' 39' ' ' SER . 26.6 mm -105.46 120.48 56.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.158 -0.964 . . . . 0.0 109.797 -179.566 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.499 HG23 ' CB ' ' A' ' 39' ' ' SER . 44.2 t -122.74 116.03 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.362 -0.836 . . . . 0.0 109.301 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -89.73 86.84 6.78 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.25 -0.906 . . . . 0.0 109.615 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.524 ' HE1' ' CG2' ' A' ' 105' ' ' THR . 1.2 ttp -83.29 125.07 31.22 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.179 -0.951 . . . . 0.0 109.328 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -87.99 -91.3 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.229 -0.919 . . . . 0.0 109.765 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.431 ' O ' ' C ' ' A' ' 34' ' ' GLY . 3.6 tmtm? -98.52 85.39 3.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.16 -0.962 . . . . 0.0 109.743 -179.679 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 43.07 33.99 1.95 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -144.4 104.11 4.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.139 -1.212 . . . . 0.0 109.504 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.459 HD11 ' OG ' ' A' ' 39' ' ' SER . 3.9 tt -53.57 118.63 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.29 -0.881 . . . . 0.0 109.232 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -127.75 26.2 5.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.227 -0.92 . . . . 0.0 109.662 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.454 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER 176.25 128.2 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.629 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.499 ' CB ' HG23 ' A' ' 29' ' ' VAL . 5.5 m -156.19 112.4 3.06 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.242 -0.911 . . . . 0.0 109.304 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -130.11 139.0 50.97 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.184 -0.947 . . . . 0.0 109.707 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.3 t -92.36 154.49 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.086 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.465 HG23 ' O ' ' A' ' 42' ' ' ILE . 2.0 tt -147.47 142.53 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.125 -0.984 . . . . 0.0 109.822 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.472 ' OE2' ' CE2' ' A' ' 25' ' ' TYR . 1.9 mt-10 -88.55 79.31 7.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.319 -0.863 . . . . 0.0 109.177 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.495 ' HB2' ' CD1' ' A' ' 26' ' ' PHE . 1.4 m-80 . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.2 -0.937 . . . . 0.0 109.521 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.4 mm -72.95 -19.56 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.26 -1.141 . . . . 0.0 109.672 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 3.7 mtt-85 -74.98 -16.61 60.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.141 -0.974 . . . . 0.0 109.486 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.458 ' O ' HG21 ' A' ' 57' ' ' THR . 53.3 m -67.94 -24.9 65.23 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.271 -0.893 . . . . 0.0 109.418 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -51.9 -56.05 16.46 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.32 -0.862 . . . . 0.0 109.651 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -51.04 -36.42 39.61 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.275 -0.891 . . . . 0.0 109.777 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.413 HD13 ' HA ' ' A' ' 57' ' ' THR . 76.9 mt -63.82 -63.5 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.177 -0.952 . . . . 0.0 109.838 -179.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.444 ' O ' HG22 ' A' ' 61' ' ' ILE . 10.5 mt -53.67 -24.46 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.231 -0.918 . . . . 0.0 109.935 -179.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -65.28 -46.73 79.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.131 -0.981 . . . . 0.0 109.8 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 9.2 m-20 -77.65 6.85 6.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.275 -0.89 . . . . 0.0 110.293 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.451 ' HB3' HG23 ' A' ' 66' ' ' VAL . 0.7 OUTLIER -96.1 7.56 46.08 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.997 -1.064 . . . . 0.0 109.835 -179.859 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.432 ' O ' ' HD2' ' A' ' 2' ' ' LYS . . . 73.07 8.81 75.02 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 17.6 t -68.61 97.5 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.301 -1.117 . . . . 0.0 109.574 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.525 ' O ' ' CB ' ' A' ' 88' ' ' LYS . 13.4 tttt -79.11 -3.92 47.75 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.528 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -138.79 131.38 28.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.319 -0.863 . . . . 0.0 109.002 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.443 HG21 HG11 ' A' ' 66' ' ' VAL . 10.6 t -128.84 109.2 18.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.061 -1.024 . . . . 0.0 109.791 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.51 ' CG2' HG23 ' A' ' 5' ' ' ILE . 2.1 mp -89.51 95.09 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.133 -0.98 . . . . 0.0 109.137 179.674 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.67 171.92 10.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 109.573 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.6 p -130.52 29.67 4.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.282 -0.886 . . . . 0.0 109.498 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -49.22 151.06 2.67 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.279 -0.888 . . . . 0.0 109.636 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.29 -72.48 0.01 OUTLIER 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.705 2.27 . . . . 0.0 110.467 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.404 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -68.26 145.5 44.5 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.404 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.8 Cg_endo -78.69 6.29 4.98 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.653 2.236 . . . . 0.0 110.473 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -53.94 -57.43 11.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.281 -0.887 . . . . 0.0 109.511 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -57.6 -45.0 85.86 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.23 -0.919 . . . . 0.0 109.5 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 18.4 m-30 -56.59 -27.39 57.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.178 -0.951 . . . . 0.0 109.343 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.48 -36.85 68.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.307 -0.87 . . . . 0.0 109.465 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 41.6 t -69.19 -46.19 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.492 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.429 HD23 HG23 ' A' ' 87' ' ' ILE . 3.1 mp -53.18 -37.09 61.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.219 -0.925 . . . . 0.0 109.615 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 13.5 t-20 -61.67 -40.81 96.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 109.622 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -76.6 -20.75 56.43 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.173 -0.955 . . . . 0.0 109.555 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.528 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 0.3 OUTLIER -87.13 -14.82 40.21 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.265 -0.897 . . . . 0.0 109.522 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 86.93 11.71 69.77 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.528 ' CD1' ' HB3' ' A' ' 85' ' ' LEU . 9.3 mt -87.51 145.5 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -1.176 . . . . 0.0 109.587 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.525 ' CB ' ' O ' ' A' ' 67' ' ' LYS . 6.1 ttmm -80.05 116.75 20.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.124 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.428 HG12 ' HB2' ' A' ' 82' ' ' LEU . 3.3 mt -80.93 106.42 12.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.274 -0.891 . . . . 0.0 109.602 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.571 ' CD2' ' O ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -103.18 142.35 34.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.333 -0.855 . . . . 0.0 109.158 179.825 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.463 ' O ' ' HB3' ' A' ' 110' ' ' GLU . 20.6 ttt180 -106.02 145.76 30.97 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.182 -0.949 . . . . 0.0 109.606 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.98 92.13 8.93 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.327 -0.858 . . . . 0.0 109.277 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' THR . . . . . 0.439 HG23 ' O ' ' A' ' 93' ' ' THR . 58.9 m -107.46 -16.41 14.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.255 -0.903 . . . . 0.0 109.691 -179.744 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -66.05 -128.71 0.02 OUTLIER Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.542 HG23 ' N ' ' A' ' 96' ' ' SER . 9.8 t -142.13 -32.98 0.5 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.319 -1.107 . . . . 0.0 109.927 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.542 ' N ' HG23 ' A' ' 95' ' ' THR . 0.6 OUTLIER -133.54 151.83 51.8 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.138 -0.976 . . . . 0.0 109.356 179.958 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.448 ' CB ' HG22 ' A' ' 5' ' ' ILE . 35.1 m -71.06 -34.29 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.25 -0.906 . . . . 0.0 109.7 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.37 -47.91 83.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.245 -0.91 . . . . 0.0 109.803 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -71.75 -42.78 66.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.271 -0.893 . . . . 0.0 109.942 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 48.3 t-20 -52.91 -33.98 52.93 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.201 -0.937 . . . . 0.0 109.669 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.7 tt -57.12 -42.93 81.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.248 -0.907 . . . . 0.0 109.841 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -74.48 -33.36 62.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.117 -0.989 . . . . 0.0 110.039 -179.487 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -39.81 94.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.107 -0.996 . . . . 0.0 109.826 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.526 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 6.4 t80 -70.15 -30.02 67.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.18 -0.95 . . . . 0.0 109.813 -179.64 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.524 ' CG2' ' HE1' ' A' ' 31' ' ' MET . 0.2 OUTLIER -67.21 -29.86 69.64 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.128 -0.982 . . . . 0.0 109.935 -179.615 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -99.31 13.06 34.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.139 -0.976 . . . . 0.0 109.606 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 52.17 57.72 12.51 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.069 -1.612 . . . . 0.0 109.069 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -81.87 -54.86 5.0 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.368 -1.078 . . . . 0.0 109.781 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.455 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.2 OUTLIER 178.04 -152.03 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.093 -1.004 . . . . 0.0 109.742 -179.835 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.571 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 13.8 mt-10 60.29 25.17 14.61 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.375 -0.828 . . . . 0.0 109.459 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.476 ' HA ' ' CE1' ' A' ' 90' ' ' TYR . 7.5 pt-20 -103.94 135.95 44.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.343 -0.848 . . . . 0.0 109.358 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.459 HG13 ' O ' ' A' ' 111' ' ' GLU . 3.2 mp -153.15 135.06 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.3 -0.875 . . . . 0.0 109.421 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 26.4 ttp180 . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.224 -0.922 . . . . 0.0 109.346 179.919 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.7 mmm . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.453 ' HD3' ' O ' ' A' ' 65' ' ' GLY . 1.2 mttm -120.65 136.72 54.75 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.324 -0.86 . . . . 0.0 109.552 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.559 HD11 ' CD1' ' A' ' 104' ' ' PHE . 5.4 mt -114.44 108.43 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.318 -0.864 . . . . 0.0 109.399 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.615 ' CB ' ' CZ ' ' A' ' 26' ' ' PHE . . . -112.37 127.6 56.06 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.25 -0.906 . . . . 0.0 109.306 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.407 HG12 HD13 ' A' ' 70' ' ' ILE . 27.9 mt -102.88 139.71 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.555 -179.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.3 170.07 17.2 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.384 -0.823 . . . . 0.0 109.421 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.467 ' O ' ' HB3' ' A' ' 8' ' ' SER . 54.3 p 46.32 -141.38 0.39 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.259 -0.901 . . . . 0.0 109.333 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.529 ' HB2' ' CG1' ' A' ' 97' ' ' VAL . 42.4 t 63.61 51.81 2.41 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.119 -0.988 . . . . 0.0 109.415 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.518 ' N ' ' HB3' ' A' ' 14' ' ' SER . . . -50.87 106.23 0.25 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.461 ' OG1' ' O ' ' A' ' 9' ' ' GLY . 3.2 p 49.01 -90.65 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.343 -1.092 . . . . 0.0 109.89 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.517 ' N ' ' O ' ' A' ' 9' ' ' GLY . 1.0 OUTLIER 173.15 -150.61 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.198 -0.939 . . . . 0.0 109.446 -179.687 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.452 ' HB3' ' O ' ' A' ' 11' ' ' ASP . 12.9 tp 70.25 13.2 7.66 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.257 -0.902 . . . . 0.0 109.362 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 145.77 -23.66 1.8 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.518 ' HB3' ' N ' ' A' ' 9' ' ' GLY . 43.4 m -77.2 82.51 3.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.193 -1.18 . . . . 0.0 109.64 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.463 ' O ' HG13 ' A' ' 97' ' ' VAL . 0.2 OUTLIER -72.75 -114.2 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.202 -0.936 . . . . 0.0 109.456 -179.826 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.0 t -115.47 23.47 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 120.738 -1.227 . . . . 0.0 109.679 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 4.3 t 47.06 -150.26 0.11 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.178 -0.951 . . . . 0.0 109.345 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.55 12.95 1.53 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.192 -0.943 . . . . 0.0 109.595 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.466 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 28.1 p90 -153.8 144.52 22.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.223 -0.923 . . . . 0.0 109.66 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -123.82 89.88 3.17 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.313 -0.867 . . . . 0.0 109.218 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -145.26 -73.35 0.02 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.73 21.68 16.26 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -1.172 . . . . 0.0 109.675 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -58.33 113.25 6.18 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.243 -0.911 . . . . 0.0 109.23 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.474 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 36.8 Cg_endo -80.74 54.34 5.19 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.571 2.181 . . . . 0.0 110.867 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.474 ' CD2' ' O ' ' A' ' 24' ' ' PRO . 31.4 m-85 -160.41 70.92 0.43 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.992 -1.068 . . . . 0.0 109.214 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.615 ' CZ ' ' CB ' ' A' ' 4' ' ' ALA . 40.1 t80 -79.92 104.58 10.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.429 -0.794 . . . . 0.0 109.732 -179.718 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' MET . . . . . 0.426 ' CE ' ' O ' ' A' ' 10' ' ' THR . 0.2 OUTLIER -82.84 125.03 30.87 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.29 -0.881 . . . . 0.0 109.21 179.694 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.459 HG23 ' O ' ' A' ' 40' ' ' GLU . 1.4 tp -119.99 114.75 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.154 -0.966 . . . . 0.0 109.586 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.462 HG13 HD23 ' A' ' 101' ' ' LEU . 3.1 t -118.91 144.25 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.922 . . . . 0.0 109.408 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -117.63 136.18 53.48 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.261 -0.9 . . . . 0.0 109.445 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.8 mtt -119.86 132.18 55.49 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.209 -0.932 . . . . 0.0 109.545 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 13.4 mmtt -81.99 -79.76 0.17 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.308 -0.87 . . . . 0.0 109.299 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -126.16 86.53 2.54 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.3 -0.875 . . . . 0.0 109.174 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 48.87 34.12 14.71 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 36' ' ' ILE . 0.6 OUTLIER -149.12 100.56 3.06 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.345 -1.091 . . . . 0.0 109.461 -179.859 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.433 ' O ' HG22 ' A' ' 36' ' ' ILE . 4.3 tt -45.2 134.27 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.234 -0.916 . . . . 0.0 109.35 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.412 ' O ' ' HB2' ' A' ' 38' ' ' SER . 0.5 OUTLIER -145.65 20.11 1.49 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.303 -0.873 . . . . 0.0 109.497 -179.959 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.412 ' HB2' ' O ' ' A' ' 37' ' ' GLU . 5.1 t -179.21 129.66 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.266 -0.896 . . . . 0.0 109.471 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 96.0 p -151.2 115.3 5.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.284 -0.885 . . . . 0.0 109.337 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.459 ' O ' HG23 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -132.09 132.26 43.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.276 -0.89 . . . . 0.0 109.629 -179.799 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.7 m -97.13 137.9 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.31 -0.869 . . . . 0.0 109.328 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.407 HG21 ' N ' ' A' ' 43' ' ' GLU . 58.7 mt -123.79 145.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 0.0 109.558 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.419 ' HG2' ' CE1' ' A' ' 25' ' ' TYR . 2.8 mp0 -115.09 148.31 39.1 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.283 -0.886 . . . . 0.0 109.581 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 13.8 m-20 . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.314 179.887 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.448 HG21 ' HA ' ' A' ' 78' ' ' ALA . 34.2 mm -73.62 -16.46 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.253 -1.145 . . . . 0.0 109.825 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.18 -22.63 66.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.261 -0.899 . . . . 0.0 109.681 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 61.2 m -63.52 -21.58 66.41 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.673 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.412 ' O ' ' C ' ' A' ' 59' ' ' GLN . . . -52.99 -47.93 67.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.233 -0.917 . . . . 0.0 109.508 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.412 ' C ' ' O ' ' A' ' 58' ' ' ALA . 0.0 OUTLIER -44.09 -43.39 6.85 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.421 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 20.9 mm -73.15 -36.5 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.173 -0.954 . . . . 0.0 109.167 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 16.8 mm -50.68 -36.49 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.354 -0.842 . . . . 0.0 109.235 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.414 ' HB2' HD13 ' A' ' 87' ' ' ILE . . . -75.02 -33.39 61.78 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.277 -0.889 . . . . 0.0 109.686 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -61.5 -18.22 58.12 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.259 -0.9 . . . . 0.0 109.767 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.456 ' HB3' ' CG2' ' A' ' 66' ' ' VAL . 0.4 OUTLIER -90.68 27.36 1.78 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.082 -1.011 . . . . 0.0 109.653 -179.86 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.453 ' O ' ' HD3' ' A' ' 2' ' ' LYS . . . 43.96 40.47 5.56 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.456 ' CG2' ' HB3' ' A' ' 64' ' ' ASN . 2.9 t -86.25 96.21 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -1.136 . . . . 0.0 109.68 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.6 tptt -78.95 -11.32 60.0 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 179.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -136.58 125.29 23.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.444 -0.785 . . . . 0.0 108.964 179.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.417 ' O ' ' HB2' ' A' ' 90' ' ' TYR . 67.1 t -124.39 119.84 57.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.049 -1.032 . . . . 0.0 109.961 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.455 ' CD1' ' CG2' ' A' ' 3' ' ' ILE . 1.9 mp -102.1 114.19 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.359 -0.838 . . . . 0.0 108.98 179.606 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -151.87 172.87 15.53 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.214 -0.929 . . . . 0.0 109.865 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.439 ' O ' ' OG ' ' A' ' 72' ' ' SER . 11.9 p -135.5 55.69 1.87 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.378 -0.826 . . . . 0.0 109.245 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -55.53 152.82 16.5 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.295 -0.878 . . . . 0.0 109.645 -179.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.67 -13.65 14.55 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 C-N-CA 122.757 2.305 . . . . 0.0 110.531 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.8 161.66 26.26 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.7 -5.67 14.86 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.698 2.265 . . . . 0.0 110.415 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 16.9 t30 -57.91 -33.25 68.57 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.262 -0.899 . . . . 0.0 109.649 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.448 ' HA ' HG21 ' A' ' 55' ' ' ILE . . . -71.94 -60.43 2.24 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.251 -0.906 . . . . 0.0 109.437 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.46 ' N ' ' CD1' ' A' ' 79' ' ' PHE . 3.5 m-85 -51.7 -22.09 3.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.115 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 13.9 tt0 -63.91 -46.95 82.54 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.283 -0.885 . . . . 0.0 109.265 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.5 t -69.45 -43.66 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.194 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 1.8 mt -63.36 -21.62 66.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.516 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -77.1 -61.35 2.01 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.258 -0.901 . . . . 0.0 109.603 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -58.92 -21.56 58.1 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.22 -0.925 . . . . 0.0 109.667 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -73.14 -37.43 66.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.215 -0.928 . . . . 0.0 109.637 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.77 21.83 7.29 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.414 HD13 ' HB2' ' A' ' 62' ' ' ALA . 5.5 mt -103.94 150.3 7.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -1.165 . . . . 0.0 109.51 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 8.2 mttt -80.03 125.84 30.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.233 -0.917 . . . . 0.0 109.361 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 3.3 mp -90.31 141.06 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.161 -0.962 . . . . 0.0 109.543 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.573 ' CE1' ' HB3' ' A' ' 111' ' ' GLU . 2.2 m-85 -127.99 127.35 43.08 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.211 -0.931 . . . . 0.0 109.529 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 73.5 mtt180 -87.46 122.77 31.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.465 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.67 122.83 33.16 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.236 -0.915 . . . . 0.0 109.471 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -64.95 -40.0 94.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.363 -0.836 . . . . 0.0 109.558 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 116.76 52.47 0.35 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 30.8 m -114.37 -82.72 0.61 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -1.119 . . . . 0.0 109.351 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -157.56 128.61 6.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.396 -0.815 . . . . 0.0 109.357 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.529 ' CG1' ' HB2' ' A' ' 8' ' ' SER . 0.2 OUTLIER -51.12 -23.27 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.221 -0.924 . . . . 0.0 109.535 -179.943 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.82 -49.05 69.63 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.195 -0.941 . . . . 0.0 109.317 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.444 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 21.4 tt0 -70.88 -28.14 64.34 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.304 -0.873 . . . . 0.0 109.311 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -63.93 -49.46 72.52 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.322 -0.862 . . . . 0.0 109.42 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.462 HD23 HG13 ' A' ' 29' ' ' VAL . 37.7 tp -57.56 -57.58 12.08 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.301 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 1.3 tmtt? -56.92 -25.62 57.7 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.135 -0.978 . . . . 0.0 109.257 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.461 ' CD2' ' HB3' ' A' ' 108' ' ' ASN . 0.2 OUTLIER -71.14 -37.11 72.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.23 -0.919 . . . . 0.0 109.36 179.861 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.559 ' CD1' HD11 ' A' ' 3' ' ' ILE . 13.9 t80 -65.57 -22.99 66.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.198 -0.939 . . . . 0.0 109.175 179.661 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.34 -29.76 64.25 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.412 -0.805 . . . . 0.0 109.31 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -112.46 -2.69 14.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.603 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 61.23 39.46 97.22 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . 0.461 ' HB3' ' CD2' ' A' ' 103' ' ' LEU . 24.4 t-20 -93.97 -17.92 22.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.103 -1.233 . . . . 0.0 109.395 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' A' ' 108' ' ' ASN . 5.4 mt -55.67 -168.44 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.24 -0.913 . . . . 0.0 109.334 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.47 ' O ' ' HA ' ' A' ' 90' ' ' TYR . 1.2 tt0 -103.42 106.91 17.55 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.256 -0.903 . . . . 0.0 109.303 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.573 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 4.1 pt-20 -101.7 156.69 17.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.264 -0.898 . . . . 0.0 109.764 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.9 mt -142.8 126.11 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.89 . . . . 0.0 109.314 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.293 -0.879 . . . . 0.0 109.441 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 mmm . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.271 0.557 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.49 ' CB ' ' HA ' ' A' ' 66' ' ' VAL . 0.0 OUTLIER -154.03 160.05 41.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.289 -0.882 . . . . 0.0 109.118 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.573 HG12 ' CE2' ' A' ' 104' ' ' PHE . 6.4 mt -117.4 121.12 66.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.901 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.428 ' HA ' ' O ' ' A' ' 27' ' ' MET . . . -113.09 102.97 10.89 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.373 -0.83 . . . . 0.0 109.119 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.412 HD13 ' HB2' ' A' ' 27' ' ' MET . 0.7 OUTLIER -94.81 118.64 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -0.924 . . . . 0.0 109.742 -179.553 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.37 142.3 41.21 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.068 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.8 p -161.72 -159.92 0.66 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.119 -0.988 . . . . 0.0 109.518 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.9 m -149.06 57.09 1.02 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.287 -0.883 . . . . 0.0 109.537 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 167.08 164.5 22.85 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.45 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.0 OUTLIER -85.02 -32.62 22.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.322 -1.105 . . . . 0.0 109.472 179.981 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 18.7 p-10 171.84 172.16 0.09 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -0.919 . . . . 0.0 109.374 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.413 ' C ' ' O ' ' A' ' 11' ' ' ASP . 8.1 tp 45.35 32.77 1.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.305 -0.872 . . . . 0.0 109.191 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -175.47 -32.88 0.04 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 p -65.55 86.34 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.435 -1.038 . . . . 0.0 109.304 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.495 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 14.4 mt-10 -77.65 6.98 6.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.478 -0.764 . . . . 0.0 110.153 -179.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.495 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 15.1 t 70.62 65.6 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.937 . . . . 0.0 109.615 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 16' ' ' VAL . 3.9 m -44.64 122.83 3.32 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.328 -0.858 . . . . 0.0 109.233 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.456 ' O ' ' HG2' ' A' ' 18' ' ' ARG . 1.4 ttm-85 -61.72 -18.7 60.76 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.25 -0.906 . . . . 0.0 109.721 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.478 ' CE2' ' HG3' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -84.91 108.16 17.41 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.12 -0.987 . . . . 0.0 109.63 -179.905 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.8 t80 -106.43 125.37 50.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.263 -0.898 . . . . 0.0 109.354 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.1 -36.6 0.76 Allowed Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.461 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 1.1 mpt_? -118.62 -22.27 7.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.343 -1.093 . . . . 0.0 109.256 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -49.15 106.91 0.68 Allowed Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.304 -0.872 . . . . 0.0 109.436 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.3 Cg_endo -79.95 62.56 8.55 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.561 2.174 . . . . 0.0 110.822 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.439 ' CE1' ' HB3' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -160.52 69.58 0.38 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.008 -1.058 . . . . 0.0 109.395 179.692 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -80.46 121.1 25.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.549 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' MET . . . . . 0.428 ' O ' ' HA ' ' A' ' 4' ' ' ALA . 2.1 mmt -94.46 110.6 22.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.226 -0.921 . . . . 0.0 109.266 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.9 mm -104.02 117.99 50.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.904 . . . . 0.0 109.472 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.498 HG11 ' CB ' ' A' ' 39' ' ' SER . 13.4 m -138.04 147.59 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.209 -0.932 . . . . 0.0 109.833 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -127.26 143.26 51.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 108.899 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.2 mtt -113.81 152.03 31.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.1 -1.0 . . . . 0.0 109.938 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.35 -46.37 7.38 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.369 -0.832 . . . . 0.0 109.262 179.775 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.64 47.48 0.73 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.367 -0.833 . . . . 0.0 109.222 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.431 ' O ' ' CG2' ' A' ' 105' ' ' THR . . . 92.22 -1.43 73.38 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.423 ' O ' ' C ' ' A' ' 36' ' ' ILE . 5.6 p-10 -116.56 92.89 4.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.204 -1.174 . . . . 0.0 109.362 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.451 HD13 ' HB ' ' A' ' 29' ' ' VAL . 1.6 tt -43.95 118.61 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 109.497 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.46 ' O ' ' OE1' ' A' ' 37' ' ' GLU . 0.2 OUTLIER -123.08 20.78 9.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.329 -0.857 . . . . 0.0 109.441 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.413 ' O ' ' OG ' ' A' ' 38' ' ' SER . 12.0 p -170.82 107.46 0.29 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -0.859 . . . . 0.0 109.263 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.498 ' CB ' HG11 ' A' ' 29' ' ' VAL . 5.8 p -135.35 105.72 6.38 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.914 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.18 143.8 38.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.389 -0.819 . . . . 0.0 109.268 179.598 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 t -110.99 124.03 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.215 -0.928 . . . . 0.0 109.755 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 11.1 mt -121.57 119.43 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.262 -0.899 . . . . 0.0 109.268 179.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.439 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 4.1 pm0 -93.28 126.08 38.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.254 -0.904 . . . . 0.0 109.564 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.317 -0.864 . . . . 0.0 109.548 -179.902 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.404 HD13 ' HB1' ' A' ' 78' ' ' ALA . 39.8 mm -76.72 0.03 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.136 -1.214 . . . . 0.0 109.85 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.08 -10.96 59.83 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.192 -0.943 . . . . 0.0 109.558 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.438 ' O ' HG13 ' A' ' 61' ' ' ILE . 8.8 t -77.32 -25.86 51.59 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.667 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -48.77 -39.97 27.07 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 109.492 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 -60.4 -58.47 8.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 109.608 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.409 ' O ' HG22 ' A' ' 60' ' ' ILE . 21.1 mt -53.82 -25.48 12.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.33 -0.856 . . . . 0.0 109.589 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.49 HG21 ' CG2' ' A' ' 66' ' ' VAL . 46.3 mt -72.96 -39.66 58.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.454 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.451 ' HB1' HD12 ' A' ' 87' ' ' ILE . . . -67.17 -30.65 70.67 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.552 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -67.93 -9.08 42.26 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.294 -0.878 . . . . 0.0 109.614 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -85.9 -24.93 26.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.191 -0.943 . . . . 0.0 109.537 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 114.55 -26.0 9.91 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.49 ' HA ' ' CB ' ' A' ' 2' ' ' LYS . 4.6 m -43.44 94.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.271 -1.135 . . . . 0.0 109.559 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 65' ' ' GLY . 7.0 mmtp -79.36 -4.27 50.16 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.357 -0.84 . . . . 0.0 108.758 179.291 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -122.82 129.33 51.55 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.385 -0.822 . . . . 0.0 109.274 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 97.8 t -123.45 107.83 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.111 -0.993 . . . . 0.0 109.544 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 53.1 mt -91.99 115.52 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.36 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -164.84 176.77 8.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.217 -0.927 . . . . 0.0 109.913 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.431 ' OG ' ' HB1' ' A' ' 92' ' ' ALA . 12.5 m -140.84 59.07 1.54 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.508 -0.745 . . . . 0.0 109.176 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' SER . . . . . 0.544 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 11.6 p -49.71 152.15 2.69 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.389 -0.819 . . . . 0.0 109.791 -179.717 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.478 ' HG3' ' CE2' ' A' ' 19' ' ' PHE . 35.1 Cg_endo -78.27 -22.65 9.51 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.631 2.221 . . . . 0.0 110.17 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -134.95 164.15 24.76 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.53 27.62 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.771 2.314 . . . . 0.0 111.265 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -74.73 -68.86 0.5 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.88 -1.137 . . . . 0.0 109.588 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.404 ' HB1' HD13 ' A' ' 55' ' ' ILE . . . -62.03 -40.53 96.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -0.905 . . . . 0.0 109.714 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.544 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 4.3 m-85 -52.95 -32.46 46.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.639 -179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -75.61 -38.46 59.0 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.26 -0.9 . . . . 0.0 109.65 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 48.8 t -61.33 -53.46 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.743 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 3.2 mp -59.06 -18.7 37.38 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.274 -0.891 . . . . 0.0 109.814 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -76.47 -48.42 19.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.18 -0.95 . . . . 0.0 109.695 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.38 -35.44 80.9 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.143 -0.973 . . . . 0.0 109.563 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.511 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 0.1 OUTLIER -68.17 -16.21 63.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.491 -179.919 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 81.59 24.68 55.72 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.511 ' CD1' ' HB3' ' A' ' 85' ' ' LEU . 5.6 mt -87.47 161.5 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.252 -1.146 . . . . 0.0 109.558 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.511 ' CB ' ' O ' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -94.5 112.13 23.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 109.317 179.858 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.455 ' HB ' ' HB ' ' A' ' 112' ' ' ILE . 14.1 mt -82.03 168.14 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.67 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.584 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 1.2 m-85 -153.09 129.98 10.97 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.304 -0.873 . . . . 0.0 109.246 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.501 ' NH1' ' HA ' ' A' ' 93' ' ' THR . 0.7 OUTLIER -80.12 135.81 36.39 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.966 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.431 ' HB1' ' OG ' ' A' ' 72' ' ' SER . . . -86.64 149.79 24.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.216 -0.928 . . . . 0.0 109.627 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' THR . . . . . 0.501 ' HA ' ' NH1' ' A' ' 91' ' ' ARG . 73.4 p -86.0 -26.51 25.38 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 109.544 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.83 66.85 1.51 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.19 -67.71 0.36 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.256 -1.143 . . . . 0.0 109.466 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.4 ' HA ' HG23 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -171.56 132.95 0.77 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.304 -0.872 . . . . 0.0 109.33 -179.965 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 16.8 m -54.86 -19.76 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.168 -0.958 . . . . 0.0 109.575 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -68.27 -52.57 32.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.762 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -69.78 -39.19 76.79 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.146 -0.971 . . . . 0.0 109.498 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.427 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 5.1 m-20 -59.28 -36.73 76.09 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.163 -0.96 . . . . 0.0 109.259 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.428 ' CD2' HD11 ' A' ' 36' ' ' ILE . 11.0 tp -59.22 -50.93 72.15 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.287 -0.883 . . . . 0.0 109.308 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -70.12 -15.76 63.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.371 -0.831 . . . . 0.0 109.232 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.427 ' HB2' ' HA ' ' A' ' 100' ' ' ASN . 0.2 OUTLIER -72.6 -45.74 57.6 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.359 -0.838 . . . . 0.0 109.55 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.573 ' CE2' HG12 ' A' ' 3' ' ' ILE . 6.4 t80 -63.53 -17.23 62.58 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.865 . . . . 0.0 109.758 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.431 ' CG2' ' O ' ' A' ' 34' ' ' GLY . 19.2 m -69.2 -33.47 73.39 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 109.572 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -95.57 -14.72 23.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.527 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 71.17 45.53 48.82 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.1 t-20 -97.21 -29.31 13.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.289 -1.124 . . . . 0.0 109.544 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.411 ' HG ' HD23 ' A' ' 103' ' ' LEU . 0.6 OUTLIER -57.11 155.89 7.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.342 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 5.3 pt-20 -96.06 144.88 25.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.584 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 6.1 pm0 -114.61 165.87 12.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.92 . . . . 0.0 109.501 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.455 ' HB ' ' HB ' ' A' ' 89' ' ' ILE . 83.0 mt -136.4 120.21 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.261 -0.899 . . . . 0.0 109.254 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.339 -0.851 . . . . 0.0 109.332 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.4 ttm . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.1 mppt? -114.61 164.01 14.62 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.187 -0.945 . . . . 0.0 109.594 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.466 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 11.0 mt -131.68 135.72 58.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.291 -0.881 . . . . 0.0 109.655 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.518 ' CB ' HG22 ' A' ' 66' ' ' VAL . . . -123.48 129.96 52.0 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.57 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.421 HG21 HG22 ' A' ' 97' ' ' VAL . 6.3 mt -111.1 120.79 62.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.179 -0.951 . . . . 0.0 109.881 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.39 165.19 25.53 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.277 -0.889 . . . . 0.0 109.36 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.518 ' O ' ' CB ' ' A' ' 8' ' ' SER . 0.8 OUTLIER 70.22 -144.67 0.08 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.227 -0.921 . . . . 0.0 109.485 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.518 ' CB ' ' O ' ' A' ' 7' ' ' SER . 0.2 OUTLIER 77.02 3.35 3.31 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.139 -0.976 . . . . 0.0 109.554 -179.908 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.469 ' O ' ' HB3' ' A' ' 25' ' ' TYR . . . 46.47 -113.6 1.18 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.87 -5.85 7.41 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.225 -1.162 . . . . 0.0 109.481 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -141.18 -142.15 0.14 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.481 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.4 mt -105.11 -18.28 14.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.108 -0.995 . . . . 0.0 109.745 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -47.76 -40.32 18.22 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.406 ' O ' ' O ' ' A' ' 15' ' ' GLU . 3.6 m -75.54 81.42 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.283 -1.128 . . . . 0.0 109.636 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.464 ' O ' ' HB ' ' A' ' 97' ' ' VAL . 0.1 OUTLIER -48.17 -93.18 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.552 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 18.9 m -131.11 52.95 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.062 -1.024 . . . . 0.0 109.718 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.512 ' O ' ' CB ' ' A' ' 18' ' ' ARG . 1.3 p -99.07 136.61 38.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.174 -0.954 . . . . 0.0 109.255 179.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.512 ' CB ' ' O ' ' A' ' 17' ' ' SER . 6.3 mtt-85 75.45 78.28 0.1 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.222 -0.924 . . . . 0.0 108.916 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.432 ' O ' ' C ' ' A' ' 20' ' ' PHE . 0.5 OUTLIER -79.65 -177.52 5.9 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.335 -0.853 . . . . 0.0 109.678 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.476 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 2.6 t80 -41.24 137.84 1.31 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.485 -0.76 . . . . 0.0 109.82 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 151.14 -64.12 0.38 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.475 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 2.0 tpp180 -155.04 18.87 0.43 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.147 -1.208 . . . . 0.0 109.8 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.79 113.43 18.67 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.276 -0.89 . . . . 0.0 109.661 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.583 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.7 Cg_endo -82.08 53.9 4.77 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.61 2.207 . . . . 0.0 110.462 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.583 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 98.6 m-85 -159.8 70.82 0.46 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.163 -0.96 . . . . 0.0 109.503 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.48 ' CE1' ' OD1' ' A' ' 44' ' ' ASN . 23.7 m-85 -83.61 119.03 24.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.204 -0.935 . . . . 0.0 109.536 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -93.56 122.45 36.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.234 -0.916 . . . . 0.0 109.67 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 15.1 mm -99.17 122.15 50.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 109.176 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 54.7 t -127.97 137.74 56.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.099 -1.0 . . . . 0.0 109.651 -179.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.424 ' HB3' ' OG ' ' A' ' 38' ' ' SER . 1.7 tt0 -124.61 137.82 54.36 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.3 -0.875 . . . . 0.0 109.379 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.446 ' HE2' HG13 ' A' ' 36' ' ' ILE . 7.9 ttm -116.06 145.18 43.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.189 -0.944 . . . . 0.0 109.647 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.61 -63.48 1.29 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.332 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.66 65.29 0.87 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.287 -0.883 . . . . 0.0 109.384 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.25 17.03 70.19 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 36' ' ' ILE . 3.0 t-20 -144.38 103.17 3.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.222 -1.164 . . . . 0.0 109.451 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.446 HG13 ' HE2' ' A' ' 31' ' ' MET . 2.6 mp -44.69 137.49 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.277 -0.89 . . . . 0.0 109.461 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -144.01 16.36 1.74 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 109.48 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.424 ' OG ' ' HB3' ' A' ' 30' ' ' GLU . 0.2 OUTLIER -166.68 122.86 1.21 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.259 -0.901 . . . . 0.0 109.441 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.6 m -142.9 110.16 5.68 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.196 -0.94 . . . . 0.0 109.6 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.91 153.98 46.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.31 -0.869 . . . . 0.0 109.2 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.422 ' O ' HG12 ' A' ' 41' ' ' VAL . 8.0 p -113.76 144.34 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.204 -0.935 . . . . 0.0 109.675 -179.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.5 mt -136.42 132.7 49.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.341 -0.849 . . . . 0.0 109.37 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -106.59 131.38 53.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.241 -0.912 . . . . 0.0 109.692 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.48 ' OD1' ' CE1' ' A' ' 26' ' ' PHE . 2.7 m120 . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.28 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.428 HD12 ' CE2' ' A' ' 20' ' ' PHE . 16.6 mm -70.4 -5.58 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -1.095 . . . . 0.0 109.555 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.67 -25.28 53.55 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.195 -0.94 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.421 ' HA ' HD13 ' A' ' 60' ' ' ILE . 10.8 t -68.66 -7.9 37.49 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.201 -0.937 . . . . 0.0 109.556 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.425 ' O ' ' C ' ' A' ' 59' ' ' GLN . . . -61.67 -56.18 22.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.926 . . . . 0.0 109.249 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 58' ' ' ALA . 1.6 tm0? -44.21 -29.26 0.61 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.337 -0.852 . . . . 0.0 109.286 179.808 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.421 HD13 ' HA ' ' A' ' 57' ' ' THR . 73.1 mt -75.59 -46.66 36.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 109.179 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.522 HG21 ' CG1' ' A' ' 66' ' ' VAL . 37.8 mt -56.03 -25.24 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 109.36 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.66 -38.08 80.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.279 -0.888 . . . . 0.0 109.681 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 26.8 m-20 -72.75 -4.94 34.5 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.247 -0.908 . . . . 0.0 109.721 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -83.9 -16.1 45.57 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.06 -12.74 59.27 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.522 ' CG1' HG21 ' A' ' 61' ' ' ILE . 2.6 p -58.21 98.77 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.268 -1.136 . . . . 0.0 109.66 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.439 ' HA ' HG21 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -79.28 -6.36 56.5 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 179.234 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.556 ' HB1' ' CE2' ' A' ' 104' ' ' PHE . . . -113.67 120.66 41.63 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.284 -0.885 . . . . 0.0 109.119 179.627 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 70.6 t -108.43 112.04 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.165 -0.959 . . . . 0.0 109.852 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 3.2 mm -99.79 97.53 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.155 -0.965 . . . . 0.0 109.136 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.476 ' HB2' ' HB2' ' A' ' 20' ' ' PHE . . . -158.39 169.85 23.53 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.237 -0.914 . . . . 0.0 109.816 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.435 ' O ' ' C ' ' A' ' 73' ' ' SER . 9.1 t -133.33 50.65 2.21 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.364 -0.835 . . . . 0.0 109.048 179.79 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' SER . . . . . 0.445 ' HB3' ' HB3' ' A' ' 20' ' ' PHE . 60.5 p -41.26 149.55 0.36 Allowed Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.509 -0.745 . . . . 0.0 109.937 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.452 ' HD3' ' O ' ' A' ' 20' ' ' PHE . 36.2 Cg_endo -78.14 -35.26 1.35 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.657 2.238 . . . . 0.0 110.051 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -108.61 153.14 16.91 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.476 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 35.5 Cg_endo -77.72 1.15 9.13 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.537 2.158 . . . . 0.0 110.668 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.463 ' O ' HG21 ' A' ' 81' ' ' VAL . 5.4 t30 -59.93 -42.28 93.64 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.223 -0.923 . . . . 0.0 109.686 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -64.17 -67.59 0.42 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 109.681 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.518 ' CD1' ' CG2' ' A' ' 89' ' ' ILE . 16.6 m-30 -53.06 -19.27 2.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.232 -0.917 . . . . 0.0 109.875 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.476 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 36.3 tt0 -70.73 -49.93 41.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.122 -0.986 . . . . 0.0 109.579 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.463 HG21 ' O ' ' A' ' 77' ' ' ASN . 3.0 t -67.4 -48.19 78.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.147 -0.971 . . . . 0.0 109.665 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.405 ' HB2' HD13 ' A' ' 89' ' ' ILE . 36.1 mt -55.59 -29.32 58.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.114 -0.992 . . . . 0.0 109.508 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 64.0 t-20 -68.03 -38.89 83.07 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.265 -0.897 . . . . 0.0 109.383 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.14 -26.29 61.15 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.331 -0.856 . . . . 0.0 109.47 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.46 ' HB3' HD11 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -71.87 -37.11 70.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.955 . . . . 0.0 109.551 -179.94 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.53 13.08 25.17 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.46 HD11 ' HB3' ' A' ' 85' ' ' LEU . 3.7 mt -85.38 169.54 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.278 -1.131 . . . . 0.0 109.623 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.17 123.67 43.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.25 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.518 ' CG2' ' CD1' ' A' ' 79' ' ' PHE . 1.6 mt -95.16 161.84 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.19 -0.944 . . . . 0.0 109.757 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.532 ' CD1' ' O ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -148.21 133.93 18.9 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.444 -179.862 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.405 ' HB2' ' HB2' ' A' ' 110' ' ' GLU . 0.0 OUTLIER -89.45 123.12 33.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.148 -0.97 . . . . 0.0 109.475 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.16 87.78 5.48 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.916 . . . . 0.0 109.681 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' THR . . . . . 0.46 HG21 ' O ' ' A' ' 93' ' ' THR . 18.6 m -139.23 21.02 2.6 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.223 -0.923 . . . . 0.0 109.412 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -74.46 -77.8 0.64 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 92.8 m -159.81 -70.78 0.08 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.246 -1.15 . . . . 0.0 109.386 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 97' ' ' VAL . 37.0 m -132.38 148.71 52.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.303 -0.873 . . . . 0.0 109.384 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.464 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 12.1 p -44.36 -27.98 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.345 -0.847 . . . . 0.0 109.487 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -66.69 -52.81 40.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.337 -0.852 . . . . 0.0 109.734 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.434 ' O ' ' CG ' ' A' ' 103' ' ' LEU . 4.7 tt0 -71.02 -16.35 62.61 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.136 -0.977 . . . . 0.0 109.493 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.4 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 2.6 m120 -75.95 -40.76 53.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.397 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 30.9 tp -60.58 -47.69 85.07 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.336 -0.853 . . . . 0.0 109.433 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.87 -20.43 56.29 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.432 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.434 ' CG ' ' O ' ' A' ' 99' ' ' GLU . 6.4 mt -67.37 -43.5 81.26 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.312 -0.868 . . . . 0.0 109.676 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.556 ' CE2' ' HB1' ' A' ' 68' ' ' ALA . 7.1 t80 -61.28 -29.17 69.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.28 -0.888 . . . . 0.0 109.453 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 92.0 m -62.34 -40.59 96.88 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.211 -0.93 . . . . 0.0 109.563 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 107' ' ' GLY . 6.4 mm-40 -87.94 3.21 49.44 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.181 -0.949 . . . . 0.0 109.729 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . 44.25 39.03 5.24 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -103.22 -10.94 18.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -1.162 . . . . 0.0 109.607 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.461 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 0.7 OUTLIER -74.05 -161.17 0.11 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.208 -0.932 . . . . 0.0 109.482 -179.989 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.532 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 7.0 mt-10 -95.07 113.88 25.63 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.304 -0.872 . . . . 0.0 109.418 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -103.18 142.8 33.54 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.35 -0.844 . . . . 0.0 109.599 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.466 ' O ' ' HB2' ' A' ' 113' ' ' ARG . 13.6 mm -129.84 117.53 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.272 -0.893 . . . . 0.0 109.302 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.466 ' HB2' ' O ' ' A' ' 112' ' ' ILE . 3.4 ttt-85 . . . . . 0 N--CA 1.489 1.495 0 O-C-N 121.195 -0.94 . . . . 0.0 109.619 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.404 ' HE2' ' HB2' ' A' ' 1' ' ' MET . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.09 155.77 17.84 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.202 -0.936 . . . . 0.0 109.309 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.478 ' HA ' ' O ' ' A' ' 68' ' ' ALA . 7.8 mt -120.31 117.41 53.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.277 -0.889 . . . . 0.0 110.052 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -112.51 116.92 31.02 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.317 -0.864 . . . . 0.0 108.672 179.275 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -102.98 135.23 41.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.128 -0.983 . . . . 0.0 109.926 -179.311 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.419 ' O ' HG11 ' A' ' 16' ' ' VAL . . . -73.55 143.24 46.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.39 -0.819 . . . . 0.0 109.175 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.467 ' HB3' HG12 ' A' ' 97' ' ' VAL . 0.7 OUTLIER -151.39 157.96 43.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.208 -0.933 . . . . 0.0 109.683 -179.792 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 66.9 p -119.39 0.96 11.2 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.324 -0.86 . . . . 0.0 109.388 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.548 ' O ' ' CG ' ' A' ' 25' ' ' TYR . . . -125.62 -153.96 8.59 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.527 HG23 ' CE1' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -126.45 -30.52 2.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.183 -1.186 . . . . 0.0 109.664 -179.849 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 173.31 -43.8 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.122 -0.986 . . . . 0.0 109.528 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -80.66 5.15 16.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.299 -0.875 . . . . 0.0 109.629 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -166.31 31.43 0.21 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.467 ' HB3' ' CG2' ' A' ' 97' ' ' VAL . 5.0 m -77.06 79.43 3.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.124 -1.221 . . . . 0.0 109.357 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.488 ' O ' ' CB ' ' A' ' 16' ' ' VAL . 9.2 mm-40 -76.91 1.57 17.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.302 -0.874 . . . . 0.0 109.576 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.488 ' CB ' ' O ' ' A' ' 15' ' ' GLU . 1.9 t 73.68 18.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.403 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.1 t 59.11 176.04 0.07 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.32 -0.863 . . . . 0.0 109.399 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -109.04 -36.25 6.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -131.79 123.18 27.09 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.875 . . . . 0.0 109.363 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.449 ' C ' ' CD1' ' A' ' 20' ' ' PHE . 2.5 t80 -62.23 96.72 0.08 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.905 . . . . 0.0 109.497 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -136.76 -87.02 0.2 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.428 ' O ' ' C ' ' A' ' 23' ' ' ALA . 1.8 ptp85 -114.7 43.85 1.86 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -1.111 . . . . 0.0 109.18 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.428 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -42.79 114.14 1.45 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.406 -0.808 . . . . 0.0 109.405 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.58 21.14 0.88 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.578 2.185 . . . . 0.0 110.947 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.548 ' CG ' ' O ' ' A' ' 9' ' ' GLY . 0.5 OUTLIER -159.51 70.78 0.47 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.949 -1.094 . . . . 0.0 109.301 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.511 ' CE2' HD12 ' A' ' 61' ' ' ILE . 0.3 OUTLIER -79.52 126.27 30.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.441 -179.917 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.22 115.94 31.65 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 28.9 mm -96.78 131.43 43.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.3 -0.875 . . . . 0.0 109.661 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.5 t -130.25 137.09 57.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.295 -0.878 . . . . 0.0 109.117 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -118.17 95.99 5.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.095 -1.003 . . . . 0.0 109.816 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.442 ' HE2' HG13 ' A' ' 36' ' ' ILE . 41.1 ttm -81.91 146.06 30.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.029 179.603 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -99.96 -70.01 0.75 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.113 -0.992 . . . . 0.0 110.002 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 19.3 tttm -138.59 62.71 1.54 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.094 -1.004 . . . . 0.0 109.95 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.51 31.64 36.53 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 36' ' ' ILE . 2.9 p30 -159.58 97.47 1.33 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.169 -1.195 . . . . 0.0 109.552 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.442 HG13 ' HE2' ' A' ' 31' ' ' MET . 2.9 mp -44.06 132.39 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.247 -0.908 . . . . 0.0 109.327 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -130.01 18.97 5.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.119 -0.988 . . . . 0.0 109.737 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 175.38 129.9 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.078 -1.014 . . . . 0.0 109.619 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.4 p -149.58 107.51 3.71 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.323 -0.86 . . . . 0.0 109.373 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.22 164.27 15.42 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.234 -0.916 . . . . 0.0 109.537 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.511 HG22 ' N ' ' A' ' 42' ' ' ILE . 14.7 p -124.42 148.03 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.497 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.511 ' N ' HG22 ' A' ' 41' ' ' VAL . 2.6 tp -141.65 154.27 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.302 -0.874 . . . . 0.0 109.392 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.451 ' N ' HG13 ' A' ' 42' ' ' ILE . 26.7 mp0 -93.9 68.8 3.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.267 -0.895 . . . . 0.0 109.497 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.307 -0.87 . . . . 0.0 109.727 179.932 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.373 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.406 ' HA ' HD13 ' A' ' 55' ' ' ILE . 46.6 mm -69.77 -45.82 76.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.127 -1.219 . . . . 0.0 109.479 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.17 -33.26 75.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.221 -0.924 . . . . 0.0 109.535 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 21.6 m -58.95 -23.9 62.01 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.18 -0.95 . . . . 0.0 109.634 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -53.51 -51.94 61.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.258 -0.901 . . . . 0.0 109.574 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.498 ' OE1' ' CG1' ' A' ' 81' ' ' VAL . 1.4 tp60 -46.06 -44.73 15.64 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.188 -0.945 . . . . 0.0 109.504 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 23.5 mt -62.63 -40.22 87.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.193 -0.942 . . . . 0.0 109.522 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.511 HD12 ' CE2' ' A' ' 26' ' ' PHE . 50.3 mt -66.61 -20.38 27.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.201 -0.937 . . . . 0.0 109.487 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.16 -36.23 55.33 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.256 -0.903 . . . . 0.0 109.687 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 52.2 m-20 -75.47 -0.15 19.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.258 -0.901 . . . . 0.0 109.694 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -82.9 -7.68 59.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.129 -0.982 . . . . 0.0 109.747 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.11 -23.98 32.14 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.422 ' O ' HG21 ' A' ' 66' ' ' VAL . 19.2 m -59.51 93.9 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -1.152 . . . . 0.0 109.688 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.42 ' O ' ' HD3' ' A' ' 88' ' ' LYS . 26.9 mtpt -79.49 -3.45 46.75 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.36 -0.838 . . . . 0.0 108.793 179.286 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.478 ' O ' ' HA ' ' A' ' 3' ' ' ILE . . . -135.21 103.14 5.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.227 -0.921 . . . . 0.0 109.19 179.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 55.1 t -110.93 129.99 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.023 -1.048 . . . . 0.0 109.999 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 3.6 mp -92.68 119.38 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.286 -0.883 . . . . 0.0 109.078 179.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.444 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -157.3 176.97 12.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.169 -0.957 . . . . 0.0 109.693 -179.724 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 73' ' ' SER . 3.1 p -152.64 51.89 0.76 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.48 -0.762 . . . . 0.0 109.494 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' SER . . . . . 0.563 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 0.1 OUTLIER -44.29 167.51 0.09 OUTLIER Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.172 -0.955 . . . . 0.0 109.436 179.962 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.63 -1.92 12.02 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.613 2.209 . . . . 0.0 110.309 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -162.63 168.61 37.6 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.555 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.2 Cg_endo -79.17 7.9 4.14 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.671 2.248 . . . . 0.0 110.582 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -58.57 -44.54 89.77 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.178 -0.951 . . . . 0.0 109.649 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -77.04 -48.87 16.68 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.176 -0.952 . . . . 0.0 109.851 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.563 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 2.9 m-85 -55.06 -19.81 8.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.209 -0.932 . . . . 0.0 109.776 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.68 -46.71 24.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.147 -0.97 . . . . 0.0 109.815 -179.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.498 ' CG1' ' OE1' ' A' ' 59' ' ' GLN . 22.2 t -64.49 -51.09 72.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.154 -0.966 . . . . 0.0 109.495 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.459 ' HB2' HD12 ' A' ' 89' ' ' ILE . 0.9 OUTLIER -55.03 -46.44 75.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.903 . . . . 0.0 109.71 -179.88 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 53.6 t30 -57.81 -41.53 82.36 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.219 -0.925 . . . . 0.0 109.534 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.49 -50.39 71.89 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.497 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.528 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 2.4 mp -60.21 -28.1 67.71 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.175 -0.953 . . . . 0.0 109.477 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.43 10.24 17.77 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.528 ' CD1' ' HB3' ' A' ' 85' ' ' LEU . 3.2 mp -94.38 147.71 5.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.115 -1.226 . . . . 0.0 109.439 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.42 ' HD3' ' O ' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -104.81 155.91 18.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.259 -0.901 . . . . 0.0 109.818 -179.835 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.482 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.5 mp -136.6 140.21 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.254 -0.904 . . . . 0.0 109.507 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.556 ' CD2' ' O ' ' A' ' 109' ' ' LEU . 16.9 m-30 -102.82 167.7 9.7 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.313 -0.867 . . . . 0.0 109.53 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.53 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 0.0 OUTLIER -85.7 130.43 34.57 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.245 -0.909 . . . . 0.0 109.866 -179.615 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -87.76 116.89 26.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.422 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' THR . . . . . 0.434 HG22 HD11 ' A' ' 109' ' ' LEU . 63.4 p -61.77 -26.32 68.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.281 -0.887 . . . . 0.0 109.372 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.56 18.22 42.36 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 58.4 m -86.35 -74.88 0.41 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -1.134 . . . . 0.0 109.473 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 14' ' ' SER . 74.4 m -155.98 144.08 19.84 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.321 -0.862 . . . . 0.0 109.43 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.467 ' CG2' ' HB3' ' A' ' 14' ' ' SER . 28.8 m -68.94 -35.9 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.885 . . . . 0.0 109.698 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -60.08 -38.06 81.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.135 -0.978 . . . . 0.0 109.323 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.85 -50.69 27.32 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.335 -0.853 . . . . 0.0 109.433 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.471 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 42.2 m-20 -49.62 -34.44 18.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -0.893 . . . . 0.0 109.551 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 12.3 tp -52.99 -55.86 20.35 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.247 -0.908 . . . . 0.0 109.725 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.49 -20.49 61.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.13 -0.982 . . . . 0.0 109.728 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.471 ' HB2' ' HA ' ' A' ' 100' ' ' ASN . 23.9 mt -71.74 -25.38 62.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.174 -0.954 . . . . 0.0 109.611 -179.782 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.412 ' CD1' HD12 ' A' ' 3' ' ' ILE . 41.3 t80 -70.0 -38.11 75.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.207 -0.933 . . . . 0.0 109.237 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.424 ' O ' HG21 ' A' ' 105' ' ' THR . 48.6 m -74.56 -24.39 58.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.857 . . . . 0.0 109.504 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -80.81 -18.52 47.25 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.193 -0.942 . . . . 0.0 109.5 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 76.24 24.48 68.47 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -92.68 -37.92 12.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.14 -1.212 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.556 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 0.0 OUTLIER -88.56 119.98 29.52 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.135 -0.978 . . . . 0.0 109.479 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.517 ' HA ' ' CG ' ' A' ' 90' ' ' TYR . 16.6 pt-20 -149.29 173.83 13.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.463 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.53 ' HB2' ' N ' ' A' ' 91' ' ' ARG . 8.1 tp10 -175.77 -111.24 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.318 -0.864 . . . . 0.0 109.84 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.483 ' N ' ' HG3' ' A' ' 111' ' ' GLU . 19.8 tt -84.21 134.58 26.65 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 O-C-N 121.08 -1.012 . . . . 0.0 110.072 -179.222 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.559 0 O-C-N 121.442 -0.786 . . . . 0.0 109.285 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.3 ptp . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.486 ' CG ' ' HG3' ' A' ' 30' ' ' GLU . 0.1 OUTLIER -131.67 144.29 50.91 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.245 -0.909 . . . . 0.0 109.583 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 5.3 mt -118.32 104.45 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.288 -0.883 . . . . 0.0 109.565 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -106.16 116.41 31.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.329 -0.857 . . . . 0.0 109.31 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.458 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 2.8 mp -94.61 120.8 44.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.15 -0.969 . . . . 0.0 109.467 -179.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 7' ' ' SER . . . -61.91 150.43 37.61 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.278 -0.889 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.507 ' O ' ' CB ' ' A' ' 8' ' ' SER . 0.0 OUTLIER 53.6 169.95 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.28 -0.887 . . . . 0.0 109.598 179.963 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.507 ' CB ' ' O ' ' A' ' 7' ' ' SER . 0.2 OUTLIER 162.52 -35.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.322 -0.862 . . . . 0.0 109.321 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.459 ' HA3' ' HB2' ' A' ' 14' ' ' SER . . . 75.91 9.56 85.16 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER 61.92 16.78 8.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.244 -1.151 . . . . 0.0 109.46 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.0 t0 -173.17 -167.48 0.41 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.237 -0.915 . . . . 0.0 109.597 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.2 mt -79.85 -1.85 40.87 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.211 -0.93 . . . . 0.0 109.613 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.81 -61.62 7.01 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB2' ' HA3' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -77.31 83.23 3.76 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.198 -1.177 . . . . 0.0 109.505 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.402 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 7.2 mt-10 -72.22 83.1 1.02 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.34 -0.85 . . . . 0.0 109.176 179.724 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.417 ' O ' ' C ' ' A' ' 17' ' ' SER . 22.1 t 62.6 63.97 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.916 . . . . 0.0 109.308 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.461 ' HB3' ' CB ' ' A' ' 7' ' ' SER . 8.2 t -43.77 159.01 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.311 -0.868 . . . . 0.0 109.426 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 22.3 mtp85 -95.67 30.62 2.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.376 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -127.38 159.03 35.68 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.948 . . . . 0.0 109.474 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -133.17 -32.51 1.19 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.186 -0.946 . . . . 0.0 109.903 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -101.5 -37.29 3.55 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.462 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -84.31 -25.9 28.91 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.131 -1.217 . . . . 0.0 109.775 -179.753 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.419 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -42.49 103.01 0.29 Allowed Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.335 -0.853 . . . . 0.0 109.7 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.482 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.7 Cg_endo -80.68 41.28 1.11 Allowed 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 122.602 2.202 . . . . 0.0 110.533 179.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.482 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 84.1 m-85 -158.19 68.5 0.49 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.106 -0.996 . . . . 0.0 109.286 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.435 ' CE1' ' HA ' ' A' ' 6' ' ' ALA . 0.8 OUTLIER -83.02 116.49 22.3 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.271 -0.893 . . . . 0.0 109.585 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 1.4 ttt -94.21 132.42 38.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.156 -0.965 . . . . 0.0 109.635 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.506 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 5.1 tt -129.42 116.81 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.897 . . . . 0.0 109.401 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.459 HG12 ' O ' ' A' ' 38' ' ' SER . 94.6 t -125.11 129.7 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 109.388 -179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.486 ' HG3' ' CG ' ' A' ' 2' ' ' LYS . 26.9 tt0 -99.05 99.45 10.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.226 -0.921 . . . . 0.0 109.635 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.2 tpp -81.8 134.24 35.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.309 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -99.0 -68.66 0.79 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -0.915 . . . . 0.0 109.681 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -129.99 81.47 2.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.204 -0.935 . . . . 0.0 109.631 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.15 28.04 24.97 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.412 ' O ' ' N ' ' A' ' 37' ' ' GLU . 1.3 m-20 -147.73 108.49 4.18 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.173 -1.192 . . . . 0.0 109.536 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.457 HG23 ' OG ' ' A' ' 39' ' ' SER . 72.6 mt -48.28 98.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.169 -0.957 . . . . 0.0 109.405 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.412 ' N ' ' O ' ' A' ' 35' ' ' ASN . 34.7 mt-10 -96.46 9.77 40.3 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.614 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.459 ' O ' HG12 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -169.6 122.67 0.75 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 179.99 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.457 ' OG ' HG23 ' A' ' 36' ' ' ILE . 0.7 OUTLIER -141.03 107.95 5.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 109.541 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.411 ' O ' HG22 ' A' ' 28' ' ' ILE . 7.5 tt0 -132.38 138.59 47.77 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.197 -0.939 . . . . 0.0 109.437 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.9 t -98.63 154.72 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.269 -0.895 . . . . 0.0 109.547 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.402 HD12 HG23 ' A' ' 28' ' ' ILE . 6.6 mt -131.92 134.33 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.341 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.445 ' O ' ' C ' ' A' ' 44' ' ' ASN . 53.7 mt-10 -91.06 85.92 6.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.297 -0.877 . . . . 0.0 109.527 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.445 ' C ' ' O ' ' A' ' 43' ' ' GLU . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.653 0 O-C-N 121.371 -0.831 . . . . 0.0 109.473 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 51.0 mm -60.77 -14.08 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.258 -1.142 . . . . 0.0 109.63 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.403 ' O ' ' C ' ' A' ' 57' ' ' THR . 0.0 OUTLIER -65.01 -37.04 86.34 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.211 -0.93 . . . . 0.0 109.658 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.403 ' C ' ' O ' ' A' ' 56' ' ' ARG . 14.6 m -43.48 -33.88 1.21 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.202 -0.936 . . . . 0.0 109.723 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -51.29 -52.36 45.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -0.933 . . . . 0.0 109.771 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -54.54 -34.31 61.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.933 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.6 mt -69.39 -65.76 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.127 -0.983 . . . . 0.0 109.726 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 18.8 pt -51.71 -20.95 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.741 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.16 -47.31 58.46 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.212 -0.93 . . . . 0.0 109.621 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -76.42 1.58 16.01 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.296 -0.877 . . . . 0.0 109.757 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -95.34 -2.11 49.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.088 -1.008 . . . . 0.0 109.772 -179.757 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 93.59 -14.41 65.36 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.418 HG13 HG21 ' A' ' 69' ' ' VAL . 31.8 t -49.66 91.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -1.119 . . . . 0.0 109.632 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' GLY . 3.6 mmmp? -79.3 -7.39 58.27 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.338 -0.851 . . . . 0.0 108.811 179.371 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.466 ' HB2' ' O ' ' A' ' 2' ' ' LYS . . . -131.26 123.44 28.41 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.287 -0.883 . . . . 0.0 109.199 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.418 HG21 HG13 ' A' ' 66' ' ' VAL . 57.0 t -121.34 106.69 18.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.161 -0.962 . . . . 0.0 109.853 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.469 HD11 ' CB ' ' A' ' 90' ' ' TYR . 13.4 mm -83.2 104.32 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.18 -0.95 . . . . 0.0 109.03 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -143.74 173.5 11.62 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.22 -0.925 . . . . 0.0 109.789 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.0 p -145.49 40.01 1.19 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.374 -0.829 . . . . 0.0 109.249 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' SER . . . . . 0.403 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -45.05 149.76 0.83 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.355 -0.841 . . . . 0.0 109.669 -179.905 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.2 Cg_endo -78.61 4.97 5.92 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.737 2.291 . . . . 0.0 110.336 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.411 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -144.42 148.46 20.24 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.411 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 36.2 Cg_endo -79.38 11.16 2.75 Favored 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 122.716 2.277 . . . . 0.0 110.79 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -73.54 -36.07 65.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.077 -1.014 . . . . 0.0 109.691 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -68.21 -50.59 53.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.954 . . . . 0.0 109.628 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.536 ' N ' ' CD1' ' A' ' 79' ' ' PHE . 1.4 m-85 -65.04 -18.31 65.19 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.133 -0.98 . . . . 0.0 109.519 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -67.53 -49.67 62.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.111 -0.993 . . . . 0.0 109.538 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -71.2 -43.88 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.194 -0.941 . . . . 0.0 109.609 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.426 HD13 HG12 ' A' ' 89' ' ' ILE . 20.1 mt -49.66 -49.36 47.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.173 -0.955 . . . . 0.0 109.446 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -61.35 -34.3 75.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.228 -0.92 . . . . 0.0 109.302 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -67.31 -25.65 66.12 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.434 -0.792 . . . . 0.0 109.6 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 4.5 mt -97.7 18.43 15.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.891 . . . . 0.0 109.37 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 56.3 62.84 5.89 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 97.7 mt -132.38 144.9 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.287 -1.126 . . . . 0.0 109.306 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.47 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 0.2 OUTLIER -82.77 124.64 30.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.296 -0.877 . . . . 0.0 109.423 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.495 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.7 mt -104.16 129.95 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.52 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.587 ' CE2' ' CB ' ' A' ' 110' ' ' GLU . 3.6 m-85 -116.46 157.57 24.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.405 -0.809 . . . . 0.0 109.249 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 1.2 ttt-85 -96.09 143.22 27.42 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.245 -0.909 . . . . 0.0 109.568 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.416 ' HB1' HG13 ' A' ' 16' ' ' VAL . . . -109.97 86.72 2.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.4 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 34.1 m -149.35 26.85 0.85 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.192 -0.943 . . . . 0.0 109.421 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.524 ' CA ' HD13 ' A' ' 109' ' ' LEU . . . -79.17 -71.8 1.23 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 15.8 m -165.92 -46.17 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.205 -1.174 . . . . 0.0 109.727 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.77 162.9 38.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.23 -0.919 . . . . 0.0 109.79 -179.684 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.449 ' CG1' HG23 ' A' ' 5' ' ' ILE . 47.4 t -77.08 -40.03 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.272 -0.893 . . . . 0.0 109.351 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -59.15 -50.06 75.49 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.803 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.419 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 1.2 tt0 -72.17 -33.0 67.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.12 -0.988 . . . . 0.0 109.645 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -57.2 -43.39 82.71 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.224 -0.922 . . . . 0.0 109.759 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.435 HD21 HG11 ' A' ' 29' ' ' VAL . 51.9 tp -51.39 -43.14 61.83 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -0.933 . . . . 0.0 109.795 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 7.6 tptm -75.18 -30.5 60.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.138 -0.977 . . . . 0.0 109.762 -179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.419 ' HG ' ' O ' ' A' ' 99' ' ' GLU . 48.6 mt -67.09 -23.96 65.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.165 -0.959 . . . . 0.0 109.608 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 104' ' ' PHE . 24.4 t80 -58.79 -48.07 82.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.198 -0.939 . . . . 0.0 109.357 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 55.4 m -65.28 -39.1 92.13 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.348 -0.845 . . . . 0.0 109.304 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -70.98 -6.81 41.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.234 -0.916 . . . . 0.0 109.505 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 56.16 30.65 58.15 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.306 -1.517 . . . . 0.0 109.306 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -83.66 -28.84 28.1 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.313 -1.11 . . . . 0.0 109.529 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.524 HD13 ' CA ' ' A' ' 94' ' ' GLY . 0.2 OUTLIER -138.6 138.48 37.94 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.073 -1.017 . . . . 0.0 109.763 -179.805 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.587 ' CB ' ' CE2' ' A' ' 90' ' ' TYR . 1.7 pt-20 -170.76 -151.54 0.08 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.324 -0.86 . . . . 0.0 109.449 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.495 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 0.7 OUTLIER -163.49 -112.16 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.257 -0.902 . . . . 0.0 109.623 -179.81 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.6 mt -83.33 90.34 2.42 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 O-C-N 121.154 -0.966 . . . . 0.0 109.489 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.206 -0.934 . . . . 0.0 109.321 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.431 ' HB2' ' O ' ' A' ' 65' ' ' GLY . 4.4 mtmt -118.25 145.97 44.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.308 -0.87 . . . . 0.0 109.293 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.616 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 5.3 mt -119.76 111.1 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.348 -0.845 . . . . 0.0 109.616 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.53 ' CB ' HG12 ' A' ' 66' ' ' VAL . . . -115.27 122.86 47.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.336 -0.852 . . . . 0.0 109.219 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.5 mp -98.4 142.61 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.233 -0.917 . . . . 0.0 109.543 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.498 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -81.49 155.84 25.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.358 -0.839 . . . . 0.0 109.755 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.458 ' O ' ' HB2' ' A' ' 8' ' ' SER . 1.0 OUTLIER 52.83 -89.98 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.659 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.498 ' N ' ' O ' ' A' ' 6' ' ' ALA . 3.0 m 62.85 24.22 14.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.911 . . . . 0.0 109.566 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 44.07 -107.46 0.13 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.81 -76.91 0.13 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -1.141 . . . . 0.0 109.494 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -158.2 -43.71 0.06 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.232 -0.918 . . . . 0.0 109.614 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.59 -0.44 57.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -0.938 . . . . 0.0 109.55 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.12 19.91 1.09 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.461 ' HB3' ' O ' ' A' ' 8' ' ' SER . 9.7 p -77.02 81.91 3.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.355 -1.085 . . . . 0.0 109.464 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.449 ' O ' ' CG2' ' A' ' 97' ' ' VAL . 2.7 mt-10 -77.22 -137.5 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.192 -0.943 . . . . 0.0 109.025 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.46 ' HA ' HG11 ' A' ' 97' ' ' VAL . 6.1 p -88.75 34.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.066 -1.021 . . . . 0.0 109.587 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.427 ' HB3' ' HB2' ' A' ' 7' ' ' SER . 0.5 OUTLIER 69.32 -157.7 0.17 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.349 -0.845 . . . . 0.0 109.479 179.921 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.4 -72.88 0.12 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -112.38 -164.54 0.92 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.189 -0.944 . . . . 0.0 109.611 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.407 ' CD1' ' CB ' ' A' ' 6' ' ' ALA . 24.8 t80 -158.05 48.98 0.39 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.333 -0.854 . . . . 0.0 109.499 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -127.27 -68.44 0.15 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.424 ' O ' ' C ' ' A' ' 23' ' ' ALA . 55.1 mtt180 -112.49 16.76 19.72 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.311 -1.111 . . . . 0.0 109.398 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.424 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -43.46 107.3 0.56 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.323 -0.861 . . . . 0.0 109.619 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.57 44.05 1.66 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.601 2.2 . . . . 0.0 110.604 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.477 ' CE1' ' HG2' ' A' ' 43' ' ' GLU . 4.9 m-85 -158.02 70.09 0.55 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.112 -0.993 . . . . 0.0 109.267 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.417 ' CE2' HD11 ' A' ' 61' ' ' ILE . 4.4 m-30 -79.44 121.96 25.82 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.36 -0.837 . . . . 0.0 109.492 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.9 117.67 35.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.241 -0.912 . . . . 0.0 109.325 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 39.7 mm -104.55 130.95 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.219 -0.926 . . . . 0.0 109.526 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.436 HG13 HD22 ' A' ' 101' ' ' LEU . 82.8 t -131.33 132.17 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.328 -0.857 . . . . 0.0 109.5 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.442 ' HB2' ' CB ' ' A' ' 38' ' ' SER . 7.8 mt-10 -106.64 163.71 12.67 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.322 -0.861 . . . . 0.0 109.376 179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.52 ' HE1' ' CD1' ' A' ' 3' ' ' ILE . 41.9 ttm -147.74 139.05 23.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.174 -0.954 . . . . 0.0 109.538 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.05 -70.5 0.71 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.934 . . . . 0.0 109.578 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 6.3 mtmt -136.17 73.99 1.48 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.447 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.53 16.2 69.34 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.46 103.21 6.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.316 -1.108 . . . . 0.0 109.456 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 2.0 mt -66.68 115.53 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.238 -0.914 . . . . 0.0 109.579 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -130.97 33.63 4.16 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.219 -0.926 . . . . 0.0 109.237 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.442 ' CB ' ' HB2' ' A' ' 30' ' ' GLU . 0.6 OUTLIER -161.22 100.11 1.21 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -0.873 . . . . 0.0 109.474 -179.87 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 56.4 m -129.01 104.84 7.81 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.161 -0.962 . . . . 0.0 109.087 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -126.05 125.46 42.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.334 -0.854 . . . . 0.0 109.83 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.5 p -98.54 139.65 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.378 -0.826 . . . . 0.0 109.119 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 5.5 mt -139.81 142.68 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.177 -0.952 . . . . 0.0 109.727 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.477 ' HG2' ' CE1' ' A' ' 25' ' ' TYR . 12.4 mt-10 -94.9 142.15 27.81 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.531 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.501 ' O ' ' ND2' ' A' ' 44' ' ' ASN . 9.1 p-10 . . . . . 0 N--CA 1.49 1.568 0 O-C-N 121.231 -0.918 . . . . 0.0 109.365 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 24.2 mm -67.87 -8.03 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -1.155 . . . . 0.0 109.646 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -69.24 -33.33 73.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.927 . . . . 0.0 109.666 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 13.2 t -58.82 -15.54 12.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.297 -0.877 . . . . 0.0 109.783 -179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.85 -46.02 85.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.804 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 52.6 tt0 -65.5 -28.59 69.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.269 -0.894 . . . . 0.0 109.805 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.428 HG22 HD12 ' A' ' 60' ' ' ILE . 33.2 mm -75.9 -29.21 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.175 -0.953 . . . . 0.0 109.718 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.427 HD12 HG21 ' A' ' 61' ' ' ILE . 65.8 mt -75.27 -41.54 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.147 -0.971 . . . . 0.0 109.636 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.45 -26.29 66.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.154 -0.966 . . . . 0.0 109.627 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -76.68 -5.77 49.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.192 -0.943 . . . . 0.0 109.674 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -90.94 27.6 1.78 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.136 -0.977 . . . . 0.0 109.618 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.431 ' O ' ' HB2' ' A' ' 2' ' ' LYS . . . 66.72 11.84 58.22 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.53 HG12 ' CB ' ' A' ' 4' ' ' ALA . 96.0 t -87.06 91.81 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.2 -1.177 . . . . 0.0 109.386 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.465 ' O ' ' HB2' ' A' ' 88' ' ' LYS . 39.2 mmtt -79.43 -4.76 52.65 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.432 -0.792 . . . . 0.0 108.863 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.467 ' HB1' ' HA ' ' A' ' 3' ' ' ILE . . . -124.27 107.45 11.2 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.521 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 60.9 t -104.96 119.14 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.366 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 3.1 mm -99.24 108.19 21.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.347 -0.846 . . . . 0.0 109.397 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -153.37 173.79 15.18 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.255 -0.903 . . . . 0.0 109.557 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.33 49.32 1.43 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.444 -0.785 . . . . 0.0 109.224 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -50.42 145.53 10.39 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.328 -0.858 . . . . 0.0 109.513 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.05 -0.08 10.34 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 122.576 2.184 . . . . 0.0 110.477 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.76 154.67 24.95 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.47 -1.66 11.8 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.686 2.257 . . . . 0.0 110.574 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -53.66 -48.19 69.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.237 -0.914 . . . . 0.0 109.643 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.48 -59.29 2.94 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.279 -0.888 . . . . 0.0 109.881 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.568 ' CD1' HG23 ' A' ' 89' ' ' ILE . 25.1 m-85 -46.98 -23.52 0.47 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.934 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 14.7 mm-40 -71.16 -53.05 15.85 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.096 -1.003 . . . . 0.0 109.566 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 t -63.03 -46.46 96.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.162 -0.961 . . . . 0.0 109.432 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.441 HD23 HG12 ' A' ' 89' ' ' ILE . 0.0 OUTLIER -52.23 -56.26 15.83 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.287 -0.883 . . . . 0.0 109.399 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -54.83 -33.41 61.63 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 109.503 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -63.03 -46.22 88.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.196 -0.94 . . . . 0.0 109.427 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -64.62 -11.55 36.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.419 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 79.78 31.25 40.7 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.441 HG22 ' HA ' ' A' ' 67' ' ' LYS . 5.3 mm -98.05 172.85 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.32 -1.106 . . . . 0.0 109.326 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 67' ' ' LYS . 0.2 OUTLIER -97.82 114.41 26.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.21 -0.932 . . . . 0.0 109.631 -179.798 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.568 HG23 ' CD1' ' A' ' 79' ' ' PHE . 19.8 mt -85.6 149.02 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.38 -0.825 . . . . 0.0 109.181 179.722 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.501 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 0.4 OUTLIER -135.47 122.39 21.23 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.01 -1.056 . . . . 0.0 109.673 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.13 121.98 31.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 109.599 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.99 106.79 18.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -0.898 . . . . 0.0 109.547 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 94' ' ' GLY . 6.7 t -122.17 -20.63 6.16 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.272 -0.892 . . . . 0.0 109.732 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.443 ' O ' ' HB ' ' A' ' 95' ' ' THR . . . -43.14 -88.11 0.01 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.443 ' HB ' ' O ' ' A' ' 94' ' ' GLY . 5.2 t 176.51 -45.84 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.257 -1.143 . . . . 0.0 109.423 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.5 m -121.93 115.88 23.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.46 HG11 ' HA ' ' A' ' 16' ' ' VAL . 6.4 m -47.14 -35.96 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 109.591 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -48.19 -49.45 32.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.13 -0.981 . . . . 0.0 109.431 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -73.02 -45.36 58.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -0.9 . . . . 0.0 109.642 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.448 ' HA ' HD13 ' A' ' 103' ' ' LEU . 10.4 m-20 -51.41 -24.18 4.61 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.24 -0.913 . . . . 0.0 109.686 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.436 HD22 HG13 ' A' ' 29' ' ' VAL . 19.2 tp -65.51 -66.33 0.56 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.179 -0.951 . . . . 0.0 109.327 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 13.5 ptmt -56.1 -21.09 20.21 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -0.922 . . . . 0.0 109.348 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.5 ' HB3' ' CD1' ' A' ' 109' ' ' LEU . 10.2 mt -69.87 -45.22 68.17 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.336 -0.852 . . . . 0.0 109.54 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.616 ' CD1' ' CD1' ' A' ' 3' ' ' ILE . 21.2 t80 -55.54 -19.0 8.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.325 -0.859 . . . . 0.0 109.368 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 96.4 m -59.79 -51.2 70.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.27 -0.894 . . . . 0.0 109.483 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 0.452 ' OE2' HD21 ' A' ' 103' ' ' LEU . 13.6 pt-20 -83.4 -26.18 30.65 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.487 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.08 35.72 9.54 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -91.43 -6.33 52.95 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.247 -1.149 . . . . 0.0 109.577 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.5 ' CD1' ' HB3' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -76.63 -161.77 0.22 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.194 -0.942 . . . . 0.0 109.478 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.26 106.46 18.6 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.162 -0.961 . . . . 0.0 109.663 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.501 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 9.4 pt-20 -110.35 127.89 55.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.308 -0.87 . . . . 0.0 109.328 179.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 5.6 mt -127.83 132.19 69.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.582 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.1 ptm180 . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.283 -0.885 . . . . 0.0 109.264 179.767 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.412 ' HB3' ' HE3' ' A' ' 1' ' ' MET . 37.3 mtp . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.248 0.546 . . . . 0.0 109.543 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -114.17 150.48 34.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.917 . . . . 0.0 109.315 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.572 HG12 ' CE2' ' A' ' 104' ' ' PHE . 7.6 mt -120.89 101.82 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.279 -0.888 . . . . 0.0 109.892 -179.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.459 ' HB2' HG12 ' A' ' 66' ' ' VAL . . . -99.07 103.6 15.54 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.345 -0.847 . . . . 0.0 109.137 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.7 mt -88.13 122.19 39.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.249 -0.907 . . . . 0.0 109.807 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.436 ' O ' HG11 ' A' ' 16' ' ' VAL . . . -69.95 147.11 50.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 109.12 179.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.437 ' HB3' HG12 ' A' ' 97' ' ' VAL . 25.8 p -158.63 -178.68 7.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.165 -0.96 . . . . 0.0 109.788 -179.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -132.46 11.84 4.5 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.299 -0.876 . . . . 0.0 109.361 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -150.2 175.37 29.3 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -73.49 -44.97 56.67 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.272 -1.134 . . . . 0.0 109.46 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.426 ' OD2' ' OE1' ' A' ' 98' ' ' GLU . 10.5 t0 -176.93 -51.81 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.17 -0.956 . . . . 0.0 109.436 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.7 tt -57.06 -29.82 63.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.203 -0.936 . . . . 0.0 109.245 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 18.97 7.73 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.466 ' O ' ' HA ' ' A' ' 96' ' ' SER . 93.9 p -76.89 79.94 3.46 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.259 -1.142 . . . . 0.0 109.517 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.484 ' O ' ' CB ' ' A' ' 16' ' ' VAL . 4.7 tt0 -77.39 4.27 11.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -0.828 . . . . 0.0 109.766 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.484 ' CB ' ' O ' ' A' ' 15' ' ' GLU . 2.5 t 74.91 12.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.131 -0.98 . . . . 0.0 109.241 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.4 163.83 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.672 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.21 -44.11 3.03 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.148 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.414 ' O ' ' C ' ' A' ' 20' ' ' PHE . 33.7 m-85 -108.28 78.67 1.19 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.319 -0.863 . . . . 0.0 109.235 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.501 ' CD2' ' HB3' ' A' ' 71' ' ' ALA . 26.4 t80 -42.73 125.84 3.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.272 -0.893 . . . . 0.0 109.565 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -179.69 -66.39 0.07 OUTLIER Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.45 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 7.1 mtt180 -116.71 15.92 15.39 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.211 -1.17 . . . . 0.0 109.654 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -44.55 104.8 0.4 Allowed Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.917 . . . . 0.0 109.491 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.49 43.14 1.47 Allowed 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.692 2.261 . . . . 0.0 110.794 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 14.8 m-85 -159.91 70.45 0.44 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.118 -0.989 . . . . 0.0 109.096 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -79.72 129.35 34.4 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.253 -0.904 . . . . 0.0 109.781 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 3.2 ttt -103.64 102.68 12.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.887 . . . . 0.0 109.162 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.1 mm -90.41 116.76 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.098 -1.001 . . . . 0.0 109.552 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.456 ' CG1' HG21 ' A' ' 36' ' ' ILE . 3.9 t -118.96 160.17 19.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.705 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.481 ' HB3' ' CB ' ' A' ' 38' ' ' SER . 0.1 OUTLIER -139.18 84.6 2.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -0.866 . . . . 0.0 109.337 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 22.2 ttm -93.58 140.32 29.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.24 -0.912 . . . . 0.0 109.539 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . 0.479 ' HG2' ' N ' ' A' ' 33' ' ' LYS . 14.7 ttpp -83.61 -84.98 0.13 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -0.872 . . . . 0.0 109.495 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.479 ' N ' ' HG2' ' A' ' 32' ' ' LYS . 0.0 OUTLIER -131.38 40.31 3.44 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.265 -0.897 . . . . 0.0 109.622 -179.826 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.404 ' HA2' HG22 ' A' ' 105' ' ' THR . . . 119.96 24.93 2.65 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 68.6 m-80 -150.05 105.97 3.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.282 -1.128 . . . . 0.0 109.349 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.456 HG21 ' CG1' ' A' ' 29' ' ' VAL . 1.4 mp -66.48 114.75 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.279 -0.888 . . . . 0.0 109.584 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.21 33.06 5.68 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.481 ' CB ' ' HB3' ' A' ' 30' ' ' GLU . 0.2 OUTLIER -179.71 110.84 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.368 -0.832 . . . . 0.0 109.363 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -138.24 108.84 6.57 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.546 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -126.26 134.12 51.26 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.386 -0.821 . . . . 0.0 109.478 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.21 137.71 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.294 -0.879 . . . . 0.0 109.294 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.445 HG23 ' O ' ' A' ' 42' ' ' ILE . 0.8 OUTLIER -136.81 107.53 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.272 -0.892 . . . . 0.0 109.468 -179.935 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -74.59 171.66 13.44 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.382 -0.824 . . . . 0.0 109.409 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.29 -0.881 . . . . 0.0 109.556 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.436 ' O ' HG21 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.514 HD12 ' CB ' ' A' ' 78' ' ' ALA . 0.9 OUTLIER -74.98 -14.64 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.274 -1.133 . . . . 0.0 109.365 179.871 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.73 -13.68 61.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.861 . . . . 0.0 109.296 179.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.436 HG21 ' O ' ' A' ' 54' ' ' GLY . 9.2 t -65.78 -25.04 67.07 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.199 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.49 ' HB2' ' CD1' ' A' ' 82' ' ' LEU . . . -53.8 -42.73 68.66 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.375 -0.828 . . . . 0.0 109.527 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -58.98 -35.08 72.6 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.232 -0.918 . . . . 0.0 109.417 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 28.3 mt -72.79 -33.86 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.296 -0.877 . . . . 0.0 109.403 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.507 HG22 ' CG2' ' A' ' 66' ' ' VAL . 38.3 mt -63.19 -40.56 89.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.242 -0.911 . . . . 0.0 109.298 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.98 -23.86 67.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.207 -0.933 . . . . 0.0 109.37 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -75.15 -21.95 58.46 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 0.0 109.543 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.8 m-20 -80.16 -17.57 52.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.514 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 115.7 -15.28 17.03 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.507 ' CG2' HG22 ' A' ' 61' ' ' ILE . 57.3 t -44.4 93.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.399 -1.059 . . . . 0.0 109.806 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -79.5 -9.36 59.6 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.221 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -139.9 126.66 20.61 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.344 -0.847 . . . . 0.0 109.153 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.462 HG23 ' CG1' ' A' ' 66' ' ' VAL . 97.6 t -119.21 126.4 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.165 -0.96 . . . . 0.0 109.694 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 57.7 mt -100.33 117.47 45.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.354 -0.841 . . . . 0.0 109.349 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.501 ' HB3' ' CD2' ' A' ' 20' ' ' PHE . . . -148.25 174.51 11.93 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -0.917 . . . . 0.0 109.706 -179.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.402 ' HB3' ' HB2' ' A' ' 92' ' ' ALA . 53.7 p -143.26 40.87 1.48 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.365 -0.835 . . . . 0.0 109.373 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' SER . . . . . 0.405 ' HB2' ' HD2' ' A' ' 74' ' ' PRO . 11.4 p -51.97 159.14 1.49 Allowed Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.606 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.405 ' HD2' ' HB2' ' A' ' 73' ' ' SER . 35.1 Cg_endo -77.57 -31.05 3.56 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.609 2.206 . . . . 0.0 110.541 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -118.06 163.71 12.87 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.57 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.5 Cg_endo -79.96 17.21 1.34 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.831 2.354 . . . . 0.0 111.006 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -63.1 -52.06 64.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.949 -1.095 . . . . 0.0 109.742 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.514 ' CB ' HD12 ' A' ' 55' ' ' ILE . . . -61.77 -37.63 85.03 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.774 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.57 ' CD2' ' HA ' ' A' ' 76' ' ' PRO . 4.0 m-30 -66.17 -29.03 69.23 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.606 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -71.83 -41.5 68.12 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.167 -0.958 . . . . 0.0 109.566 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.6 t -66.78 -50.42 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.165 -0.959 . . . . 0.0 109.652 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.49 ' CD1' ' HB2' ' A' ' 58' ' ' ALA . 2.3 mp -66.77 -27.45 67.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.232 -0.917 . . . . 0.0 109.468 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -65.78 -47.32 75.58 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.216 -0.927 . . . . 0.0 109.245 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -68.25 -31.61 71.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.31 -0.869 . . . . 0.0 109.26 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.447 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.4 OUTLIER -66.92 -25.96 66.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 179.894 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 93.69 22.58 25.78 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.447 HG12 ' HB3' ' A' ' 85' ' ' LEU . 5.9 mm -101.34 163.0 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.238 -1.154 . . . . 0.0 109.456 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.412 ' CG ' ' O ' ' A' ' 113' ' ' ARG . 12.5 mttm -93.7 133.03 37.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.401 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.485 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 2.0 mt -113.49 135.83 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.19 -0.944 . . . . 0.0 109.546 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.478 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 21.5 m-85 -124.56 151.25 44.97 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.505 -0.747 . . . . 0.0 109.365 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.462 ' O ' ' HG ' ' A' ' 109' ' ' LEU . 6.9 ttt-85 -83.46 152.86 24.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.229 -0.919 . . . . 0.0 109.701 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.434 ' HA ' ' CD2' ' A' ' 109' ' ' LEU . . . -106.04 158.91 16.46 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.235 -0.915 . . . . 0.0 109.305 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.63 7.35 46.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.167 -0.958 . . . . 0.0 109.589 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 47.96 72.01 0.49 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.6 m -150.64 -61.61 0.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.308 -1.113 . . . . 0.0 109.356 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.466 ' HA ' ' O ' ' A' ' 14' ' ' SER . 66.4 m -165.98 123.11 1.4 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.233 -0.917 . . . . 0.0 109.525 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.483 HG22 ' N ' ' A' ' 98' ' ' GLU . 27.2 m -65.62 -43.92 93.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.237 -0.914 . . . . 0.0 109.378 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . 0.483 ' N ' HG22 ' A' ' 97' ' ' VAL . 0.2 OUTLIER -45.15 -44.06 10.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.229 -0.919 . . . . 0.0 109.406 179.941 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.437 ' HG3' ' CD1' ' A' ' 103' ' ' LEU . 38.7 tp10 -73.92 -46.83 41.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.275 -0.891 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.437 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 2.2 m-80 -47.55 -26.21 1.36 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.938 . . . . 0.0 109.336 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.448 HD11 HG12 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -59.09 -57.03 14.88 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -0.919 . . . . 0.0 109.291 179.867 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.04 -27.61 68.92 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.238 -0.914 . . . . 0.0 109.327 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.44 HD22 ' HB3' ' A' ' 108' ' ' ASN . 0.8 OUTLIER -63.65 -35.08 79.34 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.372 -0.83 . . . . 0.0 109.534 179.984 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.572 ' CE2' HG12 ' A' ' 3' ' ' ILE . 6.1 t80 -63.79 -27.03 68.91 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.193 -0.942 . . . . 0.0 109.608 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.404 HG22 ' HA2' ' A' ' 34' ' ' GLY . 90.8 m -74.49 -19.93 60.18 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.189 -0.945 . . . . 0.0 109.484 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -106.17 8.19 31.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.202 -0.936 . . . . 0.0 109.515 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 52.53 40.73 55.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . 0.44 ' HB3' HD22 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -83.59 -43.24 15.86 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.328 -1.101 . . . . 0.0 109.498 -179.883 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.462 ' HG ' ' O ' ' A' ' 91' ' ' ARG . 1.5 tp -96.45 147.54 23.73 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.32 -0.863 . . . . 0.0 109.292 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.426 ' HG3' ' O ' ' A' ' 109' ' ' LEU . 3.4 mt-10 -176.52 -177.75 0.86 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.091 -1.005 . . . . 0.0 109.862 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.485 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 1.1 tp10 -177.35 -111.88 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.468 -0.77 . . . . 0.0 109.067 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.515 ' CD1' ' HB3' ' A' ' 79' ' ' PHE . 8.0 mt -79.74 121.53 33.21 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 O-C-N 121.177 -0.952 . . . . 0.0 109.367 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.412 ' O ' ' CG ' ' A' ' 88' ' ' LYS . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.171 -0.955 . . . . 0.0 109.384 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.3 mmt . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.576 ' CD ' ' N ' ' A' ' 2' ' ' LYS . 0.0 OUTLIER -90.44 133.88 34.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.252 -0.905 . . . . 0.0 109.158 179.915 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.456 ' HB ' HG13 ' A' ' 29' ' ' VAL . 9.4 mm -101.29 104.33 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.338 -0.851 . . . . 0.0 110.207 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -110.23 88.46 2.77 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.5 ' CD1' HG21 ' A' ' 70' ' ' ILE . 9.5 tt -98.81 133.11 42.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.239 -0.913 . . . . 0.0 110.014 -179.142 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -57.72 156.64 8.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.354 -0.841 . . . . 0.0 109.081 179.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.421 ' OG ' ' O ' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -159.97 178.96 9.19 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.092 -1.005 . . . . 0.0 109.798 -179.873 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.538 ' C ' ' CD2' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -126.73 23.49 6.71 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.386 -0.821 . . . . 0.0 109.189 179.921 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.471 ' HA2' ' CD1' ' A' ' 25' ' ' TYR . . . 153.08 -151.51 23.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.441 HG23 HG23 ' A' ' 41' ' ' VAL . 16.1 p -124.97 101.94 7.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.185 -1.185 . . . . 0.0 109.353 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 53.9 -154.03 0.26 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.282 -0.886 . . . . 0.0 109.327 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER 60.05 17.96 7.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.27 -0.894 . . . . 0.0 109.576 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 118.85 26.06 2.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' HG22 ' A' ' 97' ' ' VAL . 4.0 m -73.59 83.46 1.54 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.301 -1.117 . . . . 0.0 109.281 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.432 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.4 OUTLIER -79.4 38.81 0.38 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.435 -0.79 . . . . 0.0 110.62 -179.967 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.432 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 21.2 t 63.55 13.08 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 120.716 -1.24 . . . . 0.0 109.413 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 65.78 177.97 0.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.226 -0.921 . . . . 0.0 109.493 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 7.5 ttt180 -120.26 7.13 10.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.184 -0.947 . . . . 0.0 109.596 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -144.02 165.9 26.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.42 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.591 ' CD2' ' CB ' ' A' ' 71' ' ' ALA . 2.3 t80 -132.68 88.81 2.56 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 109.392 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 158.85 -53.49 0.38 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.459 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 5.6 mtp180 -93.58 -19.95 20.69 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.265 -1.138 . . . . 0.0 109.67 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.53 110.24 2.12 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.183 -0.948 . . . . 0.0 109.525 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.486 ' HA ' ' CB ' ' A' ' 44' ' ' ASN . 36.9 Cg_endo -81.29 51.56 3.95 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.614 2.21 . . . . 0.0 110.715 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.538 ' CD2' ' C ' ' A' ' 8' ' ' SER . 4.9 m-85 -159.1 68.91 0.45 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.99 -1.069 . . . . 0.0 109.555 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -84.31 127.05 33.74 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.911 . . . . 0.0 109.189 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' MET . . . . . 0.419 ' HE2' ' HA ' ' A' ' 10' ' ' THR . 1.7 mtt -100.85 121.98 42.64 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.817 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.515 ' CD1' HG11 ' A' ' 66' ' ' VAL . 1.1 tp -121.36 132.2 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.357 -0.839 . . . . 0.0 109.06 179.622 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.456 HG13 ' HB ' ' A' ' 3' ' ' ILE . 14.1 p -138.89 133.41 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.221 -0.924 . . . . 0.0 109.538 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.433 ' HG2' ' N ' ' A' ' 31' ' ' MET . 3.4 tt0 -103.41 138.69 39.81 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.246 -0.909 . . . . 0.0 109.461 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.433 ' N ' ' HG2' ' A' ' 30' ' ' GLU . 11.4 ptp -130.4 153.65 48.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 109.381 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.57 -76.88 0.44 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.235 -0.915 . . . . 0.0 109.688 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.34 -73.17 0.67 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.123 -0.985 . . . . 0.0 109.646 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -142.68 26.6 2.24 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -140.36 99.52 3.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -1.16 . . . . 0.0 109.571 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.42 HG22 ' HB3' ' A' ' 31' ' ' MET . 7.2 pt -50.1 129.38 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.24 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -113.43 0.38 14.72 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.159 -0.963 . . . . 0.0 109.817 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.45 ' O ' HG21 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -156.41 110.34 2.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.031 -1.043 . . . . 0.0 110.007 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.435 ' CA ' HG21 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -120.63 100.22 7.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.313 -0.867 . . . . 0.0 108.901 179.335 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -108.05 159.46 16.55 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.188 -0.945 . . . . 0.0 109.912 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.441 HG23 HG23 ' A' ' 10' ' ' THR . 2.8 t -129.29 122.48 56.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.373 -0.83 . . . . 0.0 109.141 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.44 HG23 ' N ' ' A' ' 43' ' ' GLU . 3.3 mp -111.74 142.48 24.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.184 -0.947 . . . . 0.0 109.582 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.44 ' N ' HG23 ' A' ' 42' ' ' ILE . 5.2 mt-10 -87.95 158.09 18.76 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 0.0 109.304 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.486 ' CB ' ' HA ' ' A' ' 24' ' ' PRO . 4.0 t-20 . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.217 -0.927 . . . . 0.0 109.506 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.441 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 30.2 mm -76.02 -17.97 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.287 -1.125 . . . . 0.0 109.328 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -76.39 -16.13 59.79 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.32 -0.862 . . . . 0.0 109.307 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.441 HG22 ' O ' ' A' ' 54' ' ' GLY . 11.9 t -72.61 -24.62 61.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.282 -0.887 . . . . 0.0 109.47 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -59.65 -36.62 76.76 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.115 -0.99 . . . . 0.0 109.268 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -71.45 -23.01 61.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.294 -0.879 . . . . 0.0 109.523 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.7 mm -76.84 -54.65 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.476 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -66.79 -27.57 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.254 -0.904 . . . . 0.0 109.544 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.513 ' HB1' ' CD2' ' A' ' 85' ' ' LEU . . . -65.98 -34.07 77.26 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.183 -0.948 . . . . 0.0 109.572 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -77.03 -10.17 59.19 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 109.624 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.1 m-20 -83.61 -12.62 55.81 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.264 -0.898 . . . . 0.0 109.591 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.415 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 97.31 0.89 59.48 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.515 HG11 ' CD1' ' A' ' 28' ' ' ILE . 32.8 m -48.03 98.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.181 -1.188 . . . . 0.0 109.761 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.415 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -78.53 -11.2 59.95 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 178.951 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -139.8 126.31 20.34 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 71.4 t -126.16 124.79 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.981 -1.074 . . . . 0.0 109.755 -179.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.5 HG21 ' CD1' ' A' ' 5' ' ' ILE . 4.2 mp -104.18 96.86 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.199 -0.938 . . . . 0.0 109.314 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.591 ' CB ' ' CD2' ' A' ' 20' ' ' PHE . . . -130.1 172.36 11.85 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.401 -0.812 . . . . 0.0 109.473 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.424 ' O ' ' C ' ' A' ' 73' ' ' SER . 0.2 OUTLIER -138.64 34.22 2.23 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.29 -0.881 . . . . 0.0 109.555 -179.881 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -44.57 153.06 0.48 Allowed Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.221 -0.924 . . . . 0.0 109.315 179.914 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.23 -47.38 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.605 2.203 . . . . 0.0 110.335 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.405 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -84.67 141.55 19.62 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.405 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.6 Cg_endo -78.45 -0.68 10.93 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.501 2.134 . . . . 0.0 110.347 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -60.56 -32.51 71.57 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.308 -0.87 . . . . 0.0 109.522 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.04 -54.24 14.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.22 -0.925 . . . . 0.0 109.521 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.405 ' O ' HD13 ' A' ' 89' ' ' ILE . 11.3 m-30 -54.64 -24.2 20.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.247 -0.908 . . . . 0.0 109.738 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -72.43 -37.34 68.63 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.156 -0.965 . . . . 0.0 109.723 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 75.4 t -76.1 -36.23 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.219 -0.926 . . . . 0.0 109.77 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.523 ' CB ' HG12 ' A' ' 89' ' ' ILE . 0.7 OUTLIER -62.01 -36.58 81.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.599 -179.85 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -73.51 -24.53 60.17 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.236 -0.915 . . . . 0.0 109.46 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -76.78 -33.41 58.04 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.233 -0.917 . . . . 0.0 109.526 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.513 ' CD2' ' HB1' ' A' ' 62' ' ' ALA . 0.5 OUTLIER -77.52 -23.65 50.14 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.135 -0.978 . . . . 0.0 109.564 -179.86 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.5 21.59 14.42 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.483 HG21 ' N ' ' A' ' 88' ' ' LYS . 7.7 mt -98.83 158.33 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.257 -1.143 . . . . 0.0 109.381 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.483 ' N ' HG21 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -90.76 128.58 36.73 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.15 -0.969 . . . . 0.0 109.332 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.523 HG12 ' CB ' ' A' ' 82' ' ' LEU . 5.5 mt -98.91 151.22 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.17 -0.956 . . . . 0.0 109.29 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.565 ' CD2' ' O ' ' A' ' 110' ' ' GLU . 0.3 OUTLIER -138.54 141.15 39.3 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.321 -0.862 . . . . 0.0 109.225 -179.708 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.413 ' O ' ' HB3' ' A' ' 110' ' ' GLU . 1.5 tpp85 -92.6 128.56 38.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.939 . . . . 0.0 109.782 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.44 121.46 25.75 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.326 -0.859 . . . . 0.0 109.486 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.12 -27.89 61.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.309 -0.87 . . . . 0.0 109.505 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 97.06 61.21 0.94 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -130.51 -60.72 0.98 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.192 -1.181 . . . . 0.0 109.451 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -173.34 150.39 1.86 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.291 -0.881 . . . . 0.0 109.543 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.465 HG22 ' HB3' ' A' ' 14' ' ' SER . 4.0 m -72.16 -34.17 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.582 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -65.39 -53.29 45.46 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.474 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 0.3 OUTLIER -58.3 -45.04 88.71 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.329 -0.857 . . . . 0.0 109.709 -179.921 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -61.18 -30.27 70.31 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.205 -0.934 . . . . 0.0 109.847 -179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.413 HD23 HD13 ' A' ' 36' ' ' ILE . 31.7 tp -63.07 -56.51 16.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.176 -0.953 . . . . 0.0 109.648 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . 0.423 ' HG2' ' O ' ' A' ' 102' ' ' LYS . 0.0 OUTLIER -73.86 -11.91 60.51 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.146 -0.972 . . . . 0.0 109.5 -179.906 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.474 ' HB2' ' O ' ' A' ' 99' ' ' GLU . 0.3 OUTLIER -76.17 -45.31 34.03 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.232 -0.917 . . . . 0.0 109.497 -179.91 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.551 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 3.5 t80 -76.57 -26.31 54.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.344 -0.847 . . . . 0.0 109.49 -179.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 17.7 m -61.4 -33.59 73.94 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.229 -0.919 . . . . 0.0 109.676 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -103.43 8.94 37.95 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.104 -0.997 . . . . 0.0 109.575 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.29 59.13 10.51 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . 0.465 ' HB3' ' HG ' ' A' ' 103' ' ' LEU . 48.2 t-20 -81.18 -38.77 26.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.38 -1.071 . . . . 0.0 109.564 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.472 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.0 OUTLIER 171.0 -156.77 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.162 -0.961 . . . . 0.0 109.735 -179.942 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.565 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 23.2 mt-10 60.59 29.82 19.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.865 . . . . 0.0 109.259 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.564 ' HA ' ' CE1' ' A' ' 90' ' ' TYR . 1.0 OUTLIER -92.44 144.74 25.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.319 -0.863 . . . . 0.0 109.675 -179.823 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.476 HG12 ' O ' ' A' ' 111' ' ' GLU . 9.2 mm -155.67 125.62 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.477 -0.764 . . . . 0.0 109.15 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 0.0 109.353 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.445 ' O ' ' HE3' ' A' ' 2' ' ' LYS . 21.0 ttm . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.357 0.599 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.445 ' HE3' ' O ' ' A' ' 1' ' ' MET . 0.1 OUTLIER -143.44 106.9 4.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.203 -0.935 . . . . 0.0 109.413 -179.996 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.526 HD11 ' CE1' ' A' ' 104' ' ' PHE . 2.3 mp -107.68 114.77 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.336 -0.853 . . . . 0.0 109.414 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.57 ' HB3' ' CZ ' ' A' ' 26' ' ' PHE . . . -113.24 122.07 46.36 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.235 -0.915 . . . . 0.0 109.347 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.461 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 2.8 mp -96.93 129.22 47.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.174 -0.954 . . . . 0.0 109.568 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.429 ' O ' ' HB3' ' A' ' 7' ' ' SER . . . -68.93 146.86 52.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.257 -0.902 . . . . 0.0 109.272 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.429 ' HB3' ' O ' ' A' ' 6' ' ' ALA . 13.3 t 60.05 -94.5 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 0.0 109.426 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.465 ' O ' ' HB3' ' A' ' 14' ' ' SER . 8.7 t 63.45 31.42 14.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.161 -0.962 . . . . 0.0 109.772 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 42.53 -105.57 0.07 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -158.7 -46.44 0.06 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.251 -1.146 . . . . 0.0 109.411 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.86 -72.89 0.35 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.185 -0.947 . . . . 0.0 109.637 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 31.6 mt -107.09 -14.7 14.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.202 -0.936 . . . . 0.0 109.572 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.21 6.12 64.73 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 8' ' ' SER . 93.9 p -77.68 77.16 4.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -1.137 . . . . 0.0 109.673 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.532 ' O ' ' CG1' ' A' ' 16' ' ' VAL . 0.1 OUTLIER -77.81 78.49 4.31 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.235 -0.916 . . . . 0.0 109.456 179.881 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.532 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 11.6 p 41.1 42.31 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.427 -0.795 . . . . 0.0 109.839 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.438 ' OG ' ' C ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER 59.97 -163.54 0.24 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.249 -0.907 . . . . 0.0 109.486 -179.959 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -170.27 -36.32 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.258 -0.901 . . . . 0.0 109.373 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -148.16 140.06 23.94 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.33 -0.856 . . . . 0.0 109.471 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.428 ' CG ' ' O ' ' A' ' 20' ' ' PHE . 12.9 t80 -116.1 38.45 3.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.252 -0.905 . . . . 0.0 109.733 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -93.94 -56.76 1.37 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.447 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 18.9 mtt180 -140.16 41.74 1.94 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.29 -1.124 . . . . 0.0 109.111 179.747 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -52.3 108.8 1.17 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.41 -0.806 . . . . 0.0 109.744 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.466 ' O ' ' HB3' ' A' ' 43' ' ' GLU . 36.7 Cg_endo -80.83 40.9 1.05 Allowed 'Trans proline' 0 C--N 1.312 -1.374 0 C-N-CA 122.561 2.174 . . . . 0.0 110.434 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.422 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 6.2 m-85 -161.11 74.74 0.5 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.143 -0.973 . . . . 0.0 108.909 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.57 ' CZ ' ' HB3' ' A' ' 4' ' ' ALA . 16.5 t80 -78.26 112.52 15.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.433 -0.792 . . . . 0.0 109.496 -179.439 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 1.6 ttm -94.12 114.48 26.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.455 -0.778 . . . . 0.0 109.31 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.448 HG22 ' O ' ' A' ' 28' ' ' ILE . 0.3 OUTLIER -106.62 123.88 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.283 -0.886 . . . . 0.0 109.488 -179.869 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.505 ' CG1' HG23 ' A' ' 36' ' ' ILE . 2.1 t -121.74 120.64 62.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.912 . . . . 0.0 109.636 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -116.95 96.81 5.63 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 21.1 ptp -87.26 167.24 14.27 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.919 . . . . 0.0 109.358 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.58 -93.62 0.15 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.259 -0.9 . . . . 0.0 109.552 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.62 35.59 3.78 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.232 -0.917 . . . . 0.0 109.485 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 120.7 21.66 3.21 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 12.4 t30 -141.04 109.45 5.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.175 -1.191 . . . . 0.0 109.381 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.505 HG23 ' CG1' ' A' ' 29' ' ' VAL . 4.5 mt -63.25 114.12 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 109.631 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -123.03 28.55 7.14 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.265 -0.897 . . . . 0.0 109.27 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -172.96 96.12 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.324 -0.86 . . . . 0.0 109.434 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.1 m -125.99 103.5 7.78 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.276 -0.89 . . . . 0.0 109.147 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -114.52 142.58 46.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.255 -0.903 . . . . 0.0 110.046 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 t -116.72 96.21 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.415 -0.803 . . . . 0.0 108.955 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 13.6 mt -121.21 126.8 75.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 0.0 109.812 -179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.466 ' HB3' ' O ' ' A' ' 24' ' ' PRO . 0.0 OUTLIER -53.65 148.59 9.46 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.353 -0.842 . . . . 0.0 109.582 179.847 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.8 m120 . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.179 -0.951 . . . . 0.0 109.218 179.746 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.428 ' O ' ' CG2' ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.491 2.313 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 22.9 mm -75.61 -20.05 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.252 -1.146 . . . . 0.0 109.6 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -69.87 -25.58 63.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.323 -0.861 . . . . 0.0 109.505 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.428 ' CG2' ' O ' ' A' ' 54' ' ' GLY . 11.2 t -56.48 -25.86 52.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.561 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.448 ' O ' ' HB ' ' A' ' 61' ' ' ILE . . . -45.27 -41.84 8.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.183 -0.948 . . . . 0.0 109.356 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.82 -56.12 15.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.307 -0.871 . . . . 0.0 109.552 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.409 ' O ' HG21 ' A' ' 60' ' ' ILE . 44.6 mt -54.97 -33.74 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.231 -0.918 . . . . 0.0 109.38 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.448 ' HB ' ' O ' ' A' ' 58' ' ' ALA . 22.9 mm -59.73 -52.72 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.245 -0.909 . . . . 0.0 109.579 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.419 ' HA ' HD11 ' A' ' 87' ' ' ILE . . . -64.18 -21.52 66.59 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.277 -0.889 . . . . 0.0 109.739 -179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.96 -23.26 55.35 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -0.924 . . . . 0.0 109.656 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -83.83 -16.91 42.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.125 -0.985 . . . . 0.0 109.703 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 98.37 -2.09 59.09 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.402 ' C ' ' O ' ' A' ' 65' ' ' GLY . 3.7 t -42.37 97.87 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.315 -1.109 . . . . 0.0 109.773 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.469 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -79.22 -9.97 59.7 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.081 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.441 ' HB2' ' HA ' ' A' ' 3' ' ' ILE . . . -135.58 118.51 16.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.48 -0.763 . . . . 0.0 109.354 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.43 ' CG2' HD22 ' A' ' 82' ' ' LEU . 59.3 t -111.6 119.92 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.24 -0.913 . . . . 0.0 109.63 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.48 HG21 ' ND2' ' A' ' 100' ' ' ASN . 4.4 mm -102.69 117.12 47.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.149 -0.969 . . . . 0.0 109.551 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -160.03 171.77 18.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.745 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 37.4 t -133.71 42.98 2.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.354 -0.841 . . . . 0.0 109.278 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' SER . . . . . 0.416 ' OG ' ' HD2' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -51.81 155.57 2.91 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.42 -0.8 . . . . 0.0 109.83 -179.731 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.416 ' HD2' ' OG ' ' A' ' 73' ' ' SER . 35.2 Cg_endo -78.17 -12.1 15.99 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.725 2.283 . . . . 0.0 110.642 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -148.89 154.23 25.69 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.536 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.4 Cg_endo -79.92 38.81 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.862 2.375 . . . . 0.0 111.017 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.406 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 1.5 t-20 -77.25 -54.52 6.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.966 -1.084 . . . . 0.0 109.675 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -66.15 -38.39 88.0 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 109.644 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.598 ' N ' ' CD1' ' A' ' 79' ' ' PHE . 2.7 m-30 -55.41 -33.79 63.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.931 . . . . 0.0 109.475 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.406 ' HB2' ' O ' ' A' ' 77' ' ' ASN . 16.9 mt-10 -53.19 -55.79 21.52 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.932 . . . . 0.0 109.521 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.4 t -60.89 -39.17 81.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.476 ' CD2' HG13 ' A' ' 89' ' ' ILE . 1.3 tp -52.23 -40.8 62.11 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.396 -0.815 . . . . 0.0 109.935 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -73.98 -36.98 64.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.128 -0.983 . . . . 0.0 109.81 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -66.92 -20.04 65.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.268 -0.895 . . . . 0.0 109.822 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.418 HD23 ' HA ' ' A' ' 85' ' ' LEU . 0.2 OUTLIER -102.98 24.68 10.38 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.16 -0.963 . . . . 0.0 109.716 -179.81 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 51.94 65.2 3.37 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.419 HD11 ' HA ' ' A' ' 62' ' ' ALA . 75.0 mt -141.03 155.55 21.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -1.162 . . . . 0.0 109.299 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 15.6 mttp -101.2 130.89 47.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.126 -0.984 . . . . 0.0 109.839 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.476 HG13 ' CD2' ' A' ' 82' ' ' LEU . 2.2 mp -94.73 160.43 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.338 -0.851 . . . . 0.0 109.425 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.527 ' CE2' ' O ' ' A' ' 109' ' ' LEU . 0.2 OUTLIER -144.51 135.61 25.18 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.336 -0.852 . . . . 0.0 109.394 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.01 139.9 33.96 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.303 -0.873 . . . . 0.0 109.476 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -81.42 112.22 18.48 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -0.903 . . . . 0.0 109.434 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -144.32 16.23 1.68 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.256 -0.902 . . . . 0.0 109.45 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -92.13 -130.45 5.11 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 51.9 m -122.91 -54.87 1.82 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.218 -1.166 . . . . 0.0 109.489 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 2.3 m -127.52 172.09 11.02 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.245 -0.909 . . . . 0.0 109.457 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.419 HG13 ' OG ' ' A' ' 8' ' ' SER . 49.4 t -77.33 -43.82 30.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.319 -0.863 . . . . 0.0 109.612 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.46 -34.79 67.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.26 -0.9 . . . . 0.0 109.551 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -75.85 -59.52 2.72 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.252 -0.905 . . . . 0.0 109.518 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.48 ' ND2' HG21 ' A' ' 70' ' ' ILE . 47.1 t30 -51.02 -22.19 2.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.224 -0.923 . . . . 0.0 109.463 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 24.0 tp -64.18 -69.59 0.27 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.196 -0.94 . . . . 0.0 109.306 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -62.76 -14.82 49.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.335 -0.853 . . . . 0.0 109.458 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -77.0 -32.51 57.26 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 109.619 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.548 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 1.9 t80 -71.28 -31.08 67.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -0.889 . . . . 0.0 109.59 -179.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 51.6 m -74.26 -21.08 59.92 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.045 -1.034 . . . . 0.0 109.99 -179.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.1 mm-40 -92.07 11.86 23.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.064 -1.023 . . . . 0.0 109.514 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 53.06 53.68 32.83 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . 0.466 ' O ' ' HB3' ' A' ' 109' ' ' LEU . 1.6 t-20 -79.88 -63.82 1.33 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.348 -1.089 . . . . 0.0 109.469 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.527 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.6 OUTLIER 177.87 -153.56 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.306 -0.871 . . . . 0.0 109.528 179.989 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.501 ' HG3' ' CD1' ' A' ' 109' ' ' LEU . 79.4 mt-10 62.15 27.9 16.78 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.208 -0.933 . . . . 0.0 109.287 -179.867 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.478 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 7.9 pt-20 -108.7 147.74 31.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.757 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.452 ' O ' HD13 ' A' ' 89' ' ' ILE . 14.4 mt -151.76 128.39 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.323 -0.861 . . . . 0.0 109.193 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.235 -0.916 . . . . 0.0 109.805 -179.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 mtp . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.461 ' O ' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -139.42 140.56 37.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.195 -0.94 . . . . 0.0 109.667 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.512 HD11 ' CD1' ' A' ' 104' ' ' PHE . 5.5 mt -110.41 99.67 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.46 -0.775 . . . . 0.0 109.824 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.517 ' HB3' ' CG1' ' A' ' 66' ' ' VAL . . . -100.07 115.39 29.64 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.337 -0.852 . . . . 0.0 109.08 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 3.4 mp -92.04 142.47 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.217 -0.927 . . . . 0.0 109.756 -179.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.502 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -80.39 171.62 14.83 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.295 -0.878 . . . . 0.0 109.546 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 71.7 m 47.95 -93.02 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.251 -0.906 . . . . 0.0 109.522 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.502 ' N ' ' O ' ' A' ' 6' ' ' ALA . 41.0 t 52.9 25.39 3.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.083 -1.011 . . . . 0.0 109.528 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 44.38 -101.41 0.03 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.59 -67.1 0.19 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.212 -1.17 . . . . 0.0 109.479 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -158.66 -79.41 0.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.156 -0.965 . . . . 0.0 109.592 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.17 -19.82 55.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.147 -0.971 . . . . 0.0 109.515 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -130.68 37.46 2.11 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.6 m -76.49 82.07 3.19 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -1.153 . . . . 0.0 109.254 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.502 ' HG3' ' N ' ' A' ' 16' ' ' VAL . 5.3 pt-20 -77.14 -134.38 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.266 -0.896 . . . . 0.0 109.054 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.512 ' O ' ' CG1' ' A' ' 16' ' ' VAL . 12.2 p -154.45 67.24 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 120.99 -1.069 . . . . 0.0 109.422 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.0 m -52.6 156.94 1.69 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -102.53 12.85 35.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.287 -0.883 . . . . 0.0 109.447 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -107.49 103.54 12.89 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.274 -0.891 . . . . 0.0 109.451 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.419 ' CG ' ' HB3' ' A' ' 71' ' ' ALA . 11.0 t80 -101.79 127.51 48.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.162 -0.961 . . . . 0.0 109.435 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 150.29 -64.49 0.39 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.471 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.6 ttt180 -91.85 -12.44 33.64 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -1.16 . . . . 0.0 109.362 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.573 ' O ' ' CE1' ' A' ' 26' ' ' PHE . . . -41.48 101.82 0.25 Allowed Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.528 -0.732 . . . . 0.0 109.752 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.491 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.8 Cg_endo -80.91 44.23 1.71 Allowed 'Trans proline' 0 C--N 1.311 -1.419 0 C-N-CA 122.653 2.236 . . . . 0.0 110.574 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.491 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 31.6 m-85 -160.07 70.21 0.43 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.015 -1.053 . . . . 0.0 109.641 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.573 ' CE1' ' O ' ' A' ' 23' ' ' ALA . 18.8 m-30 -80.35 111.5 16.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.178 -0.951 . . . . 0.0 109.377 179.704 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 6.3 ttm -90.56 116.67 28.64 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.276 -0.89 . . . . 0.0 109.509 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.436 HD11 ' CB ' ' A' ' 4' ' ' ALA . 7.2 mm -101.99 108.36 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.893 . . . . 0.0 109.437 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.432 HG12 HD13 ' A' ' 36' ' ' ILE . 96.8 t -104.47 142.34 18.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.553 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.467 ' O ' ' OG ' ' A' ' 38' ' ' SER . 32.5 tt0 -137.28 100.87 4.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.329 -0.857 . . . . 0.0 109.53 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 4.5 ptp -95.75 155.22 16.84 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.276 -0.89 . . . . 0.0 109.252 179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 27.4 mmtm -102.26 -46.77 4.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.241 -0.912 . . . . 0.0 109.877 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 34' ' ' GLY . 1.5 ttpp -146.27 92.62 2.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.21 -0.931 . . . . 0.0 109.639 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 43.36 28.2 0.88 Allowed Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -151.06 111.01 4.08 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.205 -1.173 . . . . 0.0 109.387 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.432 HD13 HG12 ' A' ' 29' ' ' VAL . 49.1 mm -56.74 116.91 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.236 -0.915 . . . . 0.0 109.588 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.34 18.54 15.19 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.317 -0.864 . . . . 0.0 109.415 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.467 ' OG ' ' O ' ' A' ' 30' ' ' GLU . 0.7 OUTLIER -174.94 127.52 0.29 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.317 -0.864 . . . . 0.0 109.527 -179.877 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.22 110.94 6.48 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.329 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -125.15 106.34 9.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 109.74 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 p -97.15 124.49 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.24 -0.912 . . . . 0.0 109.247 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.0 pt -122.52 161.02 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.26 -0.9 . . . . 0.0 109.778 -179.656 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -104.0 159.81 15.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.346 -0.846 . . . . 0.0 109.379 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.9 m120 . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.297 -0.877 . . . . 0.0 109.238 179.741 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.8 mt -73.88 -9.18 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.303 -1.116 . . . . 0.0 109.47 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . 0.454 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -69.03 -23.44 64.07 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.211 -0.93 . . . . 0.0 109.532 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.442 ' HA ' HD11 ' A' ' 60' ' ' ILE . 13.0 t -64.29 -14.18 54.36 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.673 -179.795 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -54.25 -46.11 72.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.167 -0.958 . . . . 0.0 109.439 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.455 ' OE1' HD13 ' A' ' 85' ' ' LEU . 0.3 OUTLIER -52.11 -36.77 52.06 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.141 -0.974 . . . . 0.0 109.472 179.976 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.442 HD11 ' HA ' ' A' ' 57' ' ' THR . 6.6 mt -74.81 -33.56 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.266 -0.896 . . . . 0.0 109.609 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 61.0 mt -61.39 -36.69 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.178 -0.951 . . . . 0.0 109.4 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -70.72 -21.68 62.52 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.281 -0.887 . . . . 0.0 109.61 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -75.09 -9.68 58.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.118 -0.989 . . . . 0.0 109.283 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -88.59 -21.83 23.84 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.245 -0.909 . . . . 0.0 109.476 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 120.02 17.66 4.49 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.517 ' CG1' ' HB3' ' A' ' 4' ' ' ALA . 17.9 t -87.16 89.9 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.222 -1.164 . . . . 0.0 109.483 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.3 tttp -79.54 -7.97 58.84 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.364 -0.835 . . . . 0.0 108.984 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 2' ' ' LYS . . . -130.83 113.96 14.73 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.112 -0.993 . . . . 0.0 109.319 179.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.448 HG23 HG13 ' A' ' 66' ' ' VAL . 93.4 t -112.02 123.84 68.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.106 -0.996 . . . . 0.0 109.705 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.495 HD13 ' CG2' ' A' ' 3' ' ' ILE . 80.9 mt -103.14 116.36 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.397 -0.814 . . . . 0.0 109.186 179.766 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.419 ' HB3' ' CG ' ' A' ' 20' ' ' PHE . . . -147.91 175.42 10.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 109.934 -179.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.02 57.36 1.48 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.508 -0.745 . . . . 0.0 109.23 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.2 m -65.18 155.57 83.96 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.199 -0.938 . . . . 0.0 109.614 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.18 -18.8 12.49 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.752 2.301 . . . . 0.0 110.312 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -129.99 162.38 23.01 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.16 9.9 3.18 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.814 2.343 . . . . 0.0 110.755 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -60.9 -55.03 37.82 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.065 -1.022 . . . . 0.0 109.655 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -56.06 -52.33 64.66 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.246 -0.909 . . . . 0.0 109.498 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.561 ' CD1' HG22 ' A' ' 89' ' ' ILE . 12.9 m-30 -53.55 -30.1 40.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.226 -0.921 . . . . 0.0 109.628 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -68.79 -42.51 77.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.276 -0.89 . . . . 0.0 109.632 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.36 -53.09 44.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.184 -0.947 . . . . 0.0 109.478 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.446 HD13 HG12 ' A' ' 89' ' ' ILE . 53.5 mt -59.66 -28.01 66.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.27 -0.894 . . . . 0.0 109.639 -179.765 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.469 ' HB2' ' O ' ' A' ' 79' ' ' PHE . 1.4 t-20 -69.06 -44.81 71.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.94 . . . . 0.0 109.268 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -68.85 -23.58 64.26 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.207 -0.933 . . . . 0.0 109.17 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.455 HD13 ' OE1' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -75.21 -35.39 61.5 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.271 -0.893 . . . . 0.0 109.484 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 101.75 25.01 8.29 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 30.5 mm -105.49 169.9 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.253 -1.145 . . . . 0.0 109.592 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.464 ' HG2' ' HA ' ' A' ' 113' ' ' ARG . 5.4 mttt -93.71 134.91 35.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.285 -0.884 . . . . 0.0 109.536 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.561 HG22 ' CD1' ' A' ' 79' ' ' PHE . 4.3 mt -107.06 142.55 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.287 -0.883 . . . . 0.0 109.464 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.551 ' N ' ' CD1' ' A' ' 90' ' ' TYR . 4.5 m-85 -130.8 148.76 52.62 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.514 -0.741 . . . . 0.0 109.558 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.42 ' HB2' ' CD ' ' A' ' 111' ' ' GLU . 1.1 ttt180 -104.61 128.86 52.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.251 -0.906 . . . . 0.0 109.351 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.49 116.51 32.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.159 -0.963 . . . . 0.0 109.713 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 4.4 m -145.59 21.3 1.49 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.348 -0.845 . . . . 0.0 109.37 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.79 -111.63 0.03 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 1.6 t -142.08 -40.39 0.36 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.236 -1.155 . . . . 0.0 109.803 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 3.1 m -142.6 131.23 22.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.21 -0.931 . . . . 0.0 109.615 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 15' ' ' GLU . 19.9 t -56.18 -19.99 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.308 -0.87 . . . . 0.0 109.307 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -60.37 -64.3 1.0 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.278 -0.889 . . . . 0.0 109.313 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.419 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 4.6 mt-10 -67.21 -24.59 65.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.355 -0.84 . . . . 0.0 109.305 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.453 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 18.1 t-20 -68.19 -29.48 68.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.885 . . . . 0.0 109.427 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 33.2 tp -62.66 -68.67 0.31 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.182 -0.949 . . . . 0.0 109.164 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 10.0 tttp -59.24 -21.94 60.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.204 -0.935 . . . . 0.0 109.149 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.462 HD21 ' HB2' ' A' ' 108' ' ' ASN . 1.5 mt -68.73 -34.92 76.43 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.394 -0.817 . . . . 0.0 109.448 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.536 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.5 t80 -53.94 -30.71 47.8 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.203 -0.936 . . . . 0.0 109.254 179.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 34.9 m -64.19 -39.62 94.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.42 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 0.415 ' OE1' ' HA ' ' A' ' 103' ' ' LEU . 0.7 OUTLIER -82.99 -11.85 57.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.297 -0.877 . . . . 0.0 109.338 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.465 ' HA2' ' OE2' ' A' ' 110' ' ' GLU . . . 65.08 40.31 96.89 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . 0.462 ' HB2' HD21 ' A' ' 103' ' ' LEU . 0.2 OUTLIER -80.9 -12.87 59.33 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -1.153 . . . . 0.0 109.407 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.419 ' C ' ' HG2' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -152.6 111.37 3.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.261 -0.899 . . . . 0.0 109.259 179.867 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.465 ' OE2' ' HA2' ' A' ' 107' ' ' GLY . 5.9 mt-10 -140.97 -149.19 0.26 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.819 -179.662 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.486 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 0.5 OUTLIER -168.63 -114.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.34 -0.85 . . . . 0.0 109.315 -179.794 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.3 mt -87.81 149.56 4.03 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.092 -1.005 . . . . 0.0 109.427 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.464 ' HA ' ' HG2' ' A' ' 88' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.623 0 O-C-N 121.218 -0.926 . . . . 0.0 109.692 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.4 mtp . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.417 ' HG2' ' CG ' ' A' ' 30' ' ' GLU . 0.5 OUTLIER -91.2 142.4 27.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.293 -0.88 . . . . 0.0 109.494 179.994 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.586 ' CG2' ' CD1' ' A' ' 70' ' ' ILE . 4.9 mt -118.67 116.08 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.296 -0.877 . . . . 0.0 109.779 -179.773 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.41 ' HB2' ' CE1' ' A' ' 26' ' ' PHE . . . -114.91 119.73 37.53 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.344 -0.847 . . . . 0.0 109.03 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.519 ' CG2' HG23 ' A' ' 70' ' ' ILE . 8.6 mt -100.68 140.73 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.801 -179.56 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.564 ' HB3' ' CE2' ' A' ' 26' ' ' PHE . . . -106.73 138.49 42.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.279 -0.888 . . . . 0.0 109.141 179.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 39.4 p -163.3 -148.73 0.13 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.215 -0.928 . . . . 0.0 109.524 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.548 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 20.3 t -122.35 -65.35 1.12 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.263 -0.898 . . . . 0.0 109.546 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -59.98 168.34 8.32 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.423 HG22 ' CD1' ' A' ' 25' ' ' TYR . 1.2 p -87.38 -42.27 12.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.209 -1.171 . . . . 0.0 109.512 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -173.81 -40.74 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.193 -0.942 . . . . 0.0 109.709 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.1 mt -84.19 -10.85 57.39 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.156 -0.965 . . . . 0.0 109.629 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -137.91 8.31 3.58 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 79.9 p -77.11 80.17 3.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.184 -1.186 . . . . 0.0 109.467 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.446 ' O ' ' CB ' ' A' ' 16' ' ' VAL . 2.6 pt-20 -76.85 1.68 16.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.255 -0.903 . . . . 0.0 109.702 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.517 HG21 ' N ' ' A' ' 96' ' ' SER . 3.5 t 71.38 73.29 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.13 -0.981 . . . . 0.0 109.655 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.22 -164.46 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.46 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -118.98 26.74 9.31 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.214 -0.929 . . . . 0.0 109.617 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -117.23 115.31 25.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.914 . . . . 0.0 109.604 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.589 ' CG ' ' O ' ' A' ' 20' ' ' PHE . 45.6 t80 -112.44 38.4 2.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.309 -0.869 . . . . 0.0 109.159 179.731 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -99.27 -84.37 1.79 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.468 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.0 OUTLIER -90.21 67.46 6.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -1.144 . . . . 0.0 109.485 -179.946 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -47.1 105.45 0.49 Allowed Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.356 -0.84 . . . . 0.0 109.567 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.549 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.0 Cg_endo -78.73 -3.37 13.22 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.461 2.107 . . . . 0.0 110.365 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.549 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 71.4 m-85 -160.52 72.67 0.48 Allowed 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.177 -0.952 . . . . 0.0 109.235 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.564 ' CE2' ' HB3' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -79.02 114.8 18.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.471 -179.768 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -87.57 114.15 23.91 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.339 -0.851 . . . . 0.0 109.39 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.445 ' O ' HG23 ' A' ' 28' ' ' ILE . 0.5 OUTLIER -102.61 126.73 56.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.261 -0.899 . . . . 0.0 109.594 -179.934 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 69.4 t -124.01 138.44 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.289 -0.882 . . . . 0.0 109.293 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.417 ' CG ' ' HG2' ' A' ' 2' ' ' LYS . 0.5 OUTLIER -124.28 116.8 23.24 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.209 -0.932 . . . . 0.0 109.544 179.938 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.468 ' SD ' ' CD1' ' A' ' 3' ' ' ILE . 4.4 ptp -114.68 141.92 47.17 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 2.7 tttp -84.48 -80.83 0.19 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.285 -0.884 . . . . 0.0 109.455 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 12.4 tppt? -117.12 87.45 2.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.225 -0.922 . . . . 0.0 109.391 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 51.66 26.52 16.82 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -140.8 97.62 3.23 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -1.168 . . . . 0.0 109.559 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.413 ' HA ' ' HB3' ' A' ' 31' ' ' MET . 6.6 tt -49.67 137.12 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.196 -0.94 . . . . 0.0 109.55 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.432 ' C ' ' OG ' ' A' ' 38' ' ' SER . 0.0 OUTLIER -135.54 18.79 3.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.526 179.939 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.432 ' OG ' ' C ' ' A' ' 37' ' ' GLU . 0.0 OUTLIER -178.05 128.79 0.13 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.17 -0.956 . . . . 0.0 109.6 -179.958 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -143.39 111.46 6.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.291 -0.881 . . . . 0.0 109.151 179.696 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -131.01 162.93 28.69 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.242 -0.911 . . . . 0.0 109.799 -179.617 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.8 t -120.45 148.61 23.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.371 -0.831 . . . . 0.0 109.184 179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.404 ' O ' ' HA ' ' A' ' 25' ' ' TYR . 7.1 mt -123.07 129.92 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -108.88 100.12 9.37 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.307 -0.87 . . . . 0.0 109.211 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.273 -0.892 . . . . 0.0 109.617 -179.7 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 47.5 mm -66.15 -14.65 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -1.189 . . . . 0.0 109.525 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.78 -22.87 60.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.256 -0.902 . . . . 0.0 109.433 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.464 ' O ' HG13 ' A' ' 61' ' ' ILE . 21.8 m -55.7 -25.32 39.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 109.533 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.31 -55.65 32.07 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.233 -0.917 . . . . 0.0 109.641 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.69 -37.93 52.81 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 72.9 mt -64.28 -38.01 81.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.29 -0.882 . . . . 0.0 109.655 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.464 HG13 ' O ' ' A' ' 57' ' ' THR . 36.7 mt -72.95 -21.96 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.22 -0.925 . . . . 0.0 109.652 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.454 ' HB1' HD11 ' A' ' 85' ' ' LEU . . . -71.46 -28.66 64.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.165 -0.959 . . . . 0.0 109.487 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -74.78 -2.72 27.83 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.347 -0.845 . . . . 0.0 109.687 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -98.61 -18.25 18.21 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.094 -1.004 . . . . 0.0 109.603 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.521 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 102.8 -9.51 55.33 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 94.0 t -42.61 94.99 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.327 -1.102 . . . . 0.0 109.702 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.521 ' N ' ' O ' ' A' ' 65' ' ' GLY . 24.0 mmtt -79.3 -3.81 47.83 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.379 -0.826 . . . . 0.0 108.863 179.398 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.47 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -139.67 132.29 28.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.274 -0.891 . . . . 0.0 109.449 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 89.8 t -128.66 122.19 56.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.182 -0.949 . . . . 0.0 109.752 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.586 ' CD1' ' CG2' ' A' ' 3' ' ' ILE . 2.1 mp -99.28 116.61 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.226 -0.921 . . . . 0.0 109.245 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -152.46 175.01 13.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.258 -0.901 . . . . 0.0 109.567 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.7 m -137.14 39.66 2.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.428 -0.795 . . . . 0.0 109.288 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.4 m -50.1 134.64 22.64 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.242 -0.911 . . . . 0.0 109.41 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -79.66 -20.72 9.08 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.458 2.106 . . . . 0.0 110.456 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -104.69 149.43 16.91 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.39 -0.33 10.61 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.717 2.278 . . . . 0.0 110.287 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -67.56 -49.88 61.1 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.261 -0.899 . . . . 0.0 109.487 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.447 ' O ' HD22 ' A' ' 82' ' ' LEU . . . -61.28 -53.4 57.21 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.329 -0.857 . . . . 0.0 109.458 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -56.39 -20.3 18.82 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.341 -0.85 . . . . 0.0 109.522 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.425 ' O ' ' HG3' ' A' ' 84' ' ' GLU . 1.2 tp10 -75.27 -45.88 37.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.228 -0.92 . . . . 0.0 109.557 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.428 ' HA ' ' HB2' ' A' ' 84' ' ' GLU . 6.3 t -67.58 -41.71 86.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 0.0 109.587 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.447 HD22 ' O ' ' A' ' 78' ' ' ALA . 4.2 mm? -51.75 -56.93 10.93 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.127 -0.983 . . . . 0.0 109.48 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -65.15 -22.14 66.88 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.881 . . . . 0.0 109.444 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.428 ' HB2' ' HA ' ' A' ' 81' ' ' VAL . 5.1 mt-10 -74.17 -25.75 59.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.265 -0.897 . . . . 0.0 109.403 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.454 HD11 ' HB1' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -88.13 -30.85 19.52 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.224 -0.922 . . . . 0.0 109.488 -179.991 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 104.63 42.58 1.82 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.7 mt -122.66 155.98 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.275 -1.133 . . . . 0.0 109.375 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.515 ' HD2' ' N ' ' A' ' 88' ' ' LYS . 0.0 OUTLIER -81.66 138.22 35.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.167 -0.958 . . . . 0.0 109.521 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 3.0 mt -106.98 155.42 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.208 -0.932 . . . . 0.0 109.539 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.567 ' CZ ' ' CD2' ' A' ' 104' ' ' PHE . 1.0 OUTLIER -133.9 138.84 45.79 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.286 -0.884 . . . . 0.0 109.531 179.97 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.505 ' NE ' ' HA ' ' A' ' 110' ' ' GLU . 1.3 ptt-85 -97.76 113.4 25.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.289 -0.882 . . . . 0.0 109.291 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.76 125.0 29.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.259 -0.9 . . . . 0.0 109.565 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 76.0 p -67.57 -42.12 83.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.259 -0.901 . . . . 0.0 109.433 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 119.73 97.74 1.71 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -168.87 -69.87 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.2 -1.177 . . . . 0.0 109.474 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.517 ' N ' HG21 ' A' ' 16' ' ' VAL . 0.4 OUTLIER -166.64 120.07 1.04 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.194 -0.941 . . . . 0.0 109.493 179.833 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.432 ' CG1' HG21 ' A' ' 5' ' ' ILE . 35.8 m -55.33 -21.47 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 109.589 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -61.48 -51.23 69.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.156 -0.965 . . . . 0.0 109.585 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -77.19 -32.93 56.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.922 . . . . 0.0 109.768 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -60.21 -30.64 69.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.571 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 36.1 tp -68.25 -57.65 5.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.171 -0.955 . . . . 0.0 109.547 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 106' ' ' GLU . 0.0 OUTLIER -62.04 -20.54 64.06 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.224 -0.923 . . . . 0.0 109.518 -179.923 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.44 HD21 ' CB ' ' A' ' 108' ' ' ASN . 0.1 OUTLIER -76.96 -41.29 43.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.131 -0.981 . . . . 0.0 109.701 -179.876 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.567 ' CD2' ' CZ ' ' A' ' 90' ' ' TYR . 4.3 t80 -57.7 -53.8 54.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.197 -0.939 . . . . 0.0 109.312 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' THR . . . . . 0.419 ' OG1' ' HE1' ' A' ' 31' ' ' MET . 9.7 m -67.87 -19.54 65.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.252 -0.905 . . . . 0.0 109.475 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . 0.427 ' CG ' ' O ' ' A' ' 102' ' ' LYS . 4.4 mm-40 -83.44 9.27 11.52 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.337 -0.852 . . . . 0.0 109.302 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 51.66 45.13 54.78 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . 0.481 ' O ' ' HB3' ' A' ' 109' ' ' LEU . 1.9 m120 -79.84 -66.32 0.89 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.306 -1.114 . . . . 0.0 109.498 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.507 ' CD1' ' HG3' ' A' ' 110' ' ' GLU . 0.7 OUTLIER 173.81 -159.83 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.301 -0.875 . . . . 0.0 109.372 -179.906 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.524 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 30.8 mt-10 73.29 30.03 1.6 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.282 -0.886 . . . . 0.0 109.482 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -104.44 147.12 27.92 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -0.913 . . . . 0.0 109.536 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 7.8 mt -142.15 125.21 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.153 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.449 ' HG2' ' HE2' ' A' ' 88' ' ' LYS . 21.6 mtt180 . . . . . 0 N--CA 1.49 1.574 0 O-C-N 121.347 -0.846 . . . . 0.0 109.846 -179.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 121.254 0.55 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 68' ' ' ALA . 12.9 mttt -112.65 144.09 42.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.213 -0.93 . . . . 0.0 109.268 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.572 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.7 mt -121.96 106.78 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.184 -0.948 . . . . 0.0 110.339 -179.404 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.47 ' HB2' HG12 ' A' ' 28' ' ' ILE . . . -106.02 111.54 24.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.302 -0.873 . . . . 0.0 108.706 179.064 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.469 ' CG2' ' HB ' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -100.48 131.86 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.861 -179.379 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -63.56 139.16 58.74 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.303 -0.873 . . . . 0.0 109.113 179.549 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.44 ' HB3' ' O ' ' A' ' 25' ' ' TYR . 17.4 t -126.84 172.99 9.92 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.086 -1.009 . . . . 0.0 109.772 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -122.44 -32.61 3.59 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.408 -0.808 . . . . 0.0 109.266 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.539 ' O ' ' CE2' ' A' ' 25' ' ' TYR . . . -113.98 -82.44 1.1 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -169.67 -62.14 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.288 -1.125 . . . . 0.0 109.589 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -145.33 -55.17 0.31 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.888 . . . . 0.0 109.572 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.1 mt -75.93 -38.77 57.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.227 -0.921 . . . . 0.0 109.645 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.42 17.12 57.24 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 96' ' ' SER . 89.7 p -77.19 78.42 3.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -1.148 . . . . 0.0 109.757 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.464 ' O ' ' CB ' ' A' ' 16' ' ' VAL . 44.2 tt0 -77.25 -0.29 24.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.253 -0.904 . . . . 0.0 109.408 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.464 ' CB ' ' O ' ' A' ' 15' ' ' GLU . 2.5 t 73.73 74.55 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.26 -0.9 . . . . 0.0 109.64 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -46.65 151.7 0.55 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.168 -0.957 . . . . 0.0 109.289 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 3.2 ptm180 -104.92 31.74 4.61 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.927 . . . . 0.0 109.625 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -119.2 115.58 24.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.518 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -91.34 78.02 5.79 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.23 -0.918 . . . . 0.0 109.352 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.61 -20.98 0.71 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.475 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.4 ttm-85 -111.17 -40.31 4.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.368 -1.077 . . . . 0.0 109.28 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.442 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -41.78 101.98 0.26 Allowed Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.533 -0.729 . . . . 0.0 109.643 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.01 41.04 1.05 Allowed 'Trans proline' 0 C--N 1.312 -1.395 0 C-N-CA 122.579 2.186 . . . . 0.0 110.89 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.539 ' CE2' ' O ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -160.39 71.07 0.43 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.98 -1.075 . . . . 0.0 109.448 179.952 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.448 ' CE2' HD12 ' A' ' 61' ' ' ILE . 0.1 OUTLIER -79.5 117.08 20.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.287 -0.883 . . . . 0.0 109.549 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 3.2 ttt -95.62 104.26 16.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.928 . . . . 0.0 109.297 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.47 HG12 ' HB2' ' A' ' 4' ' ' ALA . 27.2 mt -100.83 126.13 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.266 -0.896 . . . . 0.0 109.709 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 38' ' ' SER . 90.5 t -123.95 117.82 52.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.298 -0.876 . . . . 0.0 109.349 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -83.92 115.97 22.56 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.221 -0.925 . . . . 0.0 109.622 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.428 ' HG2' ' HA ' ' A' ' 36' ' ' ILE . 0.3 OUTLIER -96.88 138.76 33.94 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.268 -0.895 . . . . 0.0 109.514 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 1.2 tptp -96.76 -62.45 1.26 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.889 . . . . 0.0 109.326 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . 0.401 ' O ' ' C ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -139.88 89.45 2.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.161 179.725 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 45.66 30.41 3.34 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -150.52 114.42 5.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -1.126 . . . . 0.0 109.555 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.428 ' HA ' ' HG2' ' A' ' 31' ' ' MET . 2.1 mp -54.14 132.4 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.164 -0.96 . . . . 0.0 109.41 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -133.28 12.82 4.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.255 -0.903 . . . . 0.0 109.375 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.456 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 0.3 OUTLIER -174.28 116.87 0.21 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 109.502 -179.981 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.5 p -129.73 104.23 7.29 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.536 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -122.91 139.59 53.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.392 -0.818 . . . . 0.0 109.375 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 73.9 t -114.11 119.31 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.531 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.4 mt -118.28 143.03 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.364 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 44' ' ' ASN . 29.6 mp0 -86.1 118.91 25.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.15 -0.969 . . . . 0.0 109.391 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.414 ' C ' ' O ' ' A' ' 43' ' ' GLU . 2.0 t30 . . . . . 0 N--CA 1.49 1.574 0 O-C-N 121.244 -0.91 . . . . 0.0 109.365 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.461 ' O ' HG23 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.3 mm -76.58 -14.95 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.27 -1.135 . . . . 0.0 109.573 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -58.46 -17.63 22.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.227 -0.921 . . . . 0.0 109.662 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.461 HG23 ' O ' ' A' ' 54' ' ' GLY . 6.0 t -63.38 -37.74 88.43 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.171 -0.956 . . . . 0.0 109.812 -179.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.458 ' N ' HG22 ' A' ' 57' ' ' THR . . . -45.42 -34.51 3.15 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.176 -0.953 . . . . 0.0 109.817 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -61.29 -64.59 0.9 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.237 -0.914 . . . . 0.0 109.847 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 57' ' ' THR . 0.9 OUTLIER -58.8 -18.41 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.245 -0.91 . . . . 0.0 109.926 -179.593 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.459 ' O ' HG22 ' A' ' 66' ' ' VAL . 19.3 mm -75.56 -36.38 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.688 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.462 ' HB1' HD12 ' A' ' 87' ' ' ILE . . . -73.38 -28.37 61.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.225 -0.922 . . . . 0.0 109.757 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -77.25 -9.81 59.03 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.087 -1.008 . . . . 0.0 109.906 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.45 ' HB2' HG22 ' A' ' 66' ' ' VAL . 57.9 m-20 -88.13 7.65 30.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.108 -0.995 . . . . 0.0 109.629 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 69.24 10.67 62.92 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.464 HG12 ' HB3' ' A' ' 4' ' ' ALA . 2.0 t -67.65 89.54 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.198 -1.178 . . . . 0.0 109.415 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.448 ' O ' ' HG3' ' A' ' 88' ' ' LYS . 0.5 OUTLIER -79.6 -7.4 58.51 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.348 -0.845 . . . . 0.0 108.92 179.648 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 3' ' ' ILE . . . -137.53 103.64 5.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.19 -0.944 . . . . 0.0 109.273 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.462 HG23 ' CG1' ' A' ' 66' ' ' VAL . 56.9 t -112.01 132.1 61.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.054 -1.029 . . . . 0.0 109.817 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.497 ' CD1' HG22 ' A' ' 3' ' ' ILE . 3.2 mp -104.61 112.76 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.352 -0.843 . . . . 0.0 109.199 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -149.61 -178.04 6.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.22 -0.925 . . . . 0.0 109.979 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -146.12 46.89 1.24 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.642 -0.661 . . . . 0.0 109.524 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' SER . . . . . 0.553 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 2.6 p -45.49 151.94 0.72 Allowed Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.224 -0.922 . . . . 0.0 109.624 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.84 -25.99 7.18 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.719 2.279 . . . . 0.0 110.615 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -121.73 152.22 16.86 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.17 -16.57 13.88 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.602 2.202 . . . . 0.0 110.483 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -46.94 -47.06 21.81 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.922 . . . . 0.0 109.619 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -67.51 -34.98 78.22 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.256 -0.903 . . . . 0.0 109.628 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.553 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 8.7 m-30 -71.59 -17.16 62.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.632 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.435 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 4.3 mm-40 -73.24 -42.92 61.99 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.124 -0.985 . . . . 0.0 108.967 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.3 t -76.63 -30.05 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.435 -0.79 . . . . 0.0 109.254 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.512 ' N ' HD12 ' A' ' 82' ' ' LEU . 4.8 mp -61.54 -56.29 21.59 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.354 -0.841 . . . . 0.0 109.575 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.435 ' OD1' ' O ' ' A' ' 80' ' ' GLU . 9.6 p-10 -69.64 -14.12 62.66 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.293 -0.879 . . . . 0.0 109.578 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -76.98 -36.34 56.52 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.284 -0.885 . . . . 0.0 109.606 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.438 ' HB2' HD12 ' A' ' 87' ' ' ILE . 73.8 mt -86.0 12.38 9.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.189 -0.945 . . . . 0.0 109.669 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 80.99 8.71 87.14 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.462 HD12 ' HB1' ' A' ' 62' ' ' ALA . 18.3 mt -81.19 144.72 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.191 -1.182 . . . . 0.0 109.604 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.448 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 20.1 mttt -92.55 128.67 38.49 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.209 -0.932 . . . . 0.0 109.226 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.483 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.5 mt -99.22 128.66 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.178 -0.951 . . . . 0.0 109.582 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.582 ' CD2' ' HA ' ' A' ' 110' ' ' GLU . 2.0 m-30 -117.95 152.21 35.9 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.462 -0.774 . . . . 0.0 109.12 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.521 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 7.5 tpt180 -98.66 120.23 38.72 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.153 -0.967 . . . . 0.0 109.71 -179.714 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.01 132.24 34.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -0.904 . . . . 0.0 109.495 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 3.7 m -71.9 -38.16 69.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.232 -0.918 . . . . 0.0 109.41 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 114.09 14.35 9.27 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -79.7 -68.74 0.64 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.246 -1.149 . . . . 0.0 109.244 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 14' ' ' SER . 0.2 OUTLIER -171.16 132.72 0.83 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.204 -0.935 . . . . 0.0 109.341 179.927 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 23.8 m -56.56 -23.61 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.917 . . . . 0.0 109.527 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -68.81 -38.83 80.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.256 -0.902 . . . . 0.0 109.449 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -77.27 -42.24 37.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.232 -0.917 . . . . 0.0 109.68 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -64.89 -27.75 69.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.692 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.421 ' C ' HD21 ' A' ' 101' ' ' LEU . 0.6 OUTLIER -59.63 -61.56 2.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.185 -0.947 . . . . 0.0 109.634 -179.913 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.53 -28.54 69.71 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.426 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -66.92 -29.04 68.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.664 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.574 ' CD1' ' O ' ' A' ' 104' ' ' PHE . 9.3 t80 -75.5 -26.48 58.16 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.186 -0.946 . . . . 0.0 109.631 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 14.6 m -63.1 -20.59 65.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.231 -0.918 . . . . 0.0 109.728 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -103.88 -30.46 10.33 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.179 -0.951 . . . . 0.0 109.455 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.92 42.0 6.14 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 32.9 m-20 -95.61 -20.09 19.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -1.162 . . . . 0.0 109.318 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -127.87 143.29 51.11 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.402 -0.811 . . . . 0.0 109.044 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.582 ' HA ' ' CD2' ' A' ' 90' ' ' TYR . 4.7 pt-20 -172.38 -157.28 0.1 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.149 -0.969 . . . . 0.0 109.888 -179.718 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.521 ' HB2' ' N ' ' A' ' 91' ' ' ARG . 3.0 tt0 -158.66 -104.21 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.368 -0.833 . . . . 0.0 109.365 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.457 ' N ' ' CG ' ' A' ' 111' ' ' GLU . 46.8 mm -93.17 111.32 24.5 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 O-C-N 121.27 -0.894 . . . . 0.0 109.586 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.599 0 O-C-N 121.326 -0.858 . . . . 0.0 109.44 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -90.65 121.48 32.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.245 -0.909 . . . . 0.0 109.345 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.578 HG12 ' CD2' ' A' ' 104' ' ' PHE . 4.1 mt -100.26 111.7 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.291 -0.881 . . . . 0.0 109.853 -179.781 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.5 ' HB3' ' CE2' ' A' ' 26' ' ' PHE . . . -104.12 112.69 25.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -0.921 . . . . 0.0 109.397 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.512 ' CG2' HG13 ' A' ' 97' ' ' VAL . 14.4 mm -87.78 117.62 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.226 -0.921 . . . . 0.0 109.525 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.46 ' O ' ' HB3' ' A' ' 7' ' ' SER . . . -62.64 153.78 31.23 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.289 -0.882 . . . . 0.0 109.608 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.46 ' HB3' ' O ' ' A' ' 6' ' ' ALA . 2.4 t 61.62 -88.96 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.522 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.46 ' HA ' HG21 ' A' ' 97' ' ' VAL . 0.2 OUTLIER 57.95 22.62 8.96 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.193 -0.942 . . . . 0.0 109.457 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 48.94 -102.12 0.05 OUTLIER Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -155.85 -47.05 0.08 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -1.173 . . . . 0.0 109.46 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -155.59 -62.05 0.11 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.448 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.9 mp -108.17 -15.81 14.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.204 -0.935 . . . . 0.0 109.529 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -94.19 27.49 13.19 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.6 p -78.28 74.34 4.82 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.391 -1.064 . . . . 0.0 109.695 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.522 ' O ' ' CG ' ' A' ' 15' ' ' GLU . 32.4 tt0 -78.33 5.55 10.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.023 -1.048 . . . . 0.0 109.815 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.498 ' CG2' ' CA ' ' A' ' 96' ' ' SER . 2.1 t 68.37 54.15 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.168 -0.957 . . . . 0.0 109.116 -179.559 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 16' ' ' VAL . 1.0 OUTLIER -42.74 159.47 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.411 -0.806 . . . . 0.0 109.688 -179.844 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -111.32 39.08 2.39 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.265 -0.897 . . . . 0.0 109.428 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.442 ' O ' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -129.22 103.49 6.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.255 -0.903 . . . . 0.0 109.508 -179.962 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.5 t80 -102.41 142.01 34.31 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.516 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 114.25 -46.73 1.13 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.47 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 7.9 ttp180 -103.12 -37.36 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.371 -1.076 . . . . 0.0 109.141 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.442 ' HB3' ' O ' ' A' ' 19' ' ' PHE . . . -41.47 102.0 0.26 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.569 -0.707 . . . . 0.0 109.821 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.493 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 36.7 Cg_endo -81.21 54.73 5.33 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.652 2.235 . . . . 0.0 110.478 179.688 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.458 ' O ' ' O ' ' A' ' 7' ' ' SER . 68.5 m-85 -154.15 68.5 0.75 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.108 -0.995 . . . . 0.0 109.204 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.5 ' CE2' ' HB3' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -79.39 111.13 15.34 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.256 -0.903 . . . . 0.0 109.337 -179.907 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' MET . . . . . 0.451 ' HB2' ' CB ' ' A' ' 8' ' ' SER . 7.2 ttm -88.76 102.09 14.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.3 -0.875 . . . . 0.0 109.559 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.463 HG22 ' O ' ' A' ' 40' ' ' GLU . 6.1 tp -83.61 114.67 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.363 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.7 t -126.11 128.71 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.155 -0.966 . . . . 0.0 109.653 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -111.21 113.86 26.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.283 -0.886 . . . . 0.0 109.368 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.439 ' SD ' ' CA ' ' A' ' 34' ' ' GLY . 0.7 OUTLIER -112.53 132.65 54.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -0.92 . . . . 0.0 109.6 -179.851 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 7.2 mmmt -87.67 -55.81 3.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.268 -0.895 . . . . 0.0 109.33 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.15 68.24 0.93 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.336 -0.853 . . . . 0.0 109.209 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.439 ' CA ' ' SD ' ' A' ' 31' ' ' MET . . . 75.92 8.6 84.9 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -130.52 98.35 4.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.176 -1.19 . . . . 0.0 109.493 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 2.9 mt -57.43 127.49 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.251 -0.906 . . . . 0.0 109.658 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.456 ' O ' ' HB3' ' A' ' 38' ' ' SER . 0.5 OUTLIER -101.66 -2.3 30.65 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.401 179.68 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.456 ' HB3' ' O ' ' A' ' 37' ' ' GLU . 77.3 p 176.8 125.55 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.201 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -136.85 106.97 6.33 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.208 -0.932 . . . . 0.0 109.644 -179.759 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.463 ' O ' HG22 ' A' ' 28' ' ' ILE . 0.9 OUTLIER -112.87 163.62 14.41 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 179.922 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.489 ' O ' ' CG1' ' A' ' 41' ' ' VAL . 7.6 p -134.6 118.66 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.331 -0.855 . . . . 0.0 109.447 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.5 pt -126.88 133.63 68.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.218 -0.926 . . . . 0.0 109.569 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.493 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 1.3 mt-10 -74.46 146.61 42.67 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.369 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 12.2 m-20 . . . . . 0 N--CA 1.49 1.53 0 O-C-N 121.242 -0.911 . . . . 0.0 109.318 -179.983 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.244 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 47.2 mm -66.49 -14.15 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.279 -1.13 . . . . 0.0 109.484 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -8.9 38.79 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.29 -0.881 . . . . 0.0 109.496 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 14.8 t -76.93 -16.04 59.49 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.191 -0.943 . . . . 0.0 109.529 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.401 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -57.28 -32.35 66.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 109.536 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 21.8 tt0 -65.11 -52.98 52.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 35.9 mm -62.72 -25.6 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.228 -0.92 . . . . 0.0 109.326 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.436 HD11 ' CZ ' ' A' ' 26' ' ' PHE . 45.5 mt -69.71 -39.28 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 109.276 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.419 ' HB3' HD11 ' A' ' 87' ' ' ILE . . . -74.6 -25.44 59.26 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.248 -0.908 . . . . 0.0 109.429 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -77.09 -5.15 47.83 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.237 -0.914 . . . . 0.0 109.51 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.436 ' HB2' HG21 ' A' ' 66' ' ' VAL . 6.8 m-20 -100.26 1.86 42.18 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.134 -0.979 . . . . 0.0 109.527 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.499 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 90.89 -5.94 81.95 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.448 HG12 HG22 ' A' ' 69' ' ' VAL . 48.3 t -53.5 88.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -1.176 . . . . 0.0 109.858 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.499 ' N ' ' O ' ' A' ' 65' ' ' GLY . 6.4 tttp -79.75 -12.46 59.79 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.119 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.456 ' HB2' ' HA ' ' A' ' 3' ' ' ILE . . . -127.62 131.99 49.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.436 -0.79 . . . . 0.0 109.108 179.685 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.448 HG22 HG12 ' A' ' 66' ' ' VAL . 2.4 t -129.64 105.49 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.123 -0.985 . . . . 0.0 109.806 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.451 HG12 ' HB2' ' A' ' 90' ' ' TYR . 23.3 mt -91.41 119.96 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.277 -0.89 . . . . 0.0 109.01 179.595 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -149.12 177.08 9.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.152 -0.967 . . . . 0.0 109.938 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.04 35.38 3.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.535 -0.728 . . . . 0.0 109.14 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' SER . . . . . 0.423 ' HB2' ' CE1' ' A' ' 79' ' ' PHE . 0.1 OUTLIER -44.87 134.23 4.99 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.286 -0.884 . . . . 0.0 109.465 -179.807 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.75 -19.78 10.96 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.436 2.091 . . . . 0.0 110.351 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -114.15 148.31 18.77 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.83 9.16 3.38 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.631 2.221 . . . . 0.0 110.706 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -74.44 -42.62 58.81 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.095 -1.003 . . . . 0.0 109.722 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -68.69 -50.78 48.22 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.588 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.423 ' CE1' ' HB2' ' A' ' 73' ' ' SER . 11.3 m-30 -48.81 -38.43 22.12 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.264 -0.898 . . . . 0.0 109.652 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.474 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 0.6 OUTLIER -65.75 -47.4 75.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.188 -0.945 . . . . 0.0 109.71 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 86.7 t -52.89 -50.85 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.182 -0.949 . . . . 0.0 109.466 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.422 HD23 ' HB ' ' A' ' 87' ' ' ILE . 1.9 mt -56.47 -31.15 63.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.474 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 3.2 m-20 -61.96 -51.26 68.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.163 -0.961 . . . . 0.0 109.301 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -62.81 -27.67 69.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.21 179.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.1 mt -72.03 -34.21 68.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.174 -0.954 . . . . 0.0 109.527 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.1 19.98 19.72 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.422 ' HB ' HD23 ' A' ' 82' ' ' LEU . 27.7 mt -103.83 163.03 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.289 -1.124 . . . . 0.0 109.617 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 3.4 mptt -91.74 147.07 23.26 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.253 -0.904 . . . . 0.0 109.263 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.503 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.3 mt -120.76 131.76 72.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.112 -0.992 . . . . 0.0 109.211 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.476 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 12.8 m-85 -119.47 161.26 20.85 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.476 -0.765 . . . . 0.0 109.547 -179.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.466 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 0.1 OUTLIER -99.25 136.78 38.7 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.264 -0.897 . . . . 0.0 109.627 -179.909 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.64 129.33 34.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.259 -0.901 . . . . 0.0 109.443 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.35 -40.33 96.05 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.26 -0.9 . . . . 0.0 109.476 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 102.94 22.07 9.66 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.73 -83.75 0.54 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.128 -1.219 . . . . 0.0 109.4 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.498 ' CA ' ' CG2' ' A' ' 16' ' ' VAL . 3.3 m -146.71 137.65 24.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.324 -0.86 . . . . 0.0 109.315 179.814 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.512 HG13 ' CG2' ' A' ' 5' ' ' ILE . 86.8 t -64.2 -31.18 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -0.882 . . . . 0.0 109.609 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.58 -44.36 80.95 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.194 -0.941 . . . . 0.0 109.465 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -75.46 -35.8 60.82 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.45 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 15.1 m-20 -54.44 -37.71 65.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.224 -0.922 . . . . 0.0 109.669 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -49.43 -53.48 22.58 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.283 -0.885 . . . . 0.0 109.651 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 6.0 mmtm -69.64 -33.43 72.6 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.23 -0.919 . . . . 0.0 109.656 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.475 ' CD1' ' HB3' ' A' ' 108' ' ' ASN . 2.2 mm? -57.94 -31.75 67.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.205 -0.934 . . . . 0.0 109.438 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.578 ' CD2' HG12 ' A' ' 3' ' ' ILE . 20.9 t80 -72.75 -38.61 67.31 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.384 -0.823 . . . . 0.0 109.779 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 17.6 m -70.56 -25.69 63.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.266 -0.896 . . . . 0.0 109.751 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -88.1 -0.51 57.14 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.204 -0.935 . . . . 0.0 109.674 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . 0.456 ' HA2' ' OE2' ' A' ' 110' ' ' GLU . . . 59.95 25.42 61.75 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . 0.475 ' HB3' ' CD1' ' A' ' 103' ' ' LEU . 1.2 m-20 -88.48 -53.28 4.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.204 -1.174 . . . . 0.0 109.424 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 11.9 tp -85.19 129.75 34.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.243 -0.911 . . . . 0.0 109.202 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.456 ' OE2' ' HA2' ' A' ' 107' ' ' GLY . 0.3 OUTLIER -165.68 -166.31 0.94 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.198 -0.939 . . . . 0.0 109.729 -179.818 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.503 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 68.5 tt0 -172.68 -113.85 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.285 -0.885 . . . . 0.0 109.371 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.484 ' N ' ' HG2' ' A' ' 111' ' ' GLU . 5.3 mt -82.31 140.37 16.53 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 O-C-N 121.093 -1.005 . . . . 0.0 109.253 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.488 ' NH1' ' HG2' ' A' ' 113' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.51 0 O-C-N 121.203 -0.935 . . . . 0.0 109.623 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.428 ' HG3' ' HB2' ' A' ' 67' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.28 0.562 . . . . 0.0 109.514 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.93 139.68 36.98 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.219 -0.926 . . . . 0.0 109.201 179.825 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.473 ' HA ' ' HB2' ' A' ' 68' ' ' ALA . 4.8 mt -115.24 113.49 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.12 -0.987 . . . . 0.0 110.006 -179.609 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.03 119.55 39.78 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.507 -0.746 . . . . 0.0 109.024 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 3.3 mp -98.15 136.94 27.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.128 -0.982 . . . . 0.0 109.879 -179.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.569 ' HB1' ' CZ ' ' A' ' 26' ' ' PHE . . . -89.74 121.99 32.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.296 -0.877 . . . . 0.0 109.138 179.725 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.402 ' O ' ' HB3' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -142.08 170.82 14.99 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.143 -0.973 . . . . 0.0 109.728 -179.832 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 51.5 p -116.32 25.31 10.73 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.316 -0.865 . . . . 0.0 109.299 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -162.64 -145.27 4.29 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.17 22.56 1.2 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.243 -1.151 . . . . 0.0 109.521 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -147.57 -178.68 6.38 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.199 -0.938 . . . . 0.0 109.602 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.425 ' HG ' ' HB3' ' A' ' 96' ' ' SER . 6.6 tt -64.39 -14.24 55.44 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.337 -0.852 . . . . 0.0 109.571 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -56.74 -52.4 50.87 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.08 86.57 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.335 -1.097 . . . . 0.0 109.397 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.46 81.21 1.44 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.476 -0.765 . . . . 0.0 109.54 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.505 HG12 ' CB ' ' A' ' 92' ' ' ALA . 59.3 t 54.54 30.45 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.665 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 26.6 p 46.14 -160.66 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.275 -0.891 . . . . 0.0 109.433 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 2.9 mtt-85 -98.2 -46.92 5.66 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.898 . . . . 0.0 109.376 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -150.27 122.65 8.44 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.364 -0.835 . . . . 0.0 109.429 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -57.65 124.49 19.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.238 -0.914 . . . . 0.0 109.391 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -171.98 -49.37 0.04 OUTLIER Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.95 45.4 1.46 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.283 -1.128 . . . . 0.0 109.446 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.402 ' HB3' ' O ' ' A' ' 7' ' ' SER . . . -54.6 112.65 4.21 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.352 -0.842 . . . . 0.0 109.516 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.452 ' O ' ' CB ' ' A' ' 43' ' ' GLU . 36.6 Cg_endo -80.61 20.53 0.95 Allowed 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.606 2.204 . . . . 0.0 110.947 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -154.8 69.79 0.75 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.036 -1.04 . . . . 0.0 108.942 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.569 ' CZ ' ' HB1' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -79.1 125.21 29.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.348 -0.845 . . . . 0.0 109.722 -179.456 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 10.7 mtt -90.06 110.69 21.67 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.289 -0.882 . . . . 0.0 109.369 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 31.6 mm -93.46 107.45 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.467 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.474 ' CG1' HG22 ' A' ' 36' ' ' ILE . 23.3 t -115.63 116.35 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.266 -0.896 . . . . 0.0 109.429 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -103.81 114.81 29.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.554 -179.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 12.6 ptp -116.3 160.33 20.63 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.241 -0.912 . . . . 0.0 109.419 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -109.71 -94.98 0.41 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.256 -0.903 . . . . 0.0 109.626 -179.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -89.5 62.35 5.92 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.116 -0.99 . . . . 0.0 109.348 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.13 35.58 92.28 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 36' ' ' ILE . 44.9 t30 -138.96 84.26 2.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.302 -1.116 . . . . 0.0 109.462 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.474 HG22 ' CG1' ' A' ' 29' ' ' VAL . 50.6 mt -45.41 111.27 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.221 -0.924 . . . . 0.0 109.419 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -111.49 9.26 21.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.232 -0.917 . . . . 0.0 109.482 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -167.28 124.18 1.19 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.187 -0.946 . . . . 0.0 109.485 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.2 p -144.96 107.9 4.51 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.284 -0.885 . . . . 0.0 109.478 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -123.37 148.2 46.29 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.526 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.4 t -103.99 137.82 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.87 . . . . 0.0 109.519 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -139.33 136.28 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.259 -0.9 . . . . 0.0 109.421 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.452 ' CB ' ' O ' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -96.85 120.66 37.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 179.915 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.21 -0.931 . . . . 0.0 109.357 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.485 HG23 ' CA ' ' A' ' 78' ' ' ALA . 20.7 mm -71.85 -39.88 68.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.191 -1.182 . . . . 0.0 109.42 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 7.3 mmm-85 -65.67 -11.13 42.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.557 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.529 ' O ' ' CG2' ' A' ' 60' ' ' ILE . 44.8 m -70.3 -33.47 71.58 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 0.0 109.312 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -50.83 -23.84 3.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.243 -0.91 . . . . 0.0 109.318 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -70.67 -51.58 26.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.247 -0.908 . . . . 0.0 109.485 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.529 ' CG2' ' O ' ' A' ' 57' ' ' THR . 0.3 OUTLIER -59.03 -33.43 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.412 -179.98 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.564 HD11 ' CZ ' ' A' ' 26' ' ' PHE . 96.0 mt -67.38 -40.96 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.206 -0.934 . . . . 0.0 109.215 179.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.01 -18.64 59.18 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.338 -0.851 . . . . 0.0 109.461 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -74.55 -17.63 60.71 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.931 . . . . 0.0 109.399 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -86.77 11.75 12.43 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.28 -0.888 . . . . 0.0 109.56 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.454 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 88.6 -6.24 83.82 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.514 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 96.8 t -54.78 89.76 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.283 -1.128 . . . . 0.0 109.878 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.454 ' N ' ' O ' ' A' ' 65' ' ' GLY . 16.5 mmtm -79.18 2.24 21.69 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.139 -0.975 . . . . 0.0 109.017 179.427 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.514 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -142.96 140.05 30.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.236 -0.915 . . . . 0.0 109.06 179.656 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.453 HG22 HG11 ' A' ' 66' ' ' VAL . 42.2 t -139.76 131.15 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.077 -1.014 . . . . 0.0 110.049 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.463 HD12 ' CB ' ' A' ' 90' ' ' TYR . 1.3 mm -108.33 111.63 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.305 -0.872 . . . . 0.0 108.85 179.461 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -154.13 177.05 11.52 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.164 -0.96 . . . . 0.0 109.968 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.5 44.87 1.73 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.53 -0.731 . . . . 0.0 109.23 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -45.74 150.61 0.94 Allowed Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.333 -0.855 . . . . 0.0 109.533 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.83 -38.88 0.57 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.677 2.251 . . . . 0.0 110.292 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.16 146.28 16.89 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.68 8.09 3.89 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.605 2.203 . . . . 0.0 110.663 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -63.93 -46.39 84.99 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.151 -0.968 . . . . 0.0 109.612 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.485 ' CA ' HG23 ' A' ' 55' ' ' ILE . . . -67.4 -50.24 60.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 109.557 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.573 ' CD1' HG23 ' A' ' 89' ' ' ILE . 12.8 m-85 -52.08 -33.16 38.16 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.642 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -67.01 -41.81 86.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.251 -0.905 . . . . 0.0 109.736 -179.732 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.21 -53.77 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.167 -0.958 . . . . 0.0 109.751 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 25.0 mt -60.38 -18.38 50.07 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.27 -0.894 . . . . 0.0 109.719 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.457 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 6.9 m-20 -69.61 -56.37 7.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.275 -0.891 . . . . 0.0 109.716 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -66.12 -34.81 78.89 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.145 -0.972 . . . . 0.0 109.676 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.5 -13.41 20.72 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.237 -0.914 . . . . 0.0 109.416 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 77.61 24.06 65.99 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.2 mm -92.32 144.34 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.239 -1.154 . . . . 0.0 109.4 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.87 110.37 15.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.249 -0.907 . . . . 0.0 109.442 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.573 HG23 ' CD1' ' A' ' 79' ' ' PHE . 13.0 mt -86.76 151.48 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.344 -0.848 . . . . 0.0 109.655 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.545 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 1.1 m-85 -134.87 134.02 40.3 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -0.873 . . . . 0.0 109.453 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.96 132.72 35.19 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.225 -0.922 . . . . 0.0 109.405 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.505 ' CB ' HG12 ' A' ' 16' ' ' VAL . . . -84.6 66.0 9.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.226 -0.921 . . . . 0.0 109.614 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' THR . . . . . 0.506 HG23 ' N ' ' A' ' 94' ' ' GLY . 9.5 t -74.2 -28.14 61.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.158 -0.964 . . . . 0.0 109.463 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.506 ' N ' HG23 ' A' ' 93' ' ' THR . . . -59.1 -106.21 0.01 OUTLIER Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.0 t 178.31 -44.09 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.217 -1.166 . . . . 0.0 109.592 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.425 ' HB3' ' HG ' ' A' ' 12' ' ' LEU . 7.2 m -95.66 125.52 40.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.231 -0.918 . . . . 0.0 109.444 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.5 m -63.46 -34.99 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.238 -0.914 . . . . 0.0 109.402 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -64.42 -35.27 80.36 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.198 -0.939 . . . . 0.0 109.29 179.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.461 ' O ' HD22 ' A' ' 103' ' ' LEU . 20.7 tt0 -73.32 -36.78 66.28 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.334 -0.854 . . . . 0.0 109.403 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.467 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 98.9 m-20 -67.74 -27.79 67.09 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.171 -0.955 . . . . 0.0 109.424 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 24.9 tp -58.28 -62.24 1.98 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.358 -0.839 . . . . 0.0 109.674 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -68.19 -24.97 65.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.153 -0.967 . . . . 0.0 109.443 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.467 ' HB2' ' HA ' ' A' ' 100' ' ' ASN . 0.9 OUTLIER -65.0 -29.58 70.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.305 -0.872 . . . . 0.0 109.482 179.929 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.528 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 9.8 t80 -64.12 -43.89 93.92 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.156 -0.965 . . . . 0.0 109.501 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 86.4 m -57.31 -31.36 65.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.753 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -87.64 -22.78 24.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.242 -0.911 . . . . 0.0 109.578 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 77.02 24.36 66.73 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -80.31 -32.52 37.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.179 -1.189 . . . . 0.0 109.367 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 3.4 tp -66.59 -163.89 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.274 -0.891 . . . . 0.0 109.519 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -110.58 137.54 48.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 109.263 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.545 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 20.8 pt-20 -127.58 165.08 20.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.236 -0.915 . . . . 0.0 109.69 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 10.3 mt -151.54 104.26 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.147 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.463 0 O-C-N 121.236 -0.915 . . . . 0.0 109.838 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -111.14 137.26 49.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.25 -0.906 . . . . 0.0 109.449 179.867 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.574 HG12 ' CZ ' ' A' ' 104' ' ' PHE . 4.9 mt -102.84 101.89 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.377 -0.827 . . . . 0.0 109.72 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.513 ' CB ' HG12 ' A' ' 66' ' ' VAL . . . -103.66 101.22 11.06 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.318 -0.864 . . . . 0.0 109.147 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 14.7 tt -98.25 130.19 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.256 -0.902 . . . . 0.0 109.592 -179.69 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -59.26 146.09 40.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.406 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.487 ' HB3' ' CB ' ' A' ' 14' ' ' SER . 0.8 OUTLIER -135.85 162.12 33.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.921 . . . . 0.0 109.594 -179.863 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.82 -20.43 12.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.872 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.571 ' O ' ' CD1' ' A' ' 25' ' ' TYR . . . -119.81 -124.66 3.24 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.78 -37.21 1.03 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.19 -1.182 . . . . 0.0 109.544 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -144.92 -73.11 0.25 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.704 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -89.58 -29.76 18.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.254 -0.904 . . . . 0.0 109.514 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.19 -15.12 72.0 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.492 ' OG ' ' CG2' ' A' ' 97' ' ' VAL . 0.8 OUTLIER -77.39 82.62 3.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.196 -1.179 . . . . 0.0 109.479 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.466 ' HG2' ' O ' ' A' ' 95' ' ' THR . 13.2 tt0 -77.34 3.66 12.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.279 -0.888 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.448 ' O ' ' O ' ' A' ' 17' ' ' SER . 9.7 t 66.62 65.96 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.16 -0.962 . . . . 0.0 109.227 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.448 ' O ' ' O ' ' A' ' 16' ' ' VAL . 60.2 p -57.65 -159.35 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.258 -0.901 . . . . 0.0 109.703 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.45 54.18 1.93 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.47 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -136.95 71.41 1.41 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.211 -0.931 . . . . 0.0 109.438 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.434 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . 5.7 t80 -65.58 100.93 0.55 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.29 -0.881 . . . . 0.0 109.61 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 151.91 -42.97 0.69 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.486 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 5.5 ttt85 -104.51 -33.9 8.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.203 -1.175 . . . . 0.0 109.783 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.457 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -39.22 99.02 0.19 Allowed Pre-proline 0 N--CA 1.495 1.809 0 O-C-N 121.543 -0.723 . . . . 0.0 109.78 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.5 Cg_endo -81.03 45.39 1.98 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 122.716 2.277 . . . . 0.0 110.927 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.571 ' CD1' ' O ' ' A' ' 9' ' ' GLY . 1.9 m-85 -161.05 72.34 0.43 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.946 -1.096 . . . . 0.0 109.627 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -79.7 150.01 31.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.305 -0.872 . . . . 0.0 109.438 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' MET . . . . . 0.411 ' HB2' ' OG ' ' A' ' 7' ' ' SER . 5.2 ttt -123.54 122.1 37.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -0.939 . . . . 0.0 109.402 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.478 ' CD1' HD11 ' A' ' 42' ' ' ILE . 28.3 mt -114.08 129.34 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.899 . . . . 0.0 109.547 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 73.6 t -138.69 136.18 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.218 -0.926 . . . . 0.0 109.532 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -120.73 94.66 4.43 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.193 -0.942 . . . . 0.0 109.444 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.497 ' SD ' ' CD1' ' A' ' 3' ' ' ILE . 0.0 OUTLIER -83.44 152.31 25.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.385 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -96.73 -94.02 0.21 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.189 -0.944 . . . . 0.0 109.492 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -101.43 65.22 1.04 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.133 -0.979 . . . . 0.0 109.299 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 70.25 37.59 71.48 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -150.41 116.15 5.54 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.316 -1.108 . . . . 0.0 109.308 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.441 HD12 HD13 ' A' ' 101' ' ' LEU . 5.9 mm -64.12 122.81 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -0.881 . . . . 0.0 109.593 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.453 ' O ' ' OG ' ' A' ' 38' ' ' SER . 2.3 tm-20 -130.77 16.61 5.26 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.188 -0.945 . . . . 0.0 109.318 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.453 ' OG ' ' O ' ' A' ' 37' ' ' GLU . 17.1 m -173.51 101.29 0.12 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.382 -0.824 . . . . 0.0 109.245 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.55 101.06 7.12 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.94 155.91 19.78 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.336 -0.853 . . . . 0.0 109.418 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 3.1 t -125.99 129.6 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.205 -0.935 . . . . 0.0 109.337 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.478 HD11 ' CD1' ' A' ' 28' ' ' ILE . 92.8 mt -110.32 143.05 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.264 -0.897 . . . . 0.0 109.853 -179.758 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -109.73 128.94 55.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.314 -0.866 . . . . 0.0 109.281 179.852 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.199 -0.938 . . . . 0.0 109.407 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.445 ' O ' HG23 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.492 2.372 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.484 ' CG2' ' HB1' ' A' ' 78' ' ' ALA . 22.2 mt -76.08 0.1 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -1.144 . . . . 0.0 109.619 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.17 -9.57 58.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.199 -0.938 . . . . 0.0 109.553 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.445 HG23 ' O ' ' A' ' 54' ' ' GLY . 7.2 t -76.96 -19.0 57.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -0.89 . . . . 0.0 109.583 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -56.55 -38.45 71.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.289 -0.882 . . . . 0.0 109.581 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -56.46 -39.31 72.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.68 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.4 mt -75.6 -35.44 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 109.648 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 48.8 mt -62.1 -29.05 45.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.54 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.516 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . . . -71.82 -34.89 69.71 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.7 -179.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -76.8 -0.42 23.84 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.173 -0.954 . . . . 0.0 109.687 -179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.432 ' HB3' HG21 ' A' ' 66' ' ' VAL . 10.3 t-20 -94.27 8.34 42.15 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.213 -0.929 . . . . 0.0 109.586 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 87.34 -11.21 66.3 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.513 HG12 ' CB ' ' A' ' 4' ' ' ALA . 70.0 t -58.44 91.62 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.226 -1.161 . . . . 0.0 109.489 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.53 -7.34 58.41 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.372 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.454 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -132.98 137.63 46.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 0.0 109.273 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.434 HG21 HG11 ' A' ' 66' ' ' VAL . 32.3 t -134.28 111.86 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.15 -0.969 . . . . 0.0 109.646 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.427 HD12 ' CG2' ' A' ' 3' ' ' ILE . 11.7 mt -95.71 116.9 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.289 -0.882 . . . . 0.0 109.261 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.434 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -148.78 173.83 12.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.156 -0.965 . . . . 0.0 109.684 -179.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.73 38.89 3.96 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.393 -0.817 . . . . 0.0 109.422 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -50.17 141.25 15.74 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.264 -0.898 . . . . 0.0 109.406 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.59 -62.95 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.593 2.195 . . . . 0.0 110.474 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -74.28 155.78 49.31 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.446 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.3 Cg_endo -78.6 4.7 6.15 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.702 2.268 . . . . 0.0 110.535 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -62.4 -56.86 14.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.207 -0.933 . . . . 0.0 109.512 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.484 ' HB1' ' CG2' ' A' ' 55' ' ' ILE . . . -57.26 -54.41 47.08 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.164 -0.96 . . . . 0.0 109.536 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -55.64 -22.25 21.82 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.3 -0.875 . . . . 0.0 109.523 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.446 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.2 OUTLIER -74.84 -37.01 62.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.162 -0.961 . . . . 0.0 109.467 -179.982 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.3 t -73.12 -50.68 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.911 . . . . 0.0 109.377 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.476 ' HB2' ' CD1' ' A' ' 89' ' ' ILE . 14.9 mt -50.1 -50.69 47.51 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.333 -0.854 . . . . 0.0 109.396 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -65.2 -33.36 75.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.242 -0.911 . . . . 0.0 109.431 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -58.37 -35.26 71.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.507 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -82.36 -37.39 25.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.341 -0.849 . . . . 0.0 109.379 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.36 22.1 6.61 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.516 ' CD1' ' HB3' ' A' ' 62' ' ' ALA . 6.0 mt -88.46 160.18 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.222 -1.163 . . . . 0.0 109.495 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.515 ' N ' HG21 ' A' ' 87' ' ' ILE . 2.1 mttt -86.15 113.31 22.09 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.768 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.541 ' O ' ' CB ' ' A' ' 111' ' ' GLU . 43.5 mt -88.38 161.92 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.267 -0.895 . . . . 0.0 108.938 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.566 ' CZ ' ' HG2' ' A' ' 111' ' ' GLU . 2.6 m-85 -139.9 137.68 35.03 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.966 -1.084 . . . . 0.0 109.702 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 17.6 mmm180 -87.99 119.42 28.34 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.409 -0.807 . . . . 0.0 109.558 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.41 108.04 20.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.875 . . . . 0.0 109.387 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' THR . . . . . 0.414 ' CG2' ' N ' ' A' ' 94' ' ' GLY . 8.1 t -53.86 -47.19 71.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.414 ' N ' ' CG2' ' A' ' 93' ' ' THR . . . 125.31 83.47 0.53 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.466 ' O ' ' HG2' ' A' ' 15' ' ' GLU . 17.5 m -137.65 -92.8 0.22 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.236 -1.155 . . . . 0.0 109.459 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.443 ' CA ' HG22 ' A' ' 16' ' ' VAL . 0.2 OUTLIER -153.01 130.74 11.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.157 -0.965 . . . . 0.0 109.399 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.492 ' CG2' ' OG ' ' A' ' 14' ' ' SER . 22.2 m -52.05 -20.9 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 109.676 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -66.62 -57.97 6.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.238 -0.914 . . . . 0.0 109.522 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 32.3 mm-40 -66.0 -29.49 69.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.889 . . . . 0.0 109.524 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 96' ' ' SER . 33.2 m120 -60.9 -46.16 91.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.132 -0.98 . . . . 0.0 109.34 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.441 HD13 HD12 ' A' ' 36' ' ' ILE . 0.1 OUTLIER -58.51 -37.04 74.76 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.216 -0.927 . . . . 0.0 109.148 179.781 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . 0.409 ' HE2' ' HB2' ' A' ' 102' ' ' LYS . 0.3 OUTLIER -73.9 -22.06 59.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.287 -0.883 . . . . 0.0 109.311 179.822 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.54 -38.06 55.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.247 179.82 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.574 ' CZ ' HG12 ' A' ' 3' ' ' ILE . 0.5 OUTLIER -70.39 -6.64 36.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.3 -0.875 . . . . 0.0 109.551 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 51.6 m -73.34 -39.09 65.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 0.0 109.682 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -94.19 -41.87 9.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.32 -0.862 . . . . 0.0 109.505 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 110.78 25.78 5.01 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.93 -21.6 43.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.278 -1.131 . . . . 0.0 109.374 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.561 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 2.8 mt -59.41 144.99 45.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.373 -0.829 . . . . 0.0 109.421 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.512 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 1.4 pt-20 -94.72 145.62 24.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.182 -0.949 . . . . 0.0 109.303 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.566 ' HG2' ' CZ ' ' A' ' 90' ' ' TYR . 0.4 OUTLIER -139.32 -178.58 5.43 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.161 -0.962 . . . . 0.0 109.816 -179.603 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.9 mp -138.34 134.26 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.406 -0.809 . . . . 0.0 109.294 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.213 -0.929 . . . . 0.0 109.544 -179.979 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.451 ' O ' ' HG3' ' A' ' 1' ' ' MET . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.495 ' CE ' ' OE1' ' A' ' 30' ' ' GLU . 17.2 mttp -102.71 146.67 27.87 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.259 -0.901 . . . . 0.0 109.366 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.591 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 6.8 mt -113.27 131.5 64.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.3 -0.875 . . . . 0.0 109.918 -179.692 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.451 ' HB2' HD13 ' A' ' 28' ' ' ILE . . . -125.74 146.56 49.7 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.415 -0.803 . . . . 0.0 108.855 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.449 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 1.6 mp -132.35 127.52 57.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 109.718 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -63.5 148.64 48.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.351 -0.843 . . . . 0.0 109.403 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.434 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -143.91 164.99 28.99 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.138 -0.976 . . . . 0.0 109.549 -179.95 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.96 -6.46 23.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.319 -0.863 . . . . 0.0 109.597 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.556 ' O ' ' CG ' ' A' ' 25' ' ' TYR . . . -148.15 -145.37 4.15 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.518 ' OG1' ' CE1' ' A' ' 25' ' ' TYR . 96.7 m -135.6 18.56 3.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.241 -1.152 . . . . 0.0 109.433 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -141.6 -174.47 4.06 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.222 -0.924 . . . . 0.0 109.529 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -66.61 -22.22 66.12 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.22 -0.925 . . . . 0.0 109.482 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.73 -50.44 57.84 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 15' ' ' GLU . 81.4 p -76.81 84.39 3.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.294 -1.121 . . . . 0.0 109.244 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.482 ' HG2' ' CB ' ' A' ' 96' ' ' SER . 18.6 mt-10 -46.89 -98.11 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.398 -0.814 . . . . 0.0 109.859 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.432 HG11 ' HB3' ' A' ' 92' ' ' ALA . 4.2 t -123.06 33.76 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.939 -1.101 . . . . 0.0 109.782 -179.709 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.401 ' C ' ' O ' ' A' ' 16' ' ' VAL . 7.2 p 43.93 -162.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.883 . . . . 0.0 109.533 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.546 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -140.34 11.91 2.35 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.338 -0.851 . . . . 0.0 109.388 179.908 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.546 ' CD1' ' O ' ' A' ' 18' ' ' ARG . 32.6 m-85 -142.64 -165.3 2.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.52 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -133.88 -61.81 0.79 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.316 -0.865 . . . . 0.0 109.355 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -79.81 2.28 74.83 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.444 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.1 OUTLIER -103.91 -64.51 1.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.183 -1.187 . . . . 0.0 109.489 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.434 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -44.24 104.58 0.39 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.287 -0.883 . . . . 0.0 109.404 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.515 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.6 Cg_endo -79.94 61.49 8.21 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.656 2.237 . . . . 0.0 110.927 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.556 ' CG ' ' O ' ' A' ' 9' ' ' GLY . 51.1 m-85 -160.54 70.45 0.41 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.04 -1.037 . . . . 0.0 109.325 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 48.5 m-85 -79.85 109.22 14.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.206 -0.934 . . . . 0.0 109.321 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' MET . . . . . 0.452 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 0.0 OUTLIER -79.6 141.37 36.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.332 -0.855 . . . . 0.0 109.742 -179.65 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.451 HD13 ' HB2' ' A' ' 4' ' ' ALA . 7.8 mm -125.04 139.32 51.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.32 -0.863 . . . . 0.0 109.235 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.455 HG11 ' O ' ' A' ' 38' ' ' SER . 10.6 t -140.63 144.64 26.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -0.892 . . . . 0.0 109.499 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.495 ' OE1' ' CE ' ' A' ' 2' ' ' LYS . 6.2 mt-10 -125.33 107.95 11.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.237 -0.914 . . . . 0.0 109.545 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.1 mtt -81.56 149.82 28.47 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.204 -0.935 . . . . 0.0 109.382 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.04 -51.79 2.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.184 -0.948 . . . . 0.0 109.587 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.02 53.25 0.57 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.498 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.4 21.83 55.61 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.403 ' O ' ' C ' ' A' ' 36' ' ' ILE . 1.6 t30 -148.13 95.43 2.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.254 -1.145 . . . . 0.0 109.477 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.43 ' O ' HG13 ' A' ' 36' ' ' ILE . 9.5 pt -45.47 114.16 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.168 -0.957 . . . . 0.0 109.295 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -113.68 9.4 17.78 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -0.933 . . . . 0.0 109.411 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.455 ' O ' HG11 ' A' ' 29' ' ' VAL . 53.5 p -163.46 113.4 1.32 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 109.36 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -135.03 104.6 6.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.288 -0.883 . . . . 0.0 109.493 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.96 -174.58 2.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.309 -0.869 . . . . 0.0 109.245 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 27' ' ' MET . 14.8 p -131.93 166.65 28.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.074 -1.016 . . . . 0.0 109.648 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.446 ' CG1' ' CG1' ' A' ' 28' ' ' ILE . 7.4 mm -129.97 99.37 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.35 -0.844 . . . . 0.0 109.501 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.526 ' HG3' ' CE1' ' A' ' 25' ' ' TYR . 31.8 tt0 -77.88 126.3 30.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.275 -0.891 . . . . 0.0 109.299 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.8 m120 . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.214 -0.929 . . . . 0.0 109.647 -179.819 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.51 ' O ' ' CG2' ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.6 mm -76.76 -28.87 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -1.142 . . . . 0.0 109.499 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 8.0 mmm180 -76.69 -34.11 58.2 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.183 -0.948 . . . . 0.0 109.594 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.51 ' CG2' ' O ' ' A' ' 54' ' ' GLY . 14.8 t -49.11 -23.63 1.31 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.737 -179.832 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -45.25 -47.25 12.82 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.272 -0.892 . . . . 0.0 109.9 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -53.83 -48.43 69.93 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.195 -0.941 . . . . 0.0 109.92 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 80.2 mt -60.91 -36.73 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.213 -0.929 . . . . 0.0 110.115 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 32.7 mt -62.94 -40.95 90.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 109.947 -179.582 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.38 -28.73 64.24 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.149 -0.969 . . . . 0.0 109.791 -179.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -77.32 4.39 10.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -0.929 . . . . 0.0 109.947 -179.796 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -106.6 2.54 26.1 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.018 -1.051 . . . . 0.0 109.661 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.03 -11.21 62.2 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.422 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 81.8 t -62.61 88.27 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -1.146 . . . . 0.0 109.61 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.66 -2.74 44.12 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.291 -0.88 . . . . 0.0 108.986 179.467 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.414 ' HB2' ' CZ ' ' A' ' 104' ' ' PHE . . . -127.8 127.54 43.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.34 -0.85 . . . . 0.0 109.172 179.849 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.44 HG21 HD23 ' A' ' 82' ' ' LEU . 74.8 t -125.57 112.43 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.17 -0.956 . . . . 0.0 109.78 -179.667 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.449 ' HB ' ' HA ' ' A' ' 5' ' ' ILE . 3.5 mt -99.33 124.31 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.192 -0.942 . . . . 0.0 109.129 179.549 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -158.52 172.81 17.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.175 -0.953 . . . . 0.0 109.766 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.15 49.18 2.31 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.367 -0.833 . . . . 0.0 109.514 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.86 160.11 22.38 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.201 -0.937 . . . . 0.0 109.407 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.85 -89.9 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.557 2.172 . . . . 0.0 110.296 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.6 162.96 36.91 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . 0.471 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.7 Cg_endo -80.29 27.74 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.825 2.35 . . . . 0.0 111.17 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -76.7 -59.84 2.6 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.879 -1.138 . . . . 0.0 109.423 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.412 ' O ' ' HB ' ' A' ' 81' ' ' VAL . . . -55.61 -43.51 76.15 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.266 -0.896 . . . . 0.0 109.389 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.507 ' CA ' HD13 ' A' ' 89' ' ' ILE . 3.8 m-30 -60.2 -49.17 78.7 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.264 -0.898 . . . . 0.0 109.498 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.471 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.3 OUTLIER -61.36 -21.03 63.67 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 109.331 179.798 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.412 ' HB ' ' O ' ' A' ' 78' ' ' ALA . 95.5 t -73.28 -63.12 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.217 -0.927 . . . . 0.0 109.373 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.44 HD23 HG21 ' A' ' 69' ' ' VAL . 1.5 mt -57.74 -27.09 62.7 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.179 -0.951 . . . . 0.0 109.302 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -62.06 -51.32 68.44 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.322 -0.861 . . . . 0.0 109.332 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -77.01 -12.28 59.92 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.262 -0.899 . . . . 0.0 109.362 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.43 ' HB2' ' HA ' ' A' ' 82' ' ' LEU . 55.5 mt -77.49 -23.63 50.28 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.921 . . . . 0.0 109.365 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 100.86 41.42 2.67 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.3 mp -137.7 161.87 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -1.156 . . . . 0.0 109.512 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 4.6 mmtm -92.56 131.5 37.63 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -0.901 . . . . 0.0 109.627 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.507 HD13 ' CA ' ' A' ' 79' ' ' PHE . 50.9 mt -92.29 157.35 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.251 -0.906 . . . . 0.0 109.51 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.511 ' CE2' ' CE2' ' A' ' 104' ' ' PHE . 0.3 OUTLIER -142.33 143.12 32.61 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.336 -0.852 . . . . 0.0 109.44 -179.898 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.455 ' O ' ' CD2' ' A' ' 109' ' ' LEU . 12.4 mmt180 -100.15 125.28 46.25 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 109.428 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . 0.432 ' HB3' HG11 ' A' ' 16' ' ' VAL . . . -82.97 113.84 20.83 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.217 -0.927 . . . . 0.0 109.473 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 3.8 m -144.98 13.03 1.45 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.233 -0.917 . . . . 0.0 109.518 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.02 -121.68 0.31 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.436 HG23 ' OG ' ' A' ' 96' ' ' SER . 17.3 m -129.59 -54.5 1.16 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.356 -1.085 . . . . 0.0 109.385 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.482 ' CB ' ' HG2' ' A' ' 15' ' ' GLU . 0.8 OUTLIER -139.19 143.53 38.13 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.275 -0.891 . . . . 0.0 109.367 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.448 HG12 ' O ' ' A' ' 15' ' ' GLU . 15.0 m -44.1 -26.72 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.295 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . 0.407 ' N ' ' O ' ' A' ' 96' ' ' SER . 3.3 tp10 -64.27 -51.76 61.96 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.264 -0.897 . . . . 0.0 109.246 179.702 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.434 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 3.0 tp10 -64.15 -37.46 87.52 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.297 -0.877 . . . . 0.0 109.068 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -63.89 -30.73 71.79 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.331 -0.856 . . . . 0.0 109.218 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 6.4 tp -55.98 -55.85 27.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.363 -0.835 . . . . 0.0 109.219 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 44.4 mttt -76.82 -13.94 59.96 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.25 179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.44 HD23 HD13 ' A' ' 109' ' ' LEU . 6.1 tp -77.16 -23.39 51.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.909 . . . . 0.0 109.579 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.591 ' CD1' ' CD1' ' A' ' 3' ' ' ILE . 32.2 t80 -75.58 -23.75 56.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.234 -0.916 . . . . 0.0 109.106 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.6 m -74.57 -34.05 62.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.319 -0.863 . . . . 0.0 109.259 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -90.73 -0.28 57.65 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.287 -0.883 . . . . 0.0 109.487 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.73 37.87 62.7 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -82.74 -23.1 34.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.217 -1.167 . . . . 0.0 109.473 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.455 ' CD2' ' O ' ' A' ' 91' ' ' ARG . 0.8 OUTLIER -83.69 162.03 20.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.235 -0.916 . . . . 0.0 109.289 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -87.63 146.95 25.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.184 -0.947 . . . . 0.0 109.91 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.507 ' HB3' ' CE2' ' A' ' 90' ' ' TYR . 9.2 pt-20 -135.79 179.8 6.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.43 -0.794 . . . . 0.0 109.077 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.8 mt -149.84 127.13 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.708 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.414 ' N ' ' CD ' ' A' ' 113' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.37 -0.831 . . . . 0.0 109.356 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.463 ' O ' ' HB2' ' A' ' 68' ' ' ALA . 36.7 mttt -147.01 126.73 13.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.269 -0.895 . . . . 0.0 109.221 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.489 ' HA ' ' CB ' ' A' ' 68' ' ' ALA . 4.3 mt -111.16 116.44 52.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.248 -0.908 . . . . 0.0 109.832 -179.582 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.486 ' CB ' ' O ' ' A' ' 27' ' ' MET . . . -108.28 146.57 32.7 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.248 -0.908 . . . . 0.0 109.394 179.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.447 HD11 ' HB ' ' A' ' 70' ' ' ILE . 5.4 mm -114.73 121.12 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.206 -0.934 . . . . 0.0 109.53 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.486 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -47.63 144.79 3.0 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.192 -0.943 . . . . 0.0 109.362 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 25' ' ' TYR . 11.3 t 49.99 -93.19 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.234 -0.916 . . . . 0.0 109.458 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.486 ' N ' ' O ' ' A' ' 6' ' ' ALA . 0.5 OUTLIER 66.81 8.68 6.18 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.169 -0.957 . . . . 0.0 109.518 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.517 ' N ' ' HB2' ' A' ' 14' ' ' SER . . . 44.06 -128.13 6.53 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.07 -13.59 11.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.304 -1.115 . . . . 0.0 109.546 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -171.32 -70.61 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.195 -0.941 . . . . 0.0 109.921 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 13' ' ' GLY . 0.3 OUTLIER -122.37 -22.54 5.48 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 0.0 110.022 -179.619 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 12' ' ' LEU . . . -42.19 -42.34 4.18 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.517 ' HB2' ' N ' ' A' ' 9' ' ' GLY . 27.3 t -77.87 85.28 4.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.272 -1.134 . . . . 0.0 109.674 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.457 ' C ' ' CG2' ' A' ' 16' ' ' VAL . 1.7 mt-10 -67.96 85.32 0.23 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.413 -0.805 . . . . 0.0 109.214 179.802 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.457 ' CG2' ' C ' ' A' ' 15' ' ' GLU . 1.5 t 70.58 30.98 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.451 -0.781 . . . . 0.0 109.265 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.466 ' HA ' ' OG ' ' A' ' 14' ' ' SER . 4.3 p 62.45 -160.99 0.3 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.339 -0.851 . . . . 0.0 109.543 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.0 ttm180 -154.8 -46.43 0.09 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.399 -0.813 . . . . 0.0 109.053 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -145.72 147.8 32.32 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.369 -0.832 . . . . 0.0 109.095 179.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.456 ' CG ' ' HB1' ' A' ' 71' ' ' ALA . 85.1 t80 -118.32 138.19 52.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.161 -0.962 . . . . 0.0 109.578 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.472 ' O ' ' CA ' ' A' ' 54' ' ' GLY . . . 139.84 -59.12 0.59 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.484 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.1 OUTLIER -116.98 13.45 14.87 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.2 -1.177 . . . . 0.0 109.774 -179.753 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.96 109.53 1.71 Allowed Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.233 -0.917 . . . . 0.0 109.884 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.9 Cg_endo -81.17 41.37 1.13 Allowed 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.548 2.165 . . . . 0.0 110.485 179.699 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.418 ' O ' ' O ' ' A' ' 7' ' ' SER . 0.4 OUTLIER -158.74 69.82 0.49 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.09 -1.006 . . . . 0.0 109.314 -179.911 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.507 ' CZ ' HD11 ' A' ' 61' ' ' ILE . 0.3 OUTLIER -82.27 112.69 19.5 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.62 -179.854 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' MET . . . . . 0.512 ' HG3' ' CG1' ' A' ' 41' ' ' VAL . 0.0 OUTLIER -85.15 144.69 28.03 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.877 . . . . 0.0 109.308 -179.996 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.442 HG12 ' HB1' ' A' ' 4' ' ' ALA . 39.4 mt -139.76 126.18 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.228 -0.92 . . . . 0.0 109.518 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 38' ' ' SER . 34.8 t -124.09 128.67 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.35 -0.844 . . . . 0.0 109.471 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -98.88 167.22 10.89 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.368 -0.833 . . . . 0.0 109.237 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.437 ' CE ' ' CG2' ' A' ' 36' ' ' ILE . 29.9 mtt -133.19 138.91 46.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.932 . . . . 0.0 109.448 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 6.7 ttmm -98.93 -48.06 5.04 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -0.913 . . . . 0.0 109.464 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 15.8 mtmm -148.81 66.59 1.05 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.341 -0.849 . . . . 0.0 109.218 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.77 12.59 42.46 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.419 ' O ' ' C ' ' A' ' 36' ' ' ILE . 8.2 t-20 -130.83 94.36 3.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -1.17 . . . . 0.0 109.462 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.46 ' O ' HG13 ' A' ' 36' ' ' ILE . 26.3 pt -43.64 126.07 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.702 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -137.06 16.53 3.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.344 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.451 ' O ' HG12 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -154.94 117.12 4.2 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 0.0 109.14 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 80.9 p -143.77 112.45 6.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.532 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -124.91 171.95 9.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.893 . . . . 0.0 109.373 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.512 ' CG1' ' HG3' ' A' ' 27' ' ' MET . 20.8 m -131.73 115.87 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.274 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.2 tp -105.06 152.6 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.245 -0.909 . . . . 0.0 109.413 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -105.1 145.12 30.96 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.223 -0.923 . . . . 0.0 109.399 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . 0.423 ' HB2' ' HA ' ' A' ' 24' ' ' PRO . 4.7 m-20 . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.278 -0.889 . . . . 0.0 109.558 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.472 ' CA ' ' O ' ' A' ' 21' ' ' GLY . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 42.9 mm -68.55 -11.55 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.157 -1.202 . . . . 0.0 109.376 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.5 ttt180 -76.36 -16.32 59.77 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.327 -0.858 . . . . 0.0 109.6 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.418 ' HA ' HD12 ' A' ' 60' ' ' ILE . 10.6 t -63.34 -25.94 68.53 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.253 -0.904 . . . . 0.0 109.252 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . 0.461 ' O ' HG13 ' A' ' 61' ' ' ILE . . . -54.36 -36.17 63.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 109.588 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -74.01 -32.55 63.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.141 -0.974 . . . . 0.0 109.425 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.418 HD12 ' HA ' ' A' ' 57' ' ' THR . 81.9 mt -65.96 -40.7 88.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.267 -0.896 . . . . 0.0 109.541 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.507 HD11 ' CZ ' ' A' ' 26' ' ' PHE . 8.6 pt -76.69 -29.23 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.576 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -62.57 -39.26 93.1 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.187 -0.946 . . . . 0.0 109.711 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -68.98 -12.68 61.89 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.237 -0.914 . . . . 0.0 109.831 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -89.15 -7.84 54.88 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.182 -0.949 . . . . 0.0 109.542 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.522 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 100.8 -12.04 59.26 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.452 HG13 ' O ' ' A' ' 68' ' ' ALA . 16.4 t -51.81 89.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.375 -1.073 . . . . 0.0 109.489 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.522 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -80.91 -5.66 57.7 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.307 -0.871 . . . . 0.0 109.099 179.568 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.489 ' CB ' ' HA ' ' A' ' 3' ' ' ILE . . . -125.2 134.84 52.21 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.211 -0.931 . . . . 0.0 109.523 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.46 HG21 HD12 ' A' ' 61' ' ' ILE . 86.4 t -137.27 111.93 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.162 -0.961 . . . . 0.0 109.919 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.492 ' N ' ' CD1' ' A' ' 70' ' ' ILE . 1.7 mp -94.88 106.11 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.313 -0.867 . . . . 0.0 108.979 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.456 ' HB1' ' CG ' ' A' ' 20' ' ' PHE . . . -135.78 173.57 11.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.129 -0.982 . . . . 0.0 109.86 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.26 40.54 2.46 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.428 -0.795 . . . . 0.0 109.44 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 t -45.98 146.67 1.98 Allowed Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.207 -0.933 . . . . 0.0 109.41 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -77.98 -17.92 13.36 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.642 2.228 . . . . 0.0 110.492 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -127.02 164.76 20.48 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.87 4.65 5.92 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.626 2.217 . . . . 0.0 110.431 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . 0.463 ' O ' ' HB3' ' A' ' 80' ' ' GLU . 2.9 t-20 -62.3 -43.16 99.47 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.314 -0.866 . . . . 0.0 109.545 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -64.13 -57.71 8.78 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.283 -0.886 . . . . 0.0 109.53 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . 0.564 ' CE2' ' OE1' ' A' ' 111' ' ' GLU . 9.2 m-85 -58.21 -21.42 47.81 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.58 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.463 ' HB3' ' O ' ' A' ' 77' ' ' ASN . 29.7 tt0 -62.17 -59.6 4.81 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.197 -0.939 . . . . 0.0 109.393 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.4 t -61.22 -44.88 99.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.235 -0.916 . . . . 0.0 109.203 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.464 HD22 ' CD1' ' A' ' 87' ' ' ILE . 14.3 mt -50.35 -37.94 39.63 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.248 -0.907 . . . . 0.0 109.307 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -64.31 -42.87 96.13 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.344 -0.848 . . . . 0.0 109.363 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -69.98 -15.69 63.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.328 -0.858 . . . . 0.0 109.338 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.443 ' HB3' HG13 ' A' ' 87' ' ' ILE . 17.9 mt -95.6 -8.1 35.9 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.181 -0.95 . . . . 0.0 109.517 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 63.03 32.83 85.46 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.464 ' CD1' HD22 ' A' ' 82' ' ' LEU . 13.1 mt -96.22 171.4 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.234 -1.157 . . . . 0.0 109.511 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 8.0 mttt -91.86 117.08 29.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.646 -179.767 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.55 ' CG2' ' CD1' ' A' ' 79' ' ' PHE . 10.5 mt -94.29 128.18 45.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.346 -0.846 . . . . 0.0 109.388 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.551 ' CE2' ' O ' ' A' ' 109' ' ' LEU . 2.2 m-85 -123.21 144.01 49.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.278 -0.889 . . . . 0.0 109.334 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . 0.5 ' HG2' ' CG ' ' A' ' 111' ' ' GLU . 0.0 OUTLIER -91.21 132.05 36.35 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.158 -0.964 . . . . 0.0 109.653 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.02 94.3 9.57 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.239 -0.913 . . . . 0.0 109.409 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -135.46 23.14 3.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.125 -0.984 . . . . 0.0 109.624 -179.808 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -86.69 -134.26 3.84 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.669 -1.373 . . . . 0.0 109.669 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.441 ' C ' HG23 ' A' ' 16' ' ' VAL . 5.2 t -136.14 -38.35 0.7 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.267 -1.137 . . . . 0.0 109.447 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 29.0 t -125.77 137.08 53.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.314 -0.866 . . . . 0.0 109.502 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.454 HG13 ' HA ' ' A' ' 8' ' ' SER . 0.3 OUTLIER -55.03 -35.59 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -0.858 . . . . 0.0 109.406 179.916 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -69.2 -51.83 33.95 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.233 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.49 ' O ' ' CD1' ' A' ' 103' ' ' LEU . 3.2 tt0 -52.18 -31.67 32.71 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.244 -0.91 . . . . 0.0 109.166 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -72.39 -49.73 31.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.342 -0.848 . . . . 0.0 109.152 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.452 HD21 HG21 ' A' ' 36' ' ' ILE . 27.1 tp -50.4 -51.31 47.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.284 -0.885 . . . . 0.0 109.513 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -65.77 -35.4 80.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.205 -0.935 . . . . 0.0 109.492 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.49 ' CD1' ' O ' ' A' ' 99' ' ' GLU . 0.7 OUTLIER -71.71 -11.17 60.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.269 -0.895 . . . . 0.0 109.537 179.947 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.504 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.8 t80 -76.93 -38.3 53.68 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.263 -0.898 . . . . 0.0 109.453 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 28.8 m -72.09 -13.78 61.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.464 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -96.45 -17.23 20.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.182 -0.949 . . . . 0.0 109.49 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 74.43 29.45 61.89 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . 0.458 ' HB3' HD22 ' A' ' 103' ' ' LEU . 0.4 OUTLIER -79.96 -44.11 20.86 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.297 -1.119 . . . . 0.0 109.693 -179.882 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.551 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.4 OUTLIER -123.28 146.62 47.73 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.235 -0.916 . . . . 0.0 109.463 -179.949 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.519 ' HA ' ' CG ' ' A' ' 90' ' ' TYR . 1.1 pm0 -171.66 -156.79 0.11 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.904 . . . . 0.0 109.458 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.564 ' OE1' ' CE2' ' A' ' 79' ' ' PHE . 0.0 OUTLIER -146.29 -87.19 0.1 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.27 -0.894 . . . . 0.0 109.678 179.951 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.443 HG23 ' N ' ' A' ' 113' ' ' ARG . 7.0 mt -131.37 151.37 35.51 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.192 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.443 ' N ' HG23 ' A' ' 112' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 O-C-N 121.34 -0.85 . . . . 0.0 109.382 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.423 ' O ' ' HG2' ' A' ' 1' ' ' MET . 5.1 ttt . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.445 ' O ' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -131.18 156.05 45.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.218 -0.926 . . . . 0.0 109.521 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ILE . . . . . 0.526 HD13 ' CD1' ' A' ' 104' ' ' PHE . 7.0 mt -116.01 107.47 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.552 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.578 ' HB3' ' CZ ' ' A' ' 26' ' ' PHE . . . -97.18 170.85 8.83 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.326 -0.859 . . . . 0.0 109.13 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.411 HG13 ' C ' ' A' ' 4' ' ' ALA . 98.1 mt -148.13 119.93 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.172 -0.955 . . . . 0.0 109.889 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.525 ' HB3' ' CD1' ' A' ' 20' ' ' PHE . . . -87.14 143.95 27.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 108.949 179.565 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.434 ' OG ' ' O ' ' A' ' 19' ' ' PHE . 1.2 m 61.77 81.74 0.19 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.055 -1.028 . . . . 0.0 109.129 -179.723 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.499 ' O ' ' CB ' ' A' ' 14' ' ' SER . 0.0 OUTLIER -136.32 -37.63 0.7 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.308 -179.788 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.49 -171.95 27.05 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.05 9.99 15.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.175 -1.191 . . . . 0.0 109.454 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 47.5 p-10 -170.25 -174.14 1.65 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.483 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.523 ' CB ' ' HB2' ' A' ' 98' ' ' GLU . 0.7 OUTLIER -75.66 -20.97 58.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.21 -0.932 . . . . 0.0 109.456 179.941 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.486 ' N ' ' HG ' ' A' ' 12' ' ' LEU . . . -46.38 -45.5 16.45 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.499 ' CB ' ' O ' ' A' ' 8' ' ' SER . 0.6 OUTLIER -76.15 81.43 2.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.278 -1.131 . . . . 0.0 109.429 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLU . . . . . 0.534 ' O ' ' CB ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER -73.27 83.06 1.38 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.339 -0.851 . . . . 0.0 109.359 179.874 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.534 ' CB ' ' O ' ' A' ' 15' ' ' GLU . 2.6 t 78.01 77.56 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.485 -0.759 . . . . 0.0 109.478 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 16' ' ' VAL . 0.1 OUTLIER -43.59 -73.92 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -0.914 . . . . 0.0 109.594 -179.93 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -140.33 -82.06 0.25 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.23 -0.919 . . . . 0.0 109.542 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.434 ' O ' ' OG ' ' A' ' 7' ' ' SER . 24.2 m-85 -146.29 -144.71 0.16 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.29 -0.882 . . . . 0.0 109.332 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.525 ' CD1' ' HB3' ' A' ' 6' ' ' ALA . 16.6 t80 -121.5 27.5 8.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.172 -0.955 . . . . 0.0 109.497 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -83.07 -74.7 1.2 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.447 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.5 OUTLIER -123.0 27.98 7.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.277 -1.131 . . . . 0.0 109.349 179.929 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -50.91 108.46 1.05 Allowed Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.371 -0.83 . . . . 0.0 109.34 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.447 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.3 Cg_endo -79.57 39.27 0.81 Allowed 'Trans proline' 0 C--N 1.311 -1.425 0 C-N-CA 122.566 2.178 . . . . 0.0 111.077 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.537 ' CD1' ' HG2' ' A' ' 43' ' ' GLU . 48.1 m-85 -155.55 67.16 0.63 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.98 -1.075 . . . . 0.0 109.065 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . 0.578 ' CZ ' ' HB3' ' A' ' 4' ' ' ALA . 9.2 t80 -81.88 120.25 24.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.436 -0.79 . . . . 0.0 109.592 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 4.5 ttm -103.45 159.99 15.1 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.277 -0.889 . . . . 0.0 109.558 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.528 ' CD1' HG22 ' A' ' 66' ' ' VAL . 1.1 tp -148.53 133.01 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.268 -0.895 . . . . 0.0 109.54 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.402 HG11 ' O ' ' A' ' 38' ' ' SER . 39.5 t -143.11 124.83 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.592 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -99.09 171.4 8.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.235 -0.916 . . . . 0.0 109.317 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' MET . . . . . 0.453 ' HE1' HG23 ' A' ' 36' ' ' ILE . 13.6 ttm -139.66 138.93 36.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -0.893 . . . . 0.0 109.583 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.74 -47.82 6.02 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.21 -0.931 . . . . 0.0 109.522 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 13.1 mttp -153.27 41.09 0.55 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.235 -0.916 . . . . 0.0 109.463 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.99 -8.53 55.92 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.464 ' O ' ' HG2' ' A' ' 37' ' ' GLU . 6.9 m-20 -117.02 97.18 5.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -1.157 . . . . 0.0 109.356 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.469 ' O ' HG13 ' A' ' 36' ' ' ILE . 5.6 pt -47.25 113.02 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.412 -0.805 . . . . 0.0 109.586 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.464 ' HG2' ' O ' ' A' ' 35' ' ' ASN . 14.9 mm-40 -109.72 19.26 19.36 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -0.917 . . . . 0.0 109.664 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.402 ' O ' HG11 ' A' ' 29' ' ' VAL . 2.1 p -163.53 120.78 1.82 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 109.319 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 5.7 p -149.28 107.53 3.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.539 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -117.3 156.27 28.09 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.171 -0.955 . . . . 0.0 109.516 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.425 ' C ' HG21 ' A' ' 42' ' ' ILE . 2.2 p -126.19 138.71 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.257 -0.902 . . . . 0.0 109.402 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.425 HG21 ' C ' ' A' ' 41' ' ' VAL . 40.8 pt -135.71 146.43 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.351 -0.843 . . . . 0.0 109.614 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.537 ' HG2' ' CD1' ' A' ' 25' ' ' TYR . 42.0 mt-10 -98.25 55.61 1.14 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.231 -0.918 . . . . 0.0 109.13 179.7 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.501 0 O-C-N 121.323 -0.86 . . . . 0.0 109.372 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . 0.433 HG23 ' N ' ' A' ' 78' ' ' ALA . 34.6 mm -65.35 -33.24 62.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.319 -1.106 . . . . 0.0 109.648 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.74 -14.77 62.11 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.208 -0.932 . . . . 0.0 109.717 -179.826 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 85.7 m -67.53 -18.02 64.88 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.114 -0.991 . . . . 0.0 109.744 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -60.28 -28.16 67.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.235 -0.916 . . . . 0.0 109.654 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -62.67 -49.75 73.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.295 -0.878 . . . . 0.0 109.687 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.7 mt -64.04 -45.67 96.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.892 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.49 HG21 ' CZ ' ' A' ' 26' ' ' PHE . 41.6 mt -52.2 -48.0 43.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.237 -0.914 . . . . 0.0 109.957 -179.676 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.74 -37.45 84.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.171 -0.955 . . . . 0.0 109.998 -179.524 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -66.25 -11.1 48.15 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.097 -1.002 . . . . 0.0 109.851 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -88.99 16.75 6.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.117 -0.989 . . . . 0.0 109.556 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.453 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 95.31 -20.75 47.89 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . 0.528 HG22 ' CD1' ' A' ' 28' ' ' ILE . 97.1 t -57.06 88.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.312 -1.111 . . . . 0.0 109.506 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.453 ' N ' ' O ' ' A' ' 65' ' ' GLY . 14.0 mttt -79.91 -8.45 59.33 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.329 -0.857 . . . . 0.0 108.777 179.331 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ALA . . . . . 0.475 ' O ' HG21 ' A' ' 69' ' ' VAL . . . -128.05 138.61 52.64 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' VAL . . . . . 0.475 HG21 ' O ' ' A' ' 68' ' ' ALA . 95.3 t -141.37 122.08 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.112 -0.993 . . . . 0.0 109.821 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.572 ' N ' ' CD1' ' A' ' 70' ' ' ILE . 1.3 mp -93.43 144.5 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.345 -0.847 . . . . 0.0 108.804 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -176.81 175.94 1.56 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.127 -0.983 . . . . 0.0 109.755 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -153.04 66.51 0.79 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.412 -0.805 . . . . 0.0 109.347 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -73.02 158.92 86.43 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.238 -0.914 . . . . 0.0 109.568 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.55 -39.2 0.42 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.658 2.239 . . . . 0.0 110.764 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -121.22 178.45 16.38 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -179.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.28 40.67 1.0 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.853 2.369 . . . . 0.0 110.753 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 52.5 m-20 -76.1 -67.54 0.67 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.085 -1.01 . . . . 0.0 109.314 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ALA . . . . . 0.433 ' N ' HG23 ' A' ' 55' ' ' ILE . . . -74.66 -25.91 59.51 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.32 179.733 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -66.23 -21.11 66.29 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.373 -0.829 . . . . 0.0 109.398 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.412 ' O ' ' HB2' ' A' ' 84' ' ' GLU . 11.8 mt-10 -77.4 -46.84 21.44 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.233 -0.917 . . . . 0.0 109.833 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.4 t -68.65 -36.13 73.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.132 -0.98 . . . . 0.0 109.824 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . 0.474 ' HB3' ' CG1' ' A' ' 89' ' ' ILE . 8.7 mt -73.75 -57.61 3.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.268 -0.895 . . . . 0.0 109.707 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 8.2 t-20 -49.53 -37.78 28.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.212 -0.93 . . . . 0.0 109.6 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . 0.412 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 0.3 OUTLIER -73.02 -39.34 66.08 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.217 -0.927 . . . . 0.0 109.403 -179.947 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' LEU . . . . . 0.404 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.3 OUTLIER -64.54 -13.12 51.06 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.134 -0.979 . . . . 0.0 109.475 -179.943 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 75.13 26.57 66.05 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ILE . . . . . 0.406 ' CG2' ' N ' ' A' ' 88' ' ' LYS . 23.1 mm -91.91 160.85 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.345 -1.091 . . . . 0.0 109.423 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' LYS . . . . . 0.406 ' N ' ' CG2' ' A' ' 87' ' ' ILE . 7.8 mtpt -83.01 105.14 13.76 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.169 -0.957 . . . . 0.0 109.309 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ILE . . . . . 0.511 ' O ' ' CB ' ' A' ' 111' ' ' GLU . 3.1 mt -90.75 152.33 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.182 -0.949 . . . . 0.0 109.513 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' TYR . . . . . 0.484 ' CD1' ' O ' ' A' ' 110' ' ' GLU . 1.1 m-85 -136.63 141.27 43.22 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -0.875 . . . . 0.0 109.404 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.25 149.19 22.85 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.537 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.86 141.04 38.72 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.277 -0.889 . . . . 0.0 109.365 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.98 -17.28 24.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.541 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.463 ' HA2' ' CG2' ' A' ' 16' ' ' VAL . . . 101.94 13.55 31.4 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 52.0 m -81.19 -55.3 4.83 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -1.16 . . . . 0.0 109.459 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 173.16 130.19 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.321 -0.862 . . . . 0.0 109.572 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.45 HG23 ' N ' ' A' ' 98' ' ' GLU . 33.6 m -65.02 -23.79 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.374 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . 0.523 ' HB2' ' CB ' ' A' ' 12' ' ' LEU . 1.5 tt0 -65.89 -60.05 3.24 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.277 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.408 ' O ' ' CD1' ' A' ' 103' ' ' LEU . 36.1 mm-40 -60.38 -28.66 68.39 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.291 -0.881 . . . . 0.0 109.33 179.793 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ASN . . . . . 0.417 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 6.4 m-20 -69.68 -30.58 68.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.286 -0.884 . . . . 0.0 109.409 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' LEU . . . . . 0.477 HD23 ' N ' ' A' ' 102' ' ' LYS . 6.8 tt -59.87 -60.08 4.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.404 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' LYS . . . . . 0.477 ' N ' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -64.94 -29.07 69.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.319 -0.863 . . . . 0.0 109.38 179.922 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.417 ' HB2' ' HA ' ' A' ' 100' ' ' ASN . 0.4 OUTLIER -65.46 -30.69 71.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.239 -0.913 . . . . 0.0 109.627 -179.935 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' PHE . . . . . 0.526 ' CD1' HD13 ' A' ' 3' ' ' ILE . 23.4 t80 -59.75 -32.1 70.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.192 -0.942 . . . . 0.0 109.589 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 28.3 m -67.19 -40.92 86.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.887 . . . . 0.0 109.73 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -79.8 4.99 14.76 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.276 -0.89 . . . . 0.0 109.553 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 46.09 28.98 3.23 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -80.01 -33.2 39.48 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.193 -1.181 . . . . 0.0 109.379 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.413 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 45.5 mt -65.84 -176.93 0.42 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.313 -0.867 . . . . 0.0 109.306 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.484 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 11.3 pt-20 -108.48 143.59 37.24 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.572 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' GLU . . . . . 0.511 ' CB ' ' O ' ' A' ' 89' ' ' ILE . 0.0 OUTLIER -137.06 -174.01 3.62 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.276 -0.89 . . . . 0.0 109.298 179.863 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 111' ' ' GLU . 2.3 mp -147.99 147.48 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.18 -0.95 . . . . 0.0 109.493 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ARG . . . . . 0.446 ' HB2' ' O ' ' A' ' 112' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.331 -0.855 . . . . 0.0 109.417 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.271 0.558 . . . . 0.0 109.513 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.468 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 23.2 mttp -110.91 128.27 55.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.232 -0.917 . . . . 0.0 109.501 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.633 ' CD1' ' CD2' ' A' ' 104' ' ' PHE . 3.9 mt -95.51 128.05 47.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.301 -0.875 . . . . 0.0 109.57 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.448 ' HB3' ' CG1' ' A' ' 66' ' ' VAL . . . -116.33 122.55 45.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.205 -0.934 . . . . 0.0 109.451 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.514 ' N ' ' CD1' ' A' ' 5' ' ' ILE . 1.2 mm -97.24 115.53 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.196 -0.94 . . . . 0.0 109.485 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.557 ' HB3' ' CE1' ' A' ' 26' ' ' PHE . . . -59.01 146.58 37.73 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.297 -0.877 . . . . 0.0 109.626 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 2.4 m 52.73 -98.09 0.07 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -0.851 . . . . 0.0 109.611 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.454 ' OG ' HG13 ' A' ' 97' ' ' VAL . 75.4 m 59.05 15.36 3.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.078 -1.014 . . . . 0.0 109.448 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.536 ' N ' ' HB3' ' A' ' 14' ' ' SER . . . 52.69 -150.96 8.78 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.3 m -129.5 -8.38 4.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.243 -1.151 . . . . 0.0 110.092 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -131.19 -89.17 0.46 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.965 -1.084 . . . . 0.0 109.873 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -158.99 26.33 0.21 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.167 -0.958 . . . . 0.0 109.669 -179.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.86 -41.17 1.47 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.536 ' HB3' ' N ' ' A' ' 9' ' ' GLY . 0.7 OUTLIER -77.34 84.17 3.77 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.251 -1.146 . . . . 0.0 109.48 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.473 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER -72.44 83.31 1.08 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.441 -0.787 . . . . 0.0 109.556 179.982 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.473 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 14.2 t 70.23 5.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.383 -0.823 . . . . 0.0 109.769 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 51.6 -95.91 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.286 -0.884 . . . . 0.0 109.682 179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.408 ' N ' ' O ' ' A' ' 16' ' ' VAL . 2.2 mtt180 -158.35 -77.93 0.07 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.029 -1.044 . . . . 0.0 109.707 -179.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.421 ' CD2' ' O ' ' A' ' 72' ' ' SER . 22.4 m-85 -117.17 174.3 6.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.221 -0.924 . . . . 0.0 109.632 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.513 ' CB ' ' HB2' ' A' ' 71' ' ' ALA . 2.9 t80 -117.04 104.72 11.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.254 -0.903 . . . . 0.0 109.402 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.45 ' HA2' ' CD1' ' A' ' 55' ' ' ILE . . . -143.01 -57.94 0.03 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.456 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.6 mtp85 -128.75 17.2 6.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.307 -1.114 . . . . 0.0 109.24 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -48.16 106.63 0.63 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.337 -0.852 . . . . 0.0 109.776 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.503 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 37.0 Cg_endo -80.74 42.23 1.29 Allowed 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.609 2.206 . . . . 0.0 110.477 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.503 ' CD2' ' O ' ' A' ' 24' ' ' PRO . 5.7 m-85 -159.83 69.53 0.42 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.09 -1.007 . . . . 0.0 109.584 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.571 ' CE2' HD13 ' A' ' 61' ' ' ILE . 0.1 OUTLIER -84.61 112.86 20.82 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.214 -0.929 . . . . 0.0 109.215 179.865 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -79.74 135.39 36.5 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.291 -0.88 . . . . 0.0 109.77 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 14.3 mm -108.25 138.47 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.209 -0.932 . . . . 0.0 109.323 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 75.8 t -131.92 103.83 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.385 -0.822 . . . . 0.0 109.459 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -85.43 88.65 7.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.183 -0.948 . . . . 0.0 109.539 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -82.83 141.73 32.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.316 -0.865 . . . . 0.0 109.386 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 4.9 tptt -117.58 -72.08 0.71 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.127 -0.983 . . . . 0.0 109.463 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 23.3 mttm -110.58 58.84 0.61 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.206 -0.934 . . . . 0.0 109.395 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 65.0 13.5 57.47 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 36' ' ' ILE . 25.0 t30 -132.74 105.87 7.42 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.293 -1.122 . . . . 0.0 109.403 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.406 ' C ' ' O ' ' A' ' 35' ' ' ASN . 3.3 mp -42.97 114.25 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.311 -0.868 . . . . 0.0 109.577 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -96.76 -9.52 28.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 109.492 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -159.62 119.23 2.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.27 -0.894 . . . . 0.0 109.513 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.6 p -120.83 102.89 8.67 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.229 -0.919 . . . . 0.0 108.906 179.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -121.7 -176.45 3.32 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.371 -0.831 . . . . 0.0 109.859 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.8 p -151.98 130.4 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.408 -0.808 . . . . 0.0 109.309 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.403 ' O ' HG13 ' A' ' 42' ' ' ILE . 12.2 pt -114.12 131.22 66.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.189 -0.944 . . . . 0.0 109.671 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -97.73 150.42 21.23 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.285 -0.884 . . . . 0.0 109.429 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.437 ' HB2' ' HB3' ' A' ' 24' ' ' PRO . 55.6 m-20 -66.88 152.92 95.15 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.319 -0.863 . . . . 0.0 109.404 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.34 -78.71 0.01 OUTLIER 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.624 2.216 . . . . 0.0 110.402 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.34 74.6 1.25 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.303 -0.873 . . . . 0.0 109.351 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -75.43 -14.79 60.47 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.175 -0.953 . . . . 0.0 109.602 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -118.23 66.06 0.76 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.191 -0.943 . . . . 0.0 109.503 -179.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -179.79 -52.44 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.156 -0.965 . . . . 0.0 109.495 179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -55.23 170.74 0.19 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.252 -0.905 . . . . 0.0 109.471 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.35 134.31 11.64 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 50.1 84.28 0.02 OUTLIER Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -136.16 -150.28 0.36 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -1.16 . . . . 0.0 109.483 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 82.85 -81.2 1.75 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.45 ' CD1' ' HA2' ' A' ' 21' ' ' GLY . 7.1 mm -74.82 -7.32 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.268 -1.136 . . . . 0.0 109.516 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.33 -23.07 60.2 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.237 -0.914 . . . . 0.0 109.23 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 6.1 t -57.47 -22.77 45.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.39 -0.819 . . . . 0.0 109.468 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.453 ' HA ' HD11 ' A' ' 61' ' ' ILE . . . -53.71 -50.0 66.88 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.306 -0.871 . . . . 0.0 109.624 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -46.41 -41.24 13.41 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.91 . . . . 0.0 109.625 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 50.4 mt -71.51 -39.97 71.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.237 -0.914 . . . . 0.0 109.703 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.571 HD13 ' CE2' ' A' ' 26' ' ' PHE . 63.4 mt -56.11 -32.82 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.226 -0.922 . . . . 0.0 109.473 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.443 ' HB2' ' CD1' ' A' ' 87' ' ' ILE . . . -76.67 -31.19 57.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.285 -0.884 . . . . 0.0 109.477 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 27.7 t30 -72.71 -14.38 61.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -0.876 . . . . 0.0 109.639 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -90.08 -1.22 57.92 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.206 -0.934 . . . . 0.0 109.649 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.52 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 87.4 -6.37 83.49 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.468 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 96.0 t -48.09 92.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -1.103 . . . . 0.0 109.662 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.52 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.6 OUTLIER -79.5 -2.09 40.54 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.371 -0.83 . . . . 0.0 108.813 179.38 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.438 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -134.79 129.52 34.7 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.861 . . . . 0.0 109.373 179.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.4 t -130.46 96.84 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.163 -0.96 . . . . 0.0 109.613 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.452 ' HA ' ' HB3' ' A' ' 90' ' ' TYR . 7.0 mt -91.22 109.73 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.213 -0.929 . . . . 0.0 109.288 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.513 ' HB2' ' CB ' ' A' ' 20' ' ' PHE . . . -144.08 176.94 8.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.248 -0.908 . . . . 0.0 109.778 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.421 ' O ' ' CD2' ' A' ' 19' ' ' PHE . 75.1 m -133.38 41.6 3.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.527 -0.733 . . . . 0.0 109.435 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -53.64 143.12 39.91 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.307 -0.871 . . . . 0.0 109.459 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -79.03 88.04 1.5 Allowed 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 122.639 2.226 . . . . 0.0 110.601 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 122.5 162.6 11.6 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.84 7.88 4.05 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 C-N-CA 122.75 2.3 . . . . 0.0 110.591 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.453 ' O ' ' HB3' ' A' ' 80' ' ' GLU . 1.5 m120 -55.25 -65.66 0.55 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.226 -0.921 . . . . 0.0 109.583 -179.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.8 -51.93 67.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.906 . . . . 0.0 109.675 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.8 m-30 -57.76 -15.97 9.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.223 -0.923 . . . . 0.0 109.754 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.453 ' HB3' ' O ' ' A' ' 77' ' ' ASN . 54.0 tt0 -72.82 -50.34 24.77 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.197 -0.939 . . . . 0.0 109.302 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 82' ' ' LEU . 2.4 t -71.3 -53.16 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 O-C-N 121.289 -0.882 . . . . 0.0 109.258 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.51 HD21 ' N ' ' A' ' 82' ' ' LEU . 4.4 mm? -45.75 -30.09 1.51 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.14 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -77.06 -47.75 19.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.336 -0.853 . . . . 0.0 109.346 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -68.02 -8.63 39.18 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.244 -0.91 . . . . 0.0 109.59 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.6 mp -86.48 -48.4 8.43 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.22 -0.925 . . . . 0.0 109.539 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.35 11.1 9.96 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.443 ' CD1' ' HB2' ' A' ' 62' ' ' ALA . 1.6 mt -91.69 172.37 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.24 -1.153 . . . . 0.0 109.419 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.463 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 0.1 OUTLIER -90.35 114.66 26.8 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.269 -0.894 . . . . 0.0 109.669 -179.926 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.494 ' CG1' ' HB3' ' A' ' 82' ' ' LEU . 5.9 mt -82.77 150.37 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.294 -0.879 . . . . 0.0 108.939 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.541 ' CE2' ' HB3' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -139.68 148.17 42.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.625 -179.95 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.42 140.2 39.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.315 -0.866 . . . . 0.0 109.614 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -110.32 88.04 2.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.936 . . . . 0.0 109.677 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.92 -40.32 42.98 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -0.901 . . . . 0.0 109.29 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 128.3 116.43 1.95 Allowed Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -164.38 -67.3 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.198 -1.178 . . . . 0.0 109.471 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.462 ' O ' ' HB2' ' A' ' 100' ' ' ASN . 0.1 OUTLIER 171.71 157.21 0.09 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.244 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.454 HG13 ' OG ' ' A' ' 8' ' ' SER . 1.8 t -74.28 -48.07 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.278 -0.889 . . . . 0.0 109.651 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -50.93 -50.16 58.29 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.276 -0.89 . . . . 0.0 109.846 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 31.0 mm-40 -70.55 -35.58 73.18 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.224 -0.923 . . . . 0.0 109.893 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.462 ' HB2' ' O ' ' A' ' 96' ' ' SER . 7.4 t30 -56.23 -39.08 71.96 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.165 -0.96 . . . . 0.0 109.735 -179.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 75.7 mt -57.77 -62.92 1.45 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.233 -0.917 . . . . 0.0 109.558 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 5.7 ttpt -62.52 -15.11 48.77 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.212 -0.93 . . . . 0.0 109.575 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -77.09 -33.55 56.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.224 -0.922 . . . . 0.0 109.799 -179.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.633 ' CD2' ' CD1' ' A' ' 3' ' ' ILE . 79.3 t80 -74.2 -24.78 59.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.163 -0.961 . . . . 0.0 109.765 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 61.3 m -72.24 -22.91 61.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.227 -0.92 . . . . 0.0 109.674 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -103.79 4.95 35.67 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 109.597 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 55.95 40.54 82.17 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 -79.96 -51.45 9.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.192 -1.181 . . . . 0.0 109.558 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 13.8 mt -56.34 176.8 0.08 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 109.497 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.425 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 8.7 pt-20 -109.65 148.4 31.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.286 -0.884 . . . . 0.0 109.42 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.541 ' HB3' ' CE2' ' A' ' 90' ' ' TYR . 6.1 pt-20 -134.25 155.68 49.75 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.232 -0.917 . . . . 0.0 109.656 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 67.5 mt -135.36 143.44 36.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.321 -0.862 . . . . 0.0 109.047 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -139.76 -172.41 3.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.112 -0.992 . . . . 0.0 109.909 -179.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 29.1 t -156.94 95.23 2.2 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.441 -0.787 . . . . 0.0 109.19 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.64 152.64 29.6 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.533 2.156 . . . . 0.0 110.584 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -128.89 18.79 5.59 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 2.6 p -132.22 60.89 1.67 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.351 -1.088 . . . . 0.0 109.369 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.07 169.25 13.89 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 49.33 88.68 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.338 -1.095 . . . . 0.0 109.66 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -76.71 105.5 2.03 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.22 77.57 1.41 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.162 -1.199 . . . . 0.0 109.728 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -83.35 149.71 26.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.161 -0.962 . . . . 0.0 109.303 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.505 ' O ' ' CG ' ' A' ' 124' ' ' ARG . 1.2 mtt180 -90.08 106.93 18.81 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.215 -0.928 . . . . 0.0 109.668 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.505 ' CG ' ' O ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.508 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.447 ' HA ' ' CB ' ' A' ' 67' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.432 ' HD2' ' O ' ' A' ' 65' ' ' GLY . 0.5 OUTLIER -89.29 147.4 24.13 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.223 -0.923 . . . . 0.0 109.474 -179.926 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.464 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 5.3 mt -115.08 119.86 62.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.212 -0.93 . . . . 0.0 109.701 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.463 ' CB ' HG12 ' A' ' 66' ' ' VAL . . . -112.87 111.45 22.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.279 -0.888 . . . . 0.0 109.073 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.51 HG23 ' CG2' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -98.41 126.19 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.228 -0.92 . . . . 0.0 109.8 -179.487 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.49 134.27 42.28 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.302 -0.874 . . . . 0.0 109.153 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.411 ' OG ' ' HG3' ' A' ' 27' ' ' MET . 0.0 OUTLIER -144.45 156.08 44.03 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.067 -1.02 . . . . 0.0 109.768 -179.814 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.42 -26.56 11.4 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.345 -0.847 . . . . 0.0 109.427 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -87.63 -105.62 0.9 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -148.73 -45.05 0.15 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.155 -1.203 . . . . 0.0 109.407 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' A' ' 11' ' ' ASP . 2.3 t70 -154.47 -55.29 0.1 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 109.367 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.2 tt -105.62 -37.69 6.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.18 -0.95 . . . . 0.0 109.337 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -57.71 -26.47 57.5 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.413 ' O ' ' OG ' ' A' ' 14' ' ' SER . 54.4 p -76.92 80.14 3.48 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.271 -1.135 . . . . 0.0 109.439 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.458 ' O ' ' CB ' ' A' ' 16' ' ' VAL . 0.3 OUTLIER -76.88 82.0 3.45 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.261 -0.899 . . . . 0.0 109.575 -179.88 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 95' ' ' THR . 3.0 t 73.16 19.64 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.255 -0.903 . . . . 0.0 109.651 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 44.36 -163.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.209 -0.932 . . . . 0.0 109.422 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.32 -32.71 2.67 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -0.902 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -150.12 -179.83 7.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.141 -0.974 . . . . 0.0 109.666 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.7 t80 -121.77 83.78 2.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.356 -0.84 . . . . 0.0 109.404 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 147.1 -18.64 1.56 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.458 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 1.6 mtp180 -110.55 -29.41 8.07 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.257 -1.143 . . . . 0.0 109.373 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.37 110.61 2.47 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.917 . . . . 0.0 109.399 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.458 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.5 46.65 2.31 Favored 'Trans proline' 0 C--N 1.312 -1.369 0 C-N-CA 122.692 2.261 . . . . 0.0 110.948 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.472 ' CE2' ' OE2' ' A' ' 43' ' ' GLU . 11.3 m-85 -158.51 70.01 0.51 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.99 -1.068 . . . . 0.0 109.417 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.495 ' CD1' ' HB2' ' A' ' 44' ' ' ASN . 46.1 m-85 -81.4 153.53 26.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.2 -0.937 . . . . 0.0 109.737 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' MET . . . . . 0.441 ' O ' ' HA ' ' A' ' 4' ' ' ALA . 37.9 mtp -120.3 114.16 21.47 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.34 -0.85 . . . . 0.0 109.041 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.439 ' O ' ' HA ' ' A' ' 39' ' ' SER . 26.6 mm -105.46 120.48 56.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.158 -0.964 . . . . 0.0 109.797 -179.566 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.499 HG23 ' CB ' ' A' ' 39' ' ' SER . 44.2 t -122.74 116.03 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.362 -0.836 . . . . 0.0 109.301 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -89.73 86.84 6.78 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.25 -0.906 . . . . 0.0 109.615 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.524 ' HE1' ' CG2' ' A' ' 105' ' ' THR . 1.2 ttp -83.29 125.07 31.22 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.179 -0.951 . . . . 0.0 109.328 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -87.99 -91.3 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.229 -0.919 . . . . 0.0 109.765 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.431 ' O ' ' C ' ' A' ' 34' ' ' GLY . 3.6 tmtm? -98.52 85.39 3.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.16 -0.962 . . . . 0.0 109.743 -179.679 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 43.07 33.99 1.95 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -144.4 104.11 4.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.139 -1.212 . . . . 0.0 109.504 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.459 HD11 ' OG ' ' A' ' 39' ' ' SER . 3.9 tt -53.57 118.63 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.29 -0.881 . . . . 0.0 109.232 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -127.75 26.2 5.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.227 -0.92 . . . . 0.0 109.662 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.454 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER 176.25 128.2 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.629 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.499 ' CB ' HG23 ' A' ' 29' ' ' VAL . 5.5 m -156.19 112.4 3.06 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.242 -0.911 . . . . 0.0 109.304 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -130.11 139.0 50.97 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.184 -0.947 . . . . 0.0 109.707 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.3 t -92.36 154.49 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.086 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.465 HG23 ' O ' ' A' ' 42' ' ' ILE . 2.0 tt -147.47 142.53 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.125 -0.984 . . . . 0.0 109.822 -179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.472 ' OE2' ' CE2' ' A' ' 25' ' ' TYR . 1.9 mt-10 -88.55 79.31 7.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.319 -0.863 . . . . 0.0 109.177 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.495 ' HB2' ' CD1' ' A' ' 26' ' ' PHE . 1.4 m-80 -44.83 147.19 1.16 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.2 -0.937 . . . . 0.0 109.521 -179.774 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.08 -167.01 0.44 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.595 2.196 . . . . 0.0 110.43 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 68.7 7.29 6.01 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.249 -0.907 . . . . 0.0 109.579 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -73.57 -41.15 63.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.925 . . . . 0.0 109.318 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -140.49 57.28 1.58 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.359 -0.838 . . . . 0.0 109.311 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -103.27 61.33 0.77 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.363 -0.835 . . . . 0.0 109.301 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.405 ' O ' ' O ' ' A' ' 51' ' ' GLY . 1.7 t 50.58 52.07 15.61 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.288 -0.883 . . . . 0.0 109.428 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.405 ' O ' ' O ' ' A' ' 50' ' ' SER . . . 62.54 142.66 0.01 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -169.9 -172.01 36.0 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -107.0 144.68 33.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.294 -1.121 . . . . 0.0 109.523 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.78 -6.73 46.01 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.4 mm -72.95 -19.56 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.26 -1.141 . . . . 0.0 109.672 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 3.7 mtt-85 -74.98 -16.61 60.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.141 -0.974 . . . . 0.0 109.486 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.458 ' O ' HG21 ' A' ' 57' ' ' THR . 53.3 m -67.94 -24.9 65.23 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.271 -0.893 . . . . 0.0 109.418 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -51.9 -56.05 16.46 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.32 -0.862 . . . . 0.0 109.651 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -51.04 -36.42 39.61 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.275 -0.891 . . . . 0.0 109.777 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.413 HD13 ' HA ' ' A' ' 57' ' ' THR . 76.9 mt -63.82 -63.5 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.177 -0.952 . . . . 0.0 109.838 -179.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.444 ' O ' HG22 ' A' ' 61' ' ' ILE . 10.5 mt -53.67 -24.46 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.231 -0.918 . . . . 0.0 109.935 -179.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -65.28 -46.73 79.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.131 -0.981 . . . . 0.0 109.8 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 9.2 m-20 -77.65 6.85 6.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.275 -0.89 . . . . 0.0 110.293 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.451 ' HB3' HG23 ' A' ' 66' ' ' VAL . 0.7 OUTLIER -96.1 7.56 46.08 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.997 -1.064 . . . . 0.0 109.835 -179.859 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.432 ' O ' ' HD2' ' A' ' 2' ' ' LYS . . . 73.07 8.81 75.02 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 17.6 t -68.61 97.5 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.301 -1.117 . . . . 0.0 109.574 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.525 ' O ' ' CB ' ' A' ' 88' ' ' LYS . 13.4 tttt -79.11 -3.92 47.75 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.528 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -138.79 131.38 28.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.319 -0.863 . . . . 0.0 109.002 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.443 HG21 HG11 ' A' ' 66' ' ' VAL . 10.6 t -128.84 109.2 18.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.061 -1.024 . . . . 0.0 109.791 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.51 ' CG2' HG23 ' A' ' 5' ' ' ILE . 2.1 mp -89.51 95.09 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.133 -0.98 . . . . 0.0 109.137 179.674 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -126.67 171.92 10.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 109.573 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.6 p -130.52 29.67 4.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.282 -0.886 . . . . 0.0 109.498 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -49.22 151.06 2.67 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.279 -0.888 . . . . 0.0 109.636 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.29 -72.48 0.01 OUTLIER 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.705 2.27 . . . . 0.0 110.467 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.404 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -68.26 145.5 44.5 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.404 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.8 Cg_endo -78.69 6.29 4.98 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.653 2.236 . . . . 0.0 110.473 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -53.94 -57.43 11.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.281 -0.887 . . . . 0.0 109.511 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -57.6 -45.0 85.86 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.23 -0.919 . . . . 0.0 109.5 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 18.4 m-30 -56.59 -27.39 57.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.178 -0.951 . . . . 0.0 109.343 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.48 -36.85 68.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.307 -0.87 . . . . 0.0 109.465 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 41.6 t -69.19 -46.19 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.492 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.429 HD23 HG23 ' A' ' 87' ' ' ILE . 3.1 mp -53.18 -37.09 61.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.219 -0.925 . . . . 0.0 109.615 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 13.5 t-20 -61.67 -40.81 96.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 109.622 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -76.6 -20.75 56.43 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.173 -0.955 . . . . 0.0 109.555 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.528 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 0.3 OUTLIER -87.13 -14.82 40.21 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.265 -0.897 . . . . 0.0 109.522 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 86.93 11.71 69.77 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.528 ' CD1' ' HB3' ' A' ' 85' ' ' LEU . 9.3 mt -87.51 145.5 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -1.176 . . . . 0.0 109.587 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.525 ' CB ' ' O ' ' A' ' 67' ' ' LYS . 6.1 ttmm -80.05 116.75 20.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.124 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.428 HG12 ' HB2' ' A' ' 82' ' ' LEU . 3.3 mt -80.93 106.42 12.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.274 -0.891 . . . . 0.0 109.602 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.571 ' CD2' ' O ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -103.18 142.35 34.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.333 -0.855 . . . . 0.0 109.158 179.825 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.463 ' O ' ' HB3' ' A' ' 110' ' ' GLU . 20.6 ttt180 -106.02 145.76 30.97 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.182 -0.949 . . . . 0.0 109.606 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.98 92.13 8.93 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.327 -0.858 . . . . 0.0 109.277 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.439 HG23 ' O ' ' A' ' 93' ' ' THR . 58.9 m -107.46 -16.41 14.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.255 -0.903 . . . . 0.0 109.691 -179.744 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -66.05 -128.71 0.02 OUTLIER Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.542 HG23 ' N ' ' A' ' 96' ' ' SER . 9.8 t -142.13 -32.98 0.5 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.319 -1.107 . . . . 0.0 109.927 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.542 ' N ' HG23 ' A' ' 95' ' ' THR . 0.6 OUTLIER -133.54 151.83 51.8 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.138 -0.976 . . . . 0.0 109.356 179.958 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.448 ' CB ' HG22 ' A' ' 5' ' ' ILE . 35.1 m -71.06 -34.29 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.25 -0.906 . . . . 0.0 109.7 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.37 -47.91 83.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.245 -0.91 . . . . 0.0 109.803 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -71.75 -42.78 66.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.271 -0.893 . . . . 0.0 109.942 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 48.3 t-20 -52.91 -33.98 52.93 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.201 -0.937 . . . . 0.0 109.669 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 1.7 tt -57.12 -42.93 81.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.248 -0.907 . . . . 0.0 109.841 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -74.48 -33.36 62.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.117 -0.989 . . . . 0.0 110.039 -179.487 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -39.81 94.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.107 -0.996 . . . . 0.0 109.826 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.526 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 6.4 t80 -70.15 -30.02 67.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.18 -0.95 . . . . 0.0 109.813 -179.64 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.524 ' CG2' ' HE1' ' A' ' 31' ' ' MET . 0.2 OUTLIER -67.21 -29.86 69.64 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.128 -0.982 . . . . 0.0 109.935 -179.615 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -99.31 13.06 34.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.139 -0.976 . . . . 0.0 109.606 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 52.17 57.72 12.51 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.069 -1.612 . . . . 0.0 109.069 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -81.87 -54.86 5.0 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.368 -1.078 . . . . 0.0 109.781 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.455 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.2 OUTLIER 178.04 -152.03 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.093 -1.004 . . . . 0.0 109.742 -179.835 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.571 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 13.8 mt-10 60.29 25.17 14.61 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.375 -0.828 . . . . 0.0 109.459 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.476 ' HA ' ' CE1' ' A' ' 90' ' ' TYR . 7.5 pt-20 -103.94 135.95 44.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.343 -0.848 . . . . 0.0 109.358 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.459 HG13 ' O ' ' A' ' 111' ' ' GLU . 3.2 mp -153.15 135.06 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.3 -0.875 . . . . 0.0 109.421 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 26.4 ttp180 -134.26 -45.47 0.77 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.224 -0.922 . . . . 0.0 109.346 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.453 ' O ' ' OG ' ' A' ' 114' ' ' SER . 0.5 OUTLIER -127.15 81.08 70.61 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.267 -0.896 . . . . 0.0 109.36 179.872 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.418 ' O ' ' C ' ' A' ' 116' ' ' GLY . 35.9 Cg_endo -77.93 -168.61 0.63 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.604 2.203 . . . . 0.0 110.356 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.418 ' C ' ' O ' ' A' ' 115' ' ' PRO . . . 44.59 79.7 0.06 OUTLIER Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -112.17 -66.39 1.09 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.252 -1.146 . . . . 0.0 109.346 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 134.42 81.27 0.15 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.44 76.48 1.54 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.231 -1.158 . . . . 0.0 109.431 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 127.22 165.39 11.9 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.41 ' O ' ' C ' ' A' ' 122' ' ' ARG . 3.6 ttt180 -129.5 101.63 6.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.233 -1.157 . . . . 0.0 109.495 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.41 ' C ' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -44.54 141.96 1.8 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.308 -0.87 . . . . 0.0 109.485 179.958 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.2 tpp180 -95.27 140.56 30.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.899 . . . . 0.0 109.442 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 10.5 mmm180 . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 117.98 -1.009 . . . . 0.0 109.363 179.99 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.7 mmm . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.453 ' HD3' ' O ' ' A' ' 65' ' ' GLY . 1.2 mttm -120.65 136.72 54.75 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.324 -0.86 . . . . 0.0 109.552 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.559 HD11 ' CD1' ' A' ' 104' ' ' PHE . 5.4 mt -114.44 108.43 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.318 -0.864 . . . . 0.0 109.399 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.615 ' CB ' ' CZ ' ' A' ' 26' ' ' PHE . . . -112.37 127.6 56.06 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.25 -0.906 . . . . 0.0 109.306 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.407 HG12 HD13 ' A' ' 70' ' ' ILE . 27.9 mt -102.88 139.71 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.555 -179.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.3 170.07 17.2 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.384 -0.823 . . . . 0.0 109.421 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.467 ' O ' ' HB3' ' A' ' 8' ' ' SER . 54.3 p 46.32 -141.38 0.39 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.259 -0.901 . . . . 0.0 109.333 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.529 ' HB2' ' CG1' ' A' ' 97' ' ' VAL . 42.4 t 63.61 51.81 2.41 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.119 -0.988 . . . . 0.0 109.415 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.518 ' N ' ' HB3' ' A' ' 14' ' ' SER . . . -50.87 106.23 0.25 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.461 ' OG1' ' O ' ' A' ' 9' ' ' GLY . 3.2 p 49.01 -90.65 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.343 -1.092 . . . . 0.0 109.89 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.517 ' N ' ' O ' ' A' ' 9' ' ' GLY . 1.0 OUTLIER 173.15 -150.61 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.198 -0.939 . . . . 0.0 109.446 -179.687 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.452 ' HB3' ' O ' ' A' ' 11' ' ' ASP . 12.9 tp 70.25 13.2 7.66 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.257 -0.902 . . . . 0.0 109.362 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 145.77 -23.66 1.8 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.518 ' HB3' ' N ' ' A' ' 9' ' ' GLY . 43.4 m -77.2 82.51 3.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.193 -1.18 . . . . 0.0 109.64 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.463 ' O ' HG13 ' A' ' 97' ' ' VAL . 0.2 OUTLIER -72.75 -114.2 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.202 -0.936 . . . . 0.0 109.456 -179.826 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.0 t -115.47 23.47 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 120.738 -1.227 . . . . 0.0 109.679 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 4.3 t 47.06 -150.26 0.11 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.178 -0.951 . . . . 0.0 109.345 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.55 12.95 1.53 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.192 -0.943 . . . . 0.0 109.595 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.466 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 28.1 p90 -153.8 144.52 22.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.223 -0.923 . . . . 0.0 109.66 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -123.82 89.88 3.17 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.313 -0.867 . . . . 0.0 109.218 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -145.26 -73.35 0.02 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.73 21.68 16.26 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -1.172 . . . . 0.0 109.675 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -58.33 113.25 6.18 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.243 -0.911 . . . . 0.0 109.23 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.474 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 36.8 Cg_endo -80.74 54.34 5.19 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.571 2.181 . . . . 0.0 110.867 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.474 ' CD2' ' O ' ' A' ' 24' ' ' PRO . 31.4 m-85 -160.41 70.92 0.43 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.992 -1.068 . . . . 0.0 109.214 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.615 ' CZ ' ' CB ' ' A' ' 4' ' ' ALA . 40.1 t80 -79.92 104.58 10.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.429 -0.794 . . . . 0.0 109.732 -179.718 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' MET . . . . . 0.426 ' CE ' ' O ' ' A' ' 10' ' ' THR . 0.2 OUTLIER -82.84 125.03 30.87 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.29 -0.881 . . . . 0.0 109.21 179.694 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.459 HG23 ' O ' ' A' ' 40' ' ' GLU . 1.4 tp -119.99 114.75 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.154 -0.966 . . . . 0.0 109.586 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.462 HG13 HD23 ' A' ' 101' ' ' LEU . 3.1 t -118.91 144.25 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.922 . . . . 0.0 109.408 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -117.63 136.18 53.48 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.261 -0.9 . . . . 0.0 109.445 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.8 mtt -119.86 132.18 55.49 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.209 -0.932 . . . . 0.0 109.545 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 13.4 mmtt -81.99 -79.76 0.17 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.308 -0.87 . . . . 0.0 109.299 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -126.16 86.53 2.54 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.3 -0.875 . . . . 0.0 109.174 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 48.87 34.12 14.71 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 36' ' ' ILE . 0.6 OUTLIER -149.12 100.56 3.06 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.345 -1.091 . . . . 0.0 109.461 -179.859 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.433 ' O ' HG22 ' A' ' 36' ' ' ILE . 4.3 tt -45.2 134.27 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.234 -0.916 . . . . 0.0 109.35 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.412 ' O ' ' HB2' ' A' ' 38' ' ' SER . 0.5 OUTLIER -145.65 20.11 1.49 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.303 -0.873 . . . . 0.0 109.497 -179.959 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.412 ' HB2' ' O ' ' A' ' 37' ' ' GLU . 5.1 t -179.21 129.66 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.266 -0.896 . . . . 0.0 109.471 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 96.0 p -151.2 115.3 5.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.284 -0.885 . . . . 0.0 109.337 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.459 ' O ' HG23 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -132.09 132.26 43.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.276 -0.89 . . . . 0.0 109.629 -179.799 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.7 m -97.13 137.9 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.31 -0.869 . . . . 0.0 109.328 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.407 HG21 ' N ' ' A' ' 43' ' ' GLU . 58.7 mt -123.79 145.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 0.0 109.558 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.419 ' HG2' ' CE1' ' A' ' 25' ' ' TYR . 2.8 mp0 -115.09 148.31 39.1 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.283 -0.886 . . . . 0.0 109.581 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 13.8 m-20 -134.82 79.99 50.67 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.314 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.494 ' O ' ' CB ' ' A' ' 46' ' ' SER . 35.5 Cg_endo -77.8 123.2 6.21 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.657 2.238 . . . . 0.0 110.512 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 45' ' ' PRO . 0.1 OUTLIER 74.6 36.67 0.59 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.897 . . . . 0.0 109.47 179.921 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -54.49 -62.82 1.41 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.293 -0.879 . . . . 0.0 109.492 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -98.34 75.17 2.23 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.241 -0.912 . . . . 0.0 109.557 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.25 -21.86 28.87 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.248 -0.907 . . . . 0.0 109.398 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.1 m -100.91 58.93 0.91 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.887 . . . . 0.0 109.417 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 116.72 162.2 12.71 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -79.01 157.98 43.87 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -140.5 -86.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.277 -1.131 . . . . 0.0 109.302 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 81.16 -95.79 1.68 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.448 HG21 ' HA ' ' A' ' 78' ' ' ALA . 34.2 mm -73.62 -16.46 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.253 -1.145 . . . . 0.0 109.825 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.18 -22.63 66.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.261 -0.899 . . . . 0.0 109.681 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 61.2 m -63.52 -21.58 66.41 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.673 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.412 ' O ' ' C ' ' A' ' 59' ' ' GLN . . . -52.99 -47.93 67.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.233 -0.917 . . . . 0.0 109.508 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.412 ' C ' ' O ' ' A' ' 58' ' ' ALA . 0.0 OUTLIER -44.09 -43.39 6.85 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.421 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 20.9 mm -73.15 -36.5 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.173 -0.954 . . . . 0.0 109.167 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 16.8 mm -50.68 -36.49 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.354 -0.842 . . . . 0.0 109.235 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.414 ' HB2' HD13 ' A' ' 87' ' ' ILE . . . -75.02 -33.39 61.78 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.277 -0.889 . . . . 0.0 109.686 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -61.5 -18.22 58.12 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.259 -0.9 . . . . 0.0 109.767 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.456 ' HB3' ' CG2' ' A' ' 66' ' ' VAL . 0.4 OUTLIER -90.68 27.36 1.78 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.082 -1.011 . . . . 0.0 109.653 -179.86 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.453 ' O ' ' HD3' ' A' ' 2' ' ' LYS . . . 43.96 40.47 5.56 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.456 ' CG2' ' HB3' ' A' ' 64' ' ' ASN . 2.9 t -86.25 96.21 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -1.136 . . . . 0.0 109.68 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.6 tptt -78.95 -11.32 60.0 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 179.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -136.58 125.29 23.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.444 -0.785 . . . . 0.0 108.964 179.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.417 ' O ' ' HB2' ' A' ' 90' ' ' TYR . 67.1 t -124.39 119.84 57.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.049 -1.032 . . . . 0.0 109.961 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.455 ' CD1' ' CG2' ' A' ' 3' ' ' ILE . 1.9 mp -102.1 114.19 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.359 -0.838 . . . . 0.0 108.98 179.606 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -151.87 172.87 15.53 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.214 -0.929 . . . . 0.0 109.865 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.439 ' O ' ' OG ' ' A' ' 72' ' ' SER . 11.9 p -135.5 55.69 1.87 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.378 -0.826 . . . . 0.0 109.245 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -55.53 152.82 16.5 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.295 -0.878 . . . . 0.0 109.645 -179.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.67 -13.65 14.55 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 C-N-CA 122.757 2.305 . . . . 0.0 110.531 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.8 161.66 26.26 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.7 -5.67 14.86 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.698 2.265 . . . . 0.0 110.415 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 16.9 t30 -57.91 -33.25 68.57 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.262 -0.899 . . . . 0.0 109.649 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.448 ' HA ' HG21 ' A' ' 55' ' ' ILE . . . -71.94 -60.43 2.24 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.251 -0.906 . . . . 0.0 109.437 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.46 ' N ' ' CD1' ' A' ' 79' ' ' PHE . 3.5 m-85 -51.7 -22.09 3.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.115 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 13.9 tt0 -63.91 -46.95 82.54 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.283 -0.885 . . . . 0.0 109.265 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.5 t -69.45 -43.66 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.194 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 1.8 mt -63.36 -21.62 66.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.516 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -77.1 -61.35 2.01 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.258 -0.901 . . . . 0.0 109.603 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -58.92 -21.56 58.1 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.22 -0.925 . . . . 0.0 109.667 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -73.14 -37.43 66.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.215 -0.928 . . . . 0.0 109.637 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.77 21.83 7.29 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.414 HD13 ' HB2' ' A' ' 62' ' ' ALA . 5.5 mt -103.94 150.3 7.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -1.165 . . . . 0.0 109.51 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 8.2 mttt -80.03 125.84 30.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.233 -0.917 . . . . 0.0 109.361 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 3.3 mp -90.31 141.06 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.161 -0.962 . . . . 0.0 109.543 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.573 ' CE1' ' HB3' ' A' ' 111' ' ' GLU . 2.2 m-85 -127.99 127.35 43.08 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.211 -0.931 . . . . 0.0 109.529 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 73.5 mtt180 -87.46 122.77 31.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.465 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.67 122.83 33.16 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.236 -0.915 . . . . 0.0 109.471 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -64.95 -40.0 94.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.363 -0.836 . . . . 0.0 109.558 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 116.76 52.47 0.35 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 30.8 m -114.37 -82.72 0.61 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -1.119 . . . . 0.0 109.351 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -157.56 128.61 6.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.396 -0.815 . . . . 0.0 109.357 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.529 ' CG1' ' HB2' ' A' ' 8' ' ' SER . 0.2 OUTLIER -51.12 -23.27 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.221 -0.924 . . . . 0.0 109.535 -179.943 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.82 -49.05 69.63 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.195 -0.941 . . . . 0.0 109.317 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.444 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 21.4 tt0 -70.88 -28.14 64.34 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.304 -0.873 . . . . 0.0 109.311 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -63.93 -49.46 72.52 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.322 -0.862 . . . . 0.0 109.42 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.462 HD23 HG13 ' A' ' 29' ' ' VAL . 37.7 tp -57.56 -57.58 12.08 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.301 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 1.3 tmtt? -56.92 -25.62 57.7 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.135 -0.978 . . . . 0.0 109.257 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.461 ' CD2' ' HB3' ' A' ' 108' ' ' ASN . 0.2 OUTLIER -71.14 -37.11 72.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.23 -0.919 . . . . 0.0 109.36 179.861 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.559 ' CD1' HD11 ' A' ' 3' ' ' ILE . 13.9 t80 -65.57 -22.99 66.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.198 -0.939 . . . . 0.0 109.175 179.661 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.34 -29.76 64.25 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.412 -0.805 . . . . 0.0 109.31 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -112.46 -2.69 14.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.603 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 61.23 39.46 97.22 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . 0.461 ' HB3' ' CD2' ' A' ' 103' ' ' LEU . 24.4 t-20 -93.97 -17.92 22.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.103 -1.233 . . . . 0.0 109.395 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' A' ' 108' ' ' ASN . 5.4 mt -55.67 -168.44 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.24 -0.913 . . . . 0.0 109.334 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.47 ' O ' ' HA ' ' A' ' 90' ' ' TYR . 1.2 tt0 -103.42 106.91 17.55 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.256 -0.903 . . . . 0.0 109.303 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.573 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 4.1 pt-20 -101.7 156.69 17.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.264 -0.898 . . . . 0.0 109.764 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.9 mt -142.8 126.11 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.89 . . . . 0.0 109.314 179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -147.85 93.61 2.22 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.293 -0.879 . . . . 0.0 109.441 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 1.1 p -104.13 155.3 37.36 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.204 -0.935 . . . . 0.0 109.565 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.17 -169.79 0.84 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.671 2.247 . . . . 0.0 110.56 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' A' ' 117' ' ' SER . . . -89.63 140.78 15.78 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.465 ' O ' ' OG ' ' A' ' 117' ' ' SER . 0.0 OUTLIER 49.64 97.45 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.26 -1.141 . . . . 0.0 109.353 -179.957 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 164.89 43.0 0.02 OUTLIER Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -138.2 142.72 40.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.187 -1.184 . . . . 0.0 109.355 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 139.54 146.02 4.82 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 23.7 mtt180 -96.58 -47.34 5.97 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.281 -1.129 . . . . 0.0 109.513 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.403 ' O ' ' HG3' ' A' ' 123' ' ' ARG . 0.3 OUTLIER -91.32 142.11 28.05 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.275 -0.89 . . . . 0.0 109.359 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.403 ' HG3' ' O ' ' A' ' 122' ' ' ARG . 0.0 OUTLIER -146.64 -64.35 0.29 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.142 -0.974 . . . . 0.0 109.571 179.978 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.103 -0.951 . . . . 0.0 109.547 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 mmm . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.271 0.557 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.49 ' CB ' ' HA ' ' A' ' 66' ' ' VAL . 0.0 OUTLIER -154.03 160.05 41.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.289 -0.882 . . . . 0.0 109.118 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.573 HG12 ' CE2' ' A' ' 104' ' ' PHE . 6.4 mt -117.4 121.12 66.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.901 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.428 ' HA ' ' O ' ' A' ' 27' ' ' MET . . . -113.09 102.97 10.89 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.373 -0.83 . . . . 0.0 109.119 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.412 HD13 ' HB2' ' A' ' 27' ' ' MET . 0.7 OUTLIER -94.81 118.64 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -0.924 . . . . 0.0 109.742 -179.553 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.37 142.3 41.21 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.068 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.8 p -161.72 -159.92 0.66 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.119 -0.988 . . . . 0.0 109.518 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.9 m -149.06 57.09 1.02 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.287 -0.883 . . . . 0.0 109.537 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 167.08 164.5 22.85 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.45 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.0 OUTLIER -85.02 -32.62 22.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.322 -1.105 . . . . 0.0 109.472 179.981 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 18.7 p-10 171.84 172.16 0.09 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -0.919 . . . . 0.0 109.374 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.413 ' C ' ' O ' ' A' ' 11' ' ' ASP . 8.1 tp 45.35 32.77 1.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.305 -0.872 . . . . 0.0 109.191 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -175.47 -32.88 0.04 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 p -65.55 86.34 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.435 -1.038 . . . . 0.0 109.304 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.495 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 14.4 mt-10 -77.65 6.98 6.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.478 -0.764 . . . . 0.0 110.153 -179.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.495 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 15.1 t 70.62 65.6 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.937 . . . . 0.0 109.615 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 16' ' ' VAL . 3.9 m -44.64 122.83 3.32 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.328 -0.858 . . . . 0.0 109.233 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.456 ' O ' ' HG2' ' A' ' 18' ' ' ARG . 1.4 ttm-85 -61.72 -18.7 60.76 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.25 -0.906 . . . . 0.0 109.721 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.478 ' CE2' ' HG3' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -84.91 108.16 17.41 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.12 -0.987 . . . . 0.0 109.63 -179.905 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 21.8 t80 -106.43 125.37 50.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.263 -0.898 . . . . 0.0 109.354 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.1 -36.6 0.76 Allowed Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.461 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 1.1 mpt_? -118.62 -22.27 7.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.343 -1.093 . . . . 0.0 109.256 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -49.15 106.91 0.68 Allowed Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.304 -0.872 . . . . 0.0 109.436 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.461 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.3 Cg_endo -79.95 62.56 8.55 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.561 2.174 . . . . 0.0 110.822 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.439 ' CE1' ' HB3' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -160.52 69.58 0.38 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.008 -1.058 . . . . 0.0 109.395 179.692 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -80.46 121.1 25.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.549 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' MET . . . . . 0.428 ' O ' ' HA ' ' A' ' 4' ' ' ALA . 2.1 mmt -94.46 110.6 22.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.226 -0.921 . . . . 0.0 109.266 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.9 mm -104.02 117.99 50.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.904 . . . . 0.0 109.472 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.498 HG11 ' CB ' ' A' ' 39' ' ' SER . 13.4 m -138.04 147.59 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.209 -0.932 . . . . 0.0 109.833 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -127.26 143.26 51.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 108.899 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.2 mtt -113.81 152.03 31.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.1 -1.0 . . . . 0.0 109.938 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.35 -46.37 7.38 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.369 -0.832 . . . . 0.0 109.262 179.775 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.64 47.48 0.73 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.367 -0.833 . . . . 0.0 109.222 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.431 ' O ' ' CG2' ' A' ' 105' ' ' THR . . . 92.22 -1.43 73.38 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.423 ' O ' ' C ' ' A' ' 36' ' ' ILE . 5.6 p-10 -116.56 92.89 4.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.204 -1.174 . . . . 0.0 109.362 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.451 HD13 ' HB ' ' A' ' 29' ' ' VAL . 1.6 tt -43.95 118.61 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 109.497 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.46 ' O ' ' OE1' ' A' ' 37' ' ' GLU . 0.2 OUTLIER -123.08 20.78 9.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.329 -0.857 . . . . 0.0 109.441 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.413 ' O ' ' OG ' ' A' ' 38' ' ' SER . 12.0 p -170.82 107.46 0.29 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -0.859 . . . . 0.0 109.263 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.498 ' CB ' HG11 ' A' ' 29' ' ' VAL . 5.8 p -135.35 105.72 6.38 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.914 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.18 143.8 38.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.389 -0.819 . . . . 0.0 109.268 179.598 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 t -110.99 124.03 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.215 -0.928 . . . . 0.0 109.755 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 11.1 mt -121.57 119.43 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.262 -0.899 . . . . 0.0 109.268 179.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.439 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 4.1 pm0 -93.28 126.08 38.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.254 -0.904 . . . . 0.0 109.564 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -55.91 115.82 10.65 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.317 -0.864 . . . . 0.0 109.548 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.05 -37.88 0.73 Allowed 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.458 2.105 . . . . 0.0 110.495 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.2 p -74.45 -11.98 60.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.268 -0.895 . . . . 0.0 109.536 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.422 ' CB ' ' HB3' ' A' ' 24' ' ' PRO . . . -46.06 -40.94 11.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 109.402 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -115.83 92.11 3.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.439 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 176.81 -57.84 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.315 -0.865 . . . . 0.0 109.37 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.0 t -115.01 88.52 2.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.28 -0.887 . . . . 0.0 109.333 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.79 173.39 41.52 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 132.52 -53.14 0.81 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -136.34 -165.9 1.8 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.291 -1.123 . . . . 0.0 109.274 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -175.77 -35.07 0.04 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.404 HD13 ' HB1' ' A' ' 78' ' ' ALA . 39.8 mm -76.72 0.03 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.136 -1.214 . . . . 0.0 109.85 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.08 -10.96 59.83 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.192 -0.943 . . . . 0.0 109.558 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.438 ' O ' HG13 ' A' ' 61' ' ' ILE . 8.8 t -77.32 -25.86 51.59 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.667 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -48.77 -39.97 27.07 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 109.492 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 -60.4 -58.47 8.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 109.608 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.409 ' O ' HG22 ' A' ' 60' ' ' ILE . 21.1 mt -53.82 -25.48 12.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.33 -0.856 . . . . 0.0 109.589 -179.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.49 HG21 ' CG2' ' A' ' 66' ' ' VAL . 46.3 mt -72.96 -39.66 58.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.454 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.451 ' HB1' HD12 ' A' ' 87' ' ' ILE . . . -67.17 -30.65 70.67 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.552 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -67.93 -9.08 42.26 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.294 -0.878 . . . . 0.0 109.614 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -85.9 -24.93 26.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.191 -0.943 . . . . 0.0 109.537 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 114.55 -26.0 9.91 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.49 ' HA ' ' CB ' ' A' ' 2' ' ' LYS . 4.6 m -43.44 94.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.271 -1.135 . . . . 0.0 109.559 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 65' ' ' GLY . 7.0 mmtp -79.36 -4.27 50.16 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.357 -0.84 . . . . 0.0 108.758 179.291 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -122.82 129.33 51.55 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.385 -0.822 . . . . 0.0 109.274 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 97.8 t -123.45 107.83 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.111 -0.993 . . . . 0.0 109.544 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 53.1 mt -91.99 115.52 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.36 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -164.84 176.77 8.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.217 -0.927 . . . . 0.0 109.913 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.431 ' OG ' ' HB1' ' A' ' 92' ' ' ALA . 12.5 m -140.84 59.07 1.54 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.508 -0.745 . . . . 0.0 109.176 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' SER . . . . . 0.544 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 11.6 p -49.71 152.15 2.69 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.389 -0.819 . . . . 0.0 109.791 -179.717 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.478 ' HG3' ' CE2' ' A' ' 19' ' ' PHE . 35.1 Cg_endo -78.27 -22.65 9.51 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.631 2.221 . . . . 0.0 110.17 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -134.95 164.15 24.76 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.53 27.62 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.771 2.314 . . . . 0.0 111.265 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -74.73 -68.86 0.5 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.88 -1.137 . . . . 0.0 109.588 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.404 ' HB1' HD13 ' A' ' 55' ' ' ILE . . . -62.03 -40.53 96.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -0.905 . . . . 0.0 109.714 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.544 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 4.3 m-85 -52.95 -32.46 46.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.639 -179.879 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -75.61 -38.46 59.0 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.26 -0.9 . . . . 0.0 109.65 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 48.8 t -61.33 -53.46 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.743 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 3.2 mp -59.06 -18.7 37.38 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.274 -0.891 . . . . 0.0 109.814 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -76.47 -48.42 19.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.18 -0.95 . . . . 0.0 109.695 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.38 -35.44 80.9 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.143 -0.973 . . . . 0.0 109.563 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.511 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 0.1 OUTLIER -68.17 -16.21 63.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.491 -179.919 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 81.59 24.68 55.72 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.511 ' CD1' ' HB3' ' A' ' 85' ' ' LEU . 5.6 mt -87.47 161.5 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.252 -1.146 . . . . 0.0 109.558 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.511 ' CB ' ' O ' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -94.5 112.13 23.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 109.317 179.858 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.455 ' HB ' ' HB ' ' A' ' 112' ' ' ILE . 14.1 mt -82.03 168.14 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.67 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.584 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 1.2 m-85 -153.09 129.98 10.97 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.304 -0.873 . . . . 0.0 109.246 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.501 ' NH1' ' HA ' ' A' ' 93' ' ' THR . 0.7 OUTLIER -80.12 135.81 36.39 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.966 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.431 ' HB1' ' OG ' ' A' ' 72' ' ' SER . . . -86.64 149.79 24.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.216 -0.928 . . . . 0.0 109.627 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.501 ' HA ' ' NH1' ' A' ' 91' ' ' ARG . 73.4 p -86.0 -26.51 25.38 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 109.544 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.83 66.85 1.51 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.19 -67.71 0.36 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.256 -1.143 . . . . 0.0 109.466 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.4 ' HA ' HG23 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -171.56 132.95 0.77 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.304 -0.872 . . . . 0.0 109.33 -179.965 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 16.8 m -54.86 -19.76 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.168 -0.958 . . . . 0.0 109.575 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -68.27 -52.57 32.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.762 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -69.78 -39.19 76.79 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.146 -0.971 . . . . 0.0 109.498 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.427 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 5.1 m-20 -59.28 -36.73 76.09 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.163 -0.96 . . . . 0.0 109.259 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.428 ' CD2' HD11 ' A' ' 36' ' ' ILE . 11.0 tp -59.22 -50.93 72.15 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.287 -0.883 . . . . 0.0 109.308 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -70.12 -15.76 63.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.371 -0.831 . . . . 0.0 109.232 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.427 ' HB2' ' HA ' ' A' ' 100' ' ' ASN . 0.2 OUTLIER -72.6 -45.74 57.6 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.359 -0.838 . . . . 0.0 109.55 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.573 ' CE2' HG12 ' A' ' 3' ' ' ILE . 6.4 t80 -63.53 -17.23 62.58 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.865 . . . . 0.0 109.758 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.431 ' CG2' ' O ' ' A' ' 34' ' ' GLY . 19.2 m -69.2 -33.47 73.39 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 109.572 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -95.57 -14.72 23.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.527 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 71.17 45.53 48.82 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 10.1 t-20 -97.21 -29.31 13.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.289 -1.124 . . . . 0.0 109.544 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.411 ' HG ' HD23 ' A' ' 103' ' ' LEU . 0.6 OUTLIER -57.11 155.89 7.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.342 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 5.3 pt-20 -96.06 144.88 25.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.584 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 6.1 pm0 -114.61 165.87 12.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.92 . . . . 0.0 109.501 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.455 ' HB ' ' HB ' ' A' ' 89' ' ' ILE . 83.0 mt -136.4 120.21 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.261 -0.899 . . . . 0.0 109.254 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -113.96 -21.69 10.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.339 -0.851 . . . . 0.0 109.332 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 68.3 p -139.74 157.98 68.81 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.237 -0.914 . . . . 0.0 109.554 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -78.68 178.72 7.23 Favored 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.585 2.19 . . . . 0.0 110.438 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.46 -179.68 16.97 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -170.37 -173.09 1.38 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.266 -1.138 . . . . 0.0 109.545 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -89.77 146.02 18.6 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.7 ttm-85 -53.57 145.63 14.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.235 -1.156 . . . . 0.0 109.365 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 123.39 175.05 14.38 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.469 ' HG2' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -118.02 138.39 52.24 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.159 -1.201 . . . . 0.0 109.676 -179.882 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.484 ' HA ' ' NE ' ' A' ' 122' ' ' ARG . 0.2 OUTLIER -117.99 105.12 11.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.314 -0.867 . . . . 0.0 109.181 179.818 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.24 -19.87 11.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.267 -0.896 . . . . 0.0 109.655 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.494 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.4 ttm . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.1 mppt? -114.61 164.01 14.62 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.187 -0.945 . . . . 0.0 109.594 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.466 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 11.0 mt -131.68 135.72 58.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.291 -0.881 . . . . 0.0 109.655 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.518 ' CB ' HG22 ' A' ' 66' ' ' VAL . . . -123.48 129.96 52.0 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.57 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.421 HG21 HG22 ' A' ' 97' ' ' VAL . 6.3 mt -111.1 120.79 62.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.179 -0.951 . . . . 0.0 109.881 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.39 165.19 25.53 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.277 -0.889 . . . . 0.0 109.36 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.518 ' O ' ' CB ' ' A' ' 8' ' ' SER . 0.8 OUTLIER 70.22 -144.67 0.08 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.227 -0.921 . . . . 0.0 109.485 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.518 ' CB ' ' O ' ' A' ' 7' ' ' SER . 0.2 OUTLIER 77.02 3.35 3.31 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.139 -0.976 . . . . 0.0 109.554 -179.908 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.469 ' O ' ' HB3' ' A' ' 25' ' ' TYR . . . 46.47 -113.6 1.18 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.87 -5.85 7.41 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.225 -1.162 . . . . 0.0 109.481 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -141.18 -142.15 0.14 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.481 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.4 mt -105.11 -18.28 14.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.108 -0.995 . . . . 0.0 109.745 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -47.76 -40.32 18.22 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.406 ' O ' ' O ' ' A' ' 15' ' ' GLU . 3.6 m -75.54 81.42 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.283 -1.128 . . . . 0.0 109.636 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.464 ' O ' ' HB ' ' A' ' 97' ' ' VAL . 0.1 OUTLIER -48.17 -93.18 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.552 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 18.9 m -131.11 52.95 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.062 -1.024 . . . . 0.0 109.718 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.512 ' O ' ' CB ' ' A' ' 18' ' ' ARG . 1.3 p -99.07 136.61 38.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.174 -0.954 . . . . 0.0 109.255 179.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.512 ' CB ' ' O ' ' A' ' 17' ' ' SER . 6.3 mtt-85 75.45 78.28 0.1 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.222 -0.924 . . . . 0.0 108.916 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.432 ' O ' ' C ' ' A' ' 20' ' ' PHE . 0.5 OUTLIER -79.65 -177.52 5.9 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.335 -0.853 . . . . 0.0 109.678 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.476 ' HB2' ' HB2' ' A' ' 71' ' ' ALA . 2.6 t80 -41.24 137.84 1.31 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.485 -0.76 . . . . 0.0 109.82 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 151.14 -64.12 0.38 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.475 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 2.0 tpp180 -155.04 18.87 0.43 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.147 -1.208 . . . . 0.0 109.8 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.79 113.43 18.67 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.276 -0.89 . . . . 0.0 109.661 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.583 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.7 Cg_endo -82.08 53.9 4.77 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.61 2.207 . . . . 0.0 110.462 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.583 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 98.6 m-85 -159.8 70.82 0.46 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.163 -0.96 . . . . 0.0 109.503 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.48 ' CE1' ' OD1' ' A' ' 44' ' ' ASN . 23.7 m-85 -83.61 119.03 24.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.204 -0.935 . . . . 0.0 109.536 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -93.56 122.45 36.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.234 -0.916 . . . . 0.0 109.67 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 15.1 mm -99.17 122.15 50.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 109.176 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 54.7 t -127.97 137.74 56.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.099 -1.0 . . . . 0.0 109.651 -179.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.424 ' HB3' ' OG ' ' A' ' 38' ' ' SER . 1.7 tt0 -124.61 137.82 54.36 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.3 -0.875 . . . . 0.0 109.379 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.446 ' HE2' HG13 ' A' ' 36' ' ' ILE . 7.9 ttm -116.06 145.18 43.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.189 -0.944 . . . . 0.0 109.647 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.61 -63.48 1.29 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.332 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.66 65.29 0.87 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.287 -0.883 . . . . 0.0 109.384 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.25 17.03 70.19 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 36' ' ' ILE . 3.0 t-20 -144.38 103.17 3.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.222 -1.164 . . . . 0.0 109.451 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.446 HG13 ' HE2' ' A' ' 31' ' ' MET . 2.6 mp -44.69 137.49 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.277 -0.89 . . . . 0.0 109.461 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -144.01 16.36 1.74 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 109.48 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.424 ' OG ' ' HB3' ' A' ' 30' ' ' GLU . 0.2 OUTLIER -166.68 122.86 1.21 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.259 -0.901 . . . . 0.0 109.441 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.6 m -142.9 110.16 5.68 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.196 -0.94 . . . . 0.0 109.6 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.91 153.98 46.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.31 -0.869 . . . . 0.0 109.2 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.422 ' O ' HG12 ' A' ' 41' ' ' VAL . 8.0 p -113.76 144.34 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.204 -0.935 . . . . 0.0 109.675 -179.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.5 mt -136.42 132.7 49.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.341 -0.849 . . . . 0.0 109.37 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.459 ' O ' ' HD3' ' A' ' 45' ' ' PRO . 1.6 mp0 -106.59 131.38 53.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.241 -0.912 . . . . 0.0 109.692 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.48 ' OD1' ' CE1' ' A' ' 26' ' ' PHE . 2.7 m120 -55.61 109.93 1.94 Allowed Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.28 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.459 ' HD3' ' O ' ' A' ' 43' ' ' GLU . 35.4 Cg_endo -77.46 -75.63 0.01 OUTLIER 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.376 2.051 . . . . 0.0 110.578 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.6 m -99.55 68.96 1.61 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.614 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -77.26 -37.12 53.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.223 -0.923 . . . . 0.0 109.421 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -101.55 92.55 4.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.317 -0.865 . . . . 0.0 109.456 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -172.75 -47.97 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.301 -0.875 . . . . 0.0 109.357 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.84 94.51 4.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.332 -0.855 . . . . 0.0 109.208 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 113.08 -60.59 0.34 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 59.96 91.55 0.01 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -172.96 -47.89 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.181 -1.188 . . . . 0.0 109.538 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 111.34 -50.01 0.8 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.428 HD12 ' CE2' ' A' ' 20' ' ' PHE . 16.6 mm -70.4 -5.58 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -1.095 . . . . 0.0 109.555 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.67 -25.28 53.55 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.195 -0.94 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.421 ' HA ' HD13 ' A' ' 60' ' ' ILE . 10.8 t -68.66 -7.9 37.49 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.201 -0.937 . . . . 0.0 109.556 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.425 ' O ' ' C ' ' A' ' 59' ' ' GLN . . . -61.67 -56.18 22.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.926 . . . . 0.0 109.249 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 58' ' ' ALA . 1.6 tm0? -44.21 -29.26 0.61 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.337 -0.852 . . . . 0.0 109.286 179.808 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.421 HD13 ' HA ' ' A' ' 57' ' ' THR . 73.1 mt -75.59 -46.66 36.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 109.179 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.522 HG21 ' CG1' ' A' ' 66' ' ' VAL . 37.8 mt -56.03 -25.24 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 109.36 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.66 -38.08 80.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.279 -0.888 . . . . 0.0 109.681 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 26.8 m-20 -72.75 -4.94 34.5 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.247 -0.908 . . . . 0.0 109.721 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -83.9 -16.1 45.57 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.06 -12.74 59.27 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.522 ' CG1' HG21 ' A' ' 61' ' ' ILE . 2.6 p -58.21 98.77 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.268 -1.136 . . . . 0.0 109.66 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.439 ' HA ' HG21 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -79.28 -6.36 56.5 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 179.234 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.556 ' HB1' ' CE2' ' A' ' 104' ' ' PHE . . . -113.67 120.66 41.63 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.284 -0.885 . . . . 0.0 109.119 179.627 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 70.6 t -108.43 112.04 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.165 -0.959 . . . . 0.0 109.852 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 3.2 mm -99.79 97.53 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.155 -0.965 . . . . 0.0 109.136 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.476 ' HB2' ' HB2' ' A' ' 20' ' ' PHE . . . -158.39 169.85 23.53 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.237 -0.914 . . . . 0.0 109.816 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.435 ' O ' ' C ' ' A' ' 73' ' ' SER . 9.1 t -133.33 50.65 2.21 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.364 -0.835 . . . . 0.0 109.048 179.79 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' SER . . . . . 0.445 ' HB3' ' HB3' ' A' ' 20' ' ' PHE . 60.5 p -41.26 149.55 0.36 Allowed Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.509 -0.745 . . . . 0.0 109.937 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.452 ' HD3' ' O ' ' A' ' 20' ' ' PHE . 36.2 Cg_endo -78.14 -35.26 1.35 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.657 2.238 . . . . 0.0 110.051 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -108.61 153.14 16.91 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.476 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 35.5 Cg_endo -77.72 1.15 9.13 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.537 2.158 . . . . 0.0 110.668 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.463 ' O ' HG21 ' A' ' 81' ' ' VAL . 5.4 t30 -59.93 -42.28 93.64 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.223 -0.923 . . . . 0.0 109.686 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -64.17 -67.59 0.42 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 109.681 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.518 ' CD1' ' CG2' ' A' ' 89' ' ' ILE . 16.6 m-30 -53.06 -19.27 2.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.232 -0.917 . . . . 0.0 109.875 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.476 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 36.3 tt0 -70.73 -49.93 41.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.122 -0.986 . . . . 0.0 109.579 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.463 HG21 ' O ' ' A' ' 77' ' ' ASN . 3.0 t -67.4 -48.19 78.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.147 -0.971 . . . . 0.0 109.665 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.405 ' HB2' HD13 ' A' ' 89' ' ' ILE . 36.1 mt -55.59 -29.32 58.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.114 -0.992 . . . . 0.0 109.508 -179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 64.0 t-20 -68.03 -38.89 83.07 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.265 -0.897 . . . . 0.0 109.383 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.14 -26.29 61.15 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.331 -0.856 . . . . 0.0 109.47 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.46 ' HB3' HD11 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -71.87 -37.11 70.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.955 . . . . 0.0 109.551 -179.94 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.53 13.08 25.17 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.46 HD11 ' HB3' ' A' ' 85' ' ' LEU . 3.7 mt -85.38 169.54 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.278 -1.131 . . . . 0.0 109.623 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.17 123.67 43.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.25 179.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.518 ' CG2' ' CD1' ' A' ' 79' ' ' PHE . 1.6 mt -95.16 161.84 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.19 -0.944 . . . . 0.0 109.757 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.532 ' CD1' ' O ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -148.21 133.93 18.9 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.444 -179.862 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.405 ' HB2' ' HB2' ' A' ' 110' ' ' GLU . 0.0 OUTLIER -89.45 123.12 33.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.148 -0.97 . . . . 0.0 109.475 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.16 87.78 5.48 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.916 . . . . 0.0 109.681 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.46 HG21 ' O ' ' A' ' 93' ' ' THR . 18.6 m -139.23 21.02 2.6 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.223 -0.923 . . . . 0.0 109.412 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -74.46 -77.8 0.64 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 92.8 m -159.81 -70.78 0.08 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.246 -1.15 . . . . 0.0 109.386 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.413 ' O ' ' C ' ' A' ' 97' ' ' VAL . 37.0 m -132.38 148.71 52.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.303 -0.873 . . . . 0.0 109.384 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.464 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 12.1 p -44.36 -27.98 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.345 -0.847 . . . . 0.0 109.487 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -66.69 -52.81 40.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.337 -0.852 . . . . 0.0 109.734 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.434 ' O ' ' CG ' ' A' ' 103' ' ' LEU . 4.7 tt0 -71.02 -16.35 62.61 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.136 -0.977 . . . . 0.0 109.493 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.4 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 2.6 m120 -75.95 -40.76 53.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.397 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 30.9 tp -60.58 -47.69 85.07 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.336 -0.853 . . . . 0.0 109.433 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.87 -20.43 56.29 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.432 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.434 ' CG ' ' O ' ' A' ' 99' ' ' GLU . 6.4 mt -67.37 -43.5 81.26 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.312 -0.868 . . . . 0.0 109.676 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.556 ' CE2' ' HB1' ' A' ' 68' ' ' ALA . 7.1 t80 -61.28 -29.17 69.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.28 -0.888 . . . . 0.0 109.453 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 92.0 m -62.34 -40.59 96.88 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.211 -0.93 . . . . 0.0 109.563 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 107' ' ' GLY . 6.4 mm-40 -87.94 3.21 49.44 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.181 -0.949 . . . . 0.0 109.729 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . 44.25 39.03 5.24 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -103.22 -10.94 18.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -1.162 . . . . 0.0 109.607 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.461 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 0.7 OUTLIER -74.05 -161.17 0.11 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.208 -0.932 . . . . 0.0 109.482 -179.989 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.532 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 7.0 mt-10 -95.07 113.88 25.63 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.304 -0.872 . . . . 0.0 109.418 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -103.18 142.8 33.54 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.35 -0.844 . . . . 0.0 109.599 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.466 ' O ' ' HB2' ' A' ' 113' ' ' ARG . 13.6 mm -129.84 117.53 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.272 -0.893 . . . . 0.0 109.302 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.466 ' HB2' ' O ' ' A' ' 112' ' ' ILE . 3.4 ttt-85 178.39 71.77 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.195 -0.94 . . . . 0.0 109.619 -179.802 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -134.58 89.24 26.84 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.235 -0.916 . . . . 0.0 109.555 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.468 ' O ' ' O ' ' A' ' 116' ' ' GLY . 35.7 Cg_endo -78.84 -44.6 0.13 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.635 2.224 . . . . 0.0 110.665 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 115' ' ' PRO . . . -60.59 -131.0 0.01 OUTLIER Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 116' ' ' GLY . 57.9 p 52.69 82.98 0.07 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.299 -1.118 . . . . 0.0 109.654 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 77.84 48.6 7.69 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.744 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.6 ttt-85 -119.78 66.52 0.81 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.191 -1.182 . . . . 0.0 109.571 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 151.2 -70.44 0.3 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.773 -1.331 . . . . 0.0 109.773 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -175.15 95.56 0.07 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.23 -1.159 . . . . 0.0 109.582 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.44 84.36 6.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.91 . . . . 0.0 109.366 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.435 ' O ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -52.58 128.76 27.12 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.249 -0.907 . . . . 0.0 109.582 -179.891 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.435 ' HB2' ' O ' ' A' ' 123' ' ' ARG . 2.8 tpp180 . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 117.99 -1.005 . . . . 0.0 109.436 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.404 ' HE2' ' HB2' ' A' ' 1' ' ' MET . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 . . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.09 155.77 17.84 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.202 -0.936 . . . . 0.0 109.309 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.478 ' HA ' ' O ' ' A' ' 68' ' ' ALA . 7.8 mt -120.31 117.41 53.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.277 -0.889 . . . . 0.0 110.052 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -112.51 116.92 31.02 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.317 -0.864 . . . . 0.0 108.672 179.275 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -102.98 135.23 41.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.128 -0.983 . . . . 0.0 109.926 -179.311 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.419 ' O ' HG11 ' A' ' 16' ' ' VAL . . . -73.55 143.24 46.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.39 -0.819 . . . . 0.0 109.175 179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.467 ' HB3' HG12 ' A' ' 97' ' ' VAL . 0.7 OUTLIER -151.39 157.96 43.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.208 -0.933 . . . . 0.0 109.683 -179.792 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 66.9 p -119.39 0.96 11.2 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.324 -0.86 . . . . 0.0 109.388 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.548 ' O ' ' CG ' ' A' ' 25' ' ' TYR . . . -125.62 -153.96 8.59 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.527 HG23 ' CE1' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -126.45 -30.52 2.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.183 -1.186 . . . . 0.0 109.664 -179.849 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 173.31 -43.8 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.122 -0.986 . . . . 0.0 109.528 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -80.66 5.15 16.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.299 -0.875 . . . . 0.0 109.629 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -166.31 31.43 0.21 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.467 ' HB3' ' CG2' ' A' ' 97' ' ' VAL . 5.0 m -77.06 79.43 3.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.124 -1.221 . . . . 0.0 109.357 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.488 ' O ' ' CB ' ' A' ' 16' ' ' VAL . 9.2 mm-40 -76.91 1.57 17.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.302 -0.874 . . . . 0.0 109.576 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.488 ' CB ' ' O ' ' A' ' 15' ' ' GLU . 1.9 t 73.68 18.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.403 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.1 t 59.11 176.04 0.07 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.32 -0.863 . . . . 0.0 109.399 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -109.04 -36.25 6.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -131.79 123.18 27.09 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.875 . . . . 0.0 109.363 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.449 ' C ' ' CD1' ' A' ' 20' ' ' PHE . 2.5 t80 -62.23 96.72 0.08 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.905 . . . . 0.0 109.497 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -136.76 -87.02 0.2 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.428 ' O ' ' C ' ' A' ' 23' ' ' ALA . 1.8 ptp85 -114.7 43.85 1.86 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -1.111 . . . . 0.0 109.18 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.428 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -42.79 114.14 1.45 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.406 -0.808 . . . . 0.0 109.405 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.58 21.14 0.88 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.578 2.185 . . . . 0.0 110.947 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.548 ' CG ' ' O ' ' A' ' 9' ' ' GLY . 0.5 OUTLIER -159.51 70.78 0.47 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.949 -1.094 . . . . 0.0 109.301 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.511 ' CE2' HD12 ' A' ' 61' ' ' ILE . 0.3 OUTLIER -79.52 126.27 30.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.441 -179.917 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.22 115.94 31.65 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 28.9 mm -96.78 131.43 43.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.3 -0.875 . . . . 0.0 109.661 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 4.5 t -130.25 137.09 57.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.295 -0.878 . . . . 0.0 109.117 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -118.17 95.99 5.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.095 -1.003 . . . . 0.0 109.816 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.442 ' HE2' HG13 ' A' ' 36' ' ' ILE . 41.1 ttm -81.91 146.06 30.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.029 179.603 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -99.96 -70.01 0.75 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.113 -0.992 . . . . 0.0 110.002 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 19.3 tttm -138.59 62.71 1.54 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.094 -1.004 . . . . 0.0 109.95 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.51 31.64 36.53 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 36' ' ' ILE . 2.9 p30 -159.58 97.47 1.33 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.169 -1.195 . . . . 0.0 109.552 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.442 HG13 ' HE2' ' A' ' 31' ' ' MET . 2.9 mp -44.06 132.39 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.247 -0.908 . . . . 0.0 109.327 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -130.01 18.97 5.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.119 -0.988 . . . . 0.0 109.737 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 175.38 129.9 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.078 -1.014 . . . . 0.0 109.619 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.4 p -149.58 107.51 3.71 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.323 -0.86 . . . . 0.0 109.373 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.22 164.27 15.42 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.234 -0.916 . . . . 0.0 109.537 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.511 HG22 ' N ' ' A' ' 42' ' ' ILE . 14.7 p -124.42 148.03 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.497 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.511 ' N ' HG22 ' A' ' 41' ' ' VAL . 2.6 tp -141.65 154.27 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.302 -0.874 . . . . 0.0 109.392 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.451 ' N ' HG13 ' A' ' 42' ' ' ILE . 26.7 mp0 -93.9 68.8 3.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.267 -0.895 . . . . 0.0 109.497 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.472 ' CG ' ' CB ' ' A' ' 47' ' ' ALA . 1.3 m-20 53.2 92.13 0.06 OUTLIER Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.307 -0.87 . . . . 0.0 109.727 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.46 111.32 3.14 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.572 2.181 . . . . 0.0 110.392 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.5 t 53.25 20.26 1.81 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.275 -0.89 . . . . 0.0 109.531 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.472 ' CB ' ' CG ' ' A' ' 44' ' ' ASN . . . -66.47 -26.8 67.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.272 -0.893 . . . . 0.0 109.45 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 71.2 m -137.1 45.86 2.21 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.355 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -57.92 -44.99 87.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.317 -0.865 . . . . 0.0 109.719 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 92.4 p -115.79 28.41 8.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.664 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.71 -141.51 23.68 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.39 -128.0 9.13 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -151.1 -57.48 0.16 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.234 -1.156 . . . . 0.0 109.486 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 158.0 -21.29 0.37 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.406 ' HA ' HD13 ' A' ' 55' ' ' ILE . 46.6 mm -69.77 -45.82 76.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.127 -1.219 . . . . 0.0 109.479 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.17 -33.26 75.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.221 -0.924 . . . . 0.0 109.535 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 21.6 m -58.95 -23.9 62.01 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.18 -0.95 . . . . 0.0 109.634 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -53.51 -51.94 61.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.258 -0.901 . . . . 0.0 109.574 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.498 ' OE1' ' CG1' ' A' ' 81' ' ' VAL . 1.4 tp60 -46.06 -44.73 15.64 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.188 -0.945 . . . . 0.0 109.504 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 23.5 mt -62.63 -40.22 87.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.193 -0.942 . . . . 0.0 109.522 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.511 HD12 ' CE2' ' A' ' 26' ' ' PHE . 50.3 mt -66.61 -20.38 27.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.201 -0.937 . . . . 0.0 109.487 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -77.16 -36.23 55.33 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.256 -0.903 . . . . 0.0 109.687 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 52.2 m-20 -75.47 -0.15 19.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.258 -0.901 . . . . 0.0 109.694 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -82.9 -7.68 59.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.129 -0.982 . . . . 0.0 109.747 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.11 -23.98 32.14 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.422 ' O ' HG21 ' A' ' 66' ' ' VAL . 19.2 m -59.51 93.9 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -1.152 . . . . 0.0 109.688 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.42 ' O ' ' HD3' ' A' ' 88' ' ' LYS . 26.9 mtpt -79.49 -3.45 46.75 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.36 -0.838 . . . . 0.0 108.793 179.286 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.478 ' O ' ' HA ' ' A' ' 3' ' ' ILE . . . -135.21 103.14 5.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.227 -0.921 . . . . 0.0 109.19 179.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 55.1 t -110.93 129.99 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.023 -1.048 . . . . 0.0 109.999 -179.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 3.6 mp -92.68 119.38 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.286 -0.883 . . . . 0.0 109.078 179.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.444 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -157.3 176.97 12.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.169 -0.957 . . . . 0.0 109.693 -179.724 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 73' ' ' SER . 3.1 p -152.64 51.89 0.76 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.48 -0.762 . . . . 0.0 109.494 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' SER . . . . . 0.563 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 0.1 OUTLIER -44.29 167.51 0.09 OUTLIER Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.172 -0.955 . . . . 0.0 109.436 179.962 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.63 -1.92 12.02 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.613 2.209 . . . . 0.0 110.309 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -162.63 168.61 37.6 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.555 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.2 Cg_endo -79.17 7.9 4.14 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.671 2.248 . . . . 0.0 110.582 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -58.57 -44.54 89.77 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.178 -0.951 . . . . 0.0 109.649 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -77.04 -48.87 16.68 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.176 -0.952 . . . . 0.0 109.851 -179.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.563 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 2.9 m-85 -55.06 -19.81 8.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.209 -0.932 . . . . 0.0 109.776 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.68 -46.71 24.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.147 -0.97 . . . . 0.0 109.815 -179.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.498 ' CG1' ' OE1' ' A' ' 59' ' ' GLN . 22.2 t -64.49 -51.09 72.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.154 -0.966 . . . . 0.0 109.495 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.459 ' HB2' HD12 ' A' ' 89' ' ' ILE . 0.9 OUTLIER -55.03 -46.44 75.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.903 . . . . 0.0 109.71 -179.88 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 53.6 t30 -57.81 -41.53 82.36 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.219 -0.925 . . . . 0.0 109.534 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.49 -50.39 71.89 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.497 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.528 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 2.4 mp -60.21 -28.1 67.71 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.175 -0.953 . . . . 0.0 109.477 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.43 10.24 17.77 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.528 ' CD1' ' HB3' ' A' ' 85' ' ' LEU . 3.2 mp -94.38 147.71 5.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.115 -1.226 . . . . 0.0 109.439 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.42 ' HD3' ' O ' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -104.81 155.91 18.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.259 -0.901 . . . . 0.0 109.818 -179.835 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.482 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.5 mp -136.6 140.21 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.254 -0.904 . . . . 0.0 109.507 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.556 ' CD2' ' O ' ' A' ' 109' ' ' LEU . 16.9 m-30 -102.82 167.7 9.7 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.313 -0.867 . . . . 0.0 109.53 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.53 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 0.0 OUTLIER -85.7 130.43 34.57 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.245 -0.909 . . . . 0.0 109.866 -179.615 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -87.76 116.89 26.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.422 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.434 HG22 HD11 ' A' ' 109' ' ' LEU . 63.4 p -61.77 -26.32 68.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.281 -0.887 . . . . 0.0 109.372 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.56 18.22 42.36 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 58.4 m -86.35 -74.88 0.41 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -1.134 . . . . 0.0 109.473 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.452 ' HA ' ' O ' ' A' ' 14' ' ' SER . 74.4 m -155.98 144.08 19.84 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.321 -0.862 . . . . 0.0 109.43 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.467 ' CG2' ' HB3' ' A' ' 14' ' ' SER . 28.8 m -68.94 -35.9 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.885 . . . . 0.0 109.698 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -60.08 -38.06 81.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.135 -0.978 . . . . 0.0 109.323 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -71.85 -50.69 27.32 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.335 -0.853 . . . . 0.0 109.433 179.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.471 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 42.2 m-20 -49.62 -34.44 18.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -0.893 . . . . 0.0 109.551 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 12.3 tp -52.99 -55.86 20.35 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.247 -0.908 . . . . 0.0 109.725 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.49 -20.49 61.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.13 -0.982 . . . . 0.0 109.728 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.471 ' HB2' ' HA ' ' A' ' 100' ' ' ASN . 23.9 mt -71.74 -25.38 62.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.174 -0.954 . . . . 0.0 109.611 -179.782 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.412 ' CD1' HD12 ' A' ' 3' ' ' ILE . 41.3 t80 -70.0 -38.11 75.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.207 -0.933 . . . . 0.0 109.237 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.424 ' O ' HG21 ' A' ' 105' ' ' THR . 48.6 m -74.56 -24.39 58.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.857 . . . . 0.0 109.504 179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -80.81 -18.52 47.25 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.193 -0.942 . . . . 0.0 109.5 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 76.24 24.48 68.47 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -92.68 -37.92 12.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.14 -1.212 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.556 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 0.0 OUTLIER -88.56 119.98 29.52 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.135 -0.978 . . . . 0.0 109.479 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.517 ' HA ' ' CG ' ' A' ' 90' ' ' TYR . 16.6 pt-20 -149.29 173.83 13.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.463 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.53 ' HB2' ' N ' ' A' ' 91' ' ' ARG . 8.1 tp10 -175.77 -111.24 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.318 -0.864 . . . . 0.0 109.84 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.483 ' N ' ' HG3' ' A' ' 111' ' ' GLU . 19.8 tt -84.21 134.58 26.65 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 O-C-N 121.08 -1.012 . . . . 0.0 110.072 -179.222 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -132.59 -177.63 4.57 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.442 -0.786 . . . . 0.0 109.285 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -73.69 154.72 89.37 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.145 -0.972 . . . . 0.0 109.64 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -77.52 -46.43 0.14 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 122.651 2.234 . . . . 0.0 110.305 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 117' ' ' SER . . . -123.83 -122.93 2.74 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.461 ' HB2' ' O ' ' A' ' 116' ' ' GLY . 24.8 t 177.49 37.2 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.351 -1.088 . . . . 0.0 109.444 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 138.35 -111.11 0.78 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -76.99 117.93 19.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.328 -1.101 . . . . 0.0 109.345 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -158.11 122.4 1.15 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 41.4 mtm180 -97.82 137.57 36.48 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.326 -1.102 . . . . 0.0 109.155 179.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 -138.72 133.76 32.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.278 -0.889 . . . . 0.0 109.837 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 ttp180 -140.08 25.47 2.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.321 -0.862 . . . . 0.0 109.107 179.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 7.6 mtm180 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 117.905 -1.045 . . . . 0.0 109.419 -179.809 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.3 ptp . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.486 ' CG ' ' HG3' ' A' ' 30' ' ' GLU . 0.1 OUTLIER -131.67 144.29 50.91 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.245 -0.909 . . . . 0.0 109.583 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 5.3 mt -118.32 104.45 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.288 -0.883 . . . . 0.0 109.565 -179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -106.16 116.41 31.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.329 -0.857 . . . . 0.0 109.31 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.458 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 2.8 mp -94.61 120.8 44.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.15 -0.969 . . . . 0.0 109.467 -179.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 7' ' ' SER . . . -61.91 150.43 37.61 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.278 -0.889 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.507 ' O ' ' CB ' ' A' ' 8' ' ' SER . 0.0 OUTLIER 53.6 169.95 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.28 -0.887 . . . . 0.0 109.598 179.963 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.507 ' CB ' ' O ' ' A' ' 7' ' ' SER . 0.2 OUTLIER 162.52 -35.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.322 -0.862 . . . . 0.0 109.321 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.459 ' HA3' ' HB2' ' A' ' 14' ' ' SER . . . 75.91 9.56 85.16 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER 61.92 16.78 8.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.244 -1.151 . . . . 0.0 109.46 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.0 t0 -173.17 -167.48 0.41 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.237 -0.915 . . . . 0.0 109.597 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.2 mt -79.85 -1.85 40.87 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.211 -0.93 . . . . 0.0 109.613 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.81 -61.62 7.01 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.459 ' HB2' ' HA3' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -77.31 83.23 3.76 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.198 -1.177 . . . . 0.0 109.505 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.402 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 7.2 mt-10 -72.22 83.1 1.02 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.34 -0.85 . . . . 0.0 109.176 179.724 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.417 ' O ' ' C ' ' A' ' 17' ' ' SER . 22.1 t 62.6 63.97 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.916 . . . . 0.0 109.308 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.461 ' HB3' ' CB ' ' A' ' 7' ' ' SER . 8.2 t -43.77 159.01 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.311 -0.868 . . . . 0.0 109.426 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 22.3 mtp85 -95.67 30.62 2.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.376 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -127.38 159.03 35.68 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.948 . . . . 0.0 109.474 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -133.17 -32.51 1.19 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.186 -0.946 . . . . 0.0 109.903 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -101.5 -37.29 3.55 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.462 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -84.31 -25.9 28.91 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.131 -1.217 . . . . 0.0 109.775 -179.753 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.419 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -42.49 103.01 0.29 Allowed Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.335 -0.853 . . . . 0.0 109.7 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.482 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.7 Cg_endo -80.68 41.28 1.11 Allowed 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 122.602 2.202 . . . . 0.0 110.533 179.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.482 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 84.1 m-85 -158.19 68.5 0.49 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.106 -0.996 . . . . 0.0 109.286 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.435 ' CE1' ' HA ' ' A' ' 6' ' ' ALA . 0.8 OUTLIER -83.02 116.49 22.3 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.271 -0.893 . . . . 0.0 109.585 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 1.4 ttt -94.21 132.42 38.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.156 -0.965 . . . . 0.0 109.635 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.506 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 5.1 tt -129.42 116.81 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.897 . . . . 0.0 109.401 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.459 HG12 ' O ' ' A' ' 38' ' ' SER . 94.6 t -125.11 129.7 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 109.388 -179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.486 ' HG3' ' CG ' ' A' ' 2' ' ' LYS . 26.9 tt0 -99.05 99.45 10.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.226 -0.921 . . . . 0.0 109.635 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.2 tpp -81.8 134.24 35.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.309 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -99.0 -68.66 0.79 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -0.915 . . . . 0.0 109.681 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -129.99 81.47 2.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.204 -0.935 . . . . 0.0 109.631 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.15 28.04 24.97 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.412 ' O ' ' N ' ' A' ' 37' ' ' GLU . 1.3 m-20 -147.73 108.49 4.18 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.173 -1.192 . . . . 0.0 109.536 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.457 HG23 ' OG ' ' A' ' 39' ' ' SER . 72.6 mt -48.28 98.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.169 -0.957 . . . . 0.0 109.405 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.412 ' N ' ' O ' ' A' ' 35' ' ' ASN . 34.7 mt-10 -96.46 9.77 40.3 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.614 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.459 ' O ' HG12 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -169.6 122.67 0.75 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 179.99 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.457 ' OG ' HG23 ' A' ' 36' ' ' ILE . 0.7 OUTLIER -141.03 107.95 5.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 109.541 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.411 ' O ' HG22 ' A' ' 28' ' ' ILE . 7.5 tt0 -132.38 138.59 47.77 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.197 -0.939 . . . . 0.0 109.437 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.9 t -98.63 154.72 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.269 -0.895 . . . . 0.0 109.547 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.402 HD12 HG23 ' A' ' 28' ' ' ILE . 6.6 mt -131.92 134.33 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.341 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.473 ' O ' ' HD3' ' A' ' 45' ' ' PRO . 53.7 mt-10 -91.06 85.92 6.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.297 -0.877 . . . . 0.0 109.527 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.445 ' C ' ' O ' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -41.87 101.61 0.25 Allowed Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.371 -0.831 . . . . 0.0 109.473 179.977 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.473 ' HD3' ' O ' ' A' ' 43' ' ' GLU . 36.2 Cg_endo -78.56 -166.69 0.42 Allowed 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 122.529 2.152 . . . . 0.0 110.578 -179.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.1 m 56.49 36.34 27.41 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.893 . . . . 0.0 109.395 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -76.87 -39.89 49.48 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.327 -0.858 . . . . 0.0 109.506 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.21 -27.65 29.83 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.168 -0.957 . . . . 0.0 109.351 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -86.35 151.01 23.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.217 -0.927 . . . . 0.0 109.549 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.38 132.83 54.1 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.86 . . . . 0.0 109.543 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -146.2 30.22 1.62 Allowed Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.477 ' O ' ' CB ' ' A' ' 53' ' ' ALA . . . 174.33 -82.77 0.08 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.477 ' CB ' ' O ' ' A' ' 52' ' ' GLY . . . 167.24 -31.06 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.325 -1.103 . . . . 0.0 109.453 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 136.75 -49.19 0.88 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 51.0 mm -60.77 -14.08 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.258 -1.142 . . . . 0.0 109.63 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.403 ' O ' ' C ' ' A' ' 57' ' ' THR . 0.0 OUTLIER -65.01 -37.04 86.34 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.211 -0.93 . . . . 0.0 109.658 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.403 ' C ' ' O ' ' A' ' 56' ' ' ARG . 14.6 m -43.48 -33.88 1.21 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.202 -0.936 . . . . 0.0 109.723 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -51.29 -52.36 45.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -0.933 . . . . 0.0 109.771 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -54.54 -34.31 61.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.933 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.6 mt -69.39 -65.76 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.127 -0.983 . . . . 0.0 109.726 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 18.8 pt -51.71 -20.95 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.741 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.16 -47.31 58.46 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.212 -0.93 . . . . 0.0 109.621 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -76.42 1.58 16.01 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.296 -0.877 . . . . 0.0 109.757 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -95.34 -2.11 49.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.088 -1.008 . . . . 0.0 109.772 -179.757 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 93.59 -14.41 65.36 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.418 HG13 HG21 ' A' ' 69' ' ' VAL . 31.8 t -49.66 91.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -1.119 . . . . 0.0 109.632 180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' GLY . 3.6 mmmp? -79.3 -7.39 58.27 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.338 -0.851 . . . . 0.0 108.811 179.371 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.466 ' HB2' ' O ' ' A' ' 2' ' ' LYS . . . -131.26 123.44 28.41 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.287 -0.883 . . . . 0.0 109.199 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.418 HG21 HG13 ' A' ' 66' ' ' VAL . 57.0 t -121.34 106.69 18.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.161 -0.962 . . . . 0.0 109.853 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.469 HD11 ' CB ' ' A' ' 90' ' ' TYR . 13.4 mm -83.2 104.32 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.18 -0.95 . . . . 0.0 109.03 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -143.74 173.5 11.62 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.22 -0.925 . . . . 0.0 109.789 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.0 p -145.49 40.01 1.19 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.374 -0.829 . . . . 0.0 109.249 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' SER . . . . . 0.403 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -45.05 149.76 0.83 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.355 -0.841 . . . . 0.0 109.669 -179.905 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.2 Cg_endo -78.61 4.97 5.92 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.737 2.291 . . . . 0.0 110.336 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.411 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -144.42 148.46 20.24 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.411 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 36.2 Cg_endo -79.38 11.16 2.75 Favored 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 122.716 2.277 . . . . 0.0 110.79 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -73.54 -36.07 65.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.077 -1.014 . . . . 0.0 109.691 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -68.21 -50.59 53.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.954 . . . . 0.0 109.628 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.536 ' N ' ' CD1' ' A' ' 79' ' ' PHE . 1.4 m-85 -65.04 -18.31 65.19 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.133 -0.98 . . . . 0.0 109.519 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -67.53 -49.67 62.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.111 -0.993 . . . . 0.0 109.538 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -71.2 -43.88 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.194 -0.941 . . . . 0.0 109.609 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.426 HD13 HG12 ' A' ' 89' ' ' ILE . 20.1 mt -49.66 -49.36 47.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.173 -0.955 . . . . 0.0 109.446 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -61.35 -34.3 75.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.228 -0.92 . . . . 0.0 109.302 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -67.31 -25.65 66.12 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.434 -0.792 . . . . 0.0 109.6 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 4.5 mt -97.7 18.43 15.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.891 . . . . 0.0 109.37 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 56.3 62.84 5.89 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 97.7 mt -132.38 144.9 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.287 -1.126 . . . . 0.0 109.306 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.47 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 0.2 OUTLIER -82.77 124.64 30.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.296 -0.877 . . . . 0.0 109.423 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.495 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.7 mt -104.16 129.95 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.52 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.587 ' CE2' ' CB ' ' A' ' 110' ' ' GLU . 3.6 m-85 -116.46 157.57 24.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.405 -0.809 . . . . 0.0 109.249 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 1.2 ttt-85 -96.09 143.22 27.42 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.245 -0.909 . . . . 0.0 109.568 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.416 ' HB1' HG13 ' A' ' 16' ' ' VAL . . . -109.97 86.72 2.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.4 179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 34.1 m -149.35 26.85 0.85 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.192 -0.943 . . . . 0.0 109.421 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.524 ' CA ' HD13 ' A' ' 109' ' ' LEU . . . -79.17 -71.8 1.23 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 15.8 m -165.92 -46.17 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.205 -1.174 . . . . 0.0 109.727 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.77 162.9 38.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.23 -0.919 . . . . 0.0 109.79 -179.684 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.449 ' CG1' HG23 ' A' ' 5' ' ' ILE . 47.4 t -77.08 -40.03 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.272 -0.893 . . . . 0.0 109.351 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -59.15 -50.06 75.49 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.803 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.419 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 1.2 tt0 -72.17 -33.0 67.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.12 -0.988 . . . . 0.0 109.645 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -57.2 -43.39 82.71 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.224 -0.922 . . . . 0.0 109.759 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.435 HD21 HG11 ' A' ' 29' ' ' VAL . 51.9 tp -51.39 -43.14 61.83 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -0.933 . . . . 0.0 109.795 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 7.6 tptm -75.18 -30.5 60.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.138 -0.977 . . . . 0.0 109.762 -179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.419 ' HG ' ' O ' ' A' ' 99' ' ' GLU . 48.6 mt -67.09 -23.96 65.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.165 -0.959 . . . . 0.0 109.608 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 104' ' ' PHE . 24.4 t80 -58.79 -48.07 82.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.198 -0.939 . . . . 0.0 109.357 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 55.4 m -65.28 -39.1 92.13 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.348 -0.845 . . . . 0.0 109.304 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -70.98 -6.81 41.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.234 -0.916 . . . . 0.0 109.505 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 56.16 30.65 58.15 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.306 -1.517 . . . . 0.0 109.306 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -83.66 -28.84 28.1 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.313 -1.11 . . . . 0.0 109.529 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.524 HD13 ' CA ' ' A' ' 94' ' ' GLY . 0.2 OUTLIER -138.6 138.48 37.94 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.073 -1.017 . . . . 0.0 109.763 -179.805 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.587 ' CB ' ' CE2' ' A' ' 90' ' ' TYR . 1.7 pt-20 -170.76 -151.54 0.08 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.324 -0.86 . . . . 0.0 109.449 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.495 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 0.7 OUTLIER -163.49 -112.16 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.257 -0.902 . . . . 0.0 109.623 -179.81 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.6 mt -83.33 90.34 2.42 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 O-C-N 121.154 -0.966 . . . . 0.0 109.489 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -64.58 -59.83 3.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.206 -0.934 . . . . 0.0 109.321 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -177.32 146.3 0.63 Allowed Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 109.48 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -78.06 -179.31 5.32 Favored 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 122.638 2.225 . . . . 0.0 110.366 179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 87.43 20.56 51.46 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 47.4 p -160.44 -38.51 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.198 -1.178 . . . . 0.0 109.565 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -100.43 19.48 52.47 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 3.2 ttp85 -63.15 136.81 57.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.288 -1.125 . . . . 0.0 109.595 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -84.79 -156.45 25.47 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 2.4 mtm180 -144.17 86.77 1.86 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.291 -1.123 . . . . 0.0 109.494 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.424 ' NH1' ' CG ' ' A' ' 122' ' ' ARG . 0.0 OUTLIER -92.88 173.84 7.55 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.316 -0.865 . . . . 0.0 109.211 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 62.5 mtt180 -121.89 86.0 2.5 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.171 -0.956 . . . . 0.0 109.498 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.505 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.431 ' HB2' ' O ' ' A' ' 65' ' ' GLY . 4.4 mtmt -118.25 145.97 44.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.308 -0.87 . . . . 0.0 109.293 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.616 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 5.3 mt -119.76 111.1 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.348 -0.845 . . . . 0.0 109.616 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.53 ' CB ' HG12 ' A' ' 66' ' ' VAL . . . -115.27 122.86 47.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.336 -0.852 . . . . 0.0 109.219 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 2.5 mp -98.4 142.61 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.233 -0.917 . . . . 0.0 109.543 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.498 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -81.49 155.84 25.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.358 -0.839 . . . . 0.0 109.755 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.458 ' O ' ' HB2' ' A' ' 8' ' ' SER . 1.0 OUTLIER 52.83 -89.98 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.659 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.498 ' N ' ' O ' ' A' ' 6' ' ' ALA . 3.0 m 62.85 24.22 14.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.911 . . . . 0.0 109.566 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 44.07 -107.46 0.13 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.81 -76.91 0.13 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -1.141 . . . . 0.0 109.494 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -158.2 -43.71 0.06 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.232 -0.918 . . . . 0.0 109.614 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.59 -0.44 57.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -0.938 . . . . 0.0 109.55 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.12 19.91 1.09 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.461 ' HB3' ' O ' ' A' ' 8' ' ' SER . 9.7 p -77.02 81.91 3.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.355 -1.085 . . . . 0.0 109.464 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.449 ' O ' ' CG2' ' A' ' 97' ' ' VAL . 2.7 mt-10 -77.22 -137.5 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.192 -0.943 . . . . 0.0 109.025 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.46 ' HA ' HG11 ' A' ' 97' ' ' VAL . 6.1 p -88.75 34.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.066 -1.021 . . . . 0.0 109.587 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.427 ' HB3' ' HB2' ' A' ' 7' ' ' SER . 0.5 OUTLIER 69.32 -157.7 0.17 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.349 -0.845 . . . . 0.0 109.479 179.921 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.4 -72.88 0.12 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -112.38 -164.54 0.92 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.189 -0.944 . . . . 0.0 109.611 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.407 ' CD1' ' CB ' ' A' ' 6' ' ' ALA . 24.8 t80 -158.05 48.98 0.39 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.333 -0.854 . . . . 0.0 109.499 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -127.27 -68.44 0.15 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.424 ' O ' ' C ' ' A' ' 23' ' ' ALA . 55.1 mtt180 -112.49 16.76 19.72 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.311 -1.111 . . . . 0.0 109.398 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.424 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -43.46 107.3 0.56 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.323 -0.861 . . . . 0.0 109.619 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.57 44.05 1.66 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.601 2.2 . . . . 0.0 110.604 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.477 ' CE1' ' HG2' ' A' ' 43' ' ' GLU . 4.9 m-85 -158.02 70.09 0.55 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.112 -0.993 . . . . 0.0 109.267 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.417 ' CE2' HD11 ' A' ' 61' ' ' ILE . 4.4 m-30 -79.44 121.96 25.82 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.36 -0.837 . . . . 0.0 109.492 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.9 117.67 35.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.241 -0.912 . . . . 0.0 109.325 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 39.7 mm -104.55 130.95 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.219 -0.926 . . . . 0.0 109.526 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.436 HG13 HD22 ' A' ' 101' ' ' LEU . 82.8 t -131.33 132.17 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.328 -0.857 . . . . 0.0 109.5 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.442 ' HB2' ' CB ' ' A' ' 38' ' ' SER . 7.8 mt-10 -106.64 163.71 12.67 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.322 -0.861 . . . . 0.0 109.376 179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.52 ' HE1' ' CD1' ' A' ' 3' ' ' ILE . 41.9 ttm -147.74 139.05 23.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.174 -0.954 . . . . 0.0 109.538 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.05 -70.5 0.71 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.934 . . . . 0.0 109.578 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 6.3 mtmt -136.17 73.99 1.48 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.447 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 68.53 16.2 69.34 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.46 103.21 6.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.316 -1.108 . . . . 0.0 109.456 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 2.0 mt -66.68 115.53 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.238 -0.914 . . . . 0.0 109.579 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -130.97 33.63 4.16 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.219 -0.926 . . . . 0.0 109.237 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.442 ' CB ' ' HB2' ' A' ' 30' ' ' GLU . 0.6 OUTLIER -161.22 100.11 1.21 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -0.873 . . . . 0.0 109.474 -179.87 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 56.4 m -129.01 104.84 7.81 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.161 -0.962 . . . . 0.0 109.087 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -126.05 125.46 42.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.334 -0.854 . . . . 0.0 109.83 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.5 p -98.54 139.65 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.378 -0.826 . . . . 0.0 109.119 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 5.5 mt -139.81 142.68 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.177 -0.952 . . . . 0.0 109.727 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.477 ' HG2' ' CE1' ' A' ' 25' ' ' TYR . 12.4 mt-10 -94.9 142.15 27.81 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.531 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.501 ' O ' ' ND2' ' A' ' 44' ' ' ASN . 9.1 p-10 -140.48 75.04 27.64 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.231 -0.918 . . . . 0.0 109.365 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.64 2.14 8.12 Favored 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 122.585 2.19 . . . . 0.0 110.345 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -54.93 -27.73 45.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.9 . . . . 0.0 109.273 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -71.84 -38.04 70.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.258 -0.901 . . . . 0.0 109.321 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.5 m -90.54 56.02 3.19 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.383 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -129.96 -50.52 1.13 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.299 -0.876 . . . . 0.0 109.534 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -143.74 148.64 35.96 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.146 -0.971 . . . . 0.0 109.541 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 61.08 162.34 0.15 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' A' ' 53' ' ' ALA . . . -86.89 -88.81 1.03 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.455 ' O ' ' O ' ' A' ' 52' ' ' GLY . . . 47.87 -174.28 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.21 -1.171 . . . . 0.0 109.407 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 154.0 -54.13 0.44 Allowed Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 24.2 mm -67.87 -8.03 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -1.155 . . . . 0.0 109.646 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -69.24 -33.33 73.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.927 . . . . 0.0 109.666 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 13.2 t -58.82 -15.54 12.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.297 -0.877 . . . . 0.0 109.783 -179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.85 -46.02 85.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.804 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 52.6 tt0 -65.5 -28.59 69.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.269 -0.894 . . . . 0.0 109.805 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.428 HG22 HD12 ' A' ' 60' ' ' ILE . 33.2 mm -75.9 -29.21 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.175 -0.953 . . . . 0.0 109.718 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.427 HD12 HG21 ' A' ' 61' ' ' ILE . 65.8 mt -75.27 -41.54 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.147 -0.971 . . . . 0.0 109.636 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.45 -26.29 66.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.154 -0.966 . . . . 0.0 109.627 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -76.68 -5.77 49.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.192 -0.943 . . . . 0.0 109.674 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -90.94 27.6 1.78 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.136 -0.977 . . . . 0.0 109.618 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.431 ' O ' ' HB2' ' A' ' 2' ' ' LYS . . . 66.72 11.84 58.22 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.53 HG12 ' CB ' ' A' ' 4' ' ' ALA . 96.0 t -87.06 91.81 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.2 -1.177 . . . . 0.0 109.386 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.465 ' O ' ' HB2' ' A' ' 88' ' ' LYS . 39.2 mmtt -79.43 -4.76 52.65 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.432 -0.792 . . . . 0.0 108.863 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.467 ' HB1' ' HA ' ' A' ' 3' ' ' ILE . . . -124.27 107.45 11.2 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.521 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 60.9 t -104.96 119.14 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.366 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 3.1 mm -99.24 108.19 21.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.347 -0.846 . . . . 0.0 109.397 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -153.37 173.79 15.18 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.255 -0.903 . . . . 0.0 109.557 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.33 49.32 1.43 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.444 -0.785 . . . . 0.0 109.224 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -50.42 145.53 10.39 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.328 -0.858 . . . . 0.0 109.513 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.05 -0.08 10.34 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 122.576 2.184 . . . . 0.0 110.477 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.76 154.67 24.95 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.47 -1.66 11.8 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.686 2.257 . . . . 0.0 110.574 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -53.66 -48.19 69.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.237 -0.914 . . . . 0.0 109.643 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.48 -59.29 2.94 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.279 -0.888 . . . . 0.0 109.881 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.568 ' CD1' HG23 ' A' ' 89' ' ' ILE . 25.1 m-85 -46.98 -23.52 0.47 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.934 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 14.7 mm-40 -71.16 -53.05 15.85 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.096 -1.003 . . . . 0.0 109.566 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 4.9 t -63.03 -46.46 96.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.162 -0.961 . . . . 0.0 109.432 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.441 HD23 HG12 ' A' ' 89' ' ' ILE . 0.0 OUTLIER -52.23 -56.26 15.83 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.287 -0.883 . . . . 0.0 109.399 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -54.83 -33.41 61.63 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 109.503 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -63.03 -46.22 88.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.196 -0.94 . . . . 0.0 109.427 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -64.62 -11.55 36.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.419 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 79.78 31.25 40.7 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.441 HG22 ' HA ' ' A' ' 67' ' ' LYS . 5.3 mm -98.05 172.85 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.32 -1.106 . . . . 0.0 109.326 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 67' ' ' LYS . 0.2 OUTLIER -97.82 114.41 26.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.21 -0.932 . . . . 0.0 109.631 -179.798 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.568 HG23 ' CD1' ' A' ' 79' ' ' PHE . 19.8 mt -85.6 149.02 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.38 -0.825 . . . . 0.0 109.181 179.722 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.501 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 0.4 OUTLIER -135.47 122.39 21.23 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.01 -1.056 . . . . 0.0 109.673 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.13 121.98 31.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 109.599 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.99 106.79 18.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -0.898 . . . . 0.0 109.547 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 94' ' ' GLY . 6.7 t -122.17 -20.63 6.16 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.272 -0.892 . . . . 0.0 109.732 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.443 ' O ' ' HB ' ' A' ' 95' ' ' THR . . . -43.14 -88.11 0.01 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.443 ' HB ' ' O ' ' A' ' 94' ' ' GLY . 5.2 t 176.51 -45.84 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.257 -1.143 . . . . 0.0 109.423 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.5 m -121.93 115.88 23.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.46 HG11 ' HA ' ' A' ' 16' ' ' VAL . 6.4 m -47.14 -35.96 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 109.591 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -48.19 -49.45 32.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.13 -0.981 . . . . 0.0 109.431 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -73.02 -45.36 58.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -0.9 . . . . 0.0 109.642 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.448 ' HA ' HD13 ' A' ' 103' ' ' LEU . 10.4 m-20 -51.41 -24.18 4.61 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.24 -0.913 . . . . 0.0 109.686 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.436 HD22 HG13 ' A' ' 29' ' ' VAL . 19.2 tp -65.51 -66.33 0.56 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.179 -0.951 . . . . 0.0 109.327 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 13.5 ptmt -56.1 -21.09 20.21 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -0.922 . . . . 0.0 109.348 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.5 ' HB3' ' CD1' ' A' ' 109' ' ' LEU . 10.2 mt -69.87 -45.22 68.17 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.336 -0.852 . . . . 0.0 109.54 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.616 ' CD1' ' CD1' ' A' ' 3' ' ' ILE . 21.2 t80 -55.54 -19.0 8.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.325 -0.859 . . . . 0.0 109.368 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 96.4 m -59.79 -51.2 70.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.27 -0.894 . . . . 0.0 109.483 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 0.452 ' OE2' HD21 ' A' ' 103' ' ' LEU . 13.6 pt-20 -83.4 -26.18 30.65 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.487 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.08 35.72 9.54 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -91.43 -6.33 52.95 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.247 -1.149 . . . . 0.0 109.577 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.5 ' CD1' ' HB3' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -76.63 -161.77 0.22 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.194 -0.942 . . . . 0.0 109.478 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.26 106.46 18.6 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.162 -0.961 . . . . 0.0 109.663 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.501 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 9.4 pt-20 -110.35 127.89 55.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.308 -0.87 . . . . 0.0 109.328 179.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 5.6 mt -127.83 132.19 69.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.582 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.1 ptm180 -142.18 177.47 8.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.283 -0.885 . . . . 0.0 109.264 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 3.4 m -117.72 158.65 44.94 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.547 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.12 136.48 14.61 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.645 2.23 . . . . 0.0 110.382 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -148.04 -113.07 0.71 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -148.94 152.56 36.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -1.139 . . . . 0.0 109.487 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -65.43 159.27 45.18 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.72 154.82 48.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.268 -1.137 . . . . 0.0 109.424 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -177.55 157.43 21.99 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.429 -1.469 . . . . 0.0 109.429 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.457 ' O ' ' O ' ' A' ' 122' ' ' ARG . 0.1 OUTLIER -114.64 13.8 17.48 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.256 -1.143 . . . . 0.0 109.523 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.457 ' O ' ' O ' ' A' ' 121' ' ' ARG . 54.7 mtt-85 53.63 102.67 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.943 . . . . 0.0 109.377 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -132.89 148.88 52.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.31 -0.869 . . . . 0.0 109.463 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 118.003 -0.998 . . . . 0.0 109.432 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.412 ' HB3' ' HE3' ' A' ' 1' ' ' MET . 37.3 mtp . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.248 0.546 . . . . 0.0 109.543 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -114.17 150.48 34.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.917 . . . . 0.0 109.315 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.572 HG12 ' CE2' ' A' ' 104' ' ' PHE . 7.6 mt -120.89 101.82 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.279 -0.888 . . . . 0.0 109.892 -179.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.459 ' HB2' HG12 ' A' ' 66' ' ' VAL . . . -99.07 103.6 15.54 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.345 -0.847 . . . . 0.0 109.137 179.545 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 7.7 mt -88.13 122.19 39.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.249 -0.907 . . . . 0.0 109.807 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.436 ' O ' HG11 ' A' ' 16' ' ' VAL . . . -69.95 147.11 50.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 109.12 179.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.437 ' HB3' HG12 ' A' ' 97' ' ' VAL . 25.8 p -158.63 -178.68 7.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.165 -0.96 . . . . 0.0 109.788 -179.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -132.46 11.84 4.5 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.299 -0.876 . . . . 0.0 109.361 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -150.2 175.37 29.3 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -73.49 -44.97 56.67 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.272 -1.134 . . . . 0.0 109.46 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.426 ' OD2' ' OE1' ' A' ' 98' ' ' GLU . 10.5 t0 -176.93 -51.81 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.17 -0.956 . . . . 0.0 109.436 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.7 tt -57.06 -29.82 63.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.203 -0.936 . . . . 0.0 109.245 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 18.97 7.73 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.466 ' O ' ' HA ' ' A' ' 96' ' ' SER . 93.9 p -76.89 79.94 3.46 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.259 -1.142 . . . . 0.0 109.517 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.484 ' O ' ' CB ' ' A' ' 16' ' ' VAL . 4.7 tt0 -77.39 4.27 11.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -0.828 . . . . 0.0 109.766 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.484 ' CB ' ' O ' ' A' ' 15' ' ' GLU . 2.5 t 74.91 12.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.131 -0.98 . . . . 0.0 109.241 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.4 163.83 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.672 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.21 -44.11 3.03 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.148 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.414 ' O ' ' C ' ' A' ' 20' ' ' PHE . 33.7 m-85 -108.28 78.67 1.19 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.319 -0.863 . . . . 0.0 109.235 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.501 ' CD2' ' HB3' ' A' ' 71' ' ' ALA . 26.4 t80 -42.73 125.84 3.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.272 -0.893 . . . . 0.0 109.565 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -179.69 -66.39 0.07 OUTLIER Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.45 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 7.1 mtt180 -116.71 15.92 15.39 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.211 -1.17 . . . . 0.0 109.654 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.413 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -44.55 104.8 0.4 Allowed Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.917 . . . . 0.0 109.491 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.49 43.14 1.47 Allowed 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.692 2.261 . . . . 0.0 110.794 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 14.8 m-85 -159.91 70.45 0.44 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.118 -0.989 . . . . 0.0 109.096 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 32.7 m-85 -79.72 129.35 34.4 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.253 -0.904 . . . . 0.0 109.781 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 3.2 ttt -103.64 102.68 12.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.887 . . . . 0.0 109.162 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.1 mm -90.41 116.76 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.098 -1.001 . . . . 0.0 109.552 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.456 ' CG1' HG21 ' A' ' 36' ' ' ILE . 3.9 t -118.96 160.17 19.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.705 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.481 ' HB3' ' CB ' ' A' ' 38' ' ' SER . 0.1 OUTLIER -139.18 84.6 2.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -0.866 . . . . 0.0 109.337 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 22.2 ttm -93.58 140.32 29.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.24 -0.912 . . . . 0.0 109.539 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . 0.479 ' HG2' ' N ' ' A' ' 33' ' ' LYS . 14.7 ttpp -83.61 -84.98 0.13 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -0.872 . . . . 0.0 109.495 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.479 ' N ' ' HG2' ' A' ' 32' ' ' LYS . 0.0 OUTLIER -131.38 40.31 3.44 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.265 -0.897 . . . . 0.0 109.622 -179.826 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.404 ' HA2' HG22 ' A' ' 105' ' ' THR . . . 119.96 24.93 2.65 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 68.6 m-80 -150.05 105.97 3.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.282 -1.128 . . . . 0.0 109.349 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.456 HG21 ' CG1' ' A' ' 29' ' ' VAL . 1.4 mp -66.48 114.75 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.279 -0.888 . . . . 0.0 109.584 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.21 33.06 5.68 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.481 ' CB ' ' HB3' ' A' ' 30' ' ' GLU . 0.2 OUTLIER -179.71 110.84 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.368 -0.832 . . . . 0.0 109.363 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -138.24 108.84 6.57 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.546 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -126.26 134.12 51.26 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.386 -0.821 . . . . 0.0 109.478 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.21 137.71 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.294 -0.879 . . . . 0.0 109.294 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.445 HG23 ' O ' ' A' ' 42' ' ' ILE . 0.8 OUTLIER -136.81 107.53 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.272 -0.892 . . . . 0.0 109.468 -179.935 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -74.59 171.66 13.44 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.382 -0.824 . . . . 0.0 109.409 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.459 ' N ' ' HD3' ' A' ' 45' ' ' PRO . 1.0 OUTLIER -133.85 65.09 69.47 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.29 -0.881 . . . . 0.0 109.556 179.921 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.459 ' HD3' ' N ' ' A' ' 44' ' ' ASN . 35.8 Cg_endo -78.12 172.01 16.18 Favored 'Trans proline' 0 C--N 1.309 -1.516 0 C-N-CA 122.679 2.253 . . . . 0.0 110.363 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 45' ' ' PRO . 0.5 OUTLIER 44.28 35.37 1.25 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.403 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -76.68 -18.41 58.56 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.245 -0.909 . . . . 0.0 109.462 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 50' ' ' SER . 0.6 OUTLIER -87.97 -81.97 0.24 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.285 -0.885 . . . . 0.0 109.425 179.926 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.428 ' N ' ' OG ' ' A' ' 48' ' ' SER . . . 46.36 -93.43 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.237 -0.914 . . . . 0.0 109.525 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.512 ' N ' ' O ' ' A' ' 48' ' ' SER . 0.7 OUTLIER -130.44 112.18 13.0 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.16 -0.963 . . . . 0.0 109.443 -179.937 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 106.32 143.96 11.75 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -90.96 97.69 2.35 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -112.38 105.59 13.9 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.195 -1.179 . . . . 0.0 109.467 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.436 ' O ' HG21 ' A' ' 57' ' ' THR . . . -137.11 -75.15 0.07 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.514 HD12 ' CB ' ' A' ' 78' ' ' ALA . 0.9 OUTLIER -74.98 -14.64 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.274 -1.133 . . . . 0.0 109.365 179.871 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.73 -13.68 61.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.861 . . . . 0.0 109.296 179.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.436 HG21 ' O ' ' A' ' 54' ' ' GLY . 9.2 t -65.78 -25.04 67.07 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.199 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.49 ' HB2' ' CD1' ' A' ' 82' ' ' LEU . . . -53.8 -42.73 68.66 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.375 -0.828 . . . . 0.0 109.527 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -58.98 -35.08 72.6 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.232 -0.918 . . . . 0.0 109.417 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 28.3 mt -72.79 -33.86 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.296 -0.877 . . . . 0.0 109.403 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.507 HG22 ' CG2' ' A' ' 66' ' ' VAL . 38.3 mt -63.19 -40.56 89.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.242 -0.911 . . . . 0.0 109.298 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.98 -23.86 67.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.207 -0.933 . . . . 0.0 109.37 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -75.15 -21.95 58.46 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 0.0 109.543 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.8 m-20 -80.16 -17.57 52.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.514 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 115.7 -15.28 17.03 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.507 ' CG2' HG22 ' A' ' 61' ' ' ILE . 57.3 t -44.4 93.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.399 -1.059 . . . . 0.0 109.806 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -79.5 -9.36 59.6 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.221 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -139.9 126.66 20.61 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.344 -0.847 . . . . 0.0 109.153 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.462 HG23 ' CG1' ' A' ' 66' ' ' VAL . 97.6 t -119.21 126.4 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.165 -0.96 . . . . 0.0 109.694 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 57.7 mt -100.33 117.47 45.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.354 -0.841 . . . . 0.0 109.349 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.501 ' HB3' ' CD2' ' A' ' 20' ' ' PHE . . . -148.25 174.51 11.93 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -0.917 . . . . 0.0 109.706 -179.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.402 ' HB3' ' HB2' ' A' ' 92' ' ' ALA . 53.7 p -143.26 40.87 1.48 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.365 -0.835 . . . . 0.0 109.373 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' SER . . . . . 0.405 ' HB2' ' HD2' ' A' ' 74' ' ' PRO . 11.4 p -51.97 159.14 1.49 Allowed Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.606 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.405 ' HD2' ' HB2' ' A' ' 73' ' ' SER . 35.1 Cg_endo -77.57 -31.05 3.56 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.609 2.206 . . . . 0.0 110.541 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -118.06 163.71 12.87 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.57 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.5 Cg_endo -79.96 17.21 1.34 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.831 2.354 . . . . 0.0 111.006 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -63.1 -52.06 64.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.949 -1.095 . . . . 0.0 109.742 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.514 ' CB ' HD12 ' A' ' 55' ' ' ILE . . . -61.77 -37.63 85.03 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.774 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.57 ' CD2' ' HA ' ' A' ' 76' ' ' PRO . 4.0 m-30 -66.17 -29.03 69.23 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.606 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -71.83 -41.5 68.12 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.167 -0.958 . . . . 0.0 109.566 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.6 t -66.78 -50.42 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.165 -0.959 . . . . 0.0 109.652 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.49 ' CD1' ' HB2' ' A' ' 58' ' ' ALA . 2.3 mp -66.77 -27.45 67.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.232 -0.917 . . . . 0.0 109.468 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -65.78 -47.32 75.58 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.216 -0.927 . . . . 0.0 109.245 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -68.25 -31.61 71.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.31 -0.869 . . . . 0.0 109.26 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.447 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.4 OUTLIER -66.92 -25.96 66.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 179.894 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 93.69 22.58 25.78 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.447 HG12 ' HB3' ' A' ' 85' ' ' LEU . 5.9 mm -101.34 163.0 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.238 -1.154 . . . . 0.0 109.456 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.412 ' CG ' ' O ' ' A' ' 113' ' ' ARG . 12.5 mttm -93.7 133.03 37.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.401 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.485 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 2.0 mt -113.49 135.83 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.19 -0.944 . . . . 0.0 109.546 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.478 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 21.5 m-85 -124.56 151.25 44.97 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.505 -0.747 . . . . 0.0 109.365 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.462 ' O ' ' HG ' ' A' ' 109' ' ' LEU . 6.9 ttt-85 -83.46 152.86 24.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.229 -0.919 . . . . 0.0 109.701 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.434 ' HA ' ' CD2' ' A' ' 109' ' ' LEU . . . -106.04 158.91 16.46 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.235 -0.915 . . . . 0.0 109.305 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.63 7.35 46.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.167 -0.958 . . . . 0.0 109.589 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 47.96 72.01 0.49 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.6 m -150.64 -61.61 0.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.308 -1.113 . . . . 0.0 109.356 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.466 ' HA ' ' O ' ' A' ' 14' ' ' SER . 66.4 m -165.98 123.11 1.4 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.233 -0.917 . . . . 0.0 109.525 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.483 HG22 ' N ' ' A' ' 98' ' ' GLU . 27.2 m -65.62 -43.92 93.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.237 -0.914 . . . . 0.0 109.378 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . 0.483 ' N ' HG22 ' A' ' 97' ' ' VAL . 0.2 OUTLIER -45.15 -44.06 10.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.229 -0.919 . . . . 0.0 109.406 179.941 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.437 ' HG3' ' CD1' ' A' ' 103' ' ' LEU . 38.7 tp10 -73.92 -46.83 41.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.275 -0.891 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.437 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 2.2 m-80 -47.55 -26.21 1.36 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.938 . . . . 0.0 109.336 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.448 HD11 HG12 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -59.09 -57.03 14.88 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -0.919 . . . . 0.0 109.291 179.867 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.04 -27.61 68.92 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.238 -0.914 . . . . 0.0 109.327 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.44 HD22 ' HB3' ' A' ' 108' ' ' ASN . 0.8 OUTLIER -63.65 -35.08 79.34 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.372 -0.83 . . . . 0.0 109.534 179.984 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.572 ' CE2' HG12 ' A' ' 3' ' ' ILE . 6.1 t80 -63.79 -27.03 68.91 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.193 -0.942 . . . . 0.0 109.608 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.404 HG22 ' HA2' ' A' ' 34' ' ' GLY . 90.8 m -74.49 -19.93 60.18 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.189 -0.945 . . . . 0.0 109.484 -179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -106.17 8.19 31.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.202 -0.936 . . . . 0.0 109.515 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 52.53 40.73 55.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . 0.44 ' HB3' HD22 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -83.59 -43.24 15.86 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.328 -1.101 . . . . 0.0 109.498 -179.883 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.462 ' HG ' ' O ' ' A' ' 91' ' ' ARG . 1.5 tp -96.45 147.54 23.73 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.32 -0.863 . . . . 0.0 109.292 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.426 ' HG3' ' O ' ' A' ' 109' ' ' LEU . 3.4 mt-10 -176.52 -177.75 0.86 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.091 -1.005 . . . . 0.0 109.862 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.485 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 1.1 tp10 -177.35 -111.88 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.468 -0.77 . . . . 0.0 109.067 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.515 ' CD1' ' HB3' ' A' ' 79' ' ' PHE . 8.0 mt -79.74 121.53 33.21 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 O-C-N 121.177 -0.952 . . . . 0.0 109.367 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.412 ' O ' ' CG ' ' A' ' 88' ' ' LYS . 0.7 OUTLIER -90.53 -61.56 1.65 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.171 -0.955 . . . . 0.0 109.384 179.915 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 59.29 89.96 0.1 OUTLIER Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.307 -0.871 . . . . 0.0 109.536 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.63 -167.53 0.49 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.701 2.267 . . . . 0.0 110.405 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -164.57 71.95 0.19 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.81 105.19 4.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.191 -1.182 . . . . 0.0 109.41 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 95.38 -178.2 35.36 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -167.71 128.19 1.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.267 -1.137 . . . . 0.0 109.539 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 69.64 -140.75 33.87 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.404 ' HG3' ' HD3' ' A' ' 124' ' ' ARG . 0.0 OUTLIER 58.98 26.21 14.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -1.101 . . . . 0.0 109.518 -179.964 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -83.93 -37.65 22.05 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.231 -0.918 . . . . 0.0 109.357 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 1.4 mpt_? -65.27 -60.5 2.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.275 -0.891 . . . . 0.0 109.436 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.404 ' HD3' ' HG3' ' A' ' 121' ' ' ARG . 10.3 ptm180 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.455 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.3 mmt . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.576 ' CD ' ' N ' ' A' ' 2' ' ' LYS . 0.0 OUTLIER -90.44 133.88 34.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.252 -0.905 . . . . 0.0 109.158 179.915 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.456 ' HB ' HG13 ' A' ' 29' ' ' VAL . 9.4 mm -101.29 104.33 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.338 -0.851 . . . . 0.0 110.207 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -110.23 88.46 2.77 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.5 ' CD1' HG21 ' A' ' 70' ' ' ILE . 9.5 tt -98.81 133.11 42.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.239 -0.913 . . . . 0.0 110.014 -179.142 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -57.72 156.64 8.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.354 -0.841 . . . . 0.0 109.081 179.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.421 ' OG ' ' O ' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -159.97 178.96 9.19 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.092 -1.005 . . . . 0.0 109.798 -179.873 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.538 ' C ' ' CD2' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -126.73 23.49 6.71 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.386 -0.821 . . . . 0.0 109.189 179.921 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.471 ' HA2' ' CD1' ' A' ' 25' ' ' TYR . . . 153.08 -151.51 23.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.441 HG23 HG23 ' A' ' 41' ' ' VAL . 16.1 p -124.97 101.94 7.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.185 -1.185 . . . . 0.0 109.353 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 53.9 -154.03 0.26 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.282 -0.886 . . . . 0.0 109.327 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER 60.05 17.96 7.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.27 -0.894 . . . . 0.0 109.576 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 118.85 26.06 2.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' HG22 ' A' ' 97' ' ' VAL . 4.0 m -73.59 83.46 1.54 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.301 -1.117 . . . . 0.0 109.281 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.432 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.4 OUTLIER -79.4 38.81 0.38 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.435 -0.79 . . . . 0.0 110.62 -179.967 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.432 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 21.2 t 63.55 13.08 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 120.716 -1.24 . . . . 0.0 109.413 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 65.78 177.97 0.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.226 -0.921 . . . . 0.0 109.493 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 7.5 ttt180 -120.26 7.13 10.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.184 -0.947 . . . . 0.0 109.596 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -144.02 165.9 26.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.42 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.591 ' CD2' ' CB ' ' A' ' 71' ' ' ALA . 2.3 t80 -132.68 88.81 2.56 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 109.392 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 158.85 -53.49 0.38 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.459 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 5.6 mtp180 -93.58 -19.95 20.69 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.265 -1.138 . . . . 0.0 109.67 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.53 110.24 2.12 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.183 -0.948 . . . . 0.0 109.525 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.486 ' HA ' ' CB ' ' A' ' 44' ' ' ASN . 36.9 Cg_endo -81.29 51.56 3.95 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.614 2.21 . . . . 0.0 110.715 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.538 ' CD2' ' C ' ' A' ' 8' ' ' SER . 4.9 m-85 -159.1 68.91 0.45 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.99 -1.069 . . . . 0.0 109.555 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -84.31 127.05 33.74 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.911 . . . . 0.0 109.189 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' MET . . . . . 0.419 ' HE2' ' HA ' ' A' ' 10' ' ' THR . 1.7 mtt -100.85 121.98 42.64 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.817 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.515 ' CD1' HG11 ' A' ' 66' ' ' VAL . 1.1 tp -121.36 132.2 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.357 -0.839 . . . . 0.0 109.06 179.622 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.456 HG13 ' HB ' ' A' ' 3' ' ' ILE . 14.1 p -138.89 133.41 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.221 -0.924 . . . . 0.0 109.538 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.433 ' HG2' ' N ' ' A' ' 31' ' ' MET . 3.4 tt0 -103.41 138.69 39.81 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.246 -0.909 . . . . 0.0 109.461 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.433 ' N ' ' HG2' ' A' ' 30' ' ' GLU . 11.4 ptp -130.4 153.65 48.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 109.381 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.57 -76.88 0.44 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.235 -0.915 . . . . 0.0 109.688 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.34 -73.17 0.67 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.123 -0.985 . . . . 0.0 109.646 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -142.68 26.6 2.24 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -140.36 99.52 3.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -1.16 . . . . 0.0 109.571 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.42 HG22 ' HB3' ' A' ' 31' ' ' MET . 7.2 pt -50.1 129.38 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.24 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -113.43 0.38 14.72 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.159 -0.963 . . . . 0.0 109.817 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.45 ' O ' HG21 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -156.41 110.34 2.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.031 -1.043 . . . . 0.0 110.007 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.435 ' CA ' HG21 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -120.63 100.22 7.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.313 -0.867 . . . . 0.0 108.901 179.335 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -108.05 159.46 16.55 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.188 -0.945 . . . . 0.0 109.912 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.441 HG23 HG23 ' A' ' 10' ' ' THR . 2.8 t -129.29 122.48 56.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.373 -0.83 . . . . 0.0 109.141 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.44 HG23 ' N ' ' A' ' 43' ' ' GLU . 3.3 mp -111.74 142.48 24.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.184 -0.947 . . . . 0.0 109.582 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.44 ' N ' HG23 ' A' ' 42' ' ' ILE . 5.2 mt-10 -87.95 158.09 18.76 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 0.0 109.304 179.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.486 ' CB ' ' HA ' ' A' ' 24' ' ' PRO . 4.0 t-20 -118.99 102.61 48.96 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.217 -0.927 . . . . 0.0 109.506 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -77.1 -169.09 0.67 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.407 2.071 . . . . 0.0 110.449 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 54.98 36.0 25.91 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.898 . . . . 0.0 109.317 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -72.12 -55.89 6.53 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.437 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -128.37 71.44 1.39 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.128 -0.983 . . . . 0.0 109.58 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -145.74 -87.85 0.1 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.1 t -50.42 -39.23 46.8 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.301 -0.874 . . . . 0.0 109.414 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.89 -168.11 41.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -97.53 81.89 0.68 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -79.87 128.74 33.82 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -1.106 . . . . 0.0 109.729 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.441 ' O ' HG22 ' A' ' 57' ' ' THR . . . -141.82 -61.95 0.03 OUTLIER Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 30.2 mm -76.02 -17.97 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.287 -1.125 . . . . 0.0 109.328 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -76.39 -16.13 59.79 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.32 -0.862 . . . . 0.0 109.307 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.441 HG22 ' O ' ' A' ' 54' ' ' GLY . 11.9 t -72.61 -24.62 61.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.282 -0.887 . . . . 0.0 109.47 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -59.65 -36.62 76.76 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.115 -0.99 . . . . 0.0 109.268 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -71.45 -23.01 61.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.294 -0.879 . . . . 0.0 109.523 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.7 mm -76.84 -54.65 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.476 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -66.79 -27.57 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.254 -0.904 . . . . 0.0 109.544 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.513 ' HB1' ' CD2' ' A' ' 85' ' ' LEU . . . -65.98 -34.07 77.26 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.183 -0.948 . . . . 0.0 109.572 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -77.03 -10.17 59.19 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 109.624 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.1 m-20 -83.61 -12.62 55.81 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.264 -0.898 . . . . 0.0 109.591 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.415 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 97.31 0.89 59.48 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.515 HG11 ' CD1' ' A' ' 28' ' ' ILE . 32.8 m -48.03 98.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.181 -1.188 . . . . 0.0 109.761 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.415 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -78.53 -11.2 59.95 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 178.951 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -139.8 126.31 20.34 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 71.4 t -126.16 124.79 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.981 -1.074 . . . . 0.0 109.755 -179.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.5 HG21 ' CD1' ' A' ' 5' ' ' ILE . 4.2 mp -104.18 96.86 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.199 -0.938 . . . . 0.0 109.314 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.591 ' CB ' ' CD2' ' A' ' 20' ' ' PHE . . . -130.1 172.36 11.85 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.401 -0.812 . . . . 0.0 109.473 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.424 ' O ' ' C ' ' A' ' 73' ' ' SER . 0.2 OUTLIER -138.64 34.22 2.23 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.29 -0.881 . . . . 0.0 109.555 -179.881 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -44.57 153.06 0.48 Allowed Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.221 -0.924 . . . . 0.0 109.315 179.914 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.23 -47.38 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.605 2.203 . . . . 0.0 110.335 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.405 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -84.67 141.55 19.62 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.405 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.6 Cg_endo -78.45 -0.68 10.93 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.501 2.134 . . . . 0.0 110.347 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -60.56 -32.51 71.57 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.308 -0.87 . . . . 0.0 109.522 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -70.04 -54.24 14.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.22 -0.925 . . . . 0.0 109.521 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.405 ' O ' HD13 ' A' ' 89' ' ' ILE . 11.3 m-30 -54.64 -24.2 20.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.247 -0.908 . . . . 0.0 109.738 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -72.43 -37.34 68.63 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.156 -0.965 . . . . 0.0 109.723 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 75.4 t -76.1 -36.23 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.219 -0.926 . . . . 0.0 109.77 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.523 ' CB ' HG12 ' A' ' 89' ' ' ILE . 0.7 OUTLIER -62.01 -36.58 81.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.599 -179.85 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -73.51 -24.53 60.17 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.236 -0.915 . . . . 0.0 109.46 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -76.78 -33.41 58.04 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.233 -0.917 . . . . 0.0 109.526 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.513 ' CD2' ' HB1' ' A' ' 62' ' ' ALA . 0.5 OUTLIER -77.52 -23.65 50.14 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.135 -0.978 . . . . 0.0 109.564 -179.86 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.5 21.59 14.42 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.483 HG21 ' N ' ' A' ' 88' ' ' LYS . 7.7 mt -98.83 158.33 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.257 -1.143 . . . . 0.0 109.381 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.483 ' N ' HG21 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -90.76 128.58 36.73 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.15 -0.969 . . . . 0.0 109.332 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.523 HG12 ' CB ' ' A' ' 82' ' ' LEU . 5.5 mt -98.91 151.22 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.17 -0.956 . . . . 0.0 109.29 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.565 ' CD2' ' O ' ' A' ' 110' ' ' GLU . 0.3 OUTLIER -138.54 141.15 39.3 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.321 -0.862 . . . . 0.0 109.225 -179.708 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.413 ' O ' ' HB3' ' A' ' 110' ' ' GLU . 1.5 tpp85 -92.6 128.56 38.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.939 . . . . 0.0 109.782 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.44 121.46 25.75 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.326 -0.859 . . . . 0.0 109.486 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.12 -27.89 61.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.309 -0.87 . . . . 0.0 109.505 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 97.06 61.21 0.94 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -130.51 -60.72 0.98 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.192 -1.181 . . . . 0.0 109.451 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -173.34 150.39 1.86 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.291 -0.881 . . . . 0.0 109.543 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.465 HG22 ' HB3' ' A' ' 14' ' ' SER . 4.0 m -72.16 -34.17 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.582 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -65.39 -53.29 45.46 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.474 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 0.3 OUTLIER -58.3 -45.04 88.71 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.329 -0.857 . . . . 0.0 109.709 -179.921 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -61.18 -30.27 70.31 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.205 -0.934 . . . . 0.0 109.847 -179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.413 HD23 HD13 ' A' ' 36' ' ' ILE . 31.7 tp -63.07 -56.51 16.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.176 -0.953 . . . . 0.0 109.648 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.423 ' HG2' ' O ' ' A' ' 102' ' ' LYS . 0.0 OUTLIER -73.86 -11.91 60.51 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.146 -0.972 . . . . 0.0 109.5 -179.906 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.474 ' HB2' ' O ' ' A' ' 99' ' ' GLU . 0.3 OUTLIER -76.17 -45.31 34.03 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.232 -0.917 . . . . 0.0 109.497 -179.91 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.551 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 3.5 t80 -76.57 -26.31 54.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.344 -0.847 . . . . 0.0 109.49 -179.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 17.7 m -61.4 -33.59 73.94 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.229 -0.919 . . . . 0.0 109.676 -179.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -103.43 8.94 37.95 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.104 -0.997 . . . . 0.0 109.575 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.29 59.13 10.51 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . 0.465 ' HB3' ' HG ' ' A' ' 103' ' ' LEU . 48.2 t-20 -81.18 -38.77 26.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.38 -1.071 . . . . 0.0 109.564 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.472 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.0 OUTLIER 171.0 -156.77 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.162 -0.961 . . . . 0.0 109.735 -179.942 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.565 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 23.2 mt-10 60.59 29.82 19.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.865 . . . . 0.0 109.259 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.564 ' HA ' ' CE1' ' A' ' 90' ' ' TYR . 1.0 OUTLIER -92.44 144.74 25.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.319 -0.863 . . . . 0.0 109.675 -179.823 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.476 HG12 ' O ' ' A' ' 111' ' ' GLU . 9.2 mm -155.67 125.62 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.477 -0.764 . . . . 0.0 109.15 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -129.38 9.86 5.65 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 0.0 109.353 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.425 ' N ' ' HD3' ' A' ' 115' ' ' PRO . 71.5 m 45.13 66.85 4.74 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.29 -0.881 . . . . 0.0 109.626 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.425 ' HD3' ' N ' ' A' ' 114' ' ' SER . 36.1 Cg_endo -78.51 -46.41 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.654 2.236 . . . . 0.0 110.405 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.05 119.96 0.79 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 3.8 m -101.73 20.58 16.0 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.259 -1.142 . . . . 0.0 109.479 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -81.99 117.77 4.48 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.85 -21.28 7.26 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -1.139 . . . . 0.0 109.389 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 141.52 -158.77 26.65 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 2.2 mmt85 -126.23 175.45 7.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.388 -1.066 . . . . 0.0 109.383 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.455 ' HD3' ' N ' ' A' ' 122' ' ' ARG . 0.1 OUTLIER -101.78 -21.73 14.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.204 -0.935 . . . . 0.0 109.51 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 7.7 ttt180 -74.29 82.58 1.88 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.19 -0.944 . . . . 0.0 109.511 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 1.1 ttt85 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.459 179.97 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.445 ' O ' ' HE3' ' A' ' 2' ' ' LYS . 21.0 ttm . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.357 0.599 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.445 ' HE3' ' O ' ' A' ' 1' ' ' MET . 0.1 OUTLIER -143.44 106.9 4.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.203 -0.935 . . . . 0.0 109.413 -179.996 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.526 HD11 ' CE1' ' A' ' 104' ' ' PHE . 2.3 mp -107.68 114.77 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.336 -0.853 . . . . 0.0 109.414 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.57 ' HB3' ' CZ ' ' A' ' 26' ' ' PHE . . . -113.24 122.07 46.36 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.235 -0.915 . . . . 0.0 109.347 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.461 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 2.8 mp -96.93 129.22 47.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.174 -0.954 . . . . 0.0 109.568 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.429 ' O ' ' HB3' ' A' ' 7' ' ' SER . . . -68.93 146.86 52.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.257 -0.902 . . . . 0.0 109.272 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.429 ' HB3' ' O ' ' A' ' 6' ' ' ALA . 13.3 t 60.05 -94.5 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 0.0 109.426 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.465 ' O ' ' HB3' ' A' ' 14' ' ' SER . 8.7 t 63.45 31.42 14.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.161 -0.962 . . . . 0.0 109.772 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 42.53 -105.57 0.07 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -158.7 -46.44 0.06 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.251 -1.146 . . . . 0.0 109.411 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.86 -72.89 0.35 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.185 -0.947 . . . . 0.0 109.637 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 31.6 mt -107.09 -14.7 14.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.202 -0.936 . . . . 0.0 109.572 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.21 6.12 64.73 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.465 ' HB3' ' O ' ' A' ' 8' ' ' SER . 93.9 p -77.68 77.16 4.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -1.137 . . . . 0.0 109.673 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.532 ' O ' ' CG1' ' A' ' 16' ' ' VAL . 0.1 OUTLIER -77.81 78.49 4.31 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.235 -0.916 . . . . 0.0 109.456 179.881 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.532 ' CG1' ' O ' ' A' ' 15' ' ' GLU . 11.6 p 41.1 42.31 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.427 -0.795 . . . . 0.0 109.839 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.438 ' OG ' ' C ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER 59.97 -163.54 0.24 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.249 -0.907 . . . . 0.0 109.486 -179.959 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -170.27 -36.32 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.258 -0.901 . . . . 0.0 109.373 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -148.16 140.06 23.94 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.33 -0.856 . . . . 0.0 109.471 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.428 ' CG ' ' O ' ' A' ' 20' ' ' PHE . 12.9 t80 -116.1 38.45 3.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.252 -0.905 . . . . 0.0 109.733 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -93.94 -56.76 1.37 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.447 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 18.9 mtt180 -140.16 41.74 1.94 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.29 -1.124 . . . . 0.0 109.111 179.747 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -52.3 108.8 1.17 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.41 -0.806 . . . . 0.0 109.744 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.466 ' O ' ' HB3' ' A' ' 43' ' ' GLU . 36.7 Cg_endo -80.83 40.9 1.05 Allowed 'Trans proline' 0 C--N 1.312 -1.374 0 C-N-CA 122.561 2.174 . . . . 0.0 110.434 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.422 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 6.2 m-85 -161.11 74.74 0.5 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.143 -0.973 . . . . 0.0 108.909 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.57 ' CZ ' ' HB3' ' A' ' 4' ' ' ALA . 16.5 t80 -78.26 112.52 15.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.433 -0.792 . . . . 0.0 109.496 -179.439 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 1.6 ttm -94.12 114.48 26.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.455 -0.778 . . . . 0.0 109.31 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.448 HG22 ' O ' ' A' ' 28' ' ' ILE . 0.3 OUTLIER -106.62 123.88 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.283 -0.886 . . . . 0.0 109.488 -179.869 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.505 ' CG1' HG23 ' A' ' 36' ' ' ILE . 2.1 t -121.74 120.64 62.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.912 . . . . 0.0 109.636 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -116.95 96.81 5.63 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 21.1 ptp -87.26 167.24 14.27 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.919 . . . . 0.0 109.358 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.58 -93.62 0.15 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.259 -0.9 . . . . 0.0 109.552 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.62 35.59 3.78 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.232 -0.917 . . . . 0.0 109.485 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 120.7 21.66 3.21 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 12.4 t30 -141.04 109.45 5.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.175 -1.191 . . . . 0.0 109.381 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.505 HG23 ' CG1' ' A' ' 29' ' ' VAL . 4.5 mt -63.25 114.12 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 109.631 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -123.03 28.55 7.14 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.265 -0.897 . . . . 0.0 109.27 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -172.96 96.12 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.324 -0.86 . . . . 0.0 109.434 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.1 m -125.99 103.5 7.78 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.276 -0.89 . . . . 0.0 109.147 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -114.52 142.58 46.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.255 -0.903 . . . . 0.0 110.046 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 t -116.72 96.21 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.415 -0.803 . . . . 0.0 108.955 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 13.6 mt -121.21 126.8 75.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 0.0 109.812 -179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.466 ' HB3' ' O ' ' A' ' 24' ' ' PRO . 0.0 OUTLIER -53.65 148.59 9.46 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.353 -0.842 . . . . 0.0 109.582 179.847 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -64.11 148.06 95.89 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.179 -0.951 . . . . 0.0 109.218 179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.462 ' O ' ' OG ' ' A' ' 46' ' ' SER . 35.8 Cg_endo -78.3 155.09 28.72 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.68 2.253 . . . . 0.0 110.76 -179.651 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' SER . . . . . 0.462 ' OG ' ' O ' ' A' ' 45' ' ' PRO . 13.8 p 58.31 18.02 5.17 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.347 -0.845 . . . . 0.0 109.902 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.63 -69.24 0.12 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.142 -0.974 . . . . 0.0 109.201 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.78 114.98 26.76 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 0.0 109.188 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -139.2 -172.18 3.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.219 -0.925 . . . . 0.0 109.722 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.6 m -92.61 24.0 3.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.329 -0.857 . . . . 0.0 109.495 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 167.35 76.01 0.03 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -125.98 164.82 19.41 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -121.36 -57.79 1.82 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.196 -1.179 . . . . 0.0 109.484 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.428 ' O ' ' CG2' ' A' ' 57' ' ' THR . . . 126.77 -47.99 0.99 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 22.9 mm -75.61 -20.05 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.252 -1.146 . . . . 0.0 109.6 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -69.87 -25.58 63.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.323 -0.861 . . . . 0.0 109.505 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.428 ' CG2' ' O ' ' A' ' 54' ' ' GLY . 11.2 t -56.48 -25.86 52.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.561 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.448 ' O ' ' HB ' ' A' ' 61' ' ' ILE . . . -45.27 -41.84 8.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.183 -0.948 . . . . 0.0 109.356 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.82 -56.12 15.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.307 -0.871 . . . . 0.0 109.552 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.409 ' O ' HG21 ' A' ' 60' ' ' ILE . 44.6 mt -54.97 -33.74 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.231 -0.918 . . . . 0.0 109.38 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.448 ' HB ' ' O ' ' A' ' 58' ' ' ALA . 22.9 mm -59.73 -52.72 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.245 -0.909 . . . . 0.0 109.579 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.419 ' HA ' HD11 ' A' ' 87' ' ' ILE . . . -64.18 -21.52 66.59 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.277 -0.889 . . . . 0.0 109.739 -179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.96 -23.26 55.35 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -0.924 . . . . 0.0 109.656 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -83.83 -16.91 42.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.125 -0.985 . . . . 0.0 109.703 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 98.37 -2.09 59.09 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.402 ' C ' ' O ' ' A' ' 65' ' ' GLY . 3.7 t -42.37 97.87 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.315 -1.109 . . . . 0.0 109.773 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.469 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -79.22 -9.97 59.7 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.081 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.441 ' HB2' ' HA ' ' A' ' 3' ' ' ILE . . . -135.58 118.51 16.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.48 -0.763 . . . . 0.0 109.354 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.43 ' CG2' HD22 ' A' ' 82' ' ' LEU . 59.3 t -111.6 119.92 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.24 -0.913 . . . . 0.0 109.63 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.48 HG21 ' ND2' ' A' ' 100' ' ' ASN . 4.4 mm -102.69 117.12 47.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.149 -0.969 . . . . 0.0 109.551 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -160.03 171.77 18.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.745 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 37.4 t -133.71 42.98 2.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.354 -0.841 . . . . 0.0 109.278 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' SER . . . . . 0.416 ' OG ' ' HD2' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -51.81 155.57 2.91 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.42 -0.8 . . . . 0.0 109.83 -179.731 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.416 ' HD2' ' OG ' ' A' ' 73' ' ' SER . 35.2 Cg_endo -78.17 -12.1 15.99 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.725 2.283 . . . . 0.0 110.642 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -148.89 154.23 25.69 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.536 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.4 Cg_endo -79.92 38.81 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.862 2.375 . . . . 0.0 111.017 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.406 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 1.5 t-20 -77.25 -54.52 6.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.966 -1.084 . . . . 0.0 109.675 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -66.15 -38.39 88.0 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 109.644 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.598 ' N ' ' CD1' ' A' ' 79' ' ' PHE . 2.7 m-30 -55.41 -33.79 63.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.931 . . . . 0.0 109.475 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.406 ' HB2' ' O ' ' A' ' 77' ' ' ASN . 16.9 mt-10 -53.19 -55.79 21.52 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.932 . . . . 0.0 109.521 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.4 t -60.89 -39.17 81.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.476 ' CD2' HG13 ' A' ' 89' ' ' ILE . 1.3 tp -52.23 -40.8 62.11 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.396 -0.815 . . . . 0.0 109.935 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -73.98 -36.98 64.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.128 -0.983 . . . . 0.0 109.81 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -66.92 -20.04 65.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.268 -0.895 . . . . 0.0 109.822 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.418 HD23 ' HA ' ' A' ' 85' ' ' LEU . 0.2 OUTLIER -102.98 24.68 10.38 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.16 -0.963 . . . . 0.0 109.716 -179.81 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 51.94 65.2 3.37 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.419 HD11 ' HA ' ' A' ' 62' ' ' ALA . 75.0 mt -141.03 155.55 21.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -1.162 . . . . 0.0 109.299 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 15.6 mttp -101.2 130.89 47.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.126 -0.984 . . . . 0.0 109.839 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.476 HG13 ' CD2' ' A' ' 82' ' ' LEU . 2.2 mp -94.73 160.43 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.338 -0.851 . . . . 0.0 109.425 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.527 ' CE2' ' O ' ' A' ' 109' ' ' LEU . 0.2 OUTLIER -144.51 135.61 25.18 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.336 -0.852 . . . . 0.0 109.394 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.01 139.9 33.96 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.303 -0.873 . . . . 0.0 109.476 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -81.42 112.22 18.48 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -0.903 . . . . 0.0 109.434 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -144.32 16.23 1.68 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.256 -0.902 . . . . 0.0 109.45 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -92.13 -130.45 5.11 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 51.9 m -122.91 -54.87 1.82 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.218 -1.166 . . . . 0.0 109.489 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 2.3 m -127.52 172.09 11.02 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.245 -0.909 . . . . 0.0 109.457 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.419 HG13 ' OG ' ' A' ' 8' ' ' SER . 49.4 t -77.33 -43.82 30.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.319 -0.863 . . . . 0.0 109.612 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.46 -34.79 67.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.26 -0.9 . . . . 0.0 109.551 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -75.85 -59.52 2.72 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.252 -0.905 . . . . 0.0 109.518 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.48 ' ND2' HG21 ' A' ' 70' ' ' ILE . 47.1 t30 -51.02 -22.19 2.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.224 -0.923 . . . . 0.0 109.463 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 24.0 tp -64.18 -69.59 0.27 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.196 -0.94 . . . . 0.0 109.306 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -62.76 -14.82 49.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.335 -0.853 . . . . 0.0 109.458 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -77.0 -32.51 57.26 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 109.619 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.548 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 1.9 t80 -71.28 -31.08 67.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -0.889 . . . . 0.0 109.59 -179.696 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 51.6 m -74.26 -21.08 59.92 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.045 -1.034 . . . . 0.0 109.99 -179.425 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 30.1 mm-40 -92.07 11.86 23.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.064 -1.023 . . . . 0.0 109.514 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 53.06 53.68 32.83 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . 0.466 ' O ' ' HB3' ' A' ' 109' ' ' LEU . 1.6 t-20 -79.88 -63.82 1.33 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.348 -1.089 . . . . 0.0 109.469 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.527 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.6 OUTLIER 177.87 -153.56 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.306 -0.871 . . . . 0.0 109.528 179.989 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.501 ' HG3' ' CD1' ' A' ' 109' ' ' LEU . 79.4 mt-10 62.15 27.9 16.78 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.208 -0.933 . . . . 0.0 109.287 -179.867 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.478 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 7.9 pt-20 -108.7 147.74 31.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.757 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.452 ' O ' HD13 ' A' ' 89' ' ' ILE . 14.4 mt -151.76 128.39 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.323 -0.861 . . . . 0.0 109.193 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.434 ' O ' ' O ' ' A' ' 114' ' ' SER . 0.0 OUTLIER -138.36 20.09 2.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.235 -0.916 . . . . 0.0 109.805 -179.741 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 113' ' ' ARG . 0.5 OUTLIER 59.62 154.33 0.1 OUTLIER Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.162 -0.961 . . . . 0.0 109.442 179.982 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.38 -28.84 4.25 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.566 2.177 . . . . 0.0 110.519 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 150.44 -118.55 0.93 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -151.92 26.04 0.64 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.205 -1.174 . . . . 0.0 109.561 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 160.1 149.9 5.7 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.35 139.11 24.13 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.185 -1.185 . . . . 0.0 109.499 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 144.49 86.78 0.08 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.31 -43.51 41.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.332 -1.099 . . . . 0.0 109.396 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.05 141.42 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.273 -0.892 . . . . 0.0 109.596 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.51 ' O ' ' CB ' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -151.61 25.53 0.67 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.287 -0.883 . . . . 0.0 109.257 179.852 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.51 ' CB ' ' O ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.485 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 mtp . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.461 ' O ' ' HB3' ' A' ' 68' ' ' ALA . 0.0 OUTLIER -139.42 140.56 37.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.195 -0.94 . . . . 0.0 109.667 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.512 HD11 ' CD1' ' A' ' 104' ' ' PHE . 5.5 mt -110.41 99.67 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.46 -0.775 . . . . 0.0 109.824 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.517 ' HB3' ' CG1' ' A' ' 66' ' ' VAL . . . -100.07 115.39 29.64 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.337 -0.852 . . . . 0.0 109.08 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 3.4 mp -92.04 142.47 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.217 -0.927 . . . . 0.0 109.756 -179.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.502 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -80.39 171.62 14.83 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.295 -0.878 . . . . 0.0 109.546 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 71.7 m 47.95 -93.02 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.251 -0.906 . . . . 0.0 109.522 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.502 ' N ' ' O ' ' A' ' 6' ' ' ALA . 41.0 t 52.9 25.39 3.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.083 -1.011 . . . . 0.0 109.528 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 44.38 -101.41 0.03 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.59 -67.1 0.19 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.212 -1.17 . . . . 0.0 109.479 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -158.66 -79.41 0.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.156 -0.965 . . . . 0.0 109.592 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.17 -19.82 55.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.147 -0.971 . . . . 0.0 109.515 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -130.68 37.46 2.11 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.6 m -76.49 82.07 3.19 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -1.153 . . . . 0.0 109.254 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.502 ' HG3' ' N ' ' A' ' 16' ' ' VAL . 5.3 pt-20 -77.14 -134.38 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.266 -0.896 . . . . 0.0 109.054 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.512 ' O ' ' CG1' ' A' ' 16' ' ' VAL . 12.2 p -154.45 67.24 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 120.99 -1.069 . . . . 0.0 109.422 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.0 m -52.6 156.94 1.69 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -102.53 12.85 35.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.287 -0.883 . . . . 0.0 109.447 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -107.49 103.54 12.89 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.274 -0.891 . . . . 0.0 109.451 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.419 ' CG ' ' HB3' ' A' ' 71' ' ' ALA . 11.0 t80 -101.79 127.51 48.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.162 -0.961 . . . . 0.0 109.435 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 150.29 -64.49 0.39 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.471 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.6 ttt180 -91.85 -12.44 33.64 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -1.16 . . . . 0.0 109.362 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.573 ' O ' ' CE1' ' A' ' 26' ' ' PHE . . . -41.48 101.82 0.25 Allowed Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.528 -0.732 . . . . 0.0 109.752 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.491 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.8 Cg_endo -80.91 44.23 1.71 Allowed 'Trans proline' 0 C--N 1.311 -1.419 0 C-N-CA 122.653 2.236 . . . . 0.0 110.574 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.491 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 31.6 m-85 -160.07 70.21 0.43 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.015 -1.053 . . . . 0.0 109.641 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.573 ' CE1' ' O ' ' A' ' 23' ' ' ALA . 18.8 m-30 -80.35 111.5 16.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.178 -0.951 . . . . 0.0 109.377 179.704 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 6.3 ttm -90.56 116.67 28.64 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.276 -0.89 . . . . 0.0 109.509 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.436 HD11 ' CB ' ' A' ' 4' ' ' ALA . 7.2 mm -101.99 108.36 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.893 . . . . 0.0 109.437 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.432 HG12 HD13 ' A' ' 36' ' ' ILE . 96.8 t -104.47 142.34 18.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.553 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.467 ' O ' ' OG ' ' A' ' 38' ' ' SER . 32.5 tt0 -137.28 100.87 4.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.329 -0.857 . . . . 0.0 109.53 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 4.5 ptp -95.75 155.22 16.84 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.276 -0.89 . . . . 0.0 109.252 179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 27.4 mmtm -102.26 -46.77 4.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.241 -0.912 . . . . 0.0 109.877 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 34' ' ' GLY . 1.5 ttpp -146.27 92.62 2.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.21 -0.931 . . . . 0.0 109.639 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 43.36 28.2 0.88 Allowed Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -151.06 111.01 4.08 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.205 -1.173 . . . . 0.0 109.387 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.432 HD13 HG12 ' A' ' 29' ' ' VAL . 49.1 mm -56.74 116.91 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.236 -0.915 . . . . 0.0 109.588 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.34 18.54 15.19 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.317 -0.864 . . . . 0.0 109.415 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.467 ' OG ' ' O ' ' A' ' 30' ' ' GLU . 0.7 OUTLIER -174.94 127.52 0.29 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.317 -0.864 . . . . 0.0 109.527 -179.877 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.22 110.94 6.48 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.329 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -125.15 106.34 9.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 109.74 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.9 p -97.15 124.49 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.24 -0.912 . . . . 0.0 109.247 179.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.0 pt -122.52 161.02 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.26 -0.9 . . . . 0.0 109.778 -179.656 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -104.0 159.81 15.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.346 -0.846 . . . . 0.0 109.379 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -137.15 81.95 31.01 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.297 -0.877 . . . . 0.0 109.238 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.37 -2.77 12.8 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 122.686 2.257 . . . . 0.0 110.682 -179.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.5 m -69.02 -18.08 63.99 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.177 -0.952 . . . . 0.0 109.531 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.33 -52.11 48.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.926 . . . . 0.0 109.537 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 25.9 t -99.15 47.74 0.96 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.246 -0.909 . . . . 0.0 109.567 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . 0.414 ' O ' ' C ' ' A' ' 50' ' ' SER . . . -156.6 -65.44 0.1 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 49' ' ' ALA . 15.8 m -43.85 -52.96 6.4 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.286 -0.884 . . . . 0.0 109.479 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 120.56 139.8 5.88 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 122.3 -133.84 9.47 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -111.46 -32.04 6.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.305 -1.114 . . . . 0.0 109.488 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 110.32 -33.07 6.19 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.8 mt -73.88 -9.18 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.303 -1.116 . . . . 0.0 109.47 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . 0.454 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -69.03 -23.44 64.07 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.211 -0.93 . . . . 0.0 109.532 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.442 ' HA ' HD11 ' A' ' 60' ' ' ILE . 13.0 t -64.29 -14.18 54.36 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.673 -179.795 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -54.25 -46.11 72.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.167 -0.958 . . . . 0.0 109.439 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.455 ' OE1' HD13 ' A' ' 85' ' ' LEU . 0.3 OUTLIER -52.11 -36.77 52.06 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.141 -0.974 . . . . 0.0 109.472 179.976 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.442 HD11 ' HA ' ' A' ' 57' ' ' THR . 6.6 mt -74.81 -33.56 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.266 -0.896 . . . . 0.0 109.609 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 61.0 mt -61.39 -36.69 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.178 -0.951 . . . . 0.0 109.4 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -70.72 -21.68 62.52 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.281 -0.887 . . . . 0.0 109.61 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -75.09 -9.68 58.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.118 -0.989 . . . . 0.0 109.283 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -88.59 -21.83 23.84 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.245 -0.909 . . . . 0.0 109.476 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 120.02 17.66 4.49 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.517 ' CG1' ' HB3' ' A' ' 4' ' ' ALA . 17.9 t -87.16 89.9 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.222 -1.164 . . . . 0.0 109.483 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.3 tttp -79.54 -7.97 58.84 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.364 -0.835 . . . . 0.0 108.984 179.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 2' ' ' LYS . . . -130.83 113.96 14.73 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.112 -0.993 . . . . 0.0 109.319 179.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.448 HG23 HG13 ' A' ' 66' ' ' VAL . 93.4 t -112.02 123.84 68.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.106 -0.996 . . . . 0.0 109.705 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.495 HD13 ' CG2' ' A' ' 3' ' ' ILE . 80.9 mt -103.14 116.36 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.397 -0.814 . . . . 0.0 109.186 179.766 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.419 ' HB3' ' CG ' ' A' ' 20' ' ' PHE . . . -147.91 175.42 10.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 109.934 -179.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.02 57.36 1.48 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.508 -0.745 . . . . 0.0 109.23 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.2 m -65.18 155.57 83.96 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.199 -0.938 . . . . 0.0 109.614 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.18 -18.8 12.49 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.752 2.301 . . . . 0.0 110.312 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -129.99 162.38 23.01 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.16 9.9 3.18 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.814 2.343 . . . . 0.0 110.755 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -60.9 -55.03 37.82 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.065 -1.022 . . . . 0.0 109.655 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -56.06 -52.33 64.66 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.246 -0.909 . . . . 0.0 109.498 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.561 ' CD1' HG22 ' A' ' 89' ' ' ILE . 12.9 m-30 -53.55 -30.1 40.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.226 -0.921 . . . . 0.0 109.628 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -68.79 -42.51 77.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.276 -0.89 . . . . 0.0 109.632 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.36 -53.09 44.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.184 -0.947 . . . . 0.0 109.478 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.446 HD13 HG12 ' A' ' 89' ' ' ILE . 53.5 mt -59.66 -28.01 66.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.27 -0.894 . . . . 0.0 109.639 -179.765 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.469 ' HB2' ' O ' ' A' ' 79' ' ' PHE . 1.4 t-20 -69.06 -44.81 71.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.94 . . . . 0.0 109.268 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -68.85 -23.58 64.26 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.207 -0.933 . . . . 0.0 109.17 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.455 HD13 ' OE1' ' A' ' 59' ' ' GLN . 0.0 OUTLIER -75.21 -35.39 61.5 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.271 -0.893 . . . . 0.0 109.484 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 101.75 25.01 8.29 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 30.5 mm -105.49 169.9 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.253 -1.145 . . . . 0.0 109.592 -179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.464 ' HG2' ' HA ' ' A' ' 113' ' ' ARG . 5.4 mttt -93.71 134.91 35.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.285 -0.884 . . . . 0.0 109.536 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.561 HG22 ' CD1' ' A' ' 79' ' ' PHE . 4.3 mt -107.06 142.55 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.287 -0.883 . . . . 0.0 109.464 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.551 ' N ' ' CD1' ' A' ' 90' ' ' TYR . 4.5 m-85 -130.8 148.76 52.62 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.514 -0.741 . . . . 0.0 109.558 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.42 ' HB2' ' CD ' ' A' ' 111' ' ' GLU . 1.1 ttt180 -104.61 128.86 52.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.251 -0.906 . . . . 0.0 109.351 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -108.49 116.51 32.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.159 -0.963 . . . . 0.0 109.713 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 4.4 m -145.59 21.3 1.49 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.348 -0.845 . . . . 0.0 109.37 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.79 -111.63 0.03 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 1.6 t -142.08 -40.39 0.36 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.236 -1.155 . . . . 0.0 109.803 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 3.1 m -142.6 131.23 22.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.21 -0.931 . . . . 0.0 109.615 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 15' ' ' GLU . 19.9 t -56.18 -19.99 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.308 -0.87 . . . . 0.0 109.307 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -60.37 -64.3 1.0 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.278 -0.889 . . . . 0.0 109.313 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.419 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 4.6 mt-10 -67.21 -24.59 65.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.355 -0.84 . . . . 0.0 109.305 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.453 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 18.1 t-20 -68.19 -29.48 68.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.885 . . . . 0.0 109.427 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 33.2 tp -62.66 -68.67 0.31 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.182 -0.949 . . . . 0.0 109.164 179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 10.0 tttp -59.24 -21.94 60.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.204 -0.935 . . . . 0.0 109.149 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.462 HD21 ' HB2' ' A' ' 108' ' ' ASN . 1.5 mt -68.73 -34.92 76.43 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.394 -0.817 . . . . 0.0 109.448 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.536 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.5 t80 -53.94 -30.71 47.8 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.203 -0.936 . . . . 0.0 109.254 179.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 34.9 m -64.19 -39.62 94.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.42 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 0.415 ' OE1' ' HA ' ' A' ' 103' ' ' LEU . 0.7 OUTLIER -82.99 -11.85 57.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.297 -0.877 . . . . 0.0 109.338 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.465 ' HA2' ' OE2' ' A' ' 110' ' ' GLU . . . 65.08 40.31 96.89 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . 0.462 ' HB2' HD21 ' A' ' 103' ' ' LEU . 0.2 OUTLIER -80.9 -12.87 59.33 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -1.153 . . . . 0.0 109.407 179.993 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.419 ' C ' ' HG2' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -152.6 111.37 3.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.261 -0.899 . . . . 0.0 109.259 179.867 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.465 ' OE2' ' HA2' ' A' ' 107' ' ' GLY . 5.9 mt-10 -140.97 -149.19 0.26 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.819 -179.662 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.486 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 0.5 OUTLIER -168.63 -114.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.34 -0.85 . . . . 0.0 109.315 -179.794 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.3 mt -87.81 149.56 4.03 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.092 -1.005 . . . . 0.0 109.427 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.464 ' HA ' ' HG2' ' A' ' 88' ' ' LYS . 0.1 OUTLIER -114.05 -93.73 0.48 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.218 -0.926 . . . . 0.0 109.692 -179.737 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.455 ' OG ' ' HD2' ' A' ' 115' ' ' PRO . 0.1 OUTLIER -125.6 166.0 23.51 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.197 -0.94 . . . . 0.0 109.689 -179.657 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.455 ' HD2' ' OG ' ' A' ' 114' ' ' SER . 36.1 Cg_endo -78.22 98.85 1.23 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.702 2.268 . . . . 0.0 110.448 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.55 -52.55 2.29 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 93.4 p -128.15 24.2 5.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.327 -1.102 . . . . 0.0 109.432 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -114.2 -177.15 19.14 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.5 ptp180 -59.15 -173.34 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.208 -1.172 . . . . 0.0 109.432 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 117.66 -97.53 0.73 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.82 156.95 4.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.248 -1.148 . . . . 0.0 109.403 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -95.69 -148.33 0.29 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.279 -0.888 . . . . 0.0 109.465 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 40.5 mtm180 -81.16 149.08 29.27 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.219 -0.926 . . . . 0.0 109.413 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 15.4 mtm180 . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.585 -179.967 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.4 mtp . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.417 ' HG2' ' CG ' ' A' ' 30' ' ' GLU . 0.5 OUTLIER -91.2 142.4 27.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.293 -0.88 . . . . 0.0 109.494 179.994 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.586 ' CG2' ' CD1' ' A' ' 70' ' ' ILE . 4.9 mt -118.67 116.08 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.296 -0.877 . . . . 0.0 109.779 -179.773 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.41 ' HB2' ' CE1' ' A' ' 26' ' ' PHE . . . -114.91 119.73 37.53 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.344 -0.847 . . . . 0.0 109.03 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.519 ' CG2' HG23 ' A' ' 70' ' ' ILE . 8.6 mt -100.68 140.73 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.801 -179.56 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.564 ' HB3' ' CE2' ' A' ' 26' ' ' PHE . . . -106.73 138.49 42.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.279 -0.888 . . . . 0.0 109.141 179.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 39.4 p -163.3 -148.73 0.13 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.215 -0.928 . . . . 0.0 109.524 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.548 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 20.3 t -122.35 -65.35 1.12 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.263 -0.898 . . . . 0.0 109.546 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -59.98 168.34 8.32 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.423 HG22 ' CD1' ' A' ' 25' ' ' TYR . 1.2 p -87.38 -42.27 12.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.209 -1.171 . . . . 0.0 109.512 -179.959 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -173.81 -40.74 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.193 -0.942 . . . . 0.0 109.709 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.1 mt -84.19 -10.85 57.39 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.156 -0.965 . . . . 0.0 109.629 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -137.91 8.31 3.58 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 79.9 p -77.11 80.17 3.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.184 -1.186 . . . . 0.0 109.467 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.446 ' O ' ' CB ' ' A' ' 16' ' ' VAL . 2.6 pt-20 -76.85 1.68 16.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.255 -0.903 . . . . 0.0 109.702 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.517 HG21 ' N ' ' A' ' 96' ' ' SER . 3.5 t 71.38 73.29 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.13 -0.981 . . . . 0.0 109.655 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.22 -164.46 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.46 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -118.98 26.74 9.31 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.214 -0.929 . . . . 0.0 109.617 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -117.23 115.31 25.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.914 . . . . 0.0 109.604 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.589 ' CG ' ' O ' ' A' ' 20' ' ' PHE . 45.6 t80 -112.44 38.4 2.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.309 -0.869 . . . . 0.0 109.159 179.731 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -99.27 -84.37 1.79 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.468 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.0 OUTLIER -90.21 67.46 6.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -1.144 . . . . 0.0 109.485 -179.946 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -47.1 105.45 0.49 Allowed Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.356 -0.84 . . . . 0.0 109.567 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.549 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.0 Cg_endo -78.73 -3.37 13.22 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.461 2.107 . . . . 0.0 110.365 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.549 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 71.4 m-85 -160.52 72.67 0.48 Allowed 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.177 -0.952 . . . . 0.0 109.235 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.564 ' CE2' ' HB3' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -79.02 114.8 18.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.471 -179.768 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -87.57 114.15 23.91 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.339 -0.851 . . . . 0.0 109.39 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.445 ' O ' HG23 ' A' ' 28' ' ' ILE . 0.5 OUTLIER -102.61 126.73 56.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.261 -0.899 . . . . 0.0 109.594 -179.934 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 69.4 t -124.01 138.44 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.289 -0.882 . . . . 0.0 109.293 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.417 ' CG ' ' HG2' ' A' ' 2' ' ' LYS . 0.5 OUTLIER -124.28 116.8 23.24 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.209 -0.932 . . . . 0.0 109.544 179.938 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.468 ' SD ' ' CD1' ' A' ' 3' ' ' ILE . 4.4 ptp -114.68 141.92 47.17 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 2.7 tttp -84.48 -80.83 0.19 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.285 -0.884 . . . . 0.0 109.455 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 12.4 tppt? -117.12 87.45 2.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.225 -0.922 . . . . 0.0 109.391 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 51.66 26.52 16.82 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -140.8 97.62 3.23 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -1.168 . . . . 0.0 109.559 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.413 ' HA ' ' HB3' ' A' ' 31' ' ' MET . 6.6 tt -49.67 137.12 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.196 -0.94 . . . . 0.0 109.55 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.432 ' C ' ' OG ' ' A' ' 38' ' ' SER . 0.0 OUTLIER -135.54 18.79 3.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.526 179.939 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.432 ' OG ' ' C ' ' A' ' 37' ' ' GLU . 0.0 OUTLIER -178.05 128.79 0.13 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.17 -0.956 . . . . 0.0 109.6 -179.958 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -143.39 111.46 6.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.291 -0.881 . . . . 0.0 109.151 179.696 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -131.01 162.93 28.69 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.242 -0.911 . . . . 0.0 109.799 -179.617 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 21.8 t -120.45 148.61 23.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.371 -0.831 . . . . 0.0 109.184 179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.404 ' O ' ' HA ' ' A' ' 25' ' ' TYR . 7.1 mt -123.07 129.92 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -108.88 100.12 9.37 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.307 -0.87 . . . . 0.0 109.211 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -47.28 144.3 4.47 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.273 -0.892 . . . . 0.0 109.617 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.2 -45.0 0.12 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.681 2.254 . . . . 0.0 110.596 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.13 29.61 1.6 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.215 -0.928 . . . . 0.0 109.609 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -73.93 -13.26 60.87 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.245 -0.909 . . . . 0.0 109.348 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.8 m -104.3 8.08 35.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.372 -0.83 . . . . 0.0 109.497 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -104.03 -176.53 3.11 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.187 -0.945 . . . . 0.0 109.493 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.6 t -54.59 143.86 23.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.222 -0.924 . . . . 0.0 109.528 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -104.62 87.65 0.56 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -80.54 -116.72 0.34 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -77.74 102.76 7.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -1.136 . . . . 0.0 109.47 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.77 -16.24 31.7 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 47.5 mm -66.15 -14.65 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -1.189 . . . . 0.0 109.525 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.78 -22.87 60.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.256 -0.902 . . . . 0.0 109.433 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.464 ' O ' HG13 ' A' ' 61' ' ' ILE . 21.8 m -55.7 -25.32 39.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 109.533 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.31 -55.65 32.07 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.233 -0.917 . . . . 0.0 109.641 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.69 -37.93 52.81 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 72.9 mt -64.28 -38.01 81.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.29 -0.882 . . . . 0.0 109.655 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.464 HG13 ' O ' ' A' ' 57' ' ' THR . 36.7 mt -72.95 -21.96 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.22 -0.925 . . . . 0.0 109.652 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.454 ' HB1' HD11 ' A' ' 85' ' ' LEU . . . -71.46 -28.66 64.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.165 -0.959 . . . . 0.0 109.487 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -74.78 -2.72 27.83 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.347 -0.845 . . . . 0.0 109.687 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -98.61 -18.25 18.21 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.094 -1.004 . . . . 0.0 109.603 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.521 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 102.8 -9.51 55.33 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 94.0 t -42.61 94.99 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.327 -1.102 . . . . 0.0 109.702 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.521 ' N ' ' O ' ' A' ' 65' ' ' GLY . 24.0 mmtt -79.3 -3.81 47.83 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.379 -0.826 . . . . 0.0 108.863 179.398 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.47 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -139.67 132.29 28.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.274 -0.891 . . . . 0.0 109.449 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 89.8 t -128.66 122.19 56.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.182 -0.949 . . . . 0.0 109.752 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.586 ' CD1' ' CG2' ' A' ' 3' ' ' ILE . 2.1 mp -99.28 116.61 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.226 -0.921 . . . . 0.0 109.245 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -152.46 175.01 13.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.258 -0.901 . . . . 0.0 109.567 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 3.7 m -137.14 39.66 2.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.428 -0.795 . . . . 0.0 109.288 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 7.4 m -50.1 134.64 22.64 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.242 -0.911 . . . . 0.0 109.41 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -79.66 -20.72 9.08 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.458 2.106 . . . . 0.0 110.456 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -104.69 149.43 16.91 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.39 -0.33 10.61 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.717 2.278 . . . . 0.0 110.287 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -67.56 -49.88 61.1 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.261 -0.899 . . . . 0.0 109.487 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.447 ' O ' HD22 ' A' ' 82' ' ' LEU . . . -61.28 -53.4 57.21 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.329 -0.857 . . . . 0.0 109.458 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -56.39 -20.3 18.82 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.341 -0.85 . . . . 0.0 109.522 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.425 ' O ' ' HG3' ' A' ' 84' ' ' GLU . 1.2 tp10 -75.27 -45.88 37.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.228 -0.92 . . . . 0.0 109.557 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.428 ' HA ' ' HB2' ' A' ' 84' ' ' GLU . 6.3 t -67.58 -41.71 86.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 0.0 109.587 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.447 HD22 ' O ' ' A' ' 78' ' ' ALA . 4.2 mm? -51.75 -56.93 10.93 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.127 -0.983 . . . . 0.0 109.48 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -65.15 -22.14 66.88 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.881 . . . . 0.0 109.444 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.428 ' HB2' ' HA ' ' A' ' 81' ' ' VAL . 5.1 mt-10 -74.17 -25.75 59.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.265 -0.897 . . . . 0.0 109.403 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.454 HD11 ' HB1' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -88.13 -30.85 19.52 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.224 -0.922 . . . . 0.0 109.488 -179.991 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 104.63 42.58 1.82 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.7 mt -122.66 155.98 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.275 -1.133 . . . . 0.0 109.375 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.515 ' HD2' ' N ' ' A' ' 88' ' ' LYS . 0.0 OUTLIER -81.66 138.22 35.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.167 -0.958 . . . . 0.0 109.521 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 3.0 mt -106.98 155.42 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.208 -0.932 . . . . 0.0 109.539 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.567 ' CZ ' ' CD2' ' A' ' 104' ' ' PHE . 1.0 OUTLIER -133.9 138.84 45.79 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.286 -0.884 . . . . 0.0 109.531 179.97 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.505 ' NE ' ' HA ' ' A' ' 110' ' ' GLU . 1.3 ptt-85 -97.76 113.4 25.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.289 -0.882 . . . . 0.0 109.291 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.76 125.0 29.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.259 -0.9 . . . . 0.0 109.565 -179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 76.0 p -67.57 -42.12 83.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.259 -0.901 . . . . 0.0 109.433 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 119.73 97.74 1.71 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -168.87 -69.87 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.2 -1.177 . . . . 0.0 109.474 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.517 ' N ' HG21 ' A' ' 16' ' ' VAL . 0.4 OUTLIER -166.64 120.07 1.04 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.194 -0.941 . . . . 0.0 109.493 179.833 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.432 ' CG1' HG21 ' A' ' 5' ' ' ILE . 35.8 m -55.33 -21.47 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 109.589 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -61.48 -51.23 69.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.156 -0.965 . . . . 0.0 109.585 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -77.19 -32.93 56.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.922 . . . . 0.0 109.768 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -60.21 -30.64 69.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.571 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 36.1 tp -68.25 -57.65 5.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.171 -0.955 . . . . 0.0 109.547 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 106' ' ' GLU . 0.0 OUTLIER -62.04 -20.54 64.06 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.224 -0.923 . . . . 0.0 109.518 -179.923 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.44 HD21 ' CB ' ' A' ' 108' ' ' ASN . 0.1 OUTLIER -76.96 -41.29 43.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.131 -0.981 . . . . 0.0 109.701 -179.876 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.567 ' CD2' ' CZ ' ' A' ' 90' ' ' TYR . 4.3 t80 -57.7 -53.8 54.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.197 -0.939 . . . . 0.0 109.312 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' THR . . . . . 0.419 ' OG1' ' HE1' ' A' ' 31' ' ' MET . 9.7 m -67.87 -19.54 65.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.252 -0.905 . . . . 0.0 109.475 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . 0.427 ' CG ' ' O ' ' A' ' 102' ' ' LYS . 4.4 mm-40 -83.44 9.27 11.52 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.337 -0.852 . . . . 0.0 109.302 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 51.66 45.13 54.78 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . 0.481 ' O ' ' HB3' ' A' ' 109' ' ' LEU . 1.9 m120 -79.84 -66.32 0.89 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.306 -1.114 . . . . 0.0 109.498 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.507 ' CD1' ' HG3' ' A' ' 110' ' ' GLU . 0.7 OUTLIER 173.81 -159.83 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.301 -0.875 . . . . 0.0 109.372 -179.906 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.524 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 30.8 mt-10 73.29 30.03 1.6 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.282 -0.886 . . . . 0.0 109.482 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -104.44 147.12 27.92 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -0.913 . . . . 0.0 109.536 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 7.8 mt -142.15 125.21 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.153 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.449 ' HG2' ' HE2' ' A' ' 88' ' ' LYS . 21.6 mtt180 -111.12 -58.02 2.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.347 -0.846 . . . . 0.0 109.846 -179.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.401 ' HA ' ' HD3' ' A' ' 115' ' ' PRO . 0.7 OUTLIER -153.92 145.57 16.74 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.07 -1.019 . . . . 0.0 109.782 -179.682 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 114' ' ' SER . 36.5 Cg_endo -78.88 107.28 2.22 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.668 2.245 . . . . 0.0 110.403 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.415 ' O ' ' CB ' ' A' ' 117' ' ' SER . . . 150.11 -124.81 1.83 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.415 ' CB ' ' O ' ' A' ' 116' ' ' GLY . 0.6 OUTLIER 170.13 122.77 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.239 -1.153 . . . . 0.0 109.569 179.994 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -126.92 -152.86 8.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 4.9 mtt85 -141.89 169.36 17.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.266 -1.138 . . . . 0.0 109.499 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -177.14 -112.75 0.33 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.25 98.03 3.14 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -1.133 . . . . 0.0 109.509 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.48 52.86 2.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.292 -0.88 . . . . 0.0 109.436 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 55.64 56.82 5.81 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.276 -0.89 . . . . 0.0 109.351 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.422 ' HD2' ' OXT' ' A' ' 124' ' ' ARG . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.428 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 121.254 0.55 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.451 ' O ' ' HB2' ' A' ' 68' ' ' ALA . 12.9 mttt -112.65 144.09 42.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.213 -0.93 . . . . 0.0 109.268 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.572 HD12 ' CD1' ' A' ' 104' ' ' PHE . 3.7 mt -121.96 106.78 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.184 -0.948 . . . . 0.0 110.339 -179.404 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.47 ' HB2' HG12 ' A' ' 28' ' ' ILE . . . -106.02 111.54 24.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.302 -0.873 . . . . 0.0 108.706 179.064 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.469 ' CG2' ' HB ' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -100.48 131.86 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.861 -179.379 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -63.56 139.16 58.74 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.303 -0.873 . . . . 0.0 109.113 179.549 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.44 ' HB3' ' O ' ' A' ' 25' ' ' TYR . 17.4 t -126.84 172.99 9.92 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.086 -1.009 . . . . 0.0 109.772 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -122.44 -32.61 3.59 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.408 -0.808 . . . . 0.0 109.266 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.539 ' O ' ' CE2' ' A' ' 25' ' ' TYR . . . -113.98 -82.44 1.1 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -169.67 -62.14 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.288 -1.125 . . . . 0.0 109.589 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -145.33 -55.17 0.31 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.888 . . . . 0.0 109.572 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.1 mt -75.93 -38.77 57.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.227 -0.921 . . . . 0.0 109.645 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.42 17.12 57.24 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 96' ' ' SER . 89.7 p -77.19 78.42 3.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -1.148 . . . . 0.0 109.757 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.464 ' O ' ' CB ' ' A' ' 16' ' ' VAL . 44.2 tt0 -77.25 -0.29 24.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.253 -0.904 . . . . 0.0 109.408 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.464 ' CB ' ' O ' ' A' ' 15' ' ' GLU . 2.5 t 73.73 74.55 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.26 -0.9 . . . . 0.0 109.64 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -46.65 151.7 0.55 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.168 -0.957 . . . . 0.0 109.289 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 3.2 ptm180 -104.92 31.74 4.61 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.927 . . . . 0.0 109.625 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -119.2 115.58 24.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.518 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 25.9 t80 -91.34 78.02 5.79 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.23 -0.918 . . . . 0.0 109.352 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.61 -20.98 0.71 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.475 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.4 ttm-85 -111.17 -40.31 4.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.368 -1.077 . . . . 0.0 109.28 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.442 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -41.78 101.98 0.26 Allowed Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.533 -0.729 . . . . 0.0 109.643 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.01 41.04 1.05 Allowed 'Trans proline' 0 C--N 1.312 -1.395 0 C-N-CA 122.579 2.186 . . . . 0.0 110.89 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.539 ' CE2' ' O ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -160.39 71.07 0.43 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.98 -1.075 . . . . 0.0 109.448 179.952 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.448 ' CE2' HD12 ' A' ' 61' ' ' ILE . 0.1 OUTLIER -79.5 117.08 20.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.287 -0.883 . . . . 0.0 109.549 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 3.2 ttt -95.62 104.26 16.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.928 . . . . 0.0 109.297 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.47 HG12 ' HB2' ' A' ' 4' ' ' ALA . 27.2 mt -100.83 126.13 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.266 -0.896 . . . . 0.0 109.709 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 38' ' ' SER . 90.5 t -123.95 117.82 52.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.298 -0.876 . . . . 0.0 109.349 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -83.92 115.97 22.56 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.221 -0.925 . . . . 0.0 109.622 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.428 ' HG2' ' HA ' ' A' ' 36' ' ' ILE . 0.3 OUTLIER -96.88 138.76 33.94 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.268 -0.895 . . . . 0.0 109.514 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 1.2 tptp -96.76 -62.45 1.26 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.889 . . . . 0.0 109.326 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . 0.401 ' O ' ' C ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -139.88 89.45 2.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.161 179.725 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 45.66 30.41 3.34 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -150.52 114.42 5.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -1.126 . . . . 0.0 109.555 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.428 ' HA ' ' HG2' ' A' ' 31' ' ' MET . 2.1 mp -54.14 132.4 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.164 -0.96 . . . . 0.0 109.41 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -133.28 12.82 4.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.255 -0.903 . . . . 0.0 109.375 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.456 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 0.3 OUTLIER -174.28 116.87 0.21 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 109.502 -179.981 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.5 p -129.73 104.23 7.29 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.536 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -122.91 139.59 53.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.392 -0.818 . . . . 0.0 109.375 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 73.9 t -114.11 119.31 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.531 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.4 mt -118.28 143.03 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.364 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 44' ' ' ASN . 29.6 mp0 -86.1 118.91 25.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.15 -0.969 . . . . 0.0 109.391 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.414 ' C ' ' O ' ' A' ' 43' ' ' GLU . 2.0 t30 -44.48 141.77 2.62 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.244 -0.91 . . . . 0.0 109.365 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -79.23 -25.4 5.86 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 122.569 2.18 . . . . 0.0 110.413 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.4 m -119.81 42.29 2.95 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.204 -0.935 . . . . 0.0 109.661 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -58.29 -72.51 0.09 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 109.363 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -106.28 66.94 0.72 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.318 -0.864 . . . . 0.0 109.35 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -115.76 143.46 45.35 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.328 -0.857 . . . . 0.0 109.51 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 79.3 p -63.84 -179.04 0.36 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.124 -0.985 . . . . 0.0 109.412 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 106.14 -30.86 9.0 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 177.66 -168.7 40.39 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -75.72 -15.05 60.34 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.262 -1.14 . . . . 0.0 109.503 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.461 ' O ' HG23 ' A' ' 57' ' ' THR . . . 110.47 19.02 8.14 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 23.3 mm -76.58 -14.95 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.27 -1.135 . . . . 0.0 109.573 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -58.46 -17.63 22.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.227 -0.921 . . . . 0.0 109.662 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.461 HG23 ' O ' ' A' ' 54' ' ' GLY . 6.0 t -63.38 -37.74 88.43 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.171 -0.956 . . . . 0.0 109.812 -179.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.458 ' N ' HG22 ' A' ' 57' ' ' THR . . . -45.42 -34.51 3.15 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.176 -0.953 . . . . 0.0 109.817 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -61.29 -64.59 0.9 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.237 -0.914 . . . . 0.0 109.847 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.407 HG22 ' O ' ' A' ' 57' ' ' THR . 0.9 OUTLIER -58.8 -18.41 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.245 -0.91 . . . . 0.0 109.926 -179.593 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.459 ' O ' HG22 ' A' ' 66' ' ' VAL . 19.3 mm -75.56 -36.38 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.688 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.462 ' HB1' HD12 ' A' ' 87' ' ' ILE . . . -73.38 -28.37 61.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.225 -0.922 . . . . 0.0 109.757 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -77.25 -9.81 59.03 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.087 -1.008 . . . . 0.0 109.906 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.45 ' HB2' HG22 ' A' ' 66' ' ' VAL . 57.9 m-20 -88.13 7.65 30.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.108 -0.995 . . . . 0.0 109.629 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 69.24 10.67 62.92 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.464 HG12 ' HB3' ' A' ' 4' ' ' ALA . 2.0 t -67.65 89.54 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.198 -1.178 . . . . 0.0 109.415 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.448 ' O ' ' HG3' ' A' ' 88' ' ' LYS . 0.5 OUTLIER -79.6 -7.4 58.51 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.348 -0.845 . . . . 0.0 108.92 179.648 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 3' ' ' ILE . . . -137.53 103.64 5.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.19 -0.944 . . . . 0.0 109.273 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.462 HG23 ' CG1' ' A' ' 66' ' ' VAL . 56.9 t -112.01 132.1 61.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.054 -1.029 . . . . 0.0 109.817 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.497 ' CD1' HG22 ' A' ' 3' ' ' ILE . 3.2 mp -104.61 112.76 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.352 -0.843 . . . . 0.0 109.199 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -149.61 -178.04 6.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.22 -0.925 . . . . 0.0 109.979 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -146.12 46.89 1.24 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.642 -0.661 . . . . 0.0 109.524 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' SER . . . . . 0.553 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 2.6 p -45.49 151.94 0.72 Allowed Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.224 -0.922 . . . . 0.0 109.624 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.84 -25.99 7.18 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.719 2.279 . . . . 0.0 110.615 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -121.73 152.22 16.86 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.17 -16.57 13.88 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.602 2.202 . . . . 0.0 110.483 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -46.94 -47.06 21.81 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.922 . . . . 0.0 109.619 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -67.51 -34.98 78.22 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.256 -0.903 . . . . 0.0 109.628 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.553 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 8.7 m-30 -71.59 -17.16 62.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.632 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.435 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 4.3 mm-40 -73.24 -42.92 61.99 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.124 -0.985 . . . . 0.0 108.967 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.3 t -76.63 -30.05 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.435 -0.79 . . . . 0.0 109.254 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.512 ' N ' HD12 ' A' ' 82' ' ' LEU . 4.8 mp -61.54 -56.29 21.59 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.354 -0.841 . . . . 0.0 109.575 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.435 ' OD1' ' O ' ' A' ' 80' ' ' GLU . 9.6 p-10 -69.64 -14.12 62.66 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.293 -0.879 . . . . 0.0 109.578 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -76.98 -36.34 56.52 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.284 -0.885 . . . . 0.0 109.606 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.438 ' HB2' HD12 ' A' ' 87' ' ' ILE . 73.8 mt -86.0 12.38 9.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.189 -0.945 . . . . 0.0 109.669 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 80.99 8.71 87.14 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.462 HD12 ' HB1' ' A' ' 62' ' ' ALA . 18.3 mt -81.19 144.72 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.191 -1.182 . . . . 0.0 109.604 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.448 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 20.1 mttt -92.55 128.67 38.49 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.209 -0.932 . . . . 0.0 109.226 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.483 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.5 mt -99.22 128.66 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.178 -0.951 . . . . 0.0 109.582 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.582 ' CD2' ' HA ' ' A' ' 110' ' ' GLU . 2.0 m-30 -117.95 152.21 35.9 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.462 -0.774 . . . . 0.0 109.12 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.521 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 7.5 tpt180 -98.66 120.23 38.72 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.153 -0.967 . . . . 0.0 109.71 -179.714 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.01 132.24 34.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -0.904 . . . . 0.0 109.495 179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 3.7 m -71.9 -38.16 69.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.232 -0.918 . . . . 0.0 109.41 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 114.09 14.35 9.27 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -79.7 -68.74 0.64 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.246 -1.149 . . . . 0.0 109.244 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 14' ' ' SER . 0.2 OUTLIER -171.16 132.72 0.83 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.204 -0.935 . . . . 0.0 109.341 179.927 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 23.8 m -56.56 -23.61 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.917 . . . . 0.0 109.527 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -68.81 -38.83 80.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.256 -0.902 . . . . 0.0 109.449 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -77.27 -42.24 37.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.232 -0.917 . . . . 0.0 109.68 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -64.89 -27.75 69.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.692 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.421 ' C ' HD21 ' A' ' 101' ' ' LEU . 0.6 OUTLIER -59.63 -61.56 2.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.185 -0.947 . . . . 0.0 109.634 -179.913 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.53 -28.54 69.71 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.426 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -66.92 -29.04 68.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.664 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.574 ' CD1' ' O ' ' A' ' 104' ' ' PHE . 9.3 t80 -75.5 -26.48 58.16 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.186 -0.946 . . . . 0.0 109.631 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 14.6 m -63.1 -20.59 65.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.231 -0.918 . . . . 0.0 109.728 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -103.88 -30.46 10.33 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.179 -0.951 . . . . 0.0 109.455 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.92 42.0 6.14 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 32.9 m-20 -95.61 -20.09 19.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -1.162 . . . . 0.0 109.318 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -127.87 143.29 51.11 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.402 -0.811 . . . . 0.0 109.044 179.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.582 ' HA ' ' CD2' ' A' ' 90' ' ' TYR . 4.7 pt-20 -172.38 -157.28 0.1 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.149 -0.969 . . . . 0.0 109.888 -179.718 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.521 ' HB2' ' N ' ' A' ' 91' ' ' ARG . 3.0 tt0 -158.66 -104.21 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.368 -0.833 . . . . 0.0 109.365 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.457 ' N ' ' CG ' ' A' ' 111' ' ' GLU . 46.8 mm -93.17 111.32 24.5 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 O-C-N 121.27 -0.894 . . . . 0.0 109.586 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.49 ' HG3' ' N ' ' A' ' 114' ' ' SER . 0.1 OUTLIER -129.49 -34.24 1.82 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.326 -0.858 . . . . 0.0 109.44 179.942 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.49 ' N ' ' HG3' ' A' ' 113' ' ' ARG . 0.9 OUTLIER 169.39 148.16 0.11 Allowed Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.227 -0.921 . . . . 0.0 109.474 179.917 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.57 -53.6 0.06 OUTLIER 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 122.729 2.286 . . . . 0.0 110.427 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 152.2 -46.5 0.58 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.52 154.9 40.97 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.289 -1.124 . . . . 0.0 109.522 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -106.44 -90.62 2.17 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.62 -45.43 2.7 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.244 -1.15 . . . . 0.0 109.39 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 129.06 97.76 0.86 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.85 32.15 5.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.312 -1.111 . . . . 0.0 109.437 -179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER 58.18 56.13 4.72 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.237 -0.914 . . . . 0.0 109.302 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 51.98 -173.59 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.323 -0.861 . . . . 0.0 109.391 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.41 ' NE ' ' HA ' ' A' ' 124' ' ' ARG . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 118.098 -0.953 . . . . 0.0 109.466 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -90.65 121.48 32.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.245 -0.909 . . . . 0.0 109.345 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.578 HG12 ' CD2' ' A' ' 104' ' ' PHE . 4.1 mt -100.26 111.7 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.291 -0.881 . . . . 0.0 109.853 -179.781 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.5 ' HB3' ' CE2' ' A' ' 26' ' ' PHE . . . -104.12 112.69 25.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -0.921 . . . . 0.0 109.397 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.512 ' CG2' HG13 ' A' ' 97' ' ' VAL . 14.4 mm -87.78 117.62 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.226 -0.921 . . . . 0.0 109.525 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.46 ' O ' ' HB3' ' A' ' 7' ' ' SER . . . -62.64 153.78 31.23 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.289 -0.882 . . . . 0.0 109.608 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.46 ' HB3' ' O ' ' A' ' 6' ' ' ALA . 2.4 t 61.62 -88.96 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.522 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.46 ' HA ' HG21 ' A' ' 97' ' ' VAL . 0.2 OUTLIER 57.95 22.62 8.96 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.193 -0.942 . . . . 0.0 109.457 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 48.94 -102.12 0.05 OUTLIER Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -155.85 -47.05 0.08 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -1.173 . . . . 0.0 109.46 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -155.59 -62.05 0.11 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.448 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.9 mp -108.17 -15.81 14.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.204 -0.935 . . . . 0.0 109.529 -179.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -94.19 27.49 13.19 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.6 p -78.28 74.34 4.82 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.391 -1.064 . . . . 0.0 109.695 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.522 ' O ' ' CG ' ' A' ' 15' ' ' GLU . 32.4 tt0 -78.33 5.55 10.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.023 -1.048 . . . . 0.0 109.815 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.498 ' CG2' ' CA ' ' A' ' 96' ' ' SER . 2.1 t 68.37 54.15 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.168 -0.957 . . . . 0.0 109.116 -179.559 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 16' ' ' VAL . 1.0 OUTLIER -42.74 159.47 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.411 -0.806 . . . . 0.0 109.688 -179.844 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -111.32 39.08 2.39 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.265 -0.897 . . . . 0.0 109.428 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.442 ' O ' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -129.22 103.49 6.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.255 -0.903 . . . . 0.0 109.508 -179.962 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.5 t80 -102.41 142.01 34.31 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.516 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 114.25 -46.73 1.13 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.47 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 7.9 ttp180 -103.12 -37.36 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.371 -1.076 . . . . 0.0 109.141 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.442 ' HB3' ' O ' ' A' ' 19' ' ' PHE . . . -41.47 102.0 0.26 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.569 -0.707 . . . . 0.0 109.821 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.493 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 36.7 Cg_endo -81.21 54.73 5.33 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.652 2.235 . . . . 0.0 110.478 179.688 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.458 ' O ' ' O ' ' A' ' 7' ' ' SER . 68.5 m-85 -154.15 68.5 0.75 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.108 -0.995 . . . . 0.0 109.204 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.5 ' CE2' ' HB3' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -79.39 111.13 15.34 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.256 -0.903 . . . . 0.0 109.337 -179.907 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' MET . . . . . 0.451 ' HB2' ' CB ' ' A' ' 8' ' ' SER . 7.2 ttm -88.76 102.09 14.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.3 -0.875 . . . . 0.0 109.559 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.463 HG22 ' O ' ' A' ' 40' ' ' GLU . 6.1 tp -83.61 114.67 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.363 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.7 t -126.11 128.71 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.155 -0.966 . . . . 0.0 109.653 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -111.21 113.86 26.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.283 -0.886 . . . . 0.0 109.368 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.439 ' SD ' ' CA ' ' A' ' 34' ' ' GLY . 0.7 OUTLIER -112.53 132.65 54.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -0.92 . . . . 0.0 109.6 -179.851 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 7.2 mmmt -87.67 -55.81 3.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.268 -0.895 . . . . 0.0 109.33 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.15 68.24 0.93 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.336 -0.853 . . . . 0.0 109.209 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.439 ' CA ' ' SD ' ' A' ' 31' ' ' MET . . . 75.92 8.6 84.9 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -130.52 98.35 4.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.176 -1.19 . . . . 0.0 109.493 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 2.9 mt -57.43 127.49 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.251 -0.906 . . . . 0.0 109.658 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.456 ' O ' ' HB3' ' A' ' 38' ' ' SER . 0.5 OUTLIER -101.66 -2.3 30.65 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.401 179.68 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.456 ' HB3' ' O ' ' A' ' 37' ' ' GLU . 77.3 p 176.8 125.55 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.201 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -136.85 106.97 6.33 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.208 -0.932 . . . . 0.0 109.644 -179.759 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.463 ' O ' HG22 ' A' ' 28' ' ' ILE . 0.9 OUTLIER -112.87 163.62 14.41 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 179.922 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.489 ' O ' ' CG1' ' A' ' 41' ' ' VAL . 7.6 p -134.6 118.66 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.331 -0.855 . . . . 0.0 109.447 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 21.5 pt -126.88 133.63 68.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.218 -0.926 . . . . 0.0 109.569 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.493 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 1.3 mt-10 -74.46 146.61 42.67 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.369 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 12.2 m-20 -46.19 153.43 0.7 Allowed Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.242 -0.911 . . . . 0.0 109.318 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.4 -47.79 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.639 2.226 . . . . 0.0 110.523 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.2 p -119.14 54.58 0.97 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.898 . . . . 0.0 109.56 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -58.56 -44.48 89.71 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.169 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -159.94 96.35 1.22 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.367 -0.833 . . . . 0.0 109.331 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -174.19 -60.83 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.255 -0.903 . . . . 0.0 109.488 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 26.0 t -71.18 -14.52 62.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.301 -0.874 . . . . 0.0 109.48 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.45 88.19 1.86 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -151.72 157.65 27.34 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -76.37 -20.07 57.54 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.191 -1.182 . . . . 0.0 109.52 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 113.53 -37.1 3.73 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 47.2 mm -66.49 -14.15 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.279 -1.13 . . . . 0.0 109.484 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -8.9 38.79 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.29 -0.881 . . . . 0.0 109.496 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 14.8 t -76.93 -16.04 59.49 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.191 -0.943 . . . . 0.0 109.529 179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.401 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -57.28 -32.35 66.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 109.536 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 21.8 tt0 -65.11 -52.98 52.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 35.9 mm -62.72 -25.6 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.228 -0.92 . . . . 0.0 109.326 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.436 HD11 ' CZ ' ' A' ' 26' ' ' PHE . 45.5 mt -69.71 -39.28 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 109.276 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.419 ' HB3' HD11 ' A' ' 87' ' ' ILE . . . -74.6 -25.44 59.26 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.248 -0.908 . . . . 0.0 109.429 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -77.09 -5.15 47.83 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.237 -0.914 . . . . 0.0 109.51 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.436 ' HB2' HG21 ' A' ' 66' ' ' VAL . 6.8 m-20 -100.26 1.86 42.18 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.134 -0.979 . . . . 0.0 109.527 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.499 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 90.89 -5.94 81.95 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.448 HG12 HG22 ' A' ' 69' ' ' VAL . 48.3 t -53.5 88.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -1.176 . . . . 0.0 109.858 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.499 ' N ' ' O ' ' A' ' 65' ' ' GLY . 6.4 tttp -79.75 -12.46 59.79 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.119 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.456 ' HB2' ' HA ' ' A' ' 3' ' ' ILE . . . -127.62 131.99 49.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.436 -0.79 . . . . 0.0 109.108 179.685 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.448 HG22 HG12 ' A' ' 66' ' ' VAL . 2.4 t -129.64 105.49 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.123 -0.985 . . . . 0.0 109.806 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.451 HG12 ' HB2' ' A' ' 90' ' ' TYR . 23.3 mt -91.41 119.96 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.277 -0.89 . . . . 0.0 109.01 179.595 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -149.12 177.08 9.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.152 -0.967 . . . . 0.0 109.938 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.04 35.38 3.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.535 -0.728 . . . . 0.0 109.14 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' SER . . . . . 0.423 ' HB2' ' CE1' ' A' ' 79' ' ' PHE . 0.1 OUTLIER -44.87 134.23 4.99 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.286 -0.884 . . . . 0.0 109.465 -179.807 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.75 -19.78 10.96 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.436 2.091 . . . . 0.0 110.351 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -114.15 148.31 18.77 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.83 9.16 3.38 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.631 2.221 . . . . 0.0 110.706 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -74.44 -42.62 58.81 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.095 -1.003 . . . . 0.0 109.722 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -68.69 -50.78 48.22 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.588 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.423 ' CE1' ' HB2' ' A' ' 73' ' ' SER . 11.3 m-30 -48.81 -38.43 22.12 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.264 -0.898 . . . . 0.0 109.652 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.474 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 0.6 OUTLIER -65.75 -47.4 75.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.188 -0.945 . . . . 0.0 109.71 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 86.7 t -52.89 -50.85 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.182 -0.949 . . . . 0.0 109.466 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.422 HD23 ' HB ' ' A' ' 87' ' ' ILE . 1.9 mt -56.47 -31.15 63.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.474 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 3.2 m-20 -61.96 -51.26 68.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.163 -0.961 . . . . 0.0 109.301 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -62.81 -27.67 69.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.21 179.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.1 mt -72.03 -34.21 68.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.174 -0.954 . . . . 0.0 109.527 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.1 19.98 19.72 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.422 ' HB ' HD23 ' A' ' 82' ' ' LEU . 27.7 mt -103.83 163.03 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.289 -1.124 . . . . 0.0 109.617 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 3.4 mptt -91.74 147.07 23.26 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.253 -0.904 . . . . 0.0 109.263 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.503 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.3 mt -120.76 131.76 72.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.112 -0.992 . . . . 0.0 109.211 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.476 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 12.8 m-85 -119.47 161.26 20.85 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.476 -0.765 . . . . 0.0 109.547 -179.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.466 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 0.1 OUTLIER -99.25 136.78 38.7 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.264 -0.897 . . . . 0.0 109.627 -179.909 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.64 129.33 34.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.259 -0.901 . . . . 0.0 109.443 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.35 -40.33 96.05 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.26 -0.9 . . . . 0.0 109.476 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 102.94 22.07 9.66 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.73 -83.75 0.54 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.128 -1.219 . . . . 0.0 109.4 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.498 ' CA ' ' CG2' ' A' ' 16' ' ' VAL . 3.3 m -146.71 137.65 24.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.324 -0.86 . . . . 0.0 109.315 179.814 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.512 HG13 ' CG2' ' A' ' 5' ' ' ILE . 86.8 t -64.2 -31.18 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -0.882 . . . . 0.0 109.609 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.58 -44.36 80.95 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.194 -0.941 . . . . 0.0 109.465 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -75.46 -35.8 60.82 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.45 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 15.1 m-20 -54.44 -37.71 65.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.224 -0.922 . . . . 0.0 109.669 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -49.43 -53.48 22.58 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.283 -0.885 . . . . 0.0 109.651 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 6.0 mmtm -69.64 -33.43 72.6 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.23 -0.919 . . . . 0.0 109.656 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.475 ' CD1' ' HB3' ' A' ' 108' ' ' ASN . 2.2 mm? -57.94 -31.75 67.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.205 -0.934 . . . . 0.0 109.438 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.578 ' CD2' HG12 ' A' ' 3' ' ' ILE . 20.9 t80 -72.75 -38.61 67.31 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.384 -0.823 . . . . 0.0 109.779 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 17.6 m -70.56 -25.69 63.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.266 -0.896 . . . . 0.0 109.751 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -88.1 -0.51 57.14 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.204 -0.935 . . . . 0.0 109.674 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . 0.456 ' HA2' ' OE2' ' A' ' 110' ' ' GLU . . . 59.95 25.42 61.75 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . 0.475 ' HB3' ' CD1' ' A' ' 103' ' ' LEU . 1.2 m-20 -88.48 -53.28 4.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.204 -1.174 . . . . 0.0 109.424 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 11.9 tp -85.19 129.75 34.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.243 -0.911 . . . . 0.0 109.202 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.456 ' OE2' ' HA2' ' A' ' 107' ' ' GLY . 0.3 OUTLIER -165.68 -166.31 0.94 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.198 -0.939 . . . . 0.0 109.729 -179.818 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.503 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 68.5 tt0 -172.68 -113.85 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.285 -0.885 . . . . 0.0 109.371 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.484 ' N ' ' HG2' ' A' ' 111' ' ' GLU . 5.3 mt -82.31 140.37 16.53 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 O-C-N 121.093 -1.005 . . . . 0.0 109.253 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.488 ' NH1' ' HG2' ' A' ' 113' ' ' ARG . 0.0 OUTLIER -140.65 157.84 44.86 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.203 -0.935 . . . . 0.0 109.623 -179.885 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -146.1 156.76 50.72 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.279 -0.888 . . . . 0.0 109.345 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.48 6.33 4.87 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 C-N-CA 122.696 2.264 . . . . 0.0 110.486 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 94.78 -23.95 30.4 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 4.8 t -169.59 112.0 0.48 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.214 -1.168 . . . . 0.0 109.41 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 139.44 132.8 2.95 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.3 ttp85 -173.17 -55.65 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.15 -1.206 . . . . 0.0 109.551 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.0 85.36 0.39 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.483 ' O ' ' CB ' ' A' ' 122' ' ' ARG . 1.0 OUTLIER -68.12 155.16 40.19 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.293 -1.122 . . . . 0.0 109.253 179.883 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.483 ' CB ' ' O ' ' A' ' 121' ' ' ARG . 0.1 OUTLIER 73.7 85.65 0.11 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.257 -0.902 . . . . 0.0 109.378 -179.97 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 8.1 ttt85 -148.98 150.3 32.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.209 -0.932 . . . . 0.0 109.506 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 117.978 -1.011 . . . . 0.0 109.463 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.428 ' HG3' ' HB2' ' A' ' 67' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.28 0.562 . . . . 0.0 109.514 . . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.93 139.68 36.98 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.219 -0.926 . . . . 0.0 109.201 179.825 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.473 ' HA ' ' HB2' ' A' ' 68' ' ' ALA . 4.8 mt -115.24 113.49 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.12 -0.987 . . . . 0.0 110.006 -179.609 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.03 119.55 39.78 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.507 -0.746 . . . . 0.0 109.024 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 3.3 mp -98.15 136.94 27.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.128 -0.982 . . . . 0.0 109.879 -179.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.569 ' HB1' ' CZ ' ' A' ' 26' ' ' PHE . . . -89.74 121.99 32.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.296 -0.877 . . . . 0.0 109.138 179.725 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.402 ' O ' ' HB3' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -142.08 170.82 14.99 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.143 -0.973 . . . . 0.0 109.728 -179.832 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 51.5 p -116.32 25.31 10.73 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.316 -0.865 . . . . 0.0 109.299 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -162.64 -145.27 4.29 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.17 22.56 1.2 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.243 -1.151 . . . . 0.0 109.521 -179.94 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -147.57 -178.68 6.38 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.199 -0.938 . . . . 0.0 109.602 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.425 ' HG ' ' HB3' ' A' ' 96' ' ' SER . 6.6 tt -64.39 -14.24 55.44 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.337 -0.852 . . . . 0.0 109.571 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -56.74 -52.4 50.87 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.08 86.57 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.335 -1.097 . . . . 0.0 109.397 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.46 81.21 1.44 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.476 -0.765 . . . . 0.0 109.54 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.505 HG12 ' CB ' ' A' ' 92' ' ' ALA . 59.3 t 54.54 30.45 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.665 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 26.6 p 46.14 -160.66 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.275 -0.891 . . . . 0.0 109.433 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 2.9 mtt-85 -98.2 -46.92 5.66 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.898 . . . . 0.0 109.376 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -150.27 122.65 8.44 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.364 -0.835 . . . . 0.0 109.429 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -57.65 124.49 19.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.238 -0.914 . . . . 0.0 109.391 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -171.98 -49.37 0.04 OUTLIER Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.95 45.4 1.46 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.283 -1.128 . . . . 0.0 109.446 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.402 ' HB3' ' O ' ' A' ' 7' ' ' SER . . . -54.6 112.65 4.21 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.352 -0.842 . . . . 0.0 109.516 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.452 ' O ' ' CB ' ' A' ' 43' ' ' GLU . 36.6 Cg_endo -80.61 20.53 0.95 Allowed 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.606 2.204 . . . . 0.0 110.947 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -154.8 69.79 0.75 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.036 -1.04 . . . . 0.0 108.942 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.569 ' CZ ' ' HB1' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -79.1 125.21 29.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.348 -0.845 . . . . 0.0 109.722 -179.456 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 10.7 mtt -90.06 110.69 21.67 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.289 -0.882 . . . . 0.0 109.369 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 31.6 mm -93.46 107.45 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.467 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.474 ' CG1' HG22 ' A' ' 36' ' ' ILE . 23.3 t -115.63 116.35 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.266 -0.896 . . . . 0.0 109.429 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -103.81 114.81 29.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.554 -179.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 12.6 ptp -116.3 160.33 20.63 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.241 -0.912 . . . . 0.0 109.419 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -109.71 -94.98 0.41 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.256 -0.903 . . . . 0.0 109.626 -179.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -89.5 62.35 5.92 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.116 -0.99 . . . . 0.0 109.348 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.13 35.58 92.28 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 36' ' ' ILE . 44.9 t30 -138.96 84.26 2.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.302 -1.116 . . . . 0.0 109.462 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.474 HG22 ' CG1' ' A' ' 29' ' ' VAL . 50.6 mt -45.41 111.27 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.221 -0.924 . . . . 0.0 109.419 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -111.49 9.26 21.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.232 -0.917 . . . . 0.0 109.482 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -167.28 124.18 1.19 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.187 -0.946 . . . . 0.0 109.485 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.2 p -144.96 107.9 4.51 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.284 -0.885 . . . . 0.0 109.478 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -123.37 148.2 46.29 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.526 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.4 t -103.99 137.82 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.87 . . . . 0.0 109.519 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -139.33 136.28 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.259 -0.9 . . . . 0.0 109.421 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.452 ' CB ' ' O ' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -96.85 120.66 37.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 179.915 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.418 ' CG ' ' HD2' ' A' ' 45' ' ' PRO . 0.8 OUTLIER -60.74 147.82 83.66 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.21 -0.931 . . . . 0.0 109.357 -179.911 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.418 ' HD2' ' CG ' ' A' ' 44' ' ' ASN . 35.9 Cg_endo -78.48 -34.0 1.62 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.559 2.173 . . . . 0.0 110.454 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.9 m -49.26 -23.88 1.56 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.308 -0.87 . . . . 0.0 109.529 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -61.76 -48.44 80.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.15 -0.969 . . . . 0.0 109.469 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.75 -3.71 51.89 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.592 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -112.57 95.14 5.27 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.193 -0.942 . . . . 0.0 109.484 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 10.3 p -67.62 121.3 15.57 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.277 -0.89 . . . . 0.0 109.376 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 116.45 38.28 0.94 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.44 ' O ' ' HB2' ' A' ' 53' ' ' ALA . . . -124.53 9.42 8.21 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . 0.44 ' HB2' ' O ' ' A' ' 52' ' ' GLY . . . 61.54 165.2 0.09 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.218 -1.166 . . . . 0.0 109.342 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -122.54 -36.89 0.66 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.485 HG23 ' CA ' ' A' ' 78' ' ' ALA . 20.7 mm -71.85 -39.88 68.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.191 -1.182 . . . . 0.0 109.42 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 7.3 mmm-85 -65.67 -11.13 42.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.557 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.529 ' O ' ' CG2' ' A' ' 60' ' ' ILE . 44.8 m -70.3 -33.47 71.58 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 0.0 109.312 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -50.83 -23.84 3.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.243 -0.91 . . . . 0.0 109.318 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -70.67 -51.58 26.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.247 -0.908 . . . . 0.0 109.485 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.529 ' CG2' ' O ' ' A' ' 57' ' ' THR . 0.3 OUTLIER -59.03 -33.43 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.412 -179.98 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.564 HD11 ' CZ ' ' A' ' 26' ' ' PHE . 96.0 mt -67.38 -40.96 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.206 -0.934 . . . . 0.0 109.215 179.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.01 -18.64 59.18 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.338 -0.851 . . . . 0.0 109.461 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -74.55 -17.63 60.71 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.931 . . . . 0.0 109.399 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -86.77 11.75 12.43 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.28 -0.888 . . . . 0.0 109.56 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.454 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 88.6 -6.24 83.82 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.514 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 96.8 t -54.78 89.76 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.283 -1.128 . . . . 0.0 109.878 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.454 ' N ' ' O ' ' A' ' 65' ' ' GLY . 16.5 mmtm -79.18 2.24 21.69 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.139 -0.975 . . . . 0.0 109.017 179.427 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.514 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -142.96 140.05 30.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.236 -0.915 . . . . 0.0 109.06 179.656 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.453 HG22 HG11 ' A' ' 66' ' ' VAL . 42.2 t -139.76 131.15 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.077 -1.014 . . . . 0.0 110.049 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.463 HD12 ' CB ' ' A' ' 90' ' ' TYR . 1.3 mm -108.33 111.63 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.305 -0.872 . . . . 0.0 108.85 179.461 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -154.13 177.05 11.52 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.164 -0.96 . . . . 0.0 109.968 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.5 44.87 1.73 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.53 -0.731 . . . . 0.0 109.23 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -45.74 150.61 0.94 Allowed Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.333 -0.855 . . . . 0.0 109.533 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.83 -38.88 0.57 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.677 2.251 . . . . 0.0 110.292 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.16 146.28 16.89 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.68 8.09 3.89 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.605 2.203 . . . . 0.0 110.663 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -63.93 -46.39 84.99 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.151 -0.968 . . . . 0.0 109.612 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.485 ' CA ' HG23 ' A' ' 55' ' ' ILE . . . -67.4 -50.24 60.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 109.557 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.573 ' CD1' HG23 ' A' ' 89' ' ' ILE . 12.8 m-85 -52.08 -33.16 38.16 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.642 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -67.01 -41.81 86.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.251 -0.905 . . . . 0.0 109.736 -179.732 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.21 -53.77 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.167 -0.958 . . . . 0.0 109.751 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 25.0 mt -60.38 -18.38 50.07 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.27 -0.894 . . . . 0.0 109.719 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.457 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 6.9 m-20 -69.61 -56.37 7.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.275 -0.891 . . . . 0.0 109.716 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -66.12 -34.81 78.89 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.145 -0.972 . . . . 0.0 109.676 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 6.8 mt -61.5 -13.41 20.72 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.237 -0.914 . . . . 0.0 109.416 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 77.61 24.06 65.99 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.2 mm -92.32 144.34 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.239 -1.154 . . . . 0.0 109.4 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.87 110.37 15.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.249 -0.907 . . . . 0.0 109.442 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.573 HG23 ' CD1' ' A' ' 79' ' ' PHE . 13.0 mt -86.76 151.48 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.344 -0.848 . . . . 0.0 109.655 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.545 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 1.1 m-85 -134.87 134.02 40.3 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -0.873 . . . . 0.0 109.453 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.96 132.72 35.19 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.225 -0.922 . . . . 0.0 109.405 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.505 ' CB ' HG12 ' A' ' 16' ' ' VAL . . . -84.6 66.0 9.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.226 -0.921 . . . . 0.0 109.614 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.506 HG23 ' N ' ' A' ' 94' ' ' GLY . 9.5 t -74.2 -28.14 61.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.158 -0.964 . . . . 0.0 109.463 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.506 ' N ' HG23 ' A' ' 93' ' ' THR . . . -59.1 -106.21 0.01 OUTLIER Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.0 t 178.31 -44.09 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.217 -1.166 . . . . 0.0 109.592 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.425 ' HB3' ' HG ' ' A' ' 12' ' ' LEU . 7.2 m -95.66 125.52 40.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.231 -0.918 . . . . 0.0 109.444 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.5 m -63.46 -34.99 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.238 -0.914 . . . . 0.0 109.402 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -64.42 -35.27 80.36 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.198 -0.939 . . . . 0.0 109.29 179.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.461 ' O ' HD22 ' A' ' 103' ' ' LEU . 20.7 tt0 -73.32 -36.78 66.28 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.334 -0.854 . . . . 0.0 109.403 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.467 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 98.9 m-20 -67.74 -27.79 67.09 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.171 -0.955 . . . . 0.0 109.424 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 24.9 tp -58.28 -62.24 1.98 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.358 -0.839 . . . . 0.0 109.674 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -68.19 -24.97 65.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.153 -0.967 . . . . 0.0 109.443 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.467 ' HB2' ' HA ' ' A' ' 100' ' ' ASN . 0.9 OUTLIER -65.0 -29.58 70.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.305 -0.872 . . . . 0.0 109.482 179.929 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.528 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 9.8 t80 -64.12 -43.89 93.92 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.156 -0.965 . . . . 0.0 109.501 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 86.4 m -57.31 -31.36 65.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.753 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -87.64 -22.78 24.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.242 -0.911 . . . . 0.0 109.578 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 77.02 24.36 66.73 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -80.31 -32.52 37.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.179 -1.189 . . . . 0.0 109.367 179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 3.4 tp -66.59 -163.89 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.274 -0.891 . . . . 0.0 109.519 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -110.58 137.54 48.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 109.263 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.545 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 20.8 pt-20 -127.58 165.08 20.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.236 -0.915 . . . . 0.0 109.69 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 10.3 mt -151.54 104.26 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.147 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -122.5 5.87 9.56 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.236 -0.915 . . . . 0.0 109.838 -179.496 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 3.3 m -137.2 156.25 75.52 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.086 -1.009 . . . . 0.0 109.783 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.13 170.11 19.23 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.622 2.214 . . . . 0.0 110.076 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.78 163.8 11.93 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 28.0 m 57.07 -173.88 0.07 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -1.123 . . . . 0.0 109.502 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 108.97 60.32 0.53 Allowed Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.25 159.59 16.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.223 -1.163 . . . . 0.0 109.608 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -146.44 148.14 19.59 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.8 70.61 0.76 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -1.148 . . . . 0.0 109.559 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 1.8 mpp_? -60.17 -87.47 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.148 -0.97 . . . . 0.0 109.45 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.2 mtm105 -99.24 143.21 29.77 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.914 . . . . 0.0 109.472 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.424 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -111.14 137.26 49.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.25 -0.906 . . . . 0.0 109.449 179.867 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.574 HG12 ' CZ ' ' A' ' 104' ' ' PHE . 4.9 mt -102.84 101.89 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.377 -0.827 . . . . 0.0 109.72 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.513 ' CB ' HG12 ' A' ' 66' ' ' VAL . . . -103.66 101.22 11.06 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.318 -0.864 . . . . 0.0 109.147 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 14.7 tt -98.25 130.19 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.256 -0.902 . . . . 0.0 109.592 -179.69 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -59.26 146.09 40.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.406 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.487 ' HB3' ' CB ' ' A' ' 14' ' ' SER . 0.8 OUTLIER -135.85 162.12 33.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.921 . . . . 0.0 109.594 -179.863 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.82 -20.43 12.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.872 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.571 ' O ' ' CD1' ' A' ' 25' ' ' TYR . . . -119.81 -124.66 3.24 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.78 -37.21 1.03 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.19 -1.182 . . . . 0.0 109.544 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -144.92 -73.11 0.25 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.704 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -89.58 -29.76 18.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.254 -0.904 . . . . 0.0 109.514 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.19 -15.12 72.0 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.492 ' OG ' ' CG2' ' A' ' 97' ' ' VAL . 0.8 OUTLIER -77.39 82.62 3.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.196 -1.179 . . . . 0.0 109.479 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.466 ' HG2' ' O ' ' A' ' 95' ' ' THR . 13.2 tt0 -77.34 3.66 12.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.279 -0.888 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.448 ' O ' ' O ' ' A' ' 17' ' ' SER . 9.7 t 66.62 65.96 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.16 -0.962 . . . . 0.0 109.227 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.448 ' O ' ' O ' ' A' ' 16' ' ' VAL . 60.2 p -57.65 -159.35 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.258 -0.901 . . . . 0.0 109.703 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.45 54.18 1.93 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.47 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -136.95 71.41 1.41 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.211 -0.931 . . . . 0.0 109.438 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.434 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . 5.7 t80 -65.58 100.93 0.55 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.29 -0.881 . . . . 0.0 109.61 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 151.91 -42.97 0.69 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.486 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 5.5 ttt85 -104.51 -33.9 8.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.203 -1.175 . . . . 0.0 109.783 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.457 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -39.22 99.02 0.19 Allowed Pre-proline 0 N--CA 1.495 1.809 0 O-C-N 121.543 -0.723 . . . . 0.0 109.78 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.5 Cg_endo -81.03 45.39 1.98 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 122.716 2.277 . . . . 0.0 110.927 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.571 ' CD1' ' O ' ' A' ' 9' ' ' GLY . 1.9 m-85 -161.05 72.34 0.43 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.946 -1.096 . . . . 0.0 109.627 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -79.7 150.01 31.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.305 -0.872 . . . . 0.0 109.438 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' MET . . . . . 0.411 ' HB2' ' OG ' ' A' ' 7' ' ' SER . 5.2 ttt -123.54 122.1 37.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -0.939 . . . . 0.0 109.402 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.478 ' CD1' HD11 ' A' ' 42' ' ' ILE . 28.3 mt -114.08 129.34 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.899 . . . . 0.0 109.547 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 73.6 t -138.69 136.18 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.218 -0.926 . . . . 0.0 109.532 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -120.73 94.66 4.43 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.193 -0.942 . . . . 0.0 109.444 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.497 ' SD ' ' CD1' ' A' ' 3' ' ' ILE . 0.0 OUTLIER -83.44 152.31 25.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.385 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -96.73 -94.02 0.21 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.189 -0.944 . . . . 0.0 109.492 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -101.43 65.22 1.04 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.133 -0.979 . . . . 0.0 109.299 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 70.25 37.59 71.48 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -150.41 116.15 5.54 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.316 -1.108 . . . . 0.0 109.308 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.441 HD12 HD13 ' A' ' 101' ' ' LEU . 5.9 mm -64.12 122.81 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -0.881 . . . . 0.0 109.593 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.453 ' O ' ' OG ' ' A' ' 38' ' ' SER . 2.3 tm-20 -130.77 16.61 5.26 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.188 -0.945 . . . . 0.0 109.318 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.453 ' OG ' ' O ' ' A' ' 37' ' ' GLU . 17.1 m -173.51 101.29 0.12 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.382 -0.824 . . . . 0.0 109.245 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.55 101.06 7.12 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.94 155.91 19.78 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.336 -0.853 . . . . 0.0 109.418 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 3.1 t -125.99 129.6 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.205 -0.935 . . . . 0.0 109.337 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.478 HD11 ' CD1' ' A' ' 28' ' ' ILE . 92.8 mt -110.32 143.05 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.264 -0.897 . . . . 0.0 109.853 -179.758 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -109.73 128.94 55.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.314 -0.866 . . . . 0.0 109.281 179.852 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.433 ' HB3' ' HB2' ' A' ' 47' ' ' ALA . 0.7 OUTLIER -115.58 82.72 10.26 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.199 -0.938 . . . . 0.0 109.407 -179.95 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . 0.454 ' HD3' ' O ' ' A' ' 43' ' ' GLU . 36.2 Cg_endo -78.61 -22.59 9.08 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.671 2.247 . . . . 0.0 110.427 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -108.33 18.31 21.17 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.618 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . 0.433 ' HB2' ' HB3' ' A' ' 44' ' ' ASN . . . -47.75 -66.85 0.34 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.459 ' HB3' ' CA ' ' A' ' 54' ' ' GLY . 79.0 p -129.05 -58.22 1.15 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.232 -0.917 . . . . 0.0 109.472 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 56.97 42.12 26.69 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.296 -0.878 . . . . 0.0 109.499 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 11.3 t -145.63 -53.9 0.28 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.435 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 128.57 76.17 0.19 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 135.38 -72.12 0.47 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.68 175.97 0.32 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -1.125 . . . . 0.0 109.313 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.459 ' CA ' ' HB3' ' A' ' 48' ' ' SER . . . 128.1 -19.73 5.72 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.484 ' CG2' ' HB1' ' A' ' 78' ' ' ALA . 22.2 mt -76.08 0.1 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -1.144 . . . . 0.0 109.619 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.17 -9.57 58.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.199 -0.938 . . . . 0.0 109.553 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.445 HG23 ' O ' ' A' ' 54' ' ' GLY . 7.2 t -76.96 -19.0 57.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -0.89 . . . . 0.0 109.583 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -56.55 -38.45 71.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.289 -0.882 . . . . 0.0 109.581 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -56.46 -39.31 72.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.68 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.4 mt -75.6 -35.44 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 109.648 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 48.8 mt -62.1 -29.05 45.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.54 -179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.516 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . . . -71.82 -34.89 69.71 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.7 -179.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -76.8 -0.42 23.84 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.173 -0.954 . . . . 0.0 109.687 -179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.432 ' HB3' HG21 ' A' ' 66' ' ' VAL . 10.3 t-20 -94.27 8.34 42.15 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.213 -0.929 . . . . 0.0 109.586 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 87.34 -11.21 66.3 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.513 HG12 ' CB ' ' A' ' 4' ' ' ALA . 70.0 t -58.44 91.62 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.226 -1.161 . . . . 0.0 109.489 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.53 -7.34 58.41 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.372 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.454 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -132.98 137.63 46.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 0.0 109.273 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.434 HG21 HG11 ' A' ' 66' ' ' VAL . 32.3 t -134.28 111.86 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.15 -0.969 . . . . 0.0 109.646 -179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.427 HD12 ' CG2' ' A' ' 3' ' ' ILE . 11.7 mt -95.71 116.9 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.289 -0.882 . . . . 0.0 109.261 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.434 ' HB3' ' HB2' ' A' ' 20' ' ' PHE . . . -148.78 173.83 12.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.156 -0.965 . . . . 0.0 109.684 -179.696 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.73 38.89 3.96 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.393 -0.817 . . . . 0.0 109.422 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -50.17 141.25 15.74 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.264 -0.898 . . . . 0.0 109.406 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.59 -62.95 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.593 2.195 . . . . 0.0 110.474 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -74.28 155.78 49.31 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.446 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.3 Cg_endo -78.6 4.7 6.15 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.702 2.268 . . . . 0.0 110.535 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -62.4 -56.86 14.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.207 -0.933 . . . . 0.0 109.512 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.484 ' HB1' ' CG2' ' A' ' 55' ' ' ILE . . . -57.26 -54.41 47.08 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.164 -0.96 . . . . 0.0 109.536 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -55.64 -22.25 21.82 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.3 -0.875 . . . . 0.0 109.523 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.446 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.2 OUTLIER -74.84 -37.01 62.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.162 -0.961 . . . . 0.0 109.467 -179.982 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.3 t -73.12 -50.68 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.911 . . . . 0.0 109.377 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.476 ' HB2' ' CD1' ' A' ' 89' ' ' ILE . 14.9 mt -50.1 -50.69 47.51 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.333 -0.854 . . . . 0.0 109.396 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -65.2 -33.36 75.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.242 -0.911 . . . . 0.0 109.431 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -58.37 -35.26 71.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.507 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -82.36 -37.39 25.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.341 -0.849 . . . . 0.0 109.379 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.36 22.1 6.61 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.516 ' CD1' ' HB3' ' A' ' 62' ' ' ALA . 6.0 mt -88.46 160.18 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.222 -1.163 . . . . 0.0 109.495 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.515 ' N ' HG21 ' A' ' 87' ' ' ILE . 2.1 mttt -86.15 113.31 22.09 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.768 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.541 ' O ' ' CB ' ' A' ' 111' ' ' GLU . 43.5 mt -88.38 161.92 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.267 -0.895 . . . . 0.0 108.938 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.566 ' CZ ' ' HG2' ' A' ' 111' ' ' GLU . 2.6 m-85 -139.9 137.68 35.03 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.966 -1.084 . . . . 0.0 109.702 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 17.6 mmm180 -87.99 119.42 28.34 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.409 -0.807 . . . . 0.0 109.558 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -98.41 108.04 20.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.875 . . . . 0.0 109.387 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.414 ' CG2' ' N ' ' A' ' 94' ' ' GLY . 8.1 t -53.86 -47.19 71.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.414 ' N ' ' CG2' ' A' ' 93' ' ' THR . . . 125.31 83.47 0.53 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.466 ' O ' ' HG2' ' A' ' 15' ' ' GLU . 17.5 m -137.65 -92.8 0.22 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.236 -1.155 . . . . 0.0 109.459 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.443 ' CA ' HG22 ' A' ' 16' ' ' VAL . 0.2 OUTLIER -153.01 130.74 11.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.157 -0.965 . . . . 0.0 109.399 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.492 ' CG2' ' OG ' ' A' ' 14' ' ' SER . 22.2 m -52.05 -20.9 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 109.676 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -66.62 -57.97 6.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.238 -0.914 . . . . 0.0 109.522 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 32.3 mm-40 -66.0 -29.49 69.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.889 . . . . 0.0 109.524 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 96' ' ' SER . 33.2 m120 -60.9 -46.16 91.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.132 -0.98 . . . . 0.0 109.34 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.441 HD13 HD12 ' A' ' 36' ' ' ILE . 0.1 OUTLIER -58.51 -37.04 74.76 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.216 -0.927 . . . . 0.0 109.148 179.781 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.409 ' HE2' ' HB2' ' A' ' 102' ' ' LYS . 0.3 OUTLIER -73.9 -22.06 59.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.287 -0.883 . . . . 0.0 109.311 179.822 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -76.54 -38.06 55.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.247 179.82 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.574 ' CZ ' HG12 ' A' ' 3' ' ' ILE . 0.5 OUTLIER -70.39 -6.64 36.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.3 -0.875 . . . . 0.0 109.551 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 51.6 m -73.34 -39.09 65.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 0.0 109.682 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -94.19 -41.87 9.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.32 -0.862 . . . . 0.0 109.505 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 110.78 25.78 5.01 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.93 -21.6 43.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.278 -1.131 . . . . 0.0 109.374 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.561 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 2.8 mt -59.41 144.99 45.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.373 -0.829 . . . . 0.0 109.421 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.512 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 1.4 pt-20 -94.72 145.62 24.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.182 -0.949 . . . . 0.0 109.303 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.566 ' HG2' ' CZ ' ' A' ' 90' ' ' TYR . 0.4 OUTLIER -139.32 -178.58 5.43 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.161 -0.962 . . . . 0.0 109.816 -179.603 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.9 mp -138.34 134.26 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.406 -0.809 . . . . 0.0 109.294 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 -131.23 177.3 7.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.213 -0.929 . . . . 0.0 109.544 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 3.0 p -174.95 152.07 1.47 Allowed Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.246 -0.909 . . . . 0.0 109.242 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.81 -17.81 13.72 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 C-N-CA 122.556 2.17 . . . . 0.0 110.302 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.68 119.41 1.9 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 1.6 t -154.19 125.16 7.24 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -1.138 . . . . 0.0 109.523 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -163.26 83.91 0.11 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.64 135.95 41.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.305 -1.115 . . . . 0.0 109.297 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -167.22 121.84 1.0 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 6.6 mtt180 -127.09 -176.79 3.82 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.296 -1.12 . . . . 0.0 109.448 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.95 12.8 2.45 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.711 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.454 ' O ' ' HB3' ' A' ' 124' ' ' ARG . 0.6 OUTLIER -160.51 -171.53 3.18 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 109.606 179.992 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.454 ' HB3' ' O ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.49 0 CA-C-O 118.009 -0.995 . . . . 0.0 109.523 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.451 ' O ' ' HG3' ' A' ' 1' ' ' MET . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.495 ' CE ' ' OE1' ' A' ' 30' ' ' GLU . 17.2 mttp -102.71 146.67 27.87 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.259 -0.901 . . . . 0.0 109.366 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.591 ' CD1' ' CD1' ' A' ' 104' ' ' PHE . 6.8 mt -113.27 131.5 64.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.3 -0.875 . . . . 0.0 109.918 -179.692 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.451 ' HB2' HD13 ' A' ' 28' ' ' ILE . . . -125.74 146.56 49.7 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.415 -0.803 . . . . 0.0 108.855 179.518 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.449 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 1.6 mp -132.35 127.52 57.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 109.718 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -63.5 148.64 48.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.351 -0.843 . . . . 0.0 109.403 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.434 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -143.91 164.99 28.99 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.138 -0.976 . . . . 0.0 109.549 -179.95 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.96 -6.46 23.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.319 -0.863 . . . . 0.0 109.597 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.556 ' O ' ' CG ' ' A' ' 25' ' ' TYR . . . -148.15 -145.37 4.15 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.518 ' OG1' ' CE1' ' A' ' 25' ' ' TYR . 96.7 m -135.6 18.56 3.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.241 -1.152 . . . . 0.0 109.433 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -141.6 -174.47 4.06 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.222 -0.924 . . . . 0.0 109.529 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -66.61 -22.22 66.12 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.22 -0.925 . . . . 0.0 109.482 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.73 -50.44 57.84 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 15' ' ' GLU . 81.4 p -76.81 84.39 3.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.294 -1.121 . . . . 0.0 109.244 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.482 ' HG2' ' CB ' ' A' ' 96' ' ' SER . 18.6 mt-10 -46.89 -98.11 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.398 -0.814 . . . . 0.0 109.859 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.432 HG11 ' HB3' ' A' ' 92' ' ' ALA . 4.2 t -123.06 33.76 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.939 -1.101 . . . . 0.0 109.782 -179.709 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.401 ' C ' ' O ' ' A' ' 16' ' ' VAL . 7.2 p 43.93 -162.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.883 . . . . 0.0 109.533 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.546 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -140.34 11.91 2.35 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.338 -0.851 . . . . 0.0 109.388 179.908 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.546 ' CD1' ' O ' ' A' ' 18' ' ' ARG . 32.6 m-85 -142.64 -165.3 2.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.52 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -133.88 -61.81 0.79 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.316 -0.865 . . . . 0.0 109.355 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -79.81 2.28 74.83 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.444 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.1 OUTLIER -103.91 -64.51 1.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.183 -1.187 . . . . 0.0 109.489 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.434 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -44.24 104.58 0.39 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.287 -0.883 . . . . 0.0 109.404 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.515 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.6 Cg_endo -79.94 61.49 8.21 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.656 2.237 . . . . 0.0 110.927 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.556 ' CG ' ' O ' ' A' ' 9' ' ' GLY . 51.1 m-85 -160.54 70.45 0.41 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.04 -1.037 . . . . 0.0 109.325 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 48.5 m-85 -79.85 109.22 14.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.206 -0.934 . . . . 0.0 109.321 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' MET . . . . . 0.452 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 0.0 OUTLIER -79.6 141.37 36.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.332 -0.855 . . . . 0.0 109.742 -179.65 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.451 HD13 ' HB2' ' A' ' 4' ' ' ALA . 7.8 mm -125.04 139.32 51.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.32 -0.863 . . . . 0.0 109.235 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.455 HG11 ' O ' ' A' ' 38' ' ' SER . 10.6 t -140.63 144.64 26.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -0.892 . . . . 0.0 109.499 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.495 ' OE1' ' CE ' ' A' ' 2' ' ' LYS . 6.2 mt-10 -125.33 107.95 11.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.237 -0.914 . . . . 0.0 109.545 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.1 mtt -81.56 149.82 28.47 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.204 -0.935 . . . . 0.0 109.382 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.04 -51.79 2.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.184 -0.948 . . . . 0.0 109.587 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.02 53.25 0.57 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.498 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.4 21.83 55.61 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.403 ' O ' ' C ' ' A' ' 36' ' ' ILE . 1.6 t30 -148.13 95.43 2.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.254 -1.145 . . . . 0.0 109.477 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.43 ' O ' HG13 ' A' ' 36' ' ' ILE . 9.5 pt -45.47 114.16 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.168 -0.957 . . . . 0.0 109.295 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -113.68 9.4 17.78 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -0.933 . . . . 0.0 109.411 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.455 ' O ' HG11 ' A' ' 29' ' ' VAL . 53.5 p -163.46 113.4 1.32 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 109.36 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -135.03 104.6 6.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.288 -0.883 . . . . 0.0 109.493 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.96 -174.58 2.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.309 -0.869 . . . . 0.0 109.245 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.452 ' HA ' ' HA ' ' A' ' 27' ' ' MET . 14.8 p -131.93 166.65 28.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.074 -1.016 . . . . 0.0 109.648 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.446 ' CG1' ' CG1' ' A' ' 28' ' ' ILE . 7.4 mm -129.97 99.37 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.35 -0.844 . . . . 0.0 109.501 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.526 ' HG3' ' CE1' ' A' ' 25' ' ' TYR . 31.8 tt0 -77.88 126.3 30.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.275 -0.891 . . . . 0.0 109.299 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -126.84 80.38 70.97 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.214 -0.929 . . . . 0.0 109.647 -179.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -77.99 88.07 1.46 Allowed 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.684 2.256 . . . . 0.0 110.353 179.759 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.3 p -176.75 -55.54 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.159 -0.963 . . . . 0.0 109.514 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.86 -37.6 31.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.177 -0.952 . . . . 0.0 109.373 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.68 47.91 1.12 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.256 -0.902 . . . . 0.0 109.354 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -147.7 -46.77 0.17 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.308 -0.87 . . . . 0.0 109.513 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -135.73 24.81 3.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.2 -0.937 . . . . 0.0 109.478 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.79 29.16 57.85 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -58.08 -172.42 0.32 Allowed Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -97.92 116.75 30.77 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.251 -1.147 . . . . 0.0 109.481 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.51 ' O ' ' CG2' ' A' ' 57' ' ' THR . . . -111.66 -39.27 1.34 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.6 mm -76.76 -28.87 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -1.142 . . . . 0.0 109.499 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 8.0 mmm180 -76.69 -34.11 58.2 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.183 -0.948 . . . . 0.0 109.594 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.51 ' CG2' ' O ' ' A' ' 54' ' ' GLY . 14.8 t -49.11 -23.63 1.31 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.737 -179.832 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -45.25 -47.25 12.82 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.272 -0.892 . . . . 0.0 109.9 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -53.83 -48.43 69.93 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.195 -0.941 . . . . 0.0 109.92 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 80.2 mt -60.91 -36.73 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.213 -0.929 . . . . 0.0 110.115 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 32.7 mt -62.94 -40.95 90.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 109.947 -179.582 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.38 -28.73 64.24 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.149 -0.969 . . . . 0.0 109.791 -179.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -77.32 4.39 10.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -0.929 . . . . 0.0 109.947 -179.796 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -106.6 2.54 26.1 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.018 -1.051 . . . . 0.0 109.661 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.03 -11.21 62.2 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.422 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 81.8 t -62.61 88.27 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -1.146 . . . . 0.0 109.61 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.66 -2.74 44.12 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.291 -0.88 . . . . 0.0 108.986 179.467 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.414 ' HB2' ' CZ ' ' A' ' 104' ' ' PHE . . . -127.8 127.54 43.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.34 -0.85 . . . . 0.0 109.172 179.849 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.44 HG21 HD23 ' A' ' 82' ' ' LEU . 74.8 t -125.57 112.43 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.17 -0.956 . . . . 0.0 109.78 -179.667 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.449 ' HB ' ' HA ' ' A' ' 5' ' ' ILE . 3.5 mt -99.33 124.31 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.192 -0.942 . . . . 0.0 109.129 179.549 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -158.52 172.81 17.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.175 -0.953 . . . . 0.0 109.766 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.15 49.18 2.31 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.367 -0.833 . . . . 0.0 109.514 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.86 160.11 22.38 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.201 -0.937 . . . . 0.0 109.407 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.85 -89.9 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.557 2.172 . . . . 0.0 110.296 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.6 162.96 36.91 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . 0.471 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.7 Cg_endo -80.29 27.74 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.825 2.35 . . . . 0.0 111.17 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -76.7 -59.84 2.6 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.879 -1.138 . . . . 0.0 109.423 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.412 ' O ' ' HB ' ' A' ' 81' ' ' VAL . . . -55.61 -43.51 76.15 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.266 -0.896 . . . . 0.0 109.389 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.507 ' CA ' HD13 ' A' ' 89' ' ' ILE . 3.8 m-30 -60.2 -49.17 78.7 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.264 -0.898 . . . . 0.0 109.498 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.471 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.3 OUTLIER -61.36 -21.03 63.67 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 109.331 179.798 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.412 ' HB ' ' O ' ' A' ' 78' ' ' ALA . 95.5 t -73.28 -63.12 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.217 -0.927 . . . . 0.0 109.373 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.44 HD23 HG21 ' A' ' 69' ' ' VAL . 1.5 mt -57.74 -27.09 62.7 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.179 -0.951 . . . . 0.0 109.302 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -62.06 -51.32 68.44 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.322 -0.861 . . . . 0.0 109.332 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -77.01 -12.28 59.92 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.262 -0.899 . . . . 0.0 109.362 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.43 ' HB2' ' HA ' ' A' ' 82' ' ' LEU . 55.5 mt -77.49 -23.63 50.28 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.921 . . . . 0.0 109.365 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 100.86 41.42 2.67 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.3 mp -137.7 161.87 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -1.156 . . . . 0.0 109.512 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 4.6 mmtm -92.56 131.5 37.63 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -0.901 . . . . 0.0 109.627 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.507 HD13 ' CA ' ' A' ' 79' ' ' PHE . 50.9 mt -92.29 157.35 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.251 -0.906 . . . . 0.0 109.51 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.511 ' CE2' ' CE2' ' A' ' 104' ' ' PHE . 0.3 OUTLIER -142.33 143.12 32.61 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.336 -0.852 . . . . 0.0 109.44 -179.898 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.455 ' O ' ' CD2' ' A' ' 109' ' ' LEU . 12.4 mmt180 -100.15 125.28 46.25 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 109.428 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . 0.432 ' HB3' HG11 ' A' ' 16' ' ' VAL . . . -82.97 113.84 20.83 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.217 -0.927 . . . . 0.0 109.473 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 3.8 m -144.98 13.03 1.45 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.233 -0.917 . . . . 0.0 109.518 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.02 -121.68 0.31 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.436 HG23 ' OG ' ' A' ' 96' ' ' SER . 17.3 m -129.59 -54.5 1.16 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.356 -1.085 . . . . 0.0 109.385 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.482 ' CB ' ' HG2' ' A' ' 15' ' ' GLU . 0.8 OUTLIER -139.19 143.53 38.13 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.275 -0.891 . . . . 0.0 109.367 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.448 HG12 ' O ' ' A' ' 15' ' ' GLU . 15.0 m -44.1 -26.72 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.295 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . 0.407 ' N ' ' O ' ' A' ' 96' ' ' SER . 3.3 tp10 -64.27 -51.76 61.96 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.264 -0.897 . . . . 0.0 109.246 179.702 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.434 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 3.0 tp10 -64.15 -37.46 87.52 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.297 -0.877 . . . . 0.0 109.068 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -63.89 -30.73 71.79 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.331 -0.856 . . . . 0.0 109.218 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 6.4 tp -55.98 -55.85 27.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.363 -0.835 . . . . 0.0 109.219 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 44.4 mttt -76.82 -13.94 59.96 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.25 179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.44 HD23 HD13 ' A' ' 109' ' ' LEU . 6.1 tp -77.16 -23.39 51.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.909 . . . . 0.0 109.579 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.591 ' CD1' ' CD1' ' A' ' 3' ' ' ILE . 32.2 t80 -75.58 -23.75 56.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.234 -0.916 . . . . 0.0 109.106 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.6 m -74.57 -34.05 62.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.319 -0.863 . . . . 0.0 109.259 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -90.73 -0.28 57.65 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.287 -0.883 . . . . 0.0 109.487 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.73 37.87 62.7 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -82.74 -23.1 34.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.217 -1.167 . . . . 0.0 109.473 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.455 ' CD2' ' O ' ' A' ' 91' ' ' ARG . 0.8 OUTLIER -83.69 162.03 20.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.235 -0.916 . . . . 0.0 109.289 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -87.63 146.95 25.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.184 -0.947 . . . . 0.0 109.91 -179.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.507 ' HB3' ' CE2' ' A' ' 90' ' ' TYR . 9.2 pt-20 -135.79 179.8 6.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.43 -0.794 . . . . 0.0 109.077 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.8 mt -149.84 127.13 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.708 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.414 ' N ' ' CD ' ' A' ' 113' ' ' ARG . 0.0 OUTLIER -118.99 -69.87 0.82 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.37 -0.831 . . . . 0.0 109.356 179.854 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 46.6 t -166.47 69.69 1.1 Allowed Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.25 -0.906 . . . . 0.0 109.379 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -79.13 9.47 3.34 Favored 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.656 2.238 . . . . 0.0 110.785 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 164.19 158.33 10.07 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 2.4 t -49.73 -61.77 1.94 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -1.124 . . . . 0.0 109.459 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 119' ' ' ARG . . . 132.24 -118.14 2.19 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.414 ' C ' ' O ' ' A' ' 118' ' ' GLY . 0.3 OUTLIER -44.24 145.88 0.73 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.33 -1.1 . . . . 0.0 109.591 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -152.85 -163.37 11.63 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.36 117.63 21.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.203 -1.175 . . . . 0.0 109.44 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -162.79 -163.29 0.86 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.289 -0.882 . . . . 0.0 109.457 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.65 138.98 38.32 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.198 -0.938 . . . . 0.0 109.529 -179.816 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.44 179.947 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.463 ' O ' ' HB2' ' A' ' 68' ' ' ALA . 36.7 mttt -147.01 126.73 13.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.269 -0.895 . . . . 0.0 109.221 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.489 ' HA ' ' CB ' ' A' ' 68' ' ' ALA . 4.3 mt -111.16 116.44 52.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.248 -0.908 . . . . 0.0 109.832 -179.582 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.486 ' CB ' ' O ' ' A' ' 27' ' ' MET . . . -108.28 146.57 32.7 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.248 -0.908 . . . . 0.0 109.394 179.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.447 HD11 ' HB ' ' A' ' 70' ' ' ILE . 5.4 mm -114.73 121.12 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.206 -0.934 . . . . 0.0 109.53 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.486 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -47.63 144.79 3.0 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.192 -0.943 . . . . 0.0 109.362 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 25' ' ' TYR . 11.3 t 49.99 -93.19 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.234 -0.916 . . . . 0.0 109.458 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.486 ' N ' ' O ' ' A' ' 6' ' ' ALA . 0.5 OUTLIER 66.81 8.68 6.18 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.169 -0.957 . . . . 0.0 109.518 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.517 ' N ' ' HB2' ' A' ' 14' ' ' SER . . . 44.06 -128.13 6.53 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.07 -13.59 11.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.304 -1.115 . . . . 0.0 109.546 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -171.32 -70.61 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.195 -0.941 . . . . 0.0 109.921 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 13' ' ' GLY . 0.3 OUTLIER -122.37 -22.54 5.48 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 0.0 110.022 -179.619 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 12' ' ' LEU . . . -42.19 -42.34 4.18 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.517 ' HB2' ' N ' ' A' ' 9' ' ' GLY . 27.3 t -77.87 85.28 4.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.272 -1.134 . . . . 0.0 109.674 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.457 ' C ' ' CG2' ' A' ' 16' ' ' VAL . 1.7 mt-10 -67.96 85.32 0.23 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.413 -0.805 . . . . 0.0 109.214 179.802 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.457 ' CG2' ' C ' ' A' ' 15' ' ' GLU . 1.5 t 70.58 30.98 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.451 -0.781 . . . . 0.0 109.265 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.466 ' HA ' ' OG ' ' A' ' 14' ' ' SER . 4.3 p 62.45 -160.99 0.3 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.339 -0.851 . . . . 0.0 109.543 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.0 ttm180 -154.8 -46.43 0.09 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.399 -0.813 . . . . 0.0 109.053 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -145.72 147.8 32.32 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.369 -0.832 . . . . 0.0 109.095 179.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.456 ' CG ' ' HB1' ' A' ' 71' ' ' ALA . 85.1 t80 -118.32 138.19 52.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.161 -0.962 . . . . 0.0 109.578 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.472 ' O ' ' CA ' ' A' ' 54' ' ' GLY . . . 139.84 -59.12 0.59 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.484 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.1 OUTLIER -116.98 13.45 14.87 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.2 -1.177 . . . . 0.0 109.774 -179.753 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.96 109.53 1.71 Allowed Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.233 -0.917 . . . . 0.0 109.884 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.9 Cg_endo -81.17 41.37 1.13 Allowed 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.548 2.165 . . . . 0.0 110.485 179.699 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.418 ' O ' ' O ' ' A' ' 7' ' ' SER . 0.4 OUTLIER -158.74 69.82 0.49 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.09 -1.006 . . . . 0.0 109.314 -179.911 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.507 ' CZ ' HD11 ' A' ' 61' ' ' ILE . 0.3 OUTLIER -82.27 112.69 19.5 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.62 -179.854 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' MET . . . . . 0.512 ' HG3' ' CG1' ' A' ' 41' ' ' VAL . 0.0 OUTLIER -85.15 144.69 28.03 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.877 . . . . 0.0 109.308 -179.996 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.442 HG12 ' HB1' ' A' ' 4' ' ' ALA . 39.4 mt -139.76 126.18 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.228 -0.92 . . . . 0.0 109.518 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.451 HG12 ' O ' ' A' ' 38' ' ' SER . 34.8 t -124.09 128.67 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.35 -0.844 . . . . 0.0 109.471 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -98.88 167.22 10.89 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.368 -0.833 . . . . 0.0 109.237 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.437 ' CE ' ' CG2' ' A' ' 36' ' ' ILE . 29.9 mtt -133.19 138.91 46.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.932 . . . . 0.0 109.448 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 6.7 ttmm -98.93 -48.06 5.04 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -0.913 . . . . 0.0 109.464 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 15.8 mtmm -148.81 66.59 1.05 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.341 -0.849 . . . . 0.0 109.218 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.77 12.59 42.46 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.419 ' O ' ' C ' ' A' ' 36' ' ' ILE . 8.2 t-20 -130.83 94.36 3.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -1.17 . . . . 0.0 109.462 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.46 ' O ' HG13 ' A' ' 36' ' ' ILE . 26.3 pt -43.64 126.07 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.702 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -137.06 16.53 3.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.344 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.451 ' O ' HG12 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -154.94 117.12 4.2 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 0.0 109.14 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 80.9 p -143.77 112.45 6.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.532 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -124.91 171.95 9.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.893 . . . . 0.0 109.373 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.512 ' CG1' ' HG3' ' A' ' 27' ' ' MET . 20.8 m -131.73 115.87 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.274 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.2 tp -105.06 152.6 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.245 -0.909 . . . . 0.0 109.413 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -105.1 145.12 30.96 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.223 -0.923 . . . . 0.0 109.399 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . 0.423 ' HB2' ' HA ' ' A' ' 24' ' ' PRO . 4.7 m-20 -56.68 151.45 31.03 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.278 -0.889 . . . . 0.0 109.558 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -78.22 -59.12 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.622 2.215 . . . . 0.0 110.081 179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.1 m -132.61 72.21 1.49 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.363 -0.836 . . . . 0.0 109.111 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.21 -19.79 63.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.342 -0.848 . . . . 0.0 109.811 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 m -138.32 -85.08 0.28 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.088 -1.007 . . . . 0.0 109.693 -179.845 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 53.39 -166.59 0.07 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -0.909 . . . . 0.0 109.337 -179.72 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.92 111.45 18.8 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.222 -0.924 . . . . 0.0 109.443 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 149.09 -58.61 0.46 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.27 115.15 1.67 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -162.85 -165.02 1.05 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -1.141 . . . . 0.0 109.535 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.472 ' CA ' ' O ' ' A' ' 21' ' ' GLY . . . 165.46 -54.95 0.26 Allowed Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 42.9 mm -68.55 -11.55 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.157 -1.202 . . . . 0.0 109.376 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.5 ttt180 -76.36 -16.32 59.77 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.327 -0.858 . . . . 0.0 109.6 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.418 ' HA ' HD12 ' A' ' 60' ' ' ILE . 10.6 t -63.34 -25.94 68.53 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.253 -0.904 . . . . 0.0 109.252 179.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . 0.461 ' O ' HG13 ' A' ' 61' ' ' ILE . . . -54.36 -36.17 63.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 109.588 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -74.01 -32.55 63.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.141 -0.974 . . . . 0.0 109.425 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.418 HD12 ' HA ' ' A' ' 57' ' ' THR . 81.9 mt -65.96 -40.7 88.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.267 -0.896 . . . . 0.0 109.541 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.507 HD11 ' CZ ' ' A' ' 26' ' ' PHE . 8.6 pt -76.69 -29.23 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.576 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -62.57 -39.26 93.1 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.187 -0.946 . . . . 0.0 109.711 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -68.98 -12.68 61.89 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.237 -0.914 . . . . 0.0 109.831 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -89.15 -7.84 54.88 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.182 -0.949 . . . . 0.0 109.542 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.522 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 100.8 -12.04 59.26 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.452 HG13 ' O ' ' A' ' 68' ' ' ALA . 16.4 t -51.81 89.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.375 -1.073 . . . . 0.0 109.489 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.522 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -80.91 -5.66 57.7 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.307 -0.871 . . . . 0.0 109.099 179.568 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.489 ' CB ' ' HA ' ' A' ' 3' ' ' ILE . . . -125.2 134.84 52.21 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.211 -0.931 . . . . 0.0 109.523 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.46 HG21 HD12 ' A' ' 61' ' ' ILE . 86.4 t -137.27 111.93 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.162 -0.961 . . . . 0.0 109.919 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.492 ' N ' ' CD1' ' A' ' 70' ' ' ILE . 1.7 mp -94.88 106.11 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.313 -0.867 . . . . 0.0 108.979 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.456 ' HB1' ' CG ' ' A' ' 20' ' ' PHE . . . -135.78 173.57 11.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.129 -0.982 . . . . 0.0 109.86 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.26 40.54 2.46 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.428 -0.795 . . . . 0.0 109.44 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 1.4 t -45.98 146.67 1.98 Allowed Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.207 -0.933 . . . . 0.0 109.41 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -77.98 -17.92 13.36 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.642 2.228 . . . . 0.0 110.492 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -127.02 164.76 20.48 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.87 4.65 5.92 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.626 2.217 . . . . 0.0 110.431 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.463 ' O ' ' HB3' ' A' ' 80' ' ' GLU . 2.9 t-20 -62.3 -43.16 99.47 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.314 -0.866 . . . . 0.0 109.545 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -64.13 -57.71 8.78 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.283 -0.886 . . . . 0.0 109.53 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . 0.564 ' CE2' ' OE1' ' A' ' 111' ' ' GLU . 9.2 m-85 -58.21 -21.42 47.81 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.58 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.463 ' HB3' ' O ' ' A' ' 77' ' ' ASN . 29.7 tt0 -62.17 -59.6 4.81 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.197 -0.939 . . . . 0.0 109.393 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.4 t -61.22 -44.88 99.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.235 -0.916 . . . . 0.0 109.203 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.464 HD22 ' CD1' ' A' ' 87' ' ' ILE . 14.3 mt -50.35 -37.94 39.63 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.248 -0.907 . . . . 0.0 109.307 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -64.31 -42.87 96.13 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.344 -0.848 . . . . 0.0 109.363 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -69.98 -15.69 63.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.328 -0.858 . . . . 0.0 109.338 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.443 ' HB3' HG13 ' A' ' 87' ' ' ILE . 17.9 mt -95.6 -8.1 35.9 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.181 -0.95 . . . . 0.0 109.517 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 63.03 32.83 85.46 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.464 ' CD1' HD22 ' A' ' 82' ' ' LEU . 13.1 mt -96.22 171.4 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.234 -1.157 . . . . 0.0 109.511 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 8.0 mttt -91.86 117.08 29.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.646 -179.767 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.55 ' CG2' ' CD1' ' A' ' 79' ' ' PHE . 10.5 mt -94.29 128.18 45.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.346 -0.846 . . . . 0.0 109.388 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.551 ' CE2' ' O ' ' A' ' 109' ' ' LEU . 2.2 m-85 -123.21 144.01 49.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.278 -0.889 . . . . 0.0 109.334 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . 0.5 ' HG2' ' CG ' ' A' ' 111' ' ' GLU . 0.0 OUTLIER -91.21 132.05 36.35 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.158 -0.964 . . . . 0.0 109.653 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.02 94.3 9.57 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.239 -0.913 . . . . 0.0 109.409 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -135.46 23.14 3.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.125 -0.984 . . . . 0.0 109.624 -179.808 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -86.69 -134.26 3.84 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.669 -1.373 . . . . 0.0 109.669 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.441 ' C ' HG23 ' A' ' 16' ' ' VAL . 5.2 t -136.14 -38.35 0.7 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.267 -1.137 . . . . 0.0 109.447 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 29.0 t -125.77 137.08 53.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.314 -0.866 . . . . 0.0 109.502 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.454 HG13 ' HA ' ' A' ' 8' ' ' SER . 0.3 OUTLIER -55.03 -35.59 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -0.858 . . . . 0.0 109.406 179.916 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -69.2 -51.83 33.95 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.233 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.49 ' O ' ' CD1' ' A' ' 103' ' ' LEU . 3.2 tt0 -52.18 -31.67 32.71 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.244 -0.91 . . . . 0.0 109.166 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -72.39 -49.73 31.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.342 -0.848 . . . . 0.0 109.152 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.452 HD21 HG21 ' A' ' 36' ' ' ILE . 27.1 tp -50.4 -51.31 47.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.284 -0.885 . . . . 0.0 109.513 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -65.77 -35.4 80.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.205 -0.935 . . . . 0.0 109.492 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.49 ' CD1' ' O ' ' A' ' 99' ' ' GLU . 0.7 OUTLIER -71.71 -11.17 60.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.269 -0.895 . . . . 0.0 109.537 179.947 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.504 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.8 t80 -76.93 -38.3 53.68 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.263 -0.898 . . . . 0.0 109.453 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 28.8 m -72.09 -13.78 61.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.464 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -96.45 -17.23 20.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.182 -0.949 . . . . 0.0 109.49 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 74.43 29.45 61.89 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . 0.458 ' HB3' HD22 ' A' ' 103' ' ' LEU . 0.4 OUTLIER -79.96 -44.11 20.86 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.297 -1.119 . . . . 0.0 109.693 -179.882 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.551 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.4 OUTLIER -123.28 146.62 47.73 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.235 -0.916 . . . . 0.0 109.463 -179.949 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.519 ' HA ' ' CG ' ' A' ' 90' ' ' TYR . 1.1 pm0 -171.66 -156.79 0.11 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.904 . . . . 0.0 109.458 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.564 ' OE1' ' CE2' ' A' ' 79' ' ' PHE . 0.0 OUTLIER -146.29 -87.19 0.1 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.27 -0.894 . . . . 0.0 109.678 179.951 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.443 HG23 ' N ' ' A' ' 113' ' ' ARG . 7.0 mt -131.37 151.37 35.51 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.192 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.443 ' N ' HG23 ' A' ' 112' ' ' ILE . 0.0 OUTLIER -120.89 -62.02 1.49 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.34 -0.85 . . . . 0.0 109.382 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.476 ' N ' ' HD3' ' A' ' 115' ' ' PRO . 94.9 p -179.8 63.96 0.13 Allowed Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.203 -0.936 . . . . 0.0 109.573 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . 0.476 ' HD3' ' N ' ' A' ' 114' ' ' SER . 35.6 Cg_endo -78.2 177.56 8.62 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.65 2.234 . . . . 0.0 110.319 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . 0.442 ' O ' ' N ' ' A' ' 118' ' ' GLY . . . 72.99 56.25 5.9 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 116' ' ' GLY . 0.4 OUTLIER -43.96 99.73 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.308 -1.113 . . . . 0.0 109.37 -179.967 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 116' ' ' GLY . . . -102.34 72.86 0.32 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.01 -45.97 0.2 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.242 -1.152 . . . . 0.0 109.672 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 98.27 116.0 3.56 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.73 -70.4 0.79 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.26 -1.141 . . . . 0.0 109.505 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.8 1.56 9.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.548 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . 0.505 ' NH1' ' HG3' ' A' ' 123' ' ' ARG . 0.4 OUTLIER -95.85 81.58 3.46 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.589 -179.895 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.487 0 CA-C-O 118.072 -0.966 . . . . 0.0 109.393 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.423 ' O ' ' HG2' ' A' ' 1' ' ' MET . 5.1 ttt . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.445 ' O ' ' HB2' ' A' ' 68' ' ' ALA . 0.1 OUTLIER -131.18 156.05 45.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.218 -0.926 . . . . 0.0 109.521 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.526 HD13 ' CD1' ' A' ' 104' ' ' PHE . 7.0 mt -116.01 107.47 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.552 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.578 ' HB3' ' CZ ' ' A' ' 26' ' ' PHE . . . -97.18 170.85 8.83 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.326 -0.859 . . . . 0.0 109.13 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.411 HG13 ' C ' ' A' ' 4' ' ' ALA . 98.1 mt -148.13 119.93 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.172 -0.955 . . . . 0.0 109.889 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.525 ' HB3' ' CD1' ' A' ' 20' ' ' PHE . . . -87.14 143.95 27.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 108.949 179.565 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.434 ' OG ' ' O ' ' A' ' 19' ' ' PHE . 1.2 m 61.77 81.74 0.19 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.055 -1.028 . . . . 0.0 109.129 -179.723 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.499 ' O ' ' CB ' ' A' ' 14' ' ' SER . 0.0 OUTLIER -136.32 -37.63 0.7 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.308 -179.788 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.49 -171.95 27.05 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.05 9.99 15.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.175 -1.191 . . . . 0.0 109.454 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 47.5 p-10 -170.25 -174.14 1.65 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.483 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.523 ' CB ' ' HB2' ' A' ' 98' ' ' GLU . 0.7 OUTLIER -75.66 -20.97 58.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.21 -0.932 . . . . 0.0 109.456 179.941 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.486 ' N ' ' HG ' ' A' ' 12' ' ' LEU . . . -46.38 -45.5 16.45 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.499 ' CB ' ' O ' ' A' ' 8' ' ' SER . 0.6 OUTLIER -76.15 81.43 2.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.278 -1.131 . . . . 0.0 109.429 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLU . . . . . 0.534 ' O ' ' CB ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER -73.27 83.06 1.38 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.339 -0.851 . . . . 0.0 109.359 179.874 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.534 ' CB ' ' O ' ' A' ' 15' ' ' GLU . 2.6 t 78.01 77.56 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.485 -0.759 . . . . 0.0 109.478 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 16' ' ' VAL . 0.1 OUTLIER -43.59 -73.92 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -0.914 . . . . 0.0 109.594 -179.93 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -140.33 -82.06 0.25 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.23 -0.919 . . . . 0.0 109.542 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.434 ' O ' ' OG ' ' A' ' 7' ' ' SER . 24.2 m-85 -146.29 -144.71 0.16 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.29 -0.882 . . . . 0.0 109.332 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.525 ' CD1' ' HB3' ' A' ' 6' ' ' ALA . 16.6 t80 -121.5 27.5 8.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.172 -0.955 . . . . 0.0 109.497 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -83.07 -74.7 1.2 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.447 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.5 OUTLIER -123.0 27.98 7.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.277 -1.131 . . . . 0.0 109.349 179.929 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -50.91 108.46 1.05 Allowed Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.371 -0.83 . . . . 0.0 109.34 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.447 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.3 Cg_endo -79.57 39.27 0.81 Allowed 'Trans proline' 0 C--N 1.311 -1.425 0 C-N-CA 122.566 2.178 . . . . 0.0 111.077 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.537 ' CD1' ' HG2' ' A' ' 43' ' ' GLU . 48.1 m-85 -155.55 67.16 0.63 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.98 -1.075 . . . . 0.0 109.065 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . 0.578 ' CZ ' ' HB3' ' A' ' 4' ' ' ALA . 9.2 t80 -81.88 120.25 24.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.436 -0.79 . . . . 0.0 109.592 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 4.5 ttm -103.45 159.99 15.1 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.277 -0.889 . . . . 0.0 109.558 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.528 ' CD1' HG22 ' A' ' 66' ' ' VAL . 1.1 tp -148.53 133.01 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.268 -0.895 . . . . 0.0 109.54 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.402 HG11 ' O ' ' A' ' 38' ' ' SER . 39.5 t -143.11 124.83 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.592 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -99.09 171.4 8.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.235 -0.916 . . . . 0.0 109.317 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' MET . . . . . 0.453 ' HE1' HG23 ' A' ' 36' ' ' ILE . 13.6 ttm -139.66 138.93 36.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -0.893 . . . . 0.0 109.583 179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.74 -47.82 6.02 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.21 -0.931 . . . . 0.0 109.522 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 13.1 mttp -153.27 41.09 0.55 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.235 -0.916 . . . . 0.0 109.463 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.99 -8.53 55.92 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.464 ' O ' ' HG2' ' A' ' 37' ' ' GLU . 6.9 m-20 -117.02 97.18 5.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -1.157 . . . . 0.0 109.356 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.469 ' O ' HG13 ' A' ' 36' ' ' ILE . 5.6 pt -47.25 113.02 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.412 -0.805 . . . . 0.0 109.586 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.464 ' HG2' ' O ' ' A' ' 35' ' ' ASN . 14.9 mm-40 -109.72 19.26 19.36 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -0.917 . . . . 0.0 109.664 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.402 ' O ' HG11 ' A' ' 29' ' ' VAL . 2.1 p -163.53 120.78 1.82 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 109.319 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 5.7 p -149.28 107.53 3.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.539 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -117.3 156.27 28.09 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.171 -0.955 . . . . 0.0 109.516 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.425 ' C ' HG21 ' A' ' 42' ' ' ILE . 2.2 p -126.19 138.71 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.257 -0.902 . . . . 0.0 109.402 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.425 HG21 ' C ' ' A' ' 41' ' ' VAL . 40.8 pt -135.71 146.43 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.351 -0.843 . . . . 0.0 109.614 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.537 ' HG2' ' CD1' ' A' ' 25' ' ' TYR . 42.0 mt-10 -98.25 55.61 1.14 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.231 -0.918 . . . . 0.0 109.13 179.7 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 49.77 89.08 0.1 OUTLIER Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.323 -0.86 . . . . 0.0 109.372 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -77.65 -8.47 17.02 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.643 2.228 . . . . 0.0 110.366 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.45 41.09 1.04 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.313 -0.867 . . . . 0.0 109.377 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.03 -38.5 51.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.199 -0.938 . . . . 0.0 109.546 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 28.9 t -113.17 84.81 2.06 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.239 -0.913 . . . . 0.0 109.571 -179.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -145.76 158.39 43.86 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.272 -0.892 . . . . 0.0 109.485 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -58.07 175.03 0.23 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.234 -0.916 . . . . 0.0 109.488 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 48.38 37.53 18.7 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.21 140.08 5.26 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -150.8 32.23 0.62 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.27 -1.135 . . . . 0.0 109.488 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 93.97 -91.51 1.47 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . 0.433 HG23 ' N ' ' A' ' 78' ' ' ALA . 34.6 mm -65.35 -33.24 62.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.319 -1.106 . . . . 0.0 109.648 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.74 -14.77 62.11 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.208 -0.932 . . . . 0.0 109.717 -179.826 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 85.7 m -67.53 -18.02 64.88 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.114 -0.991 . . . . 0.0 109.744 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -60.28 -28.16 67.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.235 -0.916 . . . . 0.0 109.654 -179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -62.67 -49.75 73.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.295 -0.878 . . . . 0.0 109.687 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.7 mt -64.04 -45.67 96.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.892 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.49 HG21 ' CZ ' ' A' ' 26' ' ' PHE . 41.6 mt -52.2 -48.0 43.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.237 -0.914 . . . . 0.0 109.957 -179.676 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.74 -37.45 84.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.171 -0.955 . . . . 0.0 109.998 -179.524 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -66.25 -11.1 48.15 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.097 -1.002 . . . . 0.0 109.851 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -88.99 16.75 6.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.117 -0.989 . . . . 0.0 109.556 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.453 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 95.31 -20.75 47.89 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . 0.528 HG22 ' CD1' ' A' ' 28' ' ' ILE . 97.1 t -57.06 88.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.312 -1.111 . . . . 0.0 109.506 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.453 ' N ' ' O ' ' A' ' 65' ' ' GLY . 14.0 mttt -79.91 -8.45 59.33 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.329 -0.857 . . . . 0.0 108.777 179.331 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.475 ' O ' HG21 ' A' ' 69' ' ' VAL . . . -128.05 138.61 52.64 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' VAL . . . . . 0.475 HG21 ' O ' ' A' ' 68' ' ' ALA . 95.3 t -141.37 122.08 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.112 -0.993 . . . . 0.0 109.821 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.572 ' N ' ' CD1' ' A' ' 70' ' ' ILE . 1.3 mp -93.43 144.5 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.345 -0.847 . . . . 0.0 108.804 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -176.81 175.94 1.56 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.127 -0.983 . . . . 0.0 109.755 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -153.04 66.51 0.79 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.412 -0.805 . . . . 0.0 109.347 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -73.02 158.92 86.43 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.238 -0.914 . . . . 0.0 109.568 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.55 -39.2 0.42 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.658 2.239 . . . . 0.0 110.764 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -121.22 178.45 16.38 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -179.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.28 40.67 1.0 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.853 2.369 . . . . 0.0 110.753 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 52.5 m-20 -76.1 -67.54 0.67 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.085 -1.01 . . . . 0.0 109.314 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ALA . . . . . 0.433 ' N ' HG23 ' A' ' 55' ' ' ILE . . . -74.66 -25.91 59.51 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.32 179.733 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -66.23 -21.11 66.29 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.373 -0.829 . . . . 0.0 109.398 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.412 ' O ' ' HB2' ' A' ' 84' ' ' GLU . 11.8 mt-10 -77.4 -46.84 21.44 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.233 -0.917 . . . . 0.0 109.833 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.4 t -68.65 -36.13 73.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.132 -0.98 . . . . 0.0 109.824 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . 0.474 ' HB3' ' CG1' ' A' ' 89' ' ' ILE . 8.7 mt -73.75 -57.61 3.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.268 -0.895 . . . . 0.0 109.707 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 8.2 t-20 -49.53 -37.78 28.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.212 -0.93 . . . . 0.0 109.6 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.412 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 0.3 OUTLIER -73.02 -39.34 66.08 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.217 -0.927 . . . . 0.0 109.403 -179.947 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' LEU . . . . . 0.404 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.3 OUTLIER -64.54 -13.12 51.06 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.134 -0.979 . . . . 0.0 109.475 -179.943 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 75.13 26.57 66.05 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . 0.406 ' CG2' ' N ' ' A' ' 88' ' ' LYS . 23.1 mm -91.91 160.85 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.345 -1.091 . . . . 0.0 109.423 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' LYS . . . . . 0.406 ' N ' ' CG2' ' A' ' 87' ' ' ILE . 7.8 mtpt -83.01 105.14 13.76 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.169 -0.957 . . . . 0.0 109.309 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ILE . . . . . 0.511 ' O ' ' CB ' ' A' ' 111' ' ' GLU . 3.1 mt -90.75 152.33 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.182 -0.949 . . . . 0.0 109.513 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' TYR . . . . . 0.484 ' CD1' ' O ' ' A' ' 110' ' ' GLU . 1.1 m-85 -136.63 141.27 43.22 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -0.875 . . . . 0.0 109.404 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.25 149.19 22.85 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.537 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.86 141.04 38.72 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.277 -0.889 . . . . 0.0 109.365 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.98 -17.28 24.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.541 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.463 ' HA2' ' CG2' ' A' ' 16' ' ' VAL . . . 101.94 13.55 31.4 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 52.0 m -81.19 -55.3 4.83 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -1.16 . . . . 0.0 109.459 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 173.16 130.19 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.321 -0.862 . . . . 0.0 109.572 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.45 HG23 ' N ' ' A' ' 98' ' ' GLU . 33.6 m -65.02 -23.79 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.374 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . 0.523 ' HB2' ' CB ' ' A' ' 12' ' ' LEU . 1.5 tt0 -65.89 -60.05 3.24 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.277 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.408 ' O ' ' CD1' ' A' ' 103' ' ' LEU . 36.1 mm-40 -60.38 -28.66 68.39 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.291 -0.881 . . . . 0.0 109.33 179.793 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ASN . . . . . 0.417 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 6.4 m-20 -69.68 -30.58 68.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.286 -0.884 . . . . 0.0 109.409 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' LEU . . . . . 0.477 HD23 ' N ' ' A' ' 102' ' ' LYS . 6.8 tt -59.87 -60.08 4.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.404 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' LYS . . . . . 0.477 ' N ' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -64.94 -29.07 69.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.319 -0.863 . . . . 0.0 109.38 179.922 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.417 ' HB2' ' HA ' ' A' ' 100' ' ' ASN . 0.4 OUTLIER -65.46 -30.69 71.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.239 -0.913 . . . . 0.0 109.627 -179.935 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' PHE . . . . . 0.526 ' CD1' HD13 ' A' ' 3' ' ' ILE . 23.4 t80 -59.75 -32.1 70.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.192 -0.942 . . . . 0.0 109.589 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 28.3 m -67.19 -40.92 86.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.887 . . . . 0.0 109.73 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -79.8 4.99 14.76 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.276 -0.89 . . . . 0.0 109.553 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 46.09 28.98 3.23 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -80.01 -33.2 39.48 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.193 -1.181 . . . . 0.0 109.379 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.413 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 45.5 mt -65.84 -176.93 0.42 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.313 -0.867 . . . . 0.0 109.306 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.484 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 11.3 pt-20 -108.48 143.59 37.24 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.572 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' GLU . . . . . 0.511 ' CB ' ' O ' ' A' ' 89' ' ' ILE . 0.0 OUTLIER -137.06 -174.01 3.62 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.276 -0.89 . . . . 0.0 109.298 179.863 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.457 HG13 ' O ' ' A' ' 111' ' ' GLU . 2.3 mp -147.99 147.48 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.18 -0.95 . . . . 0.0 109.493 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ARG . . . . . 0.446 ' HB2' ' O ' ' A' ' 112' ' ' ILE . 0.0 OUTLIER 179.1 -65.66 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.331 -0.855 . . . . 0.0 109.417 179.945 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -166.07 85.68 0.94 Allowed Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.241 -0.912 . . . . 0.0 109.258 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.63 12.79 2.28 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.811 2.341 . . . . 0.0 110.999 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -145.23 161.52 28.16 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 37.8 t -114.83 -10.08 12.41 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.196 -1.179 . . . . 0.0 109.479 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -67.49 -36.05 87.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.35 160.06 0.08 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.265 -1.138 . . . . 0.0 109.501 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.517 ' O ' ' CG ' ' A' ' 121' ' ' ARG . . . 157.72 96.81 0.12 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.517 ' CG ' ' O ' ' A' ' 120' ' ' GLY . 0.0 OUTLIER -179.8 58.84 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.222 -1.164 . . . . 0.0 109.385 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 3.6 mtp180 -65.41 109.75 2.41 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.258 -0.901 . . . . 0.0 109.489 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -167.69 120.61 0.91 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.174 -0.954 . . . . 0.0 109.61 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 117.955 -1.022 . . . . 0.0 109.474 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.271 0.558 . . . . 0.0 109.513 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.5 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 23.2 mttp -110.91 128.27 55.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.232 -0.917 . . . . 0.0 109.501 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.853 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 3.9 mt -95.51 128.05 47.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.301 -0.875 . . . . 0.0 109.57 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.65 ' C ' HD13 ' A' ' 5' ' ' ILE . . . -116.33 122.55 45.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.205 -0.934 . . . . 0.0 109.451 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.749 ' N ' HD13 ' A' ' 5' ' ' ILE . 1.2 mm -97.24 115.53 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.196 -0.94 . . . . 0.0 109.485 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.518 ' HA ' ' CE1' ' A' ' 26' ' ' PHE . . . -59.01 146.58 37.73 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.297 -0.877 . . . . 0.0 109.626 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 2.4 m 52.73 -98.09 0.07 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -0.851 . . . . 0.0 109.611 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.604 ' HB3' HG11 ' A' ' 97' ' ' VAL . 75.4 m 59.05 15.36 3.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.078 -1.014 . . . . 0.0 109.448 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.554 ' N ' ' HB3' ' A' ' 14' ' ' SER . . . 52.69 -150.96 8.78 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.3 m -129.5 -8.38 4.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.243 -1.151 . . . . 0.0 110.092 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.591 ' HB3' HD23 ' A' ' 12' ' ' LEU . 0.4 OUTLIER -131.19 -89.17 0.46 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.965 -1.084 . . . . 0.0 109.873 -179.845 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.591 HD23 ' HB3' ' A' ' 11' ' ' ASP . 0.7 OUTLIER -158.99 26.33 0.21 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.167 -0.958 . . . . 0.0 109.669 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.86 -41.17 1.47 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.554 ' HB3' ' N ' ' A' ' 9' ' ' GLY . 0.7 OUTLIER -77.34 84.17 3.77 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.251 -1.146 . . . . 0.0 109.48 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.482 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER -72.44 83.31 1.08 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.441 -0.787 . . . . 0.0 109.556 179.982 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.482 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 14.2 t 70.23 5.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.383 -0.823 . . . . 0.0 109.769 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 51.6 -95.91 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.286 -0.884 . . . . 0.0 109.682 179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.408 ' N ' ' O ' ' A' ' 16' ' ' VAL . 2.2 mtt180 -158.35 -77.93 0.07 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.029 -1.044 . . . . 0.0 109.707 -179.789 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.421 ' CD2' ' O ' ' A' ' 72' ' ' SER . 22.4 m-85 -117.17 174.3 6.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.221 -0.924 . . . . 0.0 109.632 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.695 ' CB ' ' HB1' ' A' ' 71' ' ' ALA . 2.9 t80 -117.04 104.72 11.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.254 -0.903 . . . . 0.0 109.402 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.459 ' HA2' ' CD1' ' A' ' 55' ' ' ILE . . . -143.01 -57.94 0.03 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.437 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.6 mtp85 -128.75 17.2 6.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.307 -1.114 . . . . 0.0 109.24 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -48.16 106.63 0.63 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.337 -0.852 . . . . 0.0 109.776 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.503 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 37.0 Cg_endo -80.74 42.23 1.29 Allowed 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.609 2.206 . . . . 0.0 110.477 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.503 ' CD2' ' O ' ' A' ' 24' ' ' PRO . 5.7 m-85 -159.83 69.53 0.42 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.09 -1.007 . . . . 0.0 109.584 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.518 ' CE1' ' HA ' ' A' ' 6' ' ' ALA . 0.1 OUTLIER -84.61 112.86 20.82 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.214 -0.929 . . . . 0.0 109.215 179.865 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -79.74 135.39 36.5 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.291 -0.88 . . . . 0.0 109.77 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 14.3 mm -108.25 138.47 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.209 -0.932 . . . . 0.0 109.323 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.425 HG13 HG23 ' A' ' 36' ' ' ILE . 75.8 t -131.92 103.83 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.385 -0.822 . . . . 0.0 109.459 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -85.43 88.65 7.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.183 -0.948 . . . . 0.0 109.539 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -82.83 141.73 32.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.316 -0.865 . . . . 0.0 109.386 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 4.9 tptt -117.58 -72.08 0.71 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.127 -0.983 . . . . 0.0 109.463 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 23.3 mttm -110.58 58.84 0.61 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.206 -0.934 . . . . 0.0 109.395 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 65.0 13.5 57.47 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 36' ' ' ILE . 25.0 t30 -132.74 105.87 7.42 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.293 -1.122 . . . . 0.0 109.403 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.47 ' H ' HD12 ' A' ' 36' ' ' ILE . 3.3 mp -42.97 114.25 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.311 -0.868 . . . . 0.0 109.577 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -96.76 -9.52 28.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 109.492 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -159.62 119.23 2.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.27 -0.894 . . . . 0.0 109.513 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.6 p -120.83 102.89 8.67 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.229 -0.919 . . . . 0.0 108.906 179.751 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -121.7 -176.45 3.32 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.371 -0.831 . . . . 0.0 109.859 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.8 p -151.98 130.4 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.408 -0.808 . . . . 0.0 109.309 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.42 ' O ' HG13 ' A' ' 42' ' ' ILE . 12.2 pt -114.12 131.22 66.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.189 -0.944 . . . . 0.0 109.671 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -97.73 150.42 21.23 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.285 -0.884 . . . . 0.0 109.429 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.471 ' HB2' ' HB3' ' A' ' 24' ' ' PRO . 55.6 m-20 . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.319 -0.863 . . . . 0.0 109.404 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.724 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.459 ' CD1' ' HA2' ' A' ' 21' ' ' GLY . 7.1 mm -74.82 -7.32 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.268 -1.136 . . . . 0.0 109.516 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.33 -23.07 60.2 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.237 -0.914 . . . . 0.0 109.23 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.724 HG22 ' O ' ' A' ' 54' ' ' GLY . 6.1 t -57.47 -22.77 45.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.39 -0.819 . . . . 0.0 109.468 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.83 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -53.71 -50.0 66.88 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.306 -0.871 . . . . 0.0 109.624 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -46.41 -41.24 13.41 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.91 . . . . 0.0 109.625 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 50.4 mt -71.51 -39.97 71.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.237 -0.914 . . . . 0.0 109.703 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.83 HD12 ' HA ' ' A' ' 58' ' ' ALA . 63.4 mt -56.11 -32.82 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.226 -0.922 . . . . 0.0 109.473 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.498 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -76.67 -31.19 57.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.285 -0.884 . . . . 0.0 109.477 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 27.7 t30 -72.71 -14.38 61.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -0.876 . . . . 0.0 109.639 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -90.08 -1.22 57.92 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.206 -0.934 . . . . 0.0 109.649 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.52 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 87.4 -6.37 83.49 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.5 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 96.0 t -48.09 92.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -1.103 . . . . 0.0 109.662 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.52 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.6 OUTLIER -79.5 -2.09 40.54 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.371 -0.83 . . . . 0.0 108.813 179.38 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.853 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -134.79 129.52 34.7 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.861 . . . . 0.0 109.373 179.739 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.4 t -130.46 96.84 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.163 -0.96 . . . . 0.0 109.613 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.509 HD13 HD21 ' A' ' 100' ' ' ASN . 7.0 mt -91.22 109.73 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.213 -0.929 . . . . 0.0 109.288 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.695 ' HB1' ' CB ' ' A' ' 20' ' ' PHE . . . -144.08 176.94 8.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.248 -0.908 . . . . 0.0 109.778 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.635 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 75.1 m -133.38 41.6 3.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.527 -0.733 . . . . 0.0 109.435 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.423 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.8 OUTLIER -53.64 143.12 39.91 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.307 -0.871 . . . . 0.0 109.459 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 35.8 Cg_endo -79.03 88.04 1.5 Allowed 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 122.639 2.226 . . . . 0.0 110.601 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 122.5 162.6 11.6 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.404 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.3 Cg_endo -78.84 7.88 4.05 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 C-N-CA 122.75 2.3 . . . . 0.0 110.591 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 80' ' ' GLU . 1.5 m120 -55.25 -65.66 0.55 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.226 -0.921 . . . . 0.0 109.583 -179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.8 -51.93 67.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.906 . . . . 0.0 109.675 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.8 m-30 -57.76 -15.97 9.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.223 -0.923 . . . . 0.0 109.754 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.472 ' HB3' ' O ' ' A' ' 77' ' ' ASN . 54.0 tt0 -72.82 -50.34 24.77 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.197 -0.939 . . . . 0.0 109.302 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 82' ' ' LEU . 2.4 t -71.3 -53.16 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 O-C-N 121.289 -0.882 . . . . 0.0 109.258 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.519 ' HB3' ' CG1' ' A' ' 89' ' ' ILE . 4.4 mm? -45.75 -30.09 1.51 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.14 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -77.06 -47.75 19.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.336 -0.853 . . . . 0.0 109.346 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -68.02 -8.63 39.18 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.244 -0.91 . . . . 0.0 109.59 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.6 mp -86.48 -48.4 8.43 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.22 -0.925 . . . . 0.0 109.539 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.35 11.1 9.96 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.498 HD11 ' HB2' ' A' ' 62' ' ' ALA . 1.6 mt -91.69 172.37 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.24 -1.153 . . . . 0.0 109.419 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.477 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 0.1 OUTLIER -90.35 114.66 26.8 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.269 -0.894 . . . . 0.0 109.669 -179.926 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.519 ' CG1' ' HB3' ' A' ' 82' ' ' LEU . 5.9 mt -82.77 150.37 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.294 -0.879 . . . . 0.0 108.939 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.566 ' CE2' ' HB3' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -139.68 148.17 42.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.625 -179.95 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.42 140.2 39.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.315 -0.866 . . . . 0.0 109.614 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.635 ' HB3' ' OG ' ' A' ' 72' ' ' SER . . . -110.32 88.04 2.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.936 . . . . 0.0 109.677 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.92 -40.32 42.98 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -0.901 . . . . 0.0 109.29 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 128.3 116.43 1.95 Allowed Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -164.38 -67.3 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.198 -1.178 . . . . 0.0 109.471 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.472 ' O ' ' HB2' ' A' ' 100' ' ' ASN . 0.1 OUTLIER 171.71 157.21 0.09 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.244 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.63 HG13 HG21 ' A' ' 5' ' ' ILE . 1.8 t -74.28 -48.07 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.278 -0.889 . . . . 0.0 109.651 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -50.93 -50.16 58.29 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.276 -0.89 . . . . 0.0 109.846 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 31.0 mm-40 -70.55 -35.58 73.18 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.224 -0.923 . . . . 0.0 109.893 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.55 ' OD1' HD11 ' A' ' 109' ' ' LEU . 7.4 t30 -56.23 -39.08 71.96 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.165 -0.96 . . . . 0.0 109.735 -179.667 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 75.7 mt -57.77 -62.92 1.45 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.233 -0.917 . . . . 0.0 109.558 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 5.7 ttpt -62.52 -15.11 48.77 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.212 -0.93 . . . . 0.0 109.575 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.469 HD12 ' HA ' ' A' ' 103' ' ' LEU . 0.9 OUTLIER -77.09 -33.55 56.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.224 -0.922 . . . . 0.0 109.799 -179.791 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.746 ' CD2' HD11 ' A' ' 3' ' ' ILE . 79.3 t80 -74.2 -24.78 59.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.163 -0.961 . . . . 0.0 109.765 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 61.3 m -72.24 -22.91 61.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.227 -0.92 . . . . 0.0 109.674 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -103.79 4.95 35.67 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 109.597 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 55.95 40.54 82.17 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 -79.96 -51.45 9.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.192 -1.181 . . . . 0.0 109.558 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.55 HD11 ' OD1' ' A' ' 100' ' ' ASN . 13.8 mt -56.34 176.8 0.08 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 109.497 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.425 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 8.7 pt-20 -109.65 148.4 31.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.286 -0.884 . . . . 0.0 109.42 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.566 ' HB3' ' CE2' ' A' ' 90' ' ' TYR . 6.1 pt-20 -134.25 155.68 49.75 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.232 -0.917 . . . . 0.0 109.656 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 67.5 mt -135.36 143.44 36.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.321 -0.862 . . . . 0.0 109.047 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.54 0 O-C-N 121.112 -0.992 . . . . 0.0 109.909 -179.543 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.476 ' HA ' ' HB2' ' A' ' 67' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.456 ' HD2' ' O ' ' A' ' 65' ' ' GLY . 0.5 OUTLIER -89.29 147.4 24.13 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.223 -0.923 . . . . 0.0 109.474 -179.926 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.531 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 5.3 mt -115.08 119.86 62.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.212 -0.93 . . . . 0.0 109.701 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.567 ' CB ' HD13 ' A' ' 28' ' ' ILE . . . -112.87 111.45 22.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.279 -0.888 . . . . 0.0 109.073 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.74 HG23 ' CG2' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -98.41 126.19 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.228 -0.92 . . . . 0.0 109.8 -179.487 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.49 134.27 42.28 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.302 -0.874 . . . . 0.0 109.153 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.414 ' OG ' ' HG3' ' A' ' 27' ' ' MET . 0.0 OUTLIER -144.45 156.08 44.03 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.067 -1.02 . . . . 0.0 109.768 -179.814 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.42 -26.56 11.4 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.345 -0.847 . . . . 0.0 109.427 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -87.63 -105.62 0.9 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -148.73 -45.05 0.15 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.155 -1.203 . . . . 0.0 109.407 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' A' ' 11' ' ' ASP . 2.3 t70 -154.47 -55.29 0.1 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 109.367 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.2 tt -105.62 -37.69 6.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.18 -0.95 . . . . 0.0 109.337 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -57.71 -26.47 57.5 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.443 ' OG ' HG22 ' A' ' 97' ' ' VAL . 54.4 p -76.92 80.14 3.48 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.271 -1.135 . . . . 0.0 109.439 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.531 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.3 OUTLIER -76.88 82.0 3.45 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.261 -0.899 . . . . 0.0 109.575 -179.88 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.531 HG23 ' C ' ' A' ' 15' ' ' GLU . 3.0 t 73.16 19.64 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.255 -0.903 . . . . 0.0 109.651 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 44.36 -163.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.209 -0.932 . . . . 0.0 109.422 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.32 -32.71 2.67 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -0.902 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -150.12 -179.83 7.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.141 -0.974 . . . . 0.0 109.666 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.452 ' CG ' ' HB1' ' A' ' 71' ' ' ALA . 21.7 t80 -121.77 83.78 2.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.356 -0.84 . . . . 0.0 109.404 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 147.1 -18.64 1.56 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.442 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 1.6 mtp180 -110.55 -29.41 8.07 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.257 -1.143 . . . . 0.0 109.373 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.37 110.61 2.47 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.917 . . . . 0.0 109.399 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.5 46.65 2.31 Favored 'Trans proline' 0 C--N 1.312 -1.369 0 C-N-CA 122.692 2.261 . . . . 0.0 110.948 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.472 ' CE2' ' OE2' ' A' ' 43' ' ' GLU . 11.3 m-85 -158.51 70.01 0.51 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.99 -1.068 . . . . 0.0 109.417 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.499 ' CD1' ' HB2' ' A' ' 44' ' ' ASN . 46.1 m-85 -81.4 153.53 26.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.2 -0.937 . . . . 0.0 109.737 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' MET . . . . . 0.45 ' O ' ' HA ' ' A' ' 4' ' ' ALA . 37.9 mtp -120.3 114.16 21.47 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.34 -0.85 . . . . 0.0 109.041 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.567 HD13 ' CB ' ' A' ' 4' ' ' ALA . 26.6 mm -105.46 120.48 56.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.158 -0.964 . . . . 0.0 109.797 -179.566 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.707 HG11 HD12 ' A' ' 36' ' ' ILE . 44.2 t -122.74 116.03 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.362 -0.836 . . . . 0.0 109.301 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -89.73 86.84 6.78 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.25 -0.906 . . . . 0.0 109.615 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.748 ' HE1' HG23 ' A' ' 105' ' ' THR . 1.2 ttp -83.29 125.07 31.22 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.179 -0.951 . . . . 0.0 109.328 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -87.99 -91.3 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.229 -0.919 . . . . 0.0 109.765 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.431 ' O ' ' C ' ' A' ' 34' ' ' GLY . 3.6 tmtm? -98.52 85.39 3.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.16 -0.962 . . . . 0.0 109.743 -179.679 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 43.07 33.99 1.95 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -144.4 104.11 4.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.139 -1.212 . . . . 0.0 109.504 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.707 HD12 HG11 ' A' ' 29' ' ' VAL . 3.9 tt -53.57 118.63 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.29 -0.881 . . . . 0.0 109.232 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -127.75 26.2 5.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.227 -0.92 . . . . 0.0 109.662 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.462 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER 176.25 128.2 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.629 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.657 ' OG ' HD11 ' A' ' 36' ' ' ILE . 5.5 m -156.19 112.4 3.06 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.242 -0.911 . . . . 0.0 109.304 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -130.11 139.0 50.97 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.184 -0.947 . . . . 0.0 109.707 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.3 t -92.36 154.49 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.086 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.0 tt -147.47 142.53 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.125 -0.984 . . . . 0.0 109.822 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.472 ' OE2' ' CE2' ' A' ' 25' ' ' TYR . 1.9 mt-10 -88.55 79.31 7.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.319 -0.863 . . . . 0.0 109.177 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.499 ' HB2' ' CD1' ' A' ' 26' ' ' PHE . 2.0 m120 . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.2 -0.937 . . . . 0.0 109.521 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.4 mm -72.95 -19.56 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.26 -1.141 . . . . 0.0 109.672 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 3.7 mtt-85 -74.98 -16.61 60.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.141 -0.974 . . . . 0.0 109.486 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.666 ' HA ' HD12 ' A' ' 60' ' ' ILE . 53.3 m -67.94 -24.9 65.23 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.271 -0.893 . . . . 0.0 109.418 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -51.9 -56.05 16.46 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.32 -0.862 . . . . 0.0 109.651 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -51.04 -36.42 39.61 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.275 -0.891 . . . . 0.0 109.777 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.666 HD12 ' HA ' ' A' ' 57' ' ' THR . 76.9 mt -63.82 -63.5 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.177 -0.952 . . . . 0.0 109.838 -179.595 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.77 HG23 HG21 ' A' ' 66' ' ' VAL . 10.5 mt -53.67 -24.46 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.231 -0.918 . . . . 0.0 109.935 -179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.596 ' CB ' HD11 ' A' ' 87' ' ' ILE . . . -65.28 -46.73 79.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.131 -0.981 . . . . 0.0 109.8 -179.656 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 9.2 m-20 -77.65 6.85 6.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.275 -0.89 . . . . 0.0 110.293 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.644 ' HB3' HG23 ' A' ' 66' ' ' VAL . 0.7 OUTLIER -96.1 7.56 46.08 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.997 -1.064 . . . . 0.0 109.835 -179.859 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.456 ' O ' ' HD2' ' A' ' 2' ' ' LYS . . . 73.07 8.81 75.02 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.77 HG21 HG23 ' A' ' 61' ' ' ILE . 17.6 t -68.61 97.5 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.301 -1.117 . . . . 0.0 109.574 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.525 ' O ' ' CB ' ' A' ' 88' ' ' LYS . 13.4 tttt -79.11 -3.92 47.75 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.647 ' O ' HG12 ' A' ' 66' ' ' VAL . . . -138.79 131.38 28.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.319 -0.863 . . . . 0.0 109.002 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.6 t -128.84 109.2 18.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.061 -1.024 . . . . 0.0 109.791 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.74 ' CG2' HG23 ' A' ' 5' ' ' ILE . 2.1 mp -89.51 95.09 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.133 -0.98 . . . . 0.0 109.137 179.674 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.452 ' HB1' ' CG ' ' A' ' 20' ' ' PHE . . . -126.67 171.92 10.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 109.573 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.6 p -130.52 29.67 4.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.282 -0.886 . . . . 0.0 109.498 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -49.22 151.06 2.67 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.279 -0.888 . . . . 0.0 109.636 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.29 -72.48 0.01 OUTLIER 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.705 2.27 . . . . 0.0 110.467 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.419 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -68.26 145.5 44.5 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.419 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.8 Cg_endo -78.69 6.29 4.98 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.653 2.236 . . . . 0.0 110.473 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -53.94 -57.43 11.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.281 -0.887 . . . . 0.0 109.511 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.691 ' O ' HD12 ' A' ' 82' ' ' LEU . . . -57.6 -45.0 85.86 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.23 -0.919 . . . . 0.0 109.5 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 18.4 m-30 -56.59 -27.39 57.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.178 -0.951 . . . . 0.0 109.343 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.48 -36.85 68.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.307 -0.87 . . . . 0.0 109.465 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 41.6 t -69.19 -46.19 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.492 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.691 HD12 ' O ' ' A' ' 78' ' ' ALA . 3.1 mp -53.18 -37.09 61.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.219 -0.925 . . . . 0.0 109.615 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 13.5 t-20 -61.67 -40.81 96.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 109.622 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -76.6 -20.75 56.43 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.173 -0.955 . . . . 0.0 109.555 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.562 ' HB3' HD12 ' A' ' 87' ' ' ILE . 0.3 OUTLIER -87.13 -14.82 40.21 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.265 -0.897 . . . . 0.0 109.522 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 86.93 11.71 69.77 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.596 HD11 ' CB ' ' A' ' 62' ' ' ALA . 9.3 mt -87.51 145.5 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -1.176 . . . . 0.0 109.587 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.525 ' CB ' ' O ' ' A' ' 67' ' ' LYS . 6.1 ttmm -80.05 116.75 20.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.124 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.671 HD12 ' HA ' ' A' ' 113' ' ' ARG . 3.3 mt -80.93 106.42 12.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.274 -0.891 . . . . 0.0 109.602 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.571 ' CD2' ' O ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -103.18 142.35 34.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.333 -0.855 . . . . 0.0 109.158 179.825 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.467 ' O ' ' HB3' ' A' ' 110' ' ' GLU . 20.6 ttt180 -106.02 145.76 30.97 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.182 -0.949 . . . . 0.0 109.606 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.98 92.13 8.93 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.327 -0.858 . . . . 0.0 109.277 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 58.9 m -107.46 -16.41 14.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.255 -0.903 . . . . 0.0 109.691 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -66.05 -128.71 0.02 OUTLIER Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.483 ' O ' HG23 ' A' ' 16' ' ' VAL . 9.8 t -142.13 -32.98 0.5 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.319 -1.107 . . . . 0.0 109.927 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -133.54 151.83 51.8 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.138 -0.976 . . . . 0.0 109.356 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.443 HG22 ' OG ' ' A' ' 14' ' ' SER . 35.1 m -71.06 -34.29 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.25 -0.906 . . . . 0.0 109.7 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.37 -47.91 83.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.245 -0.91 . . . . 0.0 109.803 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -71.75 -42.78 66.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.271 -0.893 . . . . 0.0 109.942 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 48.3 t-20 -52.91 -33.98 52.93 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.201 -0.937 . . . . 0.0 109.669 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.561 HD11 HD12 ' A' ' 36' ' ' ILE . 1.7 tt -57.12 -42.93 81.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.248 -0.907 . . . . 0.0 109.841 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.49 ' N ' HD23 ' A' ' 101' ' ' LEU . 0.5 OUTLIER -74.48 -33.36 62.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.117 -0.989 . . . . 0.0 110.039 -179.487 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -39.81 94.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.107 -0.996 . . . . 0.0 109.826 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.526 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 6.4 t80 -70.15 -30.02 67.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.18 -0.95 . . . . 0.0 109.813 -179.64 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.748 HG23 ' HE1' ' A' ' 31' ' ' MET . 0.2 OUTLIER -67.21 -29.86 69.64 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.128 -0.982 . . . . 0.0 109.935 -179.615 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -99.31 13.06 34.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.139 -0.976 . . . . 0.0 109.606 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 52.17 57.72 12.51 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.069 -1.612 . . . . 0.0 109.069 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -81.87 -54.86 5.0 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.368 -1.078 . . . . 0.0 109.781 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.541 HD23 ' H ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER 178.04 -152.03 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.093 -1.004 . . . . 0.0 109.742 -179.835 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.571 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 13.8 mt-10 60.29 25.17 14.61 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.375 -0.828 . . . . 0.0 109.459 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.592 ' C ' HD12 ' A' ' 112' ' ' ILE . 7.5 pt-20 -103.94 135.95 44.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.343 -0.848 . . . . 0.0 109.358 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.592 HD12 ' C ' ' A' ' 111' ' ' GLU . 3.2 mp -153.15 135.06 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.3 -0.875 . . . . 0.0 109.421 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.671 ' HA ' HD12 ' A' ' 89' ' ' ILE . 26.4 ttp180 . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.224 -0.922 . . . . 0.0 109.346 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.7 mmm . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.479 ' HD3' ' O ' ' A' ' 65' ' ' GLY . 1.2 mttm -120.65 136.72 54.75 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.324 -0.86 . . . . 0.0 109.552 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.497 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 5.4 mt -114.44 108.43 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.318 -0.864 . . . . 0.0 109.399 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.7 ' HB1' ' CZ ' ' A' ' 26' ' ' PHE . . . -112.37 127.6 56.06 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.25 -0.906 . . . . 0.0 109.306 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.928 HG21 HG12 ' A' ' 97' ' ' VAL . 27.9 mt -102.88 139.71 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.555 -179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.3 170.07 17.2 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.384 -0.823 . . . . 0.0 109.421 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.465 ' O ' ' HB3' ' A' ' 8' ' ' SER . 54.3 p 46.32 -141.38 0.39 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.259 -0.901 . . . . 0.0 109.333 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.9 ' HB2' HG11 ' A' ' 97' ' ' VAL . 42.4 t 63.61 51.81 2.41 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.119 -0.988 . . . . 0.0 109.415 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.537 ' N ' ' HB3' ' A' ' 14' ' ' SER . . . -50.87 106.23 0.25 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.481 ' HG1' ' H ' ' A' ' 11' ' ' ASP . 3.2 p 49.01 -90.65 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.343 -1.092 . . . . 0.0 109.89 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.517 ' N ' ' O ' ' A' ' 9' ' ' GLY . 1.0 OUTLIER 173.15 -150.61 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.198 -0.939 . . . . 0.0 109.446 -179.687 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.461 ' HB3' ' O ' ' A' ' 11' ' ' ASP . 12.9 tp 70.25 13.2 7.66 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.257 -0.902 . . . . 0.0 109.362 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 145.77 -23.66 1.8 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.537 ' HB3' ' N ' ' A' ' 9' ' ' GLY . 43.4 m -77.2 82.51 3.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.193 -1.18 . . . . 0.0 109.64 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.467 ' HA ' HG22 ' A' ' 97' ' ' VAL . 0.2 OUTLIER -72.75 -114.2 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.202 -0.936 . . . . 0.0 109.456 -179.826 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.747 HG22 HG13 ' A' ' 97' ' ' VAL . 5.0 t -115.47 23.47 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 120.738 -1.227 . . . . 0.0 109.679 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.433 ' HB2' ' HB2' ' A' ' 7' ' ' SER . 4.3 t 47.06 -150.26 0.11 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.178 -0.951 . . . . 0.0 109.345 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.55 12.95 1.53 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.192 -0.943 . . . . 0.0 109.595 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.466 ' CD1' ' O ' ' A' ' 19' ' ' PHE . 28.1 p90 -153.8 144.52 22.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.223 -0.923 . . . . 0.0 109.66 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -123.82 89.88 3.17 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.313 -0.867 . . . . 0.0 109.218 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -145.26 -73.35 0.02 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.73 21.68 16.26 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -1.172 . . . . 0.0 109.675 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -58.33 113.25 6.18 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.243 -0.911 . . . . 0.0 109.23 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.474 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 36.8 Cg_endo -80.74 54.34 5.19 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.571 2.181 . . . . 0.0 110.867 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.474 ' CD2' ' O ' ' A' ' 24' ' ' PRO . 31.4 m-85 -160.41 70.92 0.43 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.992 -1.068 . . . . 0.0 109.214 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.7 ' CZ ' ' HB1' ' A' ' 4' ' ' ALA . 40.1 t80 -79.92 104.58 10.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.429 -0.794 . . . . 0.0 109.732 -179.718 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' MET . . . . . 0.727 ' CG ' HG12 ' A' ' 41' ' ' VAL . 0.2 OUTLIER -82.84 125.03 30.87 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.29 -0.881 . . . . 0.0 109.21 179.694 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.436 ' O ' HG23 ' A' ' 28' ' ' ILE . 1.4 tp -119.99 114.75 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.154 -0.966 . . . . 0.0 109.586 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.1 t -118.91 144.25 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.922 . . . . 0.0 109.408 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -117.63 136.18 53.48 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.261 -0.9 . . . . 0.0 109.445 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.8 mtt -119.86 132.18 55.49 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.209 -0.932 . . . . 0.0 109.545 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 13.4 mmtt -81.99 -79.76 0.17 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.308 -0.87 . . . . 0.0 109.299 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -126.16 86.53 2.54 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.3 -0.875 . . . . 0.0 109.174 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 48.87 34.12 14.71 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 36' ' ' ILE . 0.6 OUTLIER -149.12 100.56 3.06 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.345 -1.091 . . . . 0.0 109.461 -179.859 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.413 ' C ' ' O ' ' A' ' 35' ' ' ASN . 4.3 tt -45.2 134.27 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.234 -0.916 . . . . 0.0 109.35 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.407 ' O ' ' HB2' ' A' ' 38' ' ' SER . 0.5 OUTLIER -145.65 20.11 1.49 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.303 -0.873 . . . . 0.0 109.497 -179.959 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.407 ' HB2' ' O ' ' A' ' 37' ' ' GLU . 5.1 t -179.21 129.66 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.266 -0.896 . . . . 0.0 109.471 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 96.0 p -151.2 115.3 5.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.284 -0.885 . . . . 0.0 109.337 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -132.09 132.26 43.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.276 -0.89 . . . . 0.0 109.629 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.727 HG12 ' CG ' ' A' ' 27' ' ' MET . 27.7 m -97.13 137.9 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.31 -0.869 . . . . 0.0 109.328 179.719 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 58.7 mt -123.79 145.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 0.0 109.558 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.442 ' HG2' ' CE1' ' A' ' 25' ' ' TYR . 2.8 mp0 -115.09 148.31 39.1 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.283 -0.886 . . . . 0.0 109.581 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 13.8 m-20 . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.314 179.887 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.628 HD12 ' HB2' ' A' ' 78' ' ' ALA . 34.2 mm -73.62 -16.46 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.253 -1.145 . . . . 0.0 109.825 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.18 -22.63 66.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.261 -0.899 . . . . 0.0 109.681 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 61.2 m -63.52 -21.58 66.41 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.673 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.412 ' O ' ' C ' ' A' ' 59' ' ' GLN . . . -52.99 -47.93 67.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.233 -0.917 . . . . 0.0 109.508 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.412 ' C ' ' O ' ' A' ' 58' ' ' ALA . 0.0 OUTLIER -44.09 -43.39 6.85 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.421 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 20.9 mm -73.15 -36.5 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.173 -0.954 . . . . 0.0 109.167 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 16.8 mm -50.68 -36.49 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.354 -0.842 . . . . 0.0 109.235 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.472 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -75.02 -33.39 61.78 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.277 -0.889 . . . . 0.0 109.686 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -61.5 -18.22 58.12 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.259 -0.9 . . . . 0.0 109.767 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.477 ' HB3' ' CG2' ' A' ' 66' ' ' VAL . 0.4 OUTLIER -90.68 27.36 1.78 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.082 -1.011 . . . . 0.0 109.653 -179.86 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.479 ' O ' ' HD3' ' A' ' 2' ' ' LYS . . . 43.96 40.47 5.56 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 68' ' ' ALA . 2.9 t -86.25 96.21 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -1.136 . . . . 0.0 109.68 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.6 tptt -78.95 -11.32 60.0 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 179.046 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.497 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -136.58 125.29 23.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.444 -0.785 . . . . 0.0 108.964 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.426 ' O ' ' HB2' ' A' ' 90' ' ' TYR . 67.1 t -124.39 119.84 57.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.049 -1.032 . . . . 0.0 109.961 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.455 ' CD1' ' CG2' ' A' ' 3' ' ' ILE . 1.9 mp -102.1 114.19 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.359 -0.838 . . . . 0.0 108.98 179.606 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -151.87 172.87 15.53 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.214 -0.929 . . . . 0.0 109.865 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.9 p -135.5 55.69 1.87 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.378 -0.826 . . . . 0.0 109.245 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -55.53 152.82 16.5 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.295 -0.878 . . . . 0.0 109.645 -179.782 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.67 -13.65 14.55 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 C-N-CA 122.757 2.305 . . . . 0.0 110.531 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.8 161.66 26.26 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.7 -5.67 14.86 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.698 2.265 . . . . 0.0 110.415 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 16.9 t30 -57.91 -33.25 68.57 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.262 -0.899 . . . . 0.0 109.649 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.628 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -71.94 -60.43 2.24 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.251 -0.906 . . . . 0.0 109.437 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.46 ' CD1' ' N ' ' A' ' 79' ' ' PHE . 3.5 m-85 -51.7 -22.09 3.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.115 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 13.9 tt0 -63.91 -46.95 82.54 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.283 -0.885 . . . . 0.0 109.265 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.4 ' O ' ' HB2' ' A' ' 85' ' ' LEU . 2.5 t -69.45 -43.66 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.194 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 1.8 mt -63.36 -21.62 66.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.516 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -77.1 -61.35 2.01 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.258 -0.901 . . . . 0.0 109.603 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -58.92 -21.56 58.1 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.22 -0.925 . . . . 0.0 109.667 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.587 ' HB3' HD12 ' A' ' 87' ' ' ILE . 0.1 OUTLIER -73.14 -37.43 66.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.215 -0.928 . . . . 0.0 109.637 -179.9 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.77 21.83 7.29 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.587 HD12 ' HB3' ' A' ' 85' ' ' LEU . 5.5 mt -103.94 150.3 7.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -1.165 . . . . 0.0 109.51 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 8.2 mttt -80.03 125.84 30.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.233 -0.917 . . . . 0.0 109.361 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 3.3 mp -90.31 141.06 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.161 -0.962 . . . . 0.0 109.543 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.597 ' CE1' ' HB3' ' A' ' 111' ' ' GLU . 2.2 m-85 -127.99 127.35 43.08 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.211 -0.931 . . . . 0.0 109.529 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 73.5 mtt180 -87.46 122.77 31.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.465 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.67 122.83 33.16 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.236 -0.915 . . . . 0.0 109.471 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -64.95 -40.0 94.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.363 -0.836 . . . . 0.0 109.558 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 116.76 52.47 0.35 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 30.8 m -114.37 -82.72 0.61 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -1.119 . . . . 0.0 109.351 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -157.56 128.61 6.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.396 -0.815 . . . . 0.0 109.357 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.928 HG12 HG21 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -51.12 -23.27 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.221 -0.924 . . . . 0.0 109.535 -179.943 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.82 -49.05 69.63 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.195 -0.941 . . . . 0.0 109.317 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.594 ' HG2' HD12 ' A' ' 103' ' ' LEU . 21.4 tt0 -70.88 -28.14 64.34 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.304 -0.873 . . . . 0.0 109.311 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -63.93 -49.46 72.52 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.322 -0.862 . . . . 0.0 109.42 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 37.7 tp -57.56 -57.58 12.08 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.301 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 1.3 tmtt? -56.92 -25.62 57.7 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.135 -0.978 . . . . 0.0 109.257 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.594 HD12 ' HG2' ' A' ' 99' ' ' GLU . 0.2 OUTLIER -71.14 -37.11 72.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.23 -0.919 . . . . 0.0 109.36 179.861 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -65.57 -22.99 66.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.198 -0.939 . . . . 0.0 109.175 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.34 -29.76 64.25 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.412 -0.805 . . . . 0.0 109.31 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -112.46 -2.69 14.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.603 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 61.23 39.46 97.22 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' ASN . . . . . 0.499 ' HB3' HD23 ' A' ' 103' ' ' LEU . 24.4 t-20 -93.97 -17.92 22.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.103 -1.233 . . . . 0.0 109.395 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.458 ' HA ' HD23 ' A' ' 109' ' ' LEU . 5.4 mt -55.67 -168.44 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.24 -0.913 . . . . 0.0 109.334 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 90' ' ' TYR . 1.2 tt0 -103.42 106.91 17.55 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.256 -0.903 . . . . 0.0 109.303 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.597 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 4.1 pt-20 -101.7 156.69 17.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.264 -0.898 . . . . 0.0 109.764 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.401 HG21 HD13 ' A' ' 112' ' ' ILE . 2.9 mt -142.8 126.11 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.89 . . . . 0.0 109.314 179.768 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.293 -0.879 . . . . 0.0 109.441 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 mmm . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.271 0.557 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.508 ' HB3' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -154.03 160.05 41.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.289 -0.882 . . . . 0.0 109.118 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.583 HG12 ' CE2' ' A' ' 104' ' ' PHE . 6.4 mt -117.4 121.12 66.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.901 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.671 ' HB2' HG11 ' A' ' 66' ' ' VAL . . . -113.09 102.97 10.89 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.373 -0.83 . . . . 0.0 109.119 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -94.81 118.64 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -0.924 . . . . 0.0 109.742 -179.553 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.37 142.3 41.21 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.068 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.513 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 3.8 p -161.72 -159.92 0.66 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.119 -0.988 . . . . 0.0 109.518 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.9 m -149.06 57.09 1.02 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.287 -0.883 . . . . 0.0 109.537 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 167.08 164.5 22.85 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.435 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.0 OUTLIER -85.02 -32.62 22.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.322 -1.105 . . . . 0.0 109.472 179.981 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 18.7 p-10 171.84 172.16 0.09 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -0.919 . . . . 0.0 109.374 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.515 ' HA ' HD12 ' A' ' 12' ' ' LEU . 8.1 tp 45.35 32.77 1.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.305 -0.872 . . . . 0.0 109.191 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -175.47 -32.88 0.04 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 p -65.55 86.34 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.435 -1.038 . . . . 0.0 109.304 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.503 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 14.4 mt-10 -77.65 6.98 6.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.478 -0.764 . . . . 0.0 110.153 -179.835 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.503 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 15.1 t 70.62 65.6 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.937 . . . . 0.0 109.615 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 16' ' ' VAL . 3.9 m -44.64 122.83 3.32 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.328 -0.858 . . . . 0.0 109.233 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.452 ' HG2' ' HB2' ' A' ' 72' ' ' SER . 1.4 ttm-85 -61.72 -18.7 60.76 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.25 -0.906 . . . . 0.0 109.721 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.492 ' CE2' ' HG3' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -84.91 108.16 17.41 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.12 -0.987 . . . . 0.0 109.63 -179.905 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.435 ' CB ' ' HB1' ' A' ' 71' ' ' ALA . 21.8 t80 -106.43 125.37 50.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.263 -0.898 . . . . 0.0 109.354 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.1 -36.6 0.76 Allowed Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.439 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 1.1 mpt_? -118.62 -22.27 7.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.343 -1.093 . . . . 0.0 109.256 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.513 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -49.15 106.91 0.68 Allowed Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.304 -0.872 . . . . 0.0 109.436 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.3 Cg_endo -79.95 62.56 8.55 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.561 2.174 . . . . 0.0 110.822 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.449 ' CE1' ' HB3' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -160.52 69.58 0.38 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.008 -1.058 . . . . 0.0 109.395 179.692 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -80.46 121.1 25.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.549 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' MET . . . . . 0.434 ' O ' ' HA ' ' A' ' 4' ' ' ALA . 2.1 mmt -94.46 110.6 22.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.226 -0.921 . . . . 0.0 109.266 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.9 mm -104.02 117.99 50.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.904 . . . . 0.0 109.472 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.912 HG21 HD11 ' A' ' 101' ' ' LEU . 13.4 m -138.04 147.59 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.209 -0.932 . . . . 0.0 109.833 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -127.26 143.26 51.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 108.899 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.2 mtt -113.81 152.03 31.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.1 -1.0 . . . . 0.0 109.938 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.35 -46.37 7.38 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.369 -0.832 . . . . 0.0 109.262 179.775 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.64 47.48 0.73 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.367 -0.833 . . . . 0.0 109.222 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.567 ' O ' HG23 ' A' ' 105' ' ' THR . . . 92.22 -1.43 73.38 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.423 ' O ' ' C ' ' A' ' 36' ' ' ILE . 5.6 p-10 -116.56 92.89 4.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.204 -1.174 . . . . 0.0 109.362 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.794 HD13 HD21 ' A' ' 101' ' ' LEU . 1.6 tt -43.95 118.61 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 109.497 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.46 ' O ' ' OE1' ' A' ' 37' ' ' GLU . 0.2 OUTLIER -123.08 20.78 9.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.329 -0.857 . . . . 0.0 109.441 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.413 ' O ' ' OG ' ' A' ' 38' ' ' SER . 12.0 p -170.82 107.46 0.29 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -0.859 . . . . 0.0 109.263 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.761 ' HA ' HG12 ' A' ' 29' ' ' VAL . 5.8 p -135.35 105.72 6.38 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.914 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.18 143.8 38.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.389 -0.819 . . . . 0.0 109.268 179.598 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.413 HG13 ' SD ' ' A' ' 27' ' ' MET . 2.2 t -110.99 124.03 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.215 -0.928 . . . . 0.0 109.755 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 11.1 mt -121.57 119.43 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.262 -0.899 . . . . 0.0 109.268 179.721 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.449 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 4.1 pm0 -93.28 126.08 38.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.254 -0.904 . . . . 0.0 109.564 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.427 ' HB2' ' HA ' ' A' ' 24' ' ' PRO . 2.5 t-20 . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.317 -0.864 . . . . 0.0 109.548 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.409 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.719 HD12 ' HB2' ' A' ' 78' ' ' ALA . 39.8 mm -76.72 0.03 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.136 -1.214 . . . . 0.0 109.85 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.08 -10.96 59.83 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.192 -0.943 . . . . 0.0 109.558 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.439 ' O ' HG13 ' A' ' 61' ' ' ILE . 8.8 t -77.32 -25.86 51.59 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.667 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -48.77 -39.97 27.07 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 109.492 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 -60.4 -58.47 8.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 109.608 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.1 mt -53.82 -25.48 12.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.33 -0.856 . . . . 0.0 109.589 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.481 HG22 HG21 ' A' ' 66' ' ' VAL . 46.3 mt -72.96 -39.66 58.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.454 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.17 -30.65 70.67 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.552 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -67.93 -9.08 42.26 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.294 -0.878 . . . . 0.0 109.614 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -85.9 -24.93 26.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.191 -0.943 . . . . 0.0 109.537 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 114.55 -26.0 9.91 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.671 HG11 ' HB2' ' A' ' 4' ' ' ALA . 4.6 m -43.44 94.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.271 -1.135 . . . . 0.0 109.559 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 65' ' ' GLY . 7.0 mmtp -79.36 -4.27 50.16 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.357 -0.84 . . . . 0.0 108.758 179.291 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -122.82 129.33 51.55 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.385 -0.822 . . . . 0.0 109.274 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.639 HG21 ' CD2' ' A' ' 82' ' ' LEU . 97.8 t -123.45 107.83 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.111 -0.993 . . . . 0.0 109.544 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 53.1 mt -91.99 115.52 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.36 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.435 ' HB1' ' CB ' ' A' ' 20' ' ' PHE . . . -164.84 176.77 8.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.217 -0.927 . . . . 0.0 109.913 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.601 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 12.5 m -140.84 59.07 1.54 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.508 -0.745 . . . . 0.0 109.176 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.487 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 11.6 p -49.71 152.15 2.69 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.389 -0.819 . . . . 0.0 109.791 -179.717 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.492 ' HG3' ' CE2' ' A' ' 19' ' ' PHE . 35.1 Cg_endo -78.27 -22.65 9.51 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.631 2.221 . . . . 0.0 110.17 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -134.95 164.15 24.76 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.53 27.62 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.771 2.314 . . . . 0.0 111.265 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -74.73 -68.86 0.5 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.88 -1.137 . . . . 0.0 109.588 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.778 ' O ' HD12 ' A' ' 82' ' ' LEU . . . -62.03 -40.53 96.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -0.905 . . . . 0.0 109.714 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.487 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 4.3 m-85 -52.95 -32.46 46.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.639 -179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -75.61 -38.46 59.0 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.26 -0.9 . . . . 0.0 109.65 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 48.8 t -61.33 -53.46 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.743 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.778 HD12 ' O ' ' A' ' 78' ' ' ALA . 3.2 mp -59.06 -18.7 37.38 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.274 -0.891 . . . . 0.0 109.814 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -76.47 -48.42 19.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.18 -0.95 . . . . 0.0 109.695 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.38 -35.44 80.9 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.143 -0.973 . . . . 0.0 109.563 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.535 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 0.1 OUTLIER -68.17 -16.21 63.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.491 -179.919 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 81.59 24.68 55.72 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.538 HG22 ' N ' ' A' ' 88' ' ' LYS . 5.6 mt -87.47 161.5 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.252 -1.146 . . . . 0.0 109.558 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.538 ' N ' HG22 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -94.5 112.13 23.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 109.317 179.858 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.563 HG22 ' N ' ' A' ' 90' ' ' TYR . 14.1 mt -82.03 168.14 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.67 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.593 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 1.2 m-85 -153.09 129.98 10.97 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.304 -0.873 . . . . 0.0 109.246 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.511 ' NH1' ' HA ' ' A' ' 93' ' ' THR . 0.7 OUTLIER -80.12 135.81 36.39 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.966 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.601 ' HB3' ' OG ' ' A' ' 72' ' ' SER . . . -86.64 149.79 24.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.216 -0.928 . . . . 0.0 109.627 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' THR . . . . . 0.511 ' HA ' ' NH1' ' A' ' 91' ' ' ARG . 73.4 p -86.0 -26.51 25.38 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 109.544 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.83 66.85 1.51 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.19 -67.71 0.36 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.256 -1.143 . . . . 0.0 109.466 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -171.56 132.95 0.77 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.304 -0.872 . . . . 0.0 109.33 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.466 HG11 ' HB3' ' A' ' 7' ' ' SER . 16.8 m -54.86 -19.76 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.168 -0.958 . . . . 0.0 109.575 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -68.27 -52.57 32.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.762 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -69.78 -39.19 76.79 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.146 -0.971 . . . . 0.0 109.498 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.443 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 5.1 m-20 -59.28 -36.73 76.09 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.163 -0.96 . . . . 0.0 109.259 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.912 HD11 HG21 ' A' ' 29' ' ' VAL . 11.0 tp -59.22 -50.93 72.15 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.287 -0.883 . . . . 0.0 109.308 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -70.12 -15.76 63.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.371 -0.831 . . . . 0.0 109.232 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.542 HD22 ' HG ' ' A' ' 109' ' ' LEU . 0.2 OUTLIER -72.6 -45.74 57.6 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.359 -0.838 . . . . 0.0 109.55 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.583 ' CE2' HG12 ' A' ' 3' ' ' ILE . 6.4 t80 -63.53 -17.23 62.58 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.865 . . . . 0.0 109.758 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.567 HG23 ' O ' ' A' ' 34' ' ' GLY . 19.2 m -69.2 -33.47 73.39 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 109.572 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -95.57 -14.72 23.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.527 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 71.17 45.53 48.82 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' ASN . . . . . 0.415 ' HB3' HD23 ' A' ' 103' ' ' LEU . 10.1 t-20 -97.21 -29.31 13.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.289 -1.124 . . . . 0.0 109.544 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.542 ' HG ' HD22 ' A' ' 103' ' ' LEU . 0.6 OUTLIER -57.11 155.89 7.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.342 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 5.3 pt-20 -96.06 144.88 25.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 6.1 pm0 -114.61 165.87 12.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.92 . . . . 0.0 109.501 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.516 ' O ' HD12 ' A' ' 89' ' ' ILE . 83.0 mt -136.4 120.21 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.261 -0.899 . . . . 0.0 109.254 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.339 -0.851 . . . . 0.0 109.332 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.4 ttm . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.414 ' CG ' ' HG3' ' A' ' 30' ' ' GLU . 2.1 mppt? -114.61 164.01 14.62 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.187 -0.945 . . . . 0.0 109.594 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.479 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 11.0 mt -131.68 135.72 58.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.291 -0.881 . . . . 0.0 109.655 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.584 ' CB ' HG21 ' A' ' 66' ' ' VAL . . . -123.48 129.96 52.0 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.57 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 1.112 HG21 HG23 ' A' ' 97' ' ' VAL . 6.3 mt -111.1 120.79 62.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.179 -0.951 . . . . 0.0 109.881 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.39 165.19 25.53 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.277 -0.889 . . . . 0.0 109.36 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.518 ' O ' ' CB ' ' A' ' 8' ' ' SER . 0.8 OUTLIER 70.22 -144.67 0.08 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.227 -0.921 . . . . 0.0 109.485 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.518 ' CB ' ' O ' ' A' ' 7' ' ' SER . 0.2 OUTLIER 77.02 3.35 3.31 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.139 -0.976 . . . . 0.0 109.554 -179.908 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.471 ' O ' ' HB3' ' A' ' 25' ' ' TYR . . . 46.47 -113.6 1.18 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.87 -5.85 7.41 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.225 -1.162 . . . . 0.0 109.481 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -141.18 -142.15 0.14 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.481 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.4 mt -105.11 -18.28 14.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.108 -0.995 . . . . 0.0 109.745 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -47.76 -40.32 18.22 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.406 ' O ' ' O ' ' A' ' 15' ' ' GLU . 3.6 m -75.54 81.42 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.283 -1.128 . . . . 0.0 109.636 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.475 ' O ' ' HB ' ' A' ' 97' ' ' VAL . 0.1 OUTLIER -48.17 -93.18 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.552 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 18.9 m -131.11 52.95 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.062 -1.024 . . . . 0.0 109.718 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.512 ' O ' ' CB ' ' A' ' 18' ' ' ARG . 1.3 p -99.07 136.61 38.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.174 -0.954 . . . . 0.0 109.255 179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.512 ' CB ' ' O ' ' A' ' 17' ' ' SER . 6.3 mtt-85 75.45 78.28 0.1 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.222 -0.924 . . . . 0.0 108.916 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.432 ' O ' ' C ' ' A' ' 20' ' ' PHE . 0.5 OUTLIER -79.65 -177.52 5.9 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.335 -0.853 . . . . 0.0 109.678 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.628 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 2.6 t80 -41.24 137.84 1.31 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.485 -0.76 . . . . 0.0 109.82 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 151.14 -64.12 0.38 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.471 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 2.0 tpp180 -155.04 18.87 0.43 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.147 -1.208 . . . . 0.0 109.8 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.79 113.43 18.67 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.276 -0.89 . . . . 0.0 109.661 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.583 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.7 Cg_endo -82.08 53.9 4.77 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.61 2.207 . . . . 0.0 110.462 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.583 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 98.6 m-85 -159.8 70.82 0.46 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.163 -0.96 . . . . 0.0 109.503 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.48 ' CE1' ' OD1' ' A' ' 44' ' ' ASN . 23.7 m-85 -83.61 119.03 24.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.204 -0.935 . . . . 0.0 109.536 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -93.56 122.45 36.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.234 -0.916 . . . . 0.0 109.67 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.515 HG12 HD12 ' A' ' 42' ' ' ILE . 15.1 mm -99.17 122.15 50.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 109.176 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 54.7 t -127.97 137.74 56.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.099 -1.0 . . . . 0.0 109.651 -179.689 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.444 ' HB3' ' OG ' ' A' ' 38' ' ' SER . 1.7 tt0 -124.61 137.82 54.36 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.3 -0.875 . . . . 0.0 109.379 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.411 ' HG3' ' HA ' ' A' ' 36' ' ' ILE . 7.9 ttm -116.06 145.18 43.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.189 -0.944 . . . . 0.0 109.647 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.61 -63.48 1.29 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.332 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.66 65.29 0.87 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.287 -0.883 . . . . 0.0 109.384 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.25 17.03 70.19 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 36' ' ' ILE . 3.0 t-20 -144.38 103.17 3.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.222 -1.164 . . . . 0.0 109.451 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.411 ' HA ' ' HG3' ' A' ' 31' ' ' MET . 2.6 mp -44.69 137.49 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.277 -0.89 . . . . 0.0 109.461 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -144.01 16.36 1.74 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 109.48 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.444 ' OG ' ' HB3' ' A' ' 30' ' ' GLU . 0.2 OUTLIER -166.68 122.86 1.21 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.259 -0.901 . . . . 0.0 109.441 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.6 m -142.9 110.16 5.68 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.196 -0.94 . . . . 0.0 109.6 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.91 153.98 46.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.31 -0.869 . . . . 0.0 109.2 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 8.0 p -113.76 144.34 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.204 -0.935 . . . . 0.0 109.675 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.515 HD12 HG12 ' A' ' 28' ' ' ILE . 23.5 mt -136.42 132.7 49.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.341 -0.849 . . . . 0.0 109.37 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -106.59 131.38 53.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.241 -0.912 . . . . 0.0 109.692 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.48 ' OD1' ' CE1' ' A' ' 26' ' ' PHE . 2.7 m120 . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.28 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.527 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.706 HD12 ' HB2' ' A' ' 78' ' ' ALA . 16.6 mm -70.4 -5.58 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -1.095 . . . . 0.0 109.555 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.67 -25.28 53.55 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.195 -0.94 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.527 HG22 ' O ' ' A' ' 54' ' ' GLY . 10.8 t -68.66 -7.9 37.49 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.201 -0.937 . . . . 0.0 109.556 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.425 ' O ' ' C ' ' A' ' 59' ' ' GLN . . . -61.67 -56.18 22.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.926 . . . . 0.0 109.249 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 58' ' ' ALA . 1.6 tm0? -44.21 -29.26 0.61 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.337 -0.852 . . . . 0.0 109.286 179.808 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 73.1 mt -75.59 -46.66 36.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 109.179 179.647 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.484 HG23 HG11 ' A' ' 66' ' ' VAL . 37.8 mt -56.03 -25.24 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 109.36 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.66 -38.08 80.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.279 -0.888 . . . . 0.0 109.681 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 26.8 m-20 -72.75 -4.94 34.5 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.247 -0.908 . . . . 0.0 109.721 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -83.9 -16.1 45.57 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.06 -12.74 59.27 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.584 HG21 ' CB ' ' A' ' 4' ' ' ALA . 2.6 p -58.21 98.77 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.268 -1.136 . . . . 0.0 109.66 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.542 ' HA ' HG23 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -79.28 -6.36 56.5 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 179.234 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.536 ' HB2' ' CE2' ' A' ' 104' ' ' PHE . . . -113.67 120.66 41.63 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.284 -0.885 . . . . 0.0 109.119 179.627 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 70.6 t -108.43 112.04 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.165 -0.959 . . . . 0.0 109.852 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.407 ' N ' HD13 ' A' ' 70' ' ' ILE . 3.2 mm -99.79 97.53 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.155 -0.965 . . . . 0.0 109.136 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.628 ' HB1' ' HB2' ' A' ' 20' ' ' PHE . . . -158.39 169.85 23.53 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.237 -0.914 . . . . 0.0 109.816 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.435 ' O ' ' C ' ' A' ' 73' ' ' SER . 9.1 t -133.33 50.65 2.21 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.364 -0.835 . . . . 0.0 109.048 179.79 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.463 ' HB3' ' HB3' ' A' ' 20' ' ' PHE . 60.5 p -41.26 149.55 0.36 Allowed Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.509 -0.745 . . . . 0.0 109.937 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 20' ' ' PHE . 36.2 Cg_endo -78.14 -35.26 1.35 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.657 2.238 . . . . 0.0 110.051 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -108.61 153.14 16.91 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.492 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 35.5 Cg_endo -77.72 1.15 9.13 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.537 2.158 . . . . 0.0 110.668 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.501 ' O ' HG23 ' A' ' 81' ' ' VAL . 5.4 t30 -59.93 -42.28 93.64 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.223 -0.923 . . . . 0.0 109.686 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.706 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -64.17 -67.59 0.42 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 109.681 -179.836 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.794 ' CD1' HG21 ' A' ' 89' ' ' ILE . 16.6 m-30 -53.06 -19.27 2.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.232 -0.917 . . . . 0.0 109.875 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.492 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 36.3 tt0 -70.73 -49.93 41.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.122 -0.986 . . . . 0.0 109.579 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 77' ' ' ASN . 3.0 t -67.4 -48.19 78.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.147 -0.971 . . . . 0.0 109.665 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 36.1 mt -55.59 -29.32 58.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.114 -0.992 . . . . 0.0 109.508 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 64.0 t-20 -68.03 -38.89 83.07 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.265 -0.897 . . . . 0.0 109.383 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.14 -26.29 61.15 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.331 -0.856 . . . . 0.0 109.47 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.673 HD13 HD11 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -71.87 -37.11 70.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.955 . . . . 0.0 109.551 -179.94 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.53 13.08 25.17 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.673 HD11 HD13 ' A' ' 85' ' ' LEU . 3.7 mt -85.38 169.54 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.278 -1.131 . . . . 0.0 109.623 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.512 ' N ' HG22 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -99.17 123.67 43.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.25 179.842 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.794 HG21 ' CD1' ' A' ' 79' ' ' PHE . 1.6 mt -95.16 161.84 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.19 -0.944 . . . . 0.0 109.757 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.532 ' CD1' ' O ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -148.21 133.93 18.9 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.444 -179.862 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.421 ' HB2' ' HB2' ' A' ' 110' ' ' GLU . 0.0 OUTLIER -89.45 123.12 33.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.148 -0.97 . . . . 0.0 109.475 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.16 87.78 5.48 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.916 . . . . 0.0 109.681 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' THR . . . . . 0.527 ' O ' HG22 ' A' ' 93' ' ' THR . 18.6 m -139.23 21.02 2.6 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.223 -0.923 . . . . 0.0 109.412 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -74.46 -77.8 0.64 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 92.8 m -159.81 -70.78 0.08 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.246 -1.15 . . . . 0.0 109.386 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.42 ' HA ' ' HB2' ' A' ' 15' ' ' GLU . 37.0 m -132.38 148.71 52.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.303 -0.873 . . . . 0.0 109.384 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 1.112 HG23 HG21 ' A' ' 5' ' ' ILE . 12.1 p -44.36 -27.98 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.345 -0.847 . . . . 0.0 109.487 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -66.69 -52.81 40.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.337 -0.852 . . . . 0.0 109.734 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.434 ' O ' ' CG ' ' A' ' 103' ' ' LEU . 4.7 tt0 -71.02 -16.35 62.61 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.136 -0.977 . . . . 0.0 109.493 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.417 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 2.1 m-80 -75.95 -40.76 53.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.397 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 30.9 tp -60.58 -47.69 85.07 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.336 -0.853 . . . . 0.0 109.433 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.87 -20.43 56.29 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.432 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.434 ' CG ' ' O ' ' A' ' 99' ' ' GLU . 6.4 mt -67.37 -43.5 81.26 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.312 -0.868 . . . . 0.0 109.676 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.541 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.1 t80 -61.28 -29.17 69.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.28 -0.888 . . . . 0.0 109.453 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 92.0 m -62.34 -40.59 96.88 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.211 -0.93 . . . . 0.0 109.563 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 107' ' ' GLY . 6.4 mm-40 -87.94 3.21 49.44 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.181 -0.949 . . . . 0.0 109.729 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . 44.25 39.03 5.24 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -103.22 -10.94 18.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -1.162 . . . . 0.0 109.607 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.482 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 0.7 OUTLIER -74.05 -161.17 0.11 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.208 -0.932 . . . . 0.0 109.482 -179.989 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.532 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 7.0 mt-10 -95.07 113.88 25.63 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.304 -0.872 . . . . 0.0 109.418 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -103.18 142.8 33.54 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.35 -0.844 . . . . 0.0 109.599 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.465 ' O ' ' HB2' ' A' ' 113' ' ' ARG . 13.6 mm -129.84 117.53 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.272 -0.893 . . . . 0.0 109.302 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.465 ' HB2' ' O ' ' A' ' 112' ' ' ILE . 3.4 ttt-85 . . . . . 0 N--CA 1.489 1.495 0 O-C-N 121.195 -0.94 . . . . 0.0 109.619 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.09 155.77 17.84 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.202 -0.936 . . . . 0.0 109.309 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.486 ' HA ' ' O ' ' A' ' 68' ' ' ALA . 7.8 mt -120.31 117.41 53.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.277 -0.889 . . . . 0.0 110.052 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.992 ' HB2' HG11 ' A' ' 66' ' ' VAL . . . -112.51 116.92 31.02 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.317 -0.864 . . . . 0.0 108.672 179.275 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.842 HG23 ' HB ' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -102.98 135.23 41.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.128 -0.983 . . . . 0.0 109.926 -179.311 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.55 143.24 46.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.39 -0.819 . . . . 0.0 109.175 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.715 ' CB ' HG11 ' A' ' 97' ' ' VAL . 0.7 OUTLIER -151.39 157.96 43.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.208 -0.933 . . . . 0.0 109.683 -179.792 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 66.9 p -119.39 0.96 11.2 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.324 -0.86 . . . . 0.0 109.388 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.548 ' O ' ' CG ' ' A' ' 25' ' ' TYR . . . -125.62 -153.96 8.59 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.561 HG23 ' CE1' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -126.45 -30.52 2.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.183 -1.186 . . . . 0.0 109.664 -179.849 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 173.31 -43.8 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.122 -0.986 . . . . 0.0 109.528 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -80.66 5.15 16.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.299 -0.875 . . . . 0.0 109.629 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -166.31 31.43 0.21 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.854 ' HB3' HG22 ' A' ' 97' ' ' VAL . 5.0 m -77.06 79.43 3.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.124 -1.221 . . . . 0.0 109.357 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.713 ' C ' HG23 ' A' ' 16' ' ' VAL . 9.2 mm-40 -76.91 1.57 17.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.302 -0.874 . . . . 0.0 109.576 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.713 HG23 ' C ' ' A' ' 15' ' ' GLU . 1.9 t 73.68 18.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.403 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.1 t 59.11 176.04 0.07 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.32 -0.863 . . . . 0.0 109.399 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -109.04 -36.25 6.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -131.79 123.18 27.09 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.875 . . . . 0.0 109.363 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.714 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 2.5 t80 -62.23 96.72 0.08 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.905 . . . . 0.0 109.497 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -136.76 -87.02 0.2 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.428 ' O ' ' C ' ' A' ' 23' ' ' ALA . 1.8 ptp85 -114.7 43.85 1.86 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -1.111 . . . . 0.0 109.18 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.446 ' HB3' ' CE1' ' A' ' 26' ' ' PHE . . . -42.79 114.14 1.45 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.406 -0.808 . . . . 0.0 109.405 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.58 21.14 0.88 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.578 2.185 . . . . 0.0 110.947 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.561 ' CE1' HG23 ' A' ' 10' ' ' THR . 0.5 OUTLIER -159.51 70.78 0.47 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.949 -1.094 . . . . 0.0 109.301 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.446 ' CE1' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -79.52 126.27 30.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.441 -179.917 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.22 115.94 31.65 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.407 HD12 HG23 ' A' ' 28' ' ' ILE . 28.9 mm -96.78 131.43 43.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.3 -0.875 . . . . 0.0 109.661 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.405 ' CG1' HG23 ' A' ' 36' ' ' ILE . 4.5 t -130.25 137.09 57.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.295 -0.878 . . . . 0.0 109.117 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -118.17 95.99 5.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.095 -1.003 . . . . 0.0 109.816 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.408 ' HE2' ' HB2' ' A' ' 31' ' ' MET . 41.1 ttm -81.91 146.06 30.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.029 179.603 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -99.96 -70.01 0.75 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.113 -0.992 . . . . 0.0 110.002 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 19.3 tttm -138.59 62.71 1.54 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.094 -1.004 . . . . 0.0 109.95 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.51 31.64 36.53 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 36' ' ' ILE . 2.9 p30 -159.58 97.47 1.33 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.169 -1.195 . . . . 0.0 109.552 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.545 HG12 HD21 ' A' ' 101' ' ' LEU . 2.9 mp -44.06 132.39 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.247 -0.908 . . . . 0.0 109.327 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -130.01 18.97 5.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.119 -0.988 . . . . 0.0 109.737 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 175.38 129.9 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.078 -1.014 . . . . 0.0 109.619 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.4 p -149.58 107.51 3.71 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.323 -0.86 . . . . 0.0 109.373 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.22 164.27 15.42 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.234 -0.916 . . . . 0.0 109.537 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.7 p -124.42 148.03 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.497 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.525 HD12 ' H ' ' A' ' 43' ' ' GLU . 2.6 tp -141.65 154.27 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.302 -0.874 . . . . 0.0 109.392 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.525 ' H ' HD12 ' A' ' 42' ' ' ILE . 26.7 mp0 -93.9 68.8 3.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.267 -0.895 . . . . 0.0 109.497 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.307 -0.87 . . . . 0.0 109.727 179.932 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.373 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.446 HD12 ' HB2' ' A' ' 78' ' ' ALA . 46.6 mm -69.77 -45.82 76.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.127 -1.219 . . . . 0.0 109.479 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.17 -33.26 75.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.221 -0.924 . . . . 0.0 109.535 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 21.6 m -58.95 -23.9 62.01 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.18 -0.95 . . . . 0.0 109.634 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -53.51 -51.94 61.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.258 -0.901 . . . . 0.0 109.574 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.498 ' OE1' ' CG1' ' A' ' 81' ' ' VAL . 1.4 tp60 -46.06 -44.73 15.64 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.188 -0.945 . . . . 0.0 109.504 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 23.5 mt -62.63 -40.22 87.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.193 -0.942 . . . . 0.0 109.522 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 50.3 mt -66.61 -20.38 27.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.201 -0.937 . . . . 0.0 109.487 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.513 ' CB ' HD23 ' A' ' 85' ' ' LEU . . . -77.16 -36.23 55.33 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.256 -0.903 . . . . 0.0 109.687 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 52.2 m-20 -75.47 -0.15 19.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.258 -0.901 . . . . 0.0 109.694 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -82.9 -7.68 59.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.129 -0.982 . . . . 0.0 109.747 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.11 -23.98 32.14 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.992 HG11 ' HB2' ' A' ' 4' ' ' ALA . 19.2 m -59.51 93.9 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -1.152 . . . . 0.0 109.688 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.419 ' O ' ' HD3' ' A' ' 88' ' ' LYS . 26.9 mtpt -79.49 -3.45 46.75 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.36 -0.838 . . . . 0.0 108.793 179.286 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' ' 3' ' ' ILE . . . -135.21 103.14 5.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.227 -0.921 . . . . 0.0 109.19 179.702 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.808 ' O ' HG23 ' A' ' 89' ' ' ILE . 55.1 t -110.93 129.99 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.023 -1.048 . . . . 0.0 109.999 -179.506 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.842 ' HB ' HG23 ' A' ' 5' ' ' ILE . 3.6 mp -92.68 119.38 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.286 -0.883 . . . . 0.0 109.078 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.714 ' HB1' ' HB2' ' A' ' 20' ' ' PHE . . . -157.3 176.97 12.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.169 -0.957 . . . . 0.0 109.693 -179.724 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 73' ' ' SER . 3.1 p -152.64 51.89 0.76 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.48 -0.762 . . . . 0.0 109.494 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.563 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 0.1 OUTLIER -44.29 167.51 0.09 OUTLIER Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.172 -0.955 . . . . 0.0 109.436 179.962 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.63 -1.92 12.02 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.613 2.209 . . . . 0.0 110.309 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -162.63 168.61 37.6 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.552 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.2 Cg_endo -79.17 7.9 4.14 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.671 2.248 . . . . 0.0 110.582 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -58.57 -44.54 89.77 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.178 -0.951 . . . . 0.0 109.649 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.446 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -77.04 -48.87 16.68 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.176 -0.952 . . . . 0.0 109.851 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.563 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 2.9 m-85 -55.06 -19.81 8.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.209 -0.932 . . . . 0.0 109.776 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.68 -46.71 24.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.147 -0.97 . . . . 0.0 109.815 -179.731 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.498 ' CG1' ' OE1' ' A' ' 59' ' ' GLN . 22.2 t -64.49 -51.09 72.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.154 -0.966 . . . . 0.0 109.495 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.792 ' HB3' HD11 ' A' ' 89' ' ' ILE . 0.9 OUTLIER -55.03 -46.44 75.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.903 . . . . 0.0 109.71 -179.88 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 53.6 t30 -57.81 -41.53 82.36 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.219 -0.925 . . . . 0.0 109.534 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.49 -50.39 71.89 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.497 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.549 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 2.4 mp -60.21 -28.1 67.71 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.175 -0.953 . . . . 0.0 109.477 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.43 10.24 17.77 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.667 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.644 HD12 ' N ' ' A' ' 87' ' ' ILE . 3.2 mp -94.38 147.71 5.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.115 -1.226 . . . . 0.0 109.439 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.419 ' HD3' ' O ' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -104.81 155.91 18.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.259 -0.901 . . . . 0.0 109.818 -179.835 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.808 HG23 ' O ' ' A' ' 69' ' ' VAL . 3.5 mp -136.6 140.21 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.254 -0.904 . . . . 0.0 109.507 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.556 ' CD2' ' O ' ' A' ' 109' ' ' LEU . 16.9 m-30 -102.82 167.7 9.7 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.313 -0.867 . . . . 0.0 109.53 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.558 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 0.0 OUTLIER -85.7 130.43 34.57 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.245 -0.909 . . . . 0.0 109.866 -179.615 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -87.76 116.89 26.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.422 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 63.4 p -61.77 -26.32 68.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.281 -0.887 . . . . 0.0 109.372 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.56 18.22 42.36 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 58.4 m -86.35 -74.88 0.41 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -1.134 . . . . 0.0 109.473 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 14' ' ' SER . 74.4 m -155.98 144.08 19.84 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.321 -0.862 . . . . 0.0 109.43 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.854 HG22 ' HB3' ' A' ' 14' ' ' SER . 28.8 m -68.94 -35.9 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.885 . . . . 0.0 109.698 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -60.08 -38.06 81.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.135 -0.978 . . . . 0.0 109.323 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.402 ' OE1' ' HA ' ' A' ' 99' ' ' GLU . 0.0 OUTLIER -71.85 -50.69 27.32 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.335 -0.853 . . . . 0.0 109.433 179.881 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.506 ' HA ' HD12 ' A' ' 103' ' ' LEU . 42.2 m-20 -49.62 -34.44 18.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -0.893 . . . . 0.0 109.551 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.545 HD21 HG12 ' A' ' 36' ' ' ILE . 12.3 tp -52.99 -55.86 20.35 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.247 -0.908 . . . . 0.0 109.725 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.49 -20.49 61.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.13 -0.982 . . . . 0.0 109.728 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.506 HD12 ' HA ' ' A' ' 100' ' ' ASN . 23.9 mt -71.74 -25.38 62.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.174 -0.954 . . . . 0.0 109.611 -179.782 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.447 ' HE2' ' HB1' ' A' ' 68' ' ' ALA . 41.3 t80 -70.0 -38.11 75.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.207 -0.933 . . . . 0.0 109.237 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 48.6 m -74.56 -24.39 58.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.857 . . . . 0.0 109.504 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -80.81 -18.52 47.25 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.193 -0.942 . . . . 0.0 109.5 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 76.24 24.48 68.47 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -92.68 -37.92 12.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.14 -1.212 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.556 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 0.0 OUTLIER -88.56 119.98 29.52 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.135 -0.978 . . . . 0.0 109.479 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.526 ' HA ' ' CG ' ' A' ' 90' ' ' TYR . 16.6 pt-20 -149.29 173.83 13.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.463 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.558 ' HB2' ' N ' ' A' ' 91' ' ' ARG . 8.1 tp10 -175.77 -111.24 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.318 -0.864 . . . . 0.0 109.84 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.478 ' N ' ' HG3' ' A' ' 111' ' ' GLU . 19.8 tt -84.21 134.58 26.65 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 O-C-N 121.08 -1.012 . . . . 0.0 110.072 -179.222 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.559 0 O-C-N 121.442 -0.786 . . . . 0.0 109.285 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.3 ptp . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.484 ' HG2' ' HG3' ' A' ' 30' ' ' GLU . 0.1 OUTLIER -131.67 144.29 50.91 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.245 -0.909 . . . . 0.0 109.583 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.569 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 5.3 mt -118.32 104.45 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.288 -0.883 . . . . 0.0 109.565 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -106.16 116.41 31.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.329 -0.857 . . . . 0.0 109.31 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.681 HG21 HG13 ' A' ' 97' ' ' VAL . 2.8 mp -94.61 120.8 44.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.15 -0.969 . . . . 0.0 109.467 -179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 7' ' ' SER . . . -61.91 150.43 37.61 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.278 -0.889 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.507 ' O ' ' CB ' ' A' ' 8' ' ' SER . 0.0 OUTLIER 53.6 169.95 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.28 -0.887 . . . . 0.0 109.598 179.963 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.758 ' HB3' HG11 ' A' ' 97' ' ' VAL . 0.2 OUTLIER 162.52 -35.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.322 -0.862 . . . . 0.0 109.321 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.457 ' HA3' ' HB2' ' A' ' 14' ' ' SER . . . 75.91 9.56 85.16 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER 61.92 16.78 8.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.244 -1.151 . . . . 0.0 109.46 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.0 t0 -173.17 -167.48 0.41 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.237 -0.915 . . . . 0.0 109.597 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.2 mt -79.85 -1.85 40.87 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.211 -0.93 . . . . 0.0 109.613 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.81 -61.62 7.01 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.457 ' HB2' ' HA3' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -77.31 83.23 3.76 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.198 -1.177 . . . . 0.0 109.505 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.404 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 7.2 mt-10 -72.22 83.1 1.02 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.34 -0.85 . . . . 0.0 109.176 179.724 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.417 ' O ' ' C ' ' A' ' 17' ' ' SER . 22.1 t 62.6 63.97 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.916 . . . . 0.0 109.308 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.479 ' HB3' ' CB ' ' A' ' 7' ' ' SER . 8.2 t -43.77 159.01 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.311 -0.868 . . . . 0.0 109.426 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 22.3 mtp85 -95.67 30.62 2.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.376 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -127.38 159.03 35.68 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.948 . . . . 0.0 109.474 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -133.17 -32.51 1.19 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.186 -0.946 . . . . 0.0 109.903 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -101.5 -37.29 3.55 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.438 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -84.31 -25.9 28.91 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.131 -1.217 . . . . 0.0 109.775 -179.753 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.419 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -42.49 103.01 0.29 Allowed Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.335 -0.853 . . . . 0.0 109.7 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.482 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.7 Cg_endo -80.68 41.28 1.11 Allowed 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 122.602 2.202 . . . . 0.0 110.533 179.714 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.482 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 84.1 m-85 -158.19 68.5 0.49 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.106 -0.996 . . . . 0.0 109.286 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.442 ' CE1' ' HA ' ' A' ' 6' ' ' ALA . 0.8 OUTLIER -83.02 116.49 22.3 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.271 -0.893 . . . . 0.0 109.585 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 1.4 ttt -94.21 132.42 38.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.156 -0.965 . . . . 0.0 109.635 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.682 ' O ' HG23 ' A' ' 28' ' ' ILE . 5.1 tt -129.42 116.81 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.897 . . . . 0.0 109.401 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.868 HG13 ' O ' ' A' ' 38' ' ' SER . 94.6 t -125.11 129.7 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 109.388 -179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.484 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 26.9 tt0 -99.05 99.45 10.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.226 -0.921 . . . . 0.0 109.635 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.2 tpp -81.8 134.24 35.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.309 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -99.0 -68.66 0.79 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -0.915 . . . . 0.0 109.681 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -129.99 81.47 2.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.204 -0.935 . . . . 0.0 109.631 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.15 28.04 24.97 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.412 ' O ' ' N ' ' A' ' 37' ' ' GLU . 1.3 m-20 -147.73 108.49 4.18 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.173 -1.192 . . . . 0.0 109.536 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.726 HG23 ' CG1' ' A' ' 29' ' ' VAL . 72.6 mt -48.28 98.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.169 -0.957 . . . . 0.0 109.405 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.412 ' N ' ' O ' ' A' ' 35' ' ' ASN . 34.7 mt-10 -96.46 9.77 40.3 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.614 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.868 ' O ' HG13 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -169.6 122.67 0.75 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 179.99 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.611 ' HA ' HG22 ' A' ' 29' ' ' VAL . 0.7 OUTLIER -141.03 107.95 5.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 109.541 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -132.38 138.59 47.77 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.197 -0.939 . . . . 0.0 109.437 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.9 t -98.63 154.72 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.269 -0.895 . . . . 0.0 109.547 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 6.6 mt -131.92 134.33 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.341 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.445 ' O ' ' C ' ' A' ' 44' ' ' ASN . 53.7 mt-10 -91.06 85.92 6.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.297 -0.877 . . . . 0.0 109.527 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.445 ' C ' ' O ' ' A' ' 43' ' ' GLU . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.653 0 O-C-N 121.371 -0.831 . . . . 0.0 109.473 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.583 HD12 ' HB2' ' A' ' 78' ' ' ALA . 51.0 mm -60.77 -14.08 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.258 -1.142 . . . . 0.0 109.63 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.403 ' O ' ' C ' ' A' ' 57' ' ' THR . 0.0 OUTLIER -65.01 -37.04 86.34 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.211 -0.93 . . . . 0.0 109.658 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.403 ' C ' ' O ' ' A' ' 56' ' ' ARG . 14.6 m -43.48 -33.88 1.21 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.202 -0.936 . . . . 0.0 109.723 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -51.29 -52.36 45.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -0.933 . . . . 0.0 109.771 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -54.54 -34.31 61.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.933 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.6 mt -69.39 -65.76 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.127 -0.983 . . . . 0.0 109.726 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 18.8 pt -51.71 -20.95 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.741 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.401 ' HB1' HD11 ' A' ' 87' ' ' ILE . . . -71.16 -47.31 58.46 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.212 -0.93 . . . . 0.0 109.621 -179.809 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -76.42 1.58 16.01 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.296 -0.877 . . . . 0.0 109.757 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -95.34 -2.11 49.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.088 -1.008 . . . . 0.0 109.772 -179.757 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 93.59 -14.41 65.36 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 31.8 t -49.66 91.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -1.119 . . . . 0.0 109.632 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' GLY . 3.6 mmmp? -79.3 -7.39 58.27 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.338 -0.851 . . . . 0.0 108.811 179.371 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.569 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -131.26 123.44 28.41 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.287 -0.883 . . . . 0.0 109.199 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 57.0 t -121.34 106.69 18.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.161 -0.962 . . . . 0.0 109.853 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.71 HD13 ' HB2' ' A' ' 90' ' ' TYR . 13.4 mm -83.2 104.32 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.18 -0.95 . . . . 0.0 109.03 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -143.74 173.5 11.62 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.22 -0.925 . . . . 0.0 109.789 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.0 p -145.49 40.01 1.19 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.374 -0.829 . . . . 0.0 109.249 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.421 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -45.05 149.76 0.83 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.355 -0.841 . . . . 0.0 109.669 -179.905 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.2 Cg_endo -78.61 4.97 5.92 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.737 2.291 . . . . 0.0 110.336 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.424 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -144.42 148.46 20.24 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.424 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 36.2 Cg_endo -79.38 11.16 2.75 Favored 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 122.716 2.277 . . . . 0.0 110.79 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -73.54 -36.07 65.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.077 -1.014 . . . . 0.0 109.691 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -68.21 -50.59 53.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.954 . . . . 0.0 109.628 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.536 ' CD1' ' N ' ' A' ' 79' ' ' PHE . 1.4 m-85 -65.04 -18.31 65.19 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.133 -0.98 . . . . 0.0 109.519 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -67.53 -49.67 62.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.111 -0.993 . . . . 0.0 109.538 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -71.2 -43.88 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.194 -0.941 . . . . 0.0 109.609 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.461 ' HA ' HD23 ' A' ' 82' ' ' LEU . 20.1 mt -49.66 -49.36 47.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.173 -0.955 . . . . 0.0 109.446 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -61.35 -34.3 75.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.228 -0.92 . . . . 0.0 109.302 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -67.31 -25.65 66.12 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.434 -0.792 . . . . 0.0 109.6 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 4.5 mt -97.7 18.43 15.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.891 . . . . 0.0 109.37 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 56.3 62.84 5.89 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.401 HD11 ' HB1' ' A' ' 62' ' ' ALA . 97.7 mt -132.38 144.9 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.287 -1.126 . . . . 0.0 109.306 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.482 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 0.2 OUTLIER -82.77 124.64 30.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.296 -0.877 . . . . 0.0 109.423 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.535 HG21 ' CD1' ' A' ' 79' ' ' PHE . 3.7 mt -104.16 129.95 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.52 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.71 ' HB2' HD13 ' A' ' 70' ' ' ILE . 3.6 m-85 -116.46 157.57 24.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.405 -0.809 . . . . 0.0 109.249 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.407 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 1.2 ttt-85 -96.09 143.22 27.42 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.245 -0.909 . . . . 0.0 109.568 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.97 86.72 2.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.4 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' THR . . . . . 0.622 ' O ' HG22 ' A' ' 93' ' ' THR . 34.1 m -149.35 26.85 0.85 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.192 -0.943 . . . . 0.0 109.421 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.17 -71.8 1.23 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 15.8 m -165.92 -46.17 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.205 -1.174 . . . . 0.0 109.727 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.77 162.9 38.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.23 -0.919 . . . . 0.0 109.79 -179.684 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.758 HG11 ' HB3' ' A' ' 8' ' ' SER . 47.4 t -77.08 -40.03 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.272 -0.893 . . . . 0.0 109.351 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -59.15 -50.06 75.49 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.803 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.428 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 1.2 tt0 -72.17 -33.0 67.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.12 -0.988 . . . . 0.0 109.645 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -57.2 -43.39 82.71 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.224 -0.922 . . . . 0.0 109.759 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.591 HD21 HG11 ' A' ' 29' ' ' VAL . 51.9 tp -51.39 -43.14 61.83 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -0.933 . . . . 0.0 109.795 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 7.6 tptm -75.18 -30.5 60.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.138 -0.977 . . . . 0.0 109.762 -179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.428 ' HG ' ' O ' ' A' ' 99' ' ' GLU . 48.6 mt -67.09 -23.96 65.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.165 -0.959 . . . . 0.0 109.608 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 104' ' ' PHE . 24.4 t80 -58.79 -48.07 82.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.198 -0.939 . . . . 0.0 109.357 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 55.4 m -65.28 -39.1 92.13 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.348 -0.845 . . . . 0.0 109.304 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -70.98 -6.81 41.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.234 -0.916 . . . . 0.0 109.505 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 56.16 30.65 58.15 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.306 -1.517 . . . . 0.0 109.306 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -83.66 -28.84 28.1 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.313 -1.11 . . . . 0.0 109.529 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -138.6 138.48 37.94 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.073 -1.017 . . . . 0.0 109.763 -179.805 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.596 ' HA ' ' CD2' ' A' ' 90' ' ' TYR . 1.7 pt-20 -170.76 -151.54 0.08 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.324 -0.86 . . . . 0.0 109.449 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.501 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 0.7 OUTLIER -163.49 -112.16 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.257 -0.902 . . . . 0.0 109.623 -179.81 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.416 HD12 HD13 ' A' ' 89' ' ' ILE . 2.6 mt -83.33 90.34 2.42 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 O-C-N 121.154 -0.966 . . . . 0.0 109.489 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.206 -0.934 . . . . 0.0 109.321 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 65' ' ' GLY . 4.4 mtmt -118.25 145.97 44.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.308 -0.87 . . . . 0.0 109.293 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.632 HD11 ' CD1' ' A' ' 104' ' ' PHE . 5.3 mt -119.76 111.1 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.348 -0.845 . . . . 0.0 109.616 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.667 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -115.27 122.86 47.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.336 -0.852 . . . . 0.0 109.219 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.631 HG23 ' HB ' ' A' ' 70' ' ' ILE . 2.5 mp -98.4 142.61 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.233 -0.917 . . . . 0.0 109.543 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.498 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -81.49 155.84 25.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.358 -0.839 . . . . 0.0 109.755 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.467 ' HB2' ' HB3' ' A' ' 17' ' ' SER . 1.0 OUTLIER 52.83 -89.98 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.659 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.498 ' N ' ' O ' ' A' ' 6' ' ' ALA . 3.0 m 62.85 24.22 14.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.911 . . . . 0.0 109.566 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 44.07 -107.46 0.13 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.81 -76.91 0.13 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -1.141 . . . . 0.0 109.494 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -158.2 -43.71 0.06 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.232 -0.918 . . . . 0.0 109.614 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.59 -0.44 57.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -0.938 . . . . 0.0 109.55 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.12 19.91 1.09 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 8' ' ' SER . 9.7 p -77.02 81.91 3.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.355 -1.085 . . . . 0.0 109.464 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.882 ' O ' HG22 ' A' ' 97' ' ' VAL . 2.7 mt-10 -77.22 -137.5 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.192 -0.943 . . . . 0.0 109.025 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.695 ' HA ' HG13 ' A' ' 97' ' ' VAL . 6.1 p -88.75 34.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.066 -1.021 . . . . 0.0 109.587 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.467 ' HB3' ' HB2' ' A' ' 7' ' ' SER . 0.5 OUTLIER 69.32 -157.7 0.17 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.349 -0.845 . . . . 0.0 109.479 179.921 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.4 -72.88 0.12 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -112.38 -164.54 0.92 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.189 -0.944 . . . . 0.0 109.611 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.487 ' CE1' ' HB2' ' A' ' 6' ' ' ALA . 24.8 t80 -158.05 48.98 0.39 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.333 -0.854 . . . . 0.0 109.499 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -127.27 -68.44 0.15 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.424 ' O ' ' C ' ' A' ' 23' ' ' ALA . 55.1 mtt180 -112.49 16.76 19.72 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.311 -1.111 . . . . 0.0 109.398 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.424 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -43.46 107.3 0.56 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.323 -0.861 . . . . 0.0 109.619 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.57 44.05 1.66 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.601 2.2 . . . . 0.0 110.604 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.488 ' CE1' ' HG2' ' A' ' 43' ' ' GLU . 4.9 m-85 -158.02 70.09 0.55 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.112 -0.993 . . . . 0.0 109.267 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.521 ' CE2' HD11 ' A' ' 61' ' ' ILE . 4.4 m-30 -79.44 121.96 25.82 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.36 -0.837 . . . . 0.0 109.492 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.9 117.67 35.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.241 -0.912 . . . . 0.0 109.325 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.422 HD13 ' HB1' ' A' ' 4' ' ' ALA . 39.7 mm -104.55 130.95 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.219 -0.926 . . . . 0.0 109.526 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.77 HG11 HD21 ' A' ' 101' ' ' LEU . 82.8 t -131.33 132.17 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.328 -0.857 . . . . 0.0 109.5 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.455 ' HB2' ' CB ' ' A' ' 38' ' ' SER . 7.8 mt-10 -106.64 163.71 12.67 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.322 -0.861 . . . . 0.0 109.376 179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.54 ' HE3' ' CD1' ' A' ' 3' ' ' ILE . 41.9 ttm -147.74 139.05 23.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.174 -0.954 . . . . 0.0 109.538 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.05 -70.5 0.71 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.934 . . . . 0.0 109.578 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 6.3 mtmt -136.17 73.99 1.48 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.447 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.617 ' HA2' HG23 ' A' ' 105' ' ' THR . . . 68.53 16.2 69.34 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.46 103.21 6.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.316 -1.108 . . . . 0.0 109.456 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.413 HG13 ' CE ' ' A' ' 31' ' ' MET . 2.0 mt -66.68 115.53 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.238 -0.914 . . . . 0.0 109.579 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -130.97 33.63 4.16 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.219 -0.926 . . . . 0.0 109.237 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.455 ' CB ' ' HB2' ' A' ' 30' ' ' GLU . 0.6 OUTLIER -161.22 100.11 1.21 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -0.873 . . . . 0.0 109.474 -179.87 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 56.4 m -129.01 104.84 7.81 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.161 -0.962 . . . . 0.0 109.087 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -126.05 125.46 42.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.334 -0.854 . . . . 0.0 109.83 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.5 p -98.54 139.65 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.378 -0.826 . . . . 0.0 109.119 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 5.5 mt -139.81 142.68 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.177 -0.952 . . . . 0.0 109.727 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.488 ' HG2' ' CE1' ' A' ' 25' ' ' TYR . 12.4 mt-10 -94.9 142.15 27.81 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.531 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.414 ' CG ' ' O ' ' A' ' 44' ' ' ASN . 3.1 p30 . . . . . 0 N--CA 1.49 1.568 0 O-C-N 121.231 -0.918 . . . . 0.0 109.365 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.607 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.438 HD12 ' HB2' ' A' ' 78' ' ' ALA . 24.2 mm -67.87 -8.03 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -1.155 . . . . 0.0 109.646 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -69.24 -33.33 73.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.927 . . . . 0.0 109.666 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.607 HG22 ' O ' ' A' ' 54' ' ' GLY . 13.2 t -58.82 -15.54 12.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.297 -0.877 . . . . 0.0 109.783 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.85 -46.02 85.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.804 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.722 ' HG3' HD11 ' A' ' 85' ' ' LEU . 52.6 tt0 -65.5 -28.59 69.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.269 -0.894 . . . . 0.0 109.805 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.2 mm -75.9 -29.21 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.175 -0.953 . . . . 0.0 109.718 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.521 HD11 ' CE2' ' A' ' 26' ' ' PHE . 65.8 mt -75.27 -41.54 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.147 -0.971 . . . . 0.0 109.636 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.45 -26.29 66.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.154 -0.966 . . . . 0.0 109.627 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -76.68 -5.77 49.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.192 -0.943 . . . . 0.0 109.674 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -90.94 27.6 1.78 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.136 -0.977 . . . . 0.0 109.618 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 2' ' ' LYS . . . 66.72 11.84 58.22 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.667 HG11 ' HB3' ' A' ' 4' ' ' ALA . 96.0 t -87.06 91.81 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.2 -1.177 . . . . 0.0 109.386 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.483 ' O ' ' HB2' ' A' ' 88' ' ' LYS . 39.2 mmtt -79.43 -4.76 52.65 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.432 -0.792 . . . . 0.0 108.863 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.463 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -124.27 107.45 11.2 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.521 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 60.9 t -104.96 119.14 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.366 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.631 ' HB ' HG23 ' A' ' 5' ' ' ILE . 3.1 mm -99.24 108.19 21.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.347 -0.846 . . . . 0.0 109.397 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -153.37 173.79 15.18 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.255 -0.903 . . . . 0.0 109.557 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.33 49.32 1.43 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.444 -0.785 . . . . 0.0 109.224 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.402 ' OG ' ' HB3' ' A' ' 20' ' ' PHE . 1.0 OUTLIER -50.42 145.53 10.39 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.328 -0.858 . . . . 0.0 109.513 -179.864 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.05 -0.08 10.34 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 122.576 2.184 . . . . 0.0 110.477 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.76 154.67 24.95 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.47 -1.66 11.8 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.686 2.257 . . . . 0.0 110.574 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -53.66 -48.19 69.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.237 -0.914 . . . . 0.0 109.643 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.438 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -70.48 -59.29 2.94 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.279 -0.888 . . . . 0.0 109.881 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.717 ' CD1' HG21 ' A' ' 89' ' ' ILE . 25.1 m-85 -46.98 -23.52 0.47 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.934 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 14.7 mm-40 -71.16 -53.05 15.85 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.096 -1.003 . . . . 0.0 109.566 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.429 ' H ' HG23 ' A' ' 81' ' ' VAL . 4.9 t -63.03 -46.46 96.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.162 -0.961 . . . . 0.0 109.432 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.522 HD22 HG12 ' A' ' 89' ' ' ILE . 0.0 OUTLIER -52.23 -56.26 15.83 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.287 -0.883 . . . . 0.0 109.399 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -54.83 -33.41 61.63 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 109.503 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -63.03 -46.22 88.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.196 -0.94 . . . . 0.0 109.427 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.722 HD11 ' HG3' ' A' ' 59' ' ' GLN . 0.2 OUTLIER -64.62 -11.55 36.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.419 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 79.78 31.25 40.7 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.505 HG22 ' H ' ' A' ' 88' ' ' LYS . 5.3 mm -98.05 172.85 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.32 -1.106 . . . . 0.0 109.326 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.505 ' H ' HG22 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -97.82 114.41 26.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.21 -0.932 . . . . 0.0 109.631 -179.798 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.717 HG21 ' CD1' ' A' ' 79' ' ' PHE . 19.8 mt -85.6 149.02 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.38 -0.825 . . . . 0.0 109.181 179.722 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.522 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 0.4 OUTLIER -135.47 122.39 21.23 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.01 -1.056 . . . . 0.0 109.673 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.13 121.98 31.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 109.599 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.99 106.79 18.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -0.898 . . . . 0.0 109.547 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 94' ' ' GLY . 6.7 t -122.17 -20.63 6.16 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.272 -0.892 . . . . 0.0 109.732 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.448 ' O ' ' HB ' ' A' ' 95' ' ' THR . . . -43.14 -88.11 0.01 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.563 HG23 ' N ' ' A' ' 96' ' ' SER . 5.2 t 176.51 -45.84 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.257 -1.143 . . . . 0.0 109.423 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.563 ' N ' HG23 ' A' ' 95' ' ' THR . 8.5 m -121.93 115.88 23.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.882 HG22 ' O ' ' A' ' 15' ' ' GLU . 6.4 m -47.14 -35.96 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 109.591 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -48.19 -49.45 32.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.13 -0.981 . . . . 0.0 109.431 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -73.02 -45.36 58.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -0.9 . . . . 0.0 109.642 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.499 ' HA ' HD12 ' A' ' 103' ' ' LEU . 10.4 m-20 -51.41 -24.18 4.61 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.24 -0.913 . . . . 0.0 109.686 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.77 HD21 HG11 ' A' ' 29' ' ' VAL . 19.2 tp -65.51 -66.33 0.56 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.179 -0.951 . . . . 0.0 109.327 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 13.5 ptmt -56.1 -21.09 20.21 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -0.922 . . . . 0.0 109.348 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.986 ' HB3' HD12 ' A' ' 109' ' ' LEU . 10.2 mt -69.87 -45.22 68.17 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.336 -0.852 . . . . 0.0 109.54 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.632 ' CD1' HD11 ' A' ' 3' ' ' ILE . 21.2 t80 -55.54 -19.0 8.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.325 -0.859 . . . . 0.0 109.368 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.617 HG23 ' HA2' ' A' ' 34' ' ' GLY . 96.4 m -59.79 -51.2 70.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.27 -0.894 . . . . 0.0 109.483 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.46 ' OE2' HD23 ' A' ' 103' ' ' LEU . 13.6 pt-20 -83.4 -26.18 30.65 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.487 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.08 35.72 9.54 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -91.43 -6.33 52.95 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.247 -1.149 . . . . 0.0 109.577 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.986 HD12 ' HB3' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -76.63 -161.77 0.22 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.194 -0.942 . . . . 0.0 109.478 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.26 106.46 18.6 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.162 -0.961 . . . . 0.0 109.663 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.522 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 9.4 pt-20 -110.35 127.89 55.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.308 -0.87 . . . . 0.0 109.328 179.643 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 5.6 mt -127.83 132.19 69.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.582 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.1 ptm180 . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.283 -0.885 . . . . 0.0 109.264 179.767 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 37.3 mtp . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.248 0.546 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -114.17 150.48 34.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.917 . . . . 0.0 109.315 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.581 HG12 ' CE2' ' A' ' 104' ' ' PHE . 7.6 mt -120.89 101.82 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.279 -0.888 . . . . 0.0 109.892 -179.655 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.07 103.6 15.54 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.345 -0.847 . . . . 0.0 109.137 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.672 HG22 HG12 ' A' ' 97' ' ' VAL . 7.7 mt -88.13 122.19 39.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.249 -0.907 . . . . 0.0 109.807 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.73 ' HB2' ' HE2' ' A' ' 20' ' ' PHE . . . -69.95 147.11 50.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 109.12 179.593 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.707 ' HB3' HG11 ' A' ' 97' ' ' VAL . 25.8 p -158.63 -178.68 7.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.165 -0.96 . . . . 0.0 109.788 -179.77 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -132.46 11.84 4.5 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.299 -0.876 . . . . 0.0 109.361 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -150.2 175.37 29.3 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -73.49 -44.97 56.67 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.272 -1.134 . . . . 0.0 109.46 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.426 ' OD2' ' OE1' ' A' ' 98' ' ' GLU . 10.5 t0 -176.93 -51.81 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.17 -0.956 . . . . 0.0 109.436 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.407 HD23 ' C ' ' A' ' 12' ' ' LEU . 8.7 tt -57.06 -29.82 63.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.203 -0.936 . . . . 0.0 109.245 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 18.97 7.73 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.475 ' O ' ' HA ' ' A' ' 96' ' ' SER . 93.9 p -76.89 79.94 3.46 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.259 -1.142 . . . . 0.0 109.517 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.613 ' C ' HG23 ' A' ' 16' ' ' VAL . 4.7 tt0 -77.39 4.27 11.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -0.828 . . . . 0.0 109.766 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.774 HG22 HG13 ' A' ' 97' ' ' VAL . 2.5 t 74.91 12.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.131 -0.98 . . . . 0.0 109.241 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.4 163.83 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.672 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.21 -44.11 3.03 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.148 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.414 ' O ' ' C ' ' A' ' 20' ' ' PHE . 33.7 m-85 -108.28 78.67 1.19 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.319 -0.863 . . . . 0.0 109.235 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.73 ' HE2' ' HB2' ' A' ' 6' ' ' ALA . 26.4 t80 -42.73 125.84 3.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.272 -0.893 . . . . 0.0 109.565 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -179.69 -66.39 0.07 OUTLIER Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.426 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 7.1 mtt180 -116.71 15.92 15.39 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.211 -1.17 . . . . 0.0 109.654 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.425 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -44.55 104.8 0.4 Allowed Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.917 . . . . 0.0 109.491 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.426 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.49 43.14 1.47 Allowed 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.692 2.261 . . . . 0.0 110.794 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 14.8 m-85 -159.91 70.45 0.44 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.118 -0.989 . . . . 0.0 109.096 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.48 ' HB2' HG23 ' A' ' 42' ' ' ILE . 32.7 m-85 -79.72 129.35 34.4 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.253 -0.904 . . . . 0.0 109.781 -179.668 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 3.2 ttt -103.64 102.68 12.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.887 . . . . 0.0 109.162 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.1 mm -90.41 116.76 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.098 -1.001 . . . . 0.0 109.552 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.553 HG11 HD11 ' A' ' 101' ' ' LEU . 3.9 t -118.96 160.17 19.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.705 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.506 ' HB3' ' CB ' ' A' ' 38' ' ' SER . 0.1 OUTLIER -139.18 84.6 2.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -0.866 . . . . 0.0 109.337 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.417 ' HB2' ' HE3' ' A' ' 31' ' ' MET . 22.2 ttm -93.58 140.32 29.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.24 -0.912 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LYS . . . . . 0.478 ' HG2' ' N ' ' A' ' 33' ' ' LYS . 14.7 ttpp -83.61 -84.98 0.13 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -0.872 . . . . 0.0 109.495 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.478 ' N ' ' HG2' ' A' ' 32' ' ' LYS . 0.0 OUTLIER -131.38 40.31 3.44 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.265 -0.897 . . . . 0.0 109.622 -179.826 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 119.96 24.93 2.65 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 68.6 m-80 -150.05 105.97 3.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.282 -1.128 . . . . 0.0 109.349 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.416 HG23 ' CG1' ' A' ' 29' ' ' VAL . 1.4 mp -66.48 114.75 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.279 -0.888 . . . . 0.0 109.584 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.21 33.06 5.68 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.506 ' CB ' ' HB3' ' A' ' 30' ' ' GLU . 0.2 OUTLIER -179.71 110.84 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.368 -0.832 . . . . 0.0 109.363 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -138.24 108.84 6.57 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.546 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -126.26 134.12 51.26 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.386 -0.821 . . . . 0.0 109.478 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.21 137.71 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.294 -0.879 . . . . 0.0 109.294 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.614 ' O ' HG23 ' A' ' 42' ' ' ILE . 0.8 OUTLIER -136.81 107.53 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.272 -0.892 . . . . 0.0 109.468 -179.935 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -74.59 171.66 13.44 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.382 -0.824 . . . . 0.0 109.409 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.29 -0.881 . . . . 0.0 109.556 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.688 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 1.101 HD11 ' HB2' ' A' ' 78' ' ' ALA . 0.9 OUTLIER -74.98 -14.64 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.274 -1.133 . . . . 0.0 109.365 179.871 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.73 -13.68 61.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.861 . . . . 0.0 109.296 179.8 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.688 HG22 ' O ' ' A' ' 54' ' ' GLY . 9.2 t -65.78 -25.04 67.07 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.199 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.691 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -53.8 -42.73 68.66 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.375 -0.828 . . . . 0.0 109.527 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -58.98 -35.08 72.6 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.232 -0.918 . . . . 0.0 109.417 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 28.3 mt -72.79 -33.86 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.296 -0.877 . . . . 0.0 109.403 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.724 HG23 HG21 ' A' ' 66' ' ' VAL . 38.3 mt -63.19 -40.56 89.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.242 -0.911 . . . . 0.0 109.298 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.98 -23.86 67.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.207 -0.933 . . . . 0.0 109.37 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -75.15 -21.95 58.46 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 0.0 109.543 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.8 m-20 -80.16 -17.57 52.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.514 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 115.7 -15.28 17.03 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.724 HG21 HG23 ' A' ' 61' ' ' ILE . 57.3 t -44.4 93.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.399 -1.059 . . . . 0.0 109.806 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -79.5 -9.36 59.6 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.221 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -139.9 126.66 20.61 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.344 -0.847 . . . . 0.0 109.153 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.601 HG21 HD21 ' A' ' 82' ' ' LEU . 97.6 t -119.21 126.4 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.165 -0.96 . . . . 0.0 109.694 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.646 HD12 HG12 ' A' ' 5' ' ' ILE . 57.7 mt -100.33 117.47 45.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.354 -0.841 . . . . 0.0 109.349 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -148.25 174.51 11.93 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -0.917 . . . . 0.0 109.706 -179.669 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.595 ' HB3' ' HB3' ' A' ' 92' ' ' ALA . 53.7 p -143.26 40.87 1.48 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.365 -0.835 . . . . 0.0 109.373 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.423 ' HB2' ' HD2' ' A' ' 74' ' ' PRO . 11.4 p -51.97 159.14 1.49 Allowed Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.606 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.423 ' HD2' ' HB2' ' A' ' 73' ' ' SER . 35.1 Cg_endo -77.57 -31.05 3.56 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.609 2.206 . . . . 0.0 110.541 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -118.06 163.71 12.87 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.571 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.5 Cg_endo -79.96 17.21 1.34 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.831 2.354 . . . . 0.0 111.006 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.404 ' O ' HG23 ' A' ' 81' ' ' VAL . 9.0 m-20 -63.1 -52.06 64.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.949 -1.095 . . . . 0.0 109.742 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 1.101 ' HB2' HD11 ' A' ' 55' ' ' ILE . . . -61.77 -37.63 85.03 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.774 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.571 ' CD2' ' HA ' ' A' ' 76' ' ' PRO . 4.0 m-30 -66.17 -29.03 69.23 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.606 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -71.83 -41.5 68.12 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.167 -0.958 . . . . 0.0 109.566 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.404 HG23 ' O ' ' A' ' 77' ' ' ASN . 3.6 t -66.78 -50.42 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.165 -0.959 . . . . 0.0 109.652 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.601 HD21 HG21 ' A' ' 69' ' ' VAL . 2.3 mp -66.77 -27.45 67.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.232 -0.917 . . . . 0.0 109.468 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 33.3 t30 -65.78 -47.32 75.58 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.216 -0.927 . . . . 0.0 109.245 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -68.25 -31.61 71.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.31 -0.869 . . . . 0.0 109.26 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.488 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.4 OUTLIER -66.92 -25.96 66.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 179.894 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 93.69 22.58 25.78 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.488 HG12 ' HB3' ' A' ' 85' ' ' LEU . 5.9 mm -101.34 163.0 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.238 -1.154 . . . . 0.0 109.456 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.412 ' CG ' ' O ' ' A' ' 113' ' ' ARG . 12.5 mttm -93.7 133.03 37.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.401 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.501 HG21 ' CD1' ' A' ' 79' ' ' PHE . 2.0 mt -113.49 135.83 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.19 -0.944 . . . . 0.0 109.546 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.505 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 21.5 m-85 -124.56 151.25 44.97 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.505 -0.747 . . . . 0.0 109.365 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.468 ' O ' ' HG ' ' A' ' 109' ' ' LEU . 6.9 ttt-85 -83.46 152.86 24.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.229 -0.919 . . . . 0.0 109.701 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.595 ' HB3' ' HB3' ' A' ' 72' ' ' SER . . . -106.04 158.91 16.46 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.235 -0.915 . . . . 0.0 109.305 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.63 7.35 46.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.167 -0.958 . . . . 0.0 109.589 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 47.96 72.01 0.49 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.6 m -150.64 -61.61 0.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.308 -1.113 . . . . 0.0 109.356 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 14' ' ' SER . 66.4 m -165.98 123.11 1.4 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.233 -0.917 . . . . 0.0 109.525 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.774 HG13 HG22 ' A' ' 16' ' ' VAL . 27.2 m -65.62 -43.92 93.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.237 -0.914 . . . . 0.0 109.378 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' GLU . . . . . 0.526 ' N ' HG23 ' A' ' 97' ' ' VAL . 0.2 OUTLIER -45.15 -44.06 10.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.229 -0.919 . . . . 0.0 109.406 179.941 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.561 ' HG3' HD13 ' A' ' 103' ' ' LEU . 38.7 tp10 -73.92 -46.83 41.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.275 -0.891 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.453 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 2.2 m-80 -47.55 -26.21 1.36 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.938 . . . . 0.0 109.336 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.553 HD11 HG11 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -59.09 -57.03 14.88 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -0.919 . . . . 0.0 109.291 179.867 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.04 -27.61 68.92 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.238 -0.914 . . . . 0.0 109.327 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.561 HD13 ' HG3' ' A' ' 99' ' ' GLU . 0.8 OUTLIER -63.65 -35.08 79.34 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.372 -0.83 . . . . 0.0 109.534 179.984 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.581 ' CE2' HG12 ' A' ' 3' ' ' ILE . 6.1 t80 -63.79 -27.03 68.91 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.193 -0.942 . . . . 0.0 109.608 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 90.8 m -74.49 -19.93 60.18 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.189 -0.945 . . . . 0.0 109.484 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -106.17 8.19 31.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.202 -0.936 . . . . 0.0 109.515 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 52.53 40.73 55.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -83.59 -43.24 15.86 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.328 -1.101 . . . . 0.0 109.498 -179.883 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.529 HD21 ' HA ' ' A' ' 92' ' ' ALA . 1.5 tp -96.45 147.54 23.73 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.32 -0.863 . . . . 0.0 109.292 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.411 ' HG3' ' O ' ' A' ' 109' ' ' LEU . 3.4 mt-10 -176.52 -177.75 0.86 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.091 -1.005 . . . . 0.0 109.862 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.505 ' HB3' ' HA ' ' A' ' 90' ' ' TYR . 1.1 tp10 -177.35 -111.88 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.468 -0.77 . . . . 0.0 109.067 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.521 ' CD1' ' HB3' ' A' ' 79' ' ' PHE . 8.0 mt -79.74 121.53 33.21 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 O-C-N 121.177 -0.952 . . . . 0.0 109.367 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.412 ' O ' ' CG ' ' A' ' 88' ' ' LYS . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.171 -0.955 . . . . 0.0 109.384 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.3 mmt . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.576 ' N ' ' CD ' ' A' ' 2' ' ' LYS . 0.0 OUTLIER -90.44 133.88 34.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.252 -0.905 . . . . 0.0 109.158 179.915 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.501 ' HB ' HG12 ' A' ' 29' ' ' VAL . 9.4 mm -101.29 104.33 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.338 -0.851 . . . . 0.0 110.207 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.864 ' HB2' HD12 ' A' ' 28' ' ' ILE . . . -110.23 88.46 2.77 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.662 HD12 HG21 ' A' ' 70' ' ' ILE . 9.5 tt -98.81 133.11 42.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.239 -0.913 . . . . 0.0 110.014 -179.142 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -57.72 156.64 8.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.354 -0.841 . . . . 0.0 109.081 179.51 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.698 ' HB3' HG11 ' A' ' 97' ' ' VAL . 0.0 OUTLIER -159.97 178.96 9.19 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.092 -1.005 . . . . 0.0 109.798 -179.873 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.538 ' C ' ' CD2' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -126.73 23.49 6.71 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.386 -0.821 . . . . 0.0 109.189 179.921 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.464 ' HA2' ' CD1' ' A' ' 25' ' ' TYR . . . 153.08 -151.51 23.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.882 HG22 HG21 ' A' ' 41' ' ' VAL . 16.1 p -124.97 101.94 7.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.185 -1.185 . . . . 0.0 109.353 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 53.9 -154.03 0.26 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.282 -0.886 . . . . 0.0 109.327 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER 60.05 17.96 7.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.27 -0.894 . . . . 0.0 109.576 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 118.85 26.06 2.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.0 m -73.59 83.46 1.54 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.301 -1.117 . . . . 0.0 109.281 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.436 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.4 OUTLIER -79.4 38.81 0.38 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.435 -0.79 . . . . 0.0 110.62 -179.967 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.541 HG12 ' O ' ' A' ' 16' ' ' VAL . 21.2 t 63.55 13.08 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 120.716 -1.24 . . . . 0.0 109.413 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 65.78 177.97 0.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.226 -0.921 . . . . 0.0 109.493 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 7.5 ttt180 -120.26 7.13 10.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.184 -0.947 . . . . 0.0 109.596 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -144.02 165.9 26.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.42 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.87 ' CD2' ' HB1' ' A' ' 71' ' ' ALA . 2.3 t80 -132.68 88.81 2.56 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 109.392 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 158.85 -53.49 0.38 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.442 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 5.6 mtp180 -93.58 -19.95 20.69 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.265 -1.138 . . . . 0.0 109.67 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.53 110.24 2.12 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.183 -0.948 . . . . 0.0 109.525 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.502 ' HA ' ' CB ' ' A' ' 44' ' ' ASN . 36.9 Cg_endo -81.29 51.56 3.95 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.614 2.21 . . . . 0.0 110.715 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.538 ' CD2' ' C ' ' A' ' 8' ' ' SER . 4.9 m-85 -159.1 68.91 0.45 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.99 -1.069 . . . . 0.0 109.555 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -84.31 127.05 33.74 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.911 . . . . 0.0 109.189 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' MET . . . . . 0.78 ' HG3' HG13 ' A' ' 41' ' ' VAL . 1.7 mtt -100.85 121.98 42.64 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.817 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.864 HD12 ' HB2' ' A' ' 4' ' ' ALA . 1.1 tp -121.36 132.2 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.357 -0.839 . . . . 0.0 109.06 179.622 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.772 HG23 ' O ' ' A' ' 38' ' ' SER . 14.1 p -138.89 133.41 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.221 -0.924 . . . . 0.0 109.538 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.431 ' HG2' ' N ' ' A' ' 31' ' ' MET . 3.4 tt0 -103.41 138.69 39.81 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.246 -0.909 . . . . 0.0 109.461 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.431 ' N ' ' HG2' ' A' ' 30' ' ' GLU . 11.4 ptp -130.4 153.65 48.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 109.381 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.57 -76.88 0.44 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.235 -0.915 . . . . 0.0 109.688 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.34 -73.17 0.67 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.123 -0.985 . . . . 0.0 109.646 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -142.68 26.6 2.24 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -140.36 99.52 3.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -1.16 . . . . 0.0 109.571 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.705 HD13 HD21 ' A' ' 101' ' ' LEU . 7.2 pt -50.1 129.38 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.24 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -113.43 0.38 14.72 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.159 -0.963 . . . . 0.0 109.817 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.772 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -156.41 110.34 2.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.031 -1.043 . . . . 0.0 110.007 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.63 100.22 7.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.313 -0.867 . . . . 0.0 108.901 179.335 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -108.05 159.46 16.55 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.188 -0.945 . . . . 0.0 109.912 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.882 HG21 HG22 ' A' ' 10' ' ' THR . 2.8 t -129.29 122.48 56.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.373 -0.83 . . . . 0.0 109.141 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.74 142.48 24.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.184 -0.947 . . . . 0.0 109.582 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -87.95 158.09 18.76 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 0.0 109.304 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.502 ' CB ' ' HA ' ' A' ' 24' ' ' PRO . 4.0 t-20 . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.217 -0.927 . . . . 0.0 109.506 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.855 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.641 HD12 ' HB2' ' A' ' 78' ' ' ALA . 30.2 mm -76.02 -17.97 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.287 -1.125 . . . . 0.0 109.328 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -76.39 -16.13 59.79 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.32 -0.862 . . . . 0.0 109.307 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.855 HG22 ' O ' ' A' ' 54' ' ' GLY . 11.9 t -72.61 -24.62 61.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.282 -0.887 . . . . 0.0 109.47 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -59.65 -36.62 76.76 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.115 -0.99 . . . . 0.0 109.268 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -71.45 -23.01 61.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.294 -0.879 . . . . 0.0 109.523 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.7 mm -76.84 -54.65 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.476 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.607 ' O ' HG22 ' A' ' 66' ' ' VAL . 0.9 OUTLIER -66.79 -27.57 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.254 -0.904 . . . . 0.0 109.544 -179.955 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.619 ' HB1' HD22 ' A' ' 85' ' ' LEU . . . -65.98 -34.07 77.26 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.183 -0.948 . . . . 0.0 109.572 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -77.03 -10.17 59.19 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 109.624 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.1 m-20 -83.61 -12.62 55.81 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.264 -0.898 . . . . 0.0 109.591 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.415 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 97.31 0.89 59.48 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.747 ' O ' HG23 ' A' ' 66' ' ' VAL . 32.8 m -48.03 98.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.181 -1.188 . . . . 0.0 109.761 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.415 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -78.53 -11.2 59.95 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 178.951 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -139.8 126.31 20.34 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 71.4 t -126.16 124.79 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.981 -1.074 . . . . 0.0 109.755 -179.326 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.662 HG21 HD12 ' A' ' 5' ' ' ILE . 4.2 mp -104.18 96.86 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.199 -0.938 . . . . 0.0 109.314 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.87 ' HB1' ' CD2' ' A' ' 20' ' ' PHE . . . -130.1 172.36 11.85 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.401 -0.812 . . . . 0.0 109.473 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.424 ' O ' ' C ' ' A' ' 73' ' ' SER . 0.2 OUTLIER -138.64 34.22 2.23 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.29 -0.881 . . . . 0.0 109.555 -179.881 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -44.57 153.06 0.48 Allowed Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.221 -0.924 . . . . 0.0 109.315 179.914 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.23 -47.38 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.605 2.203 . . . . 0.0 110.335 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.419 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -84.67 141.55 19.62 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.419 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.6 Cg_endo -78.45 -0.68 10.93 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.501 2.134 . . . . 0.0 110.347 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -60.56 -32.51 71.57 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.308 -0.87 . . . . 0.0 109.522 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.641 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -70.04 -54.24 14.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.22 -0.925 . . . . 0.0 109.521 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.412 ' CD1' HG21 ' A' ' 89' ' ' ILE . 11.3 m-30 -54.64 -24.2 20.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.247 -0.908 . . . . 0.0 109.738 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -72.43 -37.34 68.63 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.156 -0.965 . . . . 0.0 109.723 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 75.4 t -76.1 -36.23 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.219 -0.926 . . . . 0.0 109.77 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.56 HD12 ' O ' ' A' ' 78' ' ' ALA . 0.7 OUTLIER -62.01 -36.58 81.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.599 -179.85 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -73.51 -24.53 60.17 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.236 -0.915 . . . . 0.0 109.46 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -76.78 -33.41 58.04 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.233 -0.917 . . . . 0.0 109.526 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.619 HD22 ' HB1' ' A' ' 62' ' ' ALA . 0.5 OUTLIER -77.52 -23.65 50.14 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.135 -0.978 . . . . 0.0 109.564 -179.86 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.5 21.59 14.42 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.472 HG22 ' N ' ' A' ' 88' ' ' LYS . 7.7 mt -98.83 158.33 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.257 -1.143 . . . . 0.0 109.381 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.472 ' N ' HG22 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -90.76 128.58 36.73 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.15 -0.969 . . . . 0.0 109.332 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.538 HG12 ' CB ' ' A' ' 82' ' ' LEU . 5.5 mt -98.91 151.22 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.17 -0.956 . . . . 0.0 109.29 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.573 ' CE1' ' HA ' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -138.54 141.15 39.3 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.321 -0.862 . . . . 0.0 109.225 -179.708 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.42 ' O ' ' HB3' ' A' ' 110' ' ' GLU . 1.5 tpp85 -92.6 128.56 38.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.939 . . . . 0.0 109.782 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.44 121.46 25.75 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.326 -0.859 . . . . 0.0 109.486 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.12 -27.89 61.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.309 -0.87 . . . . 0.0 109.505 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 97.06 61.21 0.94 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -130.51 -60.72 0.98 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.192 -1.181 . . . . 0.0 109.451 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 0.3 OUTLIER -173.34 150.39 1.86 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.291 -0.881 . . . . 0.0 109.543 -179.878 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.698 HG11 ' HB3' ' A' ' 7' ' ' SER . 4.0 m -72.16 -34.17 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.582 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -65.39 -53.29 45.46 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.482 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 0.3 OUTLIER -58.3 -45.04 88.71 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.329 -0.857 . . . . 0.0 109.709 -179.921 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -61.18 -30.27 70.31 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.205 -0.934 . . . . 0.0 109.847 -179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.705 HD21 HD13 ' A' ' 36' ' ' ILE . 31.7 tp -63.07 -56.51 16.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.176 -0.953 . . . . 0.0 109.648 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.404 ' HG2' ' O ' ' A' ' 102' ' ' LYS . 0.0 OUTLIER -73.86 -11.91 60.51 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.146 -0.972 . . . . 0.0 109.5 -179.906 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.534 HD22 ' OE2' ' A' ' 110' ' ' GLU . 0.3 OUTLIER -76.17 -45.31 34.03 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.232 -0.917 . . . . 0.0 109.497 -179.91 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.551 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 3.5 t80 -76.57 -26.31 54.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.344 -0.847 . . . . 0.0 109.49 -179.822 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.425 HG23 ' SD ' ' A' ' 31' ' ' MET . 17.7 m -61.4 -33.59 73.94 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.229 -0.919 . . . . 0.0 109.676 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -103.43 8.94 37.95 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.104 -0.997 . . . . 0.0 109.575 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.29 59.13 10.51 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' ASN . . . . . 0.565 ' O ' HD12 ' A' ' 109' ' ' LEU . 48.2 t-20 -81.18 -38.77 26.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.38 -1.071 . . . . 0.0 109.564 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.565 HD12 ' O ' ' A' ' 108' ' ' ASN . 0.0 OUTLIER 171.0 -156.77 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.162 -0.961 . . . . 0.0 109.735 -179.942 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.565 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 23.2 mt-10 60.59 29.82 19.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.865 . . . . 0.0 109.259 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.573 ' HA ' ' CE1' ' A' ' 90' ' ' TYR . 1.0 OUTLIER -92.44 144.74 25.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.319 -0.863 . . . . 0.0 109.675 -179.823 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 111' ' ' GLU . 9.2 mm -155.67 125.62 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.477 -0.764 . . . . 0.0 109.15 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 0.0 109.353 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.448 ' O ' ' HE3' ' A' ' 2' ' ' LYS . 21.0 ttm . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.357 0.599 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.448 ' HE3' ' O ' ' A' ' 1' ' ' MET . 0.1 OUTLIER -143.44 106.9 4.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.203 -0.935 . . . . 0.0 109.413 -179.996 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.752 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 2.3 mp -107.68 114.77 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.336 -0.853 . . . . 0.0 109.414 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.566 ' HB1' ' CZ ' ' A' ' 26' ' ' PHE . . . -113.24 122.07 46.36 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.235 -0.915 . . . . 0.0 109.347 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.477 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 2.8 mp -96.93 129.22 47.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.174 -0.954 . . . . 0.0 109.568 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.419 ' O ' ' HB3' ' A' ' 7' ' ' SER . . . -68.93 146.86 52.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.257 -0.902 . . . . 0.0 109.272 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.419 ' HB3' ' O ' ' A' ' 6' ' ' ALA . 13.3 t 60.05 -94.5 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 0.0 109.426 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.621 ' OG ' HG11 ' A' ' 97' ' ' VAL . 8.7 t 63.45 31.42 14.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.161 -0.962 . . . . 0.0 109.772 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 42.53 -105.57 0.07 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -158.7 -46.44 0.06 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.251 -1.146 . . . . 0.0 109.411 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.86 -72.89 0.35 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.185 -0.947 . . . . 0.0 109.637 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 31.6 mt -107.09 -14.7 14.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.202 -0.936 . . . . 0.0 109.572 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.21 6.12 64.73 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 8' ' ' SER . 93.9 p -77.68 77.16 4.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -1.137 . . . . 0.0 109.673 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.598 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -77.81 78.49 4.31 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.235 -0.916 . . . . 0.0 109.456 179.881 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.598 HG12 ' O ' ' A' ' 15' ' ' GLU . 11.6 p 41.1 42.31 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.427 -0.795 . . . . 0.0 109.839 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.438 ' OG ' ' C ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER 59.97 -163.54 0.24 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.249 -0.907 . . . . 0.0 109.486 -179.959 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -170.27 -36.32 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.258 -0.901 . . . . 0.0 109.373 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -148.16 140.06 23.94 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.33 -0.856 . . . . 0.0 109.471 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.428 ' CG ' ' O ' ' A' ' 20' ' ' PHE . 12.9 t80 -116.1 38.45 3.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.252 -0.905 . . . . 0.0 109.733 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -93.94 -56.76 1.37 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.432 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 18.9 mtt180 -140.16 41.74 1.94 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.29 -1.124 . . . . 0.0 109.111 179.747 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -52.3 108.8 1.17 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.41 -0.806 . . . . 0.0 109.744 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.482 ' O ' ' HB3' ' A' ' 43' ' ' GLU . 36.7 Cg_endo -80.83 40.9 1.05 Allowed 'Trans proline' 0 C--N 1.312 -1.374 0 C-N-CA 122.561 2.174 . . . . 0.0 110.434 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.422 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 6.2 m-85 -161.11 74.74 0.5 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.143 -0.973 . . . . 0.0 108.909 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.566 ' CZ ' ' HB1' ' A' ' 4' ' ' ALA . 16.5 t80 -78.26 112.52 15.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.433 -0.792 . . . . 0.0 109.496 -179.439 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 1.6 ttm -94.12 114.48 26.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.455 -0.778 . . . . 0.0 109.31 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.405 HG23 ' O ' ' A' ' 28' ' ' ILE . 0.3 OUTLIER -106.62 123.88 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.283 -0.886 . . . . 0.0 109.488 -179.869 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.651 HG12 HG23 ' A' ' 36' ' ' ILE . 2.1 t -121.74 120.64 62.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.912 . . . . 0.0 109.636 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -116.95 96.81 5.63 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 21.1 ptp -87.26 167.24 14.27 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.919 . . . . 0.0 109.358 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.58 -93.62 0.15 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.259 -0.9 . . . . 0.0 109.552 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.62 35.59 3.78 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.232 -0.917 . . . . 0.0 109.485 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 120.7 21.66 3.21 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 12.4 t30 -141.04 109.45 5.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.175 -1.191 . . . . 0.0 109.381 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.651 HG23 HG12 ' A' ' 29' ' ' VAL . 4.5 mt -63.25 114.12 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 109.631 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -123.03 28.55 7.14 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.265 -0.897 . . . . 0.0 109.27 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -172.96 96.12 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.324 -0.86 . . . . 0.0 109.434 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.1 m -125.99 103.5 7.78 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.276 -0.89 . . . . 0.0 109.147 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -114.52 142.58 46.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.255 -0.903 . . . . 0.0 110.046 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 t -116.72 96.21 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.415 -0.803 . . . . 0.0 108.955 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 13.6 mt -121.21 126.8 75.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 0.0 109.812 -179.525 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.482 ' HB3' ' O ' ' A' ' 24' ' ' PRO . 0.0 OUTLIER -53.65 148.59 9.46 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.353 -0.842 . . . . 0.0 109.582 179.847 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 37.8 m-80 . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.179 -0.951 . . . . 0.0 109.218 179.746 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.842 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.491 2.313 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.568 HG23 ' HB2' ' A' ' 78' ' ' ALA . 22.9 mm -75.61 -20.05 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.252 -1.146 . . . . 0.0 109.6 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -69.87 -25.58 63.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.323 -0.861 . . . . 0.0 109.505 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.842 HG22 ' O ' ' A' ' 54' ' ' GLY . 11.2 t -56.48 -25.86 52.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.561 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.455 ' O ' ' HB ' ' A' ' 61' ' ' ILE . . . -45.27 -41.84 8.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.183 -0.948 . . . . 0.0 109.356 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.82 -56.12 15.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.307 -0.871 . . . . 0.0 109.552 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 44.6 mt -54.97 -33.74 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.231 -0.918 . . . . 0.0 109.38 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.455 ' HB ' ' O ' ' A' ' 58' ' ' ALA . 22.9 mm -59.73 -52.72 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.245 -0.909 . . . . 0.0 109.579 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -64.18 -21.52 66.59 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.277 -0.889 . . . . 0.0 109.739 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.96 -23.26 55.35 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -0.924 . . . . 0.0 109.656 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -83.83 -16.91 42.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.125 -0.985 . . . . 0.0 109.703 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 98.37 -2.09 59.09 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.436 HG23 ' H ' ' A' ' 66' ' ' VAL . 3.7 t -42.37 97.87 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.315 -1.109 . . . . 0.0 109.773 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.469 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -79.22 -9.97 59.7 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.081 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.752 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -135.58 118.51 16.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.48 -0.763 . . . . 0.0 109.354 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.637 ' CG2' HD21 ' A' ' 82' ' ' LEU . 59.3 t -111.6 119.92 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.24 -0.913 . . . . 0.0 109.63 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.477 ' HB ' ' HA ' ' A' ' 5' ' ' ILE . 4.4 mm -102.69 117.12 47.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.149 -0.969 . . . . 0.0 109.551 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -160.03 171.77 18.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.745 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 37.4 t -133.71 42.98 2.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.354 -0.841 . . . . 0.0 109.278 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.437 ' OG ' ' HD2' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -51.81 155.57 2.91 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.42 -0.8 . . . . 0.0 109.83 -179.731 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.437 ' HD2' ' OG ' ' A' ' 73' ' ' SER . 35.2 Cg_endo -78.17 -12.1 15.99 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.725 2.283 . . . . 0.0 110.642 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -148.89 154.23 25.69 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.533 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.4 Cg_endo -79.92 38.81 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.862 2.375 . . . . 0.0 111.017 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.411 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 1.5 t-20 -77.25 -54.52 6.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.966 -1.084 . . . . 0.0 109.675 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.568 ' HB2' HG23 ' A' ' 55' ' ' ILE . . . -66.15 -38.39 88.0 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 109.644 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 79' ' ' PHE . 2.7 m-30 -55.41 -33.79 63.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.931 . . . . 0.0 109.475 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.411 ' HB2' ' O ' ' A' ' 77' ' ' ASN . 16.9 mt-10 -53.19 -55.79 21.52 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.932 . . . . 0.0 109.521 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.404 HG23 ' H ' ' A' ' 81' ' ' VAL . 2.4 t -60.89 -39.17 81.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.929 HD23 HG13 ' A' ' 89' ' ' ILE . 1.3 tp -52.23 -40.8 62.11 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.396 -0.815 . . . . 0.0 109.935 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -73.98 -36.98 64.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.128 -0.983 . . . . 0.0 109.81 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -66.92 -20.04 65.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.268 -0.895 . . . . 0.0 109.822 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.492 ' HA ' HD22 ' A' ' 85' ' ' LEU . 0.2 OUTLIER -102.98 24.68 10.38 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.16 -0.963 . . . . 0.0 109.716 -179.81 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 51.94 65.2 3.37 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.401 HG22 ' N ' ' A' ' 88' ' ' LYS . 75.0 mt -141.03 155.55 21.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -1.162 . . . . 0.0 109.299 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.401 ' N ' HG22 ' A' ' 87' ' ' ILE . 15.6 mttp -101.2 130.89 47.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.126 -0.984 . . . . 0.0 109.839 -179.692 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.929 HG13 HD23 ' A' ' 82' ' ' LEU . 2.2 mp -94.73 160.43 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.338 -0.851 . . . . 0.0 109.425 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.527 ' CE2' ' O ' ' A' ' 109' ' ' LEU . 0.2 OUTLIER -144.51 135.61 25.18 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.336 -0.852 . . . . 0.0 109.394 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.01 139.9 33.96 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.303 -0.873 . . . . 0.0 109.476 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.496 ' HB1' HG22 ' A' ' 16' ' ' VAL . . . -81.42 112.22 18.48 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -0.903 . . . . 0.0 109.434 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -144.32 16.23 1.68 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.256 -0.902 . . . . 0.0 109.45 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -92.13 -130.45 5.11 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 51.9 m -122.91 -54.87 1.82 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.218 -1.166 . . . . 0.0 109.489 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 2.3 m -127.52 172.09 11.02 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.245 -0.909 . . . . 0.0 109.457 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.621 HG11 ' OG ' ' A' ' 8' ' ' SER . 49.4 t -77.33 -43.82 30.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.319 -0.863 . . . . 0.0 109.612 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.46 -34.79 67.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.26 -0.9 . . . . 0.0 109.551 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -75.85 -59.52 2.72 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.252 -0.905 . . . . 0.0 109.518 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -51.02 -22.19 2.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.224 -0.923 . . . . 0.0 109.463 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 24.0 tp -64.18 -69.59 0.27 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.196 -0.94 . . . . 0.0 109.306 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.41 ' O ' ' HG2' ' A' ' 106' ' ' GLU . 0.6 OUTLIER -62.76 -14.82 49.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.335 -0.853 . . . . 0.0 109.458 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -77.0 -32.51 57.26 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 109.619 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.633 ' CE1' HD11 ' A' ' 3' ' ' ILE . 1.9 t80 -71.28 -31.08 67.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -0.889 . . . . 0.0 109.59 -179.696 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 51.6 m -74.26 -21.08 59.92 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.045 -1.034 . . . . 0.0 109.99 -179.425 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.41 ' HG2' ' O ' ' A' ' 102' ' ' LYS . 30.1 mm-40 -92.07 11.86 23.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.064 -1.023 . . . . 0.0 109.514 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 53.06 53.68 32.83 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' ASN . . . . . 0.487 ' OD1' HD23 ' A' ' 109' ' ' LEU . 1.6 t-20 -79.88 -63.82 1.33 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.348 -1.089 . . . . 0.0 109.469 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.527 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.6 OUTLIER 177.87 -153.56 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.306 -0.871 . . . . 0.0 109.528 179.989 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.519 ' HG3' ' CD1' ' A' ' 109' ' ' LEU . 79.4 mt-10 62.15 27.9 16.78 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.208 -0.933 . . . . 0.0 109.287 -179.867 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.495 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 7.9 pt-20 -108.7 147.74 31.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.757 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.442 ' O ' HD12 ' A' ' 89' ' ' ILE . 14.4 mt -151.76 128.39 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.323 -0.861 . . . . 0.0 109.193 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.235 -0.916 . . . . 0.0 109.805 -179.741 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 mtp . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.795 ' HD3' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -139.42 140.56 37.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.195 -0.94 . . . . 0.0 109.667 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.537 ' CG2' HD11 ' A' ' 70' ' ' ILE . 5.5 mt -110.41 99.67 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.46 -0.775 . . . . 0.0 109.824 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.641 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -100.07 115.39 29.64 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.337 -0.852 . . . . 0.0 109.08 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.652 HG13 HD12 ' A' ' 70' ' ' ILE . 3.4 mp -92.04 142.47 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.217 -0.927 . . . . 0.0 109.756 -179.741 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.502 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -80.39 171.62 14.83 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.295 -0.878 . . . . 0.0 109.546 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.547 ' HA ' ' HB1' ' A' ' 23' ' ' ALA . 71.7 m 47.95 -93.02 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.251 -0.906 . . . . 0.0 109.522 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.502 ' N ' ' O ' ' A' ' 6' ' ' ALA . 41.0 t 52.9 25.39 3.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.083 -1.011 . . . . 0.0 109.528 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 44.38 -101.41 0.03 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.59 -67.1 0.19 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.212 -1.17 . . . . 0.0 109.479 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -158.66 -79.41 0.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.156 -0.965 . . . . 0.0 109.592 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.17 -19.82 55.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.147 -0.971 . . . . 0.0 109.515 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -130.68 37.46 2.11 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.6 m -76.49 82.07 3.19 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -1.153 . . . . 0.0 109.254 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.49 ' HG3' ' N ' ' A' ' 16' ' ' VAL . 5.3 pt-20 -77.14 -134.38 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.266 -0.896 . . . . 0.0 109.054 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.775 HG13 ' O ' ' A' ' 16' ' ' VAL . 12.2 p -154.45 67.24 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 120.99 -1.069 . . . . 0.0 109.422 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.0 m -52.6 156.94 1.69 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -102.53 12.85 35.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.287 -0.883 . . . . 0.0 109.447 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -107.49 103.54 12.89 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.274 -0.891 . . . . 0.0 109.451 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -101.79 127.51 48.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.162 -0.961 . . . . 0.0 109.435 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 150.29 -64.49 0.39 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.6 ttt180 -91.85 -12.44 33.64 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -1.16 . . . . 0.0 109.362 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.573 ' O ' ' CE1' ' A' ' 26' ' ' PHE . . . -41.48 101.82 0.25 Allowed Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.528 -0.732 . . . . 0.0 109.752 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.491 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.8 Cg_endo -80.91 44.23 1.71 Allowed 'Trans proline' 0 C--N 1.311 -1.419 0 C-N-CA 122.653 2.236 . . . . 0.0 110.574 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.491 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 31.6 m-85 -160.07 70.21 0.43 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.015 -1.053 . . . . 0.0 109.641 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.573 ' CE1' ' O ' ' A' ' 23' ' ' ALA . 18.8 m-30 -80.35 111.5 16.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.178 -0.951 . . . . 0.0 109.377 179.704 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' MET . . . . . 0.417 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 6.3 ttm -90.56 116.67 28.64 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.276 -0.89 . . . . 0.0 109.509 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.795 HG22 ' HD3' ' A' ' 2' ' ' LYS . 7.2 mm -101.99 108.36 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.893 . . . . 0.0 109.437 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.676 ' CG1' HD12 ' A' ' 36' ' ' ILE . 96.8 t -104.47 142.34 18.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.553 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.457 ' O ' ' OG ' ' A' ' 38' ' ' SER . 32.5 tt0 -137.28 100.87 4.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.329 -0.857 . . . . 0.0 109.53 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.886 ' HB3' HD13 ' A' ' 36' ' ' ILE . 4.5 ptp -95.75 155.22 16.84 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.276 -0.89 . . . . 0.0 109.252 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 27.4 mmtm -102.26 -46.77 4.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.241 -0.912 . . . . 0.0 109.877 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 34' ' ' GLY . 1.5 ttpp -146.27 92.62 2.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.21 -0.931 . . . . 0.0 109.639 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 43.36 28.2 0.88 Allowed Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.784 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -151.06 111.01 4.08 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.205 -1.173 . . . . 0.0 109.387 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.886 HD13 ' HB3' ' A' ' 31' ' ' MET . 49.1 mm -56.74 116.91 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.236 -0.915 . . . . 0.0 109.588 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.34 18.54 15.19 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.317 -0.864 . . . . 0.0 109.415 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 30' ' ' GLU . 0.7 OUTLIER -174.94 127.52 0.29 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.317 -0.864 . . . . 0.0 109.527 -179.877 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.22 110.94 6.48 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.329 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -125.15 106.34 9.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 109.74 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 41' ' ' VAL . 14.9 p -97.15 124.49 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.24 -0.912 . . . . 0.0 109.247 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.0 pt -122.52 161.02 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.26 -0.9 . . . . 0.0 109.778 -179.656 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -104.0 159.81 15.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.346 -0.846 . . . . 0.0 109.379 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.9 m120 . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.297 -0.877 . . . . 0.0 109.238 179.741 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.517 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.513 HG21 ' HB2' ' A' ' 78' ' ' ALA . 23.8 mt -73.88 -9.18 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.303 -1.116 . . . . 0.0 109.47 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ARG . . . . . 0.466 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -69.03 -23.44 64.07 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.211 -0.93 . . . . 0.0 109.532 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.708 ' HA ' HD12 ' A' ' 60' ' ' ILE . 13.0 t -64.29 -14.18 54.36 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.673 -179.795 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -54.25 -46.11 72.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.167 -0.958 . . . . 0.0 109.439 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -52.11 -36.77 52.06 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.141 -0.974 . . . . 0.0 109.472 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.708 HD12 ' HA ' ' A' ' 57' ' ' THR . 6.6 mt -74.81 -33.56 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.266 -0.896 . . . . 0.0 109.609 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 61.0 mt -61.39 -36.69 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.178 -0.951 . . . . 0.0 109.4 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -70.72 -21.68 62.52 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.281 -0.887 . . . . 0.0 109.61 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -75.09 -9.68 58.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.118 -0.989 . . . . 0.0 109.283 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -88.59 -21.83 23.84 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.245 -0.909 . . . . 0.0 109.476 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 120.02 17.66 4.49 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.641 HG11 ' HB3' ' A' ' 4' ' ' ALA . 17.9 t -87.16 89.9 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.222 -1.164 . . . . 0.0 109.483 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.627 ' HA ' HG23 ' A' ' 87' ' ' ILE . 4.3 tttp -79.54 -7.97 58.84 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.364 -0.835 . . . . 0.0 108.984 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 2' ' ' LYS . . . -130.83 113.96 14.73 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.112 -0.993 . . . . 0.0 109.319 179.611 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 93.4 t -112.02 123.84 68.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.106 -0.996 . . . . 0.0 109.705 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.754 ' CG2' ' HB2' ' A' ' 92' ' ' ALA . 80.9 mt -103.14 116.36 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.397 -0.814 . . . . 0.0 109.186 179.766 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.91 175.42 10.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 109.934 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.02 57.36 1.48 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.508 -0.745 . . . . 0.0 109.23 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.2 m -65.18 155.57 83.96 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.199 -0.938 . . . . 0.0 109.614 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.18 -18.8 12.49 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.752 2.301 . . . . 0.0 110.312 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -129.99 162.38 23.01 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.16 9.9 3.18 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.814 2.343 . . . . 0.0 110.755 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -60.9 -55.03 37.82 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.065 -1.022 . . . . 0.0 109.655 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.513 ' HB2' HG21 ' A' ' 55' ' ' ILE . . . -56.06 -52.33 64.66 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.246 -0.909 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.702 ' CD1' HG21 ' A' ' 89' ' ' ILE . 12.9 m-30 -53.55 -30.1 40.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.226 -0.921 . . . . 0.0 109.628 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -68.79 -42.51 77.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.276 -0.89 . . . . 0.0 109.632 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.36 -53.09 44.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.184 -0.947 . . . . 0.0 109.478 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 53.5 mt -59.66 -28.01 66.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.27 -0.894 . . . . 0.0 109.639 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.478 ' HB2' ' O ' ' A' ' 79' ' ' PHE . 1.4 t-20 -69.06 -44.81 71.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.94 . . . . 0.0 109.268 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -68.85 -23.58 64.26 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.207 -0.933 . . . . 0.0 109.17 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.43 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -75.21 -35.39 61.5 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.271 -0.893 . . . . 0.0 109.484 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 101.75 25.01 8.29 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.627 HG23 ' HA ' ' A' ' 67' ' ' LYS . 30.5 mm -105.49 169.9 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.253 -1.145 . . . . 0.0 109.592 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.554 ' N ' HG22 ' A' ' 87' ' ' ILE . 5.4 mttt -93.71 134.91 35.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.285 -0.884 . . . . 0.0 109.536 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.702 HG21 ' CD1' ' A' ' 79' ' ' PHE . 4.3 mt -107.06 142.55 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.287 -0.883 . . . . 0.0 109.464 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.551 ' N ' ' CD1' ' A' ' 90' ' ' TYR . 4.5 m-85 -130.8 148.76 52.62 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.514 -0.741 . . . . 0.0 109.558 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.428 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 1.1 ttt180 -104.61 128.86 52.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.251 -0.906 . . . . 0.0 109.351 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.754 ' HB2' ' CG2' ' A' ' 70' ' ' ILE . . . -108.49 116.51 32.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.159 -0.963 . . . . 0.0 109.713 -179.778 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 4.4 m -145.59 21.3 1.49 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.348 -0.845 . . . . 0.0 109.37 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.79 -111.63 0.03 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 1.6 t -142.08 -40.39 0.36 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.236 -1.155 . . . . 0.0 109.803 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 3.1 m -142.6 131.23 22.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.21 -0.931 . . . . 0.0 109.615 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 15' ' ' GLU . 19.9 t -56.18 -19.99 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.308 -0.87 . . . . 0.0 109.307 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -60.37 -64.3 1.0 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.278 -0.889 . . . . 0.0 109.313 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.63 ' O ' HD12 ' A' ' 103' ' ' LEU . 4.6 mt-10 -67.21 -24.59 65.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.355 -0.84 . . . . 0.0 109.305 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.476 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 18.1 t-20 -68.19 -29.48 68.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.885 . . . . 0.0 109.427 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.449 HD11 HG11 ' A' ' 29' ' ' VAL . 33.2 tp -62.66 -68.67 0.31 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.182 -0.949 . . . . 0.0 109.164 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 10.0 tttp -59.24 -21.94 60.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.204 -0.935 . . . . 0.0 109.149 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.63 HD12 ' O ' ' A' ' 99' ' ' GLU . 1.5 mt -68.73 -34.92 76.43 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.394 -0.817 . . . . 0.0 109.448 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.536 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.5 t80 -53.94 -30.71 47.8 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.203 -0.936 . . . . 0.0 109.254 179.816 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 34.9 m -64.19 -39.62 94.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.42 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.494 ' OE1' HD23 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -82.99 -11.85 57.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.297 -0.877 . . . . 0.0 109.338 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.489 ' HA2' ' OE2' ' A' ' 110' ' ' GLU . . . 65.08 40.31 96.89 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -80.9 -12.87 59.33 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -1.153 . . . . 0.0 109.407 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.43 ' C ' ' HG2' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -152.6 111.37 3.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.261 -0.899 . . . . 0.0 109.259 179.867 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.489 ' OE2' ' HA2' ' A' ' 107' ' ' GLY . 5.9 mt-10 -140.97 -149.19 0.26 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.819 -179.662 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.496 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 0.5 OUTLIER -168.63 -114.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.34 -0.85 . . . . 0.0 109.315 -179.794 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.3 mt -87.81 149.56 4.03 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.092 -1.005 . . . . 0.0 109.427 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.479 ' HA ' ' HG2' ' A' ' 88' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.623 0 O-C-N 121.218 -0.926 . . . . 0.0 109.692 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.4 mtp . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.441 ' HG2' ' CG ' ' A' ' 30' ' ' GLU . 0.5 OUTLIER -91.2 142.4 27.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.293 -0.88 . . . . 0.0 109.494 179.994 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.622 ' CG2' HD11 ' A' ' 70' ' ' ILE . 4.9 mt -118.67 116.08 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.296 -0.877 . . . . 0.0 109.779 -179.773 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.91 119.73 37.53 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.344 -0.847 . . . . 0.0 109.03 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.931 HG12 HD13 ' A' ' 70' ' ' ILE . 8.6 mt -100.68 140.73 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.801 -179.56 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.502 ' HB2' ' CE2' ' A' ' 26' ' ' PHE . . . -106.73 138.49 42.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.279 -0.888 . . . . 0.0 109.141 179.613 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.512 ' HB3' HG11 ' A' ' 97' ' ' VAL . 39.4 p -163.3 -148.73 0.13 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.215 -0.928 . . . . 0.0 109.524 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.548 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 20.3 t -122.35 -65.35 1.12 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.263 -0.898 . . . . 0.0 109.546 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -59.98 168.34 8.32 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 1.2 p -87.38 -42.27 12.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.209 -1.171 . . . . 0.0 109.512 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -173.81 -40.74 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.193 -0.942 . . . . 0.0 109.709 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.1 mt -84.19 -10.85 57.39 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.156 -0.965 . . . . 0.0 109.629 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -137.91 8.31 3.58 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.456 ' OG ' HG22 ' A' ' 97' ' ' VAL . 79.9 p -77.11 80.17 3.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.184 -1.186 . . . . 0.0 109.467 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.466 ' C ' HG23 ' A' ' 16' ' ' VAL . 2.6 pt-20 -76.85 1.68 16.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.255 -0.903 . . . . 0.0 109.702 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.685 HG22 HG13 ' A' ' 97' ' ' VAL . 3.5 t 71.38 73.29 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.13 -0.981 . . . . 0.0 109.655 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.22 -164.46 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.46 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -118.98 26.74 9.31 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.214 -0.929 . . . . 0.0 109.617 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -117.23 115.31 25.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.914 . . . . 0.0 109.604 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.589 ' CG ' ' O ' ' A' ' 20' ' ' PHE . 45.6 t80 -112.44 38.4 2.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.309 -0.869 . . . . 0.0 109.159 179.731 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -99.27 -84.37 1.79 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.449 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.0 OUTLIER -90.21 67.46 6.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -1.144 . . . . 0.0 109.485 -179.946 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -47.1 105.45 0.49 Allowed Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.356 -0.84 . . . . 0.0 109.567 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.549 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.0 Cg_endo -78.73 -3.37 13.22 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.461 2.107 . . . . 0.0 110.365 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.549 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 71.4 m-85 -160.52 72.67 0.48 Allowed 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.177 -0.952 . . . . 0.0 109.235 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.502 ' CE2' ' HB2' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -79.02 114.8 18.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.471 -179.768 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 27' ' ' MET . . . . . 0.424 ' HG3' HG22 ' A' ' 41' ' ' VAL . 0.1 OUTLIER -87.57 114.15 23.91 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.339 -0.851 . . . . 0.0 109.39 -179.974 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.469 ' O ' HG23 ' A' ' 28' ' ' ILE . 0.5 OUTLIER -102.61 126.73 56.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.261 -0.899 . . . . 0.0 109.594 -179.934 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 69.4 t -124.01 138.44 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.289 -0.882 . . . . 0.0 109.293 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.441 ' CG ' ' HG2' ' A' ' 2' ' ' LYS . 0.5 OUTLIER -124.28 116.8 23.24 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.209 -0.932 . . . . 0.0 109.544 179.938 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.468 ' SD ' ' CD1' ' A' ' 3' ' ' ILE . 4.4 ptp -114.68 141.92 47.17 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 2.7 tttp -84.48 -80.83 0.19 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.285 -0.884 . . . . 0.0 109.455 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 12.4 tppt? -117.12 87.45 2.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.225 -0.922 . . . . 0.0 109.391 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 51.66 26.52 16.82 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -140.8 97.62 3.23 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -1.168 . . . . 0.0 109.559 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.472 HD11 ' OG ' ' A' ' 39' ' ' SER . 6.6 tt -49.67 137.12 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.196 -0.94 . . . . 0.0 109.55 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.504 ' C ' ' HG ' ' A' ' 38' ' ' SER . 0.0 OUTLIER -135.54 18.79 3.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.526 179.939 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.504 ' HG ' ' C ' ' A' ' 37' ' ' GLU . 0.0 OUTLIER -178.05 128.79 0.13 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.17 -0.956 . . . . 0.0 109.6 -179.958 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.472 ' OG ' HD11 ' A' ' 36' ' ' ILE . 0.4 OUTLIER -143.39 111.46 6.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.291 -0.881 . . . . 0.0 109.151 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -131.01 162.93 28.69 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.242 -0.911 . . . . 0.0 109.799 -179.617 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.424 HG22 ' HG3' ' A' ' 27' ' ' MET . 21.8 t -120.45 148.61 23.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.371 -0.831 . . . . 0.0 109.184 179.789 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.409 ' O ' ' HA ' ' A' ' 25' ' ' TYR . 7.1 mt -123.07 129.92 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -108.88 100.12 9.37 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.307 -0.87 . . . . 0.0 109.211 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.273 -0.892 . . . . 0.0 109.617 -179.7 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.758 HD12 ' HB2' ' A' ' 78' ' ' ALA . 47.5 mm -66.15 -14.65 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -1.189 . . . . 0.0 109.525 -179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.78 -22.87 60.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.256 -0.902 . . . . 0.0 109.433 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.462 ' O ' HG13 ' A' ' 61' ' ' ILE . 21.8 m -55.7 -25.32 39.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 109.533 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.31 -55.65 32.07 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.233 -0.917 . . . . 0.0 109.641 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.69 -37.93 52.81 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 72.9 mt -64.28 -38.01 81.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.29 -0.882 . . . . 0.0 109.655 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.48 ' CG2' HG21 ' A' ' 66' ' ' VAL . 36.7 mt -72.95 -21.96 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.22 -0.925 . . . . 0.0 109.652 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.418 ' HB1' HD22 ' A' ' 85' ' ' LEU . . . -71.46 -28.66 64.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.165 -0.959 . . . . 0.0 109.487 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 -74.78 -2.72 27.83 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.347 -0.845 . . . . 0.0 109.687 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -98.61 -18.25 18.21 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.094 -1.004 . . . . 0.0 109.603 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.521 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 102.8 -9.51 55.33 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.48 HG21 ' CG2' ' A' ' 61' ' ' ILE . 94.0 t -42.61 94.99 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.327 -1.102 . . . . 0.0 109.702 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.521 ' N ' ' O ' ' A' ' 65' ' ' GLY . 24.0 mmtt -79.3 -3.81 47.83 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.379 -0.826 . . . . 0.0 108.863 179.398 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.487 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -139.67 132.29 28.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.274 -0.891 . . . . 0.0 109.449 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 89.8 t -128.66 122.19 56.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.182 -0.949 . . . . 0.0 109.752 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.931 HD13 HG12 ' A' ' 5' ' ' ILE . 2.1 mp -99.28 116.61 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.226 -0.921 . . . . 0.0 109.245 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -152.46 175.01 13.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.258 -0.901 . . . . 0.0 109.567 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.504 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 3.7 m -137.14 39.66 2.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.428 -0.795 . . . . 0.0 109.288 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.422 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 7.4 m -50.1 134.64 22.64 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.242 -0.911 . . . . 0.0 109.41 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.2 Cg_endo -79.66 -20.72 9.08 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.458 2.106 . . . . 0.0 110.456 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.4 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -104.69 149.43 16.91 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.792 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.4 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.6 Cg_endo -78.39 -0.33 10.61 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.717 2.278 . . . . 0.0 110.287 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -67.56 -49.88 61.1 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.261 -0.899 . . . . 0.0 109.487 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.758 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -61.28 -53.4 57.21 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.329 -0.857 . . . . 0.0 109.458 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -56.39 -20.3 18.82 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.341 -0.85 . . . . 0.0 109.522 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.428 ' O ' ' HG3' ' A' ' 84' ' ' GLU . 1.2 tp10 -75.27 -45.88 37.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.228 -0.92 . . . . 0.0 109.557 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.448 ' HA ' ' HB2' ' A' ' 84' ' ' GLU . 6.3 t -67.58 -41.71 86.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 0.0 109.587 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.502 ' HA ' HD13 ' A' ' 82' ' ' LEU . 4.2 mm? -51.75 -56.93 10.93 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.127 -0.983 . . . . 0.0 109.48 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -65.15 -22.14 66.88 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.881 . . . . 0.0 109.444 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.448 ' HB2' ' HA ' ' A' ' 81' ' ' VAL . 5.1 mt-10 -74.17 -25.75 59.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.265 -0.897 . . . . 0.0 109.403 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.418 HD22 ' HB1' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -88.13 -30.85 19.52 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.224 -0.922 . . . . 0.0 109.488 -179.991 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 104.63 42.58 1.82 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.7 mt -122.66 155.98 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.275 -1.133 . . . . 0.0 109.375 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.522 ' HD2' ' N ' ' A' ' 88' ' ' LYS . 0.0 OUTLIER -81.66 138.22 35.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.167 -0.958 . . . . 0.0 109.521 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 3.0 mt -106.98 155.42 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.208 -0.932 . . . . 0.0 109.539 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.567 ' CZ ' ' CD2' ' A' ' 104' ' ' PHE . 1.0 OUTLIER -133.9 138.84 45.79 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.286 -0.884 . . . . 0.0 109.531 179.97 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.515 ' NE ' ' HA ' ' A' ' 110' ' ' GLU . 1.3 ptt-85 -97.76 113.4 25.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.289 -0.882 . . . . 0.0 109.291 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.504 ' HB3' ' OG ' ' A' ' 72' ' ' SER . . . -79.76 125.0 29.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.259 -0.9 . . . . 0.0 109.565 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 76.0 p -67.57 -42.12 83.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.259 -0.901 . . . . 0.0 109.433 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 119.73 97.74 1.71 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -168.87 -69.87 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.2 -1.177 . . . . 0.0 109.474 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -166.64 120.07 1.04 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.194 -0.941 . . . . 0.0 109.493 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.685 HG13 HG22 ' A' ' 16' ' ' VAL . 35.8 m -55.33 -21.47 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 109.589 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -61.48 -51.23 69.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.156 -0.965 . . . . 0.0 109.585 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.439 ' O ' HD12 ' A' ' 103' ' ' LEU . 4.9 mt-10 -77.19 -32.93 56.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.922 . . . . 0.0 109.768 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -60.21 -30.64 69.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.571 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 36.1 tp -68.25 -57.65 5.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.171 -0.955 . . . . 0.0 109.547 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 106' ' ' GLU . 0.0 OUTLIER -62.04 -20.54 64.06 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.224 -0.923 . . . . 0.0 109.518 -179.923 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.77 HD23 ' CB ' ' A' ' 108' ' ' ASN . 0.1 OUTLIER -76.96 -41.29 43.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.131 -0.981 . . . . 0.0 109.701 -179.876 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.567 ' CD2' ' CZ ' ' A' ' 90' ' ' TYR . 4.3 t80 -57.7 -53.8 54.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.197 -0.939 . . . . 0.0 109.312 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 9.7 m -67.87 -19.54 65.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.252 -0.905 . . . . 0.0 109.475 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.427 ' CG ' ' O ' ' A' ' 102' ' ' LYS . 4.4 mm-40 -83.44 9.27 11.52 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.337 -0.852 . . . . 0.0 109.302 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 51.66 45.13 54.78 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' ASN . . . . . 0.77 ' CB ' HD23 ' A' ' 103' ' ' LEU . 1.9 m120 -79.84 -66.32 0.89 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.306 -1.114 . . . . 0.0 109.498 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.58 HD12 ' HG3' ' A' ' 110' ' ' GLU . 0.7 OUTLIER 173.81 -159.83 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.301 -0.875 . . . . 0.0 109.372 -179.906 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.58 ' HG3' HD12 ' A' ' 109' ' ' LEU . 30.8 mt-10 73.29 30.03 1.6 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.282 -0.886 . . . . 0.0 109.482 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -104.44 147.12 27.92 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -0.913 . . . . 0.0 109.536 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 7.8 mt -142.15 125.21 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.153 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.48 ' HG2' ' HE2' ' A' ' 88' ' ' LYS . 21.6 mtt180 . . . . . 0 N--CA 1.49 1.574 0 O-C-N 121.347 -0.846 . . . . 0.0 109.846 -179.613 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 121.254 0.55 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.47 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 12.9 mttt -112.65 144.09 42.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.213 -0.93 . . . . 0.0 109.268 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.555 HG23 ' CD1' ' A' ' 70' ' ' ILE . 3.7 mt -121.96 106.78 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.184 -0.948 . . . . 0.0 110.339 -179.404 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.653 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -106.02 111.54 24.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.302 -0.873 . . . . 0.0 108.706 179.064 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.924 HG23 ' HB ' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -100.48 131.86 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.861 -179.379 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -63.56 139.16 58.74 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.303 -0.873 . . . . 0.0 109.113 179.549 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.446 ' HB3' ' O ' ' A' ' 25' ' ' TYR . 17.4 t -126.84 172.99 9.92 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.086 -1.009 . . . . 0.0 109.772 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -122.44 -32.61 3.59 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.408 -0.808 . . . . 0.0 109.266 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.637 ' O ' HG23 ' A' ' 10' ' ' THR . . . -113.98 -82.44 1.1 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.637 HG23 ' O ' ' A' ' 9' ' ' GLY . 0.1 OUTLIER -169.67 -62.14 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.288 -1.125 . . . . 0.0 109.589 179.962 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -145.33 -55.17 0.31 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.888 . . . . 0.0 109.572 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.1 mt -75.93 -38.77 57.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.227 -0.921 . . . . 0.0 109.645 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.42 17.12 57.24 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.412 ' O ' ' HA ' ' A' ' 96' ' ' SER . 89.7 p -77.19 78.42 3.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -1.148 . . . . 0.0 109.757 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.595 ' C ' HG23 ' A' ' 16' ' ' VAL . 44.2 tt0 -77.25 -0.29 24.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.253 -0.904 . . . . 0.0 109.408 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.677 HG22 HG13 ' A' ' 97' ' ' VAL . 2.5 t 73.73 74.55 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.26 -0.9 . . . . 0.0 109.64 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -46.65 151.7 0.55 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.168 -0.957 . . . . 0.0 109.289 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.411 ' HG2' ' CD1' ' A' ' 19' ' ' PHE . 3.2 ptm180 -104.92 31.74 4.61 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.927 . . . . 0.0 109.625 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.411 ' CD1' ' HG2' ' A' ' 18' ' ' ARG . 45.7 m-85 -119.2 115.58 24.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.518 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.443 ' HE2' ' HB2' ' A' ' 58' ' ' ALA . 25.9 t80 -91.34 78.02 5.79 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.23 -0.918 . . . . 0.0 109.352 179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.61 -20.98 0.71 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.4 ttm-85 -111.17 -40.31 4.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.368 -1.077 . . . . 0.0 109.28 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.442 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -41.78 101.98 0.26 Allowed Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.533 -0.729 . . . . 0.0 109.643 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.01 41.04 1.05 Allowed 'Trans proline' 0 C--N 1.312 -1.395 0 C-N-CA 122.579 2.186 . . . . 0.0 110.89 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.539 ' CE2' ' O ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -160.39 71.07 0.43 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.98 -1.075 . . . . 0.0 109.448 179.952 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.551 ' CE2' HD12 ' A' ' 61' ' ' ILE . 0.1 OUTLIER -79.5 117.08 20.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.287 -0.883 . . . . 0.0 109.549 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 3.2 ttt -95.62 104.26 16.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.928 . . . . 0.0 109.297 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.498 HG23 ' HB2' ' A' ' 4' ' ' ALA . 27.2 mt -100.83 126.13 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.266 -0.896 . . . . 0.0 109.709 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.553 ' CG1' HG23 ' A' ' 36' ' ' ILE . 90.5 t -123.95 117.82 52.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.298 -0.876 . . . . 0.0 109.349 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.403 ' HG2' ' HD3' ' A' ' 2' ' ' LYS . 13.0 mt-10 -83.92 115.97 22.56 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.221 -0.925 . . . . 0.0 109.622 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.459 ' HG2' ' HA ' ' A' ' 36' ' ' ILE . 0.3 OUTLIER -96.88 138.76 33.94 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.268 -0.895 . . . . 0.0 109.514 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 1.2 tptp -96.76 -62.45 1.26 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.889 . . . . 0.0 109.326 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' LYS . . . . . 0.401 ' O ' ' C ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -139.88 89.45 2.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.161 179.725 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 45.66 30.41 3.34 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -150.52 114.42 5.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -1.126 . . . . 0.0 109.555 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.553 HG23 ' CG1' ' A' ' 29' ' ' VAL . 2.1 mp -54.14 132.4 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.164 -0.96 . . . . 0.0 109.41 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -133.28 12.82 4.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.255 -0.903 . . . . 0.0 109.375 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.502 ' O ' HG13 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -174.28 116.87 0.21 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 109.502 -179.981 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.533 ' HA ' HG22 ' A' ' 29' ' ' VAL . 4.5 p -129.73 104.23 7.29 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.536 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -122.91 139.59 53.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.392 -0.818 . . . . 0.0 109.375 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 73.9 t -114.11 119.31 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.531 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.4 mt -118.28 143.03 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.364 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 44' ' ' ASN . 29.6 mp0 -86.1 118.91 25.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.15 -0.969 . . . . 0.0 109.391 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.414 ' C ' ' O ' ' A' ' 43' ' ' GLU . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.574 0 O-C-N 121.244 -0.91 . . . . 0.0 109.365 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.447 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.417 HD12 ' HB2' ' A' ' 78' ' ' ALA . 23.3 mm -76.58 -14.95 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.27 -1.135 . . . . 0.0 109.573 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -58.46 -17.63 22.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.227 -0.921 . . . . 0.0 109.662 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.447 HG22 ' O ' ' A' ' 54' ' ' GLY . 6.0 t -63.38 -37.74 88.43 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.171 -0.956 . . . . 0.0 109.812 -179.81 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.443 ' HB2' ' HE2' ' A' ' 20' ' ' PHE . . . -45.42 -34.51 3.15 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.176 -0.953 . . . . 0.0 109.817 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -61.29 -64.59 0.9 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.237 -0.914 . . . . 0.0 109.847 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.439 HG22 ' O ' ' A' ' 57' ' ' THR . 0.9 OUTLIER -58.8 -18.41 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.245 -0.91 . . . . 0.0 109.926 -179.593 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.551 HD12 ' CE2' ' A' ' 26' ' ' PHE . 19.3 mm -75.56 -36.38 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.688 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.71 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -73.38 -28.37 61.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.225 -0.922 . . . . 0.0 109.757 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -77.25 -9.81 59.03 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.087 -1.008 . . . . 0.0 109.906 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.481 ' HB2' HG23 ' A' ' 66' ' ' VAL . 57.9 m-20 -88.13 7.65 30.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.108 -0.995 . . . . 0.0 109.629 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 69.24 10.67 62.92 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.653 HG11 ' HB3' ' A' ' 4' ' ' ALA . 2.0 t -67.65 89.54 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.198 -1.178 . . . . 0.0 109.415 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.452 ' HG2' ' HE3' ' A' ' 88' ' ' LYS . 0.5 OUTLIER -79.6 -7.4 58.51 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.348 -0.845 . . . . 0.0 108.92 179.648 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.575 ' HB1' ' CE2' ' A' ' 104' ' ' PHE . . . -137.53 103.64 5.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.19 -0.944 . . . . 0.0 109.273 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.484 HG22 HG11 ' A' ' 66' ' ' VAL . 56.9 t -112.01 132.1 61.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.054 -1.029 . . . . 0.0 109.817 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.924 ' HB ' HG23 ' A' ' 5' ' ' ILE . 3.2 mp -104.61 112.76 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.352 -0.843 . . . . 0.0 109.199 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -149.61 -178.04 6.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.22 -0.925 . . . . 0.0 109.979 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -146.12 46.89 1.24 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.642 -0.661 . . . . 0.0 109.524 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.551 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 2.6 p -45.49 151.94 0.72 Allowed Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.224 -0.922 . . . . 0.0 109.624 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.84 -25.99 7.18 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.719 2.279 . . . . 0.0 110.615 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -121.73 152.22 16.86 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.17 -16.57 13.88 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.602 2.202 . . . . 0.0 110.483 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -46.94 -47.06 21.81 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.922 . . . . 0.0 109.619 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.636 ' O ' HD13 ' A' ' 82' ' ' LEU . . . -67.51 -34.98 78.22 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.256 -0.903 . . . . 0.0 109.628 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.551 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 8.7 m-30 -71.59 -17.16 62.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.632 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.435 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 4.3 mm-40 -73.24 -42.92 61.99 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.124 -0.985 . . . . 0.0 108.967 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.417 ' H ' HG23 ' A' ' 81' ' ' VAL . 2.3 t -76.63 -30.05 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.435 -0.79 . . . . 0.0 109.254 179.725 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.636 HD13 ' O ' ' A' ' 78' ' ' ALA . 4.8 mp -61.54 -56.29 21.59 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.354 -0.841 . . . . 0.0 109.575 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.435 ' OD1' ' O ' ' A' ' 80' ' ' GLU . 9.6 p-10 -69.64 -14.12 62.66 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.293 -0.879 . . . . 0.0 109.578 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -76.98 -36.34 56.52 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.284 -0.885 . . . . 0.0 109.606 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.429 ' HA ' HD23 ' A' ' 85' ' ' LEU . 73.8 mt -86.0 12.38 9.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.189 -0.945 . . . . 0.0 109.669 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 80.99 8.71 87.14 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.71 HD11 ' HB2' ' A' ' 62' ' ' ALA . 18.3 mt -81.19 144.72 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.191 -1.182 . . . . 0.0 109.604 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.452 ' HE3' ' HG2' ' A' ' 67' ' ' LYS . 20.1 mttt -92.55 128.67 38.49 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.209 -0.932 . . . . 0.0 109.226 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.488 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.5 mt -99.22 128.66 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.178 -0.951 . . . . 0.0 109.582 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.59 ' CE1' ' HB2' ' A' ' 110' ' ' GLU . 2.0 m-30 -117.95 152.21 35.9 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.462 -0.774 . . . . 0.0 109.12 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.545 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 7.5 tpt180 -98.66 120.23 38.72 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.153 -0.967 . . . . 0.0 109.71 -179.714 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.726 ' HB2' HG22 ' A' ' 70' ' ' ILE . . . -86.01 132.24 34.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -0.904 . . . . 0.0 109.495 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 3.7 m -71.9 -38.16 69.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.232 -0.918 . . . . 0.0 109.41 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 114.09 14.35 9.27 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -79.7 -68.74 0.64 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.246 -1.149 . . . . 0.0 109.244 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 14' ' ' SER . 0.2 OUTLIER -171.16 132.72 0.83 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.204 -0.935 . . . . 0.0 109.341 179.927 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.677 HG13 HG22 ' A' ' 16' ' ' VAL . 23.8 m -56.56 -23.61 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.917 . . . . 0.0 109.527 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -68.81 -38.83 80.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.256 -0.902 . . . . 0.0 109.449 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -77.27 -42.24 37.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.232 -0.917 . . . . 0.0 109.68 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -64.89 -27.75 69.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.692 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.458 HD22 HD11 ' A' ' 36' ' ' ILE . 0.6 OUTLIER -59.63 -61.56 2.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.185 -0.947 . . . . 0.0 109.634 -179.913 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.53 -28.54 69.71 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.426 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.497 HD23 ' HB2' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -66.92 -29.04 68.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.664 -179.934 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.575 ' CE2' ' HB1' ' A' ' 68' ' ' ALA . 9.3 t80 -75.5 -26.48 58.16 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.186 -0.946 . . . . 0.0 109.631 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 14.6 m -63.1 -20.59 65.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.231 -0.918 . . . . 0.0 109.728 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -103.88 -30.46 10.33 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.179 -0.951 . . . . 0.0 109.455 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.92 42.0 6.14 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 32.9 m-20 -95.61 -20.09 19.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -1.162 . . . . 0.0 109.318 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.497 ' HB2' HD23 ' A' ' 103' ' ' LEU . 0.2 OUTLIER -127.87 143.29 51.11 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.402 -0.811 . . . . 0.0 109.044 179.807 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.59 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 4.7 pt-20 -172.38 -157.28 0.1 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.149 -0.969 . . . . 0.0 109.888 -179.718 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.545 ' HB2' ' N ' ' A' ' 91' ' ' ARG . 3.0 tt0 -158.66 -104.21 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.368 -0.833 . . . . 0.0 109.365 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.472 ' HB ' ' HB ' ' A' ' 89' ' ' ILE . 46.8 mm -93.17 111.32 24.5 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 O-C-N 121.27 -0.894 . . . . 0.0 109.586 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.599 0 O-C-N 121.326 -0.858 . . . . 0.0 109.44 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.653 ' O ' ' HB3' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -90.65 121.48 32.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.245 -0.909 . . . . 0.0 109.345 179.881 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.583 HG12 ' CD2' ' A' ' 104' ' ' PHE . 4.1 mt -100.26 111.7 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.291 -0.881 . . . . 0.0 109.853 -179.781 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.593 ' HB1' ' CE2' ' A' ' 26' ' ' PHE . . . -104.12 112.69 25.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -0.921 . . . . 0.0 109.397 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.874 HG21 HG13 ' A' ' 97' ' ' VAL . 14.4 mm -87.78 117.62 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.226 -0.921 . . . . 0.0 109.525 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.448 ' O ' ' HB3' ' A' ' 7' ' ' SER . . . -62.64 153.78 31.23 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.289 -0.882 . . . . 0.0 109.608 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' TYR . 2.4 t 61.62 -88.96 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.522 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.838 ' HA ' HG21 ' A' ' 97' ' ' VAL . 0.2 OUTLIER 57.95 22.62 8.96 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.193 -0.942 . . . . 0.0 109.457 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 48.94 -102.12 0.05 OUTLIER Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -155.85 -47.05 0.08 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -1.173 . . . . 0.0 109.46 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.706 ' HB3' HD12 ' A' ' 12' ' ' LEU . 1.7 t70 -155.59 -62.05 0.11 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.448 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.706 HD12 ' HB3' ' A' ' 11' ' ' ASP . 5.9 mp -108.17 -15.81 14.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.204 -0.935 . . . . 0.0 109.529 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -94.19 27.49 13.19 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.6 p -78.28 74.34 4.82 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.391 -1.064 . . . . 0.0 109.695 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.583 ' C ' HG23 ' A' ' 16' ' ' VAL . 32.4 tt0 -78.33 5.55 10.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.023 -1.048 . . . . 0.0 109.815 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.633 HG22 ' N ' ' A' ' 97' ' ' VAL . 2.1 t 68.37 54.15 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.168 -0.957 . . . . 0.0 109.116 -179.559 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 16' ' ' VAL . 1.0 OUTLIER -42.74 159.47 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.411 -0.806 . . . . 0.0 109.688 -179.844 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -111.32 39.08 2.39 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.265 -0.897 . . . . 0.0 109.428 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -129.22 103.49 6.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.255 -0.903 . . . . 0.0 109.508 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.5 t80 -102.41 142.01 34.31 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.516 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 114.25 -46.73 1.13 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.792 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.445 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 7.9 ttp180 -103.12 -37.36 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.371 -1.076 . . . . 0.0 109.141 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.436 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -41.47 102.0 0.26 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.569 -0.707 . . . . 0.0 109.821 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.493 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 36.7 Cg_endo -81.21 54.73 5.33 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.652 2.235 . . . . 0.0 110.478 179.688 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.458 ' O ' ' O ' ' A' ' 7' ' ' SER . 68.5 m-85 -154.15 68.5 0.75 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.108 -0.995 . . . . 0.0 109.204 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.593 ' CE2' ' HB1' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -79.39 111.13 15.34 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.256 -0.903 . . . . 0.0 109.337 -179.907 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 27' ' ' MET . . . . . 0.469 ' HB2' ' CB ' ' A' ' 8' ' ' SER . 7.2 ttm -88.76 102.09 14.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.3 -0.875 . . . . 0.0 109.559 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.612 ' O ' HG23 ' A' ' 28' ' ' ILE . 6.1 tp -83.61 114.67 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.363 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.662 HG22 ' HB3' ' A' ' 39' ' ' SER . 47.7 t -126.11 128.71 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.155 -0.966 . . . . 0.0 109.653 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -111.21 113.86 26.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.283 -0.886 . . . . 0.0 109.368 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.439 ' SD ' ' CA ' ' A' ' 34' ' ' GLY . 0.7 OUTLIER -112.53 132.65 54.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -0.92 . . . . 0.0 109.6 -179.851 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 7.2 mmmt -87.67 -55.81 3.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.268 -0.895 . . . . 0.0 109.33 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.15 68.24 0.93 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.336 -0.853 . . . . 0.0 109.209 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.439 ' CA ' ' SD ' ' A' ' 31' ' ' MET . . . 75.92 8.6 84.9 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -130.52 98.35 4.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.176 -1.19 . . . . 0.0 109.493 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.467 HD11 HD23 ' A' ' 101' ' ' LEU . 2.9 mt -57.43 127.49 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.251 -0.906 . . . . 0.0 109.658 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.443 ' O ' ' HB3' ' A' ' 38' ' ' SER . 0.5 OUTLIER -101.66 -2.3 30.65 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.401 179.68 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.443 ' HB3' ' O ' ' A' ' 37' ' ' GLU . 77.3 p 176.8 125.55 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.201 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.662 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.2 OUTLIER -136.85 106.97 6.33 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.208 -0.932 . . . . 0.0 109.644 -179.759 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 163.62 14.41 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.658 ' O ' HG13 ' A' ' 41' ' ' VAL . 7.6 p -134.6 118.66 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.331 -0.855 . . . . 0.0 109.447 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.403 ' O ' HG13 ' A' ' 42' ' ' ILE . 21.5 pt -126.88 133.63 68.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.218 -0.926 . . . . 0.0 109.569 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.493 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 1.3 mt-10 -74.46 146.61 42.67 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.369 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ASN . . . . . 0.404 ' H ' ' HA ' ' A' ' 24' ' ' PRO . 12.2 m-20 . . . . . 0 N--CA 1.49 1.53 0 O-C-N 121.242 -0.911 . . . . 0.0 109.318 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.437 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.244 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.601 HD12 ' HB2' ' A' ' 78' ' ' ALA . 47.2 mm -66.49 -14.15 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.279 -1.13 . . . . 0.0 109.484 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -8.9 38.79 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.29 -0.881 . . . . 0.0 109.496 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 54' ' ' GLY . 14.8 t -76.93 -16.04 59.49 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.191 -0.943 . . . . 0.0 109.529 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.419 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -57.28 -32.35 66.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 109.536 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 21.8 tt0 -65.11 -52.98 52.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.443 HD13 ' HA ' ' A' ' 60' ' ' ILE . 35.9 mm -62.72 -25.6 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.228 -0.92 . . . . 0.0 109.326 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.485 HD13 ' CZ ' ' A' ' 26' ' ' PHE . 45.5 mt -69.71 -39.28 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 109.276 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.797 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -74.6 -25.44 59.26 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.248 -0.908 . . . . 0.0 109.429 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -77.09 -5.15 47.83 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.237 -0.914 . . . . 0.0 109.51 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.49 ' HB2' HG23 ' A' ' 66' ' ' VAL . 6.8 m-20 -100.26 1.86 42.18 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.134 -0.979 . . . . 0.0 109.527 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.499 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 90.89 -5.94 81.95 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.49 HG23 ' HB2' ' A' ' 64' ' ' ASN . 48.3 t -53.5 88.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -1.176 . . . . 0.0 109.858 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.499 ' N ' ' O ' ' A' ' 65' ' ' GLY . 6.4 tttp -79.75 -12.46 59.79 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.119 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.653 ' HB3' ' O ' ' A' ' 2' ' ' LYS . . . -127.62 131.99 49.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.436 -0.79 . . . . 0.0 109.108 179.685 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.582 HG21 HD21 ' A' ' 82' ' ' LEU . 2.4 t -129.64 105.49 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.123 -0.985 . . . . 0.0 109.806 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.622 HD12 ' CD1' ' A' ' 5' ' ' ILE . 23.3 mt -91.41 119.96 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.277 -0.89 . . . . 0.0 109.01 179.595 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -149.12 177.08 9.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.152 -0.967 . . . . 0.0 109.938 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.04 35.38 3.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.535 -0.728 . . . . 0.0 109.14 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.451 ' HB2' ' CE1' ' A' ' 79' ' ' PHE . 0.1 OUTLIER -44.87 134.23 4.99 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.286 -0.884 . . . . 0.0 109.465 -179.807 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.75 -19.78 10.96 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.436 2.091 . . . . 0.0 110.351 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -114.15 148.31 18.77 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.83 9.16 3.38 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.631 2.221 . . . . 0.0 110.706 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -74.44 -42.62 58.81 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.095 -1.003 . . . . 0.0 109.722 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.601 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -68.69 -50.78 48.22 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.588 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.451 ' CE1' ' HB2' ' A' ' 73' ' ' SER . 11.3 m-30 -48.81 -38.43 22.12 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.264 -0.898 . . . . 0.0 109.652 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.484 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 0.6 OUTLIER -65.75 -47.4 75.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.188 -0.945 . . . . 0.0 109.71 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 86.7 t -52.89 -50.85 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.182 -0.949 . . . . 0.0 109.466 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.582 HD21 HG21 ' A' ' 69' ' ' VAL . 1.9 mt -56.47 -31.15 63.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.484 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 3.2 m-20 -61.96 -51.26 68.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.163 -0.961 . . . . 0.0 109.301 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -62.81 -27.67 69.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.21 179.814 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.1 mt -72.03 -34.21 68.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.174 -0.954 . . . . 0.0 109.527 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.1 19.98 19.72 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.797 HD11 ' HB2' ' A' ' 62' ' ' ALA . 27.7 mt -103.83 163.03 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.289 -1.124 . . . . 0.0 109.617 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.437 ' N ' HG22 ' A' ' 87' ' ' ILE . 3.4 mptt -91.74 147.07 23.26 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.253 -0.904 . . . . 0.0 109.263 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.51 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.3 mt -120.76 131.76 72.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.112 -0.992 . . . . 0.0 109.211 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.581 ' CE2' ' HB1' ' A' ' 68' ' ' ALA . 12.8 m-85 -119.47 161.26 20.85 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.476 -0.765 . . . . 0.0 109.547 -179.807 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.488 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 0.1 OUTLIER -99.25 136.78 38.7 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.264 -0.897 . . . . 0.0 109.627 -179.909 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.64 129.33 34.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.259 -0.901 . . . . 0.0 109.443 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.35 -40.33 96.05 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.26 -0.9 . . . . 0.0 109.476 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 102.94 22.07 9.66 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.73 -83.75 0.54 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.128 -1.219 . . . . 0.0 109.4 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.539 ' HA ' HG23 ' A' ' 16' ' ' VAL . 3.3 m -146.71 137.65 24.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.324 -0.86 . . . . 0.0 109.315 179.814 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.874 HG13 HG21 ' A' ' 5' ' ' ILE . 86.8 t -64.2 -31.18 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -0.882 . . . . 0.0 109.609 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.58 -44.36 80.95 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.194 -0.941 . . . . 0.0 109.465 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -75.46 -35.8 60.82 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.475 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 15.1 m-20 -54.44 -37.71 65.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.224 -0.922 . . . . 0.0 109.669 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.572 HD21 HG11 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -49.43 -53.48 22.58 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.283 -0.885 . . . . 0.0 109.651 -179.874 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 6.0 mmtm -69.64 -33.43 72.6 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.23 -0.919 . . . . 0.0 109.656 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.501 ' CD1' ' HB3' ' A' ' 108' ' ' ASN . 2.2 mm? -57.94 -31.75 67.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.205 -0.934 . . . . 0.0 109.438 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.583 ' CD2' HG12 ' A' ' 3' ' ' ILE . 20.9 t80 -72.75 -38.61 67.31 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.384 -0.823 . . . . 0.0 109.779 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 17.6 m -70.56 -25.69 63.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.266 -0.896 . . . . 0.0 109.751 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -88.1 -0.51 57.14 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.204 -0.935 . . . . 0.0 109.674 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLY . . . . . 0.456 ' HA2' ' OE2' ' A' ' 110' ' ' GLU . . . 59.95 25.42 61.75 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' ASN . . . . . 0.501 ' HB3' ' CD1' ' A' ' 103' ' ' LEU . 1.2 m-20 -88.48 -53.28 4.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.204 -1.174 . . . . 0.0 109.424 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 11.9 tp -85.19 129.75 34.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.243 -0.911 . . . . 0.0 109.202 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.456 ' OE2' ' HA2' ' A' ' 107' ' ' GLY . 0.3 OUTLIER -165.68 -166.31 0.94 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.198 -0.939 . . . . 0.0 109.729 -179.818 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.51 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 68.5 tt0 -172.68 -113.85 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.285 -0.885 . . . . 0.0 109.371 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.476 ' N ' ' HG2' ' A' ' 111' ' ' GLU . 5.3 mt -82.31 140.37 16.53 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 O-C-N 121.093 -1.005 . . . . 0.0 109.253 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.48 ' NH1' ' HG2' ' A' ' 113' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.51 0 O-C-N 121.203 -0.935 . . . . 0.0 109.623 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.461 ' HG3' ' HB2' ' A' ' 67' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.28 0.562 . . . . 0.0 109.514 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.93 139.68 36.98 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.219 -0.926 . . . . 0.0 109.201 179.825 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.493 HG23 HD11 ' A' ' 70' ' ' ILE . 4.8 mt -115.24 113.49 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.12 -0.987 . . . . 0.0 110.006 -179.609 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.03 119.55 39.78 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.507 -0.746 . . . . 0.0 109.024 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.59 HG21 ' HB ' ' A' ' 97' ' ' VAL . 3.3 mp -98.15 136.94 27.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.128 -0.982 . . . . 0.0 109.879 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.49 ' HB2' ' CZ ' ' A' ' 26' ' ' PHE . . . -89.74 121.99 32.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.296 -0.877 . . . . 0.0 109.138 179.725 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.547 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -142.08 170.82 14.99 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.143 -0.973 . . . . 0.0 109.728 -179.832 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 51.5 p -116.32 25.31 10.73 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.316 -0.865 . . . . 0.0 109.299 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -162.64 -145.27 4.29 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.632 HG23 HG11 ' A' ' 41' ' ' VAL . 0.2 OUTLIER -147.17 22.56 1.2 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.243 -1.151 . . . . 0.0 109.521 -179.94 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -147.57 -178.68 6.38 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.199 -0.938 . . . . 0.0 109.602 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.525 ' O ' HD23 ' A' ' 12' ' ' LEU . 6.6 tt -64.39 -14.24 55.44 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.337 -0.852 . . . . 0.0 109.571 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -56.74 -52.4 50.87 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.08 86.57 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.335 -1.097 . . . . 0.0 109.397 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.46 81.21 1.44 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.476 -0.765 . . . . 0.0 109.54 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.707 HG12 ' O ' ' A' ' 16' ' ' VAL . 59.3 t 54.54 30.45 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.665 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 26.6 p 46.14 -160.66 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.275 -0.891 . . . . 0.0 109.433 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 2.9 mtt-85 -98.2 -46.92 5.66 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.898 . . . . 0.0 109.376 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -150.27 122.65 8.44 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.364 -0.835 . . . . 0.0 109.429 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.442 ' CD2' ' HB1' ' A' ' 71' ' ' ALA . 4.0 t80 -57.65 124.49 19.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.238 -0.914 . . . . 0.0 109.391 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -171.98 -49.37 0.04 OUTLIER Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.95 45.4 1.46 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.283 -1.128 . . . . 0.0 109.446 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.547 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -54.6 112.65 4.21 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.352 -0.842 . . . . 0.0 109.516 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.452 ' O ' ' CB ' ' A' ' 43' ' ' GLU . 36.6 Cg_endo -80.61 20.53 0.95 Allowed 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.606 2.204 . . . . 0.0 110.947 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -154.8 69.79 0.75 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.036 -1.04 . . . . 0.0 108.942 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.49 ' CZ ' ' HB2' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -79.1 125.21 29.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.348 -0.845 . . . . 0.0 109.722 -179.456 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 10.7 mtt -90.06 110.69 21.67 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.289 -0.882 . . . . 0.0 109.369 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 31.6 mm -93.46 107.45 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.467 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.512 HG11 HD13 ' A' ' 36' ' ' ILE . 23.3 t -115.63 116.35 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.266 -0.896 . . . . 0.0 109.429 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -103.81 114.81 29.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.554 -179.751 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.418 ' HE2' HG13 ' A' ' 36' ' ' ILE . 12.6 ptp -116.3 160.33 20.63 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.241 -0.912 . . . . 0.0 109.419 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -109.71 -94.98 0.41 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.256 -0.903 . . . . 0.0 109.626 -179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -89.5 62.35 5.92 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.116 -0.99 . . . . 0.0 109.348 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.13 35.58 92.28 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 36' ' ' ILE . 44.9 t30 -138.96 84.26 2.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.302 -1.116 . . . . 0.0 109.462 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.526 HD13 HD21 ' A' ' 101' ' ' LEU . 50.6 mt -45.41 111.27 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.221 -0.924 . . . . 0.0 109.419 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -111.49 9.26 21.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.232 -0.917 . . . . 0.0 109.482 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -167.28 124.18 1.19 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.187 -0.946 . . . . 0.0 109.485 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.2 p -144.96 107.9 4.51 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.284 -0.885 . . . . 0.0 109.478 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -123.37 148.2 46.29 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.526 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.632 HG11 HG23 ' A' ' 10' ' ' THR . 61.4 t -103.99 137.82 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.87 . . . . 0.0 109.519 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -139.33 136.28 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.259 -0.9 . . . . 0.0 109.421 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.452 ' CB ' ' O ' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -96.85 120.66 37.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 179.915 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.21 -0.931 . . . . 0.0 109.357 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.7 HG23 ' HB2' ' A' ' 78' ' ' ALA . 20.7 mm -71.85 -39.88 68.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.191 -1.182 . . . . 0.0 109.42 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 7.3 mmm-85 -65.67 -11.13 42.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.557 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.786 ' O ' HG22 ' A' ' 60' ' ' ILE . 44.8 m -70.3 -33.47 71.58 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 0.0 109.312 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.684 ' HB1' HD21 ' A' ' 82' ' ' LEU . . . -50.83 -23.84 3.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.243 -0.91 . . . . 0.0 109.318 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -70.67 -51.58 26.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.247 -0.908 . . . . 0.0 109.485 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.786 HG22 ' O ' ' A' ' 57' ' ' THR . 0.3 OUTLIER -59.03 -33.43 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.412 -179.98 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.0 mt -67.38 -40.96 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.206 -0.934 . . . . 0.0 109.215 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.01 -18.64 59.18 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.338 -0.851 . . . . 0.0 109.461 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -74.55 -17.63 60.71 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.931 . . . . 0.0 109.399 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -86.77 11.75 12.43 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.28 -0.888 . . . . 0.0 109.56 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.454 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 88.6 -6.24 83.82 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.514 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 96.8 t -54.78 89.76 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.283 -1.128 . . . . 0.0 109.878 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.461 ' HB2' ' HG3' ' A' ' 1' ' ' MET . 16.5 mmtm -79.18 2.24 21.69 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.139 -0.975 . . . . 0.0 109.017 179.427 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.514 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -142.96 140.05 30.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.236 -0.915 . . . . 0.0 109.06 179.656 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.496 ' C ' HD13 ' A' ' 70' ' ' ILE . 42.2 t -139.76 131.15 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.077 -1.014 . . . . 0.0 110.049 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.496 HD13 ' C ' ' A' ' 69' ' ' VAL . 1.3 mm -108.33 111.63 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.305 -0.872 . . . . 0.0 108.85 179.461 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.442 ' HB1' ' CD2' ' A' ' 20' ' ' PHE . . . -154.13 177.05 11.52 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.164 -0.96 . . . . 0.0 109.968 -179.627 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.5 44.87 1.73 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.53 -0.731 . . . . 0.0 109.23 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -45.74 150.61 0.94 Allowed Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.333 -0.855 . . . . 0.0 109.533 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.83 -38.88 0.57 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.677 2.251 . . . . 0.0 110.292 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.16 146.28 16.89 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.68 8.09 3.89 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.605 2.203 . . . . 0.0 110.663 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.487 ' O ' HG23 ' A' ' 81' ' ' VAL . 9.2 t-20 -63.93 -46.39 84.99 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.151 -0.968 . . . . 0.0 109.612 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.7 ' HB2' HG23 ' A' ' 55' ' ' ILE . . . -67.4 -50.24 60.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 109.557 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.865 ' CD1' HG21 ' A' ' 89' ' ' ILE . 12.8 m-85 -52.08 -33.16 38.16 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.642 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.466 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -67.01 -41.81 86.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.251 -0.905 . . . . 0.0 109.736 -179.732 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 77' ' ' ASN . 2.7 t -63.21 -53.77 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.167 -0.958 . . . . 0.0 109.751 -179.793 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.684 HD21 ' HB1' ' A' ' 58' ' ' ALA . 25.0 mt -60.38 -18.38 50.07 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.27 -0.894 . . . . 0.0 109.719 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.466 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 1.3 m120 -69.61 -56.37 7.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.275 -0.891 . . . . 0.0 109.716 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -66.12 -34.81 78.89 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.145 -0.972 . . . . 0.0 109.676 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.401 ' CB ' HG12 ' A' ' 87' ' ' ILE . 6.8 mt -61.5 -13.41 20.72 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.237 -0.914 . . . . 0.0 109.416 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 77.61 24.06 65.99 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.401 HG12 ' CB ' ' A' ' 85' ' ' LEU . 5.2 mm -92.32 144.34 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.239 -1.154 . . . . 0.0 109.4 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.87 110.37 15.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.249 -0.907 . . . . 0.0 109.442 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.865 HG21 ' CD1' ' A' ' 79' ' ' PHE . 13.0 mt -86.76 151.48 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.344 -0.848 . . . . 0.0 109.655 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.568 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 1.1 m-85 -134.87 134.02 40.3 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -0.873 . . . . 0.0 109.453 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.96 132.72 35.19 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.225 -0.922 . . . . 0.0 109.405 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.51 ' HB1' HG21 ' A' ' 16' ' ' VAL . . . -84.6 66.0 9.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.226 -0.921 . . . . 0.0 109.614 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 9.5 t -74.2 -28.14 61.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.158 -0.964 . . . . 0.0 109.463 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.401 ' O ' ' HB ' ' A' ' 95' ' ' THR . . . -59.1 -106.21 0.01 OUTLIER Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.514 HG23 ' N ' ' A' ' 96' ' ' SER . 4.0 t 178.31 -44.09 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.217 -1.166 . . . . 0.0 109.592 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.514 ' N ' HG23 ' A' ' 95' ' ' THR . 7.2 m -95.66 125.52 40.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.231 -0.918 . . . . 0.0 109.444 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.59 ' HB ' HG21 ' A' ' 5' ' ' ILE . 5.5 m -63.46 -34.99 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.238 -0.914 . . . . 0.0 109.402 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -64.42 -35.27 80.36 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.198 -0.939 . . . . 0.0 109.29 179.738 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.676 ' O ' HD23 ' A' ' 103' ' ' LEU . 20.7 tt0 -73.32 -36.78 66.28 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.334 -0.854 . . . . 0.0 109.403 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.494 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 98.9 m-20 -67.74 -27.79 67.09 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.171 -0.955 . . . . 0.0 109.424 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.526 HD21 HD13 ' A' ' 36' ' ' ILE . 24.9 tp -58.28 -62.24 1.98 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.358 -0.839 . . . . 0.0 109.674 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -68.19 -24.97 65.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.153 -0.967 . . . . 0.0 109.443 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.676 HD23 ' O ' ' A' ' 99' ' ' GLU . 0.9 OUTLIER -65.0 -29.58 70.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.305 -0.872 . . . . 0.0 109.482 179.929 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.528 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 9.8 t80 -64.12 -43.89 93.92 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.156 -0.965 . . . . 0.0 109.501 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 86.4 m -57.31 -31.36 65.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.753 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -87.64 -22.78 24.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.242 -0.911 . . . . 0.0 109.578 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 77.02 24.36 66.73 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' ASN . . . . . 0.635 ' HB3' HD12 ' A' ' 103' ' ' LEU . 2.4 t30 -80.31 -32.52 37.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.179 -1.189 . . . . 0.0 109.367 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.479 ' HA ' HD12 ' A' ' 109' ' ' LEU . 3.4 tp -66.59 -163.89 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.274 -0.891 . . . . 0.0 109.519 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -110.58 137.54 48.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 109.263 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.568 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 20.8 pt-20 -127.58 165.08 20.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.236 -0.915 . . . . 0.0 109.69 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 10.3 mt -151.54 104.26 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.147 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.463 0 O-C-N 121.236 -0.915 . . . . 0.0 109.838 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -111.14 137.26 49.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.25 -0.906 . . . . 0.0 109.449 179.867 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.594 HG12 ' CZ ' ' A' ' 104' ' ' PHE . 4.9 mt -102.84 101.89 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.377 -0.827 . . . . 0.0 109.72 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.424 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -103.66 101.22 11.06 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.318 -0.864 . . . . 0.0 109.147 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.66 ' HB ' HD12 ' A' ' 70' ' ' ILE . 14.7 tt -98.25 130.19 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.256 -0.902 . . . . 0.0 109.592 -179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -59.26 146.09 40.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.406 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.494 ' HB3' ' CB ' ' A' ' 14' ' ' SER . 0.8 OUTLIER -135.85 162.12 33.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.921 . . . . 0.0 109.594 -179.863 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.82 -20.43 12.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.872 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.571 ' O ' ' CD1' ' A' ' 25' ' ' TYR . . . -119.81 -124.66 3.24 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.78 -37.21 1.03 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.19 -1.182 . . . . 0.0 109.544 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -144.92 -73.11 0.25 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.704 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -89.58 -29.76 18.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.254 -0.904 . . . . 0.0 109.514 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.19 -15.12 72.0 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.532 ' OG ' HG21 ' A' ' 97' ' ' VAL . 0.8 OUTLIER -77.39 82.62 3.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.196 -1.179 . . . . 0.0 109.479 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.487 ' HG2' ' O ' ' A' ' 95' ' ' THR . 13.2 tt0 -77.34 3.66 12.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.279 -0.888 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.576 HG22 HG13 ' A' ' 97' ' ' VAL . 9.7 t 66.62 65.96 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.16 -0.962 . . . . 0.0 109.227 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.448 ' O ' ' O ' ' A' ' 16' ' ' VAL . 60.2 p -57.65 -159.35 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.258 -0.901 . . . . 0.0 109.703 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.45 54.18 1.93 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.47 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -136.95 71.41 1.41 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.211 -0.931 . . . . 0.0 109.438 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.547 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 5.7 t80 -65.58 100.93 0.55 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.29 -0.881 . . . . 0.0 109.61 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 151.91 -42.97 0.69 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.468 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 5.5 ttt85 -104.51 -33.9 8.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.203 -1.175 . . . . 0.0 109.783 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.457 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -39.22 99.02 0.19 Allowed Pre-proline 0 N--CA 1.495 1.809 0 O-C-N 121.543 -0.723 . . . . 0.0 109.78 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.484 ' O ' ' HG2' ' A' ' 43' ' ' GLU . 36.5 Cg_endo -81.03 45.39 1.98 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 122.716 2.277 . . . . 0.0 110.927 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.571 ' CD1' ' O ' ' A' ' 9' ' ' GLY . 1.9 m-85 -161.05 72.34 0.43 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.946 -1.096 . . . . 0.0 109.627 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -79.7 150.01 31.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.305 -0.872 . . . . 0.0 109.438 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' MET . . . . . 0.431 ' HB2' ' OG ' ' A' ' 7' ' ' SER . 5.2 ttt -123.54 122.1 37.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -0.939 . . . . 0.0 109.402 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 28.3 mt -114.08 129.34 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.899 . . . . 0.0 109.547 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.414 ' CG1' HG23 ' A' ' 36' ' ' ILE . 73.6 t -138.69 136.18 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.218 -0.926 . . . . 0.0 109.532 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -120.73 94.66 4.43 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.193 -0.942 . . . . 0.0 109.444 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.497 ' SD ' ' CD1' ' A' ' 3' ' ' ILE . 0.0 OUTLIER -83.44 152.31 25.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.385 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -96.73 -94.02 0.21 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.189 -0.944 . . . . 0.0 109.492 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -101.43 65.22 1.04 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.133 -0.979 . . . . 0.0 109.299 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 70.25 37.59 71.48 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -150.41 116.15 5.54 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.316 -1.108 . . . . 0.0 109.308 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.441 ' N ' HD13 ' A' ' 36' ' ' ILE . 5.9 mm -64.12 122.81 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -0.881 . . . . 0.0 109.593 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -130.77 16.61 5.26 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.188 -0.945 . . . . 0.0 109.318 179.743 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 17.1 m -173.51 101.29 0.12 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.382 -0.824 . . . . 0.0 109.245 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.55 101.06 7.12 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.94 155.91 19.78 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.336 -0.853 . . . . 0.0 109.418 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 3.1 t -125.99 129.6 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.205 -0.935 . . . . 0.0 109.337 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 92.8 mt -110.32 143.05 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.264 -0.897 . . . . 0.0 109.853 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.484 ' HG2' ' O ' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -109.73 128.94 55.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.314 -0.866 . . . . 0.0 109.281 179.852 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.199 -0.938 . . . . 0.0 109.407 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.417 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.492 2.372 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.772 HG21 ' HB2' ' A' ' 78' ' ' ALA . 22.2 mt -76.08 0.1 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -1.144 . . . . 0.0 109.619 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.17 -9.57 58.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.199 -0.938 . . . . 0.0 109.553 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.417 HG22 ' O ' ' A' ' 54' ' ' GLY . 7.2 t -76.96 -19.0 57.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -0.89 . . . . 0.0 109.583 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -56.55 -38.45 71.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.289 -0.882 . . . . 0.0 109.581 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -56.46 -39.31 72.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.68 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.4 mt -75.6 -35.44 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 109.648 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.412 HG21 HD13 ' A' ' 61' ' ' ILE . 48.8 mt -62.1 -29.05 45.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.54 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.669 ' HB1' HD11 ' A' ' 87' ' ' ILE . . . -71.82 -34.89 69.71 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.7 -179.828 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -76.8 -0.42 23.84 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.173 -0.954 . . . . 0.0 109.687 -179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -94.27 8.34 42.15 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.213 -0.929 . . . . 0.0 109.586 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 87.34 -11.21 66.3 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.454 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 70.0 t -58.44 91.62 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.226 -1.161 . . . . 0.0 109.489 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.53 -7.34 58.41 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.372 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.454 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -132.98 137.63 46.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 0.0 109.273 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 32.3 t -134.28 111.86 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.15 -0.969 . . . . 0.0 109.646 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.733 HG22 ' HB2' ' A' ' 92' ' ' ALA . 11.7 mt -95.71 116.9 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.289 -0.882 . . . . 0.0 109.261 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.547 ' HB1' ' HB2' ' A' ' 20' ' ' PHE . . . -148.78 173.83 12.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.156 -0.965 . . . . 0.0 109.684 -179.696 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.73 38.89 3.96 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.393 -0.817 . . . . 0.0 109.422 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.401 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.1 OUTLIER -50.17 141.25 15.74 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.264 -0.898 . . . . 0.0 109.406 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.1 Cg_endo -78.59 -62.95 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.593 2.195 . . . . 0.0 110.474 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -74.28 155.78 49.31 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.45 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.3 Cg_endo -78.6 4.7 6.15 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.702 2.268 . . . . 0.0 110.535 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -62.4 -56.86 14.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.207 -0.933 . . . . 0.0 109.512 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.772 ' HB2' HG21 ' A' ' 55' ' ' ILE . . . -57.26 -54.41 47.08 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.164 -0.96 . . . . 0.0 109.536 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -55.64 -22.25 21.82 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.3 -0.875 . . . . 0.0 109.523 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.45 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.2 OUTLIER -74.84 -37.01 62.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.162 -0.961 . . . . 0.0 109.467 -179.982 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.3 t -73.12 -50.68 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.911 . . . . 0.0 109.377 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.657 ' HB2' HD11 ' A' ' 89' ' ' ILE . 14.9 mt -50.1 -50.69 47.51 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.333 -0.854 . . . . 0.0 109.396 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -65.2 -33.36 75.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.242 -0.911 . . . . 0.0 109.431 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -58.37 -35.26 71.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.507 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -82.36 -37.39 25.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.341 -0.849 . . . . 0.0 109.379 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.36 22.1 6.61 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.669 HD11 ' HB1' ' A' ' 62' ' ' ALA . 6.0 mt -88.46 160.18 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.222 -1.163 . . . . 0.0 109.495 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.472 ' N ' HG22 ' A' ' 87' ' ' ILE . 2.1 mttt -86.15 113.31 22.09 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.768 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.657 HD11 ' HB2' ' A' ' 82' ' ' LEU . 43.5 mt -88.38 161.92 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.267 -0.895 . . . . 0.0 108.938 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.581 ' CE1' ' HB3' ' A' ' 109' ' ' LEU . 2.6 m-85 -139.9 137.68 35.03 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.966 -1.084 . . . . 0.0 109.702 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 17.6 mmm180 -87.99 119.42 28.34 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.409 -0.807 . . . . 0.0 109.558 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.733 ' HB2' HG22 ' A' ' 70' ' ' ILE . . . -98.41 108.04 20.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.875 . . . . 0.0 109.387 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' THR . . . . . 0.598 HG23 ' N ' ' A' ' 94' ' ' GLY . 8.1 t -53.86 -47.19 71.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.598 ' N ' HG23 ' A' ' 93' ' ' THR . . . 125.31 83.47 0.53 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.665 HG22 ' N ' ' A' ' 96' ' ' SER . 17.5 m -137.65 -92.8 0.22 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.236 -1.155 . . . . 0.0 109.459 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.665 ' N ' HG22 ' A' ' 95' ' ' THR . 0.2 OUTLIER -153.01 130.74 11.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.157 -0.965 . . . . 0.0 109.399 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.576 HG13 HG22 ' A' ' 16' ' ' VAL . 22.2 m -52.05 -20.9 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 109.676 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -66.62 -57.97 6.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.238 -0.914 . . . . 0.0 109.522 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 32.3 mm-40 -66.0 -29.49 69.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.889 . . . . 0.0 109.524 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.541 ' OD1' HG21 ' A' ' 16' ' ' VAL . 33.2 m120 -60.9 -46.16 91.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.132 -0.98 . . . . 0.0 109.34 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -58.51 -37.04 74.76 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.216 -0.927 . . . . 0.0 109.148 179.781 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.417 ' HE2' ' HB2' ' A' ' 102' ' ' LYS . 0.3 OUTLIER -73.9 -22.06 59.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.287 -0.883 . . . . 0.0 109.311 179.822 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.464 ' HA ' HD22 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -76.54 -38.06 55.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.247 179.82 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.594 ' CZ ' HG12 ' A' ' 3' ' ' ILE . 0.5 OUTLIER -70.39 -6.64 36.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.3 -0.875 . . . . 0.0 109.551 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.421 HG22 ' OE1' ' A' ' 106' ' ' GLU . 51.6 m -73.34 -39.09 65.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 0.0 109.682 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLU . . . . . 0.421 ' OE1' HG22 ' A' ' 105' ' ' THR . 2.8 mm-40 -94.19 -41.87 9.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.32 -0.862 . . . . 0.0 109.505 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 110.78 25.78 5.01 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.93 -21.6 43.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.278 -1.131 . . . . 0.0 109.374 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.581 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 2.8 mt -59.41 144.99 45.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.373 -0.829 . . . . 0.0 109.421 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.512 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 1.4 pt-20 -94.72 145.62 24.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.182 -0.949 . . . . 0.0 109.303 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.547 ' HG2' ' CZ ' ' A' ' 90' ' ' TYR . 0.4 OUTLIER -139.32 -178.58 5.43 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.161 -0.962 . . . . 0.0 109.816 -179.603 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.9 mp -138.34 134.26 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.406 -0.809 . . . . 0.0 109.294 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.213 -0.929 . . . . 0.0 109.544 -179.979 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.462 ' HG3' ' O ' ' A' ' 1' ' ' MET . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.495 ' CE ' ' OE1' ' A' ' 30' ' ' GLU . 17.2 mttp -102.71 146.67 27.87 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.259 -0.901 . . . . 0.0 109.366 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.795 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 6.8 mt -113.27 131.5 64.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.3 -0.875 . . . . 0.0 109.918 -179.692 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -125.74 146.56 49.7 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.415 -0.803 . . . . 0.0 108.855 179.518 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.493 HG23 ' CG2' ' A' ' 70' ' ' ILE . 1.6 mp -132.35 127.52 57.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 109.718 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -63.5 148.64 48.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.351 -0.843 . . . . 0.0 109.403 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.861 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -143.91 164.99 28.99 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.138 -0.976 . . . . 0.0 109.549 -179.95 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.96 -6.46 23.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.319 -0.863 . . . . 0.0 109.597 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.556 ' O ' ' CG ' ' A' ' 25' ' ' TYR . . . -148.15 -145.37 4.15 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.724 HG22 ' O ' ' A' ' 10' ' ' THR . 96.7 m -135.6 18.56 3.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.241 -1.152 . . . . 0.0 109.433 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -141.6 -174.47 4.06 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.222 -0.924 . . . . 0.0 109.529 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -66.61 -22.22 66.12 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.22 -0.925 . . . . 0.0 109.482 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.73 -50.44 57.84 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 15' ' ' GLU . 81.4 p -76.81 84.39 3.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.294 -1.121 . . . . 0.0 109.244 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.706 ' O ' HG13 ' A' ' 97' ' ' VAL . 18.6 mt-10 -46.89 -98.11 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.398 -0.814 . . . . 0.0 109.859 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.809 HG11 ' HB1' ' A' ' 92' ' ' ALA . 4.2 t -123.06 33.76 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.939 -1.101 . . . . 0.0 109.782 -179.709 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.401 ' C ' ' O ' ' A' ' 16' ' ' VAL . 7.2 p 43.93 -162.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.883 . . . . 0.0 109.533 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.546 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -140.34 11.91 2.35 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.338 -0.851 . . . . 0.0 109.388 179.908 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.546 ' CD1' ' O ' ' A' ' 18' ' ' ARG . 32.6 m-85 -142.64 -165.3 2.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.52 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -133.88 -61.81 0.79 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.316 -0.865 . . . . 0.0 109.355 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -79.81 2.28 74.83 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.419 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.1 OUTLIER -103.91 -64.51 1.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.183 -1.187 . . . . 0.0 109.489 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.861 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -44.24 104.58 0.39 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.287 -0.883 . . . . 0.0 109.404 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.515 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.6 Cg_endo -79.94 61.49 8.21 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.656 2.237 . . . . 0.0 110.927 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.556 ' CG ' ' O ' ' A' ' 9' ' ' GLY . 51.1 m-85 -160.54 70.45 0.41 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.04 -1.037 . . . . 0.0 109.325 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 48.5 m-85 -79.85 109.22 14.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.206 -0.934 . . . . 0.0 109.321 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' MET . . . . . 0.473 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 0.0 OUTLIER -79.6 141.37 36.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.332 -0.855 . . . . 0.0 109.742 -179.65 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.482 HG12 HG12 ' A' ' 42' ' ' ILE . 7.8 mm -125.04 139.32 51.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.32 -0.863 . . . . 0.0 109.235 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.439 HG21 ' CD1' ' A' ' 101' ' ' LEU . 10.6 t -140.63 144.64 26.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -0.892 . . . . 0.0 109.499 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.495 ' OE1' ' CE ' ' A' ' 2' ' ' LYS . 6.2 mt-10 -125.33 107.95 11.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.237 -0.914 . . . . 0.0 109.545 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.1 mtt -81.56 149.82 28.47 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.204 -0.935 . . . . 0.0 109.382 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.04 -51.79 2.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.184 -0.948 . . . . 0.0 109.587 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.02 53.25 0.57 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.498 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.4 21.83 55.61 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.403 ' O ' ' C ' ' A' ' 36' ' ' ILE . 1.6 t30 -148.13 95.43 2.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.254 -1.145 . . . . 0.0 109.477 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.435 ' O ' HG13 ' A' ' 36' ' ' ILE . 9.5 pt -45.47 114.16 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.168 -0.957 . . . . 0.0 109.295 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -113.68 9.4 17.78 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -0.933 . . . . 0.0 109.411 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 53.5 p -163.46 113.4 1.32 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 109.36 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -135.03 104.6 6.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.288 -0.883 . . . . 0.0 109.493 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.96 -174.58 2.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.309 -0.869 . . . . 0.0 109.245 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.588 HG11 HG23 ' A' ' 10' ' ' THR . 14.8 p -131.93 166.65 28.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.074 -1.016 . . . . 0.0 109.648 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.587 ' N ' HG22 ' A' ' 41' ' ' VAL . 7.4 mm -129.97 99.37 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.35 -0.844 . . . . 0.0 109.501 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.526 ' HG3' ' CE1' ' A' ' 25' ' ' TYR . 31.8 tt0 -77.88 126.3 30.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.275 -0.891 . . . . 0.0 109.299 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.8 m120 . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.214 -0.929 . . . . 0.0 109.647 -179.819 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.957 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.6 mm -76.76 -28.87 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -1.142 . . . . 0.0 109.499 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 8.0 mmm180 -76.69 -34.11 58.2 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.183 -0.948 . . . . 0.0 109.594 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.957 HG22 ' O ' ' A' ' 54' ' ' GLY . 14.8 t -49.11 -23.63 1.31 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.737 -179.832 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -45.25 -47.25 12.82 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.272 -0.892 . . . . 0.0 109.9 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -53.83 -48.43 69.93 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.195 -0.941 . . . . 0.0 109.92 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 80.2 mt -60.91 -36.73 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.213 -0.929 . . . . 0.0 110.115 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 32.7 mt -62.94 -40.95 90.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 109.947 -179.582 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.38 -28.73 64.24 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.149 -0.969 . . . . 0.0 109.791 -179.642 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -77.32 4.39 10.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -0.929 . . . . 0.0 109.947 -179.796 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -106.6 2.54 26.1 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.018 -1.051 . . . . 0.0 109.661 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.03 -11.21 62.2 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.453 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 81.8 t -62.61 88.27 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -1.146 . . . . 0.0 109.61 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.66 -2.74 44.12 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.291 -0.88 . . . . 0.0 108.986 179.467 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.795 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -127.8 127.54 43.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.34 -0.85 . . . . 0.0 109.172 179.849 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.6 HG21 HD22 ' A' ' 82' ' ' LEU . 74.8 t -125.57 112.43 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.17 -0.956 . . . . 0.0 109.78 -179.667 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.493 ' CG2' HG23 ' A' ' 5' ' ' ILE . 3.5 mt -99.33 124.31 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.192 -0.942 . . . . 0.0 109.129 179.549 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -158.52 172.81 17.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.175 -0.953 . . . . 0.0 109.766 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.15 49.18 2.31 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.367 -0.833 . . . . 0.0 109.514 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.86 160.11 22.38 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.201 -0.937 . . . . 0.0 109.407 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.85 -89.9 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.557 2.172 . . . . 0.0 110.296 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.6 162.96 36.91 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.48 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.7 Cg_endo -80.29 27.74 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.825 2.35 . . . . 0.0 111.17 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.73 ' O ' HG23 ' A' ' 81' ' ' VAL . 0.9 OUTLIER -76.7 -59.84 2.6 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.879 -1.138 . . . . 0.0 109.423 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.419 ' O ' ' HB ' ' A' ' 81' ' ' VAL . . . -55.61 -43.51 76.15 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.266 -0.896 . . . . 0.0 109.389 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.632 ' O ' HD11 ' A' ' 89' ' ' ILE . 3.8 m-30 -60.2 -49.17 78.7 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.264 -0.898 . . . . 0.0 109.498 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.48 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.3 OUTLIER -61.36 -21.03 63.67 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 109.331 179.798 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 77' ' ' ASN . 95.5 t -73.28 -63.12 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.217 -0.927 . . . . 0.0 109.373 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.714 ' HA ' HD12 ' A' ' 85' ' ' LEU . 1.5 mt -57.74 -27.09 62.7 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.179 -0.951 . . . . 0.0 109.302 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -62.06 -51.32 68.44 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.322 -0.861 . . . . 0.0 109.332 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -77.01 -12.28 59.92 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.262 -0.899 . . . . 0.0 109.362 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.714 HD12 ' HA ' ' A' ' 82' ' ' LEU . 55.5 mt -77.49 -23.63 50.28 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.921 . . . . 0.0 109.365 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLY . . . . . 0.456 ' C ' HD12 ' A' ' 87' ' ' ILE . . . 100.86 41.42 2.67 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.505 HD12 ' N ' ' A' ' 87' ' ' ILE . 5.3 mp -137.7 161.87 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -1.156 . . . . 0.0 109.512 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.5 ' N ' HG22 ' A' ' 87' ' ' ILE . 4.6 mmtm -92.56 131.5 37.63 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -0.901 . . . . 0.0 109.627 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.632 HD11 ' O ' ' A' ' 79' ' ' PHE . 50.9 mt -92.29 157.35 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.251 -0.906 . . . . 0.0 109.51 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.529 ' CE2' ' HB3' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -142.33 143.12 32.61 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.336 -0.852 . . . . 0.0 109.44 -179.898 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.707 ' O ' HD22 ' A' ' 109' ' ' LEU . 12.4 mmt180 -100.15 125.28 46.25 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 109.428 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ALA . . . . . 0.809 ' HB1' HG11 ' A' ' 16' ' ' VAL . . . -82.97 113.84 20.83 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.217 -0.927 . . . . 0.0 109.473 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 3.8 m -144.98 13.03 1.45 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.233 -0.917 . . . . 0.0 109.518 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.02 -121.68 0.31 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.47 HG22 ' OG ' ' A' ' 96' ' ' SER . 17.3 m -129.59 -54.5 1.16 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.356 -1.085 . . . . 0.0 109.385 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.49 ' CB ' ' HG2' ' A' ' 15' ' ' GLU . 0.8 OUTLIER -139.19 143.53 38.13 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.275 -0.891 . . . . 0.0 109.367 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.706 HG13 ' O ' ' A' ' 15' ' ' GLU . 15.0 m -44.1 -26.72 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.295 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' GLU . . . . . 0.407 ' N ' ' O ' ' A' ' 96' ' ' SER . 3.3 tp10 -64.27 -51.76 61.96 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.264 -0.897 . . . . 0.0 109.246 179.702 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.436 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 3.0 tp10 -64.15 -37.46 87.52 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.297 -0.877 . . . . 0.0 109.068 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -63.89 -30.73 71.79 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.331 -0.856 . . . . 0.0 109.218 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.439 ' CD1' HG21 ' A' ' 29' ' ' VAL . 6.4 tp -55.98 -55.85 27.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.363 -0.835 . . . . 0.0 109.219 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 44.4 mttt -76.82 -13.94 59.96 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.25 179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.51 HD12 ' HA ' ' A' ' 103' ' ' LEU . 6.1 tp -77.16 -23.39 51.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.909 . . . . 0.0 109.579 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.591 ' CD1' ' CD1' ' A' ' 3' ' ' ILE . 32.2 t80 -75.58 -23.75 56.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.234 -0.916 . . . . 0.0 109.106 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.6 m -74.57 -34.05 62.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.319 -0.863 . . . . 0.0 109.259 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -90.73 -0.28 57.65 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.287 -0.883 . . . . 0.0 109.487 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.73 37.87 62.7 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -82.74 -23.1 34.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.217 -1.167 . . . . 0.0 109.473 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.707 HD22 ' O ' ' A' ' 91' ' ' ARG . 0.8 OUTLIER -83.69 162.03 20.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.235 -0.916 . . . . 0.0 109.289 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.4 ' HG2' ' N ' ' A' ' 111' ' ' GLU . 34.3 tt0 -87.63 146.95 25.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.184 -0.947 . . . . 0.0 109.91 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.529 ' HB3' ' CE2' ' A' ' 90' ' ' TYR . 9.2 pt-20 -135.79 179.8 6.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.43 -0.794 . . . . 0.0 109.077 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.8 mt -149.84 127.13 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.708 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.414 ' CD ' ' N ' ' A' ' 113' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.37 -0.831 . . . . 0.0 109.356 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.464 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 36.7 mttt -147.01 126.73 13.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.269 -0.895 . . . . 0.0 109.221 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.951 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 4.3 mt -111.16 116.44 52.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.248 -0.908 . . . . 0.0 109.832 -179.582 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.697 ' C ' HD13 ' A' ' 5' ' ' ILE . . . -108.28 146.57 32.7 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.248 -0.908 . . . . 0.0 109.394 179.838 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.697 HD13 ' C ' ' A' ' 4' ' ' ALA . 5.4 mm -114.73 121.12 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.206 -0.934 . . . . 0.0 109.53 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.486 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -47.63 144.79 3.0 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.192 -0.943 . . . . 0.0 109.362 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 25' ' ' TYR . 11.3 t 49.99 -93.19 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.234 -0.916 . . . . 0.0 109.458 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.955 ' HA ' HG11 ' A' ' 97' ' ' VAL . 0.5 OUTLIER 66.81 8.68 6.18 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.169 -0.957 . . . . 0.0 109.518 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLY . . . . . 0.544 ' N ' ' HB2' ' A' ' 14' ' ' SER . . . 44.06 -128.13 6.53 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.07 -13.59 11.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.304 -1.115 . . . . 0.0 109.546 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -171.32 -70.61 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.195 -0.941 . . . . 0.0 109.921 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 13' ' ' GLY . 0.3 OUTLIER -122.37 -22.54 5.48 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 0.0 110.022 -179.619 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 12' ' ' LEU . . . -42.19 -42.34 4.18 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.544 ' HB2' ' N ' ' A' ' 9' ' ' GLY . 27.3 t -77.87 85.28 4.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.272 -1.134 . . . . 0.0 109.674 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.693 ' C ' HG23 ' A' ' 16' ' ' VAL . 1.7 mt-10 -67.96 85.32 0.23 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.413 -0.805 . . . . 0.0 109.214 179.802 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.693 HG23 ' C ' ' A' ' 15' ' ' GLU . 1.5 t 70.58 30.98 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.451 -0.781 . . . . 0.0 109.265 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.474 ' HA ' ' OG ' ' A' ' 14' ' ' SER . 4.3 p 62.45 -160.99 0.3 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.339 -0.851 . . . . 0.0 109.543 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.0 ttm180 -154.8 -46.43 0.09 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.399 -0.813 . . . . 0.0 109.053 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -145.72 147.8 32.32 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.369 -0.832 . . . . 0.0 109.095 179.746 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.48 ' CG ' ' HB1' ' A' ' 71' ' ' ALA . 85.1 t80 -118.32 138.19 52.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.161 -0.962 . . . . 0.0 109.578 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.475 ' O ' ' HA2' ' A' ' 54' ' ' GLY . . . 139.84 -59.12 0.59 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.47 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.1 OUTLIER -116.98 13.45 14.87 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.2 -1.177 . . . . 0.0 109.774 -179.753 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.96 109.53 1.71 Allowed Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.233 -0.917 . . . . 0.0 109.884 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.9 Cg_endo -81.17 41.37 1.13 Allowed 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.548 2.165 . . . . 0.0 110.485 179.699 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.418 ' O ' ' O ' ' A' ' 7' ' ' SER . 0.4 OUTLIER -158.74 69.82 0.49 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.09 -1.006 . . . . 0.0 109.314 -179.911 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.538 ' CZ ' HD13 ' A' ' 61' ' ' ILE . 0.3 OUTLIER -82.27 112.69 19.5 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.62 -179.854 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 27' ' ' MET . . . . . 0.965 ' HG3' HG12 ' A' ' 41' ' ' VAL . 0.0 OUTLIER -85.15 144.69 28.03 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.877 . . . . 0.0 109.308 -179.996 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 39.4 mt -139.76 126.18 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.228 -0.92 . . . . 0.0 109.518 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.556 HG13 ' O ' ' A' ' 38' ' ' SER . 34.8 t -124.09 128.67 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.35 -0.844 . . . . 0.0 109.471 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -98.88 167.22 10.89 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.368 -0.833 . . . . 0.0 109.237 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' MET . . . . . 0.52 ' HE3' HG22 ' A' ' 36' ' ' ILE . 29.9 mtt -133.19 138.91 46.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.932 . . . . 0.0 109.448 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 6.7 ttmm -98.93 -48.06 5.04 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -0.913 . . . . 0.0 109.464 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 15.8 mtmm -148.81 66.59 1.05 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.341 -0.849 . . . . 0.0 109.218 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.77 12.59 42.46 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.419 ' O ' ' C ' ' A' ' 36' ' ' ILE . 8.2 t-20 -130.83 94.36 3.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -1.17 . . . . 0.0 109.462 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.52 HG22 ' HE3' ' A' ' 31' ' ' MET . 26.3 pt -43.64 126.07 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.702 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -137.06 16.53 3.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.344 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.556 ' O ' HG13 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -154.94 117.12 4.2 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 0.0 109.14 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 80.9 p -143.77 112.45 6.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.532 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -124.91 171.95 9.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.893 . . . . 0.0 109.373 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.965 HG12 ' HG3' ' A' ' 27' ' ' MET . 20.8 m -131.73 115.87 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.274 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.2 tp -105.06 152.6 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.245 -0.909 . . . . 0.0 109.413 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -105.1 145.12 30.96 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.223 -0.923 . . . . 0.0 109.399 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.278 -0.889 . . . . 0.0 109.558 -179.888 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 21' ' ' GLY . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.488 HG23 ' HA ' ' A' ' 78' ' ' ALA . 42.9 mm -68.55 -11.55 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.157 -1.202 . . . . 0.0 109.376 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.5 ttt180 -76.36 -16.32 59.77 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.327 -0.858 . . . . 0.0 109.6 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 10.6 t -63.34 -25.94 68.53 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.253 -0.904 . . . . 0.0 109.252 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.487 ' O ' HG13 ' A' ' 61' ' ' ILE . . . -54.36 -36.17 63.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 109.588 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -74.01 -32.55 63.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.141 -0.974 . . . . 0.0 109.425 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 81.9 mt -65.96 -40.7 88.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.267 -0.896 . . . . 0.0 109.541 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.538 HD13 ' CZ ' ' A' ' 26' ' ' PHE . 8.6 pt -76.69 -29.23 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.576 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -62.57 -39.26 93.1 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.187 -0.946 . . . . 0.0 109.711 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -68.98 -12.68 61.89 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.237 -0.914 . . . . 0.0 109.831 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -89.15 -7.84 54.88 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.182 -0.949 . . . . 0.0 109.542 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.522 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 100.8 -12.04 59.26 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.464 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 16.4 t -51.81 89.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.375 -1.073 . . . . 0.0 109.489 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.522 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -80.91 -5.66 57.7 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.307 -0.871 . . . . 0.0 109.099 179.568 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.951 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -125.2 134.84 52.21 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.211 -0.931 . . . . 0.0 109.523 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.416 ' C ' HD12 ' A' ' 70' ' ' ILE . 86.4 t -137.27 111.93 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.162 -0.961 . . . . 0.0 109.919 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.631 HD12 ' N ' ' A' ' 70' ' ' ILE . 1.7 mp -94.88 106.11 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.313 -0.867 . . . . 0.0 108.979 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.48 ' HB1' ' CG ' ' A' ' 20' ' ' PHE . . . -135.78 173.57 11.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.129 -0.982 . . . . 0.0 109.86 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.26 40.54 2.46 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.428 -0.795 . . . . 0.0 109.44 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' SER . . . . . 0.414 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 1.4 t -45.98 146.67 1.98 Allowed Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.207 -0.933 . . . . 0.0 109.41 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 35.9 Cg_endo -77.98 -17.92 13.36 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.642 2.228 . . . . 0.0 110.492 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -127.02 164.76 20.48 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.87 4.65 5.92 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.626 2.217 . . . . 0.0 110.431 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.48 ' O ' ' HB3' ' A' ' 80' ' ' GLU . 2.9 t-20 -62.3 -43.16 99.47 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.314 -0.866 . . . . 0.0 109.545 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.488 ' HA ' HG23 ' A' ' 55' ' ' ILE . . . -64.13 -57.71 8.78 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.283 -0.886 . . . . 0.0 109.53 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.695 ' CD1' HG21 ' A' ' 89' ' ' ILE . 9.2 m-85 -58.21 -21.42 47.81 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.58 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.48 ' HB3' ' O ' ' A' ' 77' ' ' ASN . 29.7 tt0 -62.17 -59.6 4.81 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.197 -0.939 . . . . 0.0 109.393 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.4 t -61.22 -44.88 99.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.235 -0.916 . . . . 0.0 109.203 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 1.008 HD23 HD12 ' A' ' 87' ' ' ILE . 14.3 mt -50.35 -37.94 39.63 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.248 -0.907 . . . . 0.0 109.307 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -64.31 -42.87 96.13 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.344 -0.848 . . . . 0.0 109.363 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -69.98 -15.69 63.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.328 -0.858 . . . . 0.0 109.338 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.476 ' HB3' HG13 ' A' ' 87' ' ' ILE . 17.9 mt -95.6 -8.1 35.9 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.181 -0.95 . . . . 0.0 109.517 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 63.03 32.83 85.46 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 1.008 HD12 HD23 ' A' ' 82' ' ' LEU . 13.1 mt -96.22 171.4 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.234 -1.157 . . . . 0.0 109.511 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.524 ' H ' HG22 ' A' ' 87' ' ' ILE . 8.0 mttt -91.86 117.08 29.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.646 -179.767 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.695 HG21 ' CD1' ' A' ' 79' ' ' PHE . 10.5 mt -94.29 128.18 45.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.346 -0.846 . . . . 0.0 109.388 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.551 ' CE2' ' O ' ' A' ' 109' ' ' LEU . 2.2 m-85 -123.21 144.01 49.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.278 -0.889 . . . . 0.0 109.334 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ARG . . . . . 0.501 ' HG2' ' CG ' ' A' ' 111' ' ' GLU . 0.0 OUTLIER -91.21 132.05 36.35 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.158 -0.964 . . . . 0.0 109.653 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.02 94.3 9.57 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.239 -0.913 . . . . 0.0 109.409 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -135.46 23.14 3.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.125 -0.984 . . . . 0.0 109.624 -179.808 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -86.69 -134.26 3.84 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.669 -1.373 . . . . 0.0 109.669 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 96' ' ' SER . 5.2 t -136.14 -38.35 0.7 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.267 -1.137 . . . . 0.0 109.447 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.443 ' N ' HG23 ' A' ' 95' ' ' THR . 29.0 t -125.77 137.08 53.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.314 -0.866 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.955 HG11 ' HA ' ' A' ' 8' ' ' SER . 0.3 OUTLIER -55.03 -35.59 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -0.858 . . . . 0.0 109.406 179.916 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -69.2 -51.83 33.95 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.233 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.548 ' O ' HD13 ' A' ' 103' ' ' LEU . 3.2 tt0 -52.18 -31.67 32.71 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.244 -0.91 . . . . 0.0 109.166 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -72.39 -49.73 31.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.342 -0.848 . . . . 0.0 109.152 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.465 HD21 HG11 ' A' ' 29' ' ' VAL . 27.1 tp -50.4 -51.31 47.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.284 -0.885 . . . . 0.0 109.513 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -65.77 -35.4 80.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.205 -0.935 . . . . 0.0 109.492 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.548 HD13 ' O ' ' A' ' 99' ' ' GLU . 0.7 OUTLIER -71.71 -11.17 60.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.269 -0.895 . . . . 0.0 109.537 179.947 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.504 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.8 t80 -76.93 -38.3 53.68 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.263 -0.898 . . . . 0.0 109.453 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' THR . . . . . 0.421 ' O ' HG22 ' A' ' 105' ' ' THR . 28.8 m -72.09 -13.78 61.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.464 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -96.45 -17.23 20.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.182 -0.949 . . . . 0.0 109.49 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 74.43 29.45 61.89 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' ASN . . . . . 0.462 ' HB3' HD23 ' A' ' 103' ' ' LEU . 0.4 OUTLIER -79.96 -44.11 20.86 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.297 -1.119 . . . . 0.0 109.693 -179.882 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.551 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.4 OUTLIER -123.28 146.62 47.73 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.235 -0.916 . . . . 0.0 109.463 -179.949 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.528 ' HA ' ' CG ' ' A' ' 90' ' ' TYR . 1.1 pm0 -171.66 -156.79 0.11 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.904 . . . . 0.0 109.458 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.564 ' OE1' ' CE2' ' A' ' 79' ' ' PHE . 0.0 OUTLIER -146.29 -87.19 0.1 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.27 -0.894 . . . . 0.0 109.678 179.951 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 7.0 mt -131.37 151.37 35.51 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.192 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.435 ' HG2' ' HG2' ' A' ' 88' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 O-C-N 121.34 -0.85 . . . . 0.0 109.382 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.42 ' O ' ' HG2' ' A' ' 1' ' ' MET . 5.1 ttt . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.455 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 0.1 OUTLIER -131.18 156.05 45.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.218 -0.926 . . . . 0.0 109.521 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ILE . . . . . 0.63 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 7.0 mt -116.01 107.47 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.552 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.697 ' HB2' HD12 ' A' ' 28' ' ' ILE . . . -97.18 170.85 8.83 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.326 -0.859 . . . . 0.0 109.13 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.732 HG21 ' HB ' ' A' ' 97' ' ' VAL . 98.1 mt -148.13 119.93 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.172 -0.955 . . . . 0.0 109.889 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.538 ' HB1' ' HD1' ' A' ' 20' ' ' PHE . . . -87.14 143.95 27.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 108.949 179.565 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.426 ' HB2' ' O ' ' A' ' 6' ' ' ALA . 1.2 m 61.77 81.74 0.19 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.055 -1.028 . . . . 0.0 109.129 -179.723 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.646 ' HB2' HG21 ' A' ' 97' ' ' VAL . 0.0 OUTLIER -136.32 -37.63 0.7 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.308 -179.788 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.49 -171.95 27.05 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.05 9.99 15.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.175 -1.191 . . . . 0.0 109.454 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 47.5 p-10 -170.25 -174.14 1.65 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.483 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.627 ' H ' HD23 ' A' ' 12' ' ' LEU . 0.7 OUTLIER -75.66 -20.97 58.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.21 -0.932 . . . . 0.0 109.456 179.941 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.496 ' N ' ' HG ' ' A' ' 12' ' ' LEU . . . -46.38 -45.5 16.45 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.499 ' CB ' ' O ' ' A' ' 8' ' ' SER . 0.6 OUTLIER -76.15 81.43 2.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.278 -1.131 . . . . 0.0 109.429 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLU . . . . . 0.66 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -73.27 83.06 1.38 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.339 -0.851 . . . . 0.0 109.359 179.874 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.885 HG21 ' HA2' ' A' ' 94' ' ' GLY . 2.6 t 78.01 77.56 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.485 -0.759 . . . . 0.0 109.478 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 16' ' ' VAL . 0.1 OUTLIER -43.59 -73.92 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -0.914 . . . . 0.0 109.594 -179.93 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -140.33 -82.06 0.25 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.23 -0.919 . . . . 0.0 109.542 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -146.29 -144.71 0.16 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.29 -0.882 . . . . 0.0 109.332 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.538 ' HD1' ' HB1' ' A' ' 6' ' ' ALA . 16.6 t80 -121.5 27.5 8.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.172 -0.955 . . . . 0.0 109.497 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -83.07 -74.7 1.2 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.427 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.5 OUTLIER -123.0 27.98 7.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.277 -1.131 . . . . 0.0 109.349 179.929 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -50.91 108.46 1.05 Allowed Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.371 -0.83 . . . . 0.0 109.34 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.3 Cg_endo -79.57 39.27 0.81 Allowed 'Trans proline' 0 C--N 1.311 -1.425 0 C-N-CA 122.566 2.178 . . . . 0.0 111.077 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.542 ' CD1' ' HG2' ' A' ' 43' ' ' GLU . 48.1 m-85 -155.55 67.16 0.63 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.98 -1.075 . . . . 0.0 109.065 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.647 ' CZ ' ' HB1' ' A' ' 4' ' ' ALA . 9.2 t80 -81.88 120.25 24.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.436 -0.79 . . . . 0.0 109.592 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 4.5 ttm -103.45 159.99 15.1 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.277 -0.889 . . . . 0.0 109.558 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.756 HD11 HG22 ' A' ' 66' ' ' VAL . 1.1 tp -148.53 133.01 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.268 -0.895 . . . . 0.0 109.54 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.591 HG11 HD11 ' A' ' 101' ' ' LEU . 39.5 t -143.11 124.83 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.592 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -99.09 171.4 8.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.235 -0.916 . . . . 0.0 109.317 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 13.6 ttm -139.66 138.93 36.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -0.893 . . . . 0.0 109.583 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.74 -47.82 6.02 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.21 -0.931 . . . . 0.0 109.522 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 13.1 mttp -153.27 41.09 0.55 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.235 -0.916 . . . . 0.0 109.463 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.99 -8.53 55.92 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.483 ' O ' ' HG2' ' A' ' 37' ' ' GLU . 6.9 m-20 -117.02 97.18 5.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -1.157 . . . . 0.0 109.356 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.486 ' O ' HG13 ' A' ' 36' ' ' ILE . 5.6 pt -47.25 113.02 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.412 -0.805 . . . . 0.0 109.586 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.483 ' HG2' ' O ' ' A' ' 35' ' ' ASN . 14.9 mm-40 -109.72 19.26 19.36 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -0.917 . . . . 0.0 109.664 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 2.1 p -163.53 120.78 1.82 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 109.319 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.441 ' CB ' HG22 ' A' ' 29' ' ' VAL . 5.7 p -149.28 107.53 3.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.539 -179.804 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -117.3 156.27 28.09 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.171 -0.955 . . . . 0.0 109.516 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -126.19 138.71 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.257 -0.902 . . . . 0.0 109.402 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 40.8 pt -135.71 146.43 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.351 -0.843 . . . . 0.0 109.614 -179.85 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.542 ' HG2' ' CD1' ' A' ' 25' ' ' TYR . 42.0 mt-10 -98.25 55.61 1.14 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.231 -0.918 . . . . 0.0 109.13 179.7 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 . . . . . 0 N--CA 1.489 1.501 0 O-C-N 121.323 -0.86 . . . . 0.0 109.372 -179.706 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.809 HG23 ' HB2' ' A' ' 78' ' ' ALA . 34.6 mm -65.35 -33.24 62.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.319 -1.106 . . . . 0.0 109.648 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.74 -14.77 62.11 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.208 -0.932 . . . . 0.0 109.717 -179.826 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.448 ' HA ' HD12 ' A' ' 60' ' ' ILE . 85.7 m -67.53 -18.02 64.88 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.114 -0.991 . . . . 0.0 109.744 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ALA . . . . . 0.431 ' HB2' ' HE2' ' A' ' 20' ' ' PHE . . . -60.28 -28.16 67.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.235 -0.916 . . . . 0.0 109.654 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -62.67 -49.75 73.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.295 -0.878 . . . . 0.0 109.687 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.448 HD12 ' HA ' ' A' ' 57' ' ' THR . 3.7 mt -64.04 -45.67 96.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.892 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 41.6 mt -52.2 -48.0 43.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.237 -0.914 . . . . 0.0 109.957 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.74 -37.45 84.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.171 -0.955 . . . . 0.0 109.998 -179.524 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -66.25 -11.1 48.15 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.097 -1.002 . . . . 0.0 109.851 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -88.99 16.75 6.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.117 -0.989 . . . . 0.0 109.556 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.453 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 95.31 -20.75 47.89 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' VAL . . . . . 0.756 HG22 HD11 ' A' ' 28' ' ' ILE . 97.1 t -57.06 88.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.312 -1.111 . . . . 0.0 109.506 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.453 ' N ' ' O ' ' A' ' 65' ' ' GLY . 14.0 mttt -79.91 -8.45 59.33 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.329 -0.857 . . . . 0.0 108.777 179.331 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ALA . . . . . 0.63 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -128.05 138.61 52.64 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' VAL . . . . . 0.433 ' C ' HD12 ' A' ' 70' ' ' ILE . 95.3 t -141.37 122.08 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.112 -0.993 . . . . 0.0 109.821 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.582 HD12 ' N ' ' A' ' 70' ' ' ILE . 1.3 mp -93.43 144.5 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.345 -0.847 . . . . 0.0 108.804 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -176.81 175.94 1.56 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.127 -0.983 . . . . 0.0 109.755 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -153.04 66.51 0.79 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.412 -0.805 . . . . 0.0 109.347 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -73.02 158.92 86.43 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.238 -0.914 . . . . 0.0 109.568 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.55 -39.2 0.42 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.658 2.239 . . . . 0.0 110.764 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -121.22 178.45 16.38 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -179.677 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' PRO . . . . . 0.428 ' HA ' ' HB2' ' A' ' 79' ' ' PHE . 36.6 Cg_endo -80.28 40.67 1.0 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.853 2.369 . . . . 0.0 110.753 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 52.5 m-20 -76.1 -67.54 0.67 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.085 -1.01 . . . . 0.0 109.314 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ALA . . . . . 0.809 ' HB2' HG23 ' A' ' 55' ' ' ILE . . . -74.66 -25.91 59.51 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.32 179.733 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' PHE . . . . . 0.428 ' HB2' ' HA ' ' A' ' 76' ' ' PRO . 3.1 m-85 -66.23 -21.11 66.29 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.373 -0.829 . . . . 0.0 109.398 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.417 ' O ' ' HB2' ' A' ' 84' ' ' GLU . 11.8 mt-10 -77.4 -46.84 21.44 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.233 -0.917 . . . . 0.0 109.833 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.4 t -68.65 -36.13 73.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.132 -0.98 . . . . 0.0 109.824 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.498 ' HB3' ' CG1' ' A' ' 89' ' ' ILE . 8.7 mt -73.75 -57.61 3.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.268 -0.895 . . . . 0.0 109.707 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.425 ' N ' HD11 ' A' ' 89' ' ' ILE . 8.2 t-20 -49.53 -37.78 28.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.212 -0.93 . . . . 0.0 109.6 -179.829 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' GLU . . . . . 0.417 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 0.3 OUTLIER -73.02 -39.34 66.08 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.217 -0.927 . . . . 0.0 109.403 -179.947 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 85' ' ' LEU . . . . . 0.424 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.3 OUTLIER -64.54 -13.12 51.06 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.134 -0.979 . . . . 0.0 109.475 -179.943 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 75.13 26.57 66.05 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ILE . . . . . 0.521 HG22 ' N ' ' A' ' 88' ' ' LYS . 23.1 mm -91.91 160.85 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.345 -1.091 . . . . 0.0 109.423 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' LYS . . . . . 0.521 ' N ' HG22 ' A' ' 87' ' ' ILE . 7.8 mtpt -83.01 105.14 13.76 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.169 -0.957 . . . . 0.0 109.309 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ILE . . . . . 0.511 ' O ' ' CB ' ' A' ' 111' ' ' GLU . 3.1 mt -90.75 152.33 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.182 -0.949 . . . . 0.0 109.513 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' TYR . . . . . 0.484 ' CD1' ' O ' ' A' ' 110' ' ' GLU . 1.1 m-85 -136.63 141.27 43.22 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -0.875 . . . . 0.0 109.404 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.25 149.19 22.85 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.537 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.86 141.04 38.72 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.277 -0.889 . . . . 0.0 109.365 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.98 -17.28 24.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.541 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.885 ' HA2' HG21 ' A' ' 16' ' ' VAL . . . 101.94 13.55 31.4 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 52.0 m -81.19 -55.3 4.83 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -1.16 . . . . 0.0 109.459 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 173.16 130.19 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.321 -0.862 . . . . 0.0 109.572 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.732 ' HB ' HG21 ' A' ' 5' ' ' ILE . 33.6 m -65.02 -23.79 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.374 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' GLU . . . . . 0.54 ' HB2' ' CB ' ' A' ' 12' ' ' LEU . 1.5 tt0 -65.89 -60.05 3.24 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.277 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.882 ' O ' HD12 ' A' ' 103' ' ' LEU . 36.1 mm-40 -60.38 -28.66 68.39 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.291 -0.881 . . . . 0.0 109.33 179.793 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ASN . . . . . 0.439 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 6.4 m-20 -69.68 -30.58 68.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.286 -0.884 . . . . 0.0 109.409 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' LEU . . . . . 0.711 HD23 ' N ' ' A' ' 102' ' ' LYS . 6.8 tt -59.87 -60.08 4.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.404 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' LYS . . . . . 0.711 ' N ' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -64.94 -29.07 69.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.319 -0.863 . . . . 0.0 109.38 179.922 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.882 HD12 ' O ' ' A' ' 99' ' ' GLU . 0.4 OUTLIER -65.46 -30.69 71.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.239 -0.913 . . . . 0.0 109.627 -179.935 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 104' ' ' PHE . . . . . 0.434 ' CD1' HD11 ' A' ' 3' ' ' ILE . 23.4 t80 -59.75 -32.1 70.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.192 -0.942 . . . . 0.0 109.589 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 28.3 m -67.19 -40.92 86.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.887 . . . . 0.0 109.73 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -79.8 4.99 14.76 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.276 -0.89 . . . . 0.0 109.553 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 46.09 28.98 3.23 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -80.01 -33.2 39.48 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.193 -1.181 . . . . 0.0 109.379 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.433 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 45.5 mt -65.84 -176.93 0.42 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.313 -0.867 . . . . 0.0 109.306 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.484 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 11.3 pt-20 -108.48 143.59 37.24 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.572 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' GLU . . . . . 0.511 ' CB ' ' O ' ' A' ' 89' ' ' ILE . 0.0 OUTLIER -137.06 -174.01 3.62 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.276 -0.89 . . . . 0.0 109.298 179.863 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.444 HG13 ' O ' ' A' ' 111' ' ' GLU . 2.3 mp -147.99 147.48 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.18 -0.95 . . . . 0.0 109.493 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ARG . . . . . 0.435 ' HB2' ' O ' ' A' ' 112' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.331 -0.855 . . . . 0.0 109.417 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.271 0.558 . . . . 0.0 109.513 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.5 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 23.2 mttp -110.91 128.27 55.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.232 -0.917 . . . . 0.0 109.501 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.853 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 3.9 mt -95.51 128.05 47.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.301 -0.875 . . . . 0.0 109.57 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.65 ' C ' HD13 ' A' ' 5' ' ' ILE . . . -116.33 122.55 45.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.205 -0.934 . . . . 0.0 109.451 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.749 ' N ' HD13 ' A' ' 5' ' ' ILE . 1.2 mm -97.24 115.53 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.196 -0.94 . . . . 0.0 109.485 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.518 ' HA ' ' CE1' ' A' ' 26' ' ' PHE . . . -59.01 146.58 37.73 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.297 -0.877 . . . . 0.0 109.626 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 2.4 m 52.73 -98.09 0.07 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -0.851 . . . . 0.0 109.611 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.604 ' HB3' HG11 ' A' ' 97' ' ' VAL . 75.4 m 59.05 15.36 3.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.078 -1.014 . . . . 0.0 109.448 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.554 ' N ' ' HB3' ' A' ' 14' ' ' SER . . . 52.69 -150.96 8.78 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.3 m -129.5 -8.38 4.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.243 -1.151 . . . . 0.0 110.092 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.591 ' HB3' HD23 ' A' ' 12' ' ' LEU . 0.4 OUTLIER -131.19 -89.17 0.46 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.965 -1.084 . . . . 0.0 109.873 -179.845 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.591 HD23 ' HB3' ' A' ' 11' ' ' ASP . 0.7 OUTLIER -158.99 26.33 0.21 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.167 -0.958 . . . . 0.0 109.669 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.86 -41.17 1.47 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.554 ' HB3' ' N ' ' A' ' 9' ' ' GLY . 0.7 OUTLIER -77.34 84.17 3.77 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.251 -1.146 . . . . 0.0 109.48 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.482 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER -72.44 83.31 1.08 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.441 -0.787 . . . . 0.0 109.556 179.982 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.482 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 14.2 t 70.23 5.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.383 -0.823 . . . . 0.0 109.769 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 51.6 -95.91 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.286 -0.884 . . . . 0.0 109.682 179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.408 ' N ' ' O ' ' A' ' 16' ' ' VAL . 2.2 mtt180 -158.35 -77.93 0.07 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.029 -1.044 . . . . 0.0 109.707 -179.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.421 ' CD2' ' O ' ' A' ' 72' ' ' SER . 22.4 m-85 -117.17 174.3 6.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.221 -0.924 . . . . 0.0 109.632 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.695 ' CB ' ' HB1' ' A' ' 71' ' ' ALA . 2.9 t80 -117.04 104.72 11.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.254 -0.903 . . . . 0.0 109.402 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.459 ' HA2' ' CD1' ' A' ' 55' ' ' ILE . . . -143.01 -57.94 0.03 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.437 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.6 mtp85 -128.75 17.2 6.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.307 -1.114 . . . . 0.0 109.24 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -48.16 106.63 0.63 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.337 -0.852 . . . . 0.0 109.776 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.503 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 37.0 Cg_endo -80.74 42.23 1.29 Allowed 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.609 2.206 . . . . 0.0 110.477 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.503 ' CD2' ' O ' ' A' ' 24' ' ' PRO . 5.7 m-85 -159.83 69.53 0.42 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.09 -1.007 . . . . 0.0 109.584 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.518 ' CE1' ' HA ' ' A' ' 6' ' ' ALA . 0.1 OUTLIER -84.61 112.86 20.82 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.214 -0.929 . . . . 0.0 109.215 179.865 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -79.74 135.39 36.5 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.291 -0.88 . . . . 0.0 109.77 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 14.3 mm -108.25 138.47 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.209 -0.932 . . . . 0.0 109.323 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.425 HG13 HG23 ' A' ' 36' ' ' ILE . 75.8 t -131.92 103.83 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.385 -0.822 . . . . 0.0 109.459 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -85.43 88.65 7.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.183 -0.948 . . . . 0.0 109.539 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -82.83 141.73 32.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.316 -0.865 . . . . 0.0 109.386 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 4.9 tptt -117.58 -72.08 0.71 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.127 -0.983 . . . . 0.0 109.463 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 23.3 mttm -110.58 58.84 0.61 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.206 -0.934 . . . . 0.0 109.395 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 65.0 13.5 57.47 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 36' ' ' ILE . 25.0 t30 -132.74 105.87 7.42 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.293 -1.122 . . . . 0.0 109.403 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.47 ' H ' HD12 ' A' ' 36' ' ' ILE . 3.3 mp -42.97 114.25 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.311 -0.868 . . . . 0.0 109.577 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -96.76 -9.52 28.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 109.492 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -159.62 119.23 2.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.27 -0.894 . . . . 0.0 109.513 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.6 p -120.83 102.89 8.67 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.229 -0.919 . . . . 0.0 108.906 179.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -121.7 -176.45 3.32 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.371 -0.831 . . . . 0.0 109.859 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.8 p -151.98 130.4 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.408 -0.808 . . . . 0.0 109.309 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.42 ' O ' HG13 ' A' ' 42' ' ' ILE . 12.2 pt -114.12 131.22 66.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.189 -0.944 . . . . 0.0 109.671 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -97.73 150.42 21.23 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.285 -0.884 . . . . 0.0 109.429 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.471 ' HB2' ' HB3' ' A' ' 24' ' ' PRO . 55.6 m-20 -66.88 152.92 95.15 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.319 -0.863 . . . . 0.0 109.404 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.34 -78.71 0.01 OUTLIER 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.624 2.216 . . . . 0.0 110.402 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.34 74.6 1.25 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.303 -0.873 . . . . 0.0 109.351 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -75.43 -14.79 60.47 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.175 -0.953 . . . . 0.0 109.602 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.402 ' O ' ' HB2' ' A' ' 49' ' ' ALA . 0.5 OUTLIER -118.23 66.06 0.76 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.191 -0.943 . . . . 0.0 109.503 -179.955 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.402 ' HB2' ' O ' ' A' ' 48' ' ' SER . . . -179.79 -52.44 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.156 -0.965 . . . . 0.0 109.495 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -55.23 170.74 0.19 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.252 -0.905 . . . . 0.0 109.471 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.35 134.31 11.64 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 50.1 84.28 0.02 OUTLIER Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -136.16 -150.28 0.36 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -1.16 . . . . 0.0 109.483 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.724 ' O ' HG22 ' A' ' 57' ' ' THR . . . 82.85 -81.2 1.75 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.459 ' CD1' ' HA2' ' A' ' 21' ' ' GLY . 7.1 mm -74.82 -7.32 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.268 -1.136 . . . . 0.0 109.516 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.33 -23.07 60.2 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.237 -0.914 . . . . 0.0 109.23 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.724 HG22 ' O ' ' A' ' 54' ' ' GLY . 6.1 t -57.47 -22.77 45.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.39 -0.819 . . . . 0.0 109.468 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.83 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -53.71 -50.0 66.88 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.306 -0.871 . . . . 0.0 109.624 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -46.41 -41.24 13.41 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.91 . . . . 0.0 109.625 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 50.4 mt -71.51 -39.97 71.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.237 -0.914 . . . . 0.0 109.703 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.83 HD12 ' HA ' ' A' ' 58' ' ' ALA . 63.4 mt -56.11 -32.82 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.226 -0.922 . . . . 0.0 109.473 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.498 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -76.67 -31.19 57.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.285 -0.884 . . . . 0.0 109.477 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 27.7 t30 -72.71 -14.38 61.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -0.876 . . . . 0.0 109.639 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -90.08 -1.22 57.92 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.206 -0.934 . . . . 0.0 109.649 -179.863 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.52 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 87.4 -6.37 83.49 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.5 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 96.0 t -48.09 92.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -1.103 . . . . 0.0 109.662 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.52 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.6 OUTLIER -79.5 -2.09 40.54 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.371 -0.83 . . . . 0.0 108.813 179.38 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.853 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -134.79 129.52 34.7 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.861 . . . . 0.0 109.373 179.739 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.4 t -130.46 96.84 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.163 -0.96 . . . . 0.0 109.613 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.509 HD13 HD21 ' A' ' 100' ' ' ASN . 7.0 mt -91.22 109.73 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.213 -0.929 . . . . 0.0 109.288 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.695 ' HB1' ' CB ' ' A' ' 20' ' ' PHE . . . -144.08 176.94 8.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.248 -0.908 . . . . 0.0 109.778 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.635 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 75.1 m -133.38 41.6 3.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.527 -0.733 . . . . 0.0 109.435 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.423 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.8 OUTLIER -53.64 143.12 39.91 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.307 -0.871 . . . . 0.0 109.459 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 35.8 Cg_endo -79.03 88.04 1.5 Allowed 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 122.639 2.226 . . . . 0.0 110.601 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 122.5 162.6 11.6 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.404 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.3 Cg_endo -78.84 7.88 4.05 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 C-N-CA 122.75 2.3 . . . . 0.0 110.591 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 80' ' ' GLU . 1.5 m120 -55.25 -65.66 0.55 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.226 -0.921 . . . . 0.0 109.583 -179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.8 -51.93 67.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.906 . . . . 0.0 109.675 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.8 m-30 -57.76 -15.97 9.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.223 -0.923 . . . . 0.0 109.754 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.472 ' HB3' ' O ' ' A' ' 77' ' ' ASN . 54.0 tt0 -72.82 -50.34 24.77 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.197 -0.939 . . . . 0.0 109.302 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 82' ' ' LEU . 2.4 t -71.3 -53.16 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 O-C-N 121.289 -0.882 . . . . 0.0 109.258 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.519 ' HB3' ' CG1' ' A' ' 89' ' ' ILE . 4.4 mm? -45.75 -30.09 1.51 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.14 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -77.06 -47.75 19.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.336 -0.853 . . . . 0.0 109.346 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -68.02 -8.63 39.18 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.244 -0.91 . . . . 0.0 109.59 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.6 mp -86.48 -48.4 8.43 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.22 -0.925 . . . . 0.0 109.539 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.35 11.1 9.96 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.498 HD11 ' HB2' ' A' ' 62' ' ' ALA . 1.6 mt -91.69 172.37 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.24 -1.153 . . . . 0.0 109.419 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.477 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 0.1 OUTLIER -90.35 114.66 26.8 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.269 -0.894 . . . . 0.0 109.669 -179.926 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.519 ' CG1' ' HB3' ' A' ' 82' ' ' LEU . 5.9 mt -82.77 150.37 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.294 -0.879 . . . . 0.0 108.939 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.566 ' CE2' ' HB3' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -139.68 148.17 42.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.625 -179.95 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.42 140.2 39.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.315 -0.866 . . . . 0.0 109.614 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.635 ' HB3' ' OG ' ' A' ' 72' ' ' SER . . . -110.32 88.04 2.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.936 . . . . 0.0 109.677 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.92 -40.32 42.98 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -0.901 . . . . 0.0 109.29 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 128.3 116.43 1.95 Allowed Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -164.38 -67.3 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.198 -1.178 . . . . 0.0 109.471 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.472 ' O ' ' HB2' ' A' ' 100' ' ' ASN . 0.1 OUTLIER 171.71 157.21 0.09 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.244 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.63 HG13 HG21 ' A' ' 5' ' ' ILE . 1.8 t -74.28 -48.07 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.278 -0.889 . . . . 0.0 109.651 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -50.93 -50.16 58.29 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.276 -0.89 . . . . 0.0 109.846 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 31.0 mm-40 -70.55 -35.58 73.18 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.224 -0.923 . . . . 0.0 109.893 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.55 ' OD1' HD11 ' A' ' 109' ' ' LEU . 7.4 t30 -56.23 -39.08 71.96 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.165 -0.96 . . . . 0.0 109.735 -179.667 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 75.7 mt -57.77 -62.92 1.45 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.233 -0.917 . . . . 0.0 109.558 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 5.7 ttpt -62.52 -15.11 48.77 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.212 -0.93 . . . . 0.0 109.575 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.469 HD12 ' HA ' ' A' ' 103' ' ' LEU . 0.9 OUTLIER -77.09 -33.55 56.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.224 -0.922 . . . . 0.0 109.799 -179.791 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.746 ' CD2' HD11 ' A' ' 3' ' ' ILE . 79.3 t80 -74.2 -24.78 59.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.163 -0.961 . . . . 0.0 109.765 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 61.3 m -72.24 -22.91 61.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.227 -0.92 . . . . 0.0 109.674 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -103.79 4.95 35.67 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 109.597 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 55.95 40.54 82.17 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 -79.96 -51.45 9.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.192 -1.181 . . . . 0.0 109.558 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.55 HD11 ' OD1' ' A' ' 100' ' ' ASN . 13.8 mt -56.34 176.8 0.08 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 109.497 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.425 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 8.7 pt-20 -109.65 148.4 31.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.286 -0.884 . . . . 0.0 109.42 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.566 ' HB3' ' CE2' ' A' ' 90' ' ' TYR . 6.1 pt-20 -134.25 155.68 49.75 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.232 -0.917 . . . . 0.0 109.656 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 67.5 mt -135.36 143.44 36.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.321 -0.862 . . . . 0.0 109.047 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -139.76 -172.41 3.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.112 -0.992 . . . . 0.0 109.909 -179.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 29.1 t -156.94 95.23 2.2 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.441 -0.787 . . . . 0.0 109.19 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.64 152.64 29.6 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.533 2.156 . . . . 0.0 110.584 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -128.89 18.79 5.59 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 2.6 p -132.22 60.89 1.67 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.351 -1.088 . . . . 0.0 109.369 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.07 169.25 13.89 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 49.33 88.68 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.338 -1.095 . . . . 0.0 109.66 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -76.71 105.5 2.03 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.22 77.57 1.41 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.162 -1.199 . . . . 0.0 109.728 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -83.35 149.71 26.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.161 -0.962 . . . . 0.0 109.303 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.505 ' O ' ' CG ' ' A' ' 124' ' ' ARG . 1.2 mtt180 -90.08 106.93 18.81 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.215 -0.928 . . . . 0.0 109.668 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.505 ' CG ' ' O ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.508 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.476 ' HA ' ' HB2' ' A' ' 67' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.456 ' HD2' ' O ' ' A' ' 65' ' ' GLY . 0.5 OUTLIER -89.29 147.4 24.13 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.223 -0.923 . . . . 0.0 109.474 -179.926 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.531 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 5.3 mt -115.08 119.86 62.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.212 -0.93 . . . . 0.0 109.701 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.567 ' CB ' HD13 ' A' ' 28' ' ' ILE . . . -112.87 111.45 22.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.279 -0.888 . . . . 0.0 109.073 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.74 HG23 ' CG2' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -98.41 126.19 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.228 -0.92 . . . . 0.0 109.8 -179.487 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.49 134.27 42.28 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.302 -0.874 . . . . 0.0 109.153 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.414 ' OG ' ' HG3' ' A' ' 27' ' ' MET . 0.0 OUTLIER -144.45 156.08 44.03 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.067 -1.02 . . . . 0.0 109.768 -179.814 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.42 -26.56 11.4 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.345 -0.847 . . . . 0.0 109.427 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -87.63 -105.62 0.9 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -148.73 -45.05 0.15 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.155 -1.203 . . . . 0.0 109.407 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' A' ' 11' ' ' ASP . 2.3 t70 -154.47 -55.29 0.1 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 109.367 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.2 tt -105.62 -37.69 6.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.18 -0.95 . . . . 0.0 109.337 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -57.71 -26.47 57.5 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.443 ' OG ' HG22 ' A' ' 97' ' ' VAL . 54.4 p -76.92 80.14 3.48 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.271 -1.135 . . . . 0.0 109.439 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.531 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.3 OUTLIER -76.88 82.0 3.45 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.261 -0.899 . . . . 0.0 109.575 -179.88 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.531 HG23 ' C ' ' A' ' 15' ' ' GLU . 3.0 t 73.16 19.64 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.255 -0.903 . . . . 0.0 109.651 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 44.36 -163.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.209 -0.932 . . . . 0.0 109.422 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.32 -32.71 2.67 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -0.902 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -150.12 -179.83 7.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.141 -0.974 . . . . 0.0 109.666 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.452 ' CG ' ' HB1' ' A' ' 71' ' ' ALA . 21.7 t80 -121.77 83.78 2.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.356 -0.84 . . . . 0.0 109.404 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 147.1 -18.64 1.56 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.442 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 1.6 mtp180 -110.55 -29.41 8.07 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.257 -1.143 . . . . 0.0 109.373 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.37 110.61 2.47 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.917 . . . . 0.0 109.399 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.5 46.65 2.31 Favored 'Trans proline' 0 C--N 1.312 -1.369 0 C-N-CA 122.692 2.261 . . . . 0.0 110.948 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.472 ' CE2' ' OE2' ' A' ' 43' ' ' GLU . 11.3 m-85 -158.51 70.01 0.51 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.99 -1.068 . . . . 0.0 109.417 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.499 ' CD1' ' HB2' ' A' ' 44' ' ' ASN . 46.1 m-85 -81.4 153.53 26.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.2 -0.937 . . . . 0.0 109.737 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' MET . . . . . 0.45 ' O ' ' HA ' ' A' ' 4' ' ' ALA . 37.9 mtp -120.3 114.16 21.47 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.34 -0.85 . . . . 0.0 109.041 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.567 HD13 ' CB ' ' A' ' 4' ' ' ALA . 26.6 mm -105.46 120.48 56.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.158 -0.964 . . . . 0.0 109.797 -179.566 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.707 HG11 HD12 ' A' ' 36' ' ' ILE . 44.2 t -122.74 116.03 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.362 -0.836 . . . . 0.0 109.301 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -89.73 86.84 6.78 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.25 -0.906 . . . . 0.0 109.615 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.748 ' HE1' HG23 ' A' ' 105' ' ' THR . 1.2 ttp -83.29 125.07 31.22 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.179 -0.951 . . . . 0.0 109.328 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -87.99 -91.3 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.229 -0.919 . . . . 0.0 109.765 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.431 ' O ' ' C ' ' A' ' 34' ' ' GLY . 3.6 tmtm? -98.52 85.39 3.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.16 -0.962 . . . . 0.0 109.743 -179.679 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 43.07 33.99 1.95 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -144.4 104.11 4.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.139 -1.212 . . . . 0.0 109.504 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.707 HD12 HG11 ' A' ' 29' ' ' VAL . 3.9 tt -53.57 118.63 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.29 -0.881 . . . . 0.0 109.232 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -127.75 26.2 5.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.227 -0.92 . . . . 0.0 109.662 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.462 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER 176.25 128.2 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.629 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.657 ' OG ' HD11 ' A' ' 36' ' ' ILE . 5.5 m -156.19 112.4 3.06 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.242 -0.911 . . . . 0.0 109.304 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -130.11 139.0 50.97 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.184 -0.947 . . . . 0.0 109.707 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.3 t -92.36 154.49 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.086 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.0 tt -147.47 142.53 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.125 -0.984 . . . . 0.0 109.822 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.472 ' OE2' ' CE2' ' A' ' 25' ' ' TYR . 1.9 mt-10 -88.55 79.31 7.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.319 -0.863 . . . . 0.0 109.177 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.499 ' HB2' ' CD1' ' A' ' 26' ' ' PHE . 2.0 m120 -44.83 147.19 1.16 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.2 -0.937 . . . . 0.0 109.521 -179.774 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.08 -167.01 0.44 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.595 2.196 . . . . 0.0 110.43 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 68.7 7.29 6.01 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.249 -0.907 . . . . 0.0 109.579 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -73.57 -41.15 63.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.925 . . . . 0.0 109.318 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -140.49 57.28 1.58 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.359 -0.838 . . . . 0.0 109.311 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -103.27 61.33 0.77 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.363 -0.835 . . . . 0.0 109.301 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.405 ' O ' ' O ' ' A' ' 51' ' ' GLY . 1.7 t 50.58 52.07 15.61 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.288 -0.883 . . . . 0.0 109.428 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.405 ' O ' ' O ' ' A' ' 50' ' ' SER . . . 62.54 142.66 0.01 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -169.9 -172.01 36.0 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -107.0 144.68 33.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.294 -1.121 . . . . 0.0 109.523 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.78 -6.73 46.01 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.4 mm -72.95 -19.56 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.26 -1.141 . . . . 0.0 109.672 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 3.7 mtt-85 -74.98 -16.61 60.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.141 -0.974 . . . . 0.0 109.486 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.666 ' HA ' HD12 ' A' ' 60' ' ' ILE . 53.3 m -67.94 -24.9 65.23 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.271 -0.893 . . . . 0.0 109.418 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -51.9 -56.05 16.46 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.32 -0.862 . . . . 0.0 109.651 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -51.04 -36.42 39.61 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.275 -0.891 . . . . 0.0 109.777 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.666 HD12 ' HA ' ' A' ' 57' ' ' THR . 76.9 mt -63.82 -63.5 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.177 -0.952 . . . . 0.0 109.838 -179.595 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.77 HG23 HG21 ' A' ' 66' ' ' VAL . 10.5 mt -53.67 -24.46 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.231 -0.918 . . . . 0.0 109.935 -179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.596 ' CB ' HD11 ' A' ' 87' ' ' ILE . . . -65.28 -46.73 79.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.131 -0.981 . . . . 0.0 109.8 -179.656 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 9.2 m-20 -77.65 6.85 6.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.275 -0.89 . . . . 0.0 110.293 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.644 ' HB3' HG23 ' A' ' 66' ' ' VAL . 0.7 OUTLIER -96.1 7.56 46.08 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.997 -1.064 . . . . 0.0 109.835 -179.859 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.456 ' O ' ' HD2' ' A' ' 2' ' ' LYS . . . 73.07 8.81 75.02 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.77 HG21 HG23 ' A' ' 61' ' ' ILE . 17.6 t -68.61 97.5 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.301 -1.117 . . . . 0.0 109.574 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.525 ' O ' ' CB ' ' A' ' 88' ' ' LYS . 13.4 tttt -79.11 -3.92 47.75 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.647 ' O ' HG12 ' A' ' 66' ' ' VAL . . . -138.79 131.38 28.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.319 -0.863 . . . . 0.0 109.002 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.6 t -128.84 109.2 18.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.061 -1.024 . . . . 0.0 109.791 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.74 ' CG2' HG23 ' A' ' 5' ' ' ILE . 2.1 mp -89.51 95.09 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.133 -0.98 . . . . 0.0 109.137 179.674 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.452 ' HB1' ' CG ' ' A' ' 20' ' ' PHE . . . -126.67 171.92 10.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 109.573 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.6 p -130.52 29.67 4.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.282 -0.886 . . . . 0.0 109.498 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -49.22 151.06 2.67 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.279 -0.888 . . . . 0.0 109.636 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.29 -72.48 0.01 OUTLIER 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.705 2.27 . . . . 0.0 110.467 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.419 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -68.26 145.5 44.5 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.419 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.8 Cg_endo -78.69 6.29 4.98 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.653 2.236 . . . . 0.0 110.473 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 7.4 t-20 -53.94 -57.43 11.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.281 -0.887 . . . . 0.0 109.511 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.691 ' O ' HD12 ' A' ' 82' ' ' LEU . . . -57.6 -45.0 85.86 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.23 -0.919 . . . . 0.0 109.5 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 18.4 m-30 -56.59 -27.39 57.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.178 -0.951 . . . . 0.0 109.343 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.48 -36.85 68.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.307 -0.87 . . . . 0.0 109.465 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 41.6 t -69.19 -46.19 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.492 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.691 HD12 ' O ' ' A' ' 78' ' ' ALA . 3.1 mp -53.18 -37.09 61.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.219 -0.925 . . . . 0.0 109.615 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 13.5 t-20 -61.67 -40.81 96.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 109.622 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -76.6 -20.75 56.43 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.173 -0.955 . . . . 0.0 109.555 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.562 ' HB3' HD12 ' A' ' 87' ' ' ILE . 0.3 OUTLIER -87.13 -14.82 40.21 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.265 -0.897 . . . . 0.0 109.522 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 86.93 11.71 69.77 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.596 HD11 ' CB ' ' A' ' 62' ' ' ALA . 9.3 mt -87.51 145.5 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -1.176 . . . . 0.0 109.587 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.525 ' CB ' ' O ' ' A' ' 67' ' ' LYS . 6.1 ttmm -80.05 116.75 20.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.124 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.671 HD12 ' HA ' ' A' ' 113' ' ' ARG . 3.3 mt -80.93 106.42 12.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.274 -0.891 . . . . 0.0 109.602 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.571 ' CD2' ' O ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -103.18 142.35 34.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.333 -0.855 . . . . 0.0 109.158 179.825 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.467 ' O ' ' HB3' ' A' ' 110' ' ' GLU . 20.6 ttt180 -106.02 145.76 30.97 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.182 -0.949 . . . . 0.0 109.606 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.98 92.13 8.93 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.327 -0.858 . . . . 0.0 109.277 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 58.9 m -107.46 -16.41 14.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.255 -0.903 . . . . 0.0 109.691 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -66.05 -128.71 0.02 OUTLIER Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.483 ' O ' HG23 ' A' ' 16' ' ' VAL . 9.8 t -142.13 -32.98 0.5 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.319 -1.107 . . . . 0.0 109.927 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -133.54 151.83 51.8 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.138 -0.976 . . . . 0.0 109.356 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.443 HG22 ' OG ' ' A' ' 14' ' ' SER . 35.1 m -71.06 -34.29 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.25 -0.906 . . . . 0.0 109.7 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.37 -47.91 83.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.245 -0.91 . . . . 0.0 109.803 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -71.75 -42.78 66.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.271 -0.893 . . . . 0.0 109.942 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 48.3 t-20 -52.91 -33.98 52.93 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.201 -0.937 . . . . 0.0 109.669 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.561 HD11 HD12 ' A' ' 36' ' ' ILE . 1.7 tt -57.12 -42.93 81.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.248 -0.907 . . . . 0.0 109.841 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.49 ' N ' HD23 ' A' ' 101' ' ' LEU . 0.5 OUTLIER -74.48 -33.36 62.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.117 -0.989 . . . . 0.0 110.039 -179.487 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -39.81 94.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.107 -0.996 . . . . 0.0 109.826 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.526 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 6.4 t80 -70.15 -30.02 67.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.18 -0.95 . . . . 0.0 109.813 -179.64 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.748 HG23 ' HE1' ' A' ' 31' ' ' MET . 0.2 OUTLIER -67.21 -29.86 69.64 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.128 -0.982 . . . . 0.0 109.935 -179.615 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -99.31 13.06 34.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.139 -0.976 . . . . 0.0 109.606 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 52.17 57.72 12.51 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.069 -1.612 . . . . 0.0 109.069 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -81.87 -54.86 5.0 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.368 -1.078 . . . . 0.0 109.781 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.541 HD23 ' H ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER 178.04 -152.03 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.093 -1.004 . . . . 0.0 109.742 -179.835 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.571 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 13.8 mt-10 60.29 25.17 14.61 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.375 -0.828 . . . . 0.0 109.459 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.592 ' C ' HD12 ' A' ' 112' ' ' ILE . 7.5 pt-20 -103.94 135.95 44.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.343 -0.848 . . . . 0.0 109.358 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.592 HD12 ' C ' ' A' ' 111' ' ' GLU . 3.2 mp -153.15 135.06 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.3 -0.875 . . . . 0.0 109.421 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.671 ' HA ' HD12 ' A' ' 89' ' ' ILE . 26.4 ttp180 -134.26 -45.47 0.77 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.224 -0.922 . . . . 0.0 109.346 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.409 ' O ' ' OG ' ' A' ' 114' ' ' SER . 0.5 OUTLIER -127.15 81.08 70.61 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.267 -0.896 . . . . 0.0 109.36 179.872 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.418 ' O ' ' C ' ' A' ' 116' ' ' GLY . 35.9 Cg_endo -77.93 -168.61 0.63 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.604 2.203 . . . . 0.0 110.356 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.418 ' C ' ' O ' ' A' ' 115' ' ' PRO . . . 44.59 79.7 0.06 OUTLIER Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -112.17 -66.39 1.09 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.252 -1.146 . . . . 0.0 109.346 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 134.42 81.27 0.15 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.44 76.48 1.54 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.231 -1.158 . . . . 0.0 109.431 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 127.22 165.39 11.9 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.41 ' O ' ' C ' ' A' ' 122' ' ' ARG . 3.6 ttt180 -129.5 101.63 6.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.233 -1.157 . . . . 0.0 109.495 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.41 ' C ' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -44.54 141.96 1.8 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.308 -0.87 . . . . 0.0 109.485 179.958 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.2 tpp180 -95.27 140.56 30.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.899 . . . . 0.0 109.442 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 10.5 mmm180 . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 117.98 -1.009 . . . . 0.0 109.363 179.99 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.7 mmm . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.479 ' HD3' ' O ' ' A' ' 65' ' ' GLY . 1.2 mttm -120.65 136.72 54.75 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.324 -0.86 . . . . 0.0 109.552 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.497 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 5.4 mt -114.44 108.43 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.318 -0.864 . . . . 0.0 109.399 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.7 ' HB1' ' CZ ' ' A' ' 26' ' ' PHE . . . -112.37 127.6 56.06 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.25 -0.906 . . . . 0.0 109.306 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.928 HG21 HG12 ' A' ' 97' ' ' VAL . 27.9 mt -102.88 139.71 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.555 -179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.3 170.07 17.2 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.384 -0.823 . . . . 0.0 109.421 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.465 ' O ' ' HB3' ' A' ' 8' ' ' SER . 54.3 p 46.32 -141.38 0.39 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.259 -0.901 . . . . 0.0 109.333 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.9 ' HB2' HG11 ' A' ' 97' ' ' VAL . 42.4 t 63.61 51.81 2.41 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.119 -0.988 . . . . 0.0 109.415 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.537 ' N ' ' HB3' ' A' ' 14' ' ' SER . . . -50.87 106.23 0.25 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.481 ' HG1' ' H ' ' A' ' 11' ' ' ASP . 3.2 p 49.01 -90.65 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.343 -1.092 . . . . 0.0 109.89 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.517 ' N ' ' O ' ' A' ' 9' ' ' GLY . 1.0 OUTLIER 173.15 -150.61 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.198 -0.939 . . . . 0.0 109.446 -179.687 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.461 ' HB3' ' O ' ' A' ' 11' ' ' ASP . 12.9 tp 70.25 13.2 7.66 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.257 -0.902 . . . . 0.0 109.362 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 145.77 -23.66 1.8 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.537 ' HB3' ' N ' ' A' ' 9' ' ' GLY . 43.4 m -77.2 82.51 3.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.193 -1.18 . . . . 0.0 109.64 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.467 ' HA ' HG22 ' A' ' 97' ' ' VAL . 0.2 OUTLIER -72.75 -114.2 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.202 -0.936 . . . . 0.0 109.456 -179.826 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.747 HG22 HG13 ' A' ' 97' ' ' VAL . 5.0 t -115.47 23.47 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 120.738 -1.227 . . . . 0.0 109.679 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.433 ' HB2' ' HB2' ' A' ' 7' ' ' SER . 4.3 t 47.06 -150.26 0.11 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.178 -0.951 . . . . 0.0 109.345 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.55 12.95 1.53 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.192 -0.943 . . . . 0.0 109.595 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.466 ' CD1' ' O ' ' A' ' 19' ' ' PHE . 28.1 p90 -153.8 144.52 22.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.223 -0.923 . . . . 0.0 109.66 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -123.82 89.88 3.17 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.313 -0.867 . . . . 0.0 109.218 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -145.26 -73.35 0.02 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.73 21.68 16.26 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -1.172 . . . . 0.0 109.675 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -58.33 113.25 6.18 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.243 -0.911 . . . . 0.0 109.23 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.474 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 36.8 Cg_endo -80.74 54.34 5.19 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.571 2.181 . . . . 0.0 110.867 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.474 ' CD2' ' O ' ' A' ' 24' ' ' PRO . 31.4 m-85 -160.41 70.92 0.43 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.992 -1.068 . . . . 0.0 109.214 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.7 ' CZ ' ' HB1' ' A' ' 4' ' ' ALA . 40.1 t80 -79.92 104.58 10.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.429 -0.794 . . . . 0.0 109.732 -179.718 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' MET . . . . . 0.727 ' CG ' HG12 ' A' ' 41' ' ' VAL . 0.2 OUTLIER -82.84 125.03 30.87 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.29 -0.881 . . . . 0.0 109.21 179.694 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.436 ' O ' HG23 ' A' ' 28' ' ' ILE . 1.4 tp -119.99 114.75 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.154 -0.966 . . . . 0.0 109.586 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.1 t -118.91 144.25 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.922 . . . . 0.0 109.408 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -117.63 136.18 53.48 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.261 -0.9 . . . . 0.0 109.445 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.8 mtt -119.86 132.18 55.49 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.209 -0.932 . . . . 0.0 109.545 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 13.4 mmtt -81.99 -79.76 0.17 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.308 -0.87 . . . . 0.0 109.299 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -126.16 86.53 2.54 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.3 -0.875 . . . . 0.0 109.174 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 48.87 34.12 14.71 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 36' ' ' ILE . 0.6 OUTLIER -149.12 100.56 3.06 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.345 -1.091 . . . . 0.0 109.461 -179.859 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.413 ' C ' ' O ' ' A' ' 35' ' ' ASN . 4.3 tt -45.2 134.27 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.234 -0.916 . . . . 0.0 109.35 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.407 ' O ' ' HB2' ' A' ' 38' ' ' SER . 0.5 OUTLIER -145.65 20.11 1.49 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.303 -0.873 . . . . 0.0 109.497 -179.959 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.407 ' HB2' ' O ' ' A' ' 37' ' ' GLU . 5.1 t -179.21 129.66 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.266 -0.896 . . . . 0.0 109.471 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 96.0 p -151.2 115.3 5.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.284 -0.885 . . . . 0.0 109.337 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -132.09 132.26 43.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.276 -0.89 . . . . 0.0 109.629 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.727 HG12 ' CG ' ' A' ' 27' ' ' MET . 27.7 m -97.13 137.9 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.31 -0.869 . . . . 0.0 109.328 179.719 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 58.7 mt -123.79 145.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 0.0 109.558 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.442 ' HG2' ' CE1' ' A' ' 25' ' ' TYR . 2.8 mp0 -115.09 148.31 39.1 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.283 -0.886 . . . . 0.0 109.581 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 13.8 m-20 -134.82 79.99 50.67 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.314 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.494 ' O ' ' CB ' ' A' ' 46' ' ' SER . 35.5 Cg_endo -77.8 123.2 6.21 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.657 2.238 . . . . 0.0 110.512 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 45' ' ' PRO . 0.1 OUTLIER 74.6 36.67 0.59 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.897 . . . . 0.0 109.47 179.921 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -54.49 -62.82 1.41 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.293 -0.879 . . . . 0.0 109.492 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -98.34 75.17 2.23 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.241 -0.912 . . . . 0.0 109.557 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.25 -21.86 28.87 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.248 -0.907 . . . . 0.0 109.398 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.1 m -100.91 58.93 0.91 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.887 . . . . 0.0 109.417 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 116.72 162.2 12.71 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -79.01 157.98 43.87 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -140.5 -86.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.277 -1.131 . . . . 0.0 109.302 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 81.16 -95.79 1.68 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.628 HD12 ' HB2' ' A' ' 78' ' ' ALA . 34.2 mm -73.62 -16.46 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.253 -1.145 . . . . 0.0 109.825 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.18 -22.63 66.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.261 -0.899 . . . . 0.0 109.681 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 61.2 m -63.52 -21.58 66.41 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.673 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.412 ' O ' ' C ' ' A' ' 59' ' ' GLN . . . -52.99 -47.93 67.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.233 -0.917 . . . . 0.0 109.508 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.412 ' C ' ' O ' ' A' ' 58' ' ' ALA . 0.0 OUTLIER -44.09 -43.39 6.85 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.421 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 20.9 mm -73.15 -36.5 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.173 -0.954 . . . . 0.0 109.167 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 16.8 mm -50.68 -36.49 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.354 -0.842 . . . . 0.0 109.235 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.472 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -75.02 -33.39 61.78 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.277 -0.889 . . . . 0.0 109.686 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -61.5 -18.22 58.12 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.259 -0.9 . . . . 0.0 109.767 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.477 ' HB3' ' CG2' ' A' ' 66' ' ' VAL . 0.4 OUTLIER -90.68 27.36 1.78 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.082 -1.011 . . . . 0.0 109.653 -179.86 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.479 ' O ' ' HD3' ' A' ' 2' ' ' LYS . . . 43.96 40.47 5.56 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 68' ' ' ALA . 2.9 t -86.25 96.21 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -1.136 . . . . 0.0 109.68 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.6 tptt -78.95 -11.32 60.0 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 179.046 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.497 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -136.58 125.29 23.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.444 -0.785 . . . . 0.0 108.964 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.426 ' O ' ' HB2' ' A' ' 90' ' ' TYR . 67.1 t -124.39 119.84 57.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.049 -1.032 . . . . 0.0 109.961 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.455 ' CD1' ' CG2' ' A' ' 3' ' ' ILE . 1.9 mp -102.1 114.19 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.359 -0.838 . . . . 0.0 108.98 179.606 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -151.87 172.87 15.53 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.214 -0.929 . . . . 0.0 109.865 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.9 p -135.5 55.69 1.87 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.378 -0.826 . . . . 0.0 109.245 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -55.53 152.82 16.5 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.295 -0.878 . . . . 0.0 109.645 -179.782 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.67 -13.65 14.55 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 C-N-CA 122.757 2.305 . . . . 0.0 110.531 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.8 161.66 26.26 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.7 -5.67 14.86 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.698 2.265 . . . . 0.0 110.415 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 16.9 t30 -57.91 -33.25 68.57 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.262 -0.899 . . . . 0.0 109.649 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.628 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -71.94 -60.43 2.24 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.251 -0.906 . . . . 0.0 109.437 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.46 ' CD1' ' N ' ' A' ' 79' ' ' PHE . 3.5 m-85 -51.7 -22.09 3.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.115 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 13.9 tt0 -63.91 -46.95 82.54 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.283 -0.885 . . . . 0.0 109.265 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.4 ' O ' ' HB2' ' A' ' 85' ' ' LEU . 2.5 t -69.45 -43.66 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.194 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 1.8 mt -63.36 -21.62 66.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.516 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -77.1 -61.35 2.01 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.258 -0.901 . . . . 0.0 109.603 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -58.92 -21.56 58.1 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.22 -0.925 . . . . 0.0 109.667 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.587 ' HB3' HD12 ' A' ' 87' ' ' ILE . 0.1 OUTLIER -73.14 -37.43 66.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.215 -0.928 . . . . 0.0 109.637 -179.9 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.77 21.83 7.29 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.587 HD12 ' HB3' ' A' ' 85' ' ' LEU . 5.5 mt -103.94 150.3 7.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -1.165 . . . . 0.0 109.51 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 8.2 mttt -80.03 125.84 30.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.233 -0.917 . . . . 0.0 109.361 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 3.3 mp -90.31 141.06 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.161 -0.962 . . . . 0.0 109.543 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.597 ' CE1' ' HB3' ' A' ' 111' ' ' GLU . 2.2 m-85 -127.99 127.35 43.08 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.211 -0.931 . . . . 0.0 109.529 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 73.5 mtt180 -87.46 122.77 31.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.465 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.67 122.83 33.16 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.236 -0.915 . . . . 0.0 109.471 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -64.95 -40.0 94.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.363 -0.836 . . . . 0.0 109.558 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 116.76 52.47 0.35 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 30.8 m -114.37 -82.72 0.61 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -1.119 . . . . 0.0 109.351 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -157.56 128.61 6.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.396 -0.815 . . . . 0.0 109.357 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.928 HG12 HG21 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -51.12 -23.27 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.221 -0.924 . . . . 0.0 109.535 -179.943 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.82 -49.05 69.63 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.195 -0.941 . . . . 0.0 109.317 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.594 ' HG2' HD12 ' A' ' 103' ' ' LEU . 21.4 tt0 -70.88 -28.14 64.34 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.304 -0.873 . . . . 0.0 109.311 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -63.93 -49.46 72.52 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.322 -0.862 . . . . 0.0 109.42 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 37.7 tp -57.56 -57.58 12.08 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.301 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 1.3 tmtt? -56.92 -25.62 57.7 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.135 -0.978 . . . . 0.0 109.257 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.594 HD12 ' HG2' ' A' ' 99' ' ' GLU . 0.2 OUTLIER -71.14 -37.11 72.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.23 -0.919 . . . . 0.0 109.36 179.861 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -65.57 -22.99 66.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.198 -0.939 . . . . 0.0 109.175 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.34 -29.76 64.25 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.412 -0.805 . . . . 0.0 109.31 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -112.46 -2.69 14.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.603 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 61.23 39.46 97.22 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ASN . . . . . 0.499 ' HB3' HD23 ' A' ' 103' ' ' LEU . 24.4 t-20 -93.97 -17.92 22.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.103 -1.233 . . . . 0.0 109.395 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.458 ' HA ' HD23 ' A' ' 109' ' ' LEU . 5.4 mt -55.67 -168.44 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.24 -0.913 . . . . 0.0 109.334 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 90' ' ' TYR . 1.2 tt0 -103.42 106.91 17.55 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.256 -0.903 . . . . 0.0 109.303 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.597 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 4.1 pt-20 -101.7 156.69 17.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.264 -0.898 . . . . 0.0 109.764 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.401 HG21 HD13 ' A' ' 112' ' ' ILE . 2.9 mt -142.8 126.11 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.89 . . . . 0.0 109.314 179.768 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -147.85 93.61 2.22 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.293 -0.879 . . . . 0.0 109.441 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 1.1 p -104.13 155.3 37.36 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.204 -0.935 . . . . 0.0 109.565 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.17 -169.79 0.84 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.671 2.247 . . . . 0.0 110.56 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' A' ' 117' ' ' SER . . . -89.63 140.78 15.78 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.465 ' O ' ' OG ' ' A' ' 117' ' ' SER . 0.0 OUTLIER 49.64 97.45 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.26 -1.141 . . . . 0.0 109.353 -179.957 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 164.89 43.0 0.02 OUTLIER Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -138.2 142.72 40.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.187 -1.184 . . . . 0.0 109.355 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 139.54 146.02 4.82 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 23.7 mtt180 -96.58 -47.34 5.97 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.281 -1.129 . . . . 0.0 109.513 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -91.32 142.11 28.05 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.275 -0.89 . . . . 0.0 109.359 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.64 -64.35 0.29 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.142 -0.974 . . . . 0.0 109.571 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.103 -0.951 . . . . 0.0 109.547 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 mmm . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.271 0.557 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.508 ' HB3' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -154.03 160.05 41.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.289 -0.882 . . . . 0.0 109.118 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.583 HG12 ' CE2' ' A' ' 104' ' ' PHE . 6.4 mt -117.4 121.12 66.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.901 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.671 ' HB2' HG11 ' A' ' 66' ' ' VAL . . . -113.09 102.97 10.89 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.373 -0.83 . . . . 0.0 109.119 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -94.81 118.64 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -0.924 . . . . 0.0 109.742 -179.553 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.37 142.3 41.21 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.068 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.513 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 3.8 p -161.72 -159.92 0.66 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.119 -0.988 . . . . 0.0 109.518 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.9 m -149.06 57.09 1.02 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.287 -0.883 . . . . 0.0 109.537 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 167.08 164.5 22.85 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.435 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.0 OUTLIER -85.02 -32.62 22.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.322 -1.105 . . . . 0.0 109.472 179.981 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 18.7 p-10 171.84 172.16 0.09 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -0.919 . . . . 0.0 109.374 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.515 ' HA ' HD12 ' A' ' 12' ' ' LEU . 8.1 tp 45.35 32.77 1.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.305 -0.872 . . . . 0.0 109.191 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -175.47 -32.88 0.04 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 p -65.55 86.34 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.435 -1.038 . . . . 0.0 109.304 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.503 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 14.4 mt-10 -77.65 6.98 6.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.478 -0.764 . . . . 0.0 110.153 -179.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.503 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 15.1 t 70.62 65.6 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.937 . . . . 0.0 109.615 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 16' ' ' VAL . 3.9 m -44.64 122.83 3.32 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.328 -0.858 . . . . 0.0 109.233 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.452 ' HG2' ' HB2' ' A' ' 72' ' ' SER . 1.4 ttm-85 -61.72 -18.7 60.76 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.25 -0.906 . . . . 0.0 109.721 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.492 ' CE2' ' HG3' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -84.91 108.16 17.41 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.12 -0.987 . . . . 0.0 109.63 -179.905 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.435 ' CB ' ' HB1' ' A' ' 71' ' ' ALA . 21.8 t80 -106.43 125.37 50.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.263 -0.898 . . . . 0.0 109.354 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.1 -36.6 0.76 Allowed Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.439 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 1.1 mpt_? -118.62 -22.27 7.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.343 -1.093 . . . . 0.0 109.256 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.513 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -49.15 106.91 0.68 Allowed Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.304 -0.872 . . . . 0.0 109.436 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.3 Cg_endo -79.95 62.56 8.55 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.561 2.174 . . . . 0.0 110.822 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.449 ' CE1' ' HB3' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -160.52 69.58 0.38 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.008 -1.058 . . . . 0.0 109.395 179.692 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -80.46 121.1 25.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.549 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' MET . . . . . 0.434 ' O ' ' HA ' ' A' ' 4' ' ' ALA . 2.1 mmt -94.46 110.6 22.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.226 -0.921 . . . . 0.0 109.266 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.9 mm -104.02 117.99 50.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.904 . . . . 0.0 109.472 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.912 HG21 HD11 ' A' ' 101' ' ' LEU . 13.4 m -138.04 147.59 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.209 -0.932 . . . . 0.0 109.833 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -127.26 143.26 51.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 108.899 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.2 mtt -113.81 152.03 31.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.1 -1.0 . . . . 0.0 109.938 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.35 -46.37 7.38 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.369 -0.832 . . . . 0.0 109.262 179.775 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.64 47.48 0.73 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.367 -0.833 . . . . 0.0 109.222 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.567 ' O ' HG23 ' A' ' 105' ' ' THR . . . 92.22 -1.43 73.38 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.423 ' O ' ' C ' ' A' ' 36' ' ' ILE . 5.6 p-10 -116.56 92.89 4.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.204 -1.174 . . . . 0.0 109.362 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.794 HD13 HD21 ' A' ' 101' ' ' LEU . 1.6 tt -43.95 118.61 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 109.497 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.46 ' O ' ' OE1' ' A' ' 37' ' ' GLU . 0.2 OUTLIER -123.08 20.78 9.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.329 -0.857 . . . . 0.0 109.441 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.413 ' O ' ' OG ' ' A' ' 38' ' ' SER . 12.0 p -170.82 107.46 0.29 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -0.859 . . . . 0.0 109.263 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.761 ' HA ' HG12 ' A' ' 29' ' ' VAL . 5.8 p -135.35 105.72 6.38 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.914 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.18 143.8 38.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.389 -0.819 . . . . 0.0 109.268 179.598 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.413 HG13 ' SD ' ' A' ' 27' ' ' MET . 2.2 t -110.99 124.03 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.215 -0.928 . . . . 0.0 109.755 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 11.1 mt -121.57 119.43 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.262 -0.899 . . . . 0.0 109.268 179.721 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.449 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 4.1 pm0 -93.28 126.08 38.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.254 -0.904 . . . . 0.0 109.564 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.672 ' HB3' ' HB2' ' A' ' 47' ' ' ALA . 2.5 t-20 -55.91 115.82 10.65 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.317 -0.864 . . . . 0.0 109.548 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.05 -37.88 0.73 Allowed 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.458 2.105 . . . . 0.0 110.495 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.2 p -74.45 -11.98 60.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.268 -0.895 . . . . 0.0 109.536 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.672 ' HB2' ' HB3' ' A' ' 44' ' ' ASN . . . -46.06 -40.94 11.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 109.402 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.455 ' O ' ' HB2' ' A' ' 49' ' ' ALA . 0.6 OUTLIER -115.83 92.11 3.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.439 179.919 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.455 ' HB2' ' O ' ' A' ' 48' ' ' SER . . . 176.81 -57.84 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.315 -0.865 . . . . 0.0 109.37 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.0 t -115.01 88.52 2.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.28 -0.887 . . . . 0.0 109.333 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.79 173.39 41.52 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 132.52 -53.14 0.81 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -136.34 -165.9 1.8 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.291 -1.123 . . . . 0.0 109.274 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.409 ' O ' HG22 ' A' ' 57' ' ' THR . . . -175.77 -35.07 0.04 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.719 HD12 ' HB2' ' A' ' 78' ' ' ALA . 39.8 mm -76.72 0.03 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.136 -1.214 . . . . 0.0 109.85 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.08 -10.96 59.83 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.192 -0.943 . . . . 0.0 109.558 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.439 ' O ' HG13 ' A' ' 61' ' ' ILE . 8.8 t -77.32 -25.86 51.59 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.667 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -48.77 -39.97 27.07 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 109.492 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 -60.4 -58.47 8.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 109.608 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.1 mt -53.82 -25.48 12.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.33 -0.856 . . . . 0.0 109.589 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.481 HG22 HG21 ' A' ' 66' ' ' VAL . 46.3 mt -72.96 -39.66 58.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.454 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.17 -30.65 70.67 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.552 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -67.93 -9.08 42.26 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.294 -0.878 . . . . 0.0 109.614 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -85.9 -24.93 26.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.191 -0.943 . . . . 0.0 109.537 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 114.55 -26.0 9.91 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.671 HG11 ' HB2' ' A' ' 4' ' ' ALA . 4.6 m -43.44 94.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.271 -1.135 . . . . 0.0 109.559 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 65' ' ' GLY . 7.0 mmtp -79.36 -4.27 50.16 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.357 -0.84 . . . . 0.0 108.758 179.291 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -122.82 129.33 51.55 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.385 -0.822 . . . . 0.0 109.274 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.639 HG21 ' CD2' ' A' ' 82' ' ' LEU . 97.8 t -123.45 107.83 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.111 -0.993 . . . . 0.0 109.544 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 53.1 mt -91.99 115.52 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.36 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.435 ' HB1' ' CB ' ' A' ' 20' ' ' PHE . . . -164.84 176.77 8.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.217 -0.927 . . . . 0.0 109.913 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.601 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 12.5 m -140.84 59.07 1.54 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.508 -0.745 . . . . 0.0 109.176 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.487 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 11.6 p -49.71 152.15 2.69 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.389 -0.819 . . . . 0.0 109.791 -179.717 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.492 ' HG3' ' CE2' ' A' ' 19' ' ' PHE . 35.1 Cg_endo -78.27 -22.65 9.51 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.631 2.221 . . . . 0.0 110.17 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -134.95 164.15 24.76 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.53 27.62 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.771 2.314 . . . . 0.0 111.265 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -74.73 -68.86 0.5 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.88 -1.137 . . . . 0.0 109.588 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.778 ' O ' HD12 ' A' ' 82' ' ' LEU . . . -62.03 -40.53 96.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -0.905 . . . . 0.0 109.714 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.487 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 4.3 m-85 -52.95 -32.46 46.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.639 -179.879 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -75.61 -38.46 59.0 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.26 -0.9 . . . . 0.0 109.65 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 48.8 t -61.33 -53.46 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.743 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.778 HD12 ' O ' ' A' ' 78' ' ' ALA . 3.2 mp -59.06 -18.7 37.38 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.274 -0.891 . . . . 0.0 109.814 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -76.47 -48.42 19.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.18 -0.95 . . . . 0.0 109.695 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.38 -35.44 80.9 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.143 -0.973 . . . . 0.0 109.563 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.535 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 0.1 OUTLIER -68.17 -16.21 63.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.491 -179.919 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 81.59 24.68 55.72 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.538 HG22 ' N ' ' A' ' 88' ' ' LYS . 5.6 mt -87.47 161.5 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.252 -1.146 . . . . 0.0 109.558 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.538 ' N ' HG22 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -94.5 112.13 23.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 109.317 179.858 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.563 HG22 ' N ' ' A' ' 90' ' ' TYR . 14.1 mt -82.03 168.14 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.67 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.593 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 1.2 m-85 -153.09 129.98 10.97 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.304 -0.873 . . . . 0.0 109.246 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.511 ' NH1' ' HA ' ' A' ' 93' ' ' THR . 0.7 OUTLIER -80.12 135.81 36.39 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.966 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.601 ' HB3' ' OG ' ' A' ' 72' ' ' SER . . . -86.64 149.79 24.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.216 -0.928 . . . . 0.0 109.627 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.511 ' HA ' ' NH1' ' A' ' 91' ' ' ARG . 73.4 p -86.0 -26.51 25.38 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 109.544 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.83 66.85 1.51 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.19 -67.71 0.36 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.256 -1.143 . . . . 0.0 109.466 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -171.56 132.95 0.77 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.304 -0.872 . . . . 0.0 109.33 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.466 HG11 ' HB3' ' A' ' 7' ' ' SER . 16.8 m -54.86 -19.76 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.168 -0.958 . . . . 0.0 109.575 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -68.27 -52.57 32.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.762 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -69.78 -39.19 76.79 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.146 -0.971 . . . . 0.0 109.498 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.443 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 5.1 m-20 -59.28 -36.73 76.09 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.163 -0.96 . . . . 0.0 109.259 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.912 HD11 HG21 ' A' ' 29' ' ' VAL . 11.0 tp -59.22 -50.93 72.15 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.287 -0.883 . . . . 0.0 109.308 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -70.12 -15.76 63.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.371 -0.831 . . . . 0.0 109.232 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.542 HD22 ' HG ' ' A' ' 109' ' ' LEU . 0.2 OUTLIER -72.6 -45.74 57.6 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.359 -0.838 . . . . 0.0 109.55 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.583 ' CE2' HG12 ' A' ' 3' ' ' ILE . 6.4 t80 -63.53 -17.23 62.58 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.865 . . . . 0.0 109.758 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.567 HG23 ' O ' ' A' ' 34' ' ' GLY . 19.2 m -69.2 -33.47 73.39 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 109.572 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -95.57 -14.72 23.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.527 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 71.17 45.53 48.82 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ASN . . . . . 0.415 ' HB3' HD23 ' A' ' 103' ' ' LEU . 10.1 t-20 -97.21 -29.31 13.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.289 -1.124 . . . . 0.0 109.544 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.542 ' HG ' HD22 ' A' ' 103' ' ' LEU . 0.6 OUTLIER -57.11 155.89 7.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.342 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 5.3 pt-20 -96.06 144.88 25.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 6.1 pm0 -114.61 165.87 12.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.92 . . . . 0.0 109.501 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.516 ' O ' HD12 ' A' ' 89' ' ' ILE . 83.0 mt -136.4 120.21 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.261 -0.899 . . . . 0.0 109.254 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -113.96 -21.69 10.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.339 -0.851 . . . . 0.0 109.332 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.416 ' HB2' ' HD2' ' A' ' 115' ' ' PRO . 68.3 p -139.74 157.98 68.81 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.237 -0.914 . . . . 0.0 109.554 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.416 ' HD2' ' HB2' ' A' ' 114' ' ' SER . 36.4 Cg_endo -78.68 178.72 7.23 Favored 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.585 2.19 . . . . 0.0 110.438 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.46 -179.68 16.97 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -170.37 -173.09 1.38 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.266 -1.138 . . . . 0.0 109.545 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -89.77 146.02 18.6 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.7 ttm-85 -53.57 145.63 14.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.235 -1.156 . . . . 0.0 109.365 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 123.39 175.05 14.38 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.793 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.471 ' HG2' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -118.02 138.39 52.24 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.159 -1.201 . . . . 0.0 109.676 -179.882 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.494 ' NE ' ' HA ' ' A' ' 122' ' ' ARG . 0.2 OUTLIER -117.99 105.12 11.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.314 -0.867 . . . . 0.0 109.181 179.818 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.24 -19.87 11.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.267 -0.896 . . . . 0.0 109.655 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.494 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.4 ttm . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.414 ' CG ' ' HG3' ' A' ' 30' ' ' GLU . 2.1 mppt? -114.61 164.01 14.62 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.187 -0.945 . . . . 0.0 109.594 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.479 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 11.0 mt -131.68 135.72 58.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.291 -0.881 . . . . 0.0 109.655 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.584 ' CB ' HG21 ' A' ' 66' ' ' VAL . . . -123.48 129.96 52.0 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.57 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 1.112 HG21 HG23 ' A' ' 97' ' ' VAL . 6.3 mt -111.1 120.79 62.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.179 -0.951 . . . . 0.0 109.881 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.39 165.19 25.53 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.277 -0.889 . . . . 0.0 109.36 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.518 ' O ' ' CB ' ' A' ' 8' ' ' SER . 0.8 OUTLIER 70.22 -144.67 0.08 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.227 -0.921 . . . . 0.0 109.485 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.518 ' CB ' ' O ' ' A' ' 7' ' ' SER . 0.2 OUTLIER 77.02 3.35 3.31 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.139 -0.976 . . . . 0.0 109.554 -179.908 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.471 ' O ' ' HB3' ' A' ' 25' ' ' TYR . . . 46.47 -113.6 1.18 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.87 -5.85 7.41 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.225 -1.162 . . . . 0.0 109.481 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -141.18 -142.15 0.14 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.481 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.4 mt -105.11 -18.28 14.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.108 -0.995 . . . . 0.0 109.745 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -47.76 -40.32 18.22 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.406 ' O ' ' O ' ' A' ' 15' ' ' GLU . 3.6 m -75.54 81.42 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.283 -1.128 . . . . 0.0 109.636 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.475 ' O ' ' HB ' ' A' ' 97' ' ' VAL . 0.1 OUTLIER -48.17 -93.18 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.552 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 18.9 m -131.11 52.95 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.062 -1.024 . . . . 0.0 109.718 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.512 ' O ' ' CB ' ' A' ' 18' ' ' ARG . 1.3 p -99.07 136.61 38.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.174 -0.954 . . . . 0.0 109.255 179.701 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.512 ' CB ' ' O ' ' A' ' 17' ' ' SER . 6.3 mtt-85 75.45 78.28 0.1 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.222 -0.924 . . . . 0.0 108.916 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.432 ' O ' ' C ' ' A' ' 20' ' ' PHE . 0.5 OUTLIER -79.65 -177.52 5.9 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.335 -0.853 . . . . 0.0 109.678 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.628 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 2.6 t80 -41.24 137.84 1.31 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.485 -0.76 . . . . 0.0 109.82 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 151.14 -64.12 0.38 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.471 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 2.0 tpp180 -155.04 18.87 0.43 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.147 -1.208 . . . . 0.0 109.8 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.79 113.43 18.67 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.276 -0.89 . . . . 0.0 109.661 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.583 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.7 Cg_endo -82.08 53.9 4.77 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.61 2.207 . . . . 0.0 110.462 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.583 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 98.6 m-85 -159.8 70.82 0.46 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.163 -0.96 . . . . 0.0 109.503 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.48 ' CE1' ' OD1' ' A' ' 44' ' ' ASN . 23.7 m-85 -83.61 119.03 24.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.204 -0.935 . . . . 0.0 109.536 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -93.56 122.45 36.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.234 -0.916 . . . . 0.0 109.67 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.515 HG12 HD12 ' A' ' 42' ' ' ILE . 15.1 mm -99.17 122.15 50.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 109.176 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 54.7 t -127.97 137.74 56.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.099 -1.0 . . . . 0.0 109.651 -179.689 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.444 ' HB3' ' OG ' ' A' ' 38' ' ' SER . 1.7 tt0 -124.61 137.82 54.36 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.3 -0.875 . . . . 0.0 109.379 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.411 ' HG3' ' HA ' ' A' ' 36' ' ' ILE . 7.9 ttm -116.06 145.18 43.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.189 -0.944 . . . . 0.0 109.647 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.61 -63.48 1.29 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.332 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.66 65.29 0.87 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.287 -0.883 . . . . 0.0 109.384 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.25 17.03 70.19 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 36' ' ' ILE . 3.0 t-20 -144.38 103.17 3.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.222 -1.164 . . . . 0.0 109.451 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.411 ' HA ' ' HG3' ' A' ' 31' ' ' MET . 2.6 mp -44.69 137.49 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.277 -0.89 . . . . 0.0 109.461 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -144.01 16.36 1.74 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 109.48 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.444 ' OG ' ' HB3' ' A' ' 30' ' ' GLU . 0.2 OUTLIER -166.68 122.86 1.21 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.259 -0.901 . . . . 0.0 109.441 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.6 m -142.9 110.16 5.68 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.196 -0.94 . . . . 0.0 109.6 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.91 153.98 46.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.31 -0.869 . . . . 0.0 109.2 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 8.0 p -113.76 144.34 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.204 -0.935 . . . . 0.0 109.675 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.515 HD12 HG12 ' A' ' 28' ' ' ILE . 23.5 mt -136.42 132.7 49.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.341 -0.849 . . . . 0.0 109.37 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.443 ' O ' ' HD3' ' A' ' 45' ' ' PRO . 1.6 mp0 -106.59 131.38 53.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.241 -0.912 . . . . 0.0 109.692 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.48 ' OD1' ' CE1' ' A' ' 26' ' ' PHE . 2.7 m120 -55.61 109.93 1.94 Allowed Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.28 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 43' ' ' GLU . 35.4 Cg_endo -77.46 -75.63 0.01 OUTLIER 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.376 2.051 . . . . 0.0 110.578 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.6 m -99.55 68.96 1.61 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.614 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.434 ' HB2' ' HB3' ' A' ' 44' ' ' ASN . . . -77.26 -37.12 53.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.223 -0.923 . . . . 0.0 109.421 179.754 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -101.55 92.55 4.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.317 -0.865 . . . . 0.0 109.456 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -172.75 -47.97 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.301 -0.875 . . . . 0.0 109.357 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.84 94.51 4.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.332 -0.855 . . . . 0.0 109.208 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 113.08 -60.59 0.34 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 59.96 91.55 0.01 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -172.96 -47.89 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.181 -1.188 . . . . 0.0 109.538 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.527 ' O ' HG22 ' A' ' 57' ' ' THR . . . 111.34 -50.01 0.8 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.706 HD12 ' HB2' ' A' ' 78' ' ' ALA . 16.6 mm -70.4 -5.58 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -1.095 . . . . 0.0 109.555 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.67 -25.28 53.55 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.195 -0.94 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.527 HG22 ' O ' ' A' ' 54' ' ' GLY . 10.8 t -68.66 -7.9 37.49 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.201 -0.937 . . . . 0.0 109.556 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.425 ' O ' ' C ' ' A' ' 59' ' ' GLN . . . -61.67 -56.18 22.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.926 . . . . 0.0 109.249 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 58' ' ' ALA . 1.6 tm0? -44.21 -29.26 0.61 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.337 -0.852 . . . . 0.0 109.286 179.808 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 73.1 mt -75.59 -46.66 36.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 109.179 179.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.484 HG23 HG11 ' A' ' 66' ' ' VAL . 37.8 mt -56.03 -25.24 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 109.36 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.66 -38.08 80.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.279 -0.888 . . . . 0.0 109.681 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 26.8 m-20 -72.75 -4.94 34.5 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.247 -0.908 . . . . 0.0 109.721 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -83.9 -16.1 45.57 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.06 -12.74 59.27 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.584 HG21 ' CB ' ' A' ' 4' ' ' ALA . 2.6 p -58.21 98.77 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.268 -1.136 . . . . 0.0 109.66 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.542 ' HA ' HG23 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -79.28 -6.36 56.5 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 179.234 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.536 ' HB2' ' CE2' ' A' ' 104' ' ' PHE . . . -113.67 120.66 41.63 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.284 -0.885 . . . . 0.0 109.119 179.627 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 70.6 t -108.43 112.04 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.165 -0.959 . . . . 0.0 109.852 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.407 ' N ' HD13 ' A' ' 70' ' ' ILE . 3.2 mm -99.79 97.53 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.155 -0.965 . . . . 0.0 109.136 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.628 ' HB1' ' HB2' ' A' ' 20' ' ' PHE . . . -158.39 169.85 23.53 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.237 -0.914 . . . . 0.0 109.816 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.435 ' O ' ' C ' ' A' ' 73' ' ' SER . 9.1 t -133.33 50.65 2.21 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.364 -0.835 . . . . 0.0 109.048 179.79 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.463 ' HB3' ' HB3' ' A' ' 20' ' ' PHE . 60.5 p -41.26 149.55 0.36 Allowed Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.509 -0.745 . . . . 0.0 109.937 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 20' ' ' PHE . 36.2 Cg_endo -78.14 -35.26 1.35 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.657 2.238 . . . . 0.0 110.051 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -108.61 153.14 16.91 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.492 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 35.5 Cg_endo -77.72 1.15 9.13 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.537 2.158 . . . . 0.0 110.668 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.501 ' O ' HG23 ' A' ' 81' ' ' VAL . 5.4 t30 -59.93 -42.28 93.64 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.223 -0.923 . . . . 0.0 109.686 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.706 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -64.17 -67.59 0.42 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 109.681 -179.836 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.794 ' CD1' HG21 ' A' ' 89' ' ' ILE . 16.6 m-30 -53.06 -19.27 2.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.232 -0.917 . . . . 0.0 109.875 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.492 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 36.3 tt0 -70.73 -49.93 41.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.122 -0.986 . . . . 0.0 109.579 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 77' ' ' ASN . 3.0 t -67.4 -48.19 78.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.147 -0.971 . . . . 0.0 109.665 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 36.1 mt -55.59 -29.32 58.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.114 -0.992 . . . . 0.0 109.508 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 64.0 t-20 -68.03 -38.89 83.07 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.265 -0.897 . . . . 0.0 109.383 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.14 -26.29 61.15 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.331 -0.856 . . . . 0.0 109.47 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.673 HD13 HD11 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -71.87 -37.11 70.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.955 . . . . 0.0 109.551 -179.94 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.53 13.08 25.17 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.673 HD11 HD13 ' A' ' 85' ' ' LEU . 3.7 mt -85.38 169.54 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.278 -1.131 . . . . 0.0 109.623 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.512 ' N ' HG22 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -99.17 123.67 43.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.25 179.842 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.794 HG21 ' CD1' ' A' ' 79' ' ' PHE . 1.6 mt -95.16 161.84 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.19 -0.944 . . . . 0.0 109.757 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.532 ' CD1' ' O ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -148.21 133.93 18.9 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.444 -179.862 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.421 ' HB2' ' HB2' ' A' ' 110' ' ' GLU . 0.0 OUTLIER -89.45 123.12 33.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.148 -0.97 . . . . 0.0 109.475 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.16 87.78 5.48 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.916 . . . . 0.0 109.681 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.527 ' O ' HG22 ' A' ' 93' ' ' THR . 18.6 m -139.23 21.02 2.6 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.223 -0.923 . . . . 0.0 109.412 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -74.46 -77.8 0.64 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 92.8 m -159.81 -70.78 0.08 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.246 -1.15 . . . . 0.0 109.386 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.42 ' HA ' ' HB2' ' A' ' 15' ' ' GLU . 37.0 m -132.38 148.71 52.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.303 -0.873 . . . . 0.0 109.384 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 1.112 HG23 HG21 ' A' ' 5' ' ' ILE . 12.1 p -44.36 -27.98 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.345 -0.847 . . . . 0.0 109.487 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -66.69 -52.81 40.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.337 -0.852 . . . . 0.0 109.734 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.434 ' O ' ' CG ' ' A' ' 103' ' ' LEU . 4.7 tt0 -71.02 -16.35 62.61 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.136 -0.977 . . . . 0.0 109.493 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.417 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 2.1 m-80 -75.95 -40.76 53.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.397 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 30.9 tp -60.58 -47.69 85.07 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.336 -0.853 . . . . 0.0 109.433 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.87 -20.43 56.29 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.432 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.434 ' CG ' ' O ' ' A' ' 99' ' ' GLU . 6.4 mt -67.37 -43.5 81.26 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.312 -0.868 . . . . 0.0 109.676 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.541 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.1 t80 -61.28 -29.17 69.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.28 -0.888 . . . . 0.0 109.453 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 92.0 m -62.34 -40.59 96.88 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.211 -0.93 . . . . 0.0 109.563 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 107' ' ' GLY . 6.4 mm-40 -87.94 3.21 49.44 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.181 -0.949 . . . . 0.0 109.729 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . 44.25 39.03 5.24 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -103.22 -10.94 18.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -1.162 . . . . 0.0 109.607 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.482 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 0.7 OUTLIER -74.05 -161.17 0.11 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.208 -0.932 . . . . 0.0 109.482 -179.989 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.532 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 7.0 mt-10 -95.07 113.88 25.63 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.304 -0.872 . . . . 0.0 109.418 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -103.18 142.8 33.54 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.35 -0.844 . . . . 0.0 109.599 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.465 ' O ' ' HB2' ' A' ' 113' ' ' ARG . 13.6 mm -129.84 117.53 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.272 -0.893 . . . . 0.0 109.302 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.465 ' HB2' ' O ' ' A' ' 112' ' ' ILE . 3.4 ttt-85 178.39 71.77 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.195 -0.94 . . . . 0.0 109.619 -179.802 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -134.58 89.24 26.84 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.235 -0.916 . . . . 0.0 109.555 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.468 ' O ' ' O ' ' A' ' 116' ' ' GLY . 35.7 Cg_endo -78.84 -44.6 0.13 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.635 2.224 . . . . 0.0 110.665 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 115' ' ' PRO . . . -60.59 -131.0 0.01 OUTLIER Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 116' ' ' GLY . 57.9 p 52.69 82.98 0.07 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.299 -1.118 . . . . 0.0 109.654 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 77.84 48.6 7.69 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.744 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.6 ttt-85 -119.78 66.52 0.81 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.191 -1.182 . . . . 0.0 109.571 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 151.2 -70.44 0.3 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.773 -1.331 . . . . 0.0 109.773 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -175.15 95.56 0.07 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.23 -1.159 . . . . 0.0 109.582 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.44 84.36 6.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.91 . . . . 0.0 109.366 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.437 ' O ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -52.58 128.76 27.12 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.249 -0.907 . . . . 0.0 109.582 -179.891 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.437 ' HB2' ' O ' ' A' ' 123' ' ' ARG . 2.8 tpp180 . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 117.99 -1.005 . . . . 0.0 109.436 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.09 155.77 17.84 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.202 -0.936 . . . . 0.0 109.309 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.486 ' HA ' ' O ' ' A' ' 68' ' ' ALA . 7.8 mt -120.31 117.41 53.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.277 -0.889 . . . . 0.0 110.052 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.992 ' HB2' HG11 ' A' ' 66' ' ' VAL . . . -112.51 116.92 31.02 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.317 -0.864 . . . . 0.0 108.672 179.275 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.842 HG23 ' HB ' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -102.98 135.23 41.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.128 -0.983 . . . . 0.0 109.926 -179.311 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.55 143.24 46.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.39 -0.819 . . . . 0.0 109.175 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.715 ' CB ' HG11 ' A' ' 97' ' ' VAL . 0.7 OUTLIER -151.39 157.96 43.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.208 -0.933 . . . . 0.0 109.683 -179.792 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 66.9 p -119.39 0.96 11.2 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.324 -0.86 . . . . 0.0 109.388 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.548 ' O ' ' CG ' ' A' ' 25' ' ' TYR . . . -125.62 -153.96 8.59 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.561 HG23 ' CE1' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -126.45 -30.52 2.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.183 -1.186 . . . . 0.0 109.664 -179.849 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 173.31 -43.8 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.122 -0.986 . . . . 0.0 109.528 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -80.66 5.15 16.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.299 -0.875 . . . . 0.0 109.629 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -166.31 31.43 0.21 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.854 ' HB3' HG22 ' A' ' 97' ' ' VAL . 5.0 m -77.06 79.43 3.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.124 -1.221 . . . . 0.0 109.357 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.713 ' C ' HG23 ' A' ' 16' ' ' VAL . 9.2 mm-40 -76.91 1.57 17.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.302 -0.874 . . . . 0.0 109.576 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.713 HG23 ' C ' ' A' ' 15' ' ' GLU . 1.9 t 73.68 18.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.403 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.1 t 59.11 176.04 0.07 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.32 -0.863 . . . . 0.0 109.399 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -109.04 -36.25 6.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -131.79 123.18 27.09 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.875 . . . . 0.0 109.363 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.714 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 2.5 t80 -62.23 96.72 0.08 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.905 . . . . 0.0 109.497 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -136.76 -87.02 0.2 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.428 ' O ' ' C ' ' A' ' 23' ' ' ALA . 1.8 ptp85 -114.7 43.85 1.86 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -1.111 . . . . 0.0 109.18 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.446 ' HB3' ' CE1' ' A' ' 26' ' ' PHE . . . -42.79 114.14 1.45 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.406 -0.808 . . . . 0.0 109.405 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.58 21.14 0.88 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.578 2.185 . . . . 0.0 110.947 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.561 ' CE1' HG23 ' A' ' 10' ' ' THR . 0.5 OUTLIER -159.51 70.78 0.47 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.949 -1.094 . . . . 0.0 109.301 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.446 ' CE1' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -79.52 126.27 30.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.441 -179.917 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.22 115.94 31.65 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.407 HD12 HG23 ' A' ' 28' ' ' ILE . 28.9 mm -96.78 131.43 43.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.3 -0.875 . . . . 0.0 109.661 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.405 ' CG1' HG23 ' A' ' 36' ' ' ILE . 4.5 t -130.25 137.09 57.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.295 -0.878 . . . . 0.0 109.117 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -118.17 95.99 5.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.095 -1.003 . . . . 0.0 109.816 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.408 ' HE2' ' HB2' ' A' ' 31' ' ' MET . 41.1 ttm -81.91 146.06 30.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.029 179.603 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -99.96 -70.01 0.75 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.113 -0.992 . . . . 0.0 110.002 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 19.3 tttm -138.59 62.71 1.54 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.094 -1.004 . . . . 0.0 109.95 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.51 31.64 36.53 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 36' ' ' ILE . 2.9 p30 -159.58 97.47 1.33 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.169 -1.195 . . . . 0.0 109.552 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.545 HG12 HD21 ' A' ' 101' ' ' LEU . 2.9 mp -44.06 132.39 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.247 -0.908 . . . . 0.0 109.327 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -130.01 18.97 5.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.119 -0.988 . . . . 0.0 109.737 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 175.38 129.9 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.078 -1.014 . . . . 0.0 109.619 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.4 p -149.58 107.51 3.71 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.323 -0.86 . . . . 0.0 109.373 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.22 164.27 15.42 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.234 -0.916 . . . . 0.0 109.537 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.7 p -124.42 148.03 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.497 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.525 HD12 ' H ' ' A' ' 43' ' ' GLU . 2.6 tp -141.65 154.27 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.302 -0.874 . . . . 0.0 109.392 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.525 ' H ' HD12 ' A' ' 42' ' ' ILE . 26.7 mp0 -93.9 68.8 3.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.267 -0.895 . . . . 0.0 109.497 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.472 ' CG ' ' CB ' ' A' ' 47' ' ' ALA . 1.3 m-20 53.2 92.13 0.06 OUTLIER Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.307 -0.87 . . . . 0.0 109.727 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.46 111.32 3.14 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.572 2.181 . . . . 0.0 110.392 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.5 t 53.25 20.26 1.81 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.275 -0.89 . . . . 0.0 109.531 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.472 ' CB ' ' CG ' ' A' ' 44' ' ' ASN . . . -66.47 -26.8 67.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.272 -0.893 . . . . 0.0 109.45 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 71.2 m -137.1 45.86 2.21 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.355 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -57.92 -44.99 87.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.317 -0.865 . . . . 0.0 109.719 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 92.4 p -115.79 28.41 8.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.664 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.71 -141.51 23.68 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.39 -128.0 9.13 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -151.1 -57.48 0.16 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.234 -1.156 . . . . 0.0 109.486 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 158.0 -21.29 0.37 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.446 HD12 ' HB2' ' A' ' 78' ' ' ALA . 46.6 mm -69.77 -45.82 76.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.127 -1.219 . . . . 0.0 109.479 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.17 -33.26 75.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.221 -0.924 . . . . 0.0 109.535 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 21.6 m -58.95 -23.9 62.01 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.18 -0.95 . . . . 0.0 109.634 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -53.51 -51.94 61.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.258 -0.901 . . . . 0.0 109.574 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.498 ' OE1' ' CG1' ' A' ' 81' ' ' VAL . 1.4 tp60 -46.06 -44.73 15.64 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.188 -0.945 . . . . 0.0 109.504 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 23.5 mt -62.63 -40.22 87.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.193 -0.942 . . . . 0.0 109.522 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 50.3 mt -66.61 -20.38 27.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.201 -0.937 . . . . 0.0 109.487 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.513 ' CB ' HD23 ' A' ' 85' ' ' LEU . . . -77.16 -36.23 55.33 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.256 -0.903 . . . . 0.0 109.687 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 52.2 m-20 -75.47 -0.15 19.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.258 -0.901 . . . . 0.0 109.694 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -82.9 -7.68 59.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.129 -0.982 . . . . 0.0 109.747 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.11 -23.98 32.14 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.992 HG11 ' HB2' ' A' ' 4' ' ' ALA . 19.2 m -59.51 93.9 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -1.152 . . . . 0.0 109.688 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.419 ' O ' ' HD3' ' A' ' 88' ' ' LYS . 26.9 mtpt -79.49 -3.45 46.75 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.36 -0.838 . . . . 0.0 108.793 179.286 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' ' 3' ' ' ILE . . . -135.21 103.14 5.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.227 -0.921 . . . . 0.0 109.19 179.702 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.808 ' O ' HG23 ' A' ' 89' ' ' ILE . 55.1 t -110.93 129.99 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.023 -1.048 . . . . 0.0 109.999 -179.506 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.842 ' HB ' HG23 ' A' ' 5' ' ' ILE . 3.6 mp -92.68 119.38 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.286 -0.883 . . . . 0.0 109.078 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.714 ' HB1' ' HB2' ' A' ' 20' ' ' PHE . . . -157.3 176.97 12.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.169 -0.957 . . . . 0.0 109.693 -179.724 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 73' ' ' SER . 3.1 p -152.64 51.89 0.76 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.48 -0.762 . . . . 0.0 109.494 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.563 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 0.1 OUTLIER -44.29 167.51 0.09 OUTLIER Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.172 -0.955 . . . . 0.0 109.436 179.962 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.63 -1.92 12.02 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.613 2.209 . . . . 0.0 110.309 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -162.63 168.61 37.6 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.552 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.2 Cg_endo -79.17 7.9 4.14 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.671 2.248 . . . . 0.0 110.582 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -58.57 -44.54 89.77 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.178 -0.951 . . . . 0.0 109.649 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.446 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -77.04 -48.87 16.68 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.176 -0.952 . . . . 0.0 109.851 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.563 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 2.9 m-85 -55.06 -19.81 8.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.209 -0.932 . . . . 0.0 109.776 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.68 -46.71 24.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.147 -0.97 . . . . 0.0 109.815 -179.731 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.498 ' CG1' ' OE1' ' A' ' 59' ' ' GLN . 22.2 t -64.49 -51.09 72.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.154 -0.966 . . . . 0.0 109.495 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.792 ' HB3' HD11 ' A' ' 89' ' ' ILE . 0.9 OUTLIER -55.03 -46.44 75.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.903 . . . . 0.0 109.71 -179.88 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 53.6 t30 -57.81 -41.53 82.36 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.219 -0.925 . . . . 0.0 109.534 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.49 -50.39 71.89 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.497 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.549 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 2.4 mp -60.21 -28.1 67.71 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.175 -0.953 . . . . 0.0 109.477 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.43 10.24 17.77 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.667 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.644 HD12 ' N ' ' A' ' 87' ' ' ILE . 3.2 mp -94.38 147.71 5.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.115 -1.226 . . . . 0.0 109.439 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.419 ' HD3' ' O ' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -104.81 155.91 18.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.259 -0.901 . . . . 0.0 109.818 -179.835 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.808 HG23 ' O ' ' A' ' 69' ' ' VAL . 3.5 mp -136.6 140.21 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.254 -0.904 . . . . 0.0 109.507 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.556 ' CD2' ' O ' ' A' ' 109' ' ' LEU . 16.9 m-30 -102.82 167.7 9.7 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.313 -0.867 . . . . 0.0 109.53 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.558 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 0.0 OUTLIER -85.7 130.43 34.57 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.245 -0.909 . . . . 0.0 109.866 -179.615 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -87.76 116.89 26.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.422 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 63.4 p -61.77 -26.32 68.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.281 -0.887 . . . . 0.0 109.372 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.56 18.22 42.36 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 58.4 m -86.35 -74.88 0.41 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -1.134 . . . . 0.0 109.473 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 14' ' ' SER . 74.4 m -155.98 144.08 19.84 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.321 -0.862 . . . . 0.0 109.43 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.854 HG22 ' HB3' ' A' ' 14' ' ' SER . 28.8 m -68.94 -35.9 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.885 . . . . 0.0 109.698 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -60.08 -38.06 81.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.135 -0.978 . . . . 0.0 109.323 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.402 ' OE1' ' HA ' ' A' ' 99' ' ' GLU . 0.0 OUTLIER -71.85 -50.69 27.32 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.335 -0.853 . . . . 0.0 109.433 179.881 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.506 ' HA ' HD12 ' A' ' 103' ' ' LEU . 42.2 m-20 -49.62 -34.44 18.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -0.893 . . . . 0.0 109.551 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.545 HD21 HG12 ' A' ' 36' ' ' ILE . 12.3 tp -52.99 -55.86 20.35 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.247 -0.908 . . . . 0.0 109.725 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.49 -20.49 61.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.13 -0.982 . . . . 0.0 109.728 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.506 HD12 ' HA ' ' A' ' 100' ' ' ASN . 23.9 mt -71.74 -25.38 62.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.174 -0.954 . . . . 0.0 109.611 -179.782 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.447 ' HE2' ' HB1' ' A' ' 68' ' ' ALA . 41.3 t80 -70.0 -38.11 75.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.207 -0.933 . . . . 0.0 109.237 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 48.6 m -74.56 -24.39 58.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.857 . . . . 0.0 109.504 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -80.81 -18.52 47.25 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.193 -0.942 . . . . 0.0 109.5 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 76.24 24.48 68.47 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -92.68 -37.92 12.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.14 -1.212 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.556 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 0.0 OUTLIER -88.56 119.98 29.52 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.135 -0.978 . . . . 0.0 109.479 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.526 ' HA ' ' CG ' ' A' ' 90' ' ' TYR . 16.6 pt-20 -149.29 173.83 13.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.463 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.558 ' HB2' ' N ' ' A' ' 91' ' ' ARG . 8.1 tp10 -175.77 -111.24 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.318 -0.864 . . . . 0.0 109.84 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.478 ' N ' ' HG3' ' A' ' 111' ' ' GLU . 19.8 tt -84.21 134.58 26.65 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 O-C-N 121.08 -1.012 . . . . 0.0 110.072 -179.222 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -132.59 -177.63 4.57 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.442 -0.786 . . . . 0.0 109.285 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -73.69 154.72 89.37 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.145 -0.972 . . . . 0.0 109.64 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -77.52 -46.43 0.14 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 122.651 2.234 . . . . 0.0 110.305 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.469 ' O ' ' HB2' ' A' ' 117' ' ' SER . . . -123.83 -122.93 2.74 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 116' ' ' GLY . 24.8 t 177.49 37.2 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.351 -1.088 . . . . 0.0 109.444 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 138.35 -111.11 0.78 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -76.99 117.93 19.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.328 -1.101 . . . . 0.0 109.345 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -158.11 122.4 1.15 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 41.4 mtm180 -97.82 137.57 36.48 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.326 -1.102 . . . . 0.0 109.155 179.694 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 -138.72 133.76 32.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.278 -0.889 . . . . 0.0 109.837 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 ttp180 -140.08 25.47 2.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.321 -0.862 . . . . 0.0 109.107 179.657 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 7.6 mtm180 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 117.905 -1.045 . . . . 0.0 109.419 -179.809 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.3 ptp . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.484 ' HG2' ' HG3' ' A' ' 30' ' ' GLU . 0.1 OUTLIER -131.67 144.29 50.91 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.245 -0.909 . . . . 0.0 109.583 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.569 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 5.3 mt -118.32 104.45 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.288 -0.883 . . . . 0.0 109.565 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -106.16 116.41 31.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.329 -0.857 . . . . 0.0 109.31 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.681 HG21 HG13 ' A' ' 97' ' ' VAL . 2.8 mp -94.61 120.8 44.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.15 -0.969 . . . . 0.0 109.467 -179.83 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 7' ' ' SER . . . -61.91 150.43 37.61 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.278 -0.889 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.507 ' O ' ' CB ' ' A' ' 8' ' ' SER . 0.0 OUTLIER 53.6 169.95 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.28 -0.887 . . . . 0.0 109.598 179.963 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.758 ' HB3' HG11 ' A' ' 97' ' ' VAL . 0.2 OUTLIER 162.52 -35.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.322 -0.862 . . . . 0.0 109.321 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.457 ' HA3' ' HB2' ' A' ' 14' ' ' SER . . . 75.91 9.56 85.16 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER 61.92 16.78 8.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.244 -1.151 . . . . 0.0 109.46 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.0 t0 -173.17 -167.48 0.41 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.237 -0.915 . . . . 0.0 109.597 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.2 mt -79.85 -1.85 40.87 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.211 -0.93 . . . . 0.0 109.613 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.81 -61.62 7.01 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.457 ' HB2' ' HA3' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -77.31 83.23 3.76 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.198 -1.177 . . . . 0.0 109.505 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.404 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 7.2 mt-10 -72.22 83.1 1.02 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.34 -0.85 . . . . 0.0 109.176 179.724 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.417 ' O ' ' C ' ' A' ' 17' ' ' SER . 22.1 t 62.6 63.97 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.916 . . . . 0.0 109.308 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.479 ' HB3' ' CB ' ' A' ' 7' ' ' SER . 8.2 t -43.77 159.01 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.311 -0.868 . . . . 0.0 109.426 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 22.3 mtp85 -95.67 30.62 2.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.376 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -127.38 159.03 35.68 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.948 . . . . 0.0 109.474 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -133.17 -32.51 1.19 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.186 -0.946 . . . . 0.0 109.903 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -101.5 -37.29 3.55 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.438 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -84.31 -25.9 28.91 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.131 -1.217 . . . . 0.0 109.775 -179.753 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.419 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -42.49 103.01 0.29 Allowed Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.335 -0.853 . . . . 0.0 109.7 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.482 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.7 Cg_endo -80.68 41.28 1.11 Allowed 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 122.602 2.202 . . . . 0.0 110.533 179.714 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.482 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 84.1 m-85 -158.19 68.5 0.49 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.106 -0.996 . . . . 0.0 109.286 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.442 ' CE1' ' HA ' ' A' ' 6' ' ' ALA . 0.8 OUTLIER -83.02 116.49 22.3 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.271 -0.893 . . . . 0.0 109.585 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 1.4 ttt -94.21 132.42 38.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.156 -0.965 . . . . 0.0 109.635 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.682 ' O ' HG23 ' A' ' 28' ' ' ILE . 5.1 tt -129.42 116.81 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.897 . . . . 0.0 109.401 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.868 HG13 ' O ' ' A' ' 38' ' ' SER . 94.6 t -125.11 129.7 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 109.388 -179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.484 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 26.9 tt0 -99.05 99.45 10.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.226 -0.921 . . . . 0.0 109.635 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.2 tpp -81.8 134.24 35.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.309 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -99.0 -68.66 0.79 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -0.915 . . . . 0.0 109.681 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -129.99 81.47 2.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.204 -0.935 . . . . 0.0 109.631 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.15 28.04 24.97 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.412 ' O ' ' N ' ' A' ' 37' ' ' GLU . 1.3 m-20 -147.73 108.49 4.18 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.173 -1.192 . . . . 0.0 109.536 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.726 HG23 ' CG1' ' A' ' 29' ' ' VAL . 72.6 mt -48.28 98.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.169 -0.957 . . . . 0.0 109.405 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.412 ' N ' ' O ' ' A' ' 35' ' ' ASN . 34.7 mt-10 -96.46 9.77 40.3 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.614 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.868 ' O ' HG13 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -169.6 122.67 0.75 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 179.99 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.611 ' HA ' HG22 ' A' ' 29' ' ' VAL . 0.7 OUTLIER -141.03 107.95 5.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 109.541 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -132.38 138.59 47.77 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.197 -0.939 . . . . 0.0 109.437 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.9 t -98.63 154.72 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.269 -0.895 . . . . 0.0 109.547 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 6.6 mt -131.92 134.33 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.341 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.453 ' O ' ' HD3' ' A' ' 45' ' ' PRO . 53.7 mt-10 -91.06 85.92 6.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.297 -0.877 . . . . 0.0 109.527 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.445 ' C ' ' O ' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -41.87 101.61 0.25 Allowed Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.371 -0.831 . . . . 0.0 109.473 179.977 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 43' ' ' GLU . 36.2 Cg_endo -78.56 -166.69 0.42 Allowed 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 122.529 2.152 . . . . 0.0 110.578 -179.637 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.1 m 56.49 36.34 27.41 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.893 . . . . 0.0 109.395 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -76.87 -39.89 49.48 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.327 -0.858 . . . . 0.0 109.506 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.21 -27.65 29.83 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.168 -0.957 . . . . 0.0 109.351 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -86.35 151.01 23.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.217 -0.927 . . . . 0.0 109.549 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.38 132.83 54.1 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.86 . . . . 0.0 109.543 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -146.2 30.22 1.62 Allowed Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.651 ' O ' ' HB2' ' A' ' 53' ' ' ALA . . . 174.33 -82.77 0.08 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.651 ' HB2' ' O ' ' A' ' 52' ' ' GLY . . . 167.24 -31.06 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.325 -1.103 . . . . 0.0 109.453 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 136.75 -49.19 0.88 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.583 HD12 ' HB2' ' A' ' 78' ' ' ALA . 51.0 mm -60.77 -14.08 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.258 -1.142 . . . . 0.0 109.63 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.403 ' O ' ' C ' ' A' ' 57' ' ' THR . 0.0 OUTLIER -65.01 -37.04 86.34 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.211 -0.93 . . . . 0.0 109.658 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.403 ' C ' ' O ' ' A' ' 56' ' ' ARG . 14.6 m -43.48 -33.88 1.21 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.202 -0.936 . . . . 0.0 109.723 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -51.29 -52.36 45.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -0.933 . . . . 0.0 109.771 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -54.54 -34.31 61.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.933 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.6 mt -69.39 -65.76 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.127 -0.983 . . . . 0.0 109.726 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 18.8 pt -51.71 -20.95 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.741 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.401 ' HB1' HD11 ' A' ' 87' ' ' ILE . . . -71.16 -47.31 58.46 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.212 -0.93 . . . . 0.0 109.621 -179.809 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -76.42 1.58 16.01 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.296 -0.877 . . . . 0.0 109.757 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -95.34 -2.11 49.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.088 -1.008 . . . . 0.0 109.772 -179.757 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 93.59 -14.41 65.36 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 31.8 t -49.66 91.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -1.119 . . . . 0.0 109.632 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' GLY . 3.6 mmmp? -79.3 -7.39 58.27 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.338 -0.851 . . . . 0.0 108.811 179.371 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.569 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -131.26 123.44 28.41 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.287 -0.883 . . . . 0.0 109.199 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 57.0 t -121.34 106.69 18.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.161 -0.962 . . . . 0.0 109.853 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.71 HD13 ' HB2' ' A' ' 90' ' ' TYR . 13.4 mm -83.2 104.32 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.18 -0.95 . . . . 0.0 109.03 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -143.74 173.5 11.62 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.22 -0.925 . . . . 0.0 109.789 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.0 p -145.49 40.01 1.19 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.374 -0.829 . . . . 0.0 109.249 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.421 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -45.05 149.76 0.83 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.355 -0.841 . . . . 0.0 109.669 -179.905 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.2 Cg_endo -78.61 4.97 5.92 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.737 2.291 . . . . 0.0 110.336 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.424 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -144.42 148.46 20.24 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.424 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 36.2 Cg_endo -79.38 11.16 2.75 Favored 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 122.716 2.277 . . . . 0.0 110.79 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -73.54 -36.07 65.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.077 -1.014 . . . . 0.0 109.691 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -68.21 -50.59 53.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.954 . . . . 0.0 109.628 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.536 ' CD1' ' N ' ' A' ' 79' ' ' PHE . 1.4 m-85 -65.04 -18.31 65.19 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.133 -0.98 . . . . 0.0 109.519 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -67.53 -49.67 62.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.111 -0.993 . . . . 0.0 109.538 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -71.2 -43.88 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.194 -0.941 . . . . 0.0 109.609 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.461 ' HA ' HD23 ' A' ' 82' ' ' LEU . 20.1 mt -49.66 -49.36 47.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.173 -0.955 . . . . 0.0 109.446 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -61.35 -34.3 75.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.228 -0.92 . . . . 0.0 109.302 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -67.31 -25.65 66.12 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.434 -0.792 . . . . 0.0 109.6 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 4.5 mt -97.7 18.43 15.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.891 . . . . 0.0 109.37 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 56.3 62.84 5.89 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.401 HD11 ' HB1' ' A' ' 62' ' ' ALA . 97.7 mt -132.38 144.9 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.287 -1.126 . . . . 0.0 109.306 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.482 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 0.2 OUTLIER -82.77 124.64 30.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.296 -0.877 . . . . 0.0 109.423 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.535 HG21 ' CD1' ' A' ' 79' ' ' PHE . 3.7 mt -104.16 129.95 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.52 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.71 ' HB2' HD13 ' A' ' 70' ' ' ILE . 3.6 m-85 -116.46 157.57 24.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.405 -0.809 . . . . 0.0 109.249 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.407 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 1.2 ttt-85 -96.09 143.22 27.42 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.245 -0.909 . . . . 0.0 109.568 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.97 86.72 2.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.4 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.622 ' O ' HG22 ' A' ' 93' ' ' THR . 34.1 m -149.35 26.85 0.85 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.192 -0.943 . . . . 0.0 109.421 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.17 -71.8 1.23 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 15.8 m -165.92 -46.17 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.205 -1.174 . . . . 0.0 109.727 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.77 162.9 38.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.23 -0.919 . . . . 0.0 109.79 -179.684 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.758 HG11 ' HB3' ' A' ' 8' ' ' SER . 47.4 t -77.08 -40.03 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.272 -0.893 . . . . 0.0 109.351 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -59.15 -50.06 75.49 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.803 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.428 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 1.2 tt0 -72.17 -33.0 67.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.12 -0.988 . . . . 0.0 109.645 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.5 m-20 -57.2 -43.39 82.71 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.224 -0.922 . . . . 0.0 109.759 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.591 HD21 HG11 ' A' ' 29' ' ' VAL . 51.9 tp -51.39 -43.14 61.83 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -0.933 . . . . 0.0 109.795 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 7.6 tptm -75.18 -30.5 60.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.138 -0.977 . . . . 0.0 109.762 -179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.428 ' HG ' ' O ' ' A' ' 99' ' ' GLU . 48.6 mt -67.09 -23.96 65.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.165 -0.959 . . . . 0.0 109.608 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 104' ' ' PHE . 24.4 t80 -58.79 -48.07 82.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.198 -0.939 . . . . 0.0 109.357 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 55.4 m -65.28 -39.1 92.13 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.348 -0.845 . . . . 0.0 109.304 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -70.98 -6.81 41.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.234 -0.916 . . . . 0.0 109.505 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 56.16 30.65 58.15 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.306 -1.517 . . . . 0.0 109.306 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -83.66 -28.84 28.1 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.313 -1.11 . . . . 0.0 109.529 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -138.6 138.48 37.94 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.073 -1.017 . . . . 0.0 109.763 -179.805 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.596 ' HA ' ' CD2' ' A' ' 90' ' ' TYR . 1.7 pt-20 -170.76 -151.54 0.08 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.324 -0.86 . . . . 0.0 109.449 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.501 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 0.7 OUTLIER -163.49 -112.16 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.257 -0.902 . . . . 0.0 109.623 -179.81 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.416 HD12 HD13 ' A' ' 89' ' ' ILE . 2.6 mt -83.33 90.34 2.42 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 O-C-N 121.154 -0.966 . . . . 0.0 109.489 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -64.58 -59.83 3.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.206 -0.934 . . . . 0.0 109.321 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.408 ' HA ' ' HD3' ' A' ' 115' ' ' PRO . 0.3 OUTLIER -177.32 146.3 0.63 Allowed Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 109.48 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 114' ' ' SER . 34.8 Cg_endo -78.06 -179.31 5.32 Favored 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 122.638 2.225 . . . . 0.0 110.366 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 87.43 20.56 51.46 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 47.4 p -160.44 -38.51 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.198 -1.178 . . . . 0.0 109.565 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -100.43 19.48 52.47 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 3.2 ttp85 -63.15 136.81 57.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.288 -1.125 . . . . 0.0 109.595 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -84.79 -156.45 25.47 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 2.4 mtm180 -144.17 86.77 1.86 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.291 -1.123 . . . . 0.0 109.494 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.424 ' NH1' ' CG ' ' A' ' 122' ' ' ARG . 0.0 OUTLIER -92.88 173.84 7.55 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.316 -0.865 . . . . 0.0 109.211 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 62.5 mtt180 -121.89 86.0 2.5 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.171 -0.956 . . . . 0.0 109.498 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.505 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 65' ' ' GLY . 4.4 mtmt -118.25 145.97 44.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.308 -0.87 . . . . 0.0 109.293 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.632 HD11 ' CD1' ' A' ' 104' ' ' PHE . 5.3 mt -119.76 111.1 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.348 -0.845 . . . . 0.0 109.616 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.667 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -115.27 122.86 47.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.336 -0.852 . . . . 0.0 109.219 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.631 HG23 ' HB ' ' A' ' 70' ' ' ILE . 2.5 mp -98.4 142.61 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.233 -0.917 . . . . 0.0 109.543 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.498 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -81.49 155.84 25.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.358 -0.839 . . . . 0.0 109.755 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.467 ' HB2' ' HB3' ' A' ' 17' ' ' SER . 1.0 OUTLIER 52.83 -89.98 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.659 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.498 ' N ' ' O ' ' A' ' 6' ' ' ALA . 3.0 m 62.85 24.22 14.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.911 . . . . 0.0 109.566 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 44.07 -107.46 0.13 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.81 -76.91 0.13 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -1.141 . . . . 0.0 109.494 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -158.2 -43.71 0.06 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.232 -0.918 . . . . 0.0 109.614 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.59 -0.44 57.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -0.938 . . . . 0.0 109.55 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.12 19.91 1.09 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 8' ' ' SER . 9.7 p -77.02 81.91 3.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.355 -1.085 . . . . 0.0 109.464 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.882 ' O ' HG22 ' A' ' 97' ' ' VAL . 2.7 mt-10 -77.22 -137.5 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.192 -0.943 . . . . 0.0 109.025 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.695 ' HA ' HG13 ' A' ' 97' ' ' VAL . 6.1 p -88.75 34.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.066 -1.021 . . . . 0.0 109.587 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.467 ' HB3' ' HB2' ' A' ' 7' ' ' SER . 0.5 OUTLIER 69.32 -157.7 0.17 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.349 -0.845 . . . . 0.0 109.479 179.921 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.4 -72.88 0.12 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -112.38 -164.54 0.92 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.189 -0.944 . . . . 0.0 109.611 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.487 ' CE1' ' HB2' ' A' ' 6' ' ' ALA . 24.8 t80 -158.05 48.98 0.39 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.333 -0.854 . . . . 0.0 109.499 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -127.27 -68.44 0.15 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.424 ' O ' ' C ' ' A' ' 23' ' ' ALA . 55.1 mtt180 -112.49 16.76 19.72 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.311 -1.111 . . . . 0.0 109.398 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.424 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -43.46 107.3 0.56 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.323 -0.861 . . . . 0.0 109.619 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.57 44.05 1.66 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.601 2.2 . . . . 0.0 110.604 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.488 ' CE1' ' HG2' ' A' ' 43' ' ' GLU . 4.9 m-85 -158.02 70.09 0.55 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.112 -0.993 . . . . 0.0 109.267 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.521 ' CE2' HD11 ' A' ' 61' ' ' ILE . 4.4 m-30 -79.44 121.96 25.82 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.36 -0.837 . . . . 0.0 109.492 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.9 117.67 35.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.241 -0.912 . . . . 0.0 109.325 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.422 HD13 ' HB1' ' A' ' 4' ' ' ALA . 39.7 mm -104.55 130.95 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.219 -0.926 . . . . 0.0 109.526 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.77 HG11 HD21 ' A' ' 101' ' ' LEU . 82.8 t -131.33 132.17 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.328 -0.857 . . . . 0.0 109.5 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.455 ' HB2' ' CB ' ' A' ' 38' ' ' SER . 7.8 mt-10 -106.64 163.71 12.67 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.322 -0.861 . . . . 0.0 109.376 179.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.54 ' HE3' ' CD1' ' A' ' 3' ' ' ILE . 41.9 ttm -147.74 139.05 23.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.174 -0.954 . . . . 0.0 109.538 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.05 -70.5 0.71 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.934 . . . . 0.0 109.578 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 6.3 mtmt -136.17 73.99 1.48 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.447 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.617 ' HA2' HG23 ' A' ' 105' ' ' THR . . . 68.53 16.2 69.34 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.46 103.21 6.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.316 -1.108 . . . . 0.0 109.456 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.413 HG13 ' CE ' ' A' ' 31' ' ' MET . 2.0 mt -66.68 115.53 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.238 -0.914 . . . . 0.0 109.579 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -130.97 33.63 4.16 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.219 -0.926 . . . . 0.0 109.237 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.455 ' CB ' ' HB2' ' A' ' 30' ' ' GLU . 0.6 OUTLIER -161.22 100.11 1.21 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -0.873 . . . . 0.0 109.474 -179.87 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 56.4 m -129.01 104.84 7.81 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.161 -0.962 . . . . 0.0 109.087 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -126.05 125.46 42.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.334 -0.854 . . . . 0.0 109.83 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.5 p -98.54 139.65 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.378 -0.826 . . . . 0.0 109.119 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 5.5 mt -139.81 142.68 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.177 -0.952 . . . . 0.0 109.727 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.488 ' HG2' ' CE1' ' A' ' 25' ' ' TYR . 12.4 mt-10 -94.9 142.15 27.81 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.531 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.414 ' CG ' ' O ' ' A' ' 44' ' ' ASN . 3.1 p30 -140.48 75.04 27.64 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.231 -0.918 . . . . 0.0 109.365 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.64 2.14 8.12 Favored 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 122.585 2.19 . . . . 0.0 110.345 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -54.93 -27.73 45.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.9 . . . . 0.0 109.273 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -71.84 -38.04 70.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.258 -0.901 . . . . 0.0 109.321 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.5 m -90.54 56.02 3.19 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.383 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -129.96 -50.52 1.13 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.299 -0.876 . . . . 0.0 109.534 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -143.74 148.64 35.96 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.146 -0.971 . . . . 0.0 109.541 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 61.08 162.34 0.15 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' A' ' 53' ' ' ALA . . . -86.89 -88.81 1.03 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.455 ' O ' ' O ' ' A' ' 52' ' ' GLY . . . 47.87 -174.28 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.21 -1.171 . . . . 0.0 109.407 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.607 ' O ' HG22 ' A' ' 57' ' ' THR . . . 154.0 -54.13 0.44 Allowed Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.438 HD12 ' HB2' ' A' ' 78' ' ' ALA . 24.2 mm -67.87 -8.03 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -1.155 . . . . 0.0 109.646 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -69.24 -33.33 73.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.927 . . . . 0.0 109.666 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.607 HG22 ' O ' ' A' ' 54' ' ' GLY . 13.2 t -58.82 -15.54 12.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.297 -0.877 . . . . 0.0 109.783 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.85 -46.02 85.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.804 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.722 ' HG3' HD11 ' A' ' 85' ' ' LEU . 52.6 tt0 -65.5 -28.59 69.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.269 -0.894 . . . . 0.0 109.805 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.2 mm -75.9 -29.21 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.175 -0.953 . . . . 0.0 109.718 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.521 HD11 ' CE2' ' A' ' 26' ' ' PHE . 65.8 mt -75.27 -41.54 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.147 -0.971 . . . . 0.0 109.636 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.45 -26.29 66.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.154 -0.966 . . . . 0.0 109.627 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -76.68 -5.77 49.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.192 -0.943 . . . . 0.0 109.674 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -90.94 27.6 1.78 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.136 -0.977 . . . . 0.0 109.618 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 2' ' ' LYS . . . 66.72 11.84 58.22 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.667 HG11 ' HB3' ' A' ' 4' ' ' ALA . 96.0 t -87.06 91.81 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.2 -1.177 . . . . 0.0 109.386 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.483 ' O ' ' HB2' ' A' ' 88' ' ' LYS . 39.2 mmtt -79.43 -4.76 52.65 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.432 -0.792 . . . . 0.0 108.863 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.463 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -124.27 107.45 11.2 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.521 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 60.9 t -104.96 119.14 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.366 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.631 ' HB ' HG23 ' A' ' 5' ' ' ILE . 3.1 mm -99.24 108.19 21.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.347 -0.846 . . . . 0.0 109.397 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -153.37 173.79 15.18 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.255 -0.903 . . . . 0.0 109.557 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.33 49.32 1.43 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.444 -0.785 . . . . 0.0 109.224 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.402 ' OG ' ' HB3' ' A' ' 20' ' ' PHE . 1.0 OUTLIER -50.42 145.53 10.39 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.328 -0.858 . . . . 0.0 109.513 -179.864 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.05 -0.08 10.34 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 122.576 2.184 . . . . 0.0 110.477 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.76 154.67 24.95 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.47 -1.66 11.8 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.686 2.257 . . . . 0.0 110.574 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -53.66 -48.19 69.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.237 -0.914 . . . . 0.0 109.643 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.438 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -70.48 -59.29 2.94 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.279 -0.888 . . . . 0.0 109.881 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.717 ' CD1' HG21 ' A' ' 89' ' ' ILE . 25.1 m-85 -46.98 -23.52 0.47 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.934 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 14.7 mm-40 -71.16 -53.05 15.85 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.096 -1.003 . . . . 0.0 109.566 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.429 ' H ' HG23 ' A' ' 81' ' ' VAL . 4.9 t -63.03 -46.46 96.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.162 -0.961 . . . . 0.0 109.432 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.522 HD22 HG12 ' A' ' 89' ' ' ILE . 0.0 OUTLIER -52.23 -56.26 15.83 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.287 -0.883 . . . . 0.0 109.399 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -54.83 -33.41 61.63 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 109.503 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -63.03 -46.22 88.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.196 -0.94 . . . . 0.0 109.427 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.722 HD11 ' HG3' ' A' ' 59' ' ' GLN . 0.2 OUTLIER -64.62 -11.55 36.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.419 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 79.78 31.25 40.7 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.505 HG22 ' H ' ' A' ' 88' ' ' LYS . 5.3 mm -98.05 172.85 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.32 -1.106 . . . . 0.0 109.326 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.505 ' H ' HG22 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -97.82 114.41 26.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.21 -0.932 . . . . 0.0 109.631 -179.798 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.717 HG21 ' CD1' ' A' ' 79' ' ' PHE . 19.8 mt -85.6 149.02 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.38 -0.825 . . . . 0.0 109.181 179.722 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.522 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 0.4 OUTLIER -135.47 122.39 21.23 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.01 -1.056 . . . . 0.0 109.673 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.13 121.98 31.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 109.599 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.99 106.79 18.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -0.898 . . . . 0.0 109.547 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 94' ' ' GLY . 6.7 t -122.17 -20.63 6.16 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.272 -0.892 . . . . 0.0 109.732 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.448 ' O ' ' HB ' ' A' ' 95' ' ' THR . . . -43.14 -88.11 0.01 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.563 HG23 ' N ' ' A' ' 96' ' ' SER . 5.2 t 176.51 -45.84 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.257 -1.143 . . . . 0.0 109.423 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.563 ' N ' HG23 ' A' ' 95' ' ' THR . 8.5 m -121.93 115.88 23.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.882 HG22 ' O ' ' A' ' 15' ' ' GLU . 6.4 m -47.14 -35.96 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 109.591 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -48.19 -49.45 32.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.13 -0.981 . . . . 0.0 109.431 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -73.02 -45.36 58.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -0.9 . . . . 0.0 109.642 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.499 ' HA ' HD12 ' A' ' 103' ' ' LEU . 10.4 m-20 -51.41 -24.18 4.61 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.24 -0.913 . . . . 0.0 109.686 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.77 HD21 HG11 ' A' ' 29' ' ' VAL . 19.2 tp -65.51 -66.33 0.56 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.179 -0.951 . . . . 0.0 109.327 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 13.5 ptmt -56.1 -21.09 20.21 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -0.922 . . . . 0.0 109.348 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.986 ' HB3' HD12 ' A' ' 109' ' ' LEU . 10.2 mt -69.87 -45.22 68.17 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.336 -0.852 . . . . 0.0 109.54 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.632 ' CD1' HD11 ' A' ' 3' ' ' ILE . 21.2 t80 -55.54 -19.0 8.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.325 -0.859 . . . . 0.0 109.368 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.617 HG23 ' HA2' ' A' ' 34' ' ' GLY . 96.4 m -59.79 -51.2 70.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.27 -0.894 . . . . 0.0 109.483 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.46 ' OE2' HD23 ' A' ' 103' ' ' LEU . 13.6 pt-20 -83.4 -26.18 30.65 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.487 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.08 35.72 9.54 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -91.43 -6.33 52.95 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.247 -1.149 . . . . 0.0 109.577 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.986 HD12 ' HB3' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -76.63 -161.77 0.22 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.194 -0.942 . . . . 0.0 109.478 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.26 106.46 18.6 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.162 -0.961 . . . . 0.0 109.663 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.522 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 9.4 pt-20 -110.35 127.89 55.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.308 -0.87 . . . . 0.0 109.328 179.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 5.6 mt -127.83 132.19 69.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.582 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.1 ptm180 -142.18 177.47 8.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.283 -0.885 . . . . 0.0 109.264 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 3.4 m -117.72 158.65 44.94 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.547 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.12 136.48 14.61 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.645 2.23 . . . . 0.0 110.382 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -148.04 -113.07 0.71 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -148.94 152.56 36.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -1.139 . . . . 0.0 109.487 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -65.43 159.27 45.18 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.72 154.82 48.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.268 -1.137 . . . . 0.0 109.424 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -177.55 157.43 21.99 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.429 -1.469 . . . . 0.0 109.429 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.457 ' O ' ' O ' ' A' ' 122' ' ' ARG . 0.1 OUTLIER -114.64 13.8 17.48 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.256 -1.143 . . . . 0.0 109.523 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.457 ' O ' ' O ' ' A' ' 121' ' ' ARG . 54.7 mtt-85 53.63 102.67 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.943 . . . . 0.0 109.377 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -132.89 148.88 52.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.31 -0.869 . . . . 0.0 109.463 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 118.003 -0.998 . . . . 0.0 109.432 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 37.3 mtp . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.248 0.546 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -114.17 150.48 34.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.917 . . . . 0.0 109.315 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.581 HG12 ' CE2' ' A' ' 104' ' ' PHE . 7.6 mt -120.89 101.82 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.279 -0.888 . . . . 0.0 109.892 -179.655 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.07 103.6 15.54 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.345 -0.847 . . . . 0.0 109.137 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.672 HG22 HG12 ' A' ' 97' ' ' VAL . 7.7 mt -88.13 122.19 39.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.249 -0.907 . . . . 0.0 109.807 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.73 ' HB2' ' HE2' ' A' ' 20' ' ' PHE . . . -69.95 147.11 50.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 109.12 179.593 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.707 ' HB3' HG11 ' A' ' 97' ' ' VAL . 25.8 p -158.63 -178.68 7.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.165 -0.96 . . . . 0.0 109.788 -179.77 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -132.46 11.84 4.5 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.299 -0.876 . . . . 0.0 109.361 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -150.2 175.37 29.3 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -73.49 -44.97 56.67 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.272 -1.134 . . . . 0.0 109.46 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.426 ' OD2' ' OE1' ' A' ' 98' ' ' GLU . 10.5 t0 -176.93 -51.81 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.17 -0.956 . . . . 0.0 109.436 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.407 HD23 ' C ' ' A' ' 12' ' ' LEU . 8.7 tt -57.06 -29.82 63.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.203 -0.936 . . . . 0.0 109.245 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 18.97 7.73 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.475 ' O ' ' HA ' ' A' ' 96' ' ' SER . 93.9 p -76.89 79.94 3.46 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.259 -1.142 . . . . 0.0 109.517 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.613 ' C ' HG23 ' A' ' 16' ' ' VAL . 4.7 tt0 -77.39 4.27 11.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -0.828 . . . . 0.0 109.766 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.774 HG22 HG13 ' A' ' 97' ' ' VAL . 2.5 t 74.91 12.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.131 -0.98 . . . . 0.0 109.241 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.4 163.83 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.672 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.21 -44.11 3.03 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.148 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.414 ' O ' ' C ' ' A' ' 20' ' ' PHE . 33.7 m-85 -108.28 78.67 1.19 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.319 -0.863 . . . . 0.0 109.235 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.73 ' HE2' ' HB2' ' A' ' 6' ' ' ALA . 26.4 t80 -42.73 125.84 3.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.272 -0.893 . . . . 0.0 109.565 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -179.69 -66.39 0.07 OUTLIER Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.426 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 7.1 mtt180 -116.71 15.92 15.39 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.211 -1.17 . . . . 0.0 109.654 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.425 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -44.55 104.8 0.4 Allowed Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.917 . . . . 0.0 109.491 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.426 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.49 43.14 1.47 Allowed 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.692 2.261 . . . . 0.0 110.794 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 14.8 m-85 -159.91 70.45 0.44 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.118 -0.989 . . . . 0.0 109.096 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.48 ' HB2' HG23 ' A' ' 42' ' ' ILE . 32.7 m-85 -79.72 129.35 34.4 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.253 -0.904 . . . . 0.0 109.781 -179.668 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 3.2 ttt -103.64 102.68 12.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.887 . . . . 0.0 109.162 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.1 mm -90.41 116.76 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.098 -1.001 . . . . 0.0 109.552 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.553 HG11 HD11 ' A' ' 101' ' ' LEU . 3.9 t -118.96 160.17 19.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.705 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.506 ' HB3' ' CB ' ' A' ' 38' ' ' SER . 0.1 OUTLIER -139.18 84.6 2.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -0.866 . . . . 0.0 109.337 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.417 ' HB2' ' HE3' ' A' ' 31' ' ' MET . 22.2 ttm -93.58 140.32 29.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.24 -0.912 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LYS . . . . . 0.478 ' HG2' ' N ' ' A' ' 33' ' ' LYS . 14.7 ttpp -83.61 -84.98 0.13 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -0.872 . . . . 0.0 109.495 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.478 ' N ' ' HG2' ' A' ' 32' ' ' LYS . 0.0 OUTLIER -131.38 40.31 3.44 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.265 -0.897 . . . . 0.0 109.622 -179.826 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 119.96 24.93 2.65 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 68.6 m-80 -150.05 105.97 3.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.282 -1.128 . . . . 0.0 109.349 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.416 HG23 ' CG1' ' A' ' 29' ' ' VAL . 1.4 mp -66.48 114.75 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.279 -0.888 . . . . 0.0 109.584 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.21 33.06 5.68 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.506 ' CB ' ' HB3' ' A' ' 30' ' ' GLU . 0.2 OUTLIER -179.71 110.84 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.368 -0.832 . . . . 0.0 109.363 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -138.24 108.84 6.57 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.546 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -126.26 134.12 51.26 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.386 -0.821 . . . . 0.0 109.478 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.21 137.71 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.294 -0.879 . . . . 0.0 109.294 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.614 ' O ' HG23 ' A' ' 42' ' ' ILE . 0.8 OUTLIER -136.81 107.53 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.272 -0.892 . . . . 0.0 109.468 -179.935 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.402 ' C ' ' HD3' ' A' ' 45' ' ' PRO . 1.9 mp0 -74.59 171.66 13.44 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.382 -0.824 . . . . 0.0 109.409 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.467 ' N ' ' HD3' ' A' ' 45' ' ' PRO . 1.0 OUTLIER -133.85 65.09 69.47 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.29 -0.881 . . . . 0.0 109.556 179.921 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.467 ' HD3' ' N ' ' A' ' 44' ' ' ASN . 35.8 Cg_endo -78.12 172.01 16.18 Favored 'Trans proline' 0 C--N 1.309 -1.516 0 C-N-CA 122.679 2.253 . . . . 0.0 110.363 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 45' ' ' PRO . 0.5 OUTLIER 44.28 35.37 1.25 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.403 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -76.68 -18.41 58.56 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.245 -0.909 . . . . 0.0 109.462 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 50' ' ' SER . 0.6 OUTLIER -87.97 -81.97 0.24 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.285 -0.885 . . . . 0.0 109.425 179.926 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.428 ' N ' ' OG ' ' A' ' 48' ' ' SER . . . 46.36 -93.43 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.237 -0.914 . . . . 0.0 109.525 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.512 ' N ' ' O ' ' A' ' 48' ' ' SER . 0.7 OUTLIER -130.44 112.18 13.0 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.16 -0.963 . . . . 0.0 109.443 -179.937 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 106.32 143.96 11.75 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -90.96 97.69 2.35 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -112.38 105.59 13.9 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.195 -1.179 . . . . 0.0 109.467 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.688 ' O ' HG22 ' A' ' 57' ' ' THR . . . -137.11 -75.15 0.07 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 1.101 HD11 ' HB2' ' A' ' 78' ' ' ALA . 0.9 OUTLIER -74.98 -14.64 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.274 -1.133 . . . . 0.0 109.365 179.871 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.73 -13.68 61.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.861 . . . . 0.0 109.296 179.8 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.688 HG22 ' O ' ' A' ' 54' ' ' GLY . 9.2 t -65.78 -25.04 67.07 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.199 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.691 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -53.8 -42.73 68.66 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.375 -0.828 . . . . 0.0 109.527 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -58.98 -35.08 72.6 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.232 -0.918 . . . . 0.0 109.417 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 28.3 mt -72.79 -33.86 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.296 -0.877 . . . . 0.0 109.403 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.724 HG23 HG21 ' A' ' 66' ' ' VAL . 38.3 mt -63.19 -40.56 89.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.242 -0.911 . . . . 0.0 109.298 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.98 -23.86 67.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.207 -0.933 . . . . 0.0 109.37 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -75.15 -21.95 58.46 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 0.0 109.543 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.8 m-20 -80.16 -17.57 52.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.514 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 115.7 -15.28 17.03 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.724 HG21 HG23 ' A' ' 61' ' ' ILE . 57.3 t -44.4 93.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.399 -1.059 . . . . 0.0 109.806 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -79.5 -9.36 59.6 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.221 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -139.9 126.66 20.61 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.344 -0.847 . . . . 0.0 109.153 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.601 HG21 HD21 ' A' ' 82' ' ' LEU . 97.6 t -119.21 126.4 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.165 -0.96 . . . . 0.0 109.694 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.646 HD12 HG12 ' A' ' 5' ' ' ILE . 57.7 mt -100.33 117.47 45.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.354 -0.841 . . . . 0.0 109.349 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -148.25 174.51 11.93 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -0.917 . . . . 0.0 109.706 -179.669 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.595 ' HB3' ' HB3' ' A' ' 92' ' ' ALA . 53.7 p -143.26 40.87 1.48 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.365 -0.835 . . . . 0.0 109.373 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.423 ' HB2' ' HD2' ' A' ' 74' ' ' PRO . 11.4 p -51.97 159.14 1.49 Allowed Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.606 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.423 ' HD2' ' HB2' ' A' ' 73' ' ' SER . 35.1 Cg_endo -77.57 -31.05 3.56 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.609 2.206 . . . . 0.0 110.541 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -118.06 163.71 12.87 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.571 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.5 Cg_endo -79.96 17.21 1.34 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.831 2.354 . . . . 0.0 111.006 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.404 ' O ' HG23 ' A' ' 81' ' ' VAL . 9.0 m-20 -63.1 -52.06 64.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.949 -1.095 . . . . 0.0 109.742 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 1.101 ' HB2' HD11 ' A' ' 55' ' ' ILE . . . -61.77 -37.63 85.03 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.774 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.571 ' CD2' ' HA ' ' A' ' 76' ' ' PRO . 4.0 m-30 -66.17 -29.03 69.23 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.606 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -71.83 -41.5 68.12 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.167 -0.958 . . . . 0.0 109.566 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.404 HG23 ' O ' ' A' ' 77' ' ' ASN . 3.6 t -66.78 -50.42 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.165 -0.959 . . . . 0.0 109.652 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.601 HD21 HG21 ' A' ' 69' ' ' VAL . 2.3 mp -66.77 -27.45 67.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.232 -0.917 . . . . 0.0 109.468 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 33.3 t30 -65.78 -47.32 75.58 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.216 -0.927 . . . . 0.0 109.245 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -68.25 -31.61 71.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.31 -0.869 . . . . 0.0 109.26 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.488 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.4 OUTLIER -66.92 -25.96 66.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 179.894 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 93.69 22.58 25.78 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.488 HG12 ' HB3' ' A' ' 85' ' ' LEU . 5.9 mm -101.34 163.0 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.238 -1.154 . . . . 0.0 109.456 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.412 ' CG ' ' O ' ' A' ' 113' ' ' ARG . 12.5 mttm -93.7 133.03 37.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.401 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.501 HG21 ' CD1' ' A' ' 79' ' ' PHE . 2.0 mt -113.49 135.83 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.19 -0.944 . . . . 0.0 109.546 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.505 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 21.5 m-85 -124.56 151.25 44.97 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.505 -0.747 . . . . 0.0 109.365 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.468 ' O ' ' HG ' ' A' ' 109' ' ' LEU . 6.9 ttt-85 -83.46 152.86 24.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.229 -0.919 . . . . 0.0 109.701 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.595 ' HB3' ' HB3' ' A' ' 72' ' ' SER . . . -106.04 158.91 16.46 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.235 -0.915 . . . . 0.0 109.305 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.63 7.35 46.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.167 -0.958 . . . . 0.0 109.589 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 47.96 72.01 0.49 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.6 m -150.64 -61.61 0.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.308 -1.113 . . . . 0.0 109.356 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 14' ' ' SER . 66.4 m -165.98 123.11 1.4 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.233 -0.917 . . . . 0.0 109.525 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.774 HG13 HG22 ' A' ' 16' ' ' VAL . 27.2 m -65.62 -43.92 93.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.237 -0.914 . . . . 0.0 109.378 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' GLU . . . . . 0.526 ' N ' HG23 ' A' ' 97' ' ' VAL . 0.2 OUTLIER -45.15 -44.06 10.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.229 -0.919 . . . . 0.0 109.406 179.941 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.561 ' HG3' HD13 ' A' ' 103' ' ' LEU . 38.7 tp10 -73.92 -46.83 41.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.275 -0.891 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.453 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 2.2 m-80 -47.55 -26.21 1.36 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.938 . . . . 0.0 109.336 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.553 HD11 HG11 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -59.09 -57.03 14.88 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -0.919 . . . . 0.0 109.291 179.867 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.04 -27.61 68.92 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.238 -0.914 . . . . 0.0 109.327 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.561 HD13 ' HG3' ' A' ' 99' ' ' GLU . 0.8 OUTLIER -63.65 -35.08 79.34 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.372 -0.83 . . . . 0.0 109.534 179.984 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.581 ' CE2' HG12 ' A' ' 3' ' ' ILE . 6.1 t80 -63.79 -27.03 68.91 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.193 -0.942 . . . . 0.0 109.608 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 90.8 m -74.49 -19.93 60.18 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.189 -0.945 . . . . 0.0 109.484 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -106.17 8.19 31.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.202 -0.936 . . . . 0.0 109.515 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 52.53 40.73 55.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -83.59 -43.24 15.86 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.328 -1.101 . . . . 0.0 109.498 -179.883 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.529 HD21 ' HA ' ' A' ' 92' ' ' ALA . 1.5 tp -96.45 147.54 23.73 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.32 -0.863 . . . . 0.0 109.292 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.411 ' HG3' ' O ' ' A' ' 109' ' ' LEU . 3.4 mt-10 -176.52 -177.75 0.86 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.091 -1.005 . . . . 0.0 109.862 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.505 ' HB3' ' HA ' ' A' ' 90' ' ' TYR . 1.1 tp10 -177.35 -111.88 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.468 -0.77 . . . . 0.0 109.067 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.521 ' CD1' ' HB3' ' A' ' 79' ' ' PHE . 8.0 mt -79.74 121.53 33.21 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 O-C-N 121.177 -0.952 . . . . 0.0 109.367 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.412 ' O ' ' CG ' ' A' ' 88' ' ' LYS . 0.7 OUTLIER -90.53 -61.56 1.65 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.171 -0.955 . . . . 0.0 109.384 179.915 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 59.29 89.96 0.1 OUTLIER Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.307 -0.871 . . . . 0.0 109.536 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.63 -167.53 0.49 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.701 2.267 . . . . 0.0 110.405 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -164.57 71.95 0.19 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.81 105.19 4.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.191 -1.182 . . . . 0.0 109.41 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 95.38 -178.2 35.36 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -167.71 128.19 1.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.267 -1.137 . . . . 0.0 109.539 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 69.64 -140.75 33.87 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.421 ' HG3' ' HD3' ' A' ' 124' ' ' ARG . 0.0 OUTLIER 58.98 26.21 14.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -1.101 . . . . 0.0 109.518 -179.964 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -83.93 -37.65 22.05 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.231 -0.918 . . . . 0.0 109.357 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 1.4 mpt_? -65.27 -60.5 2.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.275 -0.891 . . . . 0.0 109.436 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.421 ' HD3' ' HG3' ' A' ' 121' ' ' ARG . 10.3 ptm180 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.455 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.3 mmt . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.576 ' N ' ' CD ' ' A' ' 2' ' ' LYS . 0.0 OUTLIER -90.44 133.88 34.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.252 -0.905 . . . . 0.0 109.158 179.915 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.501 ' HB ' HG12 ' A' ' 29' ' ' VAL . 9.4 mm -101.29 104.33 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.338 -0.851 . . . . 0.0 110.207 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.864 ' HB2' HD12 ' A' ' 28' ' ' ILE . . . -110.23 88.46 2.77 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.662 HD12 HG21 ' A' ' 70' ' ' ILE . 9.5 tt -98.81 133.11 42.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.239 -0.913 . . . . 0.0 110.014 -179.142 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -57.72 156.64 8.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.354 -0.841 . . . . 0.0 109.081 179.51 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.698 ' HB3' HG11 ' A' ' 97' ' ' VAL . 0.0 OUTLIER -159.97 178.96 9.19 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.092 -1.005 . . . . 0.0 109.798 -179.873 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.538 ' C ' ' CD2' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -126.73 23.49 6.71 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.386 -0.821 . . . . 0.0 109.189 179.921 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.464 ' HA2' ' CD1' ' A' ' 25' ' ' TYR . . . 153.08 -151.51 23.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.882 HG22 HG21 ' A' ' 41' ' ' VAL . 16.1 p -124.97 101.94 7.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.185 -1.185 . . . . 0.0 109.353 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 53.9 -154.03 0.26 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.282 -0.886 . . . . 0.0 109.327 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER 60.05 17.96 7.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.27 -0.894 . . . . 0.0 109.576 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 118.85 26.06 2.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.0 m -73.59 83.46 1.54 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.301 -1.117 . . . . 0.0 109.281 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.436 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.4 OUTLIER -79.4 38.81 0.38 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.435 -0.79 . . . . 0.0 110.62 -179.967 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.541 HG12 ' O ' ' A' ' 16' ' ' VAL . 21.2 t 63.55 13.08 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 120.716 -1.24 . . . . 0.0 109.413 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 65.78 177.97 0.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.226 -0.921 . . . . 0.0 109.493 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 7.5 ttt180 -120.26 7.13 10.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.184 -0.947 . . . . 0.0 109.596 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -144.02 165.9 26.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.42 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.87 ' CD2' ' HB1' ' A' ' 71' ' ' ALA . 2.3 t80 -132.68 88.81 2.56 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 109.392 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 158.85 -53.49 0.38 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.442 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 5.6 mtp180 -93.58 -19.95 20.69 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.265 -1.138 . . . . 0.0 109.67 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.53 110.24 2.12 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.183 -0.948 . . . . 0.0 109.525 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.502 ' HA ' ' CB ' ' A' ' 44' ' ' ASN . 36.9 Cg_endo -81.29 51.56 3.95 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.614 2.21 . . . . 0.0 110.715 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.538 ' CD2' ' C ' ' A' ' 8' ' ' SER . 4.9 m-85 -159.1 68.91 0.45 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.99 -1.069 . . . . 0.0 109.555 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -84.31 127.05 33.74 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.911 . . . . 0.0 109.189 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' MET . . . . . 0.78 ' HG3' HG13 ' A' ' 41' ' ' VAL . 1.7 mtt -100.85 121.98 42.64 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.817 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.864 HD12 ' HB2' ' A' ' 4' ' ' ALA . 1.1 tp -121.36 132.2 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.357 -0.839 . . . . 0.0 109.06 179.622 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.772 HG23 ' O ' ' A' ' 38' ' ' SER . 14.1 p -138.89 133.41 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.221 -0.924 . . . . 0.0 109.538 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.431 ' HG2' ' N ' ' A' ' 31' ' ' MET . 3.4 tt0 -103.41 138.69 39.81 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.246 -0.909 . . . . 0.0 109.461 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.431 ' N ' ' HG2' ' A' ' 30' ' ' GLU . 11.4 ptp -130.4 153.65 48.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 109.381 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.57 -76.88 0.44 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.235 -0.915 . . . . 0.0 109.688 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.34 -73.17 0.67 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.123 -0.985 . . . . 0.0 109.646 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -142.68 26.6 2.24 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -140.36 99.52 3.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -1.16 . . . . 0.0 109.571 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.705 HD13 HD21 ' A' ' 101' ' ' LEU . 7.2 pt -50.1 129.38 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.24 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -113.43 0.38 14.72 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.159 -0.963 . . . . 0.0 109.817 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.772 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -156.41 110.34 2.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.031 -1.043 . . . . 0.0 110.007 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.63 100.22 7.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.313 -0.867 . . . . 0.0 108.901 179.335 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -108.05 159.46 16.55 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.188 -0.945 . . . . 0.0 109.912 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.882 HG21 HG22 ' A' ' 10' ' ' THR . 2.8 t -129.29 122.48 56.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.373 -0.83 . . . . 0.0 109.141 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.74 142.48 24.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.184 -0.947 . . . . 0.0 109.582 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -87.95 158.09 18.76 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 0.0 109.304 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.502 ' CB ' ' HA ' ' A' ' 24' ' ' PRO . 4.0 t-20 -118.99 102.61 48.96 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.217 -0.927 . . . . 0.0 109.506 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -77.1 -169.09 0.67 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.407 2.071 . . . . 0.0 110.449 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 54.98 36.0 25.91 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.898 . . . . 0.0 109.317 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -72.12 -55.89 6.53 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.437 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -128.37 71.44 1.39 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.128 -0.983 . . . . 0.0 109.58 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -145.74 -87.85 0.1 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.1 t -50.42 -39.23 46.8 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.301 -0.874 . . . . 0.0 109.414 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.89 -168.11 41.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -97.53 81.89 0.68 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -79.87 128.74 33.82 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -1.106 . . . . 0.0 109.729 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.855 ' O ' HG22 ' A' ' 57' ' ' THR . . . -141.82 -61.95 0.03 OUTLIER Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.641 HD12 ' HB2' ' A' ' 78' ' ' ALA . 30.2 mm -76.02 -17.97 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.287 -1.125 . . . . 0.0 109.328 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -76.39 -16.13 59.79 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.32 -0.862 . . . . 0.0 109.307 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.855 HG22 ' O ' ' A' ' 54' ' ' GLY . 11.9 t -72.61 -24.62 61.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.282 -0.887 . . . . 0.0 109.47 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -59.65 -36.62 76.76 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.115 -0.99 . . . . 0.0 109.268 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -71.45 -23.01 61.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.294 -0.879 . . . . 0.0 109.523 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.7 mm -76.84 -54.65 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.476 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.607 ' O ' HG22 ' A' ' 66' ' ' VAL . 0.9 OUTLIER -66.79 -27.57 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.254 -0.904 . . . . 0.0 109.544 -179.955 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.619 ' HB1' HD22 ' A' ' 85' ' ' LEU . . . -65.98 -34.07 77.26 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.183 -0.948 . . . . 0.0 109.572 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -77.03 -10.17 59.19 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 109.624 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.1 m-20 -83.61 -12.62 55.81 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.264 -0.898 . . . . 0.0 109.591 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.415 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 97.31 0.89 59.48 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.747 ' O ' HG23 ' A' ' 66' ' ' VAL . 32.8 m -48.03 98.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.181 -1.188 . . . . 0.0 109.761 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.415 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -78.53 -11.2 59.95 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 178.951 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -139.8 126.31 20.34 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 71.4 t -126.16 124.79 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.981 -1.074 . . . . 0.0 109.755 -179.326 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.662 HG21 HD12 ' A' ' 5' ' ' ILE . 4.2 mp -104.18 96.86 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.199 -0.938 . . . . 0.0 109.314 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.87 ' HB1' ' CD2' ' A' ' 20' ' ' PHE . . . -130.1 172.36 11.85 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.401 -0.812 . . . . 0.0 109.473 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.424 ' O ' ' C ' ' A' ' 73' ' ' SER . 0.2 OUTLIER -138.64 34.22 2.23 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.29 -0.881 . . . . 0.0 109.555 -179.881 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -44.57 153.06 0.48 Allowed Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.221 -0.924 . . . . 0.0 109.315 179.914 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.23 -47.38 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.605 2.203 . . . . 0.0 110.335 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.419 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -84.67 141.55 19.62 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.419 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.6 Cg_endo -78.45 -0.68 10.93 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.501 2.134 . . . . 0.0 110.347 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -60.56 -32.51 71.57 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.308 -0.87 . . . . 0.0 109.522 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.641 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -70.04 -54.24 14.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.22 -0.925 . . . . 0.0 109.521 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.412 ' CD1' HG21 ' A' ' 89' ' ' ILE . 11.3 m-30 -54.64 -24.2 20.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.247 -0.908 . . . . 0.0 109.738 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -72.43 -37.34 68.63 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.156 -0.965 . . . . 0.0 109.723 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 75.4 t -76.1 -36.23 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.219 -0.926 . . . . 0.0 109.77 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.56 HD12 ' O ' ' A' ' 78' ' ' ALA . 0.7 OUTLIER -62.01 -36.58 81.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.599 -179.85 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -73.51 -24.53 60.17 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.236 -0.915 . . . . 0.0 109.46 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -76.78 -33.41 58.04 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.233 -0.917 . . . . 0.0 109.526 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.619 HD22 ' HB1' ' A' ' 62' ' ' ALA . 0.5 OUTLIER -77.52 -23.65 50.14 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.135 -0.978 . . . . 0.0 109.564 -179.86 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.5 21.59 14.42 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.472 HG22 ' N ' ' A' ' 88' ' ' LYS . 7.7 mt -98.83 158.33 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.257 -1.143 . . . . 0.0 109.381 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.472 ' N ' HG22 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -90.76 128.58 36.73 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.15 -0.969 . . . . 0.0 109.332 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.538 HG12 ' CB ' ' A' ' 82' ' ' LEU . 5.5 mt -98.91 151.22 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.17 -0.956 . . . . 0.0 109.29 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.573 ' CE1' ' HA ' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -138.54 141.15 39.3 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.321 -0.862 . . . . 0.0 109.225 -179.708 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.42 ' O ' ' HB3' ' A' ' 110' ' ' GLU . 1.5 tpp85 -92.6 128.56 38.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.939 . . . . 0.0 109.782 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.44 121.46 25.75 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.326 -0.859 . . . . 0.0 109.486 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.12 -27.89 61.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.309 -0.87 . . . . 0.0 109.505 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 97.06 61.21 0.94 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -130.51 -60.72 0.98 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.192 -1.181 . . . . 0.0 109.451 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 0.3 OUTLIER -173.34 150.39 1.86 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.291 -0.881 . . . . 0.0 109.543 -179.878 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.698 HG11 ' HB3' ' A' ' 7' ' ' SER . 4.0 m -72.16 -34.17 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.582 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -65.39 -53.29 45.46 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.482 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 0.3 OUTLIER -58.3 -45.04 88.71 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.329 -0.857 . . . . 0.0 109.709 -179.921 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -61.18 -30.27 70.31 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.205 -0.934 . . . . 0.0 109.847 -179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.705 HD21 HD13 ' A' ' 36' ' ' ILE . 31.7 tp -63.07 -56.51 16.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.176 -0.953 . . . . 0.0 109.648 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.404 ' HG2' ' O ' ' A' ' 102' ' ' LYS . 0.0 OUTLIER -73.86 -11.91 60.51 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.146 -0.972 . . . . 0.0 109.5 -179.906 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.534 HD22 ' OE2' ' A' ' 110' ' ' GLU . 0.3 OUTLIER -76.17 -45.31 34.03 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.232 -0.917 . . . . 0.0 109.497 -179.91 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.551 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 3.5 t80 -76.57 -26.31 54.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.344 -0.847 . . . . 0.0 109.49 -179.822 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.425 HG23 ' SD ' ' A' ' 31' ' ' MET . 17.7 m -61.4 -33.59 73.94 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.229 -0.919 . . . . 0.0 109.676 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -103.43 8.94 37.95 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.104 -0.997 . . . . 0.0 109.575 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.29 59.13 10.51 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ASN . . . . . 0.565 ' O ' HD12 ' A' ' 109' ' ' LEU . 48.2 t-20 -81.18 -38.77 26.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.38 -1.071 . . . . 0.0 109.564 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.565 HD12 ' O ' ' A' ' 108' ' ' ASN . 0.0 OUTLIER 171.0 -156.77 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.162 -0.961 . . . . 0.0 109.735 -179.942 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.565 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 23.2 mt-10 60.59 29.82 19.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.865 . . . . 0.0 109.259 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.573 ' HA ' ' CE1' ' A' ' 90' ' ' TYR . 1.0 OUTLIER -92.44 144.74 25.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.319 -0.863 . . . . 0.0 109.675 -179.823 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 111' ' ' GLU . 9.2 mm -155.67 125.62 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.477 -0.764 . . . . 0.0 109.15 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -129.38 9.86 5.65 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 0.0 109.353 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.43 ' N ' ' HD3' ' A' ' 115' ' ' PRO . 71.5 m 45.13 66.85 4.74 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.29 -0.881 . . . . 0.0 109.626 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.43 ' HD3' ' N ' ' A' ' 114' ' ' SER . 36.1 Cg_endo -78.51 -46.41 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.654 2.236 . . . . 0.0 110.405 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.05 119.96 0.79 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 3.8 m -101.73 20.58 16.0 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.259 -1.142 . . . . 0.0 109.479 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -81.99 117.77 4.48 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.85 -21.28 7.26 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -1.139 . . . . 0.0 109.389 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 141.52 -158.77 26.65 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 2.2 mmt85 -126.23 175.45 7.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.388 -1.066 . . . . 0.0 109.383 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.468 ' HD3' ' N ' ' A' ' 122' ' ' ARG . 0.1 OUTLIER -101.78 -21.73 14.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.204 -0.935 . . . . 0.0 109.51 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 7.7 ttt180 -74.29 82.58 1.88 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.19 -0.944 . . . . 0.0 109.511 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 1.1 ttt85 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.459 179.97 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.448 ' O ' ' HE3' ' A' ' 2' ' ' LYS . 21.0 ttm . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.357 0.599 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.448 ' HE3' ' O ' ' A' ' 1' ' ' MET . 0.1 OUTLIER -143.44 106.9 4.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.203 -0.935 . . . . 0.0 109.413 -179.996 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.752 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 2.3 mp -107.68 114.77 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.336 -0.853 . . . . 0.0 109.414 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.566 ' HB1' ' CZ ' ' A' ' 26' ' ' PHE . . . -113.24 122.07 46.36 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.235 -0.915 . . . . 0.0 109.347 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.477 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 2.8 mp -96.93 129.22 47.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.174 -0.954 . . . . 0.0 109.568 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.419 ' O ' ' HB3' ' A' ' 7' ' ' SER . . . -68.93 146.86 52.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.257 -0.902 . . . . 0.0 109.272 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.419 ' HB3' ' O ' ' A' ' 6' ' ' ALA . 13.3 t 60.05 -94.5 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 0.0 109.426 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.621 ' OG ' HG11 ' A' ' 97' ' ' VAL . 8.7 t 63.45 31.42 14.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.161 -0.962 . . . . 0.0 109.772 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 42.53 -105.57 0.07 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -158.7 -46.44 0.06 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.251 -1.146 . . . . 0.0 109.411 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.86 -72.89 0.35 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.185 -0.947 . . . . 0.0 109.637 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 31.6 mt -107.09 -14.7 14.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.202 -0.936 . . . . 0.0 109.572 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.21 6.12 64.73 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 8' ' ' SER . 93.9 p -77.68 77.16 4.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -1.137 . . . . 0.0 109.673 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.598 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -77.81 78.49 4.31 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.235 -0.916 . . . . 0.0 109.456 179.881 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.598 HG12 ' O ' ' A' ' 15' ' ' GLU . 11.6 p 41.1 42.31 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.427 -0.795 . . . . 0.0 109.839 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.438 ' OG ' ' C ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER 59.97 -163.54 0.24 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.249 -0.907 . . . . 0.0 109.486 -179.959 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -170.27 -36.32 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.258 -0.901 . . . . 0.0 109.373 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -148.16 140.06 23.94 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.33 -0.856 . . . . 0.0 109.471 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.428 ' CG ' ' O ' ' A' ' 20' ' ' PHE . 12.9 t80 -116.1 38.45 3.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.252 -0.905 . . . . 0.0 109.733 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -93.94 -56.76 1.37 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.432 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 18.9 mtt180 -140.16 41.74 1.94 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.29 -1.124 . . . . 0.0 109.111 179.747 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -52.3 108.8 1.17 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.41 -0.806 . . . . 0.0 109.744 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.482 ' O ' ' HB3' ' A' ' 43' ' ' GLU . 36.7 Cg_endo -80.83 40.9 1.05 Allowed 'Trans proline' 0 C--N 1.312 -1.374 0 C-N-CA 122.561 2.174 . . . . 0.0 110.434 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.422 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 6.2 m-85 -161.11 74.74 0.5 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.143 -0.973 . . . . 0.0 108.909 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.566 ' CZ ' ' HB1' ' A' ' 4' ' ' ALA . 16.5 t80 -78.26 112.52 15.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.433 -0.792 . . . . 0.0 109.496 -179.439 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 1.6 ttm -94.12 114.48 26.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.455 -0.778 . . . . 0.0 109.31 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.405 HG23 ' O ' ' A' ' 28' ' ' ILE . 0.3 OUTLIER -106.62 123.88 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.283 -0.886 . . . . 0.0 109.488 -179.869 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.651 HG12 HG23 ' A' ' 36' ' ' ILE . 2.1 t -121.74 120.64 62.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.912 . . . . 0.0 109.636 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -116.95 96.81 5.63 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 21.1 ptp -87.26 167.24 14.27 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.919 . . . . 0.0 109.358 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.58 -93.62 0.15 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.259 -0.9 . . . . 0.0 109.552 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.62 35.59 3.78 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.232 -0.917 . . . . 0.0 109.485 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 120.7 21.66 3.21 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 12.4 t30 -141.04 109.45 5.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.175 -1.191 . . . . 0.0 109.381 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.651 HG23 HG12 ' A' ' 29' ' ' VAL . 4.5 mt -63.25 114.12 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 109.631 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -123.03 28.55 7.14 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.265 -0.897 . . . . 0.0 109.27 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -172.96 96.12 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.324 -0.86 . . . . 0.0 109.434 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.1 m -125.99 103.5 7.78 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.276 -0.89 . . . . 0.0 109.147 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -114.52 142.58 46.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.255 -0.903 . . . . 0.0 110.046 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 t -116.72 96.21 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.415 -0.803 . . . . 0.0 108.955 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 13.6 mt -121.21 126.8 75.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 0.0 109.812 -179.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.482 ' HB3' ' O ' ' A' ' 24' ' ' PRO . 0.0 OUTLIER -53.65 148.59 9.46 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.353 -0.842 . . . . 0.0 109.582 179.847 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 37.8 m-80 -64.11 148.06 95.89 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.179 -0.951 . . . . 0.0 109.218 179.746 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.3 155.09 28.72 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.68 2.253 . . . . 0.0 110.76 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.8 p 58.31 18.02 5.17 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.347 -0.845 . . . . 0.0 109.902 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.63 -69.24 0.12 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.142 -0.974 . . . . 0.0 109.201 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.78 114.98 26.76 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 0.0 109.188 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -139.2 -172.18 3.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.219 -0.925 . . . . 0.0 109.722 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.6 m -92.61 24.0 3.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.329 -0.857 . . . . 0.0 109.495 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 167.35 76.01 0.03 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -125.98 164.82 19.41 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -121.36 -57.79 1.82 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.196 -1.179 . . . . 0.0 109.484 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.842 ' O ' HG22 ' A' ' 57' ' ' THR . . . 126.77 -47.99 0.99 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.568 HG23 ' HB2' ' A' ' 78' ' ' ALA . 22.9 mm -75.61 -20.05 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.252 -1.146 . . . . 0.0 109.6 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -69.87 -25.58 63.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.323 -0.861 . . . . 0.0 109.505 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.842 HG22 ' O ' ' A' ' 54' ' ' GLY . 11.2 t -56.48 -25.86 52.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.561 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.455 ' O ' ' HB ' ' A' ' 61' ' ' ILE . . . -45.27 -41.84 8.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.183 -0.948 . . . . 0.0 109.356 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.82 -56.12 15.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.307 -0.871 . . . . 0.0 109.552 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 44.6 mt -54.97 -33.74 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.231 -0.918 . . . . 0.0 109.38 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.455 ' HB ' ' O ' ' A' ' 58' ' ' ALA . 22.9 mm -59.73 -52.72 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.245 -0.909 . . . . 0.0 109.579 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -64.18 -21.52 66.59 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.277 -0.889 . . . . 0.0 109.739 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.96 -23.26 55.35 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -0.924 . . . . 0.0 109.656 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -83.83 -16.91 42.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.125 -0.985 . . . . 0.0 109.703 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 98.37 -2.09 59.09 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.436 HG23 ' H ' ' A' ' 66' ' ' VAL . 3.7 t -42.37 97.87 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.315 -1.109 . . . . 0.0 109.773 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.469 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -79.22 -9.97 59.7 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.081 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.752 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -135.58 118.51 16.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.48 -0.763 . . . . 0.0 109.354 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.637 ' CG2' HD21 ' A' ' 82' ' ' LEU . 59.3 t -111.6 119.92 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.24 -0.913 . . . . 0.0 109.63 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.477 ' HB ' ' HA ' ' A' ' 5' ' ' ILE . 4.4 mm -102.69 117.12 47.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.149 -0.969 . . . . 0.0 109.551 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -160.03 171.77 18.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.745 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 37.4 t -133.71 42.98 2.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.354 -0.841 . . . . 0.0 109.278 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.437 ' OG ' ' HD2' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -51.81 155.57 2.91 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.42 -0.8 . . . . 0.0 109.83 -179.731 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.437 ' HD2' ' OG ' ' A' ' 73' ' ' SER . 35.2 Cg_endo -78.17 -12.1 15.99 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.725 2.283 . . . . 0.0 110.642 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -148.89 154.23 25.69 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.533 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.4 Cg_endo -79.92 38.81 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.862 2.375 . . . . 0.0 111.017 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.411 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 1.5 t-20 -77.25 -54.52 6.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.966 -1.084 . . . . 0.0 109.675 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.568 ' HB2' HG23 ' A' ' 55' ' ' ILE . . . -66.15 -38.39 88.0 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 109.644 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 79' ' ' PHE . 2.7 m-30 -55.41 -33.79 63.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.931 . . . . 0.0 109.475 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.411 ' HB2' ' O ' ' A' ' 77' ' ' ASN . 16.9 mt-10 -53.19 -55.79 21.52 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.932 . . . . 0.0 109.521 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.404 HG23 ' H ' ' A' ' 81' ' ' VAL . 2.4 t -60.89 -39.17 81.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.929 HD23 HG13 ' A' ' 89' ' ' ILE . 1.3 tp -52.23 -40.8 62.11 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.396 -0.815 . . . . 0.0 109.935 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -73.98 -36.98 64.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.128 -0.983 . . . . 0.0 109.81 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -66.92 -20.04 65.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.268 -0.895 . . . . 0.0 109.822 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.492 ' HA ' HD22 ' A' ' 85' ' ' LEU . 0.2 OUTLIER -102.98 24.68 10.38 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.16 -0.963 . . . . 0.0 109.716 -179.81 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 51.94 65.2 3.37 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.401 HG22 ' N ' ' A' ' 88' ' ' LYS . 75.0 mt -141.03 155.55 21.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -1.162 . . . . 0.0 109.299 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.401 ' N ' HG22 ' A' ' 87' ' ' ILE . 15.6 mttp -101.2 130.89 47.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.126 -0.984 . . . . 0.0 109.839 -179.692 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.929 HG13 HD23 ' A' ' 82' ' ' LEU . 2.2 mp -94.73 160.43 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.338 -0.851 . . . . 0.0 109.425 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.527 ' CE2' ' O ' ' A' ' 109' ' ' LEU . 0.2 OUTLIER -144.51 135.61 25.18 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.336 -0.852 . . . . 0.0 109.394 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.01 139.9 33.96 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.303 -0.873 . . . . 0.0 109.476 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.496 ' HB1' HG22 ' A' ' 16' ' ' VAL . . . -81.42 112.22 18.48 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -0.903 . . . . 0.0 109.434 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -144.32 16.23 1.68 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.256 -0.902 . . . . 0.0 109.45 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -92.13 -130.45 5.11 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 51.9 m -122.91 -54.87 1.82 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.218 -1.166 . . . . 0.0 109.489 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 2.3 m -127.52 172.09 11.02 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.245 -0.909 . . . . 0.0 109.457 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.621 HG11 ' OG ' ' A' ' 8' ' ' SER . 49.4 t -77.33 -43.82 30.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.319 -0.863 . . . . 0.0 109.612 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.46 -34.79 67.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.26 -0.9 . . . . 0.0 109.551 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -75.85 -59.52 2.72 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.252 -0.905 . . . . 0.0 109.518 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -51.02 -22.19 2.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.224 -0.923 . . . . 0.0 109.463 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 24.0 tp -64.18 -69.59 0.27 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.196 -0.94 . . . . 0.0 109.306 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.41 ' O ' ' HG2' ' A' ' 106' ' ' GLU . 0.6 OUTLIER -62.76 -14.82 49.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.335 -0.853 . . . . 0.0 109.458 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -77.0 -32.51 57.26 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 109.619 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.633 ' CE1' HD11 ' A' ' 3' ' ' ILE . 1.9 t80 -71.28 -31.08 67.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -0.889 . . . . 0.0 109.59 -179.696 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 51.6 m -74.26 -21.08 59.92 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.045 -1.034 . . . . 0.0 109.99 -179.425 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.41 ' HG2' ' O ' ' A' ' 102' ' ' LYS . 30.1 mm-40 -92.07 11.86 23.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.064 -1.023 . . . . 0.0 109.514 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 53.06 53.68 32.83 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ASN . . . . . 0.487 ' OD1' HD23 ' A' ' 109' ' ' LEU . 1.6 t-20 -79.88 -63.82 1.33 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.348 -1.089 . . . . 0.0 109.469 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.527 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.6 OUTLIER 177.87 -153.56 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.306 -0.871 . . . . 0.0 109.528 179.989 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.519 ' HG3' ' CD1' ' A' ' 109' ' ' LEU . 79.4 mt-10 62.15 27.9 16.78 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.208 -0.933 . . . . 0.0 109.287 -179.867 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.495 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 7.9 pt-20 -108.7 147.74 31.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.757 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.442 ' O ' HD12 ' A' ' 89' ' ' ILE . 14.4 mt -151.76 128.39 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.323 -0.861 . . . . 0.0 109.193 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.434 ' O ' ' O ' ' A' ' 114' ' ' SER . 0.0 OUTLIER -138.36 20.09 2.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.235 -0.916 . . . . 0.0 109.805 -179.741 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 113' ' ' ARG . 0.5 OUTLIER 59.62 154.33 0.1 OUTLIER Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.162 -0.961 . . . . 0.0 109.442 179.982 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.38 -28.84 4.25 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.566 2.177 . . . . 0.0 110.519 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 150.44 -118.55 0.93 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -151.92 26.04 0.64 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.205 -1.174 . . . . 0.0 109.561 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 160.1 149.9 5.7 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.35 139.11 24.13 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.185 -1.185 . . . . 0.0 109.499 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 144.49 86.78 0.08 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.31 -43.51 41.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.332 -1.099 . . . . 0.0 109.396 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.05 141.42 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.273 -0.892 . . . . 0.0 109.596 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.51 ' O ' ' CB ' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -151.61 25.53 0.67 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.287 -0.883 . . . . 0.0 109.257 179.852 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.51 ' CB ' ' O ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.485 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 mtp . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.795 ' HD3' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -139.42 140.56 37.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.195 -0.94 . . . . 0.0 109.667 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.537 ' CG2' HD11 ' A' ' 70' ' ' ILE . 5.5 mt -110.41 99.67 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.46 -0.775 . . . . 0.0 109.824 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.641 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -100.07 115.39 29.64 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.337 -0.852 . . . . 0.0 109.08 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.652 HG13 HD12 ' A' ' 70' ' ' ILE . 3.4 mp -92.04 142.47 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.217 -0.927 . . . . 0.0 109.756 -179.741 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.502 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -80.39 171.62 14.83 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.295 -0.878 . . . . 0.0 109.546 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.547 ' HA ' ' HB1' ' A' ' 23' ' ' ALA . 71.7 m 47.95 -93.02 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.251 -0.906 . . . . 0.0 109.522 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.502 ' N ' ' O ' ' A' ' 6' ' ' ALA . 41.0 t 52.9 25.39 3.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.083 -1.011 . . . . 0.0 109.528 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 44.38 -101.41 0.03 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.59 -67.1 0.19 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.212 -1.17 . . . . 0.0 109.479 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -158.66 -79.41 0.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.156 -0.965 . . . . 0.0 109.592 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.17 -19.82 55.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.147 -0.971 . . . . 0.0 109.515 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -130.68 37.46 2.11 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.6 m -76.49 82.07 3.19 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -1.153 . . . . 0.0 109.254 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.49 ' HG3' ' N ' ' A' ' 16' ' ' VAL . 5.3 pt-20 -77.14 -134.38 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.266 -0.896 . . . . 0.0 109.054 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.775 HG13 ' O ' ' A' ' 16' ' ' VAL . 12.2 p -154.45 67.24 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 120.99 -1.069 . . . . 0.0 109.422 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.0 m -52.6 156.94 1.69 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -102.53 12.85 35.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.287 -0.883 . . . . 0.0 109.447 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -107.49 103.54 12.89 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.274 -0.891 . . . . 0.0 109.451 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -101.79 127.51 48.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.162 -0.961 . . . . 0.0 109.435 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 150.29 -64.49 0.39 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.6 ttt180 -91.85 -12.44 33.64 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -1.16 . . . . 0.0 109.362 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.573 ' O ' ' CE1' ' A' ' 26' ' ' PHE . . . -41.48 101.82 0.25 Allowed Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.528 -0.732 . . . . 0.0 109.752 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.491 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.8 Cg_endo -80.91 44.23 1.71 Allowed 'Trans proline' 0 C--N 1.311 -1.419 0 C-N-CA 122.653 2.236 . . . . 0.0 110.574 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.491 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 31.6 m-85 -160.07 70.21 0.43 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.015 -1.053 . . . . 0.0 109.641 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.573 ' CE1' ' O ' ' A' ' 23' ' ' ALA . 18.8 m-30 -80.35 111.5 16.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.178 -0.951 . . . . 0.0 109.377 179.704 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' MET . . . . . 0.417 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 6.3 ttm -90.56 116.67 28.64 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.276 -0.89 . . . . 0.0 109.509 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.795 HG22 ' HD3' ' A' ' 2' ' ' LYS . 7.2 mm -101.99 108.36 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.893 . . . . 0.0 109.437 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.676 ' CG1' HD12 ' A' ' 36' ' ' ILE . 96.8 t -104.47 142.34 18.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.553 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.457 ' O ' ' OG ' ' A' ' 38' ' ' SER . 32.5 tt0 -137.28 100.87 4.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.329 -0.857 . . . . 0.0 109.53 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.886 ' HB3' HD13 ' A' ' 36' ' ' ILE . 4.5 ptp -95.75 155.22 16.84 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.276 -0.89 . . . . 0.0 109.252 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 27.4 mmtm -102.26 -46.77 4.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.241 -0.912 . . . . 0.0 109.877 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 34' ' ' GLY . 1.5 ttpp -146.27 92.62 2.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.21 -0.931 . . . . 0.0 109.639 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 43.36 28.2 0.88 Allowed Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.784 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -151.06 111.01 4.08 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.205 -1.173 . . . . 0.0 109.387 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.886 HD13 ' HB3' ' A' ' 31' ' ' MET . 49.1 mm -56.74 116.91 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.236 -0.915 . . . . 0.0 109.588 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.34 18.54 15.19 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.317 -0.864 . . . . 0.0 109.415 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 30' ' ' GLU . 0.7 OUTLIER -174.94 127.52 0.29 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.317 -0.864 . . . . 0.0 109.527 -179.877 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.22 110.94 6.48 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.329 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -125.15 106.34 9.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 109.74 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 41' ' ' VAL . 14.9 p -97.15 124.49 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.24 -0.912 . . . . 0.0 109.247 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.0 pt -122.52 161.02 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.26 -0.9 . . . . 0.0 109.778 -179.656 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -104.0 159.81 15.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.346 -0.846 . . . . 0.0 109.379 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -137.15 81.95 31.01 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.297 -0.877 . . . . 0.0 109.238 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.37 -2.77 12.8 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 122.686 2.257 . . . . 0.0 110.682 -179.642 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.5 m -69.02 -18.08 63.99 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.177 -0.952 . . . . 0.0 109.531 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.33 -52.11 48.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.926 . . . . 0.0 109.537 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 25.9 t -99.15 47.74 0.96 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.246 -0.909 . . . . 0.0 109.567 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ALA . . . . . 0.414 ' O ' ' C ' ' A' ' 50' ' ' SER . . . -156.6 -65.44 0.1 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 49' ' ' ALA . 15.8 m -43.85 -52.96 6.4 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.286 -0.884 . . . . 0.0 109.479 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 120.56 139.8 5.88 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 122.3 -133.84 9.47 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -111.46 -32.04 6.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.305 -1.114 . . . . 0.0 109.488 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.517 ' O ' HG22 ' A' ' 57' ' ' THR . . . 110.32 -33.07 6.19 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.513 HG21 ' HB2' ' A' ' 78' ' ' ALA . 23.8 mt -73.88 -9.18 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.303 -1.116 . . . . 0.0 109.47 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.466 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -69.03 -23.44 64.07 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.211 -0.93 . . . . 0.0 109.532 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.708 ' HA ' HD12 ' A' ' 60' ' ' ILE . 13.0 t -64.29 -14.18 54.36 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.673 -179.795 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -54.25 -46.11 72.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.167 -0.958 . . . . 0.0 109.439 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -52.11 -36.77 52.06 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.141 -0.974 . . . . 0.0 109.472 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.708 HD12 ' HA ' ' A' ' 57' ' ' THR . 6.6 mt -74.81 -33.56 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.266 -0.896 . . . . 0.0 109.609 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 61.0 mt -61.39 -36.69 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.178 -0.951 . . . . 0.0 109.4 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -70.72 -21.68 62.52 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.281 -0.887 . . . . 0.0 109.61 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -75.09 -9.68 58.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.118 -0.989 . . . . 0.0 109.283 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -88.59 -21.83 23.84 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.245 -0.909 . . . . 0.0 109.476 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 120.02 17.66 4.49 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.641 HG11 ' HB3' ' A' ' 4' ' ' ALA . 17.9 t -87.16 89.9 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.222 -1.164 . . . . 0.0 109.483 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.627 ' HA ' HG23 ' A' ' 87' ' ' ILE . 4.3 tttp -79.54 -7.97 58.84 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.364 -0.835 . . . . 0.0 108.984 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 2' ' ' LYS . . . -130.83 113.96 14.73 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.112 -0.993 . . . . 0.0 109.319 179.611 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 93.4 t -112.02 123.84 68.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.106 -0.996 . . . . 0.0 109.705 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.754 ' CG2' ' HB2' ' A' ' 92' ' ' ALA . 80.9 mt -103.14 116.36 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.397 -0.814 . . . . 0.0 109.186 179.766 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.91 175.42 10.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 109.934 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.02 57.36 1.48 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.508 -0.745 . . . . 0.0 109.23 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.2 m -65.18 155.57 83.96 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.199 -0.938 . . . . 0.0 109.614 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.18 -18.8 12.49 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.752 2.301 . . . . 0.0 110.312 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -129.99 162.38 23.01 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.16 9.9 3.18 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.814 2.343 . . . . 0.0 110.755 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -60.9 -55.03 37.82 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.065 -1.022 . . . . 0.0 109.655 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.513 ' HB2' HG21 ' A' ' 55' ' ' ILE . . . -56.06 -52.33 64.66 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.246 -0.909 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.702 ' CD1' HG21 ' A' ' 89' ' ' ILE . 12.9 m-30 -53.55 -30.1 40.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.226 -0.921 . . . . 0.0 109.628 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -68.79 -42.51 77.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.276 -0.89 . . . . 0.0 109.632 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.36 -53.09 44.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.184 -0.947 . . . . 0.0 109.478 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 53.5 mt -59.66 -28.01 66.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.27 -0.894 . . . . 0.0 109.639 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.478 ' HB2' ' O ' ' A' ' 79' ' ' PHE . 1.4 t-20 -69.06 -44.81 71.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.94 . . . . 0.0 109.268 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -68.85 -23.58 64.26 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.207 -0.933 . . . . 0.0 109.17 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.43 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -75.21 -35.39 61.5 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.271 -0.893 . . . . 0.0 109.484 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 101.75 25.01 8.29 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.627 HG23 ' HA ' ' A' ' 67' ' ' LYS . 30.5 mm -105.49 169.9 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.253 -1.145 . . . . 0.0 109.592 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.554 ' N ' HG22 ' A' ' 87' ' ' ILE . 5.4 mttt -93.71 134.91 35.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.285 -0.884 . . . . 0.0 109.536 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.702 HG21 ' CD1' ' A' ' 79' ' ' PHE . 4.3 mt -107.06 142.55 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.287 -0.883 . . . . 0.0 109.464 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.551 ' N ' ' CD1' ' A' ' 90' ' ' TYR . 4.5 m-85 -130.8 148.76 52.62 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.514 -0.741 . . . . 0.0 109.558 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.428 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 1.1 ttt180 -104.61 128.86 52.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.251 -0.906 . . . . 0.0 109.351 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.754 ' HB2' ' CG2' ' A' ' 70' ' ' ILE . . . -108.49 116.51 32.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.159 -0.963 . . . . 0.0 109.713 -179.778 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 4.4 m -145.59 21.3 1.49 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.348 -0.845 . . . . 0.0 109.37 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.79 -111.63 0.03 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 1.6 t -142.08 -40.39 0.36 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.236 -1.155 . . . . 0.0 109.803 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 3.1 m -142.6 131.23 22.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.21 -0.931 . . . . 0.0 109.615 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 15' ' ' GLU . 19.9 t -56.18 -19.99 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.308 -0.87 . . . . 0.0 109.307 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -60.37 -64.3 1.0 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.278 -0.889 . . . . 0.0 109.313 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.63 ' O ' HD12 ' A' ' 103' ' ' LEU . 4.6 mt-10 -67.21 -24.59 65.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.355 -0.84 . . . . 0.0 109.305 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.476 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 18.1 t-20 -68.19 -29.48 68.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.885 . . . . 0.0 109.427 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.449 HD11 HG11 ' A' ' 29' ' ' VAL . 33.2 tp -62.66 -68.67 0.31 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.182 -0.949 . . . . 0.0 109.164 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 10.0 tttp -59.24 -21.94 60.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.204 -0.935 . . . . 0.0 109.149 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.63 HD12 ' O ' ' A' ' 99' ' ' GLU . 1.5 mt -68.73 -34.92 76.43 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.394 -0.817 . . . . 0.0 109.448 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.536 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.5 t80 -53.94 -30.71 47.8 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.203 -0.936 . . . . 0.0 109.254 179.816 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 34.9 m -64.19 -39.62 94.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.42 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.494 ' OE1' HD23 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -82.99 -11.85 57.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.297 -0.877 . . . . 0.0 109.338 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.489 ' HA2' ' OE2' ' A' ' 110' ' ' GLU . . . 65.08 40.31 96.89 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -80.9 -12.87 59.33 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -1.153 . . . . 0.0 109.407 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.43 ' C ' ' HG2' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -152.6 111.37 3.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.261 -0.899 . . . . 0.0 109.259 179.867 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.489 ' OE2' ' HA2' ' A' ' 107' ' ' GLY . 5.9 mt-10 -140.97 -149.19 0.26 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.819 -179.662 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.496 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 0.5 OUTLIER -168.63 -114.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.34 -0.85 . . . . 0.0 109.315 -179.794 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.3 mt -87.81 149.56 4.03 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.092 -1.005 . . . . 0.0 109.427 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.479 ' HA ' ' HG2' ' A' ' 88' ' ' LYS . 0.1 OUTLIER -114.05 -93.73 0.48 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.218 -0.926 . . . . 0.0 109.692 -179.737 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.483 ' OG ' ' HD2' ' A' ' 115' ' ' PRO . 0.1 OUTLIER -125.6 166.0 23.51 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.197 -0.94 . . . . 0.0 109.689 -179.657 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.483 ' HD2' ' OG ' ' A' ' 114' ' ' SER . 36.1 Cg_endo -78.22 98.85 1.23 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.702 2.268 . . . . 0.0 110.448 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.55 -52.55 2.29 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 93.4 p -128.15 24.2 5.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.327 -1.102 . . . . 0.0 109.432 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -114.2 -177.15 19.14 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.5 ptp180 -59.15 -173.34 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.208 -1.172 . . . . 0.0 109.432 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 117.66 -97.53 0.73 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.82 156.95 4.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.248 -1.148 . . . . 0.0 109.403 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -95.69 -148.33 0.29 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.279 -0.888 . . . . 0.0 109.465 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 40.5 mtm180 -81.16 149.08 29.27 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.219 -0.926 . . . . 0.0 109.413 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 15.4 mtm180 . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.585 -179.967 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.4 mtp . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.441 ' HG2' ' CG ' ' A' ' 30' ' ' GLU . 0.5 OUTLIER -91.2 142.4 27.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.293 -0.88 . . . . 0.0 109.494 179.994 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.622 ' CG2' HD11 ' A' ' 70' ' ' ILE . 4.9 mt -118.67 116.08 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.296 -0.877 . . . . 0.0 109.779 -179.773 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.91 119.73 37.53 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.344 -0.847 . . . . 0.0 109.03 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.931 HG12 HD13 ' A' ' 70' ' ' ILE . 8.6 mt -100.68 140.73 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.801 -179.56 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.502 ' HB2' ' CE2' ' A' ' 26' ' ' PHE . . . -106.73 138.49 42.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.279 -0.888 . . . . 0.0 109.141 179.613 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.512 ' HB3' HG11 ' A' ' 97' ' ' VAL . 39.4 p -163.3 -148.73 0.13 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.215 -0.928 . . . . 0.0 109.524 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.548 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 20.3 t -122.35 -65.35 1.12 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.263 -0.898 . . . . 0.0 109.546 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -59.98 168.34 8.32 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 1.2 p -87.38 -42.27 12.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.209 -1.171 . . . . 0.0 109.512 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -173.81 -40.74 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.193 -0.942 . . . . 0.0 109.709 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.1 mt -84.19 -10.85 57.39 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.156 -0.965 . . . . 0.0 109.629 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -137.91 8.31 3.58 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.456 ' OG ' HG22 ' A' ' 97' ' ' VAL . 79.9 p -77.11 80.17 3.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.184 -1.186 . . . . 0.0 109.467 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.466 ' C ' HG23 ' A' ' 16' ' ' VAL . 2.6 pt-20 -76.85 1.68 16.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.255 -0.903 . . . . 0.0 109.702 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.685 HG22 HG13 ' A' ' 97' ' ' VAL . 3.5 t 71.38 73.29 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.13 -0.981 . . . . 0.0 109.655 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.22 -164.46 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.46 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -118.98 26.74 9.31 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.214 -0.929 . . . . 0.0 109.617 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -117.23 115.31 25.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.914 . . . . 0.0 109.604 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.589 ' CG ' ' O ' ' A' ' 20' ' ' PHE . 45.6 t80 -112.44 38.4 2.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.309 -0.869 . . . . 0.0 109.159 179.731 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -99.27 -84.37 1.79 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.449 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.0 OUTLIER -90.21 67.46 6.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -1.144 . . . . 0.0 109.485 -179.946 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -47.1 105.45 0.49 Allowed Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.356 -0.84 . . . . 0.0 109.567 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.549 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.0 Cg_endo -78.73 -3.37 13.22 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.461 2.107 . . . . 0.0 110.365 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.549 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 71.4 m-85 -160.52 72.67 0.48 Allowed 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.177 -0.952 . . . . 0.0 109.235 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.502 ' CE2' ' HB2' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -79.02 114.8 18.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.471 -179.768 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 27' ' ' MET . . . . . 0.424 ' HG3' HG22 ' A' ' 41' ' ' VAL . 0.1 OUTLIER -87.57 114.15 23.91 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.339 -0.851 . . . . 0.0 109.39 -179.974 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.469 ' O ' HG23 ' A' ' 28' ' ' ILE . 0.5 OUTLIER -102.61 126.73 56.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.261 -0.899 . . . . 0.0 109.594 -179.934 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 69.4 t -124.01 138.44 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.289 -0.882 . . . . 0.0 109.293 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.441 ' CG ' ' HG2' ' A' ' 2' ' ' LYS . 0.5 OUTLIER -124.28 116.8 23.24 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.209 -0.932 . . . . 0.0 109.544 179.938 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.468 ' SD ' ' CD1' ' A' ' 3' ' ' ILE . 4.4 ptp -114.68 141.92 47.17 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 2.7 tttp -84.48 -80.83 0.19 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.285 -0.884 . . . . 0.0 109.455 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 12.4 tppt? -117.12 87.45 2.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.225 -0.922 . . . . 0.0 109.391 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 51.66 26.52 16.82 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -140.8 97.62 3.23 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -1.168 . . . . 0.0 109.559 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.472 HD11 ' OG ' ' A' ' 39' ' ' SER . 6.6 tt -49.67 137.12 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.196 -0.94 . . . . 0.0 109.55 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.504 ' C ' ' HG ' ' A' ' 38' ' ' SER . 0.0 OUTLIER -135.54 18.79 3.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.526 179.939 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.504 ' HG ' ' C ' ' A' ' 37' ' ' GLU . 0.0 OUTLIER -178.05 128.79 0.13 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.17 -0.956 . . . . 0.0 109.6 -179.958 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.472 ' OG ' HD11 ' A' ' 36' ' ' ILE . 0.4 OUTLIER -143.39 111.46 6.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.291 -0.881 . . . . 0.0 109.151 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -131.01 162.93 28.69 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.242 -0.911 . . . . 0.0 109.799 -179.617 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.424 HG22 ' HG3' ' A' ' 27' ' ' MET . 21.8 t -120.45 148.61 23.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.371 -0.831 . . . . 0.0 109.184 179.789 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.409 ' O ' ' HA ' ' A' ' 25' ' ' TYR . 7.1 mt -123.07 129.92 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -108.88 100.12 9.37 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.307 -0.87 . . . . 0.0 109.211 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -47.28 144.3 4.47 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.273 -0.892 . . . . 0.0 109.617 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.2 -45.0 0.12 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.681 2.254 . . . . 0.0 110.596 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.13 29.61 1.6 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.215 -0.928 . . . . 0.0 109.609 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -73.93 -13.26 60.87 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.245 -0.909 . . . . 0.0 109.348 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.8 m -104.3 8.08 35.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.372 -0.83 . . . . 0.0 109.497 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -104.03 -176.53 3.11 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.187 -0.945 . . . . 0.0 109.493 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.6 t -54.59 143.86 23.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.222 -0.924 . . . . 0.0 109.528 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -104.62 87.65 0.56 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -80.54 -116.72 0.34 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -77.74 102.76 7.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -1.136 . . . . 0.0 109.47 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.77 -16.24 31.7 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.758 HD12 ' HB2' ' A' ' 78' ' ' ALA . 47.5 mm -66.15 -14.65 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -1.189 . . . . 0.0 109.525 -179.892 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.78 -22.87 60.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.256 -0.902 . . . . 0.0 109.433 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.462 ' O ' HG13 ' A' ' 61' ' ' ILE . 21.8 m -55.7 -25.32 39.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 109.533 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.31 -55.65 32.07 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.233 -0.917 . . . . 0.0 109.641 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.69 -37.93 52.81 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 72.9 mt -64.28 -38.01 81.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.29 -0.882 . . . . 0.0 109.655 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.48 ' CG2' HG21 ' A' ' 66' ' ' VAL . 36.7 mt -72.95 -21.96 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.22 -0.925 . . . . 0.0 109.652 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.418 ' HB1' HD22 ' A' ' 85' ' ' LEU . . . -71.46 -28.66 64.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.165 -0.959 . . . . 0.0 109.487 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 -74.78 -2.72 27.83 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.347 -0.845 . . . . 0.0 109.687 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -98.61 -18.25 18.21 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.094 -1.004 . . . . 0.0 109.603 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.521 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 102.8 -9.51 55.33 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.48 HG21 ' CG2' ' A' ' 61' ' ' ILE . 94.0 t -42.61 94.99 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.327 -1.102 . . . . 0.0 109.702 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.521 ' N ' ' O ' ' A' ' 65' ' ' GLY . 24.0 mmtt -79.3 -3.81 47.83 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.379 -0.826 . . . . 0.0 108.863 179.398 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.487 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -139.67 132.29 28.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.274 -0.891 . . . . 0.0 109.449 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 89.8 t -128.66 122.19 56.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.182 -0.949 . . . . 0.0 109.752 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.931 HD13 HG12 ' A' ' 5' ' ' ILE . 2.1 mp -99.28 116.61 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.226 -0.921 . . . . 0.0 109.245 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -152.46 175.01 13.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.258 -0.901 . . . . 0.0 109.567 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.504 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 3.7 m -137.14 39.66 2.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.428 -0.795 . . . . 0.0 109.288 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.422 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 7.4 m -50.1 134.64 22.64 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.242 -0.911 . . . . 0.0 109.41 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.2 Cg_endo -79.66 -20.72 9.08 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.458 2.106 . . . . 0.0 110.456 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.4 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -104.69 149.43 16.91 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.792 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.4 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.6 Cg_endo -78.39 -0.33 10.61 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.717 2.278 . . . . 0.0 110.287 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -67.56 -49.88 61.1 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.261 -0.899 . . . . 0.0 109.487 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.758 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -61.28 -53.4 57.21 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.329 -0.857 . . . . 0.0 109.458 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -56.39 -20.3 18.82 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.341 -0.85 . . . . 0.0 109.522 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.428 ' O ' ' HG3' ' A' ' 84' ' ' GLU . 1.2 tp10 -75.27 -45.88 37.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.228 -0.92 . . . . 0.0 109.557 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.448 ' HA ' ' HB2' ' A' ' 84' ' ' GLU . 6.3 t -67.58 -41.71 86.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 0.0 109.587 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.502 ' HA ' HD13 ' A' ' 82' ' ' LEU . 4.2 mm? -51.75 -56.93 10.93 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.127 -0.983 . . . . 0.0 109.48 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -65.15 -22.14 66.88 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.881 . . . . 0.0 109.444 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.448 ' HB2' ' HA ' ' A' ' 81' ' ' VAL . 5.1 mt-10 -74.17 -25.75 59.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.265 -0.897 . . . . 0.0 109.403 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.418 HD22 ' HB1' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -88.13 -30.85 19.52 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.224 -0.922 . . . . 0.0 109.488 -179.991 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 104.63 42.58 1.82 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.7 mt -122.66 155.98 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.275 -1.133 . . . . 0.0 109.375 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.522 ' HD2' ' N ' ' A' ' 88' ' ' LYS . 0.0 OUTLIER -81.66 138.22 35.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.167 -0.958 . . . . 0.0 109.521 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 3.0 mt -106.98 155.42 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.208 -0.932 . . . . 0.0 109.539 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.567 ' CZ ' ' CD2' ' A' ' 104' ' ' PHE . 1.0 OUTLIER -133.9 138.84 45.79 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.286 -0.884 . . . . 0.0 109.531 179.97 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.515 ' NE ' ' HA ' ' A' ' 110' ' ' GLU . 1.3 ptt-85 -97.76 113.4 25.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.289 -0.882 . . . . 0.0 109.291 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.504 ' HB3' ' OG ' ' A' ' 72' ' ' SER . . . -79.76 125.0 29.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.259 -0.9 . . . . 0.0 109.565 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 76.0 p -67.57 -42.12 83.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.259 -0.901 . . . . 0.0 109.433 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 119.73 97.74 1.71 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -168.87 -69.87 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.2 -1.177 . . . . 0.0 109.474 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -166.64 120.07 1.04 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.194 -0.941 . . . . 0.0 109.493 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.685 HG13 HG22 ' A' ' 16' ' ' VAL . 35.8 m -55.33 -21.47 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 109.589 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -61.48 -51.23 69.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.156 -0.965 . . . . 0.0 109.585 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.439 ' O ' HD12 ' A' ' 103' ' ' LEU . 4.9 mt-10 -77.19 -32.93 56.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.922 . . . . 0.0 109.768 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -60.21 -30.64 69.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.571 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 36.1 tp -68.25 -57.65 5.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.171 -0.955 . . . . 0.0 109.547 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 106' ' ' GLU . 0.0 OUTLIER -62.04 -20.54 64.06 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.224 -0.923 . . . . 0.0 109.518 -179.923 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.77 HD23 ' CB ' ' A' ' 108' ' ' ASN . 0.1 OUTLIER -76.96 -41.29 43.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.131 -0.981 . . . . 0.0 109.701 -179.876 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.567 ' CD2' ' CZ ' ' A' ' 90' ' ' TYR . 4.3 t80 -57.7 -53.8 54.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.197 -0.939 . . . . 0.0 109.312 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 9.7 m -67.87 -19.54 65.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.252 -0.905 . . . . 0.0 109.475 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.427 ' CG ' ' O ' ' A' ' 102' ' ' LYS . 4.4 mm-40 -83.44 9.27 11.52 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.337 -0.852 . . . . 0.0 109.302 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 51.66 45.13 54.78 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ASN . . . . . 0.77 ' CB ' HD23 ' A' ' 103' ' ' LEU . 1.9 m120 -79.84 -66.32 0.89 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.306 -1.114 . . . . 0.0 109.498 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.58 HD12 ' HG3' ' A' ' 110' ' ' GLU . 0.7 OUTLIER 173.81 -159.83 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.301 -0.875 . . . . 0.0 109.372 -179.906 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.58 ' HG3' HD12 ' A' ' 109' ' ' LEU . 30.8 mt-10 73.29 30.03 1.6 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.282 -0.886 . . . . 0.0 109.482 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -104.44 147.12 27.92 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -0.913 . . . . 0.0 109.536 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 7.8 mt -142.15 125.21 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.153 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.48 ' HG2' ' HE2' ' A' ' 88' ' ' LYS . 21.6 mtt180 -111.12 -58.02 2.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.347 -0.846 . . . . 0.0 109.846 -179.613 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.424 ' HA ' ' HD3' ' A' ' 115' ' ' PRO . 0.7 OUTLIER -153.92 145.57 16.74 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.07 -1.019 . . . . 0.0 109.782 -179.682 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 114' ' ' SER . 36.5 Cg_endo -78.88 107.28 2.22 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.668 2.245 . . . . 0.0 110.403 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.415 ' O ' ' CB ' ' A' ' 117' ' ' SER . . . 150.11 -124.81 1.83 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.415 ' CB ' ' O ' ' A' ' 116' ' ' GLY . 0.6 OUTLIER 170.13 122.77 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.239 -1.153 . . . . 0.0 109.569 179.994 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -126.92 -152.86 8.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 4.9 mtt85 -141.89 169.36 17.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.266 -1.138 . . . . 0.0 109.499 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -177.14 -112.75 0.33 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.25 98.03 3.14 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -1.133 . . . . 0.0 109.509 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.48 52.86 2.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.292 -0.88 . . . . 0.0 109.436 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 55.64 56.82 5.81 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.276 -0.89 . . . . 0.0 109.351 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.404 ' HD2' ' OXT' ' A' ' 124' ' ' ARG . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.428 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 121.254 0.55 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.47 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 12.9 mttt -112.65 144.09 42.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.213 -0.93 . . . . 0.0 109.268 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.555 HG23 ' CD1' ' A' ' 70' ' ' ILE . 3.7 mt -121.96 106.78 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.184 -0.948 . . . . 0.0 110.339 -179.404 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.653 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -106.02 111.54 24.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.302 -0.873 . . . . 0.0 108.706 179.064 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.924 HG23 ' HB ' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -100.48 131.86 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.861 -179.379 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -63.56 139.16 58.74 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.303 -0.873 . . . . 0.0 109.113 179.549 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.446 ' HB3' ' O ' ' A' ' 25' ' ' TYR . 17.4 t -126.84 172.99 9.92 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.086 -1.009 . . . . 0.0 109.772 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -122.44 -32.61 3.59 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.408 -0.808 . . . . 0.0 109.266 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.637 ' O ' HG23 ' A' ' 10' ' ' THR . . . -113.98 -82.44 1.1 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.637 HG23 ' O ' ' A' ' 9' ' ' GLY . 0.1 OUTLIER -169.67 -62.14 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.288 -1.125 . . . . 0.0 109.589 179.962 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -145.33 -55.17 0.31 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.888 . . . . 0.0 109.572 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.1 mt -75.93 -38.77 57.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.227 -0.921 . . . . 0.0 109.645 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.42 17.12 57.24 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.412 ' O ' ' HA ' ' A' ' 96' ' ' SER . 89.7 p -77.19 78.42 3.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -1.148 . . . . 0.0 109.757 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.595 ' C ' HG23 ' A' ' 16' ' ' VAL . 44.2 tt0 -77.25 -0.29 24.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.253 -0.904 . . . . 0.0 109.408 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.677 HG22 HG13 ' A' ' 97' ' ' VAL . 2.5 t 73.73 74.55 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.26 -0.9 . . . . 0.0 109.64 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -46.65 151.7 0.55 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.168 -0.957 . . . . 0.0 109.289 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.411 ' HG2' ' CD1' ' A' ' 19' ' ' PHE . 3.2 ptm180 -104.92 31.74 4.61 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.927 . . . . 0.0 109.625 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.411 ' CD1' ' HG2' ' A' ' 18' ' ' ARG . 45.7 m-85 -119.2 115.58 24.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.518 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.443 ' HE2' ' HB2' ' A' ' 58' ' ' ALA . 25.9 t80 -91.34 78.02 5.79 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.23 -0.918 . . . . 0.0 109.352 179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.61 -20.98 0.71 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.665 ' O ' ' HB1' ' A' ' 47' ' ' ALA . 3.4 ttm-85 -111.17 -40.31 4.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.368 -1.077 . . . . 0.0 109.28 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.442 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -41.78 101.98 0.26 Allowed Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.533 -0.729 . . . . 0.0 109.643 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.01 41.04 1.05 Allowed 'Trans proline' 0 C--N 1.312 -1.395 0 C-N-CA 122.579 2.186 . . . . 0.0 110.89 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.539 ' CE2' ' O ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -160.39 71.07 0.43 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.98 -1.075 . . . . 0.0 109.448 179.952 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.551 ' CE2' HD12 ' A' ' 61' ' ' ILE . 0.1 OUTLIER -79.5 117.08 20.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.287 -0.883 . . . . 0.0 109.549 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 3.2 ttt -95.62 104.26 16.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.928 . . . . 0.0 109.297 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.498 HG23 ' HB2' ' A' ' 4' ' ' ALA . 27.2 mt -100.83 126.13 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.266 -0.896 . . . . 0.0 109.709 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.553 ' CG1' HG23 ' A' ' 36' ' ' ILE . 90.5 t -123.95 117.82 52.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.298 -0.876 . . . . 0.0 109.349 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.403 ' HG2' ' HD3' ' A' ' 2' ' ' LYS . 13.0 mt-10 -83.92 115.97 22.56 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.221 -0.925 . . . . 0.0 109.622 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.459 ' HG2' ' HA ' ' A' ' 36' ' ' ILE . 0.3 OUTLIER -96.88 138.76 33.94 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.268 -0.895 . . . . 0.0 109.514 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 1.2 tptp -96.76 -62.45 1.26 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.889 . . . . 0.0 109.326 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LYS . . . . . 0.401 ' O ' ' C ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -139.88 89.45 2.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.161 179.725 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 45.66 30.41 3.34 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -150.52 114.42 5.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -1.126 . . . . 0.0 109.555 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.553 HG23 ' CG1' ' A' ' 29' ' ' VAL . 2.1 mp -54.14 132.4 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.164 -0.96 . . . . 0.0 109.41 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -133.28 12.82 4.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.255 -0.903 . . . . 0.0 109.375 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.502 ' O ' HG13 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -174.28 116.87 0.21 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 109.502 -179.981 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.533 ' HA ' HG22 ' A' ' 29' ' ' VAL . 4.5 p -129.73 104.23 7.29 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.536 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -122.91 139.59 53.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.392 -0.818 . . . . 0.0 109.375 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 73.9 t -114.11 119.31 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.531 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.4 mt -118.28 143.03 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.364 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 44' ' ' ASN . 29.6 mp0 -86.1 118.91 25.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.15 -0.969 . . . . 0.0 109.391 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.414 ' C ' ' O ' ' A' ' 43' ' ' GLU . 0.3 OUTLIER -44.48 141.77 2.62 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.244 -0.91 . . . . 0.0 109.365 -179.912 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -79.23 -25.4 5.86 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 122.569 2.18 . . . . 0.0 110.413 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.4 m -119.81 42.29 2.95 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.204 -0.935 . . . . 0.0 109.661 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.665 ' HB1' ' O ' ' A' ' 22' ' ' ARG . . . -58.29 -72.51 0.09 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 109.363 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -106.28 66.94 0.72 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.318 -0.864 . . . . 0.0 109.35 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -115.76 143.46 45.35 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.328 -0.857 . . . . 0.0 109.51 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 79.3 p -63.84 -179.04 0.36 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.124 -0.985 . . . . 0.0 109.412 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 106.14 -30.86 9.0 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 177.66 -168.7 40.39 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -75.72 -15.05 60.34 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.262 -1.14 . . . . 0.0 109.503 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.447 ' O ' HG22 ' A' ' 57' ' ' THR . . . 110.47 19.02 8.14 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.417 HD12 ' HB2' ' A' ' 78' ' ' ALA . 23.3 mm -76.58 -14.95 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.27 -1.135 . . . . 0.0 109.573 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -58.46 -17.63 22.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.227 -0.921 . . . . 0.0 109.662 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.447 HG22 ' O ' ' A' ' 54' ' ' GLY . 6.0 t -63.38 -37.74 88.43 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.171 -0.956 . . . . 0.0 109.812 -179.81 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.443 ' HB2' ' HE2' ' A' ' 20' ' ' PHE . . . -45.42 -34.51 3.15 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.176 -0.953 . . . . 0.0 109.817 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -61.29 -64.59 0.9 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.237 -0.914 . . . . 0.0 109.847 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.439 HG22 ' O ' ' A' ' 57' ' ' THR . 0.9 OUTLIER -58.8 -18.41 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.245 -0.91 . . . . 0.0 109.926 -179.593 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.551 HD12 ' CE2' ' A' ' 26' ' ' PHE . 19.3 mm -75.56 -36.38 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.688 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.71 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -73.38 -28.37 61.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.225 -0.922 . . . . 0.0 109.757 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -77.25 -9.81 59.03 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.087 -1.008 . . . . 0.0 109.906 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.481 ' HB2' HG23 ' A' ' 66' ' ' VAL . 57.9 m-20 -88.13 7.65 30.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.108 -0.995 . . . . 0.0 109.629 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 69.24 10.67 62.92 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.653 HG11 ' HB3' ' A' ' 4' ' ' ALA . 2.0 t -67.65 89.54 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.198 -1.178 . . . . 0.0 109.415 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.452 ' HG2' ' HE3' ' A' ' 88' ' ' LYS . 0.5 OUTLIER -79.6 -7.4 58.51 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.348 -0.845 . . . . 0.0 108.92 179.648 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.575 ' HB1' ' CE2' ' A' ' 104' ' ' PHE . . . -137.53 103.64 5.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.19 -0.944 . . . . 0.0 109.273 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.484 HG22 HG11 ' A' ' 66' ' ' VAL . 56.9 t -112.01 132.1 61.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.054 -1.029 . . . . 0.0 109.817 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.924 ' HB ' HG23 ' A' ' 5' ' ' ILE . 3.2 mp -104.61 112.76 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.352 -0.843 . . . . 0.0 109.199 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -149.61 -178.04 6.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.22 -0.925 . . . . 0.0 109.979 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -146.12 46.89 1.24 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.642 -0.661 . . . . 0.0 109.524 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.551 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 2.6 p -45.49 151.94 0.72 Allowed Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.224 -0.922 . . . . 0.0 109.624 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.84 -25.99 7.18 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.719 2.279 . . . . 0.0 110.615 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -121.73 152.22 16.86 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.17 -16.57 13.88 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.602 2.202 . . . . 0.0 110.483 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -46.94 -47.06 21.81 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.922 . . . . 0.0 109.619 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.636 ' O ' HD13 ' A' ' 82' ' ' LEU . . . -67.51 -34.98 78.22 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.256 -0.903 . . . . 0.0 109.628 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.551 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 8.7 m-30 -71.59 -17.16 62.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.632 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.435 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 4.3 mm-40 -73.24 -42.92 61.99 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.124 -0.985 . . . . 0.0 108.967 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.417 ' H ' HG23 ' A' ' 81' ' ' VAL . 2.3 t -76.63 -30.05 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.435 -0.79 . . . . 0.0 109.254 179.725 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.636 HD13 ' O ' ' A' ' 78' ' ' ALA . 4.8 mp -61.54 -56.29 21.59 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.354 -0.841 . . . . 0.0 109.575 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.435 ' OD1' ' O ' ' A' ' 80' ' ' GLU . 9.6 p-10 -69.64 -14.12 62.66 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.293 -0.879 . . . . 0.0 109.578 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -76.98 -36.34 56.52 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.284 -0.885 . . . . 0.0 109.606 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.429 ' HA ' HD23 ' A' ' 85' ' ' LEU . 73.8 mt -86.0 12.38 9.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.189 -0.945 . . . . 0.0 109.669 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 80.99 8.71 87.14 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.71 HD11 ' HB2' ' A' ' 62' ' ' ALA . 18.3 mt -81.19 144.72 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.191 -1.182 . . . . 0.0 109.604 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.452 ' HE3' ' HG2' ' A' ' 67' ' ' LYS . 20.1 mttt -92.55 128.67 38.49 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.209 -0.932 . . . . 0.0 109.226 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.488 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.5 mt -99.22 128.66 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.178 -0.951 . . . . 0.0 109.582 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.59 ' CE1' ' HB2' ' A' ' 110' ' ' GLU . 2.0 m-30 -117.95 152.21 35.9 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.462 -0.774 . . . . 0.0 109.12 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.545 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 7.5 tpt180 -98.66 120.23 38.72 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.153 -0.967 . . . . 0.0 109.71 -179.714 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.726 ' HB2' HG22 ' A' ' 70' ' ' ILE . . . -86.01 132.24 34.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -0.904 . . . . 0.0 109.495 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 3.7 m -71.9 -38.16 69.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.232 -0.918 . . . . 0.0 109.41 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 114.09 14.35 9.27 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -79.7 -68.74 0.64 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.246 -1.149 . . . . 0.0 109.244 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 14' ' ' SER . 0.2 OUTLIER -171.16 132.72 0.83 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.204 -0.935 . . . . 0.0 109.341 179.927 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.677 HG13 HG22 ' A' ' 16' ' ' VAL . 23.8 m -56.56 -23.61 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.917 . . . . 0.0 109.527 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -68.81 -38.83 80.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.256 -0.902 . . . . 0.0 109.449 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -77.27 -42.24 37.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.232 -0.917 . . . . 0.0 109.68 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -64.89 -27.75 69.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.692 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.458 HD22 HD11 ' A' ' 36' ' ' ILE . 0.6 OUTLIER -59.63 -61.56 2.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.185 -0.947 . . . . 0.0 109.634 -179.913 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.53 -28.54 69.71 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.426 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.497 HD23 ' HB2' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -66.92 -29.04 68.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.664 -179.934 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.575 ' CE2' ' HB1' ' A' ' 68' ' ' ALA . 9.3 t80 -75.5 -26.48 58.16 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.186 -0.946 . . . . 0.0 109.631 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 14.6 m -63.1 -20.59 65.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.231 -0.918 . . . . 0.0 109.728 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -103.88 -30.46 10.33 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.179 -0.951 . . . . 0.0 109.455 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.92 42.0 6.14 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 32.9 m-20 -95.61 -20.09 19.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -1.162 . . . . 0.0 109.318 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.497 ' HB2' HD23 ' A' ' 103' ' ' LEU . 0.2 OUTLIER -127.87 143.29 51.11 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.402 -0.811 . . . . 0.0 109.044 179.807 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.59 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 4.7 pt-20 -172.38 -157.28 0.1 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.149 -0.969 . . . . 0.0 109.888 -179.718 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.545 ' HB2' ' N ' ' A' ' 91' ' ' ARG . 3.0 tt0 -158.66 -104.21 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.368 -0.833 . . . . 0.0 109.365 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.472 ' HB ' ' HB ' ' A' ' 89' ' ' ILE . 46.8 mm -93.17 111.32 24.5 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 O-C-N 121.27 -0.894 . . . . 0.0 109.586 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.509 ' HG3' ' N ' ' A' ' 114' ' ' SER . 0.1 OUTLIER -129.49 -34.24 1.82 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.326 -0.858 . . . . 0.0 109.44 179.942 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.509 ' N ' ' HG3' ' A' ' 113' ' ' ARG . 0.9 OUTLIER 169.39 148.16 0.11 Allowed Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.227 -0.921 . . . . 0.0 109.474 179.917 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.57 -53.6 0.06 OUTLIER 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 122.729 2.286 . . . . 0.0 110.427 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 152.2 -46.5 0.58 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.52 154.9 40.97 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.289 -1.124 . . . . 0.0 109.522 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -106.44 -90.62 2.17 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.62 -45.43 2.7 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.244 -1.15 . . . . 0.0 109.39 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 129.06 97.76 0.86 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.85 32.15 5.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.312 -1.111 . . . . 0.0 109.437 -179.92 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER 58.18 56.13 4.72 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.237 -0.914 . . . . 0.0 109.302 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 51.98 -173.59 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.323 -0.861 . . . . 0.0 109.391 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.416 ' NE ' ' HA ' ' A' ' 124' ' ' ARG . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 118.098 -0.953 . . . . 0.0 109.466 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.653 ' O ' ' HB3' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -90.65 121.48 32.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.245 -0.909 . . . . 0.0 109.345 179.881 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.583 HG12 ' CD2' ' A' ' 104' ' ' PHE . 4.1 mt -100.26 111.7 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.291 -0.881 . . . . 0.0 109.853 -179.781 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.593 ' HB1' ' CE2' ' A' ' 26' ' ' PHE . . . -104.12 112.69 25.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -0.921 . . . . 0.0 109.397 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.874 HG21 HG13 ' A' ' 97' ' ' VAL . 14.4 mm -87.78 117.62 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.226 -0.921 . . . . 0.0 109.525 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.448 ' O ' ' HB3' ' A' ' 7' ' ' SER . . . -62.64 153.78 31.23 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.289 -0.882 . . . . 0.0 109.608 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' TYR . 2.4 t 61.62 -88.96 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.522 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.838 ' HA ' HG21 ' A' ' 97' ' ' VAL . 0.2 OUTLIER 57.95 22.62 8.96 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.193 -0.942 . . . . 0.0 109.457 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 48.94 -102.12 0.05 OUTLIER Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -155.85 -47.05 0.08 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -1.173 . . . . 0.0 109.46 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.706 ' HB3' HD12 ' A' ' 12' ' ' LEU . 1.7 t70 -155.59 -62.05 0.11 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.448 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.706 HD12 ' HB3' ' A' ' 11' ' ' ASP . 5.9 mp -108.17 -15.81 14.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.204 -0.935 . . . . 0.0 109.529 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -94.19 27.49 13.19 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.6 p -78.28 74.34 4.82 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.391 -1.064 . . . . 0.0 109.695 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.583 ' C ' HG23 ' A' ' 16' ' ' VAL . 32.4 tt0 -78.33 5.55 10.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.023 -1.048 . . . . 0.0 109.815 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.633 HG22 ' N ' ' A' ' 97' ' ' VAL . 2.1 t 68.37 54.15 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.168 -0.957 . . . . 0.0 109.116 -179.559 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 16' ' ' VAL . 1.0 OUTLIER -42.74 159.47 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.411 -0.806 . . . . 0.0 109.688 -179.844 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -111.32 39.08 2.39 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.265 -0.897 . . . . 0.0 109.428 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -129.22 103.49 6.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.255 -0.903 . . . . 0.0 109.508 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.5 t80 -102.41 142.01 34.31 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.516 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 114.25 -46.73 1.13 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.792 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.445 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 7.9 ttp180 -103.12 -37.36 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.371 -1.076 . . . . 0.0 109.141 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.436 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -41.47 102.0 0.26 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.569 -0.707 . . . . 0.0 109.821 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.493 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 36.7 Cg_endo -81.21 54.73 5.33 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.652 2.235 . . . . 0.0 110.478 179.688 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.458 ' O ' ' O ' ' A' ' 7' ' ' SER . 68.5 m-85 -154.15 68.5 0.75 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.108 -0.995 . . . . 0.0 109.204 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.593 ' CE2' ' HB1' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -79.39 111.13 15.34 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.256 -0.903 . . . . 0.0 109.337 -179.907 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 27' ' ' MET . . . . . 0.469 ' HB2' ' CB ' ' A' ' 8' ' ' SER . 7.2 ttm -88.76 102.09 14.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.3 -0.875 . . . . 0.0 109.559 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.612 ' O ' HG23 ' A' ' 28' ' ' ILE . 6.1 tp -83.61 114.67 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.363 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.662 HG22 ' HB3' ' A' ' 39' ' ' SER . 47.7 t -126.11 128.71 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.155 -0.966 . . . . 0.0 109.653 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -111.21 113.86 26.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.283 -0.886 . . . . 0.0 109.368 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.439 ' SD ' ' CA ' ' A' ' 34' ' ' GLY . 0.7 OUTLIER -112.53 132.65 54.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -0.92 . . . . 0.0 109.6 -179.851 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 7.2 mmmt -87.67 -55.81 3.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.268 -0.895 . . . . 0.0 109.33 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.15 68.24 0.93 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.336 -0.853 . . . . 0.0 109.209 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.439 ' CA ' ' SD ' ' A' ' 31' ' ' MET . . . 75.92 8.6 84.9 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -130.52 98.35 4.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.176 -1.19 . . . . 0.0 109.493 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.467 HD11 HD23 ' A' ' 101' ' ' LEU . 2.9 mt -57.43 127.49 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.251 -0.906 . . . . 0.0 109.658 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.443 ' O ' ' HB3' ' A' ' 38' ' ' SER . 0.5 OUTLIER -101.66 -2.3 30.65 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.401 179.68 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.443 ' HB3' ' O ' ' A' ' 37' ' ' GLU . 77.3 p 176.8 125.55 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.201 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.662 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.2 OUTLIER -136.85 106.97 6.33 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.208 -0.932 . . . . 0.0 109.644 -179.759 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 163.62 14.41 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.658 ' O ' HG13 ' A' ' 41' ' ' VAL . 7.6 p -134.6 118.66 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.331 -0.855 . . . . 0.0 109.447 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.403 ' O ' HG13 ' A' ' 42' ' ' ILE . 21.5 pt -126.88 133.63 68.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.218 -0.926 . . . . 0.0 109.569 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.493 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 1.3 mt-10 -74.46 146.61 42.67 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.369 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.404 ' H ' ' HA ' ' A' ' 24' ' ' PRO . 12.2 m-20 -46.19 153.43 0.7 Allowed Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.242 -0.911 . . . . 0.0 109.318 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.4 -47.79 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.639 2.226 . . . . 0.0 110.523 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.2 p -119.14 54.58 0.97 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.898 . . . . 0.0 109.56 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -58.56 -44.48 89.71 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.169 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -159.94 96.35 1.22 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.367 -0.833 . . . . 0.0 109.331 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -174.19 -60.83 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.255 -0.903 . . . . 0.0 109.488 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 26.0 t -71.18 -14.52 62.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.301 -0.874 . . . . 0.0 109.48 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.45 88.19 1.86 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -151.72 157.65 27.34 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -76.37 -20.07 57.54 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.191 -1.182 . . . . 0.0 109.52 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.437 ' O ' HG22 ' A' ' 57' ' ' THR . . . 113.53 -37.1 3.73 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.601 HD12 ' HB2' ' A' ' 78' ' ' ALA . 47.2 mm -66.49 -14.15 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.279 -1.13 . . . . 0.0 109.484 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -8.9 38.79 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.29 -0.881 . . . . 0.0 109.496 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 54' ' ' GLY . 14.8 t -76.93 -16.04 59.49 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.191 -0.943 . . . . 0.0 109.529 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.419 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -57.28 -32.35 66.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 109.536 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 21.8 tt0 -65.11 -52.98 52.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.443 HD13 ' HA ' ' A' ' 60' ' ' ILE . 35.9 mm -62.72 -25.6 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.228 -0.92 . . . . 0.0 109.326 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.485 HD13 ' CZ ' ' A' ' 26' ' ' PHE . 45.5 mt -69.71 -39.28 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 109.276 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.797 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -74.6 -25.44 59.26 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.248 -0.908 . . . . 0.0 109.429 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -77.09 -5.15 47.83 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.237 -0.914 . . . . 0.0 109.51 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.49 ' HB2' HG23 ' A' ' 66' ' ' VAL . 6.8 m-20 -100.26 1.86 42.18 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.134 -0.979 . . . . 0.0 109.527 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.499 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 90.89 -5.94 81.95 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.49 HG23 ' HB2' ' A' ' 64' ' ' ASN . 48.3 t -53.5 88.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -1.176 . . . . 0.0 109.858 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.499 ' N ' ' O ' ' A' ' 65' ' ' GLY . 6.4 tttp -79.75 -12.46 59.79 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.119 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.653 ' HB3' ' O ' ' A' ' 2' ' ' LYS . . . -127.62 131.99 49.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.436 -0.79 . . . . 0.0 109.108 179.685 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.582 HG21 HD21 ' A' ' 82' ' ' LEU . 2.4 t -129.64 105.49 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.123 -0.985 . . . . 0.0 109.806 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.622 HD12 ' CD1' ' A' ' 5' ' ' ILE . 23.3 mt -91.41 119.96 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.277 -0.89 . . . . 0.0 109.01 179.595 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -149.12 177.08 9.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.152 -0.967 . . . . 0.0 109.938 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.04 35.38 3.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.535 -0.728 . . . . 0.0 109.14 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.451 ' HB2' ' CE1' ' A' ' 79' ' ' PHE . 0.1 OUTLIER -44.87 134.23 4.99 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.286 -0.884 . . . . 0.0 109.465 -179.807 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.75 -19.78 10.96 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.436 2.091 . . . . 0.0 110.351 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -114.15 148.31 18.77 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.83 9.16 3.38 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.631 2.221 . . . . 0.0 110.706 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -74.44 -42.62 58.81 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.095 -1.003 . . . . 0.0 109.722 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.601 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -68.69 -50.78 48.22 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.588 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.451 ' CE1' ' HB2' ' A' ' 73' ' ' SER . 11.3 m-30 -48.81 -38.43 22.12 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.264 -0.898 . . . . 0.0 109.652 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.484 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 0.6 OUTLIER -65.75 -47.4 75.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.188 -0.945 . . . . 0.0 109.71 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 86.7 t -52.89 -50.85 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.182 -0.949 . . . . 0.0 109.466 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.582 HD21 HG21 ' A' ' 69' ' ' VAL . 1.9 mt -56.47 -31.15 63.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.484 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 3.2 m-20 -61.96 -51.26 68.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.163 -0.961 . . . . 0.0 109.301 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -62.81 -27.67 69.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.21 179.814 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.1 mt -72.03 -34.21 68.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.174 -0.954 . . . . 0.0 109.527 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.1 19.98 19.72 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.797 HD11 ' HB2' ' A' ' 62' ' ' ALA . 27.7 mt -103.83 163.03 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.289 -1.124 . . . . 0.0 109.617 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.437 ' N ' HG22 ' A' ' 87' ' ' ILE . 3.4 mptt -91.74 147.07 23.26 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.253 -0.904 . . . . 0.0 109.263 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.51 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.3 mt -120.76 131.76 72.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.112 -0.992 . . . . 0.0 109.211 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.581 ' CE2' ' HB1' ' A' ' 68' ' ' ALA . 12.8 m-85 -119.47 161.26 20.85 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.476 -0.765 . . . . 0.0 109.547 -179.807 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.488 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 0.1 OUTLIER -99.25 136.78 38.7 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.264 -0.897 . . . . 0.0 109.627 -179.909 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.64 129.33 34.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.259 -0.901 . . . . 0.0 109.443 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.35 -40.33 96.05 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.26 -0.9 . . . . 0.0 109.476 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 102.94 22.07 9.66 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.73 -83.75 0.54 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.128 -1.219 . . . . 0.0 109.4 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.539 ' HA ' HG23 ' A' ' 16' ' ' VAL . 3.3 m -146.71 137.65 24.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.324 -0.86 . . . . 0.0 109.315 179.814 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.874 HG13 HG21 ' A' ' 5' ' ' ILE . 86.8 t -64.2 -31.18 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -0.882 . . . . 0.0 109.609 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.58 -44.36 80.95 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.194 -0.941 . . . . 0.0 109.465 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -75.46 -35.8 60.82 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.475 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 15.1 m-20 -54.44 -37.71 65.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.224 -0.922 . . . . 0.0 109.669 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.572 HD21 HG11 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -49.43 -53.48 22.58 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.283 -0.885 . . . . 0.0 109.651 -179.874 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 6.0 mmtm -69.64 -33.43 72.6 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.23 -0.919 . . . . 0.0 109.656 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.501 ' CD1' ' HB3' ' A' ' 108' ' ' ASN . 2.2 mm? -57.94 -31.75 67.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.205 -0.934 . . . . 0.0 109.438 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.583 ' CD2' HG12 ' A' ' 3' ' ' ILE . 20.9 t80 -72.75 -38.61 67.31 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.384 -0.823 . . . . 0.0 109.779 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 17.6 m -70.56 -25.69 63.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.266 -0.896 . . . . 0.0 109.751 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -88.1 -0.51 57.14 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.204 -0.935 . . . . 0.0 109.674 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.456 ' HA2' ' OE2' ' A' ' 110' ' ' GLU . . . 59.95 25.42 61.75 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ASN . . . . . 0.501 ' HB3' ' CD1' ' A' ' 103' ' ' LEU . 1.2 m-20 -88.48 -53.28 4.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.204 -1.174 . . . . 0.0 109.424 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 11.9 tp -85.19 129.75 34.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.243 -0.911 . . . . 0.0 109.202 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.456 ' OE2' ' HA2' ' A' ' 107' ' ' GLY . 0.3 OUTLIER -165.68 -166.31 0.94 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.198 -0.939 . . . . 0.0 109.729 -179.818 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.51 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 68.5 tt0 -172.68 -113.85 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.285 -0.885 . . . . 0.0 109.371 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.476 ' N ' ' HG2' ' A' ' 111' ' ' GLU . 5.3 mt -82.31 140.37 16.53 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 O-C-N 121.093 -1.005 . . . . 0.0 109.253 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.48 ' NH1' ' HG2' ' A' ' 113' ' ' ARG . 0.0 OUTLIER -140.65 157.84 44.86 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.203 -0.935 . . . . 0.0 109.623 -179.885 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -146.1 156.76 50.72 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.279 -0.888 . . . . 0.0 109.345 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.48 6.33 4.87 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 C-N-CA 122.696 2.264 . . . . 0.0 110.486 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 94.78 -23.95 30.4 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 4.8 t -169.59 112.0 0.48 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.214 -1.168 . . . . 0.0 109.41 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 139.44 132.8 2.95 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.3 ttp85 -173.17 -55.65 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.15 -1.206 . . . . 0.0 109.551 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.0 85.36 0.39 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.483 ' O ' ' CB ' ' A' ' 122' ' ' ARG . 1.0 OUTLIER -68.12 155.16 40.19 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.293 -1.122 . . . . 0.0 109.253 179.883 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.483 ' CB ' ' O ' ' A' ' 121' ' ' ARG . 0.1 OUTLIER 73.7 85.65 0.11 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.257 -0.902 . . . . 0.0 109.378 -179.97 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 8.1 ttt85 -148.98 150.3 32.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.209 -0.932 . . . . 0.0 109.506 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 117.978 -1.011 . . . . 0.0 109.463 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.461 ' HG3' ' HB2' ' A' ' 67' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.28 0.562 . . . . 0.0 109.514 . . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.93 139.68 36.98 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.219 -0.926 . . . . 0.0 109.201 179.825 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.493 HG23 HD11 ' A' ' 70' ' ' ILE . 4.8 mt -115.24 113.49 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.12 -0.987 . . . . 0.0 110.006 -179.609 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.03 119.55 39.78 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.507 -0.746 . . . . 0.0 109.024 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.59 HG21 ' HB ' ' A' ' 97' ' ' VAL . 3.3 mp -98.15 136.94 27.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.128 -0.982 . . . . 0.0 109.879 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.49 ' HB2' ' CZ ' ' A' ' 26' ' ' PHE . . . -89.74 121.99 32.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.296 -0.877 . . . . 0.0 109.138 179.725 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.547 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -142.08 170.82 14.99 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.143 -0.973 . . . . 0.0 109.728 -179.832 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 51.5 p -116.32 25.31 10.73 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.316 -0.865 . . . . 0.0 109.299 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -162.64 -145.27 4.29 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.632 HG23 HG11 ' A' ' 41' ' ' VAL . 0.2 OUTLIER -147.17 22.56 1.2 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.243 -1.151 . . . . 0.0 109.521 -179.94 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -147.57 -178.68 6.38 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.199 -0.938 . . . . 0.0 109.602 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.525 ' O ' HD23 ' A' ' 12' ' ' LEU . 6.6 tt -64.39 -14.24 55.44 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.337 -0.852 . . . . 0.0 109.571 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -56.74 -52.4 50.87 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.08 86.57 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.335 -1.097 . . . . 0.0 109.397 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.46 81.21 1.44 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.476 -0.765 . . . . 0.0 109.54 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.707 HG12 ' O ' ' A' ' 16' ' ' VAL . 59.3 t 54.54 30.45 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.665 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 26.6 p 46.14 -160.66 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.275 -0.891 . . . . 0.0 109.433 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 2.9 mtt-85 -98.2 -46.92 5.66 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.898 . . . . 0.0 109.376 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -150.27 122.65 8.44 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.364 -0.835 . . . . 0.0 109.429 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.442 ' CD2' ' HB1' ' A' ' 71' ' ' ALA . 4.0 t80 -57.65 124.49 19.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.238 -0.914 . . . . 0.0 109.391 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -171.98 -49.37 0.04 OUTLIER Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.95 45.4 1.46 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.283 -1.128 . . . . 0.0 109.446 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.547 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -54.6 112.65 4.21 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.352 -0.842 . . . . 0.0 109.516 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.452 ' O ' ' CB ' ' A' ' 43' ' ' GLU . 36.6 Cg_endo -80.61 20.53 0.95 Allowed 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.606 2.204 . . . . 0.0 110.947 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -154.8 69.79 0.75 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.036 -1.04 . . . . 0.0 108.942 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.49 ' CZ ' ' HB2' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -79.1 125.21 29.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.348 -0.845 . . . . 0.0 109.722 -179.456 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 10.7 mtt -90.06 110.69 21.67 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.289 -0.882 . . . . 0.0 109.369 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 31.6 mm -93.46 107.45 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.467 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.512 HG11 HD13 ' A' ' 36' ' ' ILE . 23.3 t -115.63 116.35 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.266 -0.896 . . . . 0.0 109.429 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -103.81 114.81 29.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.554 -179.751 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.418 ' HE2' HG13 ' A' ' 36' ' ' ILE . 12.6 ptp -116.3 160.33 20.63 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.241 -0.912 . . . . 0.0 109.419 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -109.71 -94.98 0.41 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.256 -0.903 . . . . 0.0 109.626 -179.874 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -89.5 62.35 5.92 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.116 -0.99 . . . . 0.0 109.348 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.13 35.58 92.28 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 36' ' ' ILE . 44.9 t30 -138.96 84.26 2.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.302 -1.116 . . . . 0.0 109.462 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.526 HD13 HD21 ' A' ' 101' ' ' LEU . 50.6 mt -45.41 111.27 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.221 -0.924 . . . . 0.0 109.419 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -111.49 9.26 21.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.232 -0.917 . . . . 0.0 109.482 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -167.28 124.18 1.19 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.187 -0.946 . . . . 0.0 109.485 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.2 p -144.96 107.9 4.51 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.284 -0.885 . . . . 0.0 109.478 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -123.37 148.2 46.29 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.526 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.632 HG11 HG23 ' A' ' 10' ' ' THR . 61.4 t -103.99 137.82 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.87 . . . . 0.0 109.519 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -139.33 136.28 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.259 -0.9 . . . . 0.0 109.421 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.452 ' CB ' ' O ' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -96.85 120.66 37.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 179.915 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.441 ' CG ' ' HD2' ' A' ' 45' ' ' PRO . 0.8 OUTLIER -60.74 147.82 83.66 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.21 -0.931 . . . . 0.0 109.357 -179.911 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.441 ' HD2' ' CG ' ' A' ' 44' ' ' ASN . 35.9 Cg_endo -78.48 -34.0 1.62 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.559 2.173 . . . . 0.0 110.454 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.9 m -49.26 -23.88 1.56 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.308 -0.87 . . . . 0.0 109.529 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -61.76 -48.44 80.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.15 -0.969 . . . . 0.0 109.469 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.75 -3.71 51.89 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.592 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -112.57 95.14 5.27 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.193 -0.942 . . . . 0.0 109.484 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 10.3 p -67.62 121.3 15.57 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.277 -0.89 . . . . 0.0 109.376 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 116.45 38.28 0.94 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.442 ' O ' ' HB3' ' A' ' 53' ' ' ALA . . . -124.53 9.42 8.21 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.442 ' HB3' ' O ' ' A' ' 52' ' ' GLY . . . 61.54 165.2 0.09 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.218 -1.166 . . . . 0.0 109.342 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -122.54 -36.89 0.66 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.7 HG23 ' HB2' ' A' ' 78' ' ' ALA . 20.7 mm -71.85 -39.88 68.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.191 -1.182 . . . . 0.0 109.42 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 7.3 mmm-85 -65.67 -11.13 42.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.557 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.786 ' O ' HG22 ' A' ' 60' ' ' ILE . 44.8 m -70.3 -33.47 71.58 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 0.0 109.312 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.684 ' HB1' HD21 ' A' ' 82' ' ' LEU . . . -50.83 -23.84 3.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.243 -0.91 . . . . 0.0 109.318 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -70.67 -51.58 26.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.247 -0.908 . . . . 0.0 109.485 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.786 HG22 ' O ' ' A' ' 57' ' ' THR . 0.3 OUTLIER -59.03 -33.43 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.412 -179.98 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.0 mt -67.38 -40.96 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.206 -0.934 . . . . 0.0 109.215 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.01 -18.64 59.18 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.338 -0.851 . . . . 0.0 109.461 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -74.55 -17.63 60.71 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.931 . . . . 0.0 109.399 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -86.77 11.75 12.43 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.28 -0.888 . . . . 0.0 109.56 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.454 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 88.6 -6.24 83.82 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.514 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 96.8 t -54.78 89.76 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.283 -1.128 . . . . 0.0 109.878 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.461 ' HB2' ' HG3' ' A' ' 1' ' ' MET . 16.5 mmtm -79.18 2.24 21.69 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.139 -0.975 . . . . 0.0 109.017 179.427 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.514 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -142.96 140.05 30.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.236 -0.915 . . . . 0.0 109.06 179.656 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.496 ' C ' HD13 ' A' ' 70' ' ' ILE . 42.2 t -139.76 131.15 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.077 -1.014 . . . . 0.0 110.049 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.496 HD13 ' C ' ' A' ' 69' ' ' VAL . 1.3 mm -108.33 111.63 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.305 -0.872 . . . . 0.0 108.85 179.461 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.442 ' HB1' ' CD2' ' A' ' 20' ' ' PHE . . . -154.13 177.05 11.52 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.164 -0.96 . . . . 0.0 109.968 -179.627 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.5 44.87 1.73 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.53 -0.731 . . . . 0.0 109.23 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -45.74 150.61 0.94 Allowed Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.333 -0.855 . . . . 0.0 109.533 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.83 -38.88 0.57 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.677 2.251 . . . . 0.0 110.292 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.16 146.28 16.89 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.68 8.09 3.89 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.605 2.203 . . . . 0.0 110.663 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.487 ' O ' HG23 ' A' ' 81' ' ' VAL . 9.2 t-20 -63.93 -46.39 84.99 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.151 -0.968 . . . . 0.0 109.612 -179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.7 ' HB2' HG23 ' A' ' 55' ' ' ILE . . . -67.4 -50.24 60.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 109.557 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.865 ' CD1' HG21 ' A' ' 89' ' ' ILE . 12.8 m-85 -52.08 -33.16 38.16 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.642 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.466 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -67.01 -41.81 86.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.251 -0.905 . . . . 0.0 109.736 -179.732 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 77' ' ' ASN . 2.7 t -63.21 -53.77 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.167 -0.958 . . . . 0.0 109.751 -179.793 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.684 HD21 ' HB1' ' A' ' 58' ' ' ALA . 25.0 mt -60.38 -18.38 50.07 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.27 -0.894 . . . . 0.0 109.719 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.466 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 1.3 m120 -69.61 -56.37 7.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.275 -0.891 . . . . 0.0 109.716 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -66.12 -34.81 78.89 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.145 -0.972 . . . . 0.0 109.676 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.401 ' CB ' HG12 ' A' ' 87' ' ' ILE . 6.8 mt -61.5 -13.41 20.72 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.237 -0.914 . . . . 0.0 109.416 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 77.61 24.06 65.99 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.401 HG12 ' CB ' ' A' ' 85' ' ' LEU . 5.2 mm -92.32 144.34 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.239 -1.154 . . . . 0.0 109.4 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.87 110.37 15.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.249 -0.907 . . . . 0.0 109.442 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.865 HG21 ' CD1' ' A' ' 79' ' ' PHE . 13.0 mt -86.76 151.48 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.344 -0.848 . . . . 0.0 109.655 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.568 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 1.1 m-85 -134.87 134.02 40.3 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -0.873 . . . . 0.0 109.453 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.96 132.72 35.19 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.225 -0.922 . . . . 0.0 109.405 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.51 ' HB1' HG21 ' A' ' 16' ' ' VAL . . . -84.6 66.0 9.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.226 -0.921 . . . . 0.0 109.614 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 9.5 t -74.2 -28.14 61.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.158 -0.964 . . . . 0.0 109.463 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.401 ' O ' ' HB ' ' A' ' 95' ' ' THR . . . -59.1 -106.21 0.01 OUTLIER Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.514 HG23 ' N ' ' A' ' 96' ' ' SER . 4.0 t 178.31 -44.09 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.217 -1.166 . . . . 0.0 109.592 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.514 ' N ' HG23 ' A' ' 95' ' ' THR . 7.2 m -95.66 125.52 40.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.231 -0.918 . . . . 0.0 109.444 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.59 ' HB ' HG21 ' A' ' 5' ' ' ILE . 5.5 m -63.46 -34.99 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.238 -0.914 . . . . 0.0 109.402 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -64.42 -35.27 80.36 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.198 -0.939 . . . . 0.0 109.29 179.738 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.676 ' O ' HD23 ' A' ' 103' ' ' LEU . 20.7 tt0 -73.32 -36.78 66.28 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.334 -0.854 . . . . 0.0 109.403 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.494 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 98.9 m-20 -67.74 -27.79 67.09 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.171 -0.955 . . . . 0.0 109.424 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.526 HD21 HD13 ' A' ' 36' ' ' ILE . 24.9 tp -58.28 -62.24 1.98 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.358 -0.839 . . . . 0.0 109.674 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -68.19 -24.97 65.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.153 -0.967 . . . . 0.0 109.443 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.676 HD23 ' O ' ' A' ' 99' ' ' GLU . 0.9 OUTLIER -65.0 -29.58 70.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.305 -0.872 . . . . 0.0 109.482 179.929 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.528 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 9.8 t80 -64.12 -43.89 93.92 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.156 -0.965 . . . . 0.0 109.501 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 86.4 m -57.31 -31.36 65.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.753 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -87.64 -22.78 24.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.242 -0.911 . . . . 0.0 109.578 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 77.02 24.36 66.73 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ASN . . . . . 0.635 ' HB3' HD12 ' A' ' 103' ' ' LEU . 2.4 t30 -80.31 -32.52 37.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.179 -1.189 . . . . 0.0 109.367 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.479 ' HA ' HD12 ' A' ' 109' ' ' LEU . 3.4 tp -66.59 -163.89 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.274 -0.891 . . . . 0.0 109.519 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -110.58 137.54 48.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 109.263 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.568 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 20.8 pt-20 -127.58 165.08 20.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.236 -0.915 . . . . 0.0 109.69 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 10.3 mt -151.54 104.26 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.147 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -122.5 5.87 9.56 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.236 -0.915 . . . . 0.0 109.838 -179.496 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 3.3 m -137.2 156.25 75.52 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.086 -1.009 . . . . 0.0 109.783 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.13 170.11 19.23 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.622 2.214 . . . . 0.0 110.076 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.78 163.8 11.93 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 28.0 m 57.07 -173.88 0.07 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -1.123 . . . . 0.0 109.502 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 108.97 60.32 0.53 Allowed Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.25 159.59 16.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.223 -1.163 . . . . 0.0 109.608 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -146.44 148.14 19.59 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.8 70.61 0.76 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -1.148 . . . . 0.0 109.559 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 1.8 mpp_? -60.17 -87.47 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.148 -0.97 . . . . 0.0 109.45 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.2 mtm105 -99.24 143.21 29.77 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.914 . . . . 0.0 109.472 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.424 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -111.14 137.26 49.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.25 -0.906 . . . . 0.0 109.449 179.867 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.594 HG12 ' CZ ' ' A' ' 104' ' ' PHE . 4.9 mt -102.84 101.89 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.377 -0.827 . . . . 0.0 109.72 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.424 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -103.66 101.22 11.06 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.318 -0.864 . . . . 0.0 109.147 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.66 ' HB ' HD12 ' A' ' 70' ' ' ILE . 14.7 tt -98.25 130.19 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.256 -0.902 . . . . 0.0 109.592 -179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -59.26 146.09 40.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.406 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.494 ' HB3' ' CB ' ' A' ' 14' ' ' SER . 0.8 OUTLIER -135.85 162.12 33.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.921 . . . . 0.0 109.594 -179.863 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.82 -20.43 12.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.872 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.571 ' O ' ' CD1' ' A' ' 25' ' ' TYR . . . -119.81 -124.66 3.24 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.78 -37.21 1.03 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.19 -1.182 . . . . 0.0 109.544 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -144.92 -73.11 0.25 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.704 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -89.58 -29.76 18.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.254 -0.904 . . . . 0.0 109.514 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.19 -15.12 72.0 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.532 ' OG ' HG21 ' A' ' 97' ' ' VAL . 0.8 OUTLIER -77.39 82.62 3.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.196 -1.179 . . . . 0.0 109.479 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.487 ' HG2' ' O ' ' A' ' 95' ' ' THR . 13.2 tt0 -77.34 3.66 12.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.279 -0.888 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.576 HG22 HG13 ' A' ' 97' ' ' VAL . 9.7 t 66.62 65.96 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.16 -0.962 . . . . 0.0 109.227 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.448 ' O ' ' O ' ' A' ' 16' ' ' VAL . 60.2 p -57.65 -159.35 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.258 -0.901 . . . . 0.0 109.703 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.45 54.18 1.93 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.47 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -136.95 71.41 1.41 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.211 -0.931 . . . . 0.0 109.438 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.547 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 5.7 t80 -65.58 100.93 0.55 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.29 -0.881 . . . . 0.0 109.61 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 151.91 -42.97 0.69 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.468 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 5.5 ttt85 -104.51 -33.9 8.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.203 -1.175 . . . . 0.0 109.783 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.457 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -39.22 99.02 0.19 Allowed Pre-proline 0 N--CA 1.495 1.809 0 O-C-N 121.543 -0.723 . . . . 0.0 109.78 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.484 ' O ' ' HG2' ' A' ' 43' ' ' GLU . 36.5 Cg_endo -81.03 45.39 1.98 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 122.716 2.277 . . . . 0.0 110.927 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.571 ' CD1' ' O ' ' A' ' 9' ' ' GLY . 1.9 m-85 -161.05 72.34 0.43 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.946 -1.096 . . . . 0.0 109.627 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -79.7 150.01 31.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.305 -0.872 . . . . 0.0 109.438 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' MET . . . . . 0.431 ' HB2' ' OG ' ' A' ' 7' ' ' SER . 5.2 ttt -123.54 122.1 37.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -0.939 . . . . 0.0 109.402 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 28.3 mt -114.08 129.34 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.899 . . . . 0.0 109.547 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.414 ' CG1' HG23 ' A' ' 36' ' ' ILE . 73.6 t -138.69 136.18 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.218 -0.926 . . . . 0.0 109.532 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -120.73 94.66 4.43 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.193 -0.942 . . . . 0.0 109.444 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.497 ' SD ' ' CD1' ' A' ' 3' ' ' ILE . 0.0 OUTLIER -83.44 152.31 25.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.385 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -96.73 -94.02 0.21 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.189 -0.944 . . . . 0.0 109.492 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -101.43 65.22 1.04 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.133 -0.979 . . . . 0.0 109.299 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 70.25 37.59 71.48 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -150.41 116.15 5.54 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.316 -1.108 . . . . 0.0 109.308 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.441 ' N ' HD13 ' A' ' 36' ' ' ILE . 5.9 mm -64.12 122.81 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -0.881 . . . . 0.0 109.593 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -130.77 16.61 5.26 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.188 -0.945 . . . . 0.0 109.318 179.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 17.1 m -173.51 101.29 0.12 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.382 -0.824 . . . . 0.0 109.245 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.55 101.06 7.12 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.94 155.91 19.78 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.336 -0.853 . . . . 0.0 109.418 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 3.1 t -125.99 129.6 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.205 -0.935 . . . . 0.0 109.337 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 92.8 mt -110.32 143.05 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.264 -0.897 . . . . 0.0 109.853 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.488 ' O ' ' HD3' ' A' ' 45' ' ' PRO . 0.4 OUTLIER -109.73 128.94 55.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.314 -0.866 . . . . 0.0 109.281 179.852 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ASN . . . . . 0.437 ' HB3' ' HB2' ' A' ' 47' ' ' ALA . 0.2 OUTLIER -115.58 82.72 10.26 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.199 -0.938 . . . . 0.0 109.407 -179.95 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.488 ' HD3' ' O ' ' A' ' 43' ' ' GLU . 36.2 Cg_endo -78.61 -22.59 9.08 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.671 2.247 . . . . 0.0 110.427 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -108.33 18.31 21.17 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.618 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ALA . . . . . 0.437 ' HB2' ' HB3' ' A' ' 44' ' ' ASN . . . -47.75 -66.85 0.34 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.465 ' HB3' ' CA ' ' A' ' 54' ' ' GLY . 79.0 p -129.05 -58.22 1.15 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.232 -0.917 . . . . 0.0 109.472 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 56.97 42.12 26.69 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.296 -0.878 . . . . 0.0 109.499 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 11.3 t -145.63 -53.9 0.28 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.435 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 128.57 76.17 0.19 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 135.38 -72.12 0.47 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.68 175.97 0.32 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -1.125 . . . . 0.0 109.313 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.465 ' CA ' ' HB3' ' A' ' 48' ' ' SER . . . 128.1 -19.73 5.72 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.772 HG21 ' HB2' ' A' ' 78' ' ' ALA . 22.2 mt -76.08 0.1 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -1.144 . . . . 0.0 109.619 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.17 -9.57 58.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.199 -0.938 . . . . 0.0 109.553 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.417 HG22 ' O ' ' A' ' 54' ' ' GLY . 7.2 t -76.96 -19.0 57.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -0.89 . . . . 0.0 109.583 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -56.55 -38.45 71.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.289 -0.882 . . . . 0.0 109.581 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -56.46 -39.31 72.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.68 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.4 mt -75.6 -35.44 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 109.648 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.412 HG21 HD13 ' A' ' 61' ' ' ILE . 48.8 mt -62.1 -29.05 45.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.54 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.669 ' HB1' HD11 ' A' ' 87' ' ' ILE . . . -71.82 -34.89 69.71 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.7 -179.828 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -76.8 -0.42 23.84 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.173 -0.954 . . . . 0.0 109.687 -179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -94.27 8.34 42.15 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.213 -0.929 . . . . 0.0 109.586 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 87.34 -11.21 66.3 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.454 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 70.0 t -58.44 91.62 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.226 -1.161 . . . . 0.0 109.489 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.53 -7.34 58.41 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.372 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.454 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -132.98 137.63 46.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 0.0 109.273 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 32.3 t -134.28 111.86 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.15 -0.969 . . . . 0.0 109.646 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.733 HG22 ' HB2' ' A' ' 92' ' ' ALA . 11.7 mt -95.71 116.9 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.289 -0.882 . . . . 0.0 109.261 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.547 ' HB1' ' HB2' ' A' ' 20' ' ' PHE . . . -148.78 173.83 12.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.156 -0.965 . . . . 0.0 109.684 -179.696 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.73 38.89 3.96 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.393 -0.817 . . . . 0.0 109.422 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.401 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.1 OUTLIER -50.17 141.25 15.74 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.264 -0.898 . . . . 0.0 109.406 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.1 Cg_endo -78.59 -62.95 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.593 2.195 . . . . 0.0 110.474 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -74.28 155.78 49.31 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.45 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.3 Cg_endo -78.6 4.7 6.15 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.702 2.268 . . . . 0.0 110.535 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -62.4 -56.86 14.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.207 -0.933 . . . . 0.0 109.512 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.772 ' HB2' HG21 ' A' ' 55' ' ' ILE . . . -57.26 -54.41 47.08 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.164 -0.96 . . . . 0.0 109.536 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -55.64 -22.25 21.82 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.3 -0.875 . . . . 0.0 109.523 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.45 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.2 OUTLIER -74.84 -37.01 62.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.162 -0.961 . . . . 0.0 109.467 -179.982 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.3 t -73.12 -50.68 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.911 . . . . 0.0 109.377 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.657 ' HB2' HD11 ' A' ' 89' ' ' ILE . 14.9 mt -50.1 -50.69 47.51 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.333 -0.854 . . . . 0.0 109.396 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -65.2 -33.36 75.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.242 -0.911 . . . . 0.0 109.431 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -58.37 -35.26 71.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.507 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -82.36 -37.39 25.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.341 -0.849 . . . . 0.0 109.379 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.36 22.1 6.61 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.669 HD11 ' HB1' ' A' ' 62' ' ' ALA . 6.0 mt -88.46 160.18 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.222 -1.163 . . . . 0.0 109.495 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.472 ' N ' HG22 ' A' ' 87' ' ' ILE . 2.1 mttt -86.15 113.31 22.09 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.768 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.657 HD11 ' HB2' ' A' ' 82' ' ' LEU . 43.5 mt -88.38 161.92 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.267 -0.895 . . . . 0.0 108.938 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.581 ' CE1' ' HB3' ' A' ' 109' ' ' LEU . 2.6 m-85 -139.9 137.68 35.03 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.966 -1.084 . . . . 0.0 109.702 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 17.6 mmm180 -87.99 119.42 28.34 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.409 -0.807 . . . . 0.0 109.558 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.733 ' HB2' HG22 ' A' ' 70' ' ' ILE . . . -98.41 108.04 20.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.875 . . . . 0.0 109.387 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.598 HG23 ' N ' ' A' ' 94' ' ' GLY . 8.1 t -53.86 -47.19 71.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.598 ' N ' HG23 ' A' ' 93' ' ' THR . . . 125.31 83.47 0.53 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.665 HG22 ' N ' ' A' ' 96' ' ' SER . 17.5 m -137.65 -92.8 0.22 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.236 -1.155 . . . . 0.0 109.459 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.665 ' N ' HG22 ' A' ' 95' ' ' THR . 0.2 OUTLIER -153.01 130.74 11.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.157 -0.965 . . . . 0.0 109.399 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.576 HG13 HG22 ' A' ' 16' ' ' VAL . 22.2 m -52.05 -20.9 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 109.676 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -66.62 -57.97 6.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.238 -0.914 . . . . 0.0 109.522 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 32.3 mm-40 -66.0 -29.49 69.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.889 . . . . 0.0 109.524 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.541 ' OD1' HG21 ' A' ' 16' ' ' VAL . 33.2 m120 -60.9 -46.16 91.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.132 -0.98 . . . . 0.0 109.34 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -58.51 -37.04 74.76 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.216 -0.927 . . . . 0.0 109.148 179.781 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.417 ' HE2' ' HB2' ' A' ' 102' ' ' LYS . 0.3 OUTLIER -73.9 -22.06 59.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.287 -0.883 . . . . 0.0 109.311 179.822 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.464 ' HA ' HD22 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -76.54 -38.06 55.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.247 179.82 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.594 ' CZ ' HG12 ' A' ' 3' ' ' ILE . 0.5 OUTLIER -70.39 -6.64 36.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.3 -0.875 . . . . 0.0 109.551 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.421 HG22 ' OE1' ' A' ' 106' ' ' GLU . 51.6 m -73.34 -39.09 65.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 0.0 109.682 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLU . . . . . 0.421 ' OE1' HG22 ' A' ' 105' ' ' THR . 2.8 mm-40 -94.19 -41.87 9.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.32 -0.862 . . . . 0.0 109.505 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 110.78 25.78 5.01 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.93 -21.6 43.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.278 -1.131 . . . . 0.0 109.374 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.581 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 2.8 mt -59.41 144.99 45.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.373 -0.829 . . . . 0.0 109.421 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.512 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 1.4 pt-20 -94.72 145.62 24.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.182 -0.949 . . . . 0.0 109.303 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.547 ' HG2' ' CZ ' ' A' ' 90' ' ' TYR . 0.4 OUTLIER -139.32 -178.58 5.43 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.161 -0.962 . . . . 0.0 109.816 -179.603 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.9 mp -138.34 134.26 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.406 -0.809 . . . . 0.0 109.294 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 -131.23 177.3 7.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.213 -0.929 . . . . 0.0 109.544 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 3.0 p -174.95 152.07 1.47 Allowed Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.246 -0.909 . . . . 0.0 109.242 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.81 -17.81 13.72 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 C-N-CA 122.556 2.17 . . . . 0.0 110.302 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.68 119.41 1.9 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 1.6 t -154.19 125.16 7.24 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -1.138 . . . . 0.0 109.523 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -163.26 83.91 0.11 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.64 135.95 41.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.305 -1.115 . . . . 0.0 109.297 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -167.22 121.84 1.0 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 6.6 mtt180 -127.09 -176.79 3.82 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.296 -1.12 . . . . 0.0 109.448 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.95 12.8 2.45 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.711 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.445 ' O ' ' CB ' ' A' ' 124' ' ' ARG . 0.6 OUTLIER -160.51 -171.53 3.18 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 109.606 179.992 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.445 ' CB ' ' O ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.49 0 CA-C-O 118.009 -0.995 . . . . 0.0 109.523 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.462 ' HG3' ' O ' ' A' ' 1' ' ' MET . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.495 ' CE ' ' OE1' ' A' ' 30' ' ' GLU . 17.2 mttp -102.71 146.67 27.87 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.259 -0.901 . . . . 0.0 109.366 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.795 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 6.8 mt -113.27 131.5 64.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.3 -0.875 . . . . 0.0 109.918 -179.692 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -125.74 146.56 49.7 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.415 -0.803 . . . . 0.0 108.855 179.518 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.493 HG23 ' CG2' ' A' ' 70' ' ' ILE . 1.6 mp -132.35 127.52 57.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 109.718 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -63.5 148.64 48.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.351 -0.843 . . . . 0.0 109.403 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.861 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -143.91 164.99 28.99 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.138 -0.976 . . . . 0.0 109.549 -179.95 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.96 -6.46 23.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.319 -0.863 . . . . 0.0 109.597 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.556 ' O ' ' CG ' ' A' ' 25' ' ' TYR . . . -148.15 -145.37 4.15 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.724 HG22 ' O ' ' A' ' 10' ' ' THR . 96.7 m -135.6 18.56 3.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.241 -1.152 . . . . 0.0 109.433 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -141.6 -174.47 4.06 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.222 -0.924 . . . . 0.0 109.529 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -66.61 -22.22 66.12 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.22 -0.925 . . . . 0.0 109.482 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.73 -50.44 57.84 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 15' ' ' GLU . 81.4 p -76.81 84.39 3.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.294 -1.121 . . . . 0.0 109.244 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.706 ' O ' HG13 ' A' ' 97' ' ' VAL . 18.6 mt-10 -46.89 -98.11 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.398 -0.814 . . . . 0.0 109.859 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.809 HG11 ' HB1' ' A' ' 92' ' ' ALA . 4.2 t -123.06 33.76 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.939 -1.101 . . . . 0.0 109.782 -179.709 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.401 ' C ' ' O ' ' A' ' 16' ' ' VAL . 7.2 p 43.93 -162.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.883 . . . . 0.0 109.533 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.546 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -140.34 11.91 2.35 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.338 -0.851 . . . . 0.0 109.388 179.908 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.546 ' CD1' ' O ' ' A' ' 18' ' ' ARG . 32.6 m-85 -142.64 -165.3 2.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.52 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -133.88 -61.81 0.79 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.316 -0.865 . . . . 0.0 109.355 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -79.81 2.28 74.83 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.419 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.1 OUTLIER -103.91 -64.51 1.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.183 -1.187 . . . . 0.0 109.489 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.861 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -44.24 104.58 0.39 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.287 -0.883 . . . . 0.0 109.404 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.515 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.6 Cg_endo -79.94 61.49 8.21 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.656 2.237 . . . . 0.0 110.927 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.556 ' CG ' ' O ' ' A' ' 9' ' ' GLY . 51.1 m-85 -160.54 70.45 0.41 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.04 -1.037 . . . . 0.0 109.325 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 48.5 m-85 -79.85 109.22 14.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.206 -0.934 . . . . 0.0 109.321 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' MET . . . . . 0.473 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 0.0 OUTLIER -79.6 141.37 36.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.332 -0.855 . . . . 0.0 109.742 -179.65 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.482 HG12 HG12 ' A' ' 42' ' ' ILE . 7.8 mm -125.04 139.32 51.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.32 -0.863 . . . . 0.0 109.235 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.439 HG21 ' CD1' ' A' ' 101' ' ' LEU . 10.6 t -140.63 144.64 26.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -0.892 . . . . 0.0 109.499 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.495 ' OE1' ' CE ' ' A' ' 2' ' ' LYS . 6.2 mt-10 -125.33 107.95 11.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.237 -0.914 . . . . 0.0 109.545 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.1 mtt -81.56 149.82 28.47 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.204 -0.935 . . . . 0.0 109.382 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.04 -51.79 2.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.184 -0.948 . . . . 0.0 109.587 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.02 53.25 0.57 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.498 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.4 21.83 55.61 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.403 ' O ' ' C ' ' A' ' 36' ' ' ILE . 1.6 t30 -148.13 95.43 2.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.254 -1.145 . . . . 0.0 109.477 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.435 ' O ' HG13 ' A' ' 36' ' ' ILE . 9.5 pt -45.47 114.16 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.168 -0.957 . . . . 0.0 109.295 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -113.68 9.4 17.78 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -0.933 . . . . 0.0 109.411 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 53.5 p -163.46 113.4 1.32 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 109.36 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -135.03 104.6 6.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.288 -0.883 . . . . 0.0 109.493 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.96 -174.58 2.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.309 -0.869 . . . . 0.0 109.245 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.588 HG11 HG23 ' A' ' 10' ' ' THR . 14.8 p -131.93 166.65 28.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.074 -1.016 . . . . 0.0 109.648 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.587 ' N ' HG22 ' A' ' 41' ' ' VAL . 7.4 mm -129.97 99.37 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.35 -0.844 . . . . 0.0 109.501 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.526 ' HG3' ' CE1' ' A' ' 25' ' ' TYR . 31.8 tt0 -77.88 126.3 30.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.275 -0.891 . . . . 0.0 109.299 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -126.84 80.38 70.97 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.214 -0.929 . . . . 0.0 109.647 -179.819 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -77.99 88.07 1.46 Allowed 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.684 2.256 . . . . 0.0 110.353 179.759 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.3 p -176.75 -55.54 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.159 -0.963 . . . . 0.0 109.514 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.86 -37.6 31.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.177 -0.952 . . . . 0.0 109.373 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.68 47.91 1.12 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.256 -0.902 . . . . 0.0 109.354 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -147.7 -46.77 0.17 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.308 -0.87 . . . . 0.0 109.513 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -135.73 24.81 3.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.2 -0.937 . . . . 0.0 109.478 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.79 29.16 57.85 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -58.08 -172.42 0.32 Allowed Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.462 ' HB1' ' HB2' ' A' ' 56' ' ' ARG . . . -97.92 116.75 30.77 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.251 -1.147 . . . . 0.0 109.481 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.957 ' O ' HG22 ' A' ' 57' ' ' THR . . . -111.66 -39.27 1.34 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.6 mm -76.76 -28.87 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -1.142 . . . . 0.0 109.499 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ARG . . . . . 0.462 ' HB2' ' HB1' ' A' ' 53' ' ' ALA . 8.0 mmm180 -76.69 -34.11 58.2 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.183 -0.948 . . . . 0.0 109.594 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.957 HG22 ' O ' ' A' ' 54' ' ' GLY . 14.8 t -49.11 -23.63 1.31 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.737 -179.832 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -45.25 -47.25 12.82 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.272 -0.892 . . . . 0.0 109.9 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -53.83 -48.43 69.93 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.195 -0.941 . . . . 0.0 109.92 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 80.2 mt -60.91 -36.73 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.213 -0.929 . . . . 0.0 110.115 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 32.7 mt -62.94 -40.95 90.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 109.947 -179.582 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.38 -28.73 64.24 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.149 -0.969 . . . . 0.0 109.791 -179.642 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -77.32 4.39 10.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -0.929 . . . . 0.0 109.947 -179.796 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -106.6 2.54 26.1 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.018 -1.051 . . . . 0.0 109.661 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.03 -11.21 62.2 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.453 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 81.8 t -62.61 88.27 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -1.146 . . . . 0.0 109.61 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.66 -2.74 44.12 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.291 -0.88 . . . . 0.0 108.986 179.467 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.795 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -127.8 127.54 43.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.34 -0.85 . . . . 0.0 109.172 179.849 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.6 HG21 HD22 ' A' ' 82' ' ' LEU . 74.8 t -125.57 112.43 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.17 -0.956 . . . . 0.0 109.78 -179.667 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.493 ' CG2' HG23 ' A' ' 5' ' ' ILE . 3.5 mt -99.33 124.31 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.192 -0.942 . . . . 0.0 109.129 179.549 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -158.52 172.81 17.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.175 -0.953 . . . . 0.0 109.766 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.15 49.18 2.31 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.367 -0.833 . . . . 0.0 109.514 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.86 160.11 22.38 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.201 -0.937 . . . . 0.0 109.407 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.85 -89.9 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.557 2.172 . . . . 0.0 110.296 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.6 162.96 36.91 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.48 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.7 Cg_endo -80.29 27.74 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.825 2.35 . . . . 0.0 111.17 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.73 ' O ' HG23 ' A' ' 81' ' ' VAL . 0.9 OUTLIER -76.7 -59.84 2.6 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.879 -1.138 . . . . 0.0 109.423 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.419 ' O ' ' HB ' ' A' ' 81' ' ' VAL . . . -55.61 -43.51 76.15 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.266 -0.896 . . . . 0.0 109.389 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.632 ' O ' HD11 ' A' ' 89' ' ' ILE . 3.8 m-30 -60.2 -49.17 78.7 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.264 -0.898 . . . . 0.0 109.498 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.48 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.3 OUTLIER -61.36 -21.03 63.67 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 109.331 179.798 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 77' ' ' ASN . 95.5 t -73.28 -63.12 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.217 -0.927 . . . . 0.0 109.373 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.714 ' HA ' HD12 ' A' ' 85' ' ' LEU . 1.5 mt -57.74 -27.09 62.7 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.179 -0.951 . . . . 0.0 109.302 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -62.06 -51.32 68.44 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.322 -0.861 . . . . 0.0 109.332 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -77.01 -12.28 59.92 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.262 -0.899 . . . . 0.0 109.362 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.714 HD12 ' HA ' ' A' ' 82' ' ' LEU . 55.5 mt -77.49 -23.63 50.28 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.921 . . . . 0.0 109.365 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLY . . . . . 0.456 ' C ' HD12 ' A' ' 87' ' ' ILE . . . 100.86 41.42 2.67 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.505 HD12 ' N ' ' A' ' 87' ' ' ILE . 5.3 mp -137.7 161.87 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -1.156 . . . . 0.0 109.512 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.5 ' N ' HG22 ' A' ' 87' ' ' ILE . 4.6 mmtm -92.56 131.5 37.63 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -0.901 . . . . 0.0 109.627 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.632 HD11 ' O ' ' A' ' 79' ' ' PHE . 50.9 mt -92.29 157.35 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.251 -0.906 . . . . 0.0 109.51 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.529 ' CE2' ' HB3' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -142.33 143.12 32.61 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.336 -0.852 . . . . 0.0 109.44 -179.898 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.707 ' O ' HD22 ' A' ' 109' ' ' LEU . 12.4 mmt180 -100.15 125.28 46.25 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 109.428 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ALA . . . . . 0.809 ' HB1' HG11 ' A' ' 16' ' ' VAL . . . -82.97 113.84 20.83 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.217 -0.927 . . . . 0.0 109.473 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 3.8 m -144.98 13.03 1.45 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.233 -0.917 . . . . 0.0 109.518 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.02 -121.68 0.31 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.47 HG22 ' OG ' ' A' ' 96' ' ' SER . 17.3 m -129.59 -54.5 1.16 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.356 -1.085 . . . . 0.0 109.385 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.49 ' CB ' ' HG2' ' A' ' 15' ' ' GLU . 0.8 OUTLIER -139.19 143.53 38.13 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.275 -0.891 . . . . 0.0 109.367 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.706 HG13 ' O ' ' A' ' 15' ' ' GLU . 15.0 m -44.1 -26.72 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.295 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' GLU . . . . . 0.407 ' N ' ' O ' ' A' ' 96' ' ' SER . 3.3 tp10 -64.27 -51.76 61.96 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.264 -0.897 . . . . 0.0 109.246 179.702 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.436 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 3.0 tp10 -64.15 -37.46 87.52 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.297 -0.877 . . . . 0.0 109.068 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -63.89 -30.73 71.79 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.331 -0.856 . . . . 0.0 109.218 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.439 ' CD1' HG21 ' A' ' 29' ' ' VAL . 6.4 tp -55.98 -55.85 27.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.363 -0.835 . . . . 0.0 109.219 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 44.4 mttt -76.82 -13.94 59.96 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.25 179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.51 HD12 ' HA ' ' A' ' 103' ' ' LEU . 6.1 tp -77.16 -23.39 51.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.909 . . . . 0.0 109.579 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.591 ' CD1' ' CD1' ' A' ' 3' ' ' ILE . 32.2 t80 -75.58 -23.75 56.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.234 -0.916 . . . . 0.0 109.106 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.6 m -74.57 -34.05 62.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.319 -0.863 . . . . 0.0 109.259 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -90.73 -0.28 57.65 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.287 -0.883 . . . . 0.0 109.487 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.73 37.87 62.7 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -82.74 -23.1 34.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.217 -1.167 . . . . 0.0 109.473 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.707 HD22 ' O ' ' A' ' 91' ' ' ARG . 0.8 OUTLIER -83.69 162.03 20.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.235 -0.916 . . . . 0.0 109.289 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.4 ' HG2' ' N ' ' A' ' 111' ' ' GLU . 34.3 tt0 -87.63 146.95 25.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.184 -0.947 . . . . 0.0 109.91 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.529 ' HB3' ' CE2' ' A' ' 90' ' ' TYR . 9.2 pt-20 -135.79 179.8 6.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.43 -0.794 . . . . 0.0 109.077 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.8 mt -149.84 127.13 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.708 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.414 ' CD ' ' N ' ' A' ' 113' ' ' ARG . 0.0 OUTLIER -118.99 -69.87 0.82 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.37 -0.831 . . . . 0.0 109.356 179.854 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 46.6 t -166.47 69.69 1.1 Allowed Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.25 -0.906 . . . . 0.0 109.379 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -79.13 9.47 3.34 Favored 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.656 2.238 . . . . 0.0 110.785 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 164.19 158.33 10.07 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 2.4 t -49.73 -61.77 1.94 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -1.124 . . . . 0.0 109.459 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 119' ' ' ARG . . . 132.24 -118.14 2.19 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.414 ' C ' ' O ' ' A' ' 118' ' ' GLY . 0.3 OUTLIER -44.24 145.88 0.73 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.33 -1.1 . . . . 0.0 109.591 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -152.85 -163.37 11.63 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.36 117.63 21.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.203 -1.175 . . . . 0.0 109.44 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -162.79 -163.29 0.86 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.289 -0.882 . . . . 0.0 109.457 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.65 138.98 38.32 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.198 -0.938 . . . . 0.0 109.529 -179.816 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.44 179.947 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.464 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 36.7 mttt -147.01 126.73 13.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.269 -0.895 . . . . 0.0 109.221 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.951 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 4.3 mt -111.16 116.44 52.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.248 -0.908 . . . . 0.0 109.832 -179.582 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.697 ' C ' HD13 ' A' ' 5' ' ' ILE . . . -108.28 146.57 32.7 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.248 -0.908 . . . . 0.0 109.394 179.838 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.697 HD13 ' C ' ' A' ' 4' ' ' ALA . 5.4 mm -114.73 121.12 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.206 -0.934 . . . . 0.0 109.53 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.486 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -47.63 144.79 3.0 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.192 -0.943 . . . . 0.0 109.362 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 25' ' ' TYR . 11.3 t 49.99 -93.19 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.234 -0.916 . . . . 0.0 109.458 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.955 ' HA ' HG11 ' A' ' 97' ' ' VAL . 0.5 OUTLIER 66.81 8.68 6.18 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.169 -0.957 . . . . 0.0 109.518 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLY . . . . . 0.544 ' N ' ' HB2' ' A' ' 14' ' ' SER . . . 44.06 -128.13 6.53 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.07 -13.59 11.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.304 -1.115 . . . . 0.0 109.546 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -171.32 -70.61 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.195 -0.941 . . . . 0.0 109.921 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 13' ' ' GLY . 0.3 OUTLIER -122.37 -22.54 5.48 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 0.0 110.022 -179.619 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 12' ' ' LEU . . . -42.19 -42.34 4.18 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.544 ' HB2' ' N ' ' A' ' 9' ' ' GLY . 27.3 t -77.87 85.28 4.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.272 -1.134 . . . . 0.0 109.674 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.693 ' C ' HG23 ' A' ' 16' ' ' VAL . 1.7 mt-10 -67.96 85.32 0.23 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.413 -0.805 . . . . 0.0 109.214 179.802 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.693 HG23 ' C ' ' A' ' 15' ' ' GLU . 1.5 t 70.58 30.98 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.451 -0.781 . . . . 0.0 109.265 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.474 ' HA ' ' OG ' ' A' ' 14' ' ' SER . 4.3 p 62.45 -160.99 0.3 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.339 -0.851 . . . . 0.0 109.543 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.0 ttm180 -154.8 -46.43 0.09 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.399 -0.813 . . . . 0.0 109.053 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -145.72 147.8 32.32 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.369 -0.832 . . . . 0.0 109.095 179.746 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.48 ' CG ' ' HB1' ' A' ' 71' ' ' ALA . 85.1 t80 -118.32 138.19 52.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.161 -0.962 . . . . 0.0 109.578 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.475 ' O ' ' HA2' ' A' ' 54' ' ' GLY . . . 139.84 -59.12 0.59 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.47 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.1 OUTLIER -116.98 13.45 14.87 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.2 -1.177 . . . . 0.0 109.774 -179.753 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.96 109.53 1.71 Allowed Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.233 -0.917 . . . . 0.0 109.884 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.9 Cg_endo -81.17 41.37 1.13 Allowed 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.548 2.165 . . . . 0.0 110.485 179.699 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.418 ' O ' ' O ' ' A' ' 7' ' ' SER . 0.4 OUTLIER -158.74 69.82 0.49 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.09 -1.006 . . . . 0.0 109.314 -179.911 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.538 ' CZ ' HD13 ' A' ' 61' ' ' ILE . 0.3 OUTLIER -82.27 112.69 19.5 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.62 -179.854 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 27' ' ' MET . . . . . 0.965 ' HG3' HG12 ' A' ' 41' ' ' VAL . 0.0 OUTLIER -85.15 144.69 28.03 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.877 . . . . 0.0 109.308 -179.996 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 39.4 mt -139.76 126.18 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.228 -0.92 . . . . 0.0 109.518 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.556 HG13 ' O ' ' A' ' 38' ' ' SER . 34.8 t -124.09 128.67 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.35 -0.844 . . . . 0.0 109.471 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -98.88 167.22 10.89 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.368 -0.833 . . . . 0.0 109.237 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' MET . . . . . 0.52 ' HE3' HG22 ' A' ' 36' ' ' ILE . 29.9 mtt -133.19 138.91 46.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.932 . . . . 0.0 109.448 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 6.7 ttmm -98.93 -48.06 5.04 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -0.913 . . . . 0.0 109.464 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 15.8 mtmm -148.81 66.59 1.05 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.341 -0.849 . . . . 0.0 109.218 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.77 12.59 42.46 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.419 ' O ' ' C ' ' A' ' 36' ' ' ILE . 8.2 t-20 -130.83 94.36 3.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -1.17 . . . . 0.0 109.462 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.52 HG22 ' HE3' ' A' ' 31' ' ' MET . 26.3 pt -43.64 126.07 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.702 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -137.06 16.53 3.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.344 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.556 ' O ' HG13 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -154.94 117.12 4.2 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 0.0 109.14 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 80.9 p -143.77 112.45 6.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.532 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -124.91 171.95 9.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.893 . . . . 0.0 109.373 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.965 HG12 ' HG3' ' A' ' 27' ' ' MET . 20.8 m -131.73 115.87 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.274 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.2 tp -105.06 152.6 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.245 -0.909 . . . . 0.0 109.413 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -105.1 145.12 30.96 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.223 -0.923 . . . . 0.0 109.399 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -56.68 151.45 31.03 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.278 -0.889 . . . . 0.0 109.558 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -78.22 -59.12 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.622 2.215 . . . . 0.0 110.081 179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.1 m -132.61 72.21 1.49 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.363 -0.836 . . . . 0.0 109.111 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.21 -19.79 63.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.342 -0.848 . . . . 0.0 109.811 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 m -138.32 -85.08 0.28 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.088 -1.007 . . . . 0.0 109.693 -179.845 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 53.39 -166.59 0.07 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -0.909 . . . . 0.0 109.337 -179.72 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.92 111.45 18.8 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.222 -0.924 . . . . 0.0 109.443 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 149.09 -58.61 0.46 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.27 115.15 1.67 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -162.85 -165.02 1.05 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -1.141 . . . . 0.0 109.535 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 21' ' ' GLY . . . 165.46 -54.95 0.26 Allowed Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.488 HG23 ' HA ' ' A' ' 78' ' ' ALA . 42.9 mm -68.55 -11.55 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.157 -1.202 . . . . 0.0 109.376 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.5 ttt180 -76.36 -16.32 59.77 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.327 -0.858 . . . . 0.0 109.6 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 10.6 t -63.34 -25.94 68.53 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.253 -0.904 . . . . 0.0 109.252 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.487 ' O ' HG13 ' A' ' 61' ' ' ILE . . . -54.36 -36.17 63.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 109.588 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -74.01 -32.55 63.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.141 -0.974 . . . . 0.0 109.425 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 81.9 mt -65.96 -40.7 88.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.267 -0.896 . . . . 0.0 109.541 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.538 HD13 ' CZ ' ' A' ' 26' ' ' PHE . 8.6 pt -76.69 -29.23 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.576 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -62.57 -39.26 93.1 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.187 -0.946 . . . . 0.0 109.711 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -68.98 -12.68 61.89 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.237 -0.914 . . . . 0.0 109.831 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -89.15 -7.84 54.88 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.182 -0.949 . . . . 0.0 109.542 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.522 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 100.8 -12.04 59.26 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.464 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 16.4 t -51.81 89.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.375 -1.073 . . . . 0.0 109.489 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.522 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -80.91 -5.66 57.7 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.307 -0.871 . . . . 0.0 109.099 179.568 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.951 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -125.2 134.84 52.21 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.211 -0.931 . . . . 0.0 109.523 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.416 ' C ' HD12 ' A' ' 70' ' ' ILE . 86.4 t -137.27 111.93 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.162 -0.961 . . . . 0.0 109.919 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.631 HD12 ' N ' ' A' ' 70' ' ' ILE . 1.7 mp -94.88 106.11 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.313 -0.867 . . . . 0.0 108.979 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.48 ' HB1' ' CG ' ' A' ' 20' ' ' PHE . . . -135.78 173.57 11.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.129 -0.982 . . . . 0.0 109.86 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.26 40.54 2.46 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.428 -0.795 . . . . 0.0 109.44 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' SER . . . . . 0.414 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 1.4 t -45.98 146.67 1.98 Allowed Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.207 -0.933 . . . . 0.0 109.41 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 35.9 Cg_endo -77.98 -17.92 13.36 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.642 2.228 . . . . 0.0 110.492 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -127.02 164.76 20.48 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.87 4.65 5.92 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.626 2.217 . . . . 0.0 110.431 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.48 ' O ' ' HB3' ' A' ' 80' ' ' GLU . 2.9 t-20 -62.3 -43.16 99.47 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.314 -0.866 . . . . 0.0 109.545 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.488 ' HA ' HG23 ' A' ' 55' ' ' ILE . . . -64.13 -57.71 8.78 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.283 -0.886 . . . . 0.0 109.53 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.695 ' CD1' HG21 ' A' ' 89' ' ' ILE . 9.2 m-85 -58.21 -21.42 47.81 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.58 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.48 ' HB3' ' O ' ' A' ' 77' ' ' ASN . 29.7 tt0 -62.17 -59.6 4.81 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.197 -0.939 . . . . 0.0 109.393 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.4 t -61.22 -44.88 99.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.235 -0.916 . . . . 0.0 109.203 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 1.008 HD23 HD12 ' A' ' 87' ' ' ILE . 14.3 mt -50.35 -37.94 39.63 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.248 -0.907 . . . . 0.0 109.307 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -64.31 -42.87 96.13 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.344 -0.848 . . . . 0.0 109.363 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -69.98 -15.69 63.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.328 -0.858 . . . . 0.0 109.338 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.476 ' HB3' HG13 ' A' ' 87' ' ' ILE . 17.9 mt -95.6 -8.1 35.9 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.181 -0.95 . . . . 0.0 109.517 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 63.03 32.83 85.46 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 1.008 HD12 HD23 ' A' ' 82' ' ' LEU . 13.1 mt -96.22 171.4 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.234 -1.157 . . . . 0.0 109.511 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.524 ' H ' HG22 ' A' ' 87' ' ' ILE . 8.0 mttt -91.86 117.08 29.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.646 -179.767 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.695 HG21 ' CD1' ' A' ' 79' ' ' PHE . 10.5 mt -94.29 128.18 45.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.346 -0.846 . . . . 0.0 109.388 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.551 ' CE2' ' O ' ' A' ' 109' ' ' LEU . 2.2 m-85 -123.21 144.01 49.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.278 -0.889 . . . . 0.0 109.334 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ARG . . . . . 0.501 ' HG2' ' CG ' ' A' ' 111' ' ' GLU . 0.0 OUTLIER -91.21 132.05 36.35 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.158 -0.964 . . . . 0.0 109.653 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.02 94.3 9.57 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.239 -0.913 . . . . 0.0 109.409 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -135.46 23.14 3.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.125 -0.984 . . . . 0.0 109.624 -179.808 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -86.69 -134.26 3.84 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.669 -1.373 . . . . 0.0 109.669 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 96' ' ' SER . 5.2 t -136.14 -38.35 0.7 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.267 -1.137 . . . . 0.0 109.447 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.443 ' N ' HG23 ' A' ' 95' ' ' THR . 29.0 t -125.77 137.08 53.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.314 -0.866 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.955 HG11 ' HA ' ' A' ' 8' ' ' SER . 0.3 OUTLIER -55.03 -35.59 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -0.858 . . . . 0.0 109.406 179.916 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -69.2 -51.83 33.95 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.233 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.548 ' O ' HD13 ' A' ' 103' ' ' LEU . 3.2 tt0 -52.18 -31.67 32.71 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.244 -0.91 . . . . 0.0 109.166 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -72.39 -49.73 31.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.342 -0.848 . . . . 0.0 109.152 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.465 HD21 HG11 ' A' ' 29' ' ' VAL . 27.1 tp -50.4 -51.31 47.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.284 -0.885 . . . . 0.0 109.513 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -65.77 -35.4 80.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.205 -0.935 . . . . 0.0 109.492 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.548 HD13 ' O ' ' A' ' 99' ' ' GLU . 0.7 OUTLIER -71.71 -11.17 60.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.269 -0.895 . . . . 0.0 109.537 179.947 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.504 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.8 t80 -76.93 -38.3 53.68 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.263 -0.898 . . . . 0.0 109.453 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' THR . . . . . 0.421 ' O ' HG22 ' A' ' 105' ' ' THR . 28.8 m -72.09 -13.78 61.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.464 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -96.45 -17.23 20.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.182 -0.949 . . . . 0.0 109.49 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 74.43 29.45 61.89 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' ASN . . . . . 0.462 ' HB3' HD23 ' A' ' 103' ' ' LEU . 0.4 OUTLIER -79.96 -44.11 20.86 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.297 -1.119 . . . . 0.0 109.693 -179.882 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.551 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.4 OUTLIER -123.28 146.62 47.73 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.235 -0.916 . . . . 0.0 109.463 -179.949 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.528 ' HA ' ' CG ' ' A' ' 90' ' ' TYR . 1.1 pm0 -171.66 -156.79 0.11 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.904 . . . . 0.0 109.458 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.564 ' OE1' ' CE2' ' A' ' 79' ' ' PHE . 0.0 OUTLIER -146.29 -87.19 0.1 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.27 -0.894 . . . . 0.0 109.678 179.951 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 7.0 mt -131.37 151.37 35.51 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.192 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.435 ' HG2' ' HG2' ' A' ' 88' ' ' LYS . 0.0 OUTLIER -120.89 -62.02 1.49 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.34 -0.85 . . . . 0.0 109.382 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.489 ' N ' ' HD3' ' A' ' 115' ' ' PRO . 94.9 p -179.8 63.96 0.13 Allowed Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.203 -0.936 . . . . 0.0 109.573 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.489 ' HD3' ' N ' ' A' ' 114' ' ' SER . 35.6 Cg_endo -78.2 177.56 8.62 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.65 2.234 . . . . 0.0 110.319 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.442 ' O ' ' N ' ' A' ' 118' ' ' GLY . . . 72.99 56.25 5.9 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 116' ' ' GLY . 0.4 OUTLIER -43.96 99.73 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.308 -1.113 . . . . 0.0 109.37 -179.967 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 118' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 116' ' ' GLY . . . -102.34 72.86 0.32 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.01 -45.97 0.2 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.242 -1.152 . . . . 0.0 109.672 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 98.27 116.0 3.56 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.793 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.73 -70.4 0.79 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.26 -1.141 . . . . 0.0 109.505 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.8 1.56 9.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.548 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ARG . . . . . 0.508 ' NH1' ' HG3' ' A' ' 123' ' ' ARG . 0.4 OUTLIER -95.85 81.58 3.46 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.589 -179.895 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.487 0 CA-C-O 118.072 -0.966 . . . . 0.0 109.393 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.42 ' O ' ' HG2' ' A' ' 1' ' ' MET . 5.1 ttt . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.455 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 0.1 OUTLIER -131.18 156.05 45.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.218 -0.926 . . . . 0.0 109.521 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.63 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 7.0 mt -116.01 107.47 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.552 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.697 ' HB2' HD12 ' A' ' 28' ' ' ILE . . . -97.18 170.85 8.83 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.326 -0.859 . . . . 0.0 109.13 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.732 HG21 ' HB ' ' A' ' 97' ' ' VAL . 98.1 mt -148.13 119.93 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.172 -0.955 . . . . 0.0 109.889 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.538 ' HB1' ' HD1' ' A' ' 20' ' ' PHE . . . -87.14 143.95 27.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 108.949 179.565 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.426 ' HB2' ' O ' ' A' ' 6' ' ' ALA . 1.2 m 61.77 81.74 0.19 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.055 -1.028 . . . . 0.0 109.129 -179.723 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.646 ' HB2' HG21 ' A' ' 97' ' ' VAL . 0.0 OUTLIER -136.32 -37.63 0.7 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.308 -179.788 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.49 -171.95 27.05 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.05 9.99 15.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.175 -1.191 . . . . 0.0 109.454 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 47.5 p-10 -170.25 -174.14 1.65 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.483 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.627 ' H ' HD23 ' A' ' 12' ' ' LEU . 0.7 OUTLIER -75.66 -20.97 58.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.21 -0.932 . . . . 0.0 109.456 179.941 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.496 ' N ' ' HG ' ' A' ' 12' ' ' LEU . . . -46.38 -45.5 16.45 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.499 ' CB ' ' O ' ' A' ' 8' ' ' SER . 0.6 OUTLIER -76.15 81.43 2.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.278 -1.131 . . . . 0.0 109.429 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLU . . . . . 0.66 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -73.27 83.06 1.38 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.339 -0.851 . . . . 0.0 109.359 179.874 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.885 HG21 ' HA2' ' A' ' 94' ' ' GLY . 2.6 t 78.01 77.56 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.485 -0.759 . . . . 0.0 109.478 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 16' ' ' VAL . 0.1 OUTLIER -43.59 -73.92 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -0.914 . . . . 0.0 109.594 -179.93 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -140.33 -82.06 0.25 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.23 -0.919 . . . . 0.0 109.542 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -146.29 -144.71 0.16 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.29 -0.882 . . . . 0.0 109.332 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.538 ' HD1' ' HB1' ' A' ' 6' ' ' ALA . 16.6 t80 -121.5 27.5 8.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.172 -0.955 . . . . 0.0 109.497 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -83.07 -74.7 1.2 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.427 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.5 OUTLIER -123.0 27.98 7.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.277 -1.131 . . . . 0.0 109.349 179.929 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -50.91 108.46 1.05 Allowed Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.371 -0.83 . . . . 0.0 109.34 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.3 Cg_endo -79.57 39.27 0.81 Allowed 'Trans proline' 0 C--N 1.311 -1.425 0 C-N-CA 122.566 2.178 . . . . 0.0 111.077 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.542 ' CD1' ' HG2' ' A' ' 43' ' ' GLU . 48.1 m-85 -155.55 67.16 0.63 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.98 -1.075 . . . . 0.0 109.065 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.647 ' CZ ' ' HB1' ' A' ' 4' ' ' ALA . 9.2 t80 -81.88 120.25 24.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.436 -0.79 . . . . 0.0 109.592 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 4.5 ttm -103.45 159.99 15.1 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.277 -0.889 . . . . 0.0 109.558 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.756 HD11 HG22 ' A' ' 66' ' ' VAL . 1.1 tp -148.53 133.01 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.268 -0.895 . . . . 0.0 109.54 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.591 HG11 HD11 ' A' ' 101' ' ' LEU . 39.5 t -143.11 124.83 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.592 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -99.09 171.4 8.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.235 -0.916 . . . . 0.0 109.317 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 13.6 ttm -139.66 138.93 36.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -0.893 . . . . 0.0 109.583 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.74 -47.82 6.02 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.21 -0.931 . . . . 0.0 109.522 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 13.1 mttp -153.27 41.09 0.55 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.235 -0.916 . . . . 0.0 109.463 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.99 -8.53 55.92 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.483 ' O ' ' HG2' ' A' ' 37' ' ' GLU . 6.9 m-20 -117.02 97.18 5.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -1.157 . . . . 0.0 109.356 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.486 ' O ' HG13 ' A' ' 36' ' ' ILE . 5.6 pt -47.25 113.02 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.412 -0.805 . . . . 0.0 109.586 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.483 ' HG2' ' O ' ' A' ' 35' ' ' ASN . 14.9 mm-40 -109.72 19.26 19.36 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -0.917 . . . . 0.0 109.664 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 2.1 p -163.53 120.78 1.82 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 109.319 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.441 ' CB ' HG22 ' A' ' 29' ' ' VAL . 5.7 p -149.28 107.53 3.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.539 -179.804 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -117.3 156.27 28.09 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.171 -0.955 . . . . 0.0 109.516 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -126.19 138.71 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.257 -0.902 . . . . 0.0 109.402 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.566 HD12 ' HD3' ' A' ' 45' ' ' PRO . 40.8 pt -135.71 146.43 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.351 -0.843 . . . . 0.0 109.614 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.542 ' HG2' ' CD1' ' A' ' 25' ' ' TYR . 42.0 mt-10 -98.25 55.61 1.14 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.231 -0.918 . . . . 0.0 109.13 179.7 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 49.77 89.08 0.1 OUTLIER Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.323 -0.86 . . . . 0.0 109.372 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' PRO . . . . . 0.566 ' HD3' HD12 ' A' ' 42' ' ' ILE . 34.8 Cg_endo -77.65 -8.47 17.02 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.643 2.228 . . . . 0.0 110.366 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.45 41.09 1.04 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.313 -0.867 . . . . 0.0 109.377 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.03 -38.5 51.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.199 -0.938 . . . . 0.0 109.546 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 28.9 t -113.17 84.81 2.06 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.239 -0.913 . . . . 0.0 109.571 -179.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -145.76 158.39 43.86 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.272 -0.892 . . . . 0.0 109.485 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -58.07 175.03 0.23 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.234 -0.916 . . . . 0.0 109.488 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.519 ' O ' HD11 ' A' ' 60' ' ' ILE . . . 48.38 37.53 18.7 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.21 140.08 5.26 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -150.8 32.23 0.62 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.27 -1.135 . . . . 0.0 109.488 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 93.97 -91.51 1.47 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.809 HG23 ' HB2' ' A' ' 78' ' ' ALA . 34.6 mm -65.35 -33.24 62.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.319 -1.106 . . . . 0.0 109.648 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.74 -14.77 62.11 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.208 -0.932 . . . . 0.0 109.717 -179.826 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.448 ' HA ' HD12 ' A' ' 60' ' ' ILE . 85.7 m -67.53 -18.02 64.88 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.114 -0.991 . . . . 0.0 109.744 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ALA . . . . . 0.431 ' HB2' ' HE2' ' A' ' 20' ' ' PHE . . . -60.28 -28.16 67.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.235 -0.916 . . . . 0.0 109.654 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -62.67 -49.75 73.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.295 -0.878 . . . . 0.0 109.687 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.519 HD11 ' O ' ' A' ' 51' ' ' GLY . 3.7 mt -64.04 -45.67 96.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.892 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 41.6 mt -52.2 -48.0 43.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.237 -0.914 . . . . 0.0 109.957 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.74 -37.45 84.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.171 -0.955 . . . . 0.0 109.998 -179.524 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 13.0 m-80 -66.25 -11.1 48.15 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.097 -1.002 . . . . 0.0 109.851 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -88.99 16.75 6.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.117 -0.989 . . . . 0.0 109.556 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.453 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 95.31 -20.75 47.89 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' VAL . . . . . 0.756 HG22 HD11 ' A' ' 28' ' ' ILE . 97.1 t -57.06 88.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.312 -1.111 . . . . 0.0 109.506 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.453 ' N ' ' O ' ' A' ' 65' ' ' GLY . 14.0 mttt -79.91 -8.45 59.33 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.329 -0.857 . . . . 0.0 108.777 179.331 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.63 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -128.05 138.61 52.64 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' VAL . . . . . 0.433 ' C ' HD12 ' A' ' 70' ' ' ILE . 95.3 t -141.37 122.08 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.112 -0.993 . . . . 0.0 109.821 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.582 HD12 ' N ' ' A' ' 70' ' ' ILE . 1.3 mp -93.43 144.5 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.345 -0.847 . . . . 0.0 108.804 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -176.81 175.94 1.56 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.127 -0.983 . . . . 0.0 109.755 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -153.04 66.51 0.79 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.412 -0.805 . . . . 0.0 109.347 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -73.02 158.92 86.43 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.238 -0.914 . . . . 0.0 109.568 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.55 -39.2 0.42 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.658 2.239 . . . . 0.0 110.764 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -121.22 178.45 16.38 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -179.677 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' PRO . . . . . 0.428 ' HA ' ' HB2' ' A' ' 79' ' ' PHE . 36.6 Cg_endo -80.28 40.67 1.0 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.853 2.369 . . . . 0.0 110.753 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 52.5 m-20 -76.1 -67.54 0.67 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.085 -1.01 . . . . 0.0 109.314 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ALA . . . . . 0.809 ' HB2' HG23 ' A' ' 55' ' ' ILE . . . -74.66 -25.91 59.51 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.32 179.733 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' PHE . . . . . 0.428 ' HB2' ' HA ' ' A' ' 76' ' ' PRO . 3.1 m-85 -66.23 -21.11 66.29 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.373 -0.829 . . . . 0.0 109.398 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.417 ' O ' ' HB2' ' A' ' 84' ' ' GLU . 11.8 mt-10 -77.4 -46.84 21.44 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.233 -0.917 . . . . 0.0 109.833 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.4 t -68.65 -36.13 73.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.132 -0.98 . . . . 0.0 109.824 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.498 ' HB3' ' CG1' ' A' ' 89' ' ' ILE . 8.7 mt -73.75 -57.61 3.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.268 -0.895 . . . . 0.0 109.707 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.425 ' N ' HD11 ' A' ' 89' ' ' ILE . 8.2 t-20 -49.53 -37.78 28.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.212 -0.93 . . . . 0.0 109.6 -179.829 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.417 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 0.3 OUTLIER -73.02 -39.34 66.08 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.217 -0.927 . . . . 0.0 109.403 -179.947 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 85' ' ' LEU . . . . . 0.424 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.3 OUTLIER -64.54 -13.12 51.06 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.134 -0.979 . . . . 0.0 109.475 -179.943 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 75.13 26.57 66.05 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ILE . . . . . 0.521 HG22 ' N ' ' A' ' 88' ' ' LYS . 23.1 mm -91.91 160.85 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.345 -1.091 . . . . 0.0 109.423 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' LYS . . . . . 0.521 ' N ' HG22 ' A' ' 87' ' ' ILE . 7.8 mtpt -83.01 105.14 13.76 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.169 -0.957 . . . . 0.0 109.309 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ILE . . . . . 0.511 ' O ' ' CB ' ' A' ' 111' ' ' GLU . 3.1 mt -90.75 152.33 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.182 -0.949 . . . . 0.0 109.513 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' TYR . . . . . 0.484 ' CD1' ' O ' ' A' ' 110' ' ' GLU . 1.1 m-85 -136.63 141.27 43.22 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -0.875 . . . . 0.0 109.404 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.25 149.19 22.85 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.537 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.86 141.04 38.72 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.277 -0.889 . . . . 0.0 109.365 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.98 -17.28 24.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.541 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.885 ' HA2' HG21 ' A' ' 16' ' ' VAL . . . 101.94 13.55 31.4 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 52.0 m -81.19 -55.3 4.83 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -1.16 . . . . 0.0 109.459 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 173.16 130.19 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.321 -0.862 . . . . 0.0 109.572 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.732 ' HB ' HG21 ' A' ' 5' ' ' ILE . 33.6 m -65.02 -23.79 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.374 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' GLU . . . . . 0.54 ' HB2' ' CB ' ' A' ' 12' ' ' LEU . 1.5 tt0 -65.89 -60.05 3.24 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.277 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.882 ' O ' HD12 ' A' ' 103' ' ' LEU . 36.1 mm-40 -60.38 -28.66 68.39 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.291 -0.881 . . . . 0.0 109.33 179.793 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ASN . . . . . 0.439 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 6.4 m-20 -69.68 -30.58 68.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.286 -0.884 . . . . 0.0 109.409 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' LEU . . . . . 0.711 HD23 ' N ' ' A' ' 102' ' ' LYS . 6.8 tt -59.87 -60.08 4.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.404 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' LYS . . . . . 0.711 ' N ' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -64.94 -29.07 69.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.319 -0.863 . . . . 0.0 109.38 179.922 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.882 HD12 ' O ' ' A' ' 99' ' ' GLU . 0.4 OUTLIER -65.46 -30.69 71.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.239 -0.913 . . . . 0.0 109.627 -179.935 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 104' ' ' PHE . . . . . 0.434 ' CD1' HD11 ' A' ' 3' ' ' ILE . 23.4 t80 -59.75 -32.1 70.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.192 -0.942 . . . . 0.0 109.589 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 28.3 m -67.19 -40.92 86.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.887 . . . . 0.0 109.73 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -79.8 4.99 14.76 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.276 -0.89 . . . . 0.0 109.553 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 46.09 28.98 3.23 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -80.01 -33.2 39.48 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.193 -1.181 . . . . 0.0 109.379 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.433 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 45.5 mt -65.84 -176.93 0.42 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.313 -0.867 . . . . 0.0 109.306 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.484 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 11.3 pt-20 -108.48 143.59 37.24 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.572 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' GLU . . . . . 0.511 ' CB ' ' O ' ' A' ' 89' ' ' ILE . 0.0 OUTLIER -137.06 -174.01 3.62 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.276 -0.89 . . . . 0.0 109.298 179.863 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.444 HG13 ' O ' ' A' ' 111' ' ' GLU . 2.3 mp -147.99 147.48 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.18 -0.95 . . . . 0.0 109.493 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ARG . . . . . 0.435 ' HB2' ' O ' ' A' ' 112' ' ' ILE . 0.0 OUTLIER 179.1 -65.66 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.331 -0.855 . . . . 0.0 109.417 179.945 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -166.07 85.68 0.94 Allowed Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.241 -0.912 . . . . 0.0 109.258 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.63 12.79 2.28 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.811 2.341 . . . . 0.0 110.999 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -145.23 161.52 28.16 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 37.8 t -114.83 -10.08 12.41 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.196 -1.179 . . . . 0.0 109.479 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -67.49 -36.05 87.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.35 160.06 0.08 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.265 -1.138 . . . . 0.0 109.501 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.517 ' O ' ' CG ' ' A' ' 121' ' ' ARG . . . 157.72 96.81 0.12 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.517 ' CG ' ' O ' ' A' ' 120' ' ' GLY . 0.0 OUTLIER -179.8 58.84 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.222 -1.164 . . . . 0.0 109.385 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 3.6 mtp180 -65.41 109.75 2.41 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.258 -0.901 . . . . 0.0 109.489 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -167.69 120.61 0.91 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.174 -0.954 . . . . 0.0 109.61 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 117.955 -1.022 . . . . 0.0 109.474 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.271 0.558 . . . . 0.0 109.513 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.5 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 23.2 mttp -110.91 128.27 55.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.232 -0.917 . . . . 0.0 109.501 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.853 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 3.9 mt -95.51 128.05 47.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.301 -0.875 . . . . 0.0 109.57 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.65 ' C ' HD13 ' A' ' 5' ' ' ILE . . . -116.33 122.55 45.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.205 -0.934 . . . . 0.0 109.451 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.749 ' N ' HD13 ' A' ' 5' ' ' ILE . 1.2 mm -97.24 115.53 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.196 -0.94 . . . . 0.0 109.485 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.518 ' HA ' ' CE1' ' A' ' 26' ' ' PHE . . . -59.01 146.58 37.73 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.297 -0.877 . . . . 0.0 109.626 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 2.4 m 52.73 -98.09 0.07 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -0.851 . . . . 0.0 109.611 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.604 ' HB3' HG11 ' A' ' 97' ' ' VAL . 75.4 m 59.05 15.36 3.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.078 -1.014 . . . . 0.0 109.448 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.554 ' N ' ' HB3' ' A' ' 14' ' ' SER . . . 52.69 -150.96 8.78 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.3 m -129.5 -8.38 4.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.243 -1.151 . . . . 0.0 110.092 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.591 ' HB3' HD23 ' A' ' 12' ' ' LEU . 0.4 OUTLIER -131.19 -89.17 0.46 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.965 -1.084 . . . . 0.0 109.873 -179.845 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.591 HD23 ' HB3' ' A' ' 11' ' ' ASP . 0.7 OUTLIER -158.99 26.33 0.21 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.167 -0.958 . . . . 0.0 109.669 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.86 -41.17 1.47 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.554 ' HB3' ' N ' ' A' ' 9' ' ' GLY . 0.7 OUTLIER -77.34 84.17 3.77 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.251 -1.146 . . . . 0.0 109.48 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.482 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER -72.44 83.31 1.08 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.441 -0.787 . . . . 0.0 109.556 179.982 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.482 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 14.2 t 70.23 5.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.383 -0.823 . . . . 0.0 109.769 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 51.6 -95.91 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.286 -0.884 . . . . 0.0 109.682 179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.408 ' N ' ' O ' ' A' ' 16' ' ' VAL . 2.2 mtt180 -158.35 -77.93 0.07 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.029 -1.044 . . . . 0.0 109.707 -179.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.421 ' CD2' ' O ' ' A' ' 72' ' ' SER . 22.4 m-85 -117.17 174.3 6.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.221 -0.924 . . . . 0.0 109.632 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.695 ' CB ' ' HB1' ' A' ' 71' ' ' ALA . 2.9 t80 -117.04 104.72 11.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.254 -0.903 . . . . 0.0 109.402 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.459 ' HA2' ' CD1' ' A' ' 55' ' ' ILE . . . -143.01 -57.94 0.03 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.437 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.6 mtp85 -128.75 17.2 6.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.307 -1.114 . . . . 0.0 109.24 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -48.16 106.63 0.63 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.337 -0.852 . . . . 0.0 109.776 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.503 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 37.0 Cg_endo -80.74 42.23 1.29 Allowed 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.609 2.206 . . . . 0.0 110.477 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.503 ' CD2' ' O ' ' A' ' 24' ' ' PRO . 5.7 m-85 -159.83 69.53 0.42 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.09 -1.007 . . . . 0.0 109.584 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.518 ' CE1' ' HA ' ' A' ' 6' ' ' ALA . 0.1 OUTLIER -84.61 112.86 20.82 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.214 -0.929 . . . . 0.0 109.215 179.865 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -79.74 135.39 36.5 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.291 -0.88 . . . . 0.0 109.77 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 14.3 mm -108.25 138.47 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.209 -0.932 . . . . 0.0 109.323 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.425 HG13 HG23 ' A' ' 36' ' ' ILE . 75.8 t -131.92 103.83 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.385 -0.822 . . . . 0.0 109.459 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -85.43 88.65 7.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.183 -0.948 . . . . 0.0 109.539 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -82.83 141.73 32.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.316 -0.865 . . . . 0.0 109.386 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 4.9 tptt -117.58 -72.08 0.71 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.127 -0.983 . . . . 0.0 109.463 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 23.3 mttm -110.58 58.84 0.61 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.206 -0.934 . . . . 0.0 109.395 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 65.0 13.5 57.47 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 36' ' ' ILE . 25.0 t30 -132.74 105.87 7.42 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.293 -1.122 . . . . 0.0 109.403 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.47 ' H ' HD12 ' A' ' 36' ' ' ILE . 3.3 mp -42.97 114.25 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.311 -0.868 . . . . 0.0 109.577 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -96.76 -9.52 28.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 109.492 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -159.62 119.23 2.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.27 -0.894 . . . . 0.0 109.513 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.6 p -120.83 102.89 8.67 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.229 -0.919 . . . . 0.0 108.906 179.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -121.7 -176.45 3.32 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.371 -0.831 . . . . 0.0 109.859 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.8 p -151.98 130.4 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.408 -0.808 . . . . 0.0 109.309 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.42 ' O ' HG13 ' A' ' 42' ' ' ILE . 12.2 pt -114.12 131.22 66.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.189 -0.944 . . . . 0.0 109.671 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -97.73 150.42 21.23 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.285 -0.884 . . . . 0.0 109.429 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.471 ' HB2' ' HB3' ' A' ' 24' ' ' PRO . 55.6 m-20 . . . . . 0 N--CA 1.49 1.575 0 O-C-N 121.319 -0.863 . . . . 0.0 109.404 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.724 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.283 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.459 ' CD1' ' HA2' ' A' ' 21' ' ' GLY . 7.1 mm -74.82 -7.32 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.268 -1.136 . . . . 0.0 109.516 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.33 -23.07 60.2 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.237 -0.914 . . . . 0.0 109.23 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.724 HG22 ' O ' ' A' ' 54' ' ' GLY . 6.1 t -57.47 -22.77 45.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.39 -0.819 . . . . 0.0 109.468 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.83 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -53.71 -50.0 66.88 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.306 -0.871 . . . . 0.0 109.624 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -46.41 -41.24 13.41 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.91 . . . . 0.0 109.625 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 50.4 mt -71.51 -39.97 71.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.237 -0.914 . . . . 0.0 109.703 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.83 HD12 ' HA ' ' A' ' 58' ' ' ALA . 63.4 mt -56.11 -32.82 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.226 -0.922 . . . . 0.0 109.473 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.498 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -76.67 -31.19 57.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.285 -0.884 . . . . 0.0 109.477 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 27.7 t30 -72.71 -14.38 61.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -0.876 . . . . 0.0 109.639 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -90.08 -1.22 57.92 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.206 -0.934 . . . . 0.0 109.649 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.52 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 87.4 -6.37 83.49 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.5 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 96.0 t -48.09 92.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -1.103 . . . . 0.0 109.662 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.52 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.6 OUTLIER -79.5 -2.09 40.54 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.371 -0.83 . . . . 0.0 108.813 179.38 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.853 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -134.79 129.52 34.7 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.861 . . . . 0.0 109.373 179.739 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.4 t -130.46 96.84 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.163 -0.96 . . . . 0.0 109.613 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.509 HD13 HD21 ' A' ' 100' ' ' ASN . 7.0 mt -91.22 109.73 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.213 -0.929 . . . . 0.0 109.288 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.695 ' HB1' ' CB ' ' A' ' 20' ' ' PHE . . . -144.08 176.94 8.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.248 -0.908 . . . . 0.0 109.778 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.635 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 75.1 m -133.38 41.6 3.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.527 -0.733 . . . . 0.0 109.435 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.423 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.8 OUTLIER -53.64 143.12 39.91 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.307 -0.871 . . . . 0.0 109.459 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 35.8 Cg_endo -79.03 88.04 1.5 Allowed 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 122.639 2.226 . . . . 0.0 110.601 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 122.5 162.6 11.6 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.404 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.3 Cg_endo -78.84 7.88 4.05 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 C-N-CA 122.75 2.3 . . . . 0.0 110.591 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 80' ' ' GLU . 1.5 m120 -55.25 -65.66 0.55 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.226 -0.921 . . . . 0.0 109.583 -179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.8 -51.93 67.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.906 . . . . 0.0 109.675 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.8 m-30 -57.76 -15.97 9.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.223 -0.923 . . . . 0.0 109.754 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.472 ' HB3' ' O ' ' A' ' 77' ' ' ASN . 54.0 tt0 -72.82 -50.34 24.77 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.197 -0.939 . . . . 0.0 109.302 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 82' ' ' LEU . 2.4 t -71.3 -53.16 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 O-C-N 121.289 -0.882 . . . . 0.0 109.258 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.519 ' HB3' ' CG1' ' A' ' 89' ' ' ILE . 4.4 mm? -45.75 -30.09 1.51 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.14 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -77.06 -47.75 19.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.336 -0.853 . . . . 0.0 109.346 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -68.02 -8.63 39.18 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.244 -0.91 . . . . 0.0 109.59 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.6 mp -86.48 -48.4 8.43 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.22 -0.925 . . . . 0.0 109.539 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.35 11.1 9.96 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.498 HD11 ' HB2' ' A' ' 62' ' ' ALA . 1.6 mt -91.69 172.37 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.24 -1.153 . . . . 0.0 109.419 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.477 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 0.1 OUTLIER -90.35 114.66 26.8 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.269 -0.894 . . . . 0.0 109.669 -179.926 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.519 ' CG1' ' HB3' ' A' ' 82' ' ' LEU . 5.9 mt -82.77 150.37 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.294 -0.879 . . . . 0.0 108.939 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.566 ' CE2' ' HB3' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -139.68 148.17 42.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.625 -179.95 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.42 140.2 39.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.315 -0.866 . . . . 0.0 109.614 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.635 ' HB3' ' OG ' ' A' ' 72' ' ' SER . . . -110.32 88.04 2.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.936 . . . . 0.0 109.677 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.92 -40.32 42.98 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -0.901 . . . . 0.0 109.29 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 128.3 116.43 1.95 Allowed Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -164.38 -67.3 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.198 -1.178 . . . . 0.0 109.471 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.472 ' O ' ' HB2' ' A' ' 100' ' ' ASN . 0.1 OUTLIER 171.71 157.21 0.09 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.244 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.63 HG13 HG21 ' A' ' 5' ' ' ILE . 1.8 t -74.28 -48.07 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.278 -0.889 . . . . 0.0 109.651 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -50.93 -50.16 58.29 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.276 -0.89 . . . . 0.0 109.846 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 31.0 mm-40 -70.55 -35.58 73.18 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.224 -0.923 . . . . 0.0 109.893 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.55 ' OD1' HD11 ' A' ' 109' ' ' LEU . 7.4 t30 -56.23 -39.08 71.96 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.165 -0.96 . . . . 0.0 109.735 -179.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 75.7 mt -57.77 -62.92 1.45 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.233 -0.917 . . . . 0.0 109.558 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 5.7 ttpt -62.52 -15.11 48.77 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.212 -0.93 . . . . 0.0 109.575 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.469 HD12 ' HA ' ' A' ' 103' ' ' LEU . 0.9 OUTLIER -77.09 -33.55 56.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.224 -0.922 . . . . 0.0 109.799 -179.791 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.746 ' CD2' HD11 ' A' ' 3' ' ' ILE . 79.3 t80 -74.2 -24.78 59.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.163 -0.961 . . . . 0.0 109.765 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 61.3 m -72.24 -22.91 61.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.227 -0.92 . . . . 0.0 109.674 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -103.79 4.95 35.67 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 109.597 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 55.95 40.54 82.17 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 -79.96 -51.45 9.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.192 -1.181 . . . . 0.0 109.558 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.55 HD11 ' OD1' ' A' ' 100' ' ' ASN . 13.8 mt -56.34 176.8 0.08 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 109.497 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.425 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 8.7 pt-20 -109.65 148.4 31.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.286 -0.884 . . . . 0.0 109.42 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.566 ' HB3' ' CE2' ' A' ' 90' ' ' TYR . 6.1 pt-20 -134.25 155.68 49.75 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.232 -0.917 . . . . 0.0 109.656 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 67.5 mt -135.36 143.44 36.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.321 -0.862 . . . . 0.0 109.047 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.54 0 O-C-N 121.112 -0.992 . . . . 0.0 109.909 -179.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.476 ' HA ' ' HB2' ' A' ' 67' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.456 ' HD2' ' O ' ' A' ' 65' ' ' GLY . 0.5 OUTLIER -89.29 147.4 24.13 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.223 -0.923 . . . . 0.0 109.474 -179.926 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.531 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 5.3 mt -115.08 119.86 62.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.212 -0.93 . . . . 0.0 109.701 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.567 ' CB ' HD13 ' A' ' 28' ' ' ILE . . . -112.87 111.45 22.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.279 -0.888 . . . . 0.0 109.073 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.74 HG23 ' CG2' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -98.41 126.19 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.228 -0.92 . . . . 0.0 109.8 -179.487 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.49 134.27 42.28 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.302 -0.874 . . . . 0.0 109.153 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.414 ' OG ' ' HG3' ' A' ' 27' ' ' MET . 0.0 OUTLIER -144.45 156.08 44.03 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.067 -1.02 . . . . 0.0 109.768 -179.814 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.42 -26.56 11.4 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.345 -0.847 . . . . 0.0 109.427 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -87.63 -105.62 0.9 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -148.73 -45.05 0.15 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.155 -1.203 . . . . 0.0 109.407 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' A' ' 11' ' ' ASP . 2.3 t70 -154.47 -55.29 0.1 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 109.367 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.2 tt -105.62 -37.69 6.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.18 -0.95 . . . . 0.0 109.337 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -57.71 -26.47 57.5 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.443 ' OG ' HG22 ' A' ' 97' ' ' VAL . 54.4 p -76.92 80.14 3.48 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.271 -1.135 . . . . 0.0 109.439 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.531 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.3 OUTLIER -76.88 82.0 3.45 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.261 -0.899 . . . . 0.0 109.575 -179.88 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.531 HG23 ' C ' ' A' ' 15' ' ' GLU . 3.0 t 73.16 19.64 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.255 -0.903 . . . . 0.0 109.651 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 44.36 -163.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.209 -0.932 . . . . 0.0 109.422 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.32 -32.71 2.67 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -0.902 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -150.12 -179.83 7.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.141 -0.974 . . . . 0.0 109.666 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.452 ' CG ' ' HB1' ' A' ' 71' ' ' ALA . 21.7 t80 -121.77 83.78 2.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.356 -0.84 . . . . 0.0 109.404 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 147.1 -18.64 1.56 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.442 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 1.6 mtp180 -110.55 -29.41 8.07 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.257 -1.143 . . . . 0.0 109.373 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.37 110.61 2.47 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.917 . . . . 0.0 109.399 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.5 46.65 2.31 Favored 'Trans proline' 0 C--N 1.312 -1.369 0 C-N-CA 122.692 2.261 . . . . 0.0 110.948 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.472 ' CE2' ' OE2' ' A' ' 43' ' ' GLU . 11.3 m-85 -158.51 70.01 0.51 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.99 -1.068 . . . . 0.0 109.417 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.499 ' CD1' ' HB2' ' A' ' 44' ' ' ASN . 46.1 m-85 -81.4 153.53 26.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.2 -0.937 . . . . 0.0 109.737 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . 0.45 ' O ' ' HA ' ' A' ' 4' ' ' ALA . 37.9 mtp -120.3 114.16 21.47 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.34 -0.85 . . . . 0.0 109.041 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.567 HD13 ' CB ' ' A' ' 4' ' ' ALA . 26.6 mm -105.46 120.48 56.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.158 -0.964 . . . . 0.0 109.797 -179.566 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.707 HG11 HD12 ' A' ' 36' ' ' ILE . 44.2 t -122.74 116.03 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.362 -0.836 . . . . 0.0 109.301 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -89.73 86.84 6.78 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.25 -0.906 . . . . 0.0 109.615 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.748 ' HE1' HG23 ' A' ' 105' ' ' THR . 1.2 ttp -83.29 125.07 31.22 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.179 -0.951 . . . . 0.0 109.328 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -87.99 -91.3 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.229 -0.919 . . . . 0.0 109.765 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.431 ' O ' ' C ' ' A' ' 34' ' ' GLY . 3.6 tmtm? -98.52 85.39 3.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.16 -0.962 . . . . 0.0 109.743 -179.679 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 43.07 33.99 1.95 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -144.4 104.11 4.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.139 -1.212 . . . . 0.0 109.504 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.707 HD12 HG11 ' A' ' 29' ' ' VAL . 3.9 tt -53.57 118.63 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.29 -0.881 . . . . 0.0 109.232 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -127.75 26.2 5.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.227 -0.92 . . . . 0.0 109.662 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.462 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER 176.25 128.2 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.629 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.657 ' OG ' HD11 ' A' ' 36' ' ' ILE . 5.5 m -156.19 112.4 3.06 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.242 -0.911 . . . . 0.0 109.304 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -130.11 139.0 50.97 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.184 -0.947 . . . . 0.0 109.707 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.3 t -92.36 154.49 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.086 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.0 tt -147.47 142.53 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.125 -0.984 . . . . 0.0 109.822 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.472 ' OE2' ' CE2' ' A' ' 25' ' ' TYR . 1.9 mt-10 -88.55 79.31 7.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.319 -0.863 . . . . 0.0 109.177 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.499 ' HB2' ' CD1' ' A' ' 26' ' ' PHE . 1.4 m-80 . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.2 -0.937 . . . . 0.0 109.521 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.242 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.4 mm -72.95 -19.56 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.26 -1.141 . . . . 0.0 109.672 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 3.7 mtt-85 -74.98 -16.61 60.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.141 -0.974 . . . . 0.0 109.486 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.666 ' HA ' HD12 ' A' ' 60' ' ' ILE . 53.3 m -67.94 -24.9 65.23 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.271 -0.893 . . . . 0.0 109.418 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -51.9 -56.05 16.46 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.32 -0.862 . . . . 0.0 109.651 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -51.04 -36.42 39.61 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.275 -0.891 . . . . 0.0 109.777 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.666 HD12 ' HA ' ' A' ' 57' ' ' THR . 76.9 mt -63.82 -63.5 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.177 -0.952 . . . . 0.0 109.838 -179.595 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.77 HG23 HG21 ' A' ' 66' ' ' VAL . 10.5 mt -53.67 -24.46 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.231 -0.918 . . . . 0.0 109.935 -179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.596 ' CB ' HD11 ' A' ' 87' ' ' ILE . . . -65.28 -46.73 79.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.131 -0.981 . . . . 0.0 109.8 -179.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 9.2 m-20 -77.65 6.85 6.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.275 -0.89 . . . . 0.0 110.293 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.644 ' HB3' HG23 ' A' ' 66' ' ' VAL . 0.7 OUTLIER -96.1 7.56 46.08 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.997 -1.064 . . . . 0.0 109.835 -179.859 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.456 ' O ' ' HD2' ' A' ' 2' ' ' LYS . . . 73.07 8.81 75.02 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.77 HG21 HG23 ' A' ' 61' ' ' ILE . 17.6 t -68.61 97.5 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.301 -1.117 . . . . 0.0 109.574 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.525 ' O ' ' CB ' ' A' ' 88' ' ' LYS . 13.4 tttt -79.11 -3.92 47.75 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.647 ' O ' HG12 ' A' ' 66' ' ' VAL . . . -138.79 131.38 28.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.319 -0.863 . . . . 0.0 109.002 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.6 t -128.84 109.2 18.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.061 -1.024 . . . . 0.0 109.791 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.74 ' CG2' HG23 ' A' ' 5' ' ' ILE . 2.1 mp -89.51 95.09 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.133 -0.98 . . . . 0.0 109.137 179.674 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.452 ' HB1' ' CG ' ' A' ' 20' ' ' PHE . . . -126.67 171.92 10.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 109.573 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.6 p -130.52 29.67 4.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.282 -0.886 . . . . 0.0 109.498 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -49.22 151.06 2.67 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.279 -0.888 . . . . 0.0 109.636 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.29 -72.48 0.01 OUTLIER 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.705 2.27 . . . . 0.0 110.467 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.419 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -68.26 145.5 44.5 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.419 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.8 Cg_endo -78.69 6.29 4.98 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.653 2.236 . . . . 0.0 110.473 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -53.94 -57.43 11.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.281 -0.887 . . . . 0.0 109.511 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.691 ' O ' HD12 ' A' ' 82' ' ' LEU . . . -57.6 -45.0 85.86 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.23 -0.919 . . . . 0.0 109.5 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 18.4 m-30 -56.59 -27.39 57.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.178 -0.951 . . . . 0.0 109.343 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.48 -36.85 68.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.307 -0.87 . . . . 0.0 109.465 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 41.6 t -69.19 -46.19 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.492 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.691 HD12 ' O ' ' A' ' 78' ' ' ALA . 3.1 mp -53.18 -37.09 61.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.219 -0.925 . . . . 0.0 109.615 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 13.5 t-20 -61.67 -40.81 96.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 109.622 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -76.6 -20.75 56.43 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.173 -0.955 . . . . 0.0 109.555 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.562 ' HB3' HD12 ' A' ' 87' ' ' ILE . 0.3 OUTLIER -87.13 -14.82 40.21 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.265 -0.897 . . . . 0.0 109.522 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 86.93 11.71 69.77 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.596 HD11 ' CB ' ' A' ' 62' ' ' ALA . 9.3 mt -87.51 145.5 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -1.176 . . . . 0.0 109.587 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.525 ' CB ' ' O ' ' A' ' 67' ' ' LYS . 6.1 ttmm -80.05 116.75 20.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.124 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.671 HD12 ' HA ' ' A' ' 113' ' ' ARG . 3.3 mt -80.93 106.42 12.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.274 -0.891 . . . . 0.0 109.602 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.571 ' CD2' ' O ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -103.18 142.35 34.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.333 -0.855 . . . . 0.0 109.158 179.825 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.467 ' O ' ' HB3' ' A' ' 110' ' ' GLU . 20.6 ttt180 -106.02 145.76 30.97 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.182 -0.949 . . . . 0.0 109.606 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.98 92.13 8.93 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.327 -0.858 . . . . 0.0 109.277 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 58.9 m -107.46 -16.41 14.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.255 -0.903 . . . . 0.0 109.691 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -66.05 -128.71 0.02 OUTLIER Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.483 ' O ' HG23 ' A' ' 16' ' ' VAL . 9.8 t -142.13 -32.98 0.5 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.319 -1.107 . . . . 0.0 109.927 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -133.54 151.83 51.8 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.138 -0.976 . . . . 0.0 109.356 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.443 HG22 ' OG ' ' A' ' 14' ' ' SER . 35.1 m -71.06 -34.29 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.25 -0.906 . . . . 0.0 109.7 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.37 -47.91 83.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.245 -0.91 . . . . 0.0 109.803 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -71.75 -42.78 66.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.271 -0.893 . . . . 0.0 109.942 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 48.3 t-20 -52.91 -33.98 52.93 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.201 -0.937 . . . . 0.0 109.669 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.561 HD11 HD12 ' A' ' 36' ' ' ILE . 1.7 tt -57.12 -42.93 81.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.248 -0.907 . . . . 0.0 109.841 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.49 ' N ' HD23 ' A' ' 101' ' ' LEU . 0.5 OUTLIER -74.48 -33.36 62.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.117 -0.989 . . . . 0.0 110.039 -179.487 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -39.81 94.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.107 -0.996 . . . . 0.0 109.826 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.526 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 6.4 t80 -70.15 -30.02 67.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.18 -0.95 . . . . 0.0 109.813 -179.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.748 HG23 ' HE1' ' A' ' 31' ' ' MET . 0.2 OUTLIER -67.21 -29.86 69.64 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.128 -0.982 . . . . 0.0 109.935 -179.615 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -99.31 13.06 34.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.139 -0.976 . . . . 0.0 109.606 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 52.17 57.72 12.51 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.069 -1.612 . . . . 0.0 109.069 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -81.87 -54.86 5.0 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.368 -1.078 . . . . 0.0 109.781 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.541 HD23 ' H ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER 178.04 -152.03 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.093 -1.004 . . . . 0.0 109.742 -179.835 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.571 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 13.8 mt-10 60.29 25.17 14.61 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.375 -0.828 . . . . 0.0 109.459 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.592 ' C ' HD12 ' A' ' 112' ' ' ILE . 7.5 pt-20 -103.94 135.95 44.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.343 -0.848 . . . . 0.0 109.358 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.592 HD12 ' C ' ' A' ' 111' ' ' GLU . 3.2 mp -153.15 135.06 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.3 -0.875 . . . . 0.0 109.421 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.671 ' HA ' HD12 ' A' ' 89' ' ' ILE . 26.4 ttp180 . . . . . 0 N--CA 1.49 1.542 0 O-C-N 121.224 -0.922 . . . . 0.0 109.346 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.7 mmm . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.479 ' HD3' ' O ' ' A' ' 65' ' ' GLY . 1.2 mttm -120.65 136.72 54.75 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.324 -0.86 . . . . 0.0 109.552 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.497 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 5.4 mt -114.44 108.43 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.318 -0.864 . . . . 0.0 109.399 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.7 ' HB1' ' CZ ' ' A' ' 26' ' ' PHE . . . -112.37 127.6 56.06 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.25 -0.906 . . . . 0.0 109.306 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.928 HG21 HG12 ' A' ' 97' ' ' VAL . 27.9 mt -102.88 139.71 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.555 -179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.3 170.07 17.2 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.384 -0.823 . . . . 0.0 109.421 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.465 ' O ' ' HB3' ' A' ' 8' ' ' SER . 54.3 p 46.32 -141.38 0.39 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.259 -0.901 . . . . 0.0 109.333 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.9 ' HB2' HG11 ' A' ' 97' ' ' VAL . 42.4 t 63.61 51.81 2.41 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.119 -0.988 . . . . 0.0 109.415 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.537 ' N ' ' HB3' ' A' ' 14' ' ' SER . . . -50.87 106.23 0.25 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.481 ' HG1' ' H ' ' A' ' 11' ' ' ASP . 3.2 p 49.01 -90.65 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.343 -1.092 . . . . 0.0 109.89 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.517 ' N ' ' O ' ' A' ' 9' ' ' GLY . 1.0 OUTLIER 173.15 -150.61 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.198 -0.939 . . . . 0.0 109.446 -179.687 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.461 ' HB3' ' O ' ' A' ' 11' ' ' ASP . 12.9 tp 70.25 13.2 7.66 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.257 -0.902 . . . . 0.0 109.362 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 145.77 -23.66 1.8 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.537 ' HB3' ' N ' ' A' ' 9' ' ' GLY . 43.4 m -77.2 82.51 3.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.193 -1.18 . . . . 0.0 109.64 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.467 ' HA ' HG22 ' A' ' 97' ' ' VAL . 0.2 OUTLIER -72.75 -114.2 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.202 -0.936 . . . . 0.0 109.456 -179.826 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.747 HG22 HG13 ' A' ' 97' ' ' VAL . 5.0 t -115.47 23.47 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 120.738 -1.227 . . . . 0.0 109.679 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.433 ' HB2' ' HB2' ' A' ' 7' ' ' SER . 4.3 t 47.06 -150.26 0.11 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.178 -0.951 . . . . 0.0 109.345 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.55 12.95 1.53 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.192 -0.943 . . . . 0.0 109.595 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.466 ' CD1' ' O ' ' A' ' 19' ' ' PHE . 28.1 p90 -153.8 144.52 22.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.223 -0.923 . . . . 0.0 109.66 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -123.82 89.88 3.17 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.313 -0.867 . . . . 0.0 109.218 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -145.26 -73.35 0.02 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.73 21.68 16.26 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -1.172 . . . . 0.0 109.675 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -58.33 113.25 6.18 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.243 -0.911 . . . . 0.0 109.23 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.474 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 36.8 Cg_endo -80.74 54.34 5.19 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.571 2.181 . . . . 0.0 110.867 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.474 ' CD2' ' O ' ' A' ' 24' ' ' PRO . 31.4 m-85 -160.41 70.92 0.43 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.992 -1.068 . . . . 0.0 109.214 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.7 ' CZ ' ' HB1' ' A' ' 4' ' ' ALA . 40.1 t80 -79.92 104.58 10.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.429 -0.794 . . . . 0.0 109.732 -179.718 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . 0.727 ' CG ' HG12 ' A' ' 41' ' ' VAL . 0.2 OUTLIER -82.84 125.03 30.87 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.29 -0.881 . . . . 0.0 109.21 179.694 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.436 ' O ' HG23 ' A' ' 28' ' ' ILE . 1.4 tp -119.99 114.75 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.154 -0.966 . . . . 0.0 109.586 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.1 t -118.91 144.25 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.922 . . . . 0.0 109.408 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -117.63 136.18 53.48 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.261 -0.9 . . . . 0.0 109.445 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.8 mtt -119.86 132.18 55.49 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.209 -0.932 . . . . 0.0 109.545 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 13.4 mmtt -81.99 -79.76 0.17 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.308 -0.87 . . . . 0.0 109.299 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -126.16 86.53 2.54 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.3 -0.875 . . . . 0.0 109.174 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 48.87 34.12 14.71 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 36' ' ' ILE . 0.6 OUTLIER -149.12 100.56 3.06 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.345 -1.091 . . . . 0.0 109.461 -179.859 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.413 ' C ' ' O ' ' A' ' 35' ' ' ASN . 4.3 tt -45.2 134.27 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.234 -0.916 . . . . 0.0 109.35 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.407 ' O ' ' HB2' ' A' ' 38' ' ' SER . 0.5 OUTLIER -145.65 20.11 1.49 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.303 -0.873 . . . . 0.0 109.497 -179.959 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.407 ' HB2' ' O ' ' A' ' 37' ' ' GLU . 5.1 t -179.21 129.66 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.266 -0.896 . . . . 0.0 109.471 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 96.0 p -151.2 115.3 5.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.284 -0.885 . . . . 0.0 109.337 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -132.09 132.26 43.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.276 -0.89 . . . . 0.0 109.629 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.727 HG12 ' CG ' ' A' ' 27' ' ' MET . 27.7 m -97.13 137.9 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.31 -0.869 . . . . 0.0 109.328 179.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 58.7 mt -123.79 145.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 0.0 109.558 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.442 ' HG2' ' CE1' ' A' ' 25' ' ' TYR . 2.8 mp0 -115.09 148.31 39.1 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.283 -0.886 . . . . 0.0 109.581 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 13.8 m-20 . . . . . 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.314 179.887 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.628 HD12 ' HB2' ' A' ' 78' ' ' ALA . 34.2 mm -73.62 -16.46 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.253 -1.145 . . . . 0.0 109.825 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.18 -22.63 66.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.261 -0.899 . . . . 0.0 109.681 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 61.2 m -63.52 -21.58 66.41 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.673 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.412 ' O ' ' C ' ' A' ' 59' ' ' GLN . . . -52.99 -47.93 67.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.233 -0.917 . . . . 0.0 109.508 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.412 ' C ' ' O ' ' A' ' 58' ' ' ALA . 0.0 OUTLIER -44.09 -43.39 6.85 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.421 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 20.9 mm -73.15 -36.5 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.173 -0.954 . . . . 0.0 109.167 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 16.8 mm -50.68 -36.49 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.354 -0.842 . . . . 0.0 109.235 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.472 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -75.02 -33.39 61.78 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.277 -0.889 . . . . 0.0 109.686 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -61.5 -18.22 58.12 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.259 -0.9 . . . . 0.0 109.767 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.477 ' HB3' ' CG2' ' A' ' 66' ' ' VAL . 0.4 OUTLIER -90.68 27.36 1.78 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.082 -1.011 . . . . 0.0 109.653 -179.86 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.479 ' O ' ' HD3' ' A' ' 2' ' ' LYS . . . 43.96 40.47 5.56 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 68' ' ' ALA . 2.9 t -86.25 96.21 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -1.136 . . . . 0.0 109.68 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.6 tptt -78.95 -11.32 60.0 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 179.046 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.497 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -136.58 125.29 23.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.444 -0.785 . . . . 0.0 108.964 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.426 ' O ' ' HB2' ' A' ' 90' ' ' TYR . 67.1 t -124.39 119.84 57.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.049 -1.032 . . . . 0.0 109.961 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.455 ' CD1' ' CG2' ' A' ' 3' ' ' ILE . 1.9 mp -102.1 114.19 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.359 -0.838 . . . . 0.0 108.98 179.606 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -151.87 172.87 15.53 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.214 -0.929 . . . . 0.0 109.865 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.9 p -135.5 55.69 1.87 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.378 -0.826 . . . . 0.0 109.245 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -55.53 152.82 16.5 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.295 -0.878 . . . . 0.0 109.645 -179.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.67 -13.65 14.55 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 C-N-CA 122.757 2.305 . . . . 0.0 110.531 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.8 161.66 26.26 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.7 -5.67 14.86 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.698 2.265 . . . . 0.0 110.415 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 16.9 t30 -57.91 -33.25 68.57 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.262 -0.899 . . . . 0.0 109.649 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.628 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -71.94 -60.43 2.24 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.251 -0.906 . . . . 0.0 109.437 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.46 ' CD1' ' N ' ' A' ' 79' ' ' PHE . 3.5 m-85 -51.7 -22.09 3.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.115 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 13.9 tt0 -63.91 -46.95 82.54 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.283 -0.885 . . . . 0.0 109.265 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.4 ' O ' ' HB2' ' A' ' 85' ' ' LEU . 2.5 t -69.45 -43.66 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.194 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 1.8 mt -63.36 -21.62 66.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.516 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -77.1 -61.35 2.01 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.258 -0.901 . . . . 0.0 109.603 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -58.92 -21.56 58.1 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.22 -0.925 . . . . 0.0 109.667 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.587 ' HB3' HD12 ' A' ' 87' ' ' ILE . 0.1 OUTLIER -73.14 -37.43 66.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.215 -0.928 . . . . 0.0 109.637 -179.9 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.77 21.83 7.29 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.587 HD12 ' HB3' ' A' ' 85' ' ' LEU . 5.5 mt -103.94 150.3 7.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -1.165 . . . . 0.0 109.51 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 8.2 mttt -80.03 125.84 30.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.233 -0.917 . . . . 0.0 109.361 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 3.3 mp -90.31 141.06 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.161 -0.962 . . . . 0.0 109.543 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.597 ' CE1' ' HB3' ' A' ' 111' ' ' GLU . 2.2 m-85 -127.99 127.35 43.08 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.211 -0.931 . . . . 0.0 109.529 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 73.5 mtt180 -87.46 122.77 31.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.465 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.67 122.83 33.16 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.236 -0.915 . . . . 0.0 109.471 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -64.95 -40.0 94.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.363 -0.836 . . . . 0.0 109.558 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 116.76 52.47 0.35 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 30.8 m -114.37 -82.72 0.61 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -1.119 . . . . 0.0 109.351 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -157.56 128.61 6.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.396 -0.815 . . . . 0.0 109.357 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.928 HG12 HG21 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -51.12 -23.27 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.221 -0.924 . . . . 0.0 109.535 -179.943 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.82 -49.05 69.63 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.195 -0.941 . . . . 0.0 109.317 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.594 ' HG2' HD12 ' A' ' 103' ' ' LEU . 21.4 tt0 -70.88 -28.14 64.34 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.304 -0.873 . . . . 0.0 109.311 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -63.93 -49.46 72.52 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.322 -0.862 . . . . 0.0 109.42 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 37.7 tp -57.56 -57.58 12.08 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.301 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 1.3 tmtt? -56.92 -25.62 57.7 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.135 -0.978 . . . . 0.0 109.257 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.594 HD12 ' HG2' ' A' ' 99' ' ' GLU . 0.2 OUTLIER -71.14 -37.11 72.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.23 -0.919 . . . . 0.0 109.36 179.861 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -65.57 -22.99 66.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.198 -0.939 . . . . 0.0 109.175 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.34 -29.76 64.25 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.412 -0.805 . . . . 0.0 109.31 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -112.46 -2.69 14.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.603 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 61.23 39.46 97.22 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . 0.499 ' HB3' HD23 ' A' ' 103' ' ' LEU . 24.4 t-20 -93.97 -17.92 22.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.103 -1.233 . . . . 0.0 109.395 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.458 ' HA ' HD23 ' A' ' 109' ' ' LEU . 5.4 mt -55.67 -168.44 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.24 -0.913 . . . . 0.0 109.334 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 90' ' ' TYR . 1.2 tt0 -103.42 106.91 17.55 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.256 -0.903 . . . . 0.0 109.303 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.597 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 4.1 pt-20 -101.7 156.69 17.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.264 -0.898 . . . . 0.0 109.764 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.401 HG21 HD13 ' A' ' 112' ' ' ILE . 2.9 mt -142.8 126.11 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.89 . . . . 0.0 109.314 179.768 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.293 -0.879 . . . . 0.0 109.441 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 mmm . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.271 0.557 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.508 ' HB3' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -154.03 160.05 41.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.289 -0.882 . . . . 0.0 109.118 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.583 HG12 ' CE2' ' A' ' 104' ' ' PHE . 6.4 mt -117.4 121.12 66.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.901 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.671 ' HB2' HG11 ' A' ' 66' ' ' VAL . . . -113.09 102.97 10.89 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.373 -0.83 . . . . 0.0 109.119 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -94.81 118.64 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -0.924 . . . . 0.0 109.742 -179.553 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.37 142.3 41.21 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.068 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.513 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 3.8 p -161.72 -159.92 0.66 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.119 -0.988 . . . . 0.0 109.518 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.9 m -149.06 57.09 1.02 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.287 -0.883 . . . . 0.0 109.537 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 167.08 164.5 22.85 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.435 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.0 OUTLIER -85.02 -32.62 22.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.322 -1.105 . . . . 0.0 109.472 179.981 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 18.7 p-10 171.84 172.16 0.09 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -0.919 . . . . 0.0 109.374 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.515 ' HA ' HD12 ' A' ' 12' ' ' LEU . 8.1 tp 45.35 32.77 1.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.305 -0.872 . . . . 0.0 109.191 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -175.47 -32.88 0.04 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 p -65.55 86.34 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.435 -1.038 . . . . 0.0 109.304 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.503 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 14.4 mt-10 -77.65 6.98 6.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.478 -0.764 . . . . 0.0 110.153 -179.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.503 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 15.1 t 70.62 65.6 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.937 . . . . 0.0 109.615 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 16' ' ' VAL . 3.9 m -44.64 122.83 3.32 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.328 -0.858 . . . . 0.0 109.233 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.452 ' HG2' ' HB2' ' A' ' 72' ' ' SER . 1.4 ttm-85 -61.72 -18.7 60.76 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.25 -0.906 . . . . 0.0 109.721 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.492 ' CE2' ' HG3' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -84.91 108.16 17.41 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.12 -0.987 . . . . 0.0 109.63 -179.905 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.435 ' CB ' ' HB1' ' A' ' 71' ' ' ALA . 21.8 t80 -106.43 125.37 50.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.263 -0.898 . . . . 0.0 109.354 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.1 -36.6 0.76 Allowed Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.439 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 1.1 mpt_? -118.62 -22.27 7.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.343 -1.093 . . . . 0.0 109.256 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.513 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -49.15 106.91 0.68 Allowed Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.304 -0.872 . . . . 0.0 109.436 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.3 Cg_endo -79.95 62.56 8.55 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.561 2.174 . . . . 0.0 110.822 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.449 ' CE1' ' HB3' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -160.52 69.58 0.38 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.008 -1.058 . . . . 0.0 109.395 179.692 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -80.46 121.1 25.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.549 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . 0.434 ' O ' ' HA ' ' A' ' 4' ' ' ALA . 2.1 mmt -94.46 110.6 22.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.226 -0.921 . . . . 0.0 109.266 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.9 mm -104.02 117.99 50.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.904 . . . . 0.0 109.472 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.912 HG21 HD11 ' A' ' 101' ' ' LEU . 13.4 m -138.04 147.59 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.209 -0.932 . . . . 0.0 109.833 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -127.26 143.26 51.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 108.899 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.2 mtt -113.81 152.03 31.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.1 -1.0 . . . . 0.0 109.938 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.35 -46.37 7.38 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.369 -0.832 . . . . 0.0 109.262 179.775 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.64 47.48 0.73 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.367 -0.833 . . . . 0.0 109.222 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.567 ' O ' HG23 ' A' ' 105' ' ' THR . . . 92.22 -1.43 73.38 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.423 ' O ' ' C ' ' A' ' 36' ' ' ILE . 5.6 p-10 -116.56 92.89 4.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.204 -1.174 . . . . 0.0 109.362 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.794 HD13 HD21 ' A' ' 101' ' ' LEU . 1.6 tt -43.95 118.61 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 109.497 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.46 ' O ' ' OE1' ' A' ' 37' ' ' GLU . 0.2 OUTLIER -123.08 20.78 9.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.329 -0.857 . . . . 0.0 109.441 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.413 ' O ' ' OG ' ' A' ' 38' ' ' SER . 12.0 p -170.82 107.46 0.29 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -0.859 . . . . 0.0 109.263 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.761 ' HA ' HG12 ' A' ' 29' ' ' VAL . 5.8 p -135.35 105.72 6.38 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.914 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.18 143.8 38.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.389 -0.819 . . . . 0.0 109.268 179.598 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.413 HG13 ' SD ' ' A' ' 27' ' ' MET . 2.2 t -110.99 124.03 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.215 -0.928 . . . . 0.0 109.755 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 11.1 mt -121.57 119.43 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.262 -0.899 . . . . 0.0 109.268 179.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.449 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 4.1 pm0 -93.28 126.08 38.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.254 -0.904 . . . . 0.0 109.564 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.427 ' HB2' ' HA ' ' A' ' 24' ' ' PRO . 2.5 t-20 . . . . . 0 N--CA 1.491 1.591 0 O-C-N 121.317 -0.864 . . . . 0.0 109.548 -179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.409 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.719 HD12 ' HB2' ' A' ' 78' ' ' ALA . 39.8 mm -76.72 0.03 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.136 -1.214 . . . . 0.0 109.85 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.08 -10.96 59.83 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.192 -0.943 . . . . 0.0 109.558 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.439 ' O ' HG13 ' A' ' 61' ' ' ILE . 8.8 t -77.32 -25.86 51.59 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.667 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -48.77 -39.97 27.07 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 109.492 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 -60.4 -58.47 8.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 109.608 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.1 mt -53.82 -25.48 12.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.33 -0.856 . . . . 0.0 109.589 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.481 HG22 HG21 ' A' ' 66' ' ' VAL . 46.3 mt -72.96 -39.66 58.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.454 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.17 -30.65 70.67 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.552 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -67.93 -9.08 42.26 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.294 -0.878 . . . . 0.0 109.614 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -85.9 -24.93 26.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.191 -0.943 . . . . 0.0 109.537 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 114.55 -26.0 9.91 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.671 HG11 ' HB2' ' A' ' 4' ' ' ALA . 4.6 m -43.44 94.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.271 -1.135 . . . . 0.0 109.559 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 65' ' ' GLY . 7.0 mmtp -79.36 -4.27 50.16 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.357 -0.84 . . . . 0.0 108.758 179.291 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -122.82 129.33 51.55 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.385 -0.822 . . . . 0.0 109.274 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.639 HG21 ' CD2' ' A' ' 82' ' ' LEU . 97.8 t -123.45 107.83 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.111 -0.993 . . . . 0.0 109.544 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 53.1 mt -91.99 115.52 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.36 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.435 ' HB1' ' CB ' ' A' ' 20' ' ' PHE . . . -164.84 176.77 8.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.217 -0.927 . . . . 0.0 109.913 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.601 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 12.5 m -140.84 59.07 1.54 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.508 -0.745 . . . . 0.0 109.176 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.487 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 11.6 p -49.71 152.15 2.69 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.389 -0.819 . . . . 0.0 109.791 -179.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.492 ' HG3' ' CE2' ' A' ' 19' ' ' PHE . 35.1 Cg_endo -78.27 -22.65 9.51 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.631 2.221 . . . . 0.0 110.17 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -134.95 164.15 24.76 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.53 27.62 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.771 2.314 . . . . 0.0 111.265 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -74.73 -68.86 0.5 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.88 -1.137 . . . . 0.0 109.588 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.778 ' O ' HD12 ' A' ' 82' ' ' LEU . . . -62.03 -40.53 96.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -0.905 . . . . 0.0 109.714 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.487 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 4.3 m-85 -52.95 -32.46 46.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.639 -179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -75.61 -38.46 59.0 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.26 -0.9 . . . . 0.0 109.65 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 48.8 t -61.33 -53.46 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.743 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.778 HD12 ' O ' ' A' ' 78' ' ' ALA . 3.2 mp -59.06 -18.7 37.38 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.274 -0.891 . . . . 0.0 109.814 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -76.47 -48.42 19.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.18 -0.95 . . . . 0.0 109.695 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.38 -35.44 80.9 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.143 -0.973 . . . . 0.0 109.563 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.535 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 0.1 OUTLIER -68.17 -16.21 63.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.491 -179.919 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 81.59 24.68 55.72 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.538 HG22 ' N ' ' A' ' 88' ' ' LYS . 5.6 mt -87.47 161.5 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.252 -1.146 . . . . 0.0 109.558 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.538 ' N ' HG22 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -94.5 112.13 23.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 109.317 179.858 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.563 HG22 ' N ' ' A' ' 90' ' ' TYR . 14.1 mt -82.03 168.14 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.67 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.593 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 1.2 m-85 -153.09 129.98 10.97 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.304 -0.873 . . . . 0.0 109.246 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.511 ' NH1' ' HA ' ' A' ' 93' ' ' THR . 0.7 OUTLIER -80.12 135.81 36.39 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.966 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.601 ' HB3' ' OG ' ' A' ' 72' ' ' SER . . . -86.64 149.79 24.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.216 -0.928 . . . . 0.0 109.627 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . 0.511 ' HA ' ' NH1' ' A' ' 91' ' ' ARG . 73.4 p -86.0 -26.51 25.38 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 109.544 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.83 66.85 1.51 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.19 -67.71 0.36 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.256 -1.143 . . . . 0.0 109.466 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -171.56 132.95 0.77 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.304 -0.872 . . . . 0.0 109.33 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.466 HG11 ' HB3' ' A' ' 7' ' ' SER . 16.8 m -54.86 -19.76 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.168 -0.958 . . . . 0.0 109.575 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -68.27 -52.57 32.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.762 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -69.78 -39.19 76.79 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.146 -0.971 . . . . 0.0 109.498 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.443 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 5.1 m-20 -59.28 -36.73 76.09 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.163 -0.96 . . . . 0.0 109.259 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.912 HD11 HG21 ' A' ' 29' ' ' VAL . 11.0 tp -59.22 -50.93 72.15 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.287 -0.883 . . . . 0.0 109.308 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -70.12 -15.76 63.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.371 -0.831 . . . . 0.0 109.232 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.542 HD22 ' HG ' ' A' ' 109' ' ' LEU . 0.2 OUTLIER -72.6 -45.74 57.6 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.359 -0.838 . . . . 0.0 109.55 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.583 ' CE2' HG12 ' A' ' 3' ' ' ILE . 6.4 t80 -63.53 -17.23 62.58 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.865 . . . . 0.0 109.758 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.567 HG23 ' O ' ' A' ' 34' ' ' GLY . 19.2 m -69.2 -33.47 73.39 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 109.572 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -95.57 -14.72 23.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.527 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 71.17 45.53 48.82 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . 0.415 ' HB3' HD23 ' A' ' 103' ' ' LEU . 10.1 t-20 -97.21 -29.31 13.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.289 -1.124 . . . . 0.0 109.544 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.542 ' HG ' HD22 ' A' ' 103' ' ' LEU . 0.6 OUTLIER -57.11 155.89 7.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.342 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 5.3 pt-20 -96.06 144.88 25.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 6.1 pm0 -114.61 165.87 12.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.92 . . . . 0.0 109.501 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.516 ' O ' HD12 ' A' ' 89' ' ' ILE . 83.0 mt -136.4 120.21 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.261 -0.899 . . . . 0.0 109.254 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.339 -0.851 . . . . 0.0 109.332 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.4 ttm . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.414 ' CG ' ' HG3' ' A' ' 30' ' ' GLU . 2.1 mppt? -114.61 164.01 14.62 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.187 -0.945 . . . . 0.0 109.594 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.479 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 11.0 mt -131.68 135.72 58.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.291 -0.881 . . . . 0.0 109.655 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.584 ' CB ' HG21 ' A' ' 66' ' ' VAL . . . -123.48 129.96 52.0 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.57 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 1.112 HG21 HG23 ' A' ' 97' ' ' VAL . 6.3 mt -111.1 120.79 62.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.179 -0.951 . . . . 0.0 109.881 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.39 165.19 25.53 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.277 -0.889 . . . . 0.0 109.36 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.518 ' O ' ' CB ' ' A' ' 8' ' ' SER . 0.8 OUTLIER 70.22 -144.67 0.08 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.227 -0.921 . . . . 0.0 109.485 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.518 ' CB ' ' O ' ' A' ' 7' ' ' SER . 0.2 OUTLIER 77.02 3.35 3.31 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.139 -0.976 . . . . 0.0 109.554 -179.908 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.471 ' O ' ' HB3' ' A' ' 25' ' ' TYR . . . 46.47 -113.6 1.18 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.87 -5.85 7.41 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.225 -1.162 . . . . 0.0 109.481 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -141.18 -142.15 0.14 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.481 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.4 mt -105.11 -18.28 14.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.108 -0.995 . . . . 0.0 109.745 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -47.76 -40.32 18.22 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.406 ' O ' ' O ' ' A' ' 15' ' ' GLU . 3.6 m -75.54 81.42 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.283 -1.128 . . . . 0.0 109.636 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.475 ' O ' ' HB ' ' A' ' 97' ' ' VAL . 0.1 OUTLIER -48.17 -93.18 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.552 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 18.9 m -131.11 52.95 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.062 -1.024 . . . . 0.0 109.718 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.512 ' O ' ' CB ' ' A' ' 18' ' ' ARG . 1.3 p -99.07 136.61 38.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.174 -0.954 . . . . 0.0 109.255 179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.512 ' CB ' ' O ' ' A' ' 17' ' ' SER . 6.3 mtt-85 75.45 78.28 0.1 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.222 -0.924 . . . . 0.0 108.916 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.432 ' O ' ' C ' ' A' ' 20' ' ' PHE . 0.5 OUTLIER -79.65 -177.52 5.9 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.335 -0.853 . . . . 0.0 109.678 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.628 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 2.6 t80 -41.24 137.84 1.31 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.485 -0.76 . . . . 0.0 109.82 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 151.14 -64.12 0.38 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.471 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 2.0 tpp180 -155.04 18.87 0.43 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.147 -1.208 . . . . 0.0 109.8 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.79 113.43 18.67 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.276 -0.89 . . . . 0.0 109.661 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.583 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.7 Cg_endo -82.08 53.9 4.77 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.61 2.207 . . . . 0.0 110.462 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.583 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 98.6 m-85 -159.8 70.82 0.46 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.163 -0.96 . . . . 0.0 109.503 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.48 ' CE1' ' OD1' ' A' ' 44' ' ' ASN . 23.7 m-85 -83.61 119.03 24.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.204 -0.935 . . . . 0.0 109.536 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -93.56 122.45 36.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.234 -0.916 . . . . 0.0 109.67 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.515 HG12 HD12 ' A' ' 42' ' ' ILE . 15.1 mm -99.17 122.15 50.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 109.176 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 54.7 t -127.97 137.74 56.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.099 -1.0 . . . . 0.0 109.651 -179.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.444 ' HB3' ' OG ' ' A' ' 38' ' ' SER . 1.7 tt0 -124.61 137.82 54.36 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.3 -0.875 . . . . 0.0 109.379 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.411 ' HG3' ' HA ' ' A' ' 36' ' ' ILE . 7.9 ttm -116.06 145.18 43.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.189 -0.944 . . . . 0.0 109.647 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.61 -63.48 1.29 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.332 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.66 65.29 0.87 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.287 -0.883 . . . . 0.0 109.384 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.25 17.03 70.19 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 36' ' ' ILE . 3.0 t-20 -144.38 103.17 3.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.222 -1.164 . . . . 0.0 109.451 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.411 ' HA ' ' HG3' ' A' ' 31' ' ' MET . 2.6 mp -44.69 137.49 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.277 -0.89 . . . . 0.0 109.461 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -144.01 16.36 1.74 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 109.48 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.444 ' OG ' ' HB3' ' A' ' 30' ' ' GLU . 0.2 OUTLIER -166.68 122.86 1.21 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.259 -0.901 . . . . 0.0 109.441 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.6 m -142.9 110.16 5.68 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.196 -0.94 . . . . 0.0 109.6 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.91 153.98 46.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.31 -0.869 . . . . 0.0 109.2 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 8.0 p -113.76 144.34 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.204 -0.935 . . . . 0.0 109.675 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.515 HD12 HG12 ' A' ' 28' ' ' ILE . 23.5 mt -136.42 132.7 49.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.341 -0.849 . . . . 0.0 109.37 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -106.59 131.38 53.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.241 -0.912 . . . . 0.0 109.692 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.48 ' OD1' ' CE1' ' A' ' 26' ' ' PHE . 2.7 m120 . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.28 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.527 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.706 HD12 ' HB2' ' A' ' 78' ' ' ALA . 16.6 mm -70.4 -5.58 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -1.095 . . . . 0.0 109.555 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.67 -25.28 53.55 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.195 -0.94 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.527 HG22 ' O ' ' A' ' 54' ' ' GLY . 10.8 t -68.66 -7.9 37.49 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.201 -0.937 . . . . 0.0 109.556 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.425 ' O ' ' C ' ' A' ' 59' ' ' GLN . . . -61.67 -56.18 22.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.926 . . . . 0.0 109.249 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 58' ' ' ALA . 1.6 tm0? -44.21 -29.26 0.61 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.337 -0.852 . . . . 0.0 109.286 179.808 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 73.1 mt -75.59 -46.66 36.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 109.179 179.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.484 HG23 HG11 ' A' ' 66' ' ' VAL . 37.8 mt -56.03 -25.24 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 109.36 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.66 -38.08 80.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.279 -0.888 . . . . 0.0 109.681 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 26.8 m-20 -72.75 -4.94 34.5 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.247 -0.908 . . . . 0.0 109.721 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -83.9 -16.1 45.57 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.06 -12.74 59.27 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.584 HG21 ' CB ' ' A' ' 4' ' ' ALA . 2.6 p -58.21 98.77 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.268 -1.136 . . . . 0.0 109.66 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.542 ' HA ' HG23 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -79.28 -6.36 56.5 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 179.234 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.536 ' HB2' ' CE2' ' A' ' 104' ' ' PHE . . . -113.67 120.66 41.63 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.284 -0.885 . . . . 0.0 109.119 179.627 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 70.6 t -108.43 112.04 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.165 -0.959 . . . . 0.0 109.852 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.407 ' N ' HD13 ' A' ' 70' ' ' ILE . 3.2 mm -99.79 97.53 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.155 -0.965 . . . . 0.0 109.136 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.628 ' HB1' ' HB2' ' A' ' 20' ' ' PHE . . . -158.39 169.85 23.53 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.237 -0.914 . . . . 0.0 109.816 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.435 ' O ' ' C ' ' A' ' 73' ' ' SER . 9.1 t -133.33 50.65 2.21 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.364 -0.835 . . . . 0.0 109.048 179.79 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.463 ' HB3' ' HB3' ' A' ' 20' ' ' PHE . 60.5 p -41.26 149.55 0.36 Allowed Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.509 -0.745 . . . . 0.0 109.937 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 20' ' ' PHE . 36.2 Cg_endo -78.14 -35.26 1.35 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.657 2.238 . . . . 0.0 110.051 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -108.61 153.14 16.91 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.492 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 35.5 Cg_endo -77.72 1.15 9.13 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.537 2.158 . . . . 0.0 110.668 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.501 ' O ' HG23 ' A' ' 81' ' ' VAL . 5.4 t30 -59.93 -42.28 93.64 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.223 -0.923 . . . . 0.0 109.686 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.706 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -64.17 -67.59 0.42 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 109.681 -179.836 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.794 ' CD1' HG21 ' A' ' 89' ' ' ILE . 16.6 m-30 -53.06 -19.27 2.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.232 -0.917 . . . . 0.0 109.875 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.492 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 36.3 tt0 -70.73 -49.93 41.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.122 -0.986 . . . . 0.0 109.579 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 77' ' ' ASN . 3.0 t -67.4 -48.19 78.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.147 -0.971 . . . . 0.0 109.665 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 36.1 mt -55.59 -29.32 58.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.114 -0.992 . . . . 0.0 109.508 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 64.0 t-20 -68.03 -38.89 83.07 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.265 -0.897 . . . . 0.0 109.383 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.14 -26.29 61.15 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.331 -0.856 . . . . 0.0 109.47 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.673 HD13 HD11 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -71.87 -37.11 70.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.955 . . . . 0.0 109.551 -179.94 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.53 13.08 25.17 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.673 HD11 HD13 ' A' ' 85' ' ' LEU . 3.7 mt -85.38 169.54 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.278 -1.131 . . . . 0.0 109.623 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.512 ' N ' HG22 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -99.17 123.67 43.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.25 179.842 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.794 HG21 ' CD1' ' A' ' 79' ' ' PHE . 1.6 mt -95.16 161.84 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.19 -0.944 . . . . 0.0 109.757 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.532 ' CD1' ' O ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -148.21 133.93 18.9 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.444 -179.862 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.421 ' HB2' ' HB2' ' A' ' 110' ' ' GLU . 0.0 OUTLIER -89.45 123.12 33.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.148 -0.97 . . . . 0.0 109.475 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.16 87.78 5.48 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.916 . . . . 0.0 109.681 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . 0.527 ' O ' HG22 ' A' ' 93' ' ' THR . 18.6 m -139.23 21.02 2.6 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.223 -0.923 . . . . 0.0 109.412 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -74.46 -77.8 0.64 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 92.8 m -159.81 -70.78 0.08 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.246 -1.15 . . . . 0.0 109.386 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.42 ' HA ' ' HB2' ' A' ' 15' ' ' GLU . 37.0 m -132.38 148.71 52.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.303 -0.873 . . . . 0.0 109.384 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 1.112 HG23 HG21 ' A' ' 5' ' ' ILE . 12.1 p -44.36 -27.98 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.345 -0.847 . . . . 0.0 109.487 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -66.69 -52.81 40.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.337 -0.852 . . . . 0.0 109.734 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.434 ' O ' ' CG ' ' A' ' 103' ' ' LEU . 4.7 tt0 -71.02 -16.35 62.61 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.136 -0.977 . . . . 0.0 109.493 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.417 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 2.6 m120 -75.95 -40.76 53.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.397 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 30.9 tp -60.58 -47.69 85.07 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.336 -0.853 . . . . 0.0 109.433 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.87 -20.43 56.29 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.432 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.434 ' CG ' ' O ' ' A' ' 99' ' ' GLU . 6.4 mt -67.37 -43.5 81.26 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.312 -0.868 . . . . 0.0 109.676 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.541 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.1 t80 -61.28 -29.17 69.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.28 -0.888 . . . . 0.0 109.453 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 92.0 m -62.34 -40.59 96.88 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.211 -0.93 . . . . 0.0 109.563 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 107' ' ' GLY . 6.4 mm-40 -87.94 3.21 49.44 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.181 -0.949 . . . . 0.0 109.729 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . 44.25 39.03 5.24 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -103.22 -10.94 18.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -1.162 . . . . 0.0 109.607 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.482 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 0.7 OUTLIER -74.05 -161.17 0.11 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.208 -0.932 . . . . 0.0 109.482 -179.989 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.532 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 7.0 mt-10 -95.07 113.88 25.63 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.304 -0.872 . . . . 0.0 109.418 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -103.18 142.8 33.54 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.35 -0.844 . . . . 0.0 109.599 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.465 ' O ' ' HB2' ' A' ' 113' ' ' ARG . 13.6 mm -129.84 117.53 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.272 -0.893 . . . . 0.0 109.302 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.465 ' HB2' ' O ' ' A' ' 112' ' ' ILE . 3.4 ttt-85 . . . . . 0 N--CA 1.489 1.495 0 O-C-N 121.195 -0.94 . . . . 0.0 109.619 -179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.09 155.77 17.84 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.202 -0.936 . . . . 0.0 109.309 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.486 ' HA ' ' O ' ' A' ' 68' ' ' ALA . 7.8 mt -120.31 117.41 53.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.277 -0.889 . . . . 0.0 110.052 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.992 ' HB2' HG11 ' A' ' 66' ' ' VAL . . . -112.51 116.92 31.02 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.317 -0.864 . . . . 0.0 108.672 179.275 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.842 HG23 ' HB ' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -102.98 135.23 41.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.128 -0.983 . . . . 0.0 109.926 -179.311 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.55 143.24 46.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.39 -0.819 . . . . 0.0 109.175 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.715 ' CB ' HG11 ' A' ' 97' ' ' VAL . 0.7 OUTLIER -151.39 157.96 43.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.208 -0.933 . . . . 0.0 109.683 -179.792 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 66.9 p -119.39 0.96 11.2 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.324 -0.86 . . . . 0.0 109.388 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.548 ' O ' ' CG ' ' A' ' 25' ' ' TYR . . . -125.62 -153.96 8.59 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.561 HG23 ' CE1' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -126.45 -30.52 2.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.183 -1.186 . . . . 0.0 109.664 -179.849 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 173.31 -43.8 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.122 -0.986 . . . . 0.0 109.528 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -80.66 5.15 16.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.299 -0.875 . . . . 0.0 109.629 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -166.31 31.43 0.21 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.854 ' HB3' HG22 ' A' ' 97' ' ' VAL . 5.0 m -77.06 79.43 3.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.124 -1.221 . . . . 0.0 109.357 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.713 ' C ' HG23 ' A' ' 16' ' ' VAL . 9.2 mm-40 -76.91 1.57 17.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.302 -0.874 . . . . 0.0 109.576 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.713 HG23 ' C ' ' A' ' 15' ' ' GLU . 1.9 t 73.68 18.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.403 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.1 t 59.11 176.04 0.07 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.32 -0.863 . . . . 0.0 109.399 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -109.04 -36.25 6.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -131.79 123.18 27.09 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.875 . . . . 0.0 109.363 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.714 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 2.5 t80 -62.23 96.72 0.08 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.905 . . . . 0.0 109.497 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -136.76 -87.02 0.2 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.428 ' O ' ' C ' ' A' ' 23' ' ' ALA . 1.8 ptp85 -114.7 43.85 1.86 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -1.111 . . . . 0.0 109.18 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.446 ' HB3' ' CE1' ' A' ' 26' ' ' PHE . . . -42.79 114.14 1.45 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.406 -0.808 . . . . 0.0 109.405 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.58 21.14 0.88 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.578 2.185 . . . . 0.0 110.947 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.561 ' CE1' HG23 ' A' ' 10' ' ' THR . 0.5 OUTLIER -159.51 70.78 0.47 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.949 -1.094 . . . . 0.0 109.301 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.446 ' CE1' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -79.52 126.27 30.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.441 -179.917 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.22 115.94 31.65 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.407 HD12 HG23 ' A' ' 28' ' ' ILE . 28.9 mm -96.78 131.43 43.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.3 -0.875 . . . . 0.0 109.661 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.405 ' CG1' HG23 ' A' ' 36' ' ' ILE . 4.5 t -130.25 137.09 57.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.295 -0.878 . . . . 0.0 109.117 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -118.17 95.99 5.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.095 -1.003 . . . . 0.0 109.816 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.408 ' HE2' ' HB2' ' A' ' 31' ' ' MET . 41.1 ttm -81.91 146.06 30.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.029 179.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -99.96 -70.01 0.75 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.113 -0.992 . . . . 0.0 110.002 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 19.3 tttm -138.59 62.71 1.54 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.094 -1.004 . . . . 0.0 109.95 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.51 31.64 36.53 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 36' ' ' ILE . 2.9 p30 -159.58 97.47 1.33 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.169 -1.195 . . . . 0.0 109.552 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.545 HG12 HD21 ' A' ' 101' ' ' LEU . 2.9 mp -44.06 132.39 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.247 -0.908 . . . . 0.0 109.327 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -130.01 18.97 5.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.119 -0.988 . . . . 0.0 109.737 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 175.38 129.9 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.078 -1.014 . . . . 0.0 109.619 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.4 p -149.58 107.51 3.71 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.323 -0.86 . . . . 0.0 109.373 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.22 164.27 15.42 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.234 -0.916 . . . . 0.0 109.537 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.7 p -124.42 148.03 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.497 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.525 HD12 ' H ' ' A' ' 43' ' ' GLU . 2.6 tp -141.65 154.27 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.302 -0.874 . . . . 0.0 109.392 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.525 ' H ' HD12 ' A' ' 42' ' ' ILE . 26.7 mp0 -93.9 68.8 3.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.267 -0.895 . . . . 0.0 109.497 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.3 m-20 . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.307 -0.87 . . . . 0.0 109.727 179.932 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.373 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.446 HD12 ' HB2' ' A' ' 78' ' ' ALA . 46.6 mm -69.77 -45.82 76.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.127 -1.219 . . . . 0.0 109.479 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.17 -33.26 75.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.221 -0.924 . . . . 0.0 109.535 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 21.6 m -58.95 -23.9 62.01 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.18 -0.95 . . . . 0.0 109.634 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -53.51 -51.94 61.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.258 -0.901 . . . . 0.0 109.574 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.498 ' OE1' ' CG1' ' A' ' 81' ' ' VAL . 1.4 tp60 -46.06 -44.73 15.64 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.188 -0.945 . . . . 0.0 109.504 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 23.5 mt -62.63 -40.22 87.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.193 -0.942 . . . . 0.0 109.522 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 50.3 mt -66.61 -20.38 27.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.201 -0.937 . . . . 0.0 109.487 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.513 ' CB ' HD23 ' A' ' 85' ' ' LEU . . . -77.16 -36.23 55.33 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.256 -0.903 . . . . 0.0 109.687 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 52.2 m-20 -75.47 -0.15 19.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.258 -0.901 . . . . 0.0 109.694 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -82.9 -7.68 59.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.129 -0.982 . . . . 0.0 109.747 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.11 -23.98 32.14 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.992 HG11 ' HB2' ' A' ' 4' ' ' ALA . 19.2 m -59.51 93.9 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -1.152 . . . . 0.0 109.688 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.419 ' O ' ' HD3' ' A' ' 88' ' ' LYS . 26.9 mtpt -79.49 -3.45 46.75 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.36 -0.838 . . . . 0.0 108.793 179.286 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' ' 3' ' ' ILE . . . -135.21 103.14 5.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.227 -0.921 . . . . 0.0 109.19 179.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.808 ' O ' HG23 ' A' ' 89' ' ' ILE . 55.1 t -110.93 129.99 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.023 -1.048 . . . . 0.0 109.999 -179.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.842 ' HB ' HG23 ' A' ' 5' ' ' ILE . 3.6 mp -92.68 119.38 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.286 -0.883 . . . . 0.0 109.078 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.714 ' HB1' ' HB2' ' A' ' 20' ' ' PHE . . . -157.3 176.97 12.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.169 -0.957 . . . . 0.0 109.693 -179.724 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 73' ' ' SER . 3.1 p -152.64 51.89 0.76 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.48 -0.762 . . . . 0.0 109.494 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.563 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 0.1 OUTLIER -44.29 167.51 0.09 OUTLIER Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.172 -0.955 . . . . 0.0 109.436 179.962 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.63 -1.92 12.02 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.613 2.209 . . . . 0.0 110.309 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -162.63 168.61 37.6 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.552 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.2 Cg_endo -79.17 7.9 4.14 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.671 2.248 . . . . 0.0 110.582 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -58.57 -44.54 89.77 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.178 -0.951 . . . . 0.0 109.649 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.446 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -77.04 -48.87 16.68 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.176 -0.952 . . . . 0.0 109.851 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.563 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 2.9 m-85 -55.06 -19.81 8.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.209 -0.932 . . . . 0.0 109.776 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.68 -46.71 24.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.147 -0.97 . . . . 0.0 109.815 -179.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.498 ' CG1' ' OE1' ' A' ' 59' ' ' GLN . 22.2 t -64.49 -51.09 72.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.154 -0.966 . . . . 0.0 109.495 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.792 ' HB3' HD11 ' A' ' 89' ' ' ILE . 0.9 OUTLIER -55.03 -46.44 75.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.903 . . . . 0.0 109.71 -179.88 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 53.6 t30 -57.81 -41.53 82.36 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.219 -0.925 . . . . 0.0 109.534 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.49 -50.39 71.89 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.497 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.549 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 2.4 mp -60.21 -28.1 67.71 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.175 -0.953 . . . . 0.0 109.477 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.43 10.24 17.77 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.644 HD12 ' N ' ' A' ' 87' ' ' ILE . 3.2 mp -94.38 147.71 5.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.115 -1.226 . . . . 0.0 109.439 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.419 ' HD3' ' O ' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -104.81 155.91 18.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.259 -0.901 . . . . 0.0 109.818 -179.835 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.808 HG23 ' O ' ' A' ' 69' ' ' VAL . 3.5 mp -136.6 140.21 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.254 -0.904 . . . . 0.0 109.507 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.556 ' CD2' ' O ' ' A' ' 109' ' ' LEU . 16.9 m-30 -102.82 167.7 9.7 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.313 -0.867 . . . . 0.0 109.53 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.558 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 0.0 OUTLIER -85.7 130.43 34.57 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.245 -0.909 . . . . 0.0 109.866 -179.615 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -87.76 116.89 26.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.422 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 63.4 p -61.77 -26.32 68.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.281 -0.887 . . . . 0.0 109.372 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.56 18.22 42.36 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 58.4 m -86.35 -74.88 0.41 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -1.134 . . . . 0.0 109.473 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 14' ' ' SER . 74.4 m -155.98 144.08 19.84 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.321 -0.862 . . . . 0.0 109.43 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.854 HG22 ' HB3' ' A' ' 14' ' ' SER . 28.8 m -68.94 -35.9 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.885 . . . . 0.0 109.698 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -60.08 -38.06 81.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.135 -0.978 . . . . 0.0 109.323 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.402 ' OE1' ' HA ' ' A' ' 99' ' ' GLU . 0.0 OUTLIER -71.85 -50.69 27.32 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.335 -0.853 . . . . 0.0 109.433 179.881 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.506 ' HA ' HD12 ' A' ' 103' ' ' LEU . 42.2 m-20 -49.62 -34.44 18.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -0.893 . . . . 0.0 109.551 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.545 HD21 HG12 ' A' ' 36' ' ' ILE . 12.3 tp -52.99 -55.86 20.35 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.247 -0.908 . . . . 0.0 109.725 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.49 -20.49 61.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.13 -0.982 . . . . 0.0 109.728 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.506 HD12 ' HA ' ' A' ' 100' ' ' ASN . 23.9 mt -71.74 -25.38 62.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.174 -0.954 . . . . 0.0 109.611 -179.782 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.447 ' HE2' ' HB1' ' A' ' 68' ' ' ALA . 41.3 t80 -70.0 -38.11 75.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.207 -0.933 . . . . 0.0 109.237 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 48.6 m -74.56 -24.39 58.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.857 . . . . 0.0 109.504 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -80.81 -18.52 47.25 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.193 -0.942 . . . . 0.0 109.5 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 76.24 24.48 68.47 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -92.68 -37.92 12.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.14 -1.212 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.556 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 0.0 OUTLIER -88.56 119.98 29.52 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.135 -0.978 . . . . 0.0 109.479 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.526 ' HA ' ' CG ' ' A' ' 90' ' ' TYR . 16.6 pt-20 -149.29 173.83 13.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.463 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.558 ' HB2' ' N ' ' A' ' 91' ' ' ARG . 8.1 tp10 -175.77 -111.24 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.318 -0.864 . . . . 0.0 109.84 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.478 ' N ' ' HG3' ' A' ' 111' ' ' GLU . 19.8 tt -84.21 134.58 26.65 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 O-C-N 121.08 -1.012 . . . . 0.0 110.072 -179.222 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.559 0 O-C-N 121.442 -0.786 . . . . 0.0 109.285 179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.3 ptp . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.484 ' HG2' ' HG3' ' A' ' 30' ' ' GLU . 0.1 OUTLIER -131.67 144.29 50.91 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.245 -0.909 . . . . 0.0 109.583 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.569 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 5.3 mt -118.32 104.45 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.288 -0.883 . . . . 0.0 109.565 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -106.16 116.41 31.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.329 -0.857 . . . . 0.0 109.31 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.681 HG21 HG13 ' A' ' 97' ' ' VAL . 2.8 mp -94.61 120.8 44.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.15 -0.969 . . . . 0.0 109.467 -179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 7' ' ' SER . . . -61.91 150.43 37.61 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.278 -0.889 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.507 ' O ' ' CB ' ' A' ' 8' ' ' SER . 0.0 OUTLIER 53.6 169.95 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.28 -0.887 . . . . 0.0 109.598 179.963 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.758 ' HB3' HG11 ' A' ' 97' ' ' VAL . 0.2 OUTLIER 162.52 -35.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.322 -0.862 . . . . 0.0 109.321 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.457 ' HA3' ' HB2' ' A' ' 14' ' ' SER . . . 75.91 9.56 85.16 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER 61.92 16.78 8.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.244 -1.151 . . . . 0.0 109.46 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.0 t0 -173.17 -167.48 0.41 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.237 -0.915 . . . . 0.0 109.597 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.2 mt -79.85 -1.85 40.87 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.211 -0.93 . . . . 0.0 109.613 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.81 -61.62 7.01 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.457 ' HB2' ' HA3' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -77.31 83.23 3.76 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.198 -1.177 . . . . 0.0 109.505 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.404 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 7.2 mt-10 -72.22 83.1 1.02 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.34 -0.85 . . . . 0.0 109.176 179.724 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.417 ' O ' ' C ' ' A' ' 17' ' ' SER . 22.1 t 62.6 63.97 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.916 . . . . 0.0 109.308 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.479 ' HB3' ' CB ' ' A' ' 7' ' ' SER . 8.2 t -43.77 159.01 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.311 -0.868 . . . . 0.0 109.426 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 22.3 mtp85 -95.67 30.62 2.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.376 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -127.38 159.03 35.68 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.948 . . . . 0.0 109.474 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -133.17 -32.51 1.19 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.186 -0.946 . . . . 0.0 109.903 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -101.5 -37.29 3.55 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.438 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -84.31 -25.9 28.91 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.131 -1.217 . . . . 0.0 109.775 -179.753 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.419 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -42.49 103.01 0.29 Allowed Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.335 -0.853 . . . . 0.0 109.7 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.482 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.7 Cg_endo -80.68 41.28 1.11 Allowed 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 122.602 2.202 . . . . 0.0 110.533 179.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.482 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 84.1 m-85 -158.19 68.5 0.49 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.106 -0.996 . . . . 0.0 109.286 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.442 ' CE1' ' HA ' ' A' ' 6' ' ' ALA . 0.8 OUTLIER -83.02 116.49 22.3 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.271 -0.893 . . . . 0.0 109.585 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 1.4 ttt -94.21 132.42 38.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.156 -0.965 . . . . 0.0 109.635 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.682 ' O ' HG23 ' A' ' 28' ' ' ILE . 5.1 tt -129.42 116.81 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.897 . . . . 0.0 109.401 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.868 HG13 ' O ' ' A' ' 38' ' ' SER . 94.6 t -125.11 129.7 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 109.388 -179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.484 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 26.9 tt0 -99.05 99.45 10.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.226 -0.921 . . . . 0.0 109.635 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.2 tpp -81.8 134.24 35.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.309 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -99.0 -68.66 0.79 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -0.915 . . . . 0.0 109.681 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -129.99 81.47 2.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.204 -0.935 . . . . 0.0 109.631 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.15 28.04 24.97 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.412 ' O ' ' N ' ' A' ' 37' ' ' GLU . 1.3 m-20 -147.73 108.49 4.18 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.173 -1.192 . . . . 0.0 109.536 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.726 HG23 ' CG1' ' A' ' 29' ' ' VAL . 72.6 mt -48.28 98.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.169 -0.957 . . . . 0.0 109.405 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.412 ' N ' ' O ' ' A' ' 35' ' ' ASN . 34.7 mt-10 -96.46 9.77 40.3 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.614 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.868 ' O ' HG13 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -169.6 122.67 0.75 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 179.99 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.611 ' HA ' HG22 ' A' ' 29' ' ' VAL . 0.7 OUTLIER -141.03 107.95 5.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 109.541 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -132.38 138.59 47.77 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.197 -0.939 . . . . 0.0 109.437 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.9 t -98.63 154.72 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.269 -0.895 . . . . 0.0 109.547 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 6.6 mt -131.92 134.33 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.341 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.445 ' O ' ' C ' ' A' ' 44' ' ' ASN . 53.7 mt-10 -91.06 85.92 6.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.297 -0.877 . . . . 0.0 109.527 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.445 ' C ' ' O ' ' A' ' 43' ' ' GLU . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.653 0 O-C-N 121.371 -0.831 . . . . 0.0 109.473 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.583 HD12 ' HB2' ' A' ' 78' ' ' ALA . 51.0 mm -60.77 -14.08 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.258 -1.142 . . . . 0.0 109.63 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.403 ' O ' ' C ' ' A' ' 57' ' ' THR . 0.0 OUTLIER -65.01 -37.04 86.34 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.211 -0.93 . . . . 0.0 109.658 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.403 ' C ' ' O ' ' A' ' 56' ' ' ARG . 14.6 m -43.48 -33.88 1.21 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.202 -0.936 . . . . 0.0 109.723 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -51.29 -52.36 45.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -0.933 . . . . 0.0 109.771 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -54.54 -34.31 61.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.933 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.6 mt -69.39 -65.76 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.127 -0.983 . . . . 0.0 109.726 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 18.8 pt -51.71 -20.95 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.741 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.401 ' HB1' HD11 ' A' ' 87' ' ' ILE . . . -71.16 -47.31 58.46 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.212 -0.93 . . . . 0.0 109.621 -179.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -76.42 1.58 16.01 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.296 -0.877 . . . . 0.0 109.757 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -95.34 -2.11 49.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.088 -1.008 . . . . 0.0 109.772 -179.757 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 93.59 -14.41 65.36 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 31.8 t -49.66 91.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -1.119 . . . . 0.0 109.632 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' GLY . 3.6 mmmp? -79.3 -7.39 58.27 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.338 -0.851 . . . . 0.0 108.811 179.371 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.569 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -131.26 123.44 28.41 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.287 -0.883 . . . . 0.0 109.199 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 57.0 t -121.34 106.69 18.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.161 -0.962 . . . . 0.0 109.853 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.71 HD13 ' HB2' ' A' ' 90' ' ' TYR . 13.4 mm -83.2 104.32 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.18 -0.95 . . . . 0.0 109.03 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -143.74 173.5 11.62 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.22 -0.925 . . . . 0.0 109.789 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.0 p -145.49 40.01 1.19 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.374 -0.829 . . . . 0.0 109.249 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.421 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -45.05 149.76 0.83 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.355 -0.841 . . . . 0.0 109.669 -179.905 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.2 Cg_endo -78.61 4.97 5.92 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.737 2.291 . . . . 0.0 110.336 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.424 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -144.42 148.46 20.24 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.424 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 36.2 Cg_endo -79.38 11.16 2.75 Favored 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 122.716 2.277 . . . . 0.0 110.79 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -73.54 -36.07 65.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.077 -1.014 . . . . 0.0 109.691 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -68.21 -50.59 53.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.954 . . . . 0.0 109.628 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.536 ' CD1' ' N ' ' A' ' 79' ' ' PHE . 1.4 m-85 -65.04 -18.31 65.19 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.133 -0.98 . . . . 0.0 109.519 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -67.53 -49.67 62.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.111 -0.993 . . . . 0.0 109.538 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -71.2 -43.88 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.194 -0.941 . . . . 0.0 109.609 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.461 ' HA ' HD23 ' A' ' 82' ' ' LEU . 20.1 mt -49.66 -49.36 47.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.173 -0.955 . . . . 0.0 109.446 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -61.35 -34.3 75.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.228 -0.92 . . . . 0.0 109.302 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -67.31 -25.65 66.12 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.434 -0.792 . . . . 0.0 109.6 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 4.5 mt -97.7 18.43 15.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.891 . . . . 0.0 109.37 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 56.3 62.84 5.89 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.401 HD11 ' HB1' ' A' ' 62' ' ' ALA . 97.7 mt -132.38 144.9 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.287 -1.126 . . . . 0.0 109.306 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.482 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 0.2 OUTLIER -82.77 124.64 30.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.296 -0.877 . . . . 0.0 109.423 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.535 HG21 ' CD1' ' A' ' 79' ' ' PHE . 3.7 mt -104.16 129.95 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.52 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.71 ' HB2' HD13 ' A' ' 70' ' ' ILE . 3.6 m-85 -116.46 157.57 24.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.405 -0.809 . . . . 0.0 109.249 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.407 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 1.2 ttt-85 -96.09 143.22 27.42 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.245 -0.909 . . . . 0.0 109.568 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.97 86.72 2.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.4 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . 0.622 ' O ' HG22 ' A' ' 93' ' ' THR . 34.1 m -149.35 26.85 0.85 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.192 -0.943 . . . . 0.0 109.421 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.17 -71.8 1.23 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 15.8 m -165.92 -46.17 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.205 -1.174 . . . . 0.0 109.727 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.77 162.9 38.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.23 -0.919 . . . . 0.0 109.79 -179.684 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.758 HG11 ' HB3' ' A' ' 8' ' ' SER . 47.4 t -77.08 -40.03 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.272 -0.893 . . . . 0.0 109.351 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -59.15 -50.06 75.49 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.803 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.428 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 1.2 tt0 -72.17 -33.0 67.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.12 -0.988 . . . . 0.0 109.645 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -57.2 -43.39 82.71 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.224 -0.922 . . . . 0.0 109.759 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.591 HD21 HG11 ' A' ' 29' ' ' VAL . 51.9 tp -51.39 -43.14 61.83 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -0.933 . . . . 0.0 109.795 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 7.6 tptm -75.18 -30.5 60.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.138 -0.977 . . . . 0.0 109.762 -179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.428 ' HG ' ' O ' ' A' ' 99' ' ' GLU . 48.6 mt -67.09 -23.96 65.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.165 -0.959 . . . . 0.0 109.608 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 104' ' ' PHE . 24.4 t80 -58.79 -48.07 82.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.198 -0.939 . . . . 0.0 109.357 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 55.4 m -65.28 -39.1 92.13 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.348 -0.845 . . . . 0.0 109.304 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -70.98 -6.81 41.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.234 -0.916 . . . . 0.0 109.505 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 56.16 30.65 58.15 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.306 -1.517 . . . . 0.0 109.306 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -83.66 -28.84 28.1 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.313 -1.11 . . . . 0.0 109.529 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -138.6 138.48 37.94 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.073 -1.017 . . . . 0.0 109.763 -179.805 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.596 ' HA ' ' CD2' ' A' ' 90' ' ' TYR . 1.7 pt-20 -170.76 -151.54 0.08 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.324 -0.86 . . . . 0.0 109.449 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.501 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 0.7 OUTLIER -163.49 -112.16 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.257 -0.902 . . . . 0.0 109.623 -179.81 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.416 HD12 HD13 ' A' ' 89' ' ' ILE . 2.6 mt -83.33 90.34 2.42 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 O-C-N 121.154 -0.966 . . . . 0.0 109.489 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.206 -0.934 . . . . 0.0 109.321 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 65' ' ' GLY . 4.4 mtmt -118.25 145.97 44.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.308 -0.87 . . . . 0.0 109.293 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.632 HD11 ' CD1' ' A' ' 104' ' ' PHE . 5.3 mt -119.76 111.1 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.348 -0.845 . . . . 0.0 109.616 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.667 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -115.27 122.86 47.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.336 -0.852 . . . . 0.0 109.219 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.631 HG23 ' HB ' ' A' ' 70' ' ' ILE . 2.5 mp -98.4 142.61 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.233 -0.917 . . . . 0.0 109.543 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.498 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -81.49 155.84 25.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.358 -0.839 . . . . 0.0 109.755 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.467 ' HB2' ' HB3' ' A' ' 17' ' ' SER . 1.0 OUTLIER 52.83 -89.98 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.659 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.498 ' N ' ' O ' ' A' ' 6' ' ' ALA . 3.0 m 62.85 24.22 14.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.911 . . . . 0.0 109.566 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 44.07 -107.46 0.13 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.81 -76.91 0.13 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -1.141 . . . . 0.0 109.494 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -158.2 -43.71 0.06 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.232 -0.918 . . . . 0.0 109.614 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.59 -0.44 57.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -0.938 . . . . 0.0 109.55 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.12 19.91 1.09 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 8' ' ' SER . 9.7 p -77.02 81.91 3.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.355 -1.085 . . . . 0.0 109.464 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.882 ' O ' HG22 ' A' ' 97' ' ' VAL . 2.7 mt-10 -77.22 -137.5 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.192 -0.943 . . . . 0.0 109.025 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.695 ' HA ' HG13 ' A' ' 97' ' ' VAL . 6.1 p -88.75 34.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.066 -1.021 . . . . 0.0 109.587 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.467 ' HB3' ' HB2' ' A' ' 7' ' ' SER . 0.5 OUTLIER 69.32 -157.7 0.17 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.349 -0.845 . . . . 0.0 109.479 179.921 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.4 -72.88 0.12 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -112.38 -164.54 0.92 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.189 -0.944 . . . . 0.0 109.611 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.487 ' CE1' ' HB2' ' A' ' 6' ' ' ALA . 24.8 t80 -158.05 48.98 0.39 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.333 -0.854 . . . . 0.0 109.499 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -127.27 -68.44 0.15 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.424 ' O ' ' C ' ' A' ' 23' ' ' ALA . 55.1 mtt180 -112.49 16.76 19.72 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.311 -1.111 . . . . 0.0 109.398 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.424 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -43.46 107.3 0.56 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.323 -0.861 . . . . 0.0 109.619 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.57 44.05 1.66 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.601 2.2 . . . . 0.0 110.604 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.488 ' CE1' ' HG2' ' A' ' 43' ' ' GLU . 4.9 m-85 -158.02 70.09 0.55 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.112 -0.993 . . . . 0.0 109.267 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.521 ' CE2' HD11 ' A' ' 61' ' ' ILE . 4.4 m-30 -79.44 121.96 25.82 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.36 -0.837 . . . . 0.0 109.492 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.9 117.67 35.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.241 -0.912 . . . . 0.0 109.325 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.422 HD13 ' HB1' ' A' ' 4' ' ' ALA . 39.7 mm -104.55 130.95 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.219 -0.926 . . . . 0.0 109.526 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.77 HG11 HD21 ' A' ' 101' ' ' LEU . 82.8 t -131.33 132.17 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.328 -0.857 . . . . 0.0 109.5 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.455 ' HB2' ' CB ' ' A' ' 38' ' ' SER . 7.8 mt-10 -106.64 163.71 12.67 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.322 -0.861 . . . . 0.0 109.376 179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.54 ' HE3' ' CD1' ' A' ' 3' ' ' ILE . 41.9 ttm -147.74 139.05 23.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.174 -0.954 . . . . 0.0 109.538 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.05 -70.5 0.71 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.934 . . . . 0.0 109.578 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 6.3 mtmt -136.17 73.99 1.48 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.447 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.617 ' HA2' HG23 ' A' ' 105' ' ' THR . . . 68.53 16.2 69.34 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.46 103.21 6.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.316 -1.108 . . . . 0.0 109.456 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.413 HG13 ' CE ' ' A' ' 31' ' ' MET . 2.0 mt -66.68 115.53 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.238 -0.914 . . . . 0.0 109.579 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -130.97 33.63 4.16 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.219 -0.926 . . . . 0.0 109.237 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.455 ' CB ' ' HB2' ' A' ' 30' ' ' GLU . 0.6 OUTLIER -161.22 100.11 1.21 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -0.873 . . . . 0.0 109.474 -179.87 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 56.4 m -129.01 104.84 7.81 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.161 -0.962 . . . . 0.0 109.087 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -126.05 125.46 42.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.334 -0.854 . . . . 0.0 109.83 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.5 p -98.54 139.65 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.378 -0.826 . . . . 0.0 109.119 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 5.5 mt -139.81 142.68 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.177 -0.952 . . . . 0.0 109.727 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.488 ' HG2' ' CE1' ' A' ' 25' ' ' TYR . 12.4 mt-10 -94.9 142.15 27.81 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.531 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.501 ' ND2' ' O ' ' A' ' 44' ' ' ASN . 9.1 p-10 . . . . . 0 N--CA 1.49 1.568 0 O-C-N 121.231 -0.918 . . . . 0.0 109.365 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.607 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.438 HD12 ' HB2' ' A' ' 78' ' ' ALA . 24.2 mm -67.87 -8.03 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -1.155 . . . . 0.0 109.646 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -69.24 -33.33 73.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.927 . . . . 0.0 109.666 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.607 HG22 ' O ' ' A' ' 54' ' ' GLY . 13.2 t -58.82 -15.54 12.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.297 -0.877 . . . . 0.0 109.783 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.85 -46.02 85.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.804 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.722 ' HG3' HD11 ' A' ' 85' ' ' LEU . 52.6 tt0 -65.5 -28.59 69.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.269 -0.894 . . . . 0.0 109.805 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.2 mm -75.9 -29.21 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.175 -0.953 . . . . 0.0 109.718 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.521 HD11 ' CE2' ' A' ' 26' ' ' PHE . 65.8 mt -75.27 -41.54 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.147 -0.971 . . . . 0.0 109.636 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.45 -26.29 66.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.154 -0.966 . . . . 0.0 109.627 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -76.68 -5.77 49.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.192 -0.943 . . . . 0.0 109.674 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -90.94 27.6 1.78 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.136 -0.977 . . . . 0.0 109.618 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 2' ' ' LYS . . . 66.72 11.84 58.22 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.667 HG11 ' HB3' ' A' ' 4' ' ' ALA . 96.0 t -87.06 91.81 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.2 -1.177 . . . . 0.0 109.386 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.483 ' O ' ' HB2' ' A' ' 88' ' ' LYS . 39.2 mmtt -79.43 -4.76 52.65 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.432 -0.792 . . . . 0.0 108.863 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.463 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -124.27 107.45 11.2 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.521 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 60.9 t -104.96 119.14 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.366 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.631 ' HB ' HG23 ' A' ' 5' ' ' ILE . 3.1 mm -99.24 108.19 21.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.347 -0.846 . . . . 0.0 109.397 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -153.37 173.79 15.18 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.255 -0.903 . . . . 0.0 109.557 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.33 49.32 1.43 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.444 -0.785 . . . . 0.0 109.224 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.402 ' OG ' ' HB3' ' A' ' 20' ' ' PHE . 1.0 OUTLIER -50.42 145.53 10.39 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.328 -0.858 . . . . 0.0 109.513 -179.864 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.05 -0.08 10.34 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 122.576 2.184 . . . . 0.0 110.477 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.76 154.67 24.95 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.47 -1.66 11.8 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.686 2.257 . . . . 0.0 110.574 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -53.66 -48.19 69.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.237 -0.914 . . . . 0.0 109.643 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.438 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -70.48 -59.29 2.94 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.279 -0.888 . . . . 0.0 109.881 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.717 ' CD1' HG21 ' A' ' 89' ' ' ILE . 25.1 m-85 -46.98 -23.52 0.47 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.934 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 14.7 mm-40 -71.16 -53.05 15.85 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.096 -1.003 . . . . 0.0 109.566 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.429 ' H ' HG23 ' A' ' 81' ' ' VAL . 4.9 t -63.03 -46.46 96.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.162 -0.961 . . . . 0.0 109.432 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.522 HD22 HG12 ' A' ' 89' ' ' ILE . 0.0 OUTLIER -52.23 -56.26 15.83 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.287 -0.883 . . . . 0.0 109.399 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -54.83 -33.41 61.63 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 109.503 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -63.03 -46.22 88.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.196 -0.94 . . . . 0.0 109.427 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.722 HD11 ' HG3' ' A' ' 59' ' ' GLN . 0.2 OUTLIER -64.62 -11.55 36.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.419 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 79.78 31.25 40.7 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.505 HG22 ' H ' ' A' ' 88' ' ' LYS . 5.3 mm -98.05 172.85 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.32 -1.106 . . . . 0.0 109.326 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.505 ' H ' HG22 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -97.82 114.41 26.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.21 -0.932 . . . . 0.0 109.631 -179.798 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.717 HG21 ' CD1' ' A' ' 79' ' ' PHE . 19.8 mt -85.6 149.02 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.38 -0.825 . . . . 0.0 109.181 179.722 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.522 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 0.4 OUTLIER -135.47 122.39 21.23 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.01 -1.056 . . . . 0.0 109.673 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.13 121.98 31.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 109.599 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.99 106.79 18.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -0.898 . . . . 0.0 109.547 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 94' ' ' GLY . 6.7 t -122.17 -20.63 6.16 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.272 -0.892 . . . . 0.0 109.732 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.448 ' O ' ' HB ' ' A' ' 95' ' ' THR . . . -43.14 -88.11 0.01 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.563 HG23 ' N ' ' A' ' 96' ' ' SER . 5.2 t 176.51 -45.84 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.257 -1.143 . . . . 0.0 109.423 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.563 ' N ' HG23 ' A' ' 95' ' ' THR . 8.5 m -121.93 115.88 23.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.882 HG22 ' O ' ' A' ' 15' ' ' GLU . 6.4 m -47.14 -35.96 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 109.591 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -48.19 -49.45 32.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.13 -0.981 . . . . 0.0 109.431 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -73.02 -45.36 58.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -0.9 . . . . 0.0 109.642 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.499 ' HA ' HD12 ' A' ' 103' ' ' LEU . 10.4 m-20 -51.41 -24.18 4.61 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.24 -0.913 . . . . 0.0 109.686 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.77 HD21 HG11 ' A' ' 29' ' ' VAL . 19.2 tp -65.51 -66.33 0.56 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.179 -0.951 . . . . 0.0 109.327 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 13.5 ptmt -56.1 -21.09 20.21 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -0.922 . . . . 0.0 109.348 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.986 ' HB3' HD12 ' A' ' 109' ' ' LEU . 10.2 mt -69.87 -45.22 68.17 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.336 -0.852 . . . . 0.0 109.54 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.632 ' CD1' HD11 ' A' ' 3' ' ' ILE . 21.2 t80 -55.54 -19.0 8.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.325 -0.859 . . . . 0.0 109.368 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.617 HG23 ' HA2' ' A' ' 34' ' ' GLY . 96.4 m -59.79 -51.2 70.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.27 -0.894 . . . . 0.0 109.483 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.46 ' OE2' HD23 ' A' ' 103' ' ' LEU . 13.6 pt-20 -83.4 -26.18 30.65 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.487 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.08 35.72 9.54 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -91.43 -6.33 52.95 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.247 -1.149 . . . . 0.0 109.577 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.986 HD12 ' HB3' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -76.63 -161.77 0.22 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.194 -0.942 . . . . 0.0 109.478 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.26 106.46 18.6 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.162 -0.961 . . . . 0.0 109.663 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.522 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 9.4 pt-20 -110.35 127.89 55.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.308 -0.87 . . . . 0.0 109.328 179.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 5.6 mt -127.83 132.19 69.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.582 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.1 ptm180 . . . . . 0 N--CA 1.489 1.521 0 O-C-N 121.283 -0.885 . . . . 0.0 109.264 179.767 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 37.3 mtp . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.248 0.546 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -114.17 150.48 34.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.917 . . . . 0.0 109.315 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.581 HG12 ' CE2' ' A' ' 104' ' ' PHE . 7.6 mt -120.89 101.82 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.279 -0.888 . . . . 0.0 109.892 -179.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.07 103.6 15.54 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.345 -0.847 . . . . 0.0 109.137 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.672 HG22 HG12 ' A' ' 97' ' ' VAL . 7.7 mt -88.13 122.19 39.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.249 -0.907 . . . . 0.0 109.807 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.73 ' HB2' ' HE2' ' A' ' 20' ' ' PHE . . . -69.95 147.11 50.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 109.12 179.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.707 ' HB3' HG11 ' A' ' 97' ' ' VAL . 25.8 p -158.63 -178.68 7.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.165 -0.96 . . . . 0.0 109.788 -179.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -132.46 11.84 4.5 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.299 -0.876 . . . . 0.0 109.361 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -150.2 175.37 29.3 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -73.49 -44.97 56.67 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.272 -1.134 . . . . 0.0 109.46 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.426 ' OD2' ' OE1' ' A' ' 98' ' ' GLU . 10.5 t0 -176.93 -51.81 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.17 -0.956 . . . . 0.0 109.436 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.407 HD23 ' C ' ' A' ' 12' ' ' LEU . 8.7 tt -57.06 -29.82 63.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.203 -0.936 . . . . 0.0 109.245 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 18.97 7.73 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.475 ' O ' ' HA ' ' A' ' 96' ' ' SER . 93.9 p -76.89 79.94 3.46 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.259 -1.142 . . . . 0.0 109.517 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.613 ' C ' HG23 ' A' ' 16' ' ' VAL . 4.7 tt0 -77.39 4.27 11.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -0.828 . . . . 0.0 109.766 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.774 HG22 HG13 ' A' ' 97' ' ' VAL . 2.5 t 74.91 12.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.131 -0.98 . . . . 0.0 109.241 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.4 163.83 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.672 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.21 -44.11 3.03 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.148 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.414 ' O ' ' C ' ' A' ' 20' ' ' PHE . 33.7 m-85 -108.28 78.67 1.19 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.319 -0.863 . . . . 0.0 109.235 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.73 ' HE2' ' HB2' ' A' ' 6' ' ' ALA . 26.4 t80 -42.73 125.84 3.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.272 -0.893 . . . . 0.0 109.565 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -179.69 -66.39 0.07 OUTLIER Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.426 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 7.1 mtt180 -116.71 15.92 15.39 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.211 -1.17 . . . . 0.0 109.654 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.425 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -44.55 104.8 0.4 Allowed Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.917 . . . . 0.0 109.491 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.426 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.49 43.14 1.47 Allowed 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.692 2.261 . . . . 0.0 110.794 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 14.8 m-85 -159.91 70.45 0.44 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.118 -0.989 . . . . 0.0 109.096 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.48 ' HB2' HG23 ' A' ' 42' ' ' ILE . 32.7 m-85 -79.72 129.35 34.4 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.253 -0.904 . . . . 0.0 109.781 -179.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 3.2 ttt -103.64 102.68 12.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.887 . . . . 0.0 109.162 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.1 mm -90.41 116.76 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.098 -1.001 . . . . 0.0 109.552 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.553 HG11 HD11 ' A' ' 101' ' ' LEU . 3.9 t -118.96 160.17 19.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.705 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.506 ' HB3' ' CB ' ' A' ' 38' ' ' SER . 0.1 OUTLIER -139.18 84.6 2.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -0.866 . . . . 0.0 109.337 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.417 ' HB2' ' HE3' ' A' ' 31' ' ' MET . 22.2 ttm -93.58 140.32 29.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.24 -0.912 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . 0.478 ' HG2' ' N ' ' A' ' 33' ' ' LYS . 14.7 ttpp -83.61 -84.98 0.13 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -0.872 . . . . 0.0 109.495 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.478 ' N ' ' HG2' ' A' ' 32' ' ' LYS . 0.0 OUTLIER -131.38 40.31 3.44 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.265 -0.897 . . . . 0.0 109.622 -179.826 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 119.96 24.93 2.65 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 68.6 m-80 -150.05 105.97 3.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.282 -1.128 . . . . 0.0 109.349 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.416 HG23 ' CG1' ' A' ' 29' ' ' VAL . 1.4 mp -66.48 114.75 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.279 -0.888 . . . . 0.0 109.584 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.21 33.06 5.68 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.506 ' CB ' ' HB3' ' A' ' 30' ' ' GLU . 0.2 OUTLIER -179.71 110.84 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.368 -0.832 . . . . 0.0 109.363 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -138.24 108.84 6.57 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.546 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -126.26 134.12 51.26 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.386 -0.821 . . . . 0.0 109.478 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.21 137.71 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.294 -0.879 . . . . 0.0 109.294 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.614 ' O ' HG23 ' A' ' 42' ' ' ILE . 0.8 OUTLIER -136.81 107.53 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.272 -0.892 . . . . 0.0 109.468 -179.935 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -74.59 171.66 13.44 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.382 -0.824 . . . . 0.0 109.409 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.531 0 O-C-N 121.29 -0.881 . . . . 0.0 109.556 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.688 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 1.101 HD11 ' HB2' ' A' ' 78' ' ' ALA . 0.9 OUTLIER -74.98 -14.64 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.274 -1.133 . . . . 0.0 109.365 179.871 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.73 -13.68 61.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.861 . . . . 0.0 109.296 179.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.688 HG22 ' O ' ' A' ' 54' ' ' GLY . 9.2 t -65.78 -25.04 67.07 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.199 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.691 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -53.8 -42.73 68.66 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.375 -0.828 . . . . 0.0 109.527 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -58.98 -35.08 72.6 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.232 -0.918 . . . . 0.0 109.417 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 28.3 mt -72.79 -33.86 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.296 -0.877 . . . . 0.0 109.403 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.724 HG23 HG21 ' A' ' 66' ' ' VAL . 38.3 mt -63.19 -40.56 89.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.242 -0.911 . . . . 0.0 109.298 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.98 -23.86 67.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.207 -0.933 . . . . 0.0 109.37 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -75.15 -21.95 58.46 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 0.0 109.543 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.8 m-20 -80.16 -17.57 52.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.514 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 115.7 -15.28 17.03 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.724 HG21 HG23 ' A' ' 61' ' ' ILE . 57.3 t -44.4 93.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.399 -1.059 . . . . 0.0 109.806 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -79.5 -9.36 59.6 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.221 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -139.9 126.66 20.61 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.344 -0.847 . . . . 0.0 109.153 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.601 HG21 HD21 ' A' ' 82' ' ' LEU . 97.6 t -119.21 126.4 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.165 -0.96 . . . . 0.0 109.694 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.646 HD12 HG12 ' A' ' 5' ' ' ILE . 57.7 mt -100.33 117.47 45.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.354 -0.841 . . . . 0.0 109.349 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -148.25 174.51 11.93 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -0.917 . . . . 0.0 109.706 -179.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.595 ' HB3' ' HB3' ' A' ' 92' ' ' ALA . 53.7 p -143.26 40.87 1.48 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.365 -0.835 . . . . 0.0 109.373 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.423 ' HB2' ' HD2' ' A' ' 74' ' ' PRO . 11.4 p -51.97 159.14 1.49 Allowed Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.606 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.423 ' HD2' ' HB2' ' A' ' 73' ' ' SER . 35.1 Cg_endo -77.57 -31.05 3.56 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.609 2.206 . . . . 0.0 110.541 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -118.06 163.71 12.87 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.571 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.5 Cg_endo -79.96 17.21 1.34 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.831 2.354 . . . . 0.0 111.006 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.404 ' O ' HG23 ' A' ' 81' ' ' VAL . 2.9 m120 -63.1 -52.06 64.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.949 -1.095 . . . . 0.0 109.742 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 1.101 ' HB2' HD11 ' A' ' 55' ' ' ILE . . . -61.77 -37.63 85.03 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.774 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.571 ' CD2' ' HA ' ' A' ' 76' ' ' PRO . 4.0 m-30 -66.17 -29.03 69.23 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.606 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -71.83 -41.5 68.12 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.167 -0.958 . . . . 0.0 109.566 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.404 HG23 ' O ' ' A' ' 77' ' ' ASN . 3.6 t -66.78 -50.42 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.165 -0.959 . . . . 0.0 109.652 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.601 HD21 HG21 ' A' ' 69' ' ' VAL . 2.3 mp -66.77 -27.45 67.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.232 -0.917 . . . . 0.0 109.468 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -65.78 -47.32 75.58 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.216 -0.927 . . . . 0.0 109.245 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -68.25 -31.61 71.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.31 -0.869 . . . . 0.0 109.26 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.488 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.4 OUTLIER -66.92 -25.96 66.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 179.894 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 93.69 22.58 25.78 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.488 HG12 ' HB3' ' A' ' 85' ' ' LEU . 5.9 mm -101.34 163.0 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.238 -1.154 . . . . 0.0 109.456 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.412 ' CG ' ' O ' ' A' ' 113' ' ' ARG . 12.5 mttm -93.7 133.03 37.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.401 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.501 HG21 ' CD1' ' A' ' 79' ' ' PHE . 2.0 mt -113.49 135.83 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.19 -0.944 . . . . 0.0 109.546 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.505 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 21.5 m-85 -124.56 151.25 44.97 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.505 -0.747 . . . . 0.0 109.365 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.468 ' O ' ' HG ' ' A' ' 109' ' ' LEU . 6.9 ttt-85 -83.46 152.86 24.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.229 -0.919 . . . . 0.0 109.701 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.595 ' HB3' ' HB3' ' A' ' 72' ' ' SER . . . -106.04 158.91 16.46 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.235 -0.915 . . . . 0.0 109.305 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.63 7.35 46.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.167 -0.958 . . . . 0.0 109.589 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 47.96 72.01 0.49 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.6 m -150.64 -61.61 0.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.308 -1.113 . . . . 0.0 109.356 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 14' ' ' SER . 66.4 m -165.98 123.11 1.4 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.233 -0.917 . . . . 0.0 109.525 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.774 HG13 HG22 ' A' ' 16' ' ' VAL . 27.2 m -65.62 -43.92 93.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.237 -0.914 . . . . 0.0 109.378 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . 0.526 ' N ' HG23 ' A' ' 97' ' ' VAL . 0.2 OUTLIER -45.15 -44.06 10.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.229 -0.919 . . . . 0.0 109.406 179.941 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.561 ' HG3' HD13 ' A' ' 103' ' ' LEU . 38.7 tp10 -73.92 -46.83 41.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.275 -0.891 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.453 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 2.2 m-80 -47.55 -26.21 1.36 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.938 . . . . 0.0 109.336 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.553 HD11 HG11 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -59.09 -57.03 14.88 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -0.919 . . . . 0.0 109.291 179.867 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.04 -27.61 68.92 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.238 -0.914 . . . . 0.0 109.327 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.561 HD13 ' HG3' ' A' ' 99' ' ' GLU . 0.8 OUTLIER -63.65 -35.08 79.34 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.372 -0.83 . . . . 0.0 109.534 179.984 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.581 ' CE2' HG12 ' A' ' 3' ' ' ILE . 6.1 t80 -63.79 -27.03 68.91 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.193 -0.942 . . . . 0.0 109.608 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 90.8 m -74.49 -19.93 60.18 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.189 -0.945 . . . . 0.0 109.484 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -106.17 8.19 31.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.202 -0.936 . . . . 0.0 109.515 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 52.53 40.73 55.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -83.59 -43.24 15.86 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.328 -1.101 . . . . 0.0 109.498 -179.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.529 HD21 ' HA ' ' A' ' 92' ' ' ALA . 1.5 tp -96.45 147.54 23.73 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.32 -0.863 . . . . 0.0 109.292 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.411 ' HG3' ' O ' ' A' ' 109' ' ' LEU . 3.4 mt-10 -176.52 -177.75 0.86 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.091 -1.005 . . . . 0.0 109.862 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.505 ' HB3' ' HA ' ' A' ' 90' ' ' TYR . 1.1 tp10 -177.35 -111.88 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.468 -0.77 . . . . 0.0 109.067 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.521 ' CD1' ' HB3' ' A' ' 79' ' ' PHE . 8.0 mt -79.74 121.53 33.21 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 O-C-N 121.177 -0.952 . . . . 0.0 109.367 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.412 ' O ' ' CG ' ' A' ' 88' ' ' LYS . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.548 0 O-C-N 121.171 -0.955 . . . . 0.0 109.384 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.3 mmt . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.576 ' N ' ' CD ' ' A' ' 2' ' ' LYS . 0.0 OUTLIER -90.44 133.88 34.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.252 -0.905 . . . . 0.0 109.158 179.915 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.501 ' HB ' HG12 ' A' ' 29' ' ' VAL . 9.4 mm -101.29 104.33 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.338 -0.851 . . . . 0.0 110.207 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.864 ' HB2' HD12 ' A' ' 28' ' ' ILE . . . -110.23 88.46 2.77 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.662 HD12 HG21 ' A' ' 70' ' ' ILE . 9.5 tt -98.81 133.11 42.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.239 -0.913 . . . . 0.0 110.014 -179.142 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -57.72 156.64 8.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.354 -0.841 . . . . 0.0 109.081 179.51 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.698 ' HB3' HG11 ' A' ' 97' ' ' VAL . 0.0 OUTLIER -159.97 178.96 9.19 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.092 -1.005 . . . . 0.0 109.798 -179.873 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.538 ' C ' ' CD2' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -126.73 23.49 6.71 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.386 -0.821 . . . . 0.0 109.189 179.921 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.464 ' HA2' ' CD1' ' A' ' 25' ' ' TYR . . . 153.08 -151.51 23.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.882 HG22 HG21 ' A' ' 41' ' ' VAL . 16.1 p -124.97 101.94 7.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.185 -1.185 . . . . 0.0 109.353 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 53.9 -154.03 0.26 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.282 -0.886 . . . . 0.0 109.327 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER 60.05 17.96 7.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.27 -0.894 . . . . 0.0 109.576 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 118.85 26.06 2.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.0 m -73.59 83.46 1.54 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.301 -1.117 . . . . 0.0 109.281 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.436 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.4 OUTLIER -79.4 38.81 0.38 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.435 -0.79 . . . . 0.0 110.62 -179.967 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.541 HG12 ' O ' ' A' ' 16' ' ' VAL . 21.2 t 63.55 13.08 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 120.716 -1.24 . . . . 0.0 109.413 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 65.78 177.97 0.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.226 -0.921 . . . . 0.0 109.493 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 7.5 ttt180 -120.26 7.13 10.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.184 -0.947 . . . . 0.0 109.596 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -144.02 165.9 26.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.42 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.87 ' CD2' ' HB1' ' A' ' 71' ' ' ALA . 2.3 t80 -132.68 88.81 2.56 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 109.392 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 158.85 -53.49 0.38 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.442 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 5.6 mtp180 -93.58 -19.95 20.69 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.265 -1.138 . . . . 0.0 109.67 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.53 110.24 2.12 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.183 -0.948 . . . . 0.0 109.525 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.502 ' HA ' ' CB ' ' A' ' 44' ' ' ASN . 36.9 Cg_endo -81.29 51.56 3.95 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.614 2.21 . . . . 0.0 110.715 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.538 ' CD2' ' C ' ' A' ' 8' ' ' SER . 4.9 m-85 -159.1 68.91 0.45 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.99 -1.069 . . . . 0.0 109.555 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -84.31 127.05 33.74 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.911 . . . . 0.0 109.189 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . 0.78 ' HG3' HG13 ' A' ' 41' ' ' VAL . 1.7 mtt -100.85 121.98 42.64 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.817 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.864 HD12 ' HB2' ' A' ' 4' ' ' ALA . 1.1 tp -121.36 132.2 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.357 -0.839 . . . . 0.0 109.06 179.622 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.772 HG23 ' O ' ' A' ' 38' ' ' SER . 14.1 p -138.89 133.41 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.221 -0.924 . . . . 0.0 109.538 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.431 ' HG2' ' N ' ' A' ' 31' ' ' MET . 3.4 tt0 -103.41 138.69 39.81 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.246 -0.909 . . . . 0.0 109.461 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.431 ' N ' ' HG2' ' A' ' 30' ' ' GLU . 11.4 ptp -130.4 153.65 48.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 109.381 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.57 -76.88 0.44 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.235 -0.915 . . . . 0.0 109.688 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.34 -73.17 0.67 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.123 -0.985 . . . . 0.0 109.646 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -142.68 26.6 2.24 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -140.36 99.52 3.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -1.16 . . . . 0.0 109.571 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.705 HD13 HD21 ' A' ' 101' ' ' LEU . 7.2 pt -50.1 129.38 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.24 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -113.43 0.38 14.72 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.159 -0.963 . . . . 0.0 109.817 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.772 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -156.41 110.34 2.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.031 -1.043 . . . . 0.0 110.007 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.63 100.22 7.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.313 -0.867 . . . . 0.0 108.901 179.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -108.05 159.46 16.55 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.188 -0.945 . . . . 0.0 109.912 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.882 HG21 HG22 ' A' ' 10' ' ' THR . 2.8 t -129.29 122.48 56.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.373 -0.83 . . . . 0.0 109.141 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.74 142.48 24.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.184 -0.947 . . . . 0.0 109.582 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -87.95 158.09 18.76 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 0.0 109.304 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.502 ' CB ' ' HA ' ' A' ' 24' ' ' PRO . 4.0 t-20 . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.217 -0.927 . . . . 0.0 109.506 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.855 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.641 HD12 ' HB2' ' A' ' 78' ' ' ALA . 30.2 mm -76.02 -17.97 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.287 -1.125 . . . . 0.0 109.328 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -76.39 -16.13 59.79 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.32 -0.862 . . . . 0.0 109.307 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.855 HG22 ' O ' ' A' ' 54' ' ' GLY . 11.9 t -72.61 -24.62 61.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.282 -0.887 . . . . 0.0 109.47 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -59.65 -36.62 76.76 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.115 -0.99 . . . . 0.0 109.268 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -71.45 -23.01 61.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.294 -0.879 . . . . 0.0 109.523 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.7 mm -76.84 -54.65 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.476 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.607 ' O ' HG22 ' A' ' 66' ' ' VAL . 0.9 OUTLIER -66.79 -27.57 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.254 -0.904 . . . . 0.0 109.544 -179.955 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.619 ' HB1' HD22 ' A' ' 85' ' ' LEU . . . -65.98 -34.07 77.26 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.183 -0.948 . . . . 0.0 109.572 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -77.03 -10.17 59.19 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 109.624 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.1 m-20 -83.61 -12.62 55.81 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.264 -0.898 . . . . 0.0 109.591 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.415 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 97.31 0.89 59.48 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.747 ' O ' HG23 ' A' ' 66' ' ' VAL . 32.8 m -48.03 98.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.181 -1.188 . . . . 0.0 109.761 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.415 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -78.53 -11.2 59.95 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 178.951 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -139.8 126.31 20.34 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 71.4 t -126.16 124.79 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.981 -1.074 . . . . 0.0 109.755 -179.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.662 HG21 HD12 ' A' ' 5' ' ' ILE . 4.2 mp -104.18 96.86 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.199 -0.938 . . . . 0.0 109.314 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.87 ' HB1' ' CD2' ' A' ' 20' ' ' PHE . . . -130.1 172.36 11.85 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.401 -0.812 . . . . 0.0 109.473 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.424 ' O ' ' C ' ' A' ' 73' ' ' SER . 0.2 OUTLIER -138.64 34.22 2.23 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.29 -0.881 . . . . 0.0 109.555 -179.881 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -44.57 153.06 0.48 Allowed Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.221 -0.924 . . . . 0.0 109.315 179.914 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.23 -47.38 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.605 2.203 . . . . 0.0 110.335 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.419 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -84.67 141.55 19.62 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.419 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.6 Cg_endo -78.45 -0.68 10.93 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.501 2.134 . . . . 0.0 110.347 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -60.56 -32.51 71.57 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.308 -0.87 . . . . 0.0 109.522 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.641 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -70.04 -54.24 14.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.22 -0.925 . . . . 0.0 109.521 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.412 ' CD1' HG21 ' A' ' 89' ' ' ILE . 11.3 m-30 -54.64 -24.2 20.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.247 -0.908 . . . . 0.0 109.738 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -72.43 -37.34 68.63 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.156 -0.965 . . . . 0.0 109.723 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 75.4 t -76.1 -36.23 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.219 -0.926 . . . . 0.0 109.77 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.56 HD12 ' O ' ' A' ' 78' ' ' ALA . 0.7 OUTLIER -62.01 -36.58 81.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.599 -179.85 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -73.51 -24.53 60.17 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.236 -0.915 . . . . 0.0 109.46 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -76.78 -33.41 58.04 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.233 -0.917 . . . . 0.0 109.526 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.619 HD22 ' HB1' ' A' ' 62' ' ' ALA . 0.5 OUTLIER -77.52 -23.65 50.14 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.135 -0.978 . . . . 0.0 109.564 -179.86 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.5 21.59 14.42 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.472 HG22 ' N ' ' A' ' 88' ' ' LYS . 7.7 mt -98.83 158.33 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.257 -1.143 . . . . 0.0 109.381 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.472 ' N ' HG22 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -90.76 128.58 36.73 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.15 -0.969 . . . . 0.0 109.332 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.538 HG12 ' CB ' ' A' ' 82' ' ' LEU . 5.5 mt -98.91 151.22 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.17 -0.956 . . . . 0.0 109.29 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.573 ' CE1' ' HA ' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -138.54 141.15 39.3 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.321 -0.862 . . . . 0.0 109.225 -179.708 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.42 ' O ' ' HB3' ' A' ' 110' ' ' GLU . 1.5 tpp85 -92.6 128.56 38.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.939 . . . . 0.0 109.782 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.44 121.46 25.75 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.326 -0.859 . . . . 0.0 109.486 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.12 -27.89 61.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.309 -0.87 . . . . 0.0 109.505 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 97.06 61.21 0.94 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -130.51 -60.72 0.98 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.192 -1.181 . . . . 0.0 109.451 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 0.3 OUTLIER -173.34 150.39 1.86 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.291 -0.881 . . . . 0.0 109.543 -179.878 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.698 HG11 ' HB3' ' A' ' 7' ' ' SER . 4.0 m -72.16 -34.17 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.582 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -65.39 -53.29 45.46 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.482 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 0.3 OUTLIER -58.3 -45.04 88.71 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.329 -0.857 . . . . 0.0 109.709 -179.921 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -61.18 -30.27 70.31 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.205 -0.934 . . . . 0.0 109.847 -179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.705 HD21 HD13 ' A' ' 36' ' ' ILE . 31.7 tp -63.07 -56.51 16.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.176 -0.953 . . . . 0.0 109.648 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.404 ' HG2' ' O ' ' A' ' 102' ' ' LYS . 0.0 OUTLIER -73.86 -11.91 60.51 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.146 -0.972 . . . . 0.0 109.5 -179.906 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.534 HD22 ' OE2' ' A' ' 110' ' ' GLU . 0.3 OUTLIER -76.17 -45.31 34.03 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.232 -0.917 . . . . 0.0 109.497 -179.91 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.551 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 3.5 t80 -76.57 -26.31 54.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.344 -0.847 . . . . 0.0 109.49 -179.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.425 HG23 ' SD ' ' A' ' 31' ' ' MET . 17.7 m -61.4 -33.59 73.94 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.229 -0.919 . . . . 0.0 109.676 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -103.43 8.94 37.95 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.104 -0.997 . . . . 0.0 109.575 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.29 59.13 10.51 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . 0.565 ' O ' HD12 ' A' ' 109' ' ' LEU . 48.2 t-20 -81.18 -38.77 26.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.38 -1.071 . . . . 0.0 109.564 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.565 HD12 ' O ' ' A' ' 108' ' ' ASN . 0.0 OUTLIER 171.0 -156.77 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.162 -0.961 . . . . 0.0 109.735 -179.942 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.565 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 23.2 mt-10 60.59 29.82 19.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.865 . . . . 0.0 109.259 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.573 ' HA ' ' CE1' ' A' ' 90' ' ' TYR . 1.0 OUTLIER -92.44 144.74 25.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.319 -0.863 . . . . 0.0 109.675 -179.823 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 111' ' ' GLU . 9.2 mm -155.67 125.62 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.477 -0.764 . . . . 0.0 109.15 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 0.0 109.353 179.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.448 ' O ' ' HE3' ' A' ' 2' ' ' LYS . 21.0 ttm . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.357 0.599 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.448 ' HE3' ' O ' ' A' ' 1' ' ' MET . 0.1 OUTLIER -143.44 106.9 4.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.203 -0.935 . . . . 0.0 109.413 -179.996 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.752 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 2.3 mp -107.68 114.77 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.336 -0.853 . . . . 0.0 109.414 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.566 ' HB1' ' CZ ' ' A' ' 26' ' ' PHE . . . -113.24 122.07 46.36 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.235 -0.915 . . . . 0.0 109.347 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.477 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 2.8 mp -96.93 129.22 47.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.174 -0.954 . . . . 0.0 109.568 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.419 ' O ' ' HB3' ' A' ' 7' ' ' SER . . . -68.93 146.86 52.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.257 -0.902 . . . . 0.0 109.272 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.419 ' HB3' ' O ' ' A' ' 6' ' ' ALA . 13.3 t 60.05 -94.5 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 0.0 109.426 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.621 ' OG ' HG11 ' A' ' 97' ' ' VAL . 8.7 t 63.45 31.42 14.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.161 -0.962 . . . . 0.0 109.772 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 42.53 -105.57 0.07 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -158.7 -46.44 0.06 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.251 -1.146 . . . . 0.0 109.411 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.86 -72.89 0.35 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.185 -0.947 . . . . 0.0 109.637 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 31.6 mt -107.09 -14.7 14.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.202 -0.936 . . . . 0.0 109.572 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.21 6.12 64.73 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 8' ' ' SER . 93.9 p -77.68 77.16 4.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -1.137 . . . . 0.0 109.673 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.598 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -77.81 78.49 4.31 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.235 -0.916 . . . . 0.0 109.456 179.881 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.598 HG12 ' O ' ' A' ' 15' ' ' GLU . 11.6 p 41.1 42.31 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.427 -0.795 . . . . 0.0 109.839 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.438 ' OG ' ' C ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER 59.97 -163.54 0.24 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.249 -0.907 . . . . 0.0 109.486 -179.959 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -170.27 -36.32 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.258 -0.901 . . . . 0.0 109.373 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -148.16 140.06 23.94 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.33 -0.856 . . . . 0.0 109.471 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.428 ' CG ' ' O ' ' A' ' 20' ' ' PHE . 12.9 t80 -116.1 38.45 3.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.252 -0.905 . . . . 0.0 109.733 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -93.94 -56.76 1.37 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.432 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 18.9 mtt180 -140.16 41.74 1.94 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.29 -1.124 . . . . 0.0 109.111 179.747 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -52.3 108.8 1.17 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.41 -0.806 . . . . 0.0 109.744 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.482 ' O ' ' HB3' ' A' ' 43' ' ' GLU . 36.7 Cg_endo -80.83 40.9 1.05 Allowed 'Trans proline' 0 C--N 1.312 -1.374 0 C-N-CA 122.561 2.174 . . . . 0.0 110.434 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.422 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 6.2 m-85 -161.11 74.74 0.5 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.143 -0.973 . . . . 0.0 108.909 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.566 ' CZ ' ' HB1' ' A' ' 4' ' ' ALA . 16.5 t80 -78.26 112.52 15.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.433 -0.792 . . . . 0.0 109.496 -179.439 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 1.6 ttm -94.12 114.48 26.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.455 -0.778 . . . . 0.0 109.31 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.405 HG23 ' O ' ' A' ' 28' ' ' ILE . 0.3 OUTLIER -106.62 123.88 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.283 -0.886 . . . . 0.0 109.488 -179.869 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.651 HG12 HG23 ' A' ' 36' ' ' ILE . 2.1 t -121.74 120.64 62.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.912 . . . . 0.0 109.636 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -116.95 96.81 5.63 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 21.1 ptp -87.26 167.24 14.27 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.919 . . . . 0.0 109.358 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.58 -93.62 0.15 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.259 -0.9 . . . . 0.0 109.552 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.62 35.59 3.78 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.232 -0.917 . . . . 0.0 109.485 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 120.7 21.66 3.21 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 12.4 t30 -141.04 109.45 5.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.175 -1.191 . . . . 0.0 109.381 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.651 HG23 HG12 ' A' ' 29' ' ' VAL . 4.5 mt -63.25 114.12 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 109.631 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -123.03 28.55 7.14 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.265 -0.897 . . . . 0.0 109.27 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -172.96 96.12 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.324 -0.86 . . . . 0.0 109.434 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.1 m -125.99 103.5 7.78 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.276 -0.89 . . . . 0.0 109.147 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -114.52 142.58 46.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.255 -0.903 . . . . 0.0 110.046 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 t -116.72 96.21 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.415 -0.803 . . . . 0.0 108.955 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 13.6 mt -121.21 126.8 75.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 0.0 109.812 -179.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.482 ' HB3' ' O ' ' A' ' 24' ' ' PRO . 0.0 OUTLIER -53.65 148.59 9.46 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.353 -0.842 . . . . 0.0 109.582 179.847 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.8 m120 . . . . . 0 N--CA 1.49 1.545 0 O-C-N 121.179 -0.951 . . . . 0.0 109.218 179.746 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.842 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.491 2.313 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.568 HG23 ' HB2' ' A' ' 78' ' ' ALA . 22.9 mm -75.61 -20.05 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.252 -1.146 . . . . 0.0 109.6 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -69.87 -25.58 63.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.323 -0.861 . . . . 0.0 109.505 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.842 HG22 ' O ' ' A' ' 54' ' ' GLY . 11.2 t -56.48 -25.86 52.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.561 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.455 ' O ' ' HB ' ' A' ' 61' ' ' ILE . . . -45.27 -41.84 8.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.183 -0.948 . . . . 0.0 109.356 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.82 -56.12 15.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.307 -0.871 . . . . 0.0 109.552 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 44.6 mt -54.97 -33.74 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.231 -0.918 . . . . 0.0 109.38 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.455 ' HB ' ' O ' ' A' ' 58' ' ' ALA . 22.9 mm -59.73 -52.72 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.245 -0.909 . . . . 0.0 109.579 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -64.18 -21.52 66.59 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.277 -0.889 . . . . 0.0 109.739 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.96 -23.26 55.35 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -0.924 . . . . 0.0 109.656 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -83.83 -16.91 42.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.125 -0.985 . . . . 0.0 109.703 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 98.37 -2.09 59.09 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.436 HG23 ' H ' ' A' ' 66' ' ' VAL . 3.7 t -42.37 97.87 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.315 -1.109 . . . . 0.0 109.773 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.469 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -79.22 -9.97 59.7 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.081 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.752 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -135.58 118.51 16.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.48 -0.763 . . . . 0.0 109.354 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.637 ' CG2' HD21 ' A' ' 82' ' ' LEU . 59.3 t -111.6 119.92 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.24 -0.913 . . . . 0.0 109.63 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.477 ' HB ' ' HA ' ' A' ' 5' ' ' ILE . 4.4 mm -102.69 117.12 47.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.149 -0.969 . . . . 0.0 109.551 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -160.03 171.77 18.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.745 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 37.4 t -133.71 42.98 2.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.354 -0.841 . . . . 0.0 109.278 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.437 ' OG ' ' HD2' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -51.81 155.57 2.91 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.42 -0.8 . . . . 0.0 109.83 -179.731 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.437 ' HD2' ' OG ' ' A' ' 73' ' ' SER . 35.2 Cg_endo -78.17 -12.1 15.99 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.725 2.283 . . . . 0.0 110.642 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -148.89 154.23 25.69 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.533 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.4 Cg_endo -79.92 38.81 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.862 2.375 . . . . 0.0 111.017 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.411 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 1.5 t-20 -77.25 -54.52 6.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.966 -1.084 . . . . 0.0 109.675 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.568 ' HB2' HG23 ' A' ' 55' ' ' ILE . . . -66.15 -38.39 88.0 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 109.644 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 79' ' ' PHE . 2.7 m-30 -55.41 -33.79 63.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.931 . . . . 0.0 109.475 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.411 ' HB2' ' O ' ' A' ' 77' ' ' ASN . 16.9 mt-10 -53.19 -55.79 21.52 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.932 . . . . 0.0 109.521 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.404 HG23 ' H ' ' A' ' 81' ' ' VAL . 2.4 t -60.89 -39.17 81.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.929 HD23 HG13 ' A' ' 89' ' ' ILE . 1.3 tp -52.23 -40.8 62.11 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.396 -0.815 . . . . 0.0 109.935 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -73.98 -36.98 64.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.128 -0.983 . . . . 0.0 109.81 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -66.92 -20.04 65.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.268 -0.895 . . . . 0.0 109.822 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.492 ' HA ' HD22 ' A' ' 85' ' ' LEU . 0.2 OUTLIER -102.98 24.68 10.38 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.16 -0.963 . . . . 0.0 109.716 -179.81 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 51.94 65.2 3.37 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.401 HG22 ' N ' ' A' ' 88' ' ' LYS . 75.0 mt -141.03 155.55 21.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -1.162 . . . . 0.0 109.299 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.401 ' N ' HG22 ' A' ' 87' ' ' ILE . 15.6 mttp -101.2 130.89 47.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.126 -0.984 . . . . 0.0 109.839 -179.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.929 HG13 HD23 ' A' ' 82' ' ' LEU . 2.2 mp -94.73 160.43 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.338 -0.851 . . . . 0.0 109.425 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.527 ' CE2' ' O ' ' A' ' 109' ' ' LEU . 0.2 OUTLIER -144.51 135.61 25.18 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.336 -0.852 . . . . 0.0 109.394 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.01 139.9 33.96 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.303 -0.873 . . . . 0.0 109.476 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.496 ' HB1' HG22 ' A' ' 16' ' ' VAL . . . -81.42 112.22 18.48 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -0.903 . . . . 0.0 109.434 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -144.32 16.23 1.68 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.256 -0.902 . . . . 0.0 109.45 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -92.13 -130.45 5.11 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 51.9 m -122.91 -54.87 1.82 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.218 -1.166 . . . . 0.0 109.489 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 2.3 m -127.52 172.09 11.02 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.245 -0.909 . . . . 0.0 109.457 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.621 HG11 ' OG ' ' A' ' 8' ' ' SER . 49.4 t -77.33 -43.82 30.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.319 -0.863 . . . . 0.0 109.612 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.46 -34.79 67.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.26 -0.9 . . . . 0.0 109.551 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -75.85 -59.52 2.72 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.252 -0.905 . . . . 0.0 109.518 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.4 HD22 HG21 ' A' ' 70' ' ' ILE . 47.1 t30 -51.02 -22.19 2.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.224 -0.923 . . . . 0.0 109.463 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 24.0 tp -64.18 -69.59 0.27 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.196 -0.94 . . . . 0.0 109.306 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.41 ' O ' ' HG2' ' A' ' 106' ' ' GLU . 0.6 OUTLIER -62.76 -14.82 49.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.335 -0.853 . . . . 0.0 109.458 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -77.0 -32.51 57.26 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 109.619 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.633 ' CE1' HD11 ' A' ' 3' ' ' ILE . 1.9 t80 -71.28 -31.08 67.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -0.889 . . . . 0.0 109.59 -179.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 51.6 m -74.26 -21.08 59.92 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.045 -1.034 . . . . 0.0 109.99 -179.425 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.41 ' HG2' ' O ' ' A' ' 102' ' ' LYS . 30.1 mm-40 -92.07 11.86 23.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.064 -1.023 . . . . 0.0 109.514 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 53.06 53.68 32.83 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . 0.487 ' OD1' HD23 ' A' ' 109' ' ' LEU . 1.6 t-20 -79.88 -63.82 1.33 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.348 -1.089 . . . . 0.0 109.469 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.527 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.6 OUTLIER 177.87 -153.56 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.306 -0.871 . . . . 0.0 109.528 179.989 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.519 ' HG3' ' CD1' ' A' ' 109' ' ' LEU . 79.4 mt-10 62.15 27.9 16.78 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.208 -0.933 . . . . 0.0 109.287 -179.867 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.495 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 7.9 pt-20 -108.7 147.74 31.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.757 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.442 ' O ' HD12 ' A' ' 89' ' ' ILE . 14.4 mt -151.76 128.39 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.323 -0.861 . . . . 0.0 109.193 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.235 -0.916 . . . . 0.0 109.805 -179.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 mtp . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.795 ' HD3' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -139.42 140.56 37.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.195 -0.94 . . . . 0.0 109.667 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.537 ' CG2' HD11 ' A' ' 70' ' ' ILE . 5.5 mt -110.41 99.67 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.46 -0.775 . . . . 0.0 109.824 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.641 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -100.07 115.39 29.64 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.337 -0.852 . . . . 0.0 109.08 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.652 HG13 HD12 ' A' ' 70' ' ' ILE . 3.4 mp -92.04 142.47 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.217 -0.927 . . . . 0.0 109.756 -179.741 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.502 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -80.39 171.62 14.83 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.295 -0.878 . . . . 0.0 109.546 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.547 ' HA ' ' HB1' ' A' ' 23' ' ' ALA . 71.7 m 47.95 -93.02 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.251 -0.906 . . . . 0.0 109.522 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.502 ' N ' ' O ' ' A' ' 6' ' ' ALA . 41.0 t 52.9 25.39 3.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.083 -1.011 . . . . 0.0 109.528 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 44.38 -101.41 0.03 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.59 -67.1 0.19 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.212 -1.17 . . . . 0.0 109.479 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -158.66 -79.41 0.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.156 -0.965 . . . . 0.0 109.592 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.17 -19.82 55.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.147 -0.971 . . . . 0.0 109.515 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -130.68 37.46 2.11 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.6 m -76.49 82.07 3.19 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -1.153 . . . . 0.0 109.254 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.49 ' HG3' ' N ' ' A' ' 16' ' ' VAL . 5.3 pt-20 -77.14 -134.38 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.266 -0.896 . . . . 0.0 109.054 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.775 HG13 ' O ' ' A' ' 16' ' ' VAL . 12.2 p -154.45 67.24 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 120.99 -1.069 . . . . 0.0 109.422 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.0 m -52.6 156.94 1.69 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -102.53 12.85 35.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.287 -0.883 . . . . 0.0 109.447 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -107.49 103.54 12.89 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.274 -0.891 . . . . 0.0 109.451 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -101.79 127.51 48.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.162 -0.961 . . . . 0.0 109.435 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 150.29 -64.49 0.39 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.6 ttt180 -91.85 -12.44 33.64 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -1.16 . . . . 0.0 109.362 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.573 ' O ' ' CE1' ' A' ' 26' ' ' PHE . . . -41.48 101.82 0.25 Allowed Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.528 -0.732 . . . . 0.0 109.752 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.491 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.8 Cg_endo -80.91 44.23 1.71 Allowed 'Trans proline' 0 C--N 1.311 -1.419 0 C-N-CA 122.653 2.236 . . . . 0.0 110.574 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.491 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 31.6 m-85 -160.07 70.21 0.43 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.015 -1.053 . . . . 0.0 109.641 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.573 ' CE1' ' O ' ' A' ' 23' ' ' ALA . 18.8 m-30 -80.35 111.5 16.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.178 -0.951 . . . . 0.0 109.377 179.704 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . 0.417 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 6.3 ttm -90.56 116.67 28.64 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.276 -0.89 . . . . 0.0 109.509 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.795 HG22 ' HD3' ' A' ' 2' ' ' LYS . 7.2 mm -101.99 108.36 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.893 . . . . 0.0 109.437 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.676 ' CG1' HD12 ' A' ' 36' ' ' ILE . 96.8 t -104.47 142.34 18.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.553 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.457 ' O ' ' OG ' ' A' ' 38' ' ' SER . 32.5 tt0 -137.28 100.87 4.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.329 -0.857 . . . . 0.0 109.53 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.886 ' HB3' HD13 ' A' ' 36' ' ' ILE . 4.5 ptp -95.75 155.22 16.84 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.276 -0.89 . . . . 0.0 109.252 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 27.4 mmtm -102.26 -46.77 4.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.241 -0.912 . . . . 0.0 109.877 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 34' ' ' GLY . 1.5 ttpp -146.27 92.62 2.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.21 -0.931 . . . . 0.0 109.639 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 43.36 28.2 0.88 Allowed Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -151.06 111.01 4.08 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.205 -1.173 . . . . 0.0 109.387 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.886 HD13 ' HB3' ' A' ' 31' ' ' MET . 49.1 mm -56.74 116.91 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.236 -0.915 . . . . 0.0 109.588 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.34 18.54 15.19 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.317 -0.864 . . . . 0.0 109.415 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 30' ' ' GLU . 0.7 OUTLIER -174.94 127.52 0.29 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.317 -0.864 . . . . 0.0 109.527 -179.877 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.22 110.94 6.48 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.329 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -125.15 106.34 9.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 109.74 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 41' ' ' VAL . 14.9 p -97.15 124.49 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.24 -0.912 . . . . 0.0 109.247 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.0 pt -122.52 161.02 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.26 -0.9 . . . . 0.0 109.778 -179.656 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -104.0 159.81 15.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.346 -0.846 . . . . 0.0 109.379 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.9 m120 . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.297 -0.877 . . . . 0.0 109.238 179.741 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.517 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.513 HG21 ' HB2' ' A' ' 78' ' ' ALA . 23.8 mt -73.88 -9.18 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.303 -1.116 . . . . 0.0 109.47 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . 0.466 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -69.03 -23.44 64.07 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.211 -0.93 . . . . 0.0 109.532 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.708 ' HA ' HD12 ' A' ' 60' ' ' ILE . 13.0 t -64.29 -14.18 54.36 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.673 -179.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -54.25 -46.11 72.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.167 -0.958 . . . . 0.0 109.439 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -52.11 -36.77 52.06 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.141 -0.974 . . . . 0.0 109.472 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.708 HD12 ' HA ' ' A' ' 57' ' ' THR . 6.6 mt -74.81 -33.56 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.266 -0.896 . . . . 0.0 109.609 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 61.0 mt -61.39 -36.69 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.178 -0.951 . . . . 0.0 109.4 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -70.72 -21.68 62.52 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.281 -0.887 . . . . 0.0 109.61 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -75.09 -9.68 58.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.118 -0.989 . . . . 0.0 109.283 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -88.59 -21.83 23.84 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.245 -0.909 . . . . 0.0 109.476 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 120.02 17.66 4.49 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.641 HG11 ' HB3' ' A' ' 4' ' ' ALA . 17.9 t -87.16 89.9 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.222 -1.164 . . . . 0.0 109.483 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.627 ' HA ' HG23 ' A' ' 87' ' ' ILE . 4.3 tttp -79.54 -7.97 58.84 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.364 -0.835 . . . . 0.0 108.984 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 2' ' ' LYS . . . -130.83 113.96 14.73 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.112 -0.993 . . . . 0.0 109.319 179.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 93.4 t -112.02 123.84 68.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.106 -0.996 . . . . 0.0 109.705 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.754 ' CG2' ' HB2' ' A' ' 92' ' ' ALA . 80.9 mt -103.14 116.36 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.397 -0.814 . . . . 0.0 109.186 179.766 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.91 175.42 10.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 109.934 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.02 57.36 1.48 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.508 -0.745 . . . . 0.0 109.23 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.2 m -65.18 155.57 83.96 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.199 -0.938 . . . . 0.0 109.614 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.18 -18.8 12.49 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.752 2.301 . . . . 0.0 110.312 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -129.99 162.38 23.01 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.16 9.9 3.18 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.814 2.343 . . . . 0.0 110.755 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -60.9 -55.03 37.82 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.065 -1.022 . . . . 0.0 109.655 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.513 ' HB2' HG21 ' A' ' 55' ' ' ILE . . . -56.06 -52.33 64.66 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.246 -0.909 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.702 ' CD1' HG21 ' A' ' 89' ' ' ILE . 12.9 m-30 -53.55 -30.1 40.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.226 -0.921 . . . . 0.0 109.628 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -68.79 -42.51 77.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.276 -0.89 . . . . 0.0 109.632 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.36 -53.09 44.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.184 -0.947 . . . . 0.0 109.478 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 53.5 mt -59.66 -28.01 66.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.27 -0.894 . . . . 0.0 109.639 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.478 ' HB2' ' O ' ' A' ' 79' ' ' PHE . 1.4 t-20 -69.06 -44.81 71.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.94 . . . . 0.0 109.268 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -68.85 -23.58 64.26 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.207 -0.933 . . . . 0.0 109.17 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.43 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -75.21 -35.39 61.5 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.271 -0.893 . . . . 0.0 109.484 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 101.75 25.01 8.29 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.627 HG23 ' HA ' ' A' ' 67' ' ' LYS . 30.5 mm -105.49 169.9 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.253 -1.145 . . . . 0.0 109.592 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.554 ' N ' HG22 ' A' ' 87' ' ' ILE . 5.4 mttt -93.71 134.91 35.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.285 -0.884 . . . . 0.0 109.536 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.702 HG21 ' CD1' ' A' ' 79' ' ' PHE . 4.3 mt -107.06 142.55 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.287 -0.883 . . . . 0.0 109.464 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.551 ' N ' ' CD1' ' A' ' 90' ' ' TYR . 4.5 m-85 -130.8 148.76 52.62 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.514 -0.741 . . . . 0.0 109.558 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.428 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 1.1 ttt180 -104.61 128.86 52.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.251 -0.906 . . . . 0.0 109.351 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.754 ' HB2' ' CG2' ' A' ' 70' ' ' ILE . . . -108.49 116.51 32.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.159 -0.963 . . . . 0.0 109.713 -179.778 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 4.4 m -145.59 21.3 1.49 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.348 -0.845 . . . . 0.0 109.37 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.79 -111.63 0.03 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 1.6 t -142.08 -40.39 0.36 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.236 -1.155 . . . . 0.0 109.803 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 3.1 m -142.6 131.23 22.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.21 -0.931 . . . . 0.0 109.615 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 15' ' ' GLU . 19.9 t -56.18 -19.99 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.308 -0.87 . . . . 0.0 109.307 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -60.37 -64.3 1.0 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.278 -0.889 . . . . 0.0 109.313 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.63 ' O ' HD12 ' A' ' 103' ' ' LEU . 4.6 mt-10 -67.21 -24.59 65.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.355 -0.84 . . . . 0.0 109.305 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.476 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 18.1 t-20 -68.19 -29.48 68.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.885 . . . . 0.0 109.427 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.449 HD11 HG11 ' A' ' 29' ' ' VAL . 33.2 tp -62.66 -68.67 0.31 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.182 -0.949 . . . . 0.0 109.164 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 10.0 tttp -59.24 -21.94 60.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.204 -0.935 . . . . 0.0 109.149 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.63 HD12 ' O ' ' A' ' 99' ' ' GLU . 1.5 mt -68.73 -34.92 76.43 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.394 -0.817 . . . . 0.0 109.448 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.536 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.5 t80 -53.94 -30.71 47.8 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.203 -0.936 . . . . 0.0 109.254 179.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 34.9 m -64.19 -39.62 94.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.42 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.494 ' OE1' HD23 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -82.99 -11.85 57.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.297 -0.877 . . . . 0.0 109.338 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.489 ' HA2' ' OE2' ' A' ' 110' ' ' GLU . . . 65.08 40.31 96.89 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -80.9 -12.87 59.33 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -1.153 . . . . 0.0 109.407 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.43 ' C ' ' HG2' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -152.6 111.37 3.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.261 -0.899 . . . . 0.0 109.259 179.867 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.489 ' OE2' ' HA2' ' A' ' 107' ' ' GLY . 5.9 mt-10 -140.97 -149.19 0.26 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.819 -179.662 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.496 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 0.5 OUTLIER -168.63 -114.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.34 -0.85 . . . . 0.0 109.315 -179.794 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.3 mt -87.81 149.56 4.03 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.092 -1.005 . . . . 0.0 109.427 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.479 ' HA ' ' HG2' ' A' ' 88' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.623 0 O-C-N 121.218 -0.926 . . . . 0.0 109.692 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.4 mtp . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.441 ' HG2' ' CG ' ' A' ' 30' ' ' GLU . 0.5 OUTLIER -91.2 142.4 27.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.293 -0.88 . . . . 0.0 109.494 179.994 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.622 ' CG2' HD11 ' A' ' 70' ' ' ILE . 4.9 mt -118.67 116.08 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.296 -0.877 . . . . 0.0 109.779 -179.773 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.91 119.73 37.53 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.344 -0.847 . . . . 0.0 109.03 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.931 HG12 HD13 ' A' ' 70' ' ' ILE . 8.6 mt -100.68 140.73 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.801 -179.56 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.502 ' HB2' ' CE2' ' A' ' 26' ' ' PHE . . . -106.73 138.49 42.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.279 -0.888 . . . . 0.0 109.141 179.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.512 ' HB3' HG11 ' A' ' 97' ' ' VAL . 39.4 p -163.3 -148.73 0.13 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.215 -0.928 . . . . 0.0 109.524 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.548 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 20.3 t -122.35 -65.35 1.12 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.263 -0.898 . . . . 0.0 109.546 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -59.98 168.34 8.32 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 1.2 p -87.38 -42.27 12.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.209 -1.171 . . . . 0.0 109.512 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -173.81 -40.74 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.193 -0.942 . . . . 0.0 109.709 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.1 mt -84.19 -10.85 57.39 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.156 -0.965 . . . . 0.0 109.629 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -137.91 8.31 3.58 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.456 ' OG ' HG22 ' A' ' 97' ' ' VAL . 79.9 p -77.11 80.17 3.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.184 -1.186 . . . . 0.0 109.467 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.466 ' C ' HG23 ' A' ' 16' ' ' VAL . 2.6 pt-20 -76.85 1.68 16.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.255 -0.903 . . . . 0.0 109.702 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.685 HG22 HG13 ' A' ' 97' ' ' VAL . 3.5 t 71.38 73.29 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.13 -0.981 . . . . 0.0 109.655 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.22 -164.46 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.46 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -118.98 26.74 9.31 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.214 -0.929 . . . . 0.0 109.617 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -117.23 115.31 25.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.914 . . . . 0.0 109.604 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.589 ' CG ' ' O ' ' A' ' 20' ' ' PHE . 45.6 t80 -112.44 38.4 2.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.309 -0.869 . . . . 0.0 109.159 179.731 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -99.27 -84.37 1.79 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.449 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.0 OUTLIER -90.21 67.46 6.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -1.144 . . . . 0.0 109.485 -179.946 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -47.1 105.45 0.49 Allowed Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.356 -0.84 . . . . 0.0 109.567 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.549 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.0 Cg_endo -78.73 -3.37 13.22 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.461 2.107 . . . . 0.0 110.365 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.549 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 71.4 m-85 -160.52 72.67 0.48 Allowed 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.177 -0.952 . . . . 0.0 109.235 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.502 ' CE2' ' HB2' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -79.02 114.8 18.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.471 -179.768 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . 0.424 ' HG3' HG22 ' A' ' 41' ' ' VAL . 0.1 OUTLIER -87.57 114.15 23.91 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.339 -0.851 . . . . 0.0 109.39 -179.974 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.469 ' O ' HG23 ' A' ' 28' ' ' ILE . 0.5 OUTLIER -102.61 126.73 56.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.261 -0.899 . . . . 0.0 109.594 -179.934 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 69.4 t -124.01 138.44 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.289 -0.882 . . . . 0.0 109.293 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.441 ' CG ' ' HG2' ' A' ' 2' ' ' LYS . 0.5 OUTLIER -124.28 116.8 23.24 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.209 -0.932 . . . . 0.0 109.544 179.938 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.468 ' SD ' ' CD1' ' A' ' 3' ' ' ILE . 4.4 ptp -114.68 141.92 47.17 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 2.7 tttp -84.48 -80.83 0.19 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.285 -0.884 . . . . 0.0 109.455 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 12.4 tppt? -117.12 87.45 2.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.225 -0.922 . . . . 0.0 109.391 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 51.66 26.52 16.82 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -140.8 97.62 3.23 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -1.168 . . . . 0.0 109.559 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.472 HD11 ' OG ' ' A' ' 39' ' ' SER . 6.6 tt -49.67 137.12 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.196 -0.94 . . . . 0.0 109.55 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.504 ' C ' ' HG ' ' A' ' 38' ' ' SER . 0.0 OUTLIER -135.54 18.79 3.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.526 179.939 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.504 ' HG ' ' C ' ' A' ' 37' ' ' GLU . 0.0 OUTLIER -178.05 128.79 0.13 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.17 -0.956 . . . . 0.0 109.6 -179.958 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.472 ' OG ' HD11 ' A' ' 36' ' ' ILE . 0.4 OUTLIER -143.39 111.46 6.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.291 -0.881 . . . . 0.0 109.151 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -131.01 162.93 28.69 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.242 -0.911 . . . . 0.0 109.799 -179.617 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.424 HG22 ' HG3' ' A' ' 27' ' ' MET . 21.8 t -120.45 148.61 23.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.371 -0.831 . . . . 0.0 109.184 179.789 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.409 ' O ' ' HA ' ' A' ' 25' ' ' TYR . 7.1 mt -123.07 129.92 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -108.88 100.12 9.37 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.307 -0.87 . . . . 0.0 109.211 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.273 -0.892 . . . . 0.0 109.617 -179.7 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.758 HD12 ' HB2' ' A' ' 78' ' ' ALA . 47.5 mm -66.15 -14.65 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -1.189 . . . . 0.0 109.525 -179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.78 -22.87 60.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.256 -0.902 . . . . 0.0 109.433 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.462 ' O ' HG13 ' A' ' 61' ' ' ILE . 21.8 m -55.7 -25.32 39.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 109.533 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.31 -55.65 32.07 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.233 -0.917 . . . . 0.0 109.641 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.69 -37.93 52.81 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 72.9 mt -64.28 -38.01 81.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.29 -0.882 . . . . 0.0 109.655 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.48 ' CG2' HG21 ' A' ' 66' ' ' VAL . 36.7 mt -72.95 -21.96 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.22 -0.925 . . . . 0.0 109.652 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.418 ' HB1' HD22 ' A' ' 85' ' ' LEU . . . -71.46 -28.66 64.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.165 -0.959 . . . . 0.0 109.487 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -74.78 -2.72 27.83 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.347 -0.845 . . . . 0.0 109.687 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -98.61 -18.25 18.21 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.094 -1.004 . . . . 0.0 109.603 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.521 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 102.8 -9.51 55.33 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.48 HG21 ' CG2' ' A' ' 61' ' ' ILE . 94.0 t -42.61 94.99 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.327 -1.102 . . . . 0.0 109.702 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.521 ' N ' ' O ' ' A' ' 65' ' ' GLY . 24.0 mmtt -79.3 -3.81 47.83 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.379 -0.826 . . . . 0.0 108.863 179.398 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.487 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -139.67 132.29 28.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.274 -0.891 . . . . 0.0 109.449 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 89.8 t -128.66 122.19 56.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.182 -0.949 . . . . 0.0 109.752 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.931 HD13 HG12 ' A' ' 5' ' ' ILE . 2.1 mp -99.28 116.61 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.226 -0.921 . . . . 0.0 109.245 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -152.46 175.01 13.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.258 -0.901 . . . . 0.0 109.567 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.504 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 3.7 m -137.14 39.66 2.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.428 -0.795 . . . . 0.0 109.288 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.422 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 7.4 m -50.1 134.64 22.64 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.242 -0.911 . . . . 0.0 109.41 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.2 Cg_endo -79.66 -20.72 9.08 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.458 2.106 . . . . 0.0 110.456 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.4 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -104.69 149.43 16.91 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.4 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.6 Cg_endo -78.39 -0.33 10.61 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.717 2.278 . . . . 0.0 110.287 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -67.56 -49.88 61.1 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.261 -0.899 . . . . 0.0 109.487 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.758 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -61.28 -53.4 57.21 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.329 -0.857 . . . . 0.0 109.458 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -56.39 -20.3 18.82 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.341 -0.85 . . . . 0.0 109.522 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.428 ' O ' ' HG3' ' A' ' 84' ' ' GLU . 1.2 tp10 -75.27 -45.88 37.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.228 -0.92 . . . . 0.0 109.557 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.448 ' HA ' ' HB2' ' A' ' 84' ' ' GLU . 6.3 t -67.58 -41.71 86.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 0.0 109.587 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.502 ' HA ' HD13 ' A' ' 82' ' ' LEU . 4.2 mm? -51.75 -56.93 10.93 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.127 -0.983 . . . . 0.0 109.48 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -65.15 -22.14 66.88 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.881 . . . . 0.0 109.444 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.448 ' HB2' ' HA ' ' A' ' 81' ' ' VAL . 5.1 mt-10 -74.17 -25.75 59.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.265 -0.897 . . . . 0.0 109.403 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.418 HD22 ' HB1' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -88.13 -30.85 19.52 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.224 -0.922 . . . . 0.0 109.488 -179.991 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 104.63 42.58 1.82 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.7 mt -122.66 155.98 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.275 -1.133 . . . . 0.0 109.375 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.522 ' HD2' ' N ' ' A' ' 88' ' ' LYS . 0.0 OUTLIER -81.66 138.22 35.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.167 -0.958 . . . . 0.0 109.521 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 3.0 mt -106.98 155.42 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.208 -0.932 . . . . 0.0 109.539 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.567 ' CZ ' ' CD2' ' A' ' 104' ' ' PHE . 1.0 OUTLIER -133.9 138.84 45.79 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.286 -0.884 . . . . 0.0 109.531 179.97 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.515 ' NE ' ' HA ' ' A' ' 110' ' ' GLU . 1.3 ptt-85 -97.76 113.4 25.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.289 -0.882 . . . . 0.0 109.291 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.504 ' HB3' ' OG ' ' A' ' 72' ' ' SER . . . -79.76 125.0 29.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.259 -0.9 . . . . 0.0 109.565 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 76.0 p -67.57 -42.12 83.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.259 -0.901 . . . . 0.0 109.433 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 119.73 97.74 1.71 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -168.87 -69.87 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.2 -1.177 . . . . 0.0 109.474 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -166.64 120.07 1.04 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.194 -0.941 . . . . 0.0 109.493 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.685 HG13 HG22 ' A' ' 16' ' ' VAL . 35.8 m -55.33 -21.47 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 109.589 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -61.48 -51.23 69.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.156 -0.965 . . . . 0.0 109.585 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.439 ' O ' HD12 ' A' ' 103' ' ' LEU . 4.9 mt-10 -77.19 -32.93 56.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.922 . . . . 0.0 109.768 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -60.21 -30.64 69.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.571 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 36.1 tp -68.25 -57.65 5.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.171 -0.955 . . . . 0.0 109.547 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 106' ' ' GLU . 0.0 OUTLIER -62.04 -20.54 64.06 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.224 -0.923 . . . . 0.0 109.518 -179.923 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.77 HD23 ' CB ' ' A' ' 108' ' ' ASN . 0.1 OUTLIER -76.96 -41.29 43.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.131 -0.981 . . . . 0.0 109.701 -179.876 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.567 ' CD2' ' CZ ' ' A' ' 90' ' ' TYR . 4.3 t80 -57.7 -53.8 54.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.197 -0.939 . . . . 0.0 109.312 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 9.7 m -67.87 -19.54 65.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.252 -0.905 . . . . 0.0 109.475 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.427 ' CG ' ' O ' ' A' ' 102' ' ' LYS . 4.4 mm-40 -83.44 9.27 11.52 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.337 -0.852 . . . . 0.0 109.302 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 51.66 45.13 54.78 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . 0.77 ' CB ' HD23 ' A' ' 103' ' ' LEU . 1.9 m120 -79.84 -66.32 0.89 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.306 -1.114 . . . . 0.0 109.498 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.58 HD12 ' HG3' ' A' ' 110' ' ' GLU . 0.7 OUTLIER 173.81 -159.83 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.301 -0.875 . . . . 0.0 109.372 -179.906 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.58 ' HG3' HD12 ' A' ' 109' ' ' LEU . 30.8 mt-10 73.29 30.03 1.6 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.282 -0.886 . . . . 0.0 109.482 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -104.44 147.12 27.92 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -0.913 . . . . 0.0 109.536 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 7.8 mt -142.15 125.21 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.153 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.48 ' HG2' ' HE2' ' A' ' 88' ' ' LYS . 21.6 mtt180 . . . . . 0 N--CA 1.49 1.574 0 O-C-N 121.347 -0.846 . . . . 0.0 109.846 -179.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 121.254 0.55 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.47 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 12.9 mttt -112.65 144.09 42.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.213 -0.93 . . . . 0.0 109.268 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.555 HG23 ' CD1' ' A' ' 70' ' ' ILE . 3.7 mt -121.96 106.78 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.184 -0.948 . . . . 0.0 110.339 -179.404 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.653 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -106.02 111.54 24.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.302 -0.873 . . . . 0.0 108.706 179.064 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.924 HG23 ' HB ' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -100.48 131.86 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.861 -179.379 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -63.56 139.16 58.74 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.303 -0.873 . . . . 0.0 109.113 179.549 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.446 ' HB3' ' O ' ' A' ' 25' ' ' TYR . 17.4 t -126.84 172.99 9.92 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.086 -1.009 . . . . 0.0 109.772 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -122.44 -32.61 3.59 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.408 -0.808 . . . . 0.0 109.266 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.637 ' O ' HG23 ' A' ' 10' ' ' THR . . . -113.98 -82.44 1.1 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.637 HG23 ' O ' ' A' ' 9' ' ' GLY . 0.1 OUTLIER -169.67 -62.14 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.288 -1.125 . . . . 0.0 109.589 179.962 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -145.33 -55.17 0.31 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.888 . . . . 0.0 109.572 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.1 mt -75.93 -38.77 57.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.227 -0.921 . . . . 0.0 109.645 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.42 17.12 57.24 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.412 ' O ' ' HA ' ' A' ' 96' ' ' SER . 89.7 p -77.19 78.42 3.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -1.148 . . . . 0.0 109.757 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.595 ' C ' HG23 ' A' ' 16' ' ' VAL . 44.2 tt0 -77.25 -0.29 24.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.253 -0.904 . . . . 0.0 109.408 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.677 HG22 HG13 ' A' ' 97' ' ' VAL . 2.5 t 73.73 74.55 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.26 -0.9 . . . . 0.0 109.64 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -46.65 151.7 0.55 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.168 -0.957 . . . . 0.0 109.289 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.411 ' HG2' ' CD1' ' A' ' 19' ' ' PHE . 3.2 ptm180 -104.92 31.74 4.61 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.927 . . . . 0.0 109.625 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.411 ' CD1' ' HG2' ' A' ' 18' ' ' ARG . 45.7 m-85 -119.2 115.58 24.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.518 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.443 ' HE2' ' HB2' ' A' ' 58' ' ' ALA . 25.9 t80 -91.34 78.02 5.79 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.23 -0.918 . . . . 0.0 109.352 179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.61 -20.98 0.71 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.4 ttm-85 -111.17 -40.31 4.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.368 -1.077 . . . . 0.0 109.28 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.442 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -41.78 101.98 0.26 Allowed Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.533 -0.729 . . . . 0.0 109.643 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.01 41.04 1.05 Allowed 'Trans proline' 0 C--N 1.312 -1.395 0 C-N-CA 122.579 2.186 . . . . 0.0 110.89 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.539 ' CE2' ' O ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -160.39 71.07 0.43 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.98 -1.075 . . . . 0.0 109.448 179.952 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.551 ' CE2' HD12 ' A' ' 61' ' ' ILE . 0.1 OUTLIER -79.5 117.08 20.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.287 -0.883 . . . . 0.0 109.549 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 3.2 ttt -95.62 104.26 16.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.928 . . . . 0.0 109.297 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.498 HG23 ' HB2' ' A' ' 4' ' ' ALA . 27.2 mt -100.83 126.13 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.266 -0.896 . . . . 0.0 109.709 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.553 ' CG1' HG23 ' A' ' 36' ' ' ILE . 90.5 t -123.95 117.82 52.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.298 -0.876 . . . . 0.0 109.349 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.403 ' HG2' ' HD3' ' A' ' 2' ' ' LYS . 13.0 mt-10 -83.92 115.97 22.56 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.221 -0.925 . . . . 0.0 109.622 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.459 ' HG2' ' HA ' ' A' ' 36' ' ' ILE . 0.3 OUTLIER -96.88 138.76 33.94 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.268 -0.895 . . . . 0.0 109.514 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 1.2 tptp -96.76 -62.45 1.26 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.889 . . . . 0.0 109.326 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . 0.401 ' O ' ' C ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -139.88 89.45 2.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.161 179.725 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 45.66 30.41 3.34 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -150.52 114.42 5.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -1.126 . . . . 0.0 109.555 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.553 HG23 ' CG1' ' A' ' 29' ' ' VAL . 2.1 mp -54.14 132.4 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.164 -0.96 . . . . 0.0 109.41 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -133.28 12.82 4.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.255 -0.903 . . . . 0.0 109.375 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.502 ' O ' HG13 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -174.28 116.87 0.21 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 109.502 -179.981 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.533 ' HA ' HG22 ' A' ' 29' ' ' VAL . 4.5 p -129.73 104.23 7.29 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.536 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -122.91 139.59 53.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.392 -0.818 . . . . 0.0 109.375 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 73.9 t -114.11 119.31 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.531 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.4 mt -118.28 143.03 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.364 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 44' ' ' ASN . 29.6 mp0 -86.1 118.91 25.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.15 -0.969 . . . . 0.0 109.391 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.414 ' C ' ' O ' ' A' ' 43' ' ' GLU . 2.0 t30 . . . . . 0 N--CA 1.49 1.574 0 O-C-N 121.244 -0.91 . . . . 0.0 109.365 -179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.447 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.417 HD12 ' HB2' ' A' ' 78' ' ' ALA . 23.3 mm -76.58 -14.95 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.27 -1.135 . . . . 0.0 109.573 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -58.46 -17.63 22.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.227 -0.921 . . . . 0.0 109.662 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.447 HG22 ' O ' ' A' ' 54' ' ' GLY . 6.0 t -63.38 -37.74 88.43 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.171 -0.956 . . . . 0.0 109.812 -179.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.443 ' HB2' ' HE2' ' A' ' 20' ' ' PHE . . . -45.42 -34.51 3.15 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.176 -0.953 . . . . 0.0 109.817 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -61.29 -64.59 0.9 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.237 -0.914 . . . . 0.0 109.847 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.439 HG22 ' O ' ' A' ' 57' ' ' THR . 0.9 OUTLIER -58.8 -18.41 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.245 -0.91 . . . . 0.0 109.926 -179.593 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.551 HD12 ' CE2' ' A' ' 26' ' ' PHE . 19.3 mm -75.56 -36.38 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.688 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.71 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -73.38 -28.37 61.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.225 -0.922 . . . . 0.0 109.757 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -77.25 -9.81 59.03 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.087 -1.008 . . . . 0.0 109.906 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.481 ' HB2' HG23 ' A' ' 66' ' ' VAL . 57.9 m-20 -88.13 7.65 30.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.108 -0.995 . . . . 0.0 109.629 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 69.24 10.67 62.92 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.653 HG11 ' HB3' ' A' ' 4' ' ' ALA . 2.0 t -67.65 89.54 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.198 -1.178 . . . . 0.0 109.415 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.452 ' HG2' ' HE3' ' A' ' 88' ' ' LYS . 0.5 OUTLIER -79.6 -7.4 58.51 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.348 -0.845 . . . . 0.0 108.92 179.648 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.575 ' HB1' ' CE2' ' A' ' 104' ' ' PHE . . . -137.53 103.64 5.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.19 -0.944 . . . . 0.0 109.273 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.484 HG22 HG11 ' A' ' 66' ' ' VAL . 56.9 t -112.01 132.1 61.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.054 -1.029 . . . . 0.0 109.817 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.924 ' HB ' HG23 ' A' ' 5' ' ' ILE . 3.2 mp -104.61 112.76 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.352 -0.843 . . . . 0.0 109.199 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -149.61 -178.04 6.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.22 -0.925 . . . . 0.0 109.979 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -146.12 46.89 1.24 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.642 -0.661 . . . . 0.0 109.524 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.551 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 2.6 p -45.49 151.94 0.72 Allowed Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.224 -0.922 . . . . 0.0 109.624 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.84 -25.99 7.18 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.719 2.279 . . . . 0.0 110.615 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -121.73 152.22 16.86 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.17 -16.57 13.88 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.602 2.202 . . . . 0.0 110.483 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -46.94 -47.06 21.81 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.922 . . . . 0.0 109.619 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.636 ' O ' HD13 ' A' ' 82' ' ' LEU . . . -67.51 -34.98 78.22 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.256 -0.903 . . . . 0.0 109.628 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.551 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 8.7 m-30 -71.59 -17.16 62.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.632 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.435 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 4.3 mm-40 -73.24 -42.92 61.99 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.124 -0.985 . . . . 0.0 108.967 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.417 ' H ' HG23 ' A' ' 81' ' ' VAL . 2.3 t -76.63 -30.05 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.435 -0.79 . . . . 0.0 109.254 179.725 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.636 HD13 ' O ' ' A' ' 78' ' ' ALA . 4.8 mp -61.54 -56.29 21.59 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.354 -0.841 . . . . 0.0 109.575 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.435 ' OD1' ' O ' ' A' ' 80' ' ' GLU . 9.6 p-10 -69.64 -14.12 62.66 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.293 -0.879 . . . . 0.0 109.578 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -76.98 -36.34 56.52 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.284 -0.885 . . . . 0.0 109.606 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.429 ' HA ' HD23 ' A' ' 85' ' ' LEU . 73.8 mt -86.0 12.38 9.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.189 -0.945 . . . . 0.0 109.669 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 80.99 8.71 87.14 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.71 HD11 ' HB2' ' A' ' 62' ' ' ALA . 18.3 mt -81.19 144.72 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.191 -1.182 . . . . 0.0 109.604 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.452 ' HE3' ' HG2' ' A' ' 67' ' ' LYS . 20.1 mttt -92.55 128.67 38.49 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.209 -0.932 . . . . 0.0 109.226 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.488 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.5 mt -99.22 128.66 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.178 -0.951 . . . . 0.0 109.582 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.59 ' CE1' ' HB2' ' A' ' 110' ' ' GLU . 2.0 m-30 -117.95 152.21 35.9 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.462 -0.774 . . . . 0.0 109.12 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.545 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 7.5 tpt180 -98.66 120.23 38.72 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.153 -0.967 . . . . 0.0 109.71 -179.714 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.726 ' HB2' HG22 ' A' ' 70' ' ' ILE . . . -86.01 132.24 34.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -0.904 . . . . 0.0 109.495 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 3.7 m -71.9 -38.16 69.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.232 -0.918 . . . . 0.0 109.41 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 114.09 14.35 9.27 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -79.7 -68.74 0.64 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.246 -1.149 . . . . 0.0 109.244 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 14' ' ' SER . 0.2 OUTLIER -171.16 132.72 0.83 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.204 -0.935 . . . . 0.0 109.341 179.927 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.677 HG13 HG22 ' A' ' 16' ' ' VAL . 23.8 m -56.56 -23.61 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.917 . . . . 0.0 109.527 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -68.81 -38.83 80.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.256 -0.902 . . . . 0.0 109.449 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -77.27 -42.24 37.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.232 -0.917 . . . . 0.0 109.68 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -64.89 -27.75 69.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.692 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.458 HD22 HD11 ' A' ' 36' ' ' ILE . 0.6 OUTLIER -59.63 -61.56 2.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.185 -0.947 . . . . 0.0 109.634 -179.913 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.53 -28.54 69.71 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.426 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.497 HD23 ' HB2' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -66.92 -29.04 68.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.664 -179.934 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.575 ' CE2' ' HB1' ' A' ' 68' ' ' ALA . 9.3 t80 -75.5 -26.48 58.16 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.186 -0.946 . . . . 0.0 109.631 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 14.6 m -63.1 -20.59 65.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.231 -0.918 . . . . 0.0 109.728 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -103.88 -30.46 10.33 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.179 -0.951 . . . . 0.0 109.455 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.92 42.0 6.14 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 32.9 m-20 -95.61 -20.09 19.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -1.162 . . . . 0.0 109.318 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.497 ' HB2' HD23 ' A' ' 103' ' ' LEU . 0.2 OUTLIER -127.87 143.29 51.11 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.402 -0.811 . . . . 0.0 109.044 179.807 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.59 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 4.7 pt-20 -172.38 -157.28 0.1 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.149 -0.969 . . . . 0.0 109.888 -179.718 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.545 ' HB2' ' N ' ' A' ' 91' ' ' ARG . 3.0 tt0 -158.66 -104.21 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.368 -0.833 . . . . 0.0 109.365 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.472 ' HB ' ' HB ' ' A' ' 89' ' ' ILE . 46.8 mm -93.17 111.32 24.5 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 O-C-N 121.27 -0.894 . . . . 0.0 109.586 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.599 0 O-C-N 121.326 -0.858 . . . . 0.0 109.44 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.653 ' O ' ' HB3' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -90.65 121.48 32.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.245 -0.909 . . . . 0.0 109.345 179.881 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.583 HG12 ' CD2' ' A' ' 104' ' ' PHE . 4.1 mt -100.26 111.7 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.291 -0.881 . . . . 0.0 109.853 -179.781 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.593 ' HB1' ' CE2' ' A' ' 26' ' ' PHE . . . -104.12 112.69 25.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -0.921 . . . . 0.0 109.397 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.874 HG21 HG13 ' A' ' 97' ' ' VAL . 14.4 mm -87.78 117.62 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.226 -0.921 . . . . 0.0 109.525 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.448 ' O ' ' HB3' ' A' ' 7' ' ' SER . . . -62.64 153.78 31.23 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.289 -0.882 . . . . 0.0 109.608 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' TYR . 2.4 t 61.62 -88.96 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.522 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.838 ' HA ' HG21 ' A' ' 97' ' ' VAL . 0.2 OUTLIER 57.95 22.62 8.96 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.193 -0.942 . . . . 0.0 109.457 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 48.94 -102.12 0.05 OUTLIER Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -155.85 -47.05 0.08 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -1.173 . . . . 0.0 109.46 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.706 ' HB3' HD12 ' A' ' 12' ' ' LEU . 1.7 t70 -155.59 -62.05 0.11 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.448 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.706 HD12 ' HB3' ' A' ' 11' ' ' ASP . 5.9 mp -108.17 -15.81 14.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.204 -0.935 . . . . 0.0 109.529 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -94.19 27.49 13.19 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.6 p -78.28 74.34 4.82 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.391 -1.064 . . . . 0.0 109.695 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.583 ' C ' HG23 ' A' ' 16' ' ' VAL . 32.4 tt0 -78.33 5.55 10.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.023 -1.048 . . . . 0.0 109.815 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.633 HG22 ' N ' ' A' ' 97' ' ' VAL . 2.1 t 68.37 54.15 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.168 -0.957 . . . . 0.0 109.116 -179.559 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 16' ' ' VAL . 1.0 OUTLIER -42.74 159.47 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.411 -0.806 . . . . 0.0 109.688 -179.844 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -111.32 39.08 2.39 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.265 -0.897 . . . . 0.0 109.428 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -129.22 103.49 6.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.255 -0.903 . . . . 0.0 109.508 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.5 t80 -102.41 142.01 34.31 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.516 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 114.25 -46.73 1.13 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.445 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 7.9 ttp180 -103.12 -37.36 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.371 -1.076 . . . . 0.0 109.141 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.436 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -41.47 102.0 0.26 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.569 -0.707 . . . . 0.0 109.821 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.493 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 36.7 Cg_endo -81.21 54.73 5.33 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.652 2.235 . . . . 0.0 110.478 179.688 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.458 ' O ' ' O ' ' A' ' 7' ' ' SER . 68.5 m-85 -154.15 68.5 0.75 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.108 -0.995 . . . . 0.0 109.204 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.593 ' CE2' ' HB1' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -79.39 111.13 15.34 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.256 -0.903 . . . . 0.0 109.337 -179.907 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . 0.469 ' HB2' ' CB ' ' A' ' 8' ' ' SER . 7.2 ttm -88.76 102.09 14.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.3 -0.875 . . . . 0.0 109.559 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.612 ' O ' HG23 ' A' ' 28' ' ' ILE . 6.1 tp -83.61 114.67 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.363 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.662 HG22 ' HB3' ' A' ' 39' ' ' SER . 47.7 t -126.11 128.71 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.155 -0.966 . . . . 0.0 109.653 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -111.21 113.86 26.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.283 -0.886 . . . . 0.0 109.368 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.439 ' SD ' ' CA ' ' A' ' 34' ' ' GLY . 0.7 OUTLIER -112.53 132.65 54.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -0.92 . . . . 0.0 109.6 -179.851 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 7.2 mmmt -87.67 -55.81 3.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.268 -0.895 . . . . 0.0 109.33 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.15 68.24 0.93 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.336 -0.853 . . . . 0.0 109.209 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.439 ' CA ' ' SD ' ' A' ' 31' ' ' MET . . . 75.92 8.6 84.9 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -130.52 98.35 4.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.176 -1.19 . . . . 0.0 109.493 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.467 HD11 HD23 ' A' ' 101' ' ' LEU . 2.9 mt -57.43 127.49 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.251 -0.906 . . . . 0.0 109.658 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.443 ' O ' ' HB3' ' A' ' 38' ' ' SER . 0.5 OUTLIER -101.66 -2.3 30.65 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.401 179.68 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.443 ' HB3' ' O ' ' A' ' 37' ' ' GLU . 77.3 p 176.8 125.55 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.201 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.662 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.2 OUTLIER -136.85 106.97 6.33 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.208 -0.932 . . . . 0.0 109.644 -179.759 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 163.62 14.41 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.658 ' O ' HG13 ' A' ' 41' ' ' VAL . 7.6 p -134.6 118.66 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.331 -0.855 . . . . 0.0 109.447 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.403 ' O ' HG13 ' A' ' 42' ' ' ILE . 21.5 pt -126.88 133.63 68.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.218 -0.926 . . . . 0.0 109.569 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.493 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 1.3 mt-10 -74.46 146.61 42.67 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.369 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . 0.404 ' H ' ' HA ' ' A' ' 24' ' ' PRO . 12.2 m-20 . . . . . 0 N--CA 1.49 1.53 0 O-C-N 121.242 -0.911 . . . . 0.0 109.318 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.437 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.244 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.601 HD12 ' HB2' ' A' ' 78' ' ' ALA . 47.2 mm -66.49 -14.15 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.279 -1.13 . . . . 0.0 109.484 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -8.9 38.79 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.29 -0.881 . . . . 0.0 109.496 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 54' ' ' GLY . 14.8 t -76.93 -16.04 59.49 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.191 -0.943 . . . . 0.0 109.529 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.419 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -57.28 -32.35 66.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 109.536 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 21.8 tt0 -65.11 -52.98 52.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.443 HD13 ' HA ' ' A' ' 60' ' ' ILE . 35.9 mm -62.72 -25.6 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.228 -0.92 . . . . 0.0 109.326 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.485 HD13 ' CZ ' ' A' ' 26' ' ' PHE . 45.5 mt -69.71 -39.28 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 109.276 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.797 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -74.6 -25.44 59.26 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.248 -0.908 . . . . 0.0 109.429 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -77.09 -5.15 47.83 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.237 -0.914 . . . . 0.0 109.51 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.49 ' HB2' HG23 ' A' ' 66' ' ' VAL . 6.8 m-20 -100.26 1.86 42.18 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.134 -0.979 . . . . 0.0 109.527 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.499 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 90.89 -5.94 81.95 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.49 HG23 ' HB2' ' A' ' 64' ' ' ASN . 48.3 t -53.5 88.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -1.176 . . . . 0.0 109.858 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.499 ' N ' ' O ' ' A' ' 65' ' ' GLY . 6.4 tttp -79.75 -12.46 59.79 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.119 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.653 ' HB3' ' O ' ' A' ' 2' ' ' LYS . . . -127.62 131.99 49.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.436 -0.79 . . . . 0.0 109.108 179.685 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.582 HG21 HD21 ' A' ' 82' ' ' LEU . 2.4 t -129.64 105.49 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.123 -0.985 . . . . 0.0 109.806 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.622 HD12 ' CD1' ' A' ' 5' ' ' ILE . 23.3 mt -91.41 119.96 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.277 -0.89 . . . . 0.0 109.01 179.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -149.12 177.08 9.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.152 -0.967 . . . . 0.0 109.938 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.04 35.38 3.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.535 -0.728 . . . . 0.0 109.14 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.451 ' HB2' ' CE1' ' A' ' 79' ' ' PHE . 0.1 OUTLIER -44.87 134.23 4.99 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.286 -0.884 . . . . 0.0 109.465 -179.807 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.75 -19.78 10.96 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.436 2.091 . . . . 0.0 110.351 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -114.15 148.31 18.77 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.83 9.16 3.38 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.631 2.221 . . . . 0.0 110.706 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -74.44 -42.62 58.81 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.095 -1.003 . . . . 0.0 109.722 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.601 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -68.69 -50.78 48.22 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.588 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.451 ' CE1' ' HB2' ' A' ' 73' ' ' SER . 11.3 m-30 -48.81 -38.43 22.12 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.264 -0.898 . . . . 0.0 109.652 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.484 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 0.6 OUTLIER -65.75 -47.4 75.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.188 -0.945 . . . . 0.0 109.71 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 86.7 t -52.89 -50.85 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.182 -0.949 . . . . 0.0 109.466 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.582 HD21 HG21 ' A' ' 69' ' ' VAL . 1.9 mt -56.47 -31.15 63.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.484 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 3.2 m-20 -61.96 -51.26 68.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.163 -0.961 . . . . 0.0 109.301 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -62.81 -27.67 69.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.21 179.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.1 mt -72.03 -34.21 68.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.174 -0.954 . . . . 0.0 109.527 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.1 19.98 19.72 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.797 HD11 ' HB2' ' A' ' 62' ' ' ALA . 27.7 mt -103.83 163.03 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.289 -1.124 . . . . 0.0 109.617 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.437 ' N ' HG22 ' A' ' 87' ' ' ILE . 3.4 mptt -91.74 147.07 23.26 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.253 -0.904 . . . . 0.0 109.263 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.51 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.3 mt -120.76 131.76 72.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.112 -0.992 . . . . 0.0 109.211 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.581 ' CE2' ' HB1' ' A' ' 68' ' ' ALA . 12.8 m-85 -119.47 161.26 20.85 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.476 -0.765 . . . . 0.0 109.547 -179.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.488 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 0.1 OUTLIER -99.25 136.78 38.7 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.264 -0.897 . . . . 0.0 109.627 -179.909 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.64 129.33 34.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.259 -0.901 . . . . 0.0 109.443 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.35 -40.33 96.05 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.26 -0.9 . . . . 0.0 109.476 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 102.94 22.07 9.66 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.73 -83.75 0.54 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.128 -1.219 . . . . 0.0 109.4 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.539 ' HA ' HG23 ' A' ' 16' ' ' VAL . 3.3 m -146.71 137.65 24.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.324 -0.86 . . . . 0.0 109.315 179.814 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.874 HG13 HG21 ' A' ' 5' ' ' ILE . 86.8 t -64.2 -31.18 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -0.882 . . . . 0.0 109.609 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.58 -44.36 80.95 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.194 -0.941 . . . . 0.0 109.465 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -75.46 -35.8 60.82 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.475 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 15.1 m-20 -54.44 -37.71 65.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.224 -0.922 . . . . 0.0 109.669 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.572 HD21 HG11 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -49.43 -53.48 22.58 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.283 -0.885 . . . . 0.0 109.651 -179.874 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 6.0 mmtm -69.64 -33.43 72.6 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.23 -0.919 . . . . 0.0 109.656 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.501 ' CD1' ' HB3' ' A' ' 108' ' ' ASN . 2.2 mm? -57.94 -31.75 67.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.205 -0.934 . . . . 0.0 109.438 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.583 ' CD2' HG12 ' A' ' 3' ' ' ILE . 20.9 t80 -72.75 -38.61 67.31 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.384 -0.823 . . . . 0.0 109.779 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 17.6 m -70.56 -25.69 63.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.266 -0.896 . . . . 0.0 109.751 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -88.1 -0.51 57.14 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.204 -0.935 . . . . 0.0 109.674 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . 0.456 ' HA2' ' OE2' ' A' ' 110' ' ' GLU . . . 59.95 25.42 61.75 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . 0.501 ' HB3' ' CD1' ' A' ' 103' ' ' LEU . 1.2 m-20 -88.48 -53.28 4.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.204 -1.174 . . . . 0.0 109.424 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 11.9 tp -85.19 129.75 34.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.243 -0.911 . . . . 0.0 109.202 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.456 ' OE2' ' HA2' ' A' ' 107' ' ' GLY . 0.3 OUTLIER -165.68 -166.31 0.94 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.198 -0.939 . . . . 0.0 109.729 -179.818 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.51 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 68.5 tt0 -172.68 -113.85 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.285 -0.885 . . . . 0.0 109.371 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.476 ' N ' ' HG2' ' A' ' 111' ' ' GLU . 5.3 mt -82.31 140.37 16.53 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 O-C-N 121.093 -1.005 . . . . 0.0 109.253 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.48 ' NH1' ' HG2' ' A' ' 113' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.51 0 O-C-N 121.203 -0.935 . . . . 0.0 109.623 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.461 ' HG3' ' HB2' ' A' ' 67' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.28 0.562 . . . . 0.0 109.514 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.93 139.68 36.98 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.219 -0.926 . . . . 0.0 109.201 179.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.493 HG23 HD11 ' A' ' 70' ' ' ILE . 4.8 mt -115.24 113.49 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.12 -0.987 . . . . 0.0 110.006 -179.609 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.03 119.55 39.78 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.507 -0.746 . . . . 0.0 109.024 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.59 HG21 ' HB ' ' A' ' 97' ' ' VAL . 3.3 mp -98.15 136.94 27.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.128 -0.982 . . . . 0.0 109.879 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.49 ' HB2' ' CZ ' ' A' ' 26' ' ' PHE . . . -89.74 121.99 32.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.296 -0.877 . . . . 0.0 109.138 179.725 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.547 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -142.08 170.82 14.99 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.143 -0.973 . . . . 0.0 109.728 -179.832 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 51.5 p -116.32 25.31 10.73 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.316 -0.865 . . . . 0.0 109.299 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -162.64 -145.27 4.29 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.632 HG23 HG11 ' A' ' 41' ' ' VAL . 0.2 OUTLIER -147.17 22.56 1.2 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.243 -1.151 . . . . 0.0 109.521 -179.94 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -147.57 -178.68 6.38 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.199 -0.938 . . . . 0.0 109.602 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.525 ' O ' HD23 ' A' ' 12' ' ' LEU . 6.6 tt -64.39 -14.24 55.44 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.337 -0.852 . . . . 0.0 109.571 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -56.74 -52.4 50.87 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.08 86.57 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.335 -1.097 . . . . 0.0 109.397 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.46 81.21 1.44 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.476 -0.765 . . . . 0.0 109.54 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.707 HG12 ' O ' ' A' ' 16' ' ' VAL . 59.3 t 54.54 30.45 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.665 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 26.6 p 46.14 -160.66 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.275 -0.891 . . . . 0.0 109.433 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 2.9 mtt-85 -98.2 -46.92 5.66 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.898 . . . . 0.0 109.376 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -150.27 122.65 8.44 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.364 -0.835 . . . . 0.0 109.429 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.442 ' CD2' ' HB1' ' A' ' 71' ' ' ALA . 4.0 t80 -57.65 124.49 19.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.238 -0.914 . . . . 0.0 109.391 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -171.98 -49.37 0.04 OUTLIER Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.95 45.4 1.46 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.283 -1.128 . . . . 0.0 109.446 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.547 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -54.6 112.65 4.21 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.352 -0.842 . . . . 0.0 109.516 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.452 ' O ' ' CB ' ' A' ' 43' ' ' GLU . 36.6 Cg_endo -80.61 20.53 0.95 Allowed 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.606 2.204 . . . . 0.0 110.947 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -154.8 69.79 0.75 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.036 -1.04 . . . . 0.0 108.942 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.49 ' CZ ' ' HB2' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -79.1 125.21 29.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.348 -0.845 . . . . 0.0 109.722 -179.456 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 10.7 mtt -90.06 110.69 21.67 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.289 -0.882 . . . . 0.0 109.369 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 31.6 mm -93.46 107.45 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.467 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.512 HG11 HD13 ' A' ' 36' ' ' ILE . 23.3 t -115.63 116.35 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.266 -0.896 . . . . 0.0 109.429 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -103.81 114.81 29.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.554 -179.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.418 ' HE2' HG13 ' A' ' 36' ' ' ILE . 12.6 ptp -116.3 160.33 20.63 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.241 -0.912 . . . . 0.0 109.419 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -109.71 -94.98 0.41 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.256 -0.903 . . . . 0.0 109.626 -179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -89.5 62.35 5.92 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.116 -0.99 . . . . 0.0 109.348 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.13 35.58 92.28 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 36' ' ' ILE . 44.9 t30 -138.96 84.26 2.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.302 -1.116 . . . . 0.0 109.462 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.526 HD13 HD21 ' A' ' 101' ' ' LEU . 50.6 mt -45.41 111.27 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.221 -0.924 . . . . 0.0 109.419 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -111.49 9.26 21.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.232 -0.917 . . . . 0.0 109.482 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -167.28 124.18 1.19 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.187 -0.946 . . . . 0.0 109.485 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.2 p -144.96 107.9 4.51 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.284 -0.885 . . . . 0.0 109.478 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -123.37 148.2 46.29 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.526 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.632 HG11 HG23 ' A' ' 10' ' ' THR . 61.4 t -103.99 137.82 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.87 . . . . 0.0 109.519 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -139.33 136.28 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.259 -0.9 . . . . 0.0 109.421 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.452 ' CB ' ' O ' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -96.85 120.66 37.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 179.915 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 O-C-N 121.21 -0.931 . . . . 0.0 109.357 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.7 HG23 ' HB2' ' A' ' 78' ' ' ALA . 20.7 mm -71.85 -39.88 68.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.191 -1.182 . . . . 0.0 109.42 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 7.3 mmm-85 -65.67 -11.13 42.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.557 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.786 ' O ' HG22 ' A' ' 60' ' ' ILE . 44.8 m -70.3 -33.47 71.58 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 0.0 109.312 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.684 ' HB1' HD21 ' A' ' 82' ' ' LEU . . . -50.83 -23.84 3.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.243 -0.91 . . . . 0.0 109.318 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -70.67 -51.58 26.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.247 -0.908 . . . . 0.0 109.485 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.786 HG22 ' O ' ' A' ' 57' ' ' THR . 0.3 OUTLIER -59.03 -33.43 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.412 -179.98 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.0 mt -67.38 -40.96 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.206 -0.934 . . . . 0.0 109.215 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.01 -18.64 59.18 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.338 -0.851 . . . . 0.0 109.461 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -74.55 -17.63 60.71 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.931 . . . . 0.0 109.399 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -86.77 11.75 12.43 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.28 -0.888 . . . . 0.0 109.56 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.454 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 88.6 -6.24 83.82 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.514 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 96.8 t -54.78 89.76 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.283 -1.128 . . . . 0.0 109.878 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.461 ' HB2' ' HG3' ' A' ' 1' ' ' MET . 16.5 mmtm -79.18 2.24 21.69 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.139 -0.975 . . . . 0.0 109.017 179.427 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.514 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -142.96 140.05 30.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.236 -0.915 . . . . 0.0 109.06 179.656 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.496 ' C ' HD13 ' A' ' 70' ' ' ILE . 42.2 t -139.76 131.15 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.077 -1.014 . . . . 0.0 110.049 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.496 HD13 ' C ' ' A' ' 69' ' ' VAL . 1.3 mm -108.33 111.63 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.305 -0.872 . . . . 0.0 108.85 179.461 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.442 ' HB1' ' CD2' ' A' ' 20' ' ' PHE . . . -154.13 177.05 11.52 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.164 -0.96 . . . . 0.0 109.968 -179.627 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.5 44.87 1.73 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.53 -0.731 . . . . 0.0 109.23 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -45.74 150.61 0.94 Allowed Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.333 -0.855 . . . . 0.0 109.533 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.83 -38.88 0.57 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.677 2.251 . . . . 0.0 110.292 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.16 146.28 16.89 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.68 8.09 3.89 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.605 2.203 . . . . 0.0 110.663 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.487 ' O ' HG23 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -63.93 -46.39 84.99 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.151 -0.968 . . . . 0.0 109.612 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.7 ' HB2' HG23 ' A' ' 55' ' ' ILE . . . -67.4 -50.24 60.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 109.557 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.865 ' CD1' HG21 ' A' ' 89' ' ' ILE . 12.8 m-85 -52.08 -33.16 38.16 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.642 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.466 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -67.01 -41.81 86.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.251 -0.905 . . . . 0.0 109.736 -179.732 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 77' ' ' ASN . 2.7 t -63.21 -53.77 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.167 -0.958 . . . . 0.0 109.751 -179.793 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.684 HD21 ' HB1' ' A' ' 58' ' ' ALA . 25.0 mt -60.38 -18.38 50.07 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.27 -0.894 . . . . 0.0 109.719 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.466 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 6.9 m-20 -69.61 -56.37 7.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.275 -0.891 . . . . 0.0 109.716 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -66.12 -34.81 78.89 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.145 -0.972 . . . . 0.0 109.676 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.401 ' CB ' HG12 ' A' ' 87' ' ' ILE . 6.8 mt -61.5 -13.41 20.72 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.237 -0.914 . . . . 0.0 109.416 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 77.61 24.06 65.99 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.401 HG12 ' CB ' ' A' ' 85' ' ' LEU . 5.2 mm -92.32 144.34 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.239 -1.154 . . . . 0.0 109.4 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.87 110.37 15.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.249 -0.907 . . . . 0.0 109.442 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.865 HG21 ' CD1' ' A' ' 79' ' ' PHE . 13.0 mt -86.76 151.48 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.344 -0.848 . . . . 0.0 109.655 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.568 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 1.1 m-85 -134.87 134.02 40.3 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -0.873 . . . . 0.0 109.453 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.96 132.72 35.19 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.225 -0.922 . . . . 0.0 109.405 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.51 ' HB1' HG21 ' A' ' 16' ' ' VAL . . . -84.6 66.0 9.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.226 -0.921 . . . . 0.0 109.614 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 9.5 t -74.2 -28.14 61.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.158 -0.964 . . . . 0.0 109.463 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.401 ' O ' ' HB ' ' A' ' 95' ' ' THR . . . -59.1 -106.21 0.01 OUTLIER Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.514 HG23 ' N ' ' A' ' 96' ' ' SER . 4.0 t 178.31 -44.09 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.217 -1.166 . . . . 0.0 109.592 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.514 ' N ' HG23 ' A' ' 95' ' ' THR . 7.2 m -95.66 125.52 40.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.231 -0.918 . . . . 0.0 109.444 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.59 ' HB ' HG21 ' A' ' 5' ' ' ILE . 5.5 m -63.46 -34.99 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.238 -0.914 . . . . 0.0 109.402 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -64.42 -35.27 80.36 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.198 -0.939 . . . . 0.0 109.29 179.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.676 ' O ' HD23 ' A' ' 103' ' ' LEU . 20.7 tt0 -73.32 -36.78 66.28 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.334 -0.854 . . . . 0.0 109.403 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.494 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 98.9 m-20 -67.74 -27.79 67.09 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.171 -0.955 . . . . 0.0 109.424 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.526 HD21 HD13 ' A' ' 36' ' ' ILE . 24.9 tp -58.28 -62.24 1.98 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.358 -0.839 . . . . 0.0 109.674 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -68.19 -24.97 65.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.153 -0.967 . . . . 0.0 109.443 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.676 HD23 ' O ' ' A' ' 99' ' ' GLU . 0.9 OUTLIER -65.0 -29.58 70.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.305 -0.872 . . . . 0.0 109.482 179.929 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.528 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 9.8 t80 -64.12 -43.89 93.92 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.156 -0.965 . . . . 0.0 109.501 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 86.4 m -57.31 -31.36 65.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.753 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -87.64 -22.78 24.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.242 -0.911 . . . . 0.0 109.578 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 77.02 24.36 66.73 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . 0.635 ' HB3' HD12 ' A' ' 103' ' ' LEU . 2.4 t30 -80.31 -32.52 37.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.179 -1.189 . . . . 0.0 109.367 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.479 ' HA ' HD12 ' A' ' 109' ' ' LEU . 3.4 tp -66.59 -163.89 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.274 -0.891 . . . . 0.0 109.519 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -110.58 137.54 48.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 109.263 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.568 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 20.8 pt-20 -127.58 165.08 20.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.236 -0.915 . . . . 0.0 109.69 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 10.3 mt -151.54 104.26 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.147 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.463 0 O-C-N 121.236 -0.915 . . . . 0.0 109.838 -179.496 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -111.14 137.26 49.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.25 -0.906 . . . . 0.0 109.449 179.867 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.594 HG12 ' CZ ' ' A' ' 104' ' ' PHE . 4.9 mt -102.84 101.89 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.377 -0.827 . . . . 0.0 109.72 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.424 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -103.66 101.22 11.06 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.318 -0.864 . . . . 0.0 109.147 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.66 ' HB ' HD12 ' A' ' 70' ' ' ILE . 14.7 tt -98.25 130.19 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.256 -0.902 . . . . 0.0 109.592 -179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -59.26 146.09 40.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.406 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.494 ' HB3' ' CB ' ' A' ' 14' ' ' SER . 0.8 OUTLIER -135.85 162.12 33.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.921 . . . . 0.0 109.594 -179.863 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.82 -20.43 12.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.872 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.571 ' O ' ' CD1' ' A' ' 25' ' ' TYR . . . -119.81 -124.66 3.24 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.78 -37.21 1.03 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.19 -1.182 . . . . 0.0 109.544 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -144.92 -73.11 0.25 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.704 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -89.58 -29.76 18.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.254 -0.904 . . . . 0.0 109.514 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.19 -15.12 72.0 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.532 ' OG ' HG21 ' A' ' 97' ' ' VAL . 0.8 OUTLIER -77.39 82.62 3.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.196 -1.179 . . . . 0.0 109.479 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.487 ' HG2' ' O ' ' A' ' 95' ' ' THR . 13.2 tt0 -77.34 3.66 12.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.279 -0.888 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.576 HG22 HG13 ' A' ' 97' ' ' VAL . 9.7 t 66.62 65.96 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.16 -0.962 . . . . 0.0 109.227 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.448 ' O ' ' O ' ' A' ' 16' ' ' VAL . 60.2 p -57.65 -159.35 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.258 -0.901 . . . . 0.0 109.703 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.45 54.18 1.93 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.47 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -136.95 71.41 1.41 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.211 -0.931 . . . . 0.0 109.438 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.547 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 5.7 t80 -65.58 100.93 0.55 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.29 -0.881 . . . . 0.0 109.61 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 151.91 -42.97 0.69 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.468 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 5.5 ttt85 -104.51 -33.9 8.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.203 -1.175 . . . . 0.0 109.783 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.457 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -39.22 99.02 0.19 Allowed Pre-proline 0 N--CA 1.495 1.809 0 O-C-N 121.543 -0.723 . . . . 0.0 109.78 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.484 ' O ' ' HG2' ' A' ' 43' ' ' GLU . 36.5 Cg_endo -81.03 45.39 1.98 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 122.716 2.277 . . . . 0.0 110.927 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.571 ' CD1' ' O ' ' A' ' 9' ' ' GLY . 1.9 m-85 -161.05 72.34 0.43 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.946 -1.096 . . . . 0.0 109.627 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -79.7 150.01 31.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.305 -0.872 . . . . 0.0 109.438 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . 0.431 ' HB2' ' OG ' ' A' ' 7' ' ' SER . 5.2 ttt -123.54 122.1 37.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -0.939 . . . . 0.0 109.402 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 28.3 mt -114.08 129.34 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.899 . . . . 0.0 109.547 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.414 ' CG1' HG23 ' A' ' 36' ' ' ILE . 73.6 t -138.69 136.18 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.218 -0.926 . . . . 0.0 109.532 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -120.73 94.66 4.43 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.193 -0.942 . . . . 0.0 109.444 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.497 ' SD ' ' CD1' ' A' ' 3' ' ' ILE . 0.0 OUTLIER -83.44 152.31 25.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.385 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -96.73 -94.02 0.21 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.189 -0.944 . . . . 0.0 109.492 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -101.43 65.22 1.04 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.133 -0.979 . . . . 0.0 109.299 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 70.25 37.59 71.48 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -150.41 116.15 5.54 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.316 -1.108 . . . . 0.0 109.308 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.441 ' N ' HD13 ' A' ' 36' ' ' ILE . 5.9 mm -64.12 122.81 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -0.881 . . . . 0.0 109.593 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -130.77 16.61 5.26 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.188 -0.945 . . . . 0.0 109.318 179.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 17.1 m -173.51 101.29 0.12 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.382 -0.824 . . . . 0.0 109.245 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.55 101.06 7.12 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.94 155.91 19.78 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.336 -0.853 . . . . 0.0 109.418 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 3.1 t -125.99 129.6 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.205 -0.935 . . . . 0.0 109.337 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 92.8 mt -110.32 143.05 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.264 -0.897 . . . . 0.0 109.853 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.484 ' HG2' ' O ' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -109.73 128.94 55.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.314 -0.866 . . . . 0.0 109.281 179.852 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.199 -0.938 . . . . 0.0 109.407 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.417 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.492 2.372 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.772 HG21 ' HB2' ' A' ' 78' ' ' ALA . 22.2 mt -76.08 0.1 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -1.144 . . . . 0.0 109.619 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.17 -9.57 58.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.199 -0.938 . . . . 0.0 109.553 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.417 HG22 ' O ' ' A' ' 54' ' ' GLY . 7.2 t -76.96 -19.0 57.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -0.89 . . . . 0.0 109.583 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -56.55 -38.45 71.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.289 -0.882 . . . . 0.0 109.581 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -56.46 -39.31 72.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.68 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.4 mt -75.6 -35.44 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 109.648 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.412 HG21 HD13 ' A' ' 61' ' ' ILE . 48.8 mt -62.1 -29.05 45.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.54 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.669 ' HB1' HD11 ' A' ' 87' ' ' ILE . . . -71.82 -34.89 69.71 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.7 -179.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -76.8 -0.42 23.84 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.173 -0.954 . . . . 0.0 109.687 -179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -94.27 8.34 42.15 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.213 -0.929 . . . . 0.0 109.586 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 87.34 -11.21 66.3 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.454 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 70.0 t -58.44 91.62 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.226 -1.161 . . . . 0.0 109.489 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.53 -7.34 58.41 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.372 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.454 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -132.98 137.63 46.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 0.0 109.273 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 32.3 t -134.28 111.86 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.15 -0.969 . . . . 0.0 109.646 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.733 HG22 ' HB2' ' A' ' 92' ' ' ALA . 11.7 mt -95.71 116.9 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.289 -0.882 . . . . 0.0 109.261 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.547 ' HB1' ' HB2' ' A' ' 20' ' ' PHE . . . -148.78 173.83 12.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.156 -0.965 . . . . 0.0 109.684 -179.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.73 38.89 3.96 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.393 -0.817 . . . . 0.0 109.422 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.401 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.1 OUTLIER -50.17 141.25 15.74 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.264 -0.898 . . . . 0.0 109.406 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.1 Cg_endo -78.59 -62.95 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.593 2.195 . . . . 0.0 110.474 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -74.28 155.78 49.31 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.45 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.3 Cg_endo -78.6 4.7 6.15 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.702 2.268 . . . . 0.0 110.535 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -62.4 -56.86 14.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.207 -0.933 . . . . 0.0 109.512 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.772 ' HB2' HG21 ' A' ' 55' ' ' ILE . . . -57.26 -54.41 47.08 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.164 -0.96 . . . . 0.0 109.536 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -55.64 -22.25 21.82 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.3 -0.875 . . . . 0.0 109.523 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.45 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.2 OUTLIER -74.84 -37.01 62.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.162 -0.961 . . . . 0.0 109.467 -179.982 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.3 t -73.12 -50.68 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.911 . . . . 0.0 109.377 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.657 ' HB2' HD11 ' A' ' 89' ' ' ILE . 14.9 mt -50.1 -50.69 47.51 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.333 -0.854 . . . . 0.0 109.396 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -65.2 -33.36 75.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.242 -0.911 . . . . 0.0 109.431 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -58.37 -35.26 71.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.507 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -82.36 -37.39 25.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.341 -0.849 . . . . 0.0 109.379 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.36 22.1 6.61 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.669 HD11 ' HB1' ' A' ' 62' ' ' ALA . 6.0 mt -88.46 160.18 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.222 -1.163 . . . . 0.0 109.495 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.472 ' N ' HG22 ' A' ' 87' ' ' ILE . 2.1 mttt -86.15 113.31 22.09 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.768 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.657 HD11 ' HB2' ' A' ' 82' ' ' LEU . 43.5 mt -88.38 161.92 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.267 -0.895 . . . . 0.0 108.938 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.581 ' CE1' ' HB3' ' A' ' 109' ' ' LEU . 2.6 m-85 -139.9 137.68 35.03 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.966 -1.084 . . . . 0.0 109.702 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 17.6 mmm180 -87.99 119.42 28.34 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.409 -0.807 . . . . 0.0 109.558 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.733 ' HB2' HG22 ' A' ' 70' ' ' ILE . . . -98.41 108.04 20.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.875 . . . . 0.0 109.387 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . 0.598 HG23 ' N ' ' A' ' 94' ' ' GLY . 8.1 t -53.86 -47.19 71.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.598 ' N ' HG23 ' A' ' 93' ' ' THR . . . 125.31 83.47 0.53 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.665 HG22 ' N ' ' A' ' 96' ' ' SER . 17.5 m -137.65 -92.8 0.22 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.236 -1.155 . . . . 0.0 109.459 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.665 ' N ' HG22 ' A' ' 95' ' ' THR . 0.2 OUTLIER -153.01 130.74 11.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.157 -0.965 . . . . 0.0 109.399 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.576 HG13 HG22 ' A' ' 16' ' ' VAL . 22.2 m -52.05 -20.9 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 109.676 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -66.62 -57.97 6.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.238 -0.914 . . . . 0.0 109.522 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 32.3 mm-40 -66.0 -29.49 69.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.889 . . . . 0.0 109.524 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.541 ' OD1' HG21 ' A' ' 16' ' ' VAL . 33.2 m120 -60.9 -46.16 91.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.132 -0.98 . . . . 0.0 109.34 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -58.51 -37.04 74.76 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.216 -0.927 . . . . 0.0 109.148 179.781 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.417 ' HE2' ' HB2' ' A' ' 102' ' ' LYS . 0.3 OUTLIER -73.9 -22.06 59.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.287 -0.883 . . . . 0.0 109.311 179.822 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.464 ' HA ' HD22 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -76.54 -38.06 55.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.247 179.82 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.594 ' CZ ' HG12 ' A' ' 3' ' ' ILE . 0.5 OUTLIER -70.39 -6.64 36.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.3 -0.875 . . . . 0.0 109.551 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.421 HG22 ' OE1' ' A' ' 106' ' ' GLU . 51.6 m -73.34 -39.09 65.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 0.0 109.682 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . 0.421 ' OE1' HG22 ' A' ' 105' ' ' THR . 2.8 mm-40 -94.19 -41.87 9.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.32 -0.862 . . . . 0.0 109.505 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 110.78 25.78 5.01 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.93 -21.6 43.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.278 -1.131 . . . . 0.0 109.374 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.581 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 2.8 mt -59.41 144.99 45.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.373 -0.829 . . . . 0.0 109.421 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.512 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 1.4 pt-20 -94.72 145.62 24.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.182 -0.949 . . . . 0.0 109.303 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.547 ' HG2' ' CZ ' ' A' ' 90' ' ' TYR . 0.4 OUTLIER -139.32 -178.58 5.43 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.161 -0.962 . . . . 0.0 109.816 -179.603 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.9 mp -138.34 134.26 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.406 -0.809 . . . . 0.0 109.294 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.213 -0.929 . . . . 0.0 109.544 -179.979 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.462 ' HG3' ' O ' ' A' ' 1' ' ' MET . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.495 ' CE ' ' OE1' ' A' ' 30' ' ' GLU . 17.2 mttp -102.71 146.67 27.87 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.259 -0.901 . . . . 0.0 109.366 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.795 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 6.8 mt -113.27 131.5 64.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.3 -0.875 . . . . 0.0 109.918 -179.692 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -125.74 146.56 49.7 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.415 -0.803 . . . . 0.0 108.855 179.518 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.493 HG23 ' CG2' ' A' ' 70' ' ' ILE . 1.6 mp -132.35 127.52 57.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 109.718 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -63.5 148.64 48.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.351 -0.843 . . . . 0.0 109.403 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.861 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -143.91 164.99 28.99 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.138 -0.976 . . . . 0.0 109.549 -179.95 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.96 -6.46 23.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.319 -0.863 . . . . 0.0 109.597 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.556 ' O ' ' CG ' ' A' ' 25' ' ' TYR . . . -148.15 -145.37 4.15 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.724 HG22 ' O ' ' A' ' 10' ' ' THR . 96.7 m -135.6 18.56 3.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.241 -1.152 . . . . 0.0 109.433 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -141.6 -174.47 4.06 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.222 -0.924 . . . . 0.0 109.529 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -66.61 -22.22 66.12 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.22 -0.925 . . . . 0.0 109.482 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.73 -50.44 57.84 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 15' ' ' GLU . 81.4 p -76.81 84.39 3.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.294 -1.121 . . . . 0.0 109.244 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.706 ' O ' HG13 ' A' ' 97' ' ' VAL . 18.6 mt-10 -46.89 -98.11 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.398 -0.814 . . . . 0.0 109.859 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.809 HG11 ' HB1' ' A' ' 92' ' ' ALA . 4.2 t -123.06 33.76 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.939 -1.101 . . . . 0.0 109.782 -179.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.401 ' C ' ' O ' ' A' ' 16' ' ' VAL . 7.2 p 43.93 -162.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.883 . . . . 0.0 109.533 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.546 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -140.34 11.91 2.35 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.338 -0.851 . . . . 0.0 109.388 179.908 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.546 ' CD1' ' O ' ' A' ' 18' ' ' ARG . 32.6 m-85 -142.64 -165.3 2.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.52 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -133.88 -61.81 0.79 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.316 -0.865 . . . . 0.0 109.355 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -79.81 2.28 74.83 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.419 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.1 OUTLIER -103.91 -64.51 1.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.183 -1.187 . . . . 0.0 109.489 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.861 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -44.24 104.58 0.39 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.287 -0.883 . . . . 0.0 109.404 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.515 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.6 Cg_endo -79.94 61.49 8.21 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.656 2.237 . . . . 0.0 110.927 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.556 ' CG ' ' O ' ' A' ' 9' ' ' GLY . 51.1 m-85 -160.54 70.45 0.41 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.04 -1.037 . . . . 0.0 109.325 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 48.5 m-85 -79.85 109.22 14.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.206 -0.934 . . . . 0.0 109.321 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . 0.473 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 0.0 OUTLIER -79.6 141.37 36.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.332 -0.855 . . . . 0.0 109.742 -179.65 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.482 HG12 HG12 ' A' ' 42' ' ' ILE . 7.8 mm -125.04 139.32 51.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.32 -0.863 . . . . 0.0 109.235 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.439 HG21 ' CD1' ' A' ' 101' ' ' LEU . 10.6 t -140.63 144.64 26.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -0.892 . . . . 0.0 109.499 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.495 ' OE1' ' CE ' ' A' ' 2' ' ' LYS . 6.2 mt-10 -125.33 107.95 11.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.237 -0.914 . . . . 0.0 109.545 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.1 mtt -81.56 149.82 28.47 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.204 -0.935 . . . . 0.0 109.382 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.04 -51.79 2.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.184 -0.948 . . . . 0.0 109.587 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.02 53.25 0.57 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.498 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.4 21.83 55.61 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.403 ' O ' ' C ' ' A' ' 36' ' ' ILE . 1.6 t30 -148.13 95.43 2.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.254 -1.145 . . . . 0.0 109.477 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.435 ' O ' HG13 ' A' ' 36' ' ' ILE . 9.5 pt -45.47 114.16 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.168 -0.957 . . . . 0.0 109.295 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -113.68 9.4 17.78 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -0.933 . . . . 0.0 109.411 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 53.5 p -163.46 113.4 1.32 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 109.36 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -135.03 104.6 6.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.288 -0.883 . . . . 0.0 109.493 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.96 -174.58 2.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.309 -0.869 . . . . 0.0 109.245 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.588 HG11 HG23 ' A' ' 10' ' ' THR . 14.8 p -131.93 166.65 28.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.074 -1.016 . . . . 0.0 109.648 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.587 ' N ' HG22 ' A' ' 41' ' ' VAL . 7.4 mm -129.97 99.37 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.35 -0.844 . . . . 0.0 109.501 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.526 ' HG3' ' CE1' ' A' ' 25' ' ' TYR . 31.8 tt0 -77.88 126.3 30.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.275 -0.891 . . . . 0.0 109.299 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.8 m120 . . . . . 0 N--CA 1.491 1.592 0 O-C-N 121.214 -0.929 . . . . 0.0 109.647 -179.819 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.957 ' O ' HG22 ' A' ' 57' ' ' THR . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.6 mm -76.76 -28.87 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -1.142 . . . . 0.0 109.499 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 8.0 mmm180 -76.69 -34.11 58.2 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.183 -0.948 . . . . 0.0 109.594 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.957 HG22 ' O ' ' A' ' 54' ' ' GLY . 14.8 t -49.11 -23.63 1.31 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.737 -179.832 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -45.25 -47.25 12.82 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.272 -0.892 . . . . 0.0 109.9 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -53.83 -48.43 69.93 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.195 -0.941 . . . . 0.0 109.92 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 80.2 mt -60.91 -36.73 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.213 -0.929 . . . . 0.0 110.115 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 32.7 mt -62.94 -40.95 90.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 109.947 -179.582 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.38 -28.73 64.24 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.149 -0.969 . . . . 0.0 109.791 -179.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -77.32 4.39 10.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -0.929 . . . . 0.0 109.947 -179.796 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -106.6 2.54 26.1 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.018 -1.051 . . . . 0.0 109.661 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.03 -11.21 62.2 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.453 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 81.8 t -62.61 88.27 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -1.146 . . . . 0.0 109.61 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.66 -2.74 44.12 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.291 -0.88 . . . . 0.0 108.986 179.467 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.795 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -127.8 127.54 43.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.34 -0.85 . . . . 0.0 109.172 179.849 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.6 HG21 HD22 ' A' ' 82' ' ' LEU . 74.8 t -125.57 112.43 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.17 -0.956 . . . . 0.0 109.78 -179.667 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.493 ' CG2' HG23 ' A' ' 5' ' ' ILE . 3.5 mt -99.33 124.31 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.192 -0.942 . . . . 0.0 109.129 179.549 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -158.52 172.81 17.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.175 -0.953 . . . . 0.0 109.766 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.15 49.18 2.31 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.367 -0.833 . . . . 0.0 109.514 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.86 160.11 22.38 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.201 -0.937 . . . . 0.0 109.407 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.85 -89.9 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.557 2.172 . . . . 0.0 110.296 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.6 162.96 36.91 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.48 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.7 Cg_endo -80.29 27.74 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.825 2.35 . . . . 0.0 111.17 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.73 ' O ' HG23 ' A' ' 81' ' ' VAL . 0.9 OUTLIER -76.7 -59.84 2.6 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.879 -1.138 . . . . 0.0 109.423 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.419 ' O ' ' HB ' ' A' ' 81' ' ' VAL . . . -55.61 -43.51 76.15 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.266 -0.896 . . . . 0.0 109.389 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.632 ' O ' HD11 ' A' ' 89' ' ' ILE . 3.8 m-30 -60.2 -49.17 78.7 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.264 -0.898 . . . . 0.0 109.498 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.48 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.3 OUTLIER -61.36 -21.03 63.67 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 109.331 179.798 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 77' ' ' ASN . 95.5 t -73.28 -63.12 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.217 -0.927 . . . . 0.0 109.373 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.714 ' HA ' HD12 ' A' ' 85' ' ' LEU . 1.5 mt -57.74 -27.09 62.7 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.179 -0.951 . . . . 0.0 109.302 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -62.06 -51.32 68.44 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.322 -0.861 . . . . 0.0 109.332 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -77.01 -12.28 59.92 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.262 -0.899 . . . . 0.0 109.362 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.714 HD12 ' HA ' ' A' ' 82' ' ' LEU . 55.5 mt -77.49 -23.63 50.28 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.921 . . . . 0.0 109.365 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . 0.456 ' C ' HD12 ' A' ' 87' ' ' ILE . . . 100.86 41.42 2.67 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.505 HD12 ' N ' ' A' ' 87' ' ' ILE . 5.3 mp -137.7 161.87 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -1.156 . . . . 0.0 109.512 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.5 ' N ' HG22 ' A' ' 87' ' ' ILE . 4.6 mmtm -92.56 131.5 37.63 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -0.901 . . . . 0.0 109.627 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.632 HD11 ' O ' ' A' ' 79' ' ' PHE . 50.9 mt -92.29 157.35 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.251 -0.906 . . . . 0.0 109.51 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.529 ' CE2' ' HB3' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -142.33 143.12 32.61 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.336 -0.852 . . . . 0.0 109.44 -179.898 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.707 ' O ' HD22 ' A' ' 109' ' ' LEU . 12.4 mmt180 -100.15 125.28 46.25 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 109.428 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . 0.809 ' HB1' HG11 ' A' ' 16' ' ' VAL . . . -82.97 113.84 20.83 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.217 -0.927 . . . . 0.0 109.473 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 3.8 m -144.98 13.03 1.45 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.233 -0.917 . . . . 0.0 109.518 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.02 -121.68 0.31 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.47 HG22 ' OG ' ' A' ' 96' ' ' SER . 17.3 m -129.59 -54.5 1.16 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.356 -1.085 . . . . 0.0 109.385 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.49 ' CB ' ' HG2' ' A' ' 15' ' ' GLU . 0.8 OUTLIER -139.19 143.53 38.13 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.275 -0.891 . . . . 0.0 109.367 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.706 HG13 ' O ' ' A' ' 15' ' ' GLU . 15.0 m -44.1 -26.72 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.295 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . 0.407 ' N ' ' O ' ' A' ' 96' ' ' SER . 3.3 tp10 -64.27 -51.76 61.96 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.264 -0.897 . . . . 0.0 109.246 179.702 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.436 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 3.0 tp10 -64.15 -37.46 87.52 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.297 -0.877 . . . . 0.0 109.068 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -63.89 -30.73 71.79 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.331 -0.856 . . . . 0.0 109.218 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.439 ' CD1' HG21 ' A' ' 29' ' ' VAL . 6.4 tp -55.98 -55.85 27.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.363 -0.835 . . . . 0.0 109.219 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 44.4 mttt -76.82 -13.94 59.96 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.25 179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.51 HD12 ' HA ' ' A' ' 103' ' ' LEU . 6.1 tp -77.16 -23.39 51.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.909 . . . . 0.0 109.579 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.591 ' CD1' ' CD1' ' A' ' 3' ' ' ILE . 32.2 t80 -75.58 -23.75 56.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.234 -0.916 . . . . 0.0 109.106 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.6 m -74.57 -34.05 62.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.319 -0.863 . . . . 0.0 109.259 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -90.73 -0.28 57.65 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.287 -0.883 . . . . 0.0 109.487 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.73 37.87 62.7 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -82.74 -23.1 34.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.217 -1.167 . . . . 0.0 109.473 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.707 HD22 ' O ' ' A' ' 91' ' ' ARG . 0.8 OUTLIER -83.69 162.03 20.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.235 -0.916 . . . . 0.0 109.289 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.4 ' HG2' ' N ' ' A' ' 111' ' ' GLU . 34.3 tt0 -87.63 146.95 25.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.184 -0.947 . . . . 0.0 109.91 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.529 ' HB3' ' CE2' ' A' ' 90' ' ' TYR . 9.2 pt-20 -135.79 179.8 6.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.43 -0.794 . . . . 0.0 109.077 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.8 mt -149.84 127.13 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.708 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.414 ' CD ' ' N ' ' A' ' 113' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.37 -0.831 . . . . 0.0 109.356 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.464 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 36.7 mttt -147.01 126.73 13.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.269 -0.895 . . . . 0.0 109.221 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.951 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 4.3 mt -111.16 116.44 52.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.248 -0.908 . . . . 0.0 109.832 -179.582 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.697 ' C ' HD13 ' A' ' 5' ' ' ILE . . . -108.28 146.57 32.7 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.248 -0.908 . . . . 0.0 109.394 179.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.697 HD13 ' C ' ' A' ' 4' ' ' ALA . 5.4 mm -114.73 121.12 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.206 -0.934 . . . . 0.0 109.53 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.486 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -47.63 144.79 3.0 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.192 -0.943 . . . . 0.0 109.362 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 25' ' ' TYR . 11.3 t 49.99 -93.19 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.234 -0.916 . . . . 0.0 109.458 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.955 ' HA ' HG11 ' A' ' 97' ' ' VAL . 0.5 OUTLIER 66.81 8.68 6.18 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.169 -0.957 . . . . 0.0 109.518 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . 0.544 ' N ' ' HB2' ' A' ' 14' ' ' SER . . . 44.06 -128.13 6.53 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.07 -13.59 11.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.304 -1.115 . . . . 0.0 109.546 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -171.32 -70.61 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.195 -0.941 . . . . 0.0 109.921 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 13' ' ' GLY . 0.3 OUTLIER -122.37 -22.54 5.48 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 0.0 110.022 -179.619 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 12' ' ' LEU . . . -42.19 -42.34 4.18 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.544 ' HB2' ' N ' ' A' ' 9' ' ' GLY . 27.3 t -77.87 85.28 4.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.272 -1.134 . . . . 0.0 109.674 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.693 ' C ' HG23 ' A' ' 16' ' ' VAL . 1.7 mt-10 -67.96 85.32 0.23 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.413 -0.805 . . . . 0.0 109.214 179.802 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.693 HG23 ' C ' ' A' ' 15' ' ' GLU . 1.5 t 70.58 30.98 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.451 -0.781 . . . . 0.0 109.265 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.474 ' HA ' ' OG ' ' A' ' 14' ' ' SER . 4.3 p 62.45 -160.99 0.3 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.339 -0.851 . . . . 0.0 109.543 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.0 ttm180 -154.8 -46.43 0.09 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.399 -0.813 . . . . 0.0 109.053 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -145.72 147.8 32.32 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.369 -0.832 . . . . 0.0 109.095 179.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.48 ' CG ' ' HB1' ' A' ' 71' ' ' ALA . 85.1 t80 -118.32 138.19 52.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.161 -0.962 . . . . 0.0 109.578 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.475 ' O ' ' HA2' ' A' ' 54' ' ' GLY . . . 139.84 -59.12 0.59 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.47 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.1 OUTLIER -116.98 13.45 14.87 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.2 -1.177 . . . . 0.0 109.774 -179.753 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.96 109.53 1.71 Allowed Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.233 -0.917 . . . . 0.0 109.884 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.9 Cg_endo -81.17 41.37 1.13 Allowed 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.548 2.165 . . . . 0.0 110.485 179.699 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.418 ' O ' ' O ' ' A' ' 7' ' ' SER . 0.4 OUTLIER -158.74 69.82 0.49 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.09 -1.006 . . . . 0.0 109.314 -179.911 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.538 ' CZ ' HD13 ' A' ' 61' ' ' ILE . 0.3 OUTLIER -82.27 112.69 19.5 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.62 -179.854 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . 0.965 ' HG3' HG12 ' A' ' 41' ' ' VAL . 0.0 OUTLIER -85.15 144.69 28.03 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.877 . . . . 0.0 109.308 -179.996 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 39.4 mt -139.76 126.18 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.228 -0.92 . . . . 0.0 109.518 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.556 HG13 ' O ' ' A' ' 38' ' ' SER . 34.8 t -124.09 128.67 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.35 -0.844 . . . . 0.0 109.471 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -98.88 167.22 10.89 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.368 -0.833 . . . . 0.0 109.237 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . 0.52 ' HE3' HG22 ' A' ' 36' ' ' ILE . 29.9 mtt -133.19 138.91 46.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.932 . . . . 0.0 109.448 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 6.7 ttmm -98.93 -48.06 5.04 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -0.913 . . . . 0.0 109.464 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 15.8 mtmm -148.81 66.59 1.05 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.341 -0.849 . . . . 0.0 109.218 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.77 12.59 42.46 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.419 ' O ' ' C ' ' A' ' 36' ' ' ILE . 8.2 t-20 -130.83 94.36 3.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -1.17 . . . . 0.0 109.462 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.52 HG22 ' HE3' ' A' ' 31' ' ' MET . 26.3 pt -43.64 126.07 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.702 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -137.06 16.53 3.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.344 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.556 ' O ' HG13 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -154.94 117.12 4.2 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 0.0 109.14 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 80.9 p -143.77 112.45 6.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.532 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -124.91 171.95 9.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.893 . . . . 0.0 109.373 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.965 HG12 ' HG3' ' A' ' 27' ' ' MET . 20.8 m -131.73 115.87 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.274 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.2 tp -105.06 152.6 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.245 -0.909 . . . . 0.0 109.413 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -105.1 145.12 30.96 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.223 -0.923 . . . . 0.0 109.399 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.278 -0.889 . . . . 0.0 109.558 -179.888 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 21' ' ' GLY . . . . . . . . 0 N--CA 1.49 2.3 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.488 HG23 ' HA ' ' A' ' 78' ' ' ALA . 42.9 mm -68.55 -11.55 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.157 -1.202 . . . . 0.0 109.376 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.5 ttt180 -76.36 -16.32 59.77 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.327 -0.858 . . . . 0.0 109.6 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 10.6 t -63.34 -25.94 68.53 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.253 -0.904 . . . . 0.0 109.252 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.487 ' O ' HG13 ' A' ' 61' ' ' ILE . . . -54.36 -36.17 63.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 109.588 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -74.01 -32.55 63.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.141 -0.974 . . . . 0.0 109.425 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 81.9 mt -65.96 -40.7 88.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.267 -0.896 . . . . 0.0 109.541 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.538 HD13 ' CZ ' ' A' ' 26' ' ' PHE . 8.6 pt -76.69 -29.23 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.576 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -62.57 -39.26 93.1 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.187 -0.946 . . . . 0.0 109.711 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -68.98 -12.68 61.89 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.237 -0.914 . . . . 0.0 109.831 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -89.15 -7.84 54.88 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.182 -0.949 . . . . 0.0 109.542 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.522 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 100.8 -12.04 59.26 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.464 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 16.4 t -51.81 89.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.375 -1.073 . . . . 0.0 109.489 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.522 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -80.91 -5.66 57.7 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.307 -0.871 . . . . 0.0 109.099 179.568 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.951 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -125.2 134.84 52.21 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.211 -0.931 . . . . 0.0 109.523 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.416 ' C ' HD12 ' A' ' 70' ' ' ILE . 86.4 t -137.27 111.93 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.162 -0.961 . . . . 0.0 109.919 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.631 HD12 ' N ' ' A' ' 70' ' ' ILE . 1.7 mp -94.88 106.11 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.313 -0.867 . . . . 0.0 108.979 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.48 ' HB1' ' CG ' ' A' ' 20' ' ' PHE . . . -135.78 173.57 11.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.129 -0.982 . . . . 0.0 109.86 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.26 40.54 2.46 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.428 -0.795 . . . . 0.0 109.44 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . 0.414 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 1.4 t -45.98 146.67 1.98 Allowed Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.207 -0.933 . . . . 0.0 109.41 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 35.9 Cg_endo -77.98 -17.92 13.36 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.642 2.228 . . . . 0.0 110.492 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -127.02 164.76 20.48 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.87 4.65 5.92 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.626 2.217 . . . . 0.0 110.431 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.48 ' O ' ' HB3' ' A' ' 80' ' ' GLU . 2.9 t-20 -62.3 -43.16 99.47 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.314 -0.866 . . . . 0.0 109.545 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.488 ' HA ' HG23 ' A' ' 55' ' ' ILE . . . -64.13 -57.71 8.78 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.283 -0.886 . . . . 0.0 109.53 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.695 ' CD1' HG21 ' A' ' 89' ' ' ILE . 9.2 m-85 -58.21 -21.42 47.81 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.58 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.48 ' HB3' ' O ' ' A' ' 77' ' ' ASN . 29.7 tt0 -62.17 -59.6 4.81 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.197 -0.939 . . . . 0.0 109.393 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.4 t -61.22 -44.88 99.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.235 -0.916 . . . . 0.0 109.203 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 1.008 HD23 HD12 ' A' ' 87' ' ' ILE . 14.3 mt -50.35 -37.94 39.63 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.248 -0.907 . . . . 0.0 109.307 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -64.31 -42.87 96.13 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.344 -0.848 . . . . 0.0 109.363 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -69.98 -15.69 63.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.328 -0.858 . . . . 0.0 109.338 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.476 ' HB3' HG13 ' A' ' 87' ' ' ILE . 17.9 mt -95.6 -8.1 35.9 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.181 -0.95 . . . . 0.0 109.517 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 63.03 32.83 85.46 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 1.008 HD12 HD23 ' A' ' 82' ' ' LEU . 13.1 mt -96.22 171.4 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.234 -1.157 . . . . 0.0 109.511 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.524 ' H ' HG22 ' A' ' 87' ' ' ILE . 8.0 mttt -91.86 117.08 29.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.646 -179.767 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.695 HG21 ' CD1' ' A' ' 79' ' ' PHE . 10.5 mt -94.29 128.18 45.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.346 -0.846 . . . . 0.0 109.388 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.551 ' CE2' ' O ' ' A' ' 109' ' ' LEU . 2.2 m-85 -123.21 144.01 49.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.278 -0.889 . . . . 0.0 109.334 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . 0.501 ' HG2' ' CG ' ' A' ' 111' ' ' GLU . 0.0 OUTLIER -91.21 132.05 36.35 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.158 -0.964 . . . . 0.0 109.653 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.02 94.3 9.57 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.239 -0.913 . . . . 0.0 109.409 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -135.46 23.14 3.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.125 -0.984 . . . . 0.0 109.624 -179.808 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -86.69 -134.26 3.84 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.669 -1.373 . . . . 0.0 109.669 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 96' ' ' SER . 5.2 t -136.14 -38.35 0.7 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.267 -1.137 . . . . 0.0 109.447 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.443 ' N ' HG23 ' A' ' 95' ' ' THR . 29.0 t -125.77 137.08 53.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.314 -0.866 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.955 HG11 ' HA ' ' A' ' 8' ' ' SER . 0.3 OUTLIER -55.03 -35.59 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -0.858 . . . . 0.0 109.406 179.916 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -69.2 -51.83 33.95 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.233 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.548 ' O ' HD13 ' A' ' 103' ' ' LEU . 3.2 tt0 -52.18 -31.67 32.71 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.244 -0.91 . . . . 0.0 109.166 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -72.39 -49.73 31.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.342 -0.848 . . . . 0.0 109.152 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.465 HD21 HG11 ' A' ' 29' ' ' VAL . 27.1 tp -50.4 -51.31 47.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.284 -0.885 . . . . 0.0 109.513 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -65.77 -35.4 80.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.205 -0.935 . . . . 0.0 109.492 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.548 HD13 ' O ' ' A' ' 99' ' ' GLU . 0.7 OUTLIER -71.71 -11.17 60.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.269 -0.895 . . . . 0.0 109.537 179.947 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.504 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.8 t80 -76.93 -38.3 53.68 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.263 -0.898 . . . . 0.0 109.453 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . 0.421 ' O ' HG22 ' A' ' 105' ' ' THR . 28.8 m -72.09 -13.78 61.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.464 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -96.45 -17.23 20.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.182 -0.949 . . . . 0.0 109.49 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 74.43 29.45 61.89 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . 0.462 ' HB3' HD23 ' A' ' 103' ' ' LEU . 0.4 OUTLIER -79.96 -44.11 20.86 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.297 -1.119 . . . . 0.0 109.693 -179.882 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.551 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.4 OUTLIER -123.28 146.62 47.73 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.235 -0.916 . . . . 0.0 109.463 -179.949 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.528 ' HA ' ' CG ' ' A' ' 90' ' ' TYR . 1.1 pm0 -171.66 -156.79 0.11 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.904 . . . . 0.0 109.458 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.564 ' OE1' ' CE2' ' A' ' 79' ' ' PHE . 0.0 OUTLIER -146.29 -87.19 0.1 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.27 -0.894 . . . . 0.0 109.678 179.951 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 7.0 mt -131.37 151.37 35.51 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.192 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.435 ' HG2' ' HG2' ' A' ' 88' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 O-C-N 121.34 -0.85 . . . . 0.0 109.382 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.42 ' O ' ' HG2' ' A' ' 1' ' ' MET . 5.1 ttt . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.455 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 0.1 OUTLIER -131.18 156.05 45.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.218 -0.926 . . . . 0.0 109.521 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ILE . . . . . 0.63 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 7.0 mt -116.01 107.47 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.552 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.697 ' HB2' HD12 ' A' ' 28' ' ' ILE . . . -97.18 170.85 8.83 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.326 -0.859 . . . . 0.0 109.13 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.732 HG21 ' HB ' ' A' ' 97' ' ' VAL . 98.1 mt -148.13 119.93 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.172 -0.955 . . . . 0.0 109.889 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.538 ' HB1' ' HD1' ' A' ' 20' ' ' PHE . . . -87.14 143.95 27.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 108.949 179.565 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.426 ' HB2' ' O ' ' A' ' 6' ' ' ALA . 1.2 m 61.77 81.74 0.19 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.055 -1.028 . . . . 0.0 109.129 -179.723 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.646 ' HB2' HG21 ' A' ' 97' ' ' VAL . 0.0 OUTLIER -136.32 -37.63 0.7 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.308 -179.788 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.49 -171.95 27.05 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.05 9.99 15.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.175 -1.191 . . . . 0.0 109.454 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 47.5 p-10 -170.25 -174.14 1.65 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.483 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.627 ' H ' HD23 ' A' ' 12' ' ' LEU . 0.7 OUTLIER -75.66 -20.97 58.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.21 -0.932 . . . . 0.0 109.456 179.941 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.496 ' N ' ' HG ' ' A' ' 12' ' ' LEU . . . -46.38 -45.5 16.45 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.499 ' CB ' ' O ' ' A' ' 8' ' ' SER . 0.6 OUTLIER -76.15 81.43 2.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.278 -1.131 . . . . 0.0 109.429 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLU . . . . . 0.66 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -73.27 83.06 1.38 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.339 -0.851 . . . . 0.0 109.359 179.874 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.885 HG21 ' HA2' ' A' ' 94' ' ' GLY . 2.6 t 78.01 77.56 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.485 -0.759 . . . . 0.0 109.478 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 16' ' ' VAL . 0.1 OUTLIER -43.59 -73.92 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -0.914 . . . . 0.0 109.594 -179.93 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -140.33 -82.06 0.25 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.23 -0.919 . . . . 0.0 109.542 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -146.29 -144.71 0.16 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.29 -0.882 . . . . 0.0 109.332 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.538 ' HD1' ' HB1' ' A' ' 6' ' ' ALA . 16.6 t80 -121.5 27.5 8.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.172 -0.955 . . . . 0.0 109.497 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -83.07 -74.7 1.2 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.427 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.5 OUTLIER -123.0 27.98 7.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.277 -1.131 . . . . 0.0 109.349 179.929 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -50.91 108.46 1.05 Allowed Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.371 -0.83 . . . . 0.0 109.34 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.3 Cg_endo -79.57 39.27 0.81 Allowed 'Trans proline' 0 C--N 1.311 -1.425 0 C-N-CA 122.566 2.178 . . . . 0.0 111.077 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.542 ' CD1' ' HG2' ' A' ' 43' ' ' GLU . 48.1 m-85 -155.55 67.16 0.63 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.98 -1.075 . . . . 0.0 109.065 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.647 ' CZ ' ' HB1' ' A' ' 4' ' ' ALA . 9.2 t80 -81.88 120.25 24.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.436 -0.79 . . . . 0.0 109.592 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 4.5 ttm -103.45 159.99 15.1 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.277 -0.889 . . . . 0.0 109.558 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.756 HD11 HG22 ' A' ' 66' ' ' VAL . 1.1 tp -148.53 133.01 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.268 -0.895 . . . . 0.0 109.54 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.591 HG11 HD11 ' A' ' 101' ' ' LEU . 39.5 t -143.11 124.83 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.592 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -99.09 171.4 8.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.235 -0.916 . . . . 0.0 109.317 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 13.6 ttm -139.66 138.93 36.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -0.893 . . . . 0.0 109.583 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.74 -47.82 6.02 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.21 -0.931 . . . . 0.0 109.522 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 13.1 mttp -153.27 41.09 0.55 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.235 -0.916 . . . . 0.0 109.463 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.99 -8.53 55.92 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.483 ' O ' ' HG2' ' A' ' 37' ' ' GLU . 6.9 m-20 -117.02 97.18 5.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -1.157 . . . . 0.0 109.356 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.486 ' O ' HG13 ' A' ' 36' ' ' ILE . 5.6 pt -47.25 113.02 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.412 -0.805 . . . . 0.0 109.586 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.483 ' HG2' ' O ' ' A' ' 35' ' ' ASN . 14.9 mm-40 -109.72 19.26 19.36 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -0.917 . . . . 0.0 109.664 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 2.1 p -163.53 120.78 1.82 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 109.319 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.441 ' CB ' HG22 ' A' ' 29' ' ' VAL . 5.7 p -149.28 107.53 3.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.539 -179.804 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -117.3 156.27 28.09 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.171 -0.955 . . . . 0.0 109.516 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -126.19 138.71 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.257 -0.902 . . . . 0.0 109.402 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 40.8 pt -135.71 146.43 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.351 -0.843 . . . . 0.0 109.614 -179.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.542 ' HG2' ' CD1' ' A' ' 25' ' ' TYR . 42.0 mt-10 -98.25 55.61 1.14 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.231 -0.918 . . . . 0.0 109.13 179.7 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.501 0 O-C-N 121.323 -0.86 . . . . 0.0 109.372 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.809 HG23 ' HB2' ' A' ' 78' ' ' ALA . 34.6 mm -65.35 -33.24 62.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.319 -1.106 . . . . 0.0 109.648 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.74 -14.77 62.11 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.208 -0.932 . . . . 0.0 109.717 -179.826 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.448 ' HA ' HD12 ' A' ' 60' ' ' ILE . 85.7 m -67.53 -18.02 64.88 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.114 -0.991 . . . . 0.0 109.744 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ALA . . . . . 0.431 ' HB2' ' HE2' ' A' ' 20' ' ' PHE . . . -60.28 -28.16 67.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.235 -0.916 . . . . 0.0 109.654 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -62.67 -49.75 73.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.295 -0.878 . . . . 0.0 109.687 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.448 HD12 ' HA ' ' A' ' 57' ' ' THR . 3.7 mt -64.04 -45.67 96.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.892 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 41.6 mt -52.2 -48.0 43.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.237 -0.914 . . . . 0.0 109.957 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.74 -37.45 84.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.171 -0.955 . . . . 0.0 109.998 -179.524 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -66.25 -11.1 48.15 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.097 -1.002 . . . . 0.0 109.851 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -88.99 16.75 6.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.117 -0.989 . . . . 0.0 109.556 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.453 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 95.31 -20.75 47.89 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . 0.756 HG22 HD11 ' A' ' 28' ' ' ILE . 97.1 t -57.06 88.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.312 -1.111 . . . . 0.0 109.506 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.453 ' N ' ' O ' ' A' ' 65' ' ' GLY . 14.0 mttt -79.91 -8.45 59.33 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.329 -0.857 . . . . 0.0 108.777 179.331 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ALA . . . . . 0.63 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -128.05 138.61 52.64 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' VAL . . . . . 0.433 ' C ' HD12 ' A' ' 70' ' ' ILE . 95.3 t -141.37 122.08 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.112 -0.993 . . . . 0.0 109.821 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.582 HD12 ' N ' ' A' ' 70' ' ' ILE . 1.3 mp -93.43 144.5 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.345 -0.847 . . . . 0.0 108.804 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -176.81 175.94 1.56 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.127 -0.983 . . . . 0.0 109.755 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -153.04 66.51 0.79 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.412 -0.805 . . . . 0.0 109.347 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -73.02 158.92 86.43 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.238 -0.914 . . . . 0.0 109.568 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.55 -39.2 0.42 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.658 2.239 . . . . 0.0 110.764 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -121.22 178.45 16.38 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -179.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' PRO . . . . . 0.428 ' HA ' ' HB2' ' A' ' 79' ' ' PHE . 36.6 Cg_endo -80.28 40.67 1.0 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.853 2.369 . . . . 0.0 110.753 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 52.5 m-20 -76.1 -67.54 0.67 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.085 -1.01 . . . . 0.0 109.314 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ALA . . . . . 0.809 ' HB2' HG23 ' A' ' 55' ' ' ILE . . . -74.66 -25.91 59.51 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.32 179.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' PHE . . . . . 0.428 ' HB2' ' HA ' ' A' ' 76' ' ' PRO . 3.1 m-85 -66.23 -21.11 66.29 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.373 -0.829 . . . . 0.0 109.398 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.417 ' O ' ' HB2' ' A' ' 84' ' ' GLU . 11.8 mt-10 -77.4 -46.84 21.44 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.233 -0.917 . . . . 0.0 109.833 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.4 t -68.65 -36.13 73.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.132 -0.98 . . . . 0.0 109.824 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.498 ' HB3' ' CG1' ' A' ' 89' ' ' ILE . 8.7 mt -73.75 -57.61 3.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.268 -0.895 . . . . 0.0 109.707 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.425 ' N ' HD11 ' A' ' 89' ' ' ILE . 8.2 t-20 -49.53 -37.78 28.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.212 -0.93 . . . . 0.0 109.6 -179.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . 0.417 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 0.3 OUTLIER -73.02 -39.34 66.08 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.217 -0.927 . . . . 0.0 109.403 -179.947 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' LEU . . . . . 0.424 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.3 OUTLIER -64.54 -13.12 51.06 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.134 -0.979 . . . . 0.0 109.475 -179.943 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 75.13 26.57 66.05 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ILE . . . . . 0.521 HG22 ' N ' ' A' ' 88' ' ' LYS . 23.1 mm -91.91 160.85 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.345 -1.091 . . . . 0.0 109.423 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' LYS . . . . . 0.521 ' N ' HG22 ' A' ' 87' ' ' ILE . 7.8 mtpt -83.01 105.14 13.76 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.169 -0.957 . . . . 0.0 109.309 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ILE . . . . . 0.511 ' O ' ' CB ' ' A' ' 111' ' ' GLU . 3.1 mt -90.75 152.33 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.182 -0.949 . . . . 0.0 109.513 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' TYR . . . . . 0.484 ' CD1' ' O ' ' A' ' 110' ' ' GLU . 1.1 m-85 -136.63 141.27 43.22 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -0.875 . . . . 0.0 109.404 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.25 149.19 22.85 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.537 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.86 141.04 38.72 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.277 -0.889 . . . . 0.0 109.365 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.98 -17.28 24.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.541 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.885 ' HA2' HG21 ' A' ' 16' ' ' VAL . . . 101.94 13.55 31.4 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 52.0 m -81.19 -55.3 4.83 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -1.16 . . . . 0.0 109.459 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 173.16 130.19 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.321 -0.862 . . . . 0.0 109.572 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.732 ' HB ' HG21 ' A' ' 5' ' ' ILE . 33.6 m -65.02 -23.79 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.374 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . 0.54 ' HB2' ' CB ' ' A' ' 12' ' ' LEU . 1.5 tt0 -65.89 -60.05 3.24 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.277 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.882 ' O ' HD12 ' A' ' 103' ' ' LEU . 36.1 mm-40 -60.38 -28.66 68.39 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.291 -0.881 . . . . 0.0 109.33 179.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ASN . . . . . 0.439 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 6.4 m-20 -69.68 -30.58 68.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.286 -0.884 . . . . 0.0 109.409 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' LEU . . . . . 0.711 HD23 ' N ' ' A' ' 102' ' ' LYS . 6.8 tt -59.87 -60.08 4.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.404 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' LYS . . . . . 0.711 ' N ' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -64.94 -29.07 69.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.319 -0.863 . . . . 0.0 109.38 179.922 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.882 HD12 ' O ' ' A' ' 99' ' ' GLU . 0.4 OUTLIER -65.46 -30.69 71.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.239 -0.913 . . . . 0.0 109.627 -179.935 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' PHE . . . . . 0.434 ' CD1' HD11 ' A' ' 3' ' ' ILE . 23.4 t80 -59.75 -32.1 70.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.192 -0.942 . . . . 0.0 109.589 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 28.3 m -67.19 -40.92 86.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.887 . . . . 0.0 109.73 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -79.8 4.99 14.76 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.276 -0.89 . . . . 0.0 109.553 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 46.09 28.98 3.23 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -80.01 -33.2 39.48 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.193 -1.181 . . . . 0.0 109.379 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.433 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 45.5 mt -65.84 -176.93 0.42 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.313 -0.867 . . . . 0.0 109.306 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.484 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 11.3 pt-20 -108.48 143.59 37.24 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.572 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' GLU . . . . . 0.511 ' CB ' ' O ' ' A' ' 89' ' ' ILE . 0.0 OUTLIER -137.06 -174.01 3.62 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.276 -0.89 . . . . 0.0 109.298 179.863 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.444 HG13 ' O ' ' A' ' 111' ' ' GLU . 2.3 mp -147.99 147.48 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.18 -0.95 . . . . 0.0 109.493 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ARG . . . . . 0.435 ' HB2' ' O ' ' A' ' 112' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.331 -0.855 . . . . 0.0 109.417 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.271 0.558 . . . . 0.0 109.513 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.5 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 23.2 mttp -110.91 128.27 55.75 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.232 -0.917 . . . . 0.0 109.501 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.853 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 3.9 mt -95.51 128.05 47.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.301 -0.875 . . . . 0.0 109.57 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.65 ' C ' HD13 ' A' ' 5' ' ' ILE . . . -116.33 122.55 45.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.205 -0.934 . . . . 0.0 109.451 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.749 ' N ' HD13 ' A' ' 5' ' ' ILE . 1.2 mm -97.24 115.53 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.196 -0.94 . . . . 0.0 109.485 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.518 ' HA ' ' CE1' ' A' ' 26' ' ' PHE . . . -59.01 146.58 37.73 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.297 -0.877 . . . . 0.0 109.626 -179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 2.4 m 52.73 -98.09 0.07 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.339 -0.851 . . . . 0.0 109.611 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.604 ' HB3' HG11 ' A' ' 97' ' ' VAL . 75.4 m 59.05 15.36 3.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.078 -1.014 . . . . 0.0 109.448 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.554 ' N ' ' HB3' ' A' ' 14' ' ' SER . . . 52.69 -150.96 8.78 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.3 m -129.5 -8.38 4.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.243 -1.151 . . . . 0.0 110.092 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.591 ' HB3' HD23 ' A' ' 12' ' ' LEU . 0.4 OUTLIER -131.19 -89.17 0.46 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.965 -1.084 . . . . 0.0 109.873 -179.845 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.591 HD23 ' HB3' ' A' ' 11' ' ' ASP . 0.7 OUTLIER -158.99 26.33 0.21 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.167 -0.958 . . . . 0.0 109.669 -179.706 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -108.86 -41.17 1.47 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.554 ' HB3' ' N ' ' A' ' 9' ' ' GLY . 0.7 OUTLIER -77.34 84.17 3.77 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.251 -1.146 . . . . 0.0 109.48 -179.947 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.482 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER -72.44 83.31 1.08 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.441 -0.787 . . . . 0.0 109.556 179.982 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.482 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 14.2 t 70.23 5.3 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.383 -0.823 . . . . 0.0 109.769 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 51.6 -95.91 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.286 -0.884 . . . . 0.0 109.682 179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.408 ' N ' ' O ' ' A' ' 16' ' ' VAL . 2.2 mtt180 -158.35 -77.93 0.07 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.029 -1.044 . . . . 0.0 109.707 -179.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.421 ' CD2' ' O ' ' A' ' 72' ' ' SER . 22.4 m-85 -117.17 174.3 6.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.221 -0.924 . . . . 0.0 109.632 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.695 ' CB ' ' HB1' ' A' ' 71' ' ' ALA . 2.9 t80 -117.04 104.72 11.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.254 -0.903 . . . . 0.0 109.402 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.459 ' HA2' ' CD1' ' A' ' 55' ' ' ILE . . . -143.01 -57.94 0.03 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.491 -1.444 . . . . 0.0 109.491 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.437 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.6 mtp85 -128.75 17.2 6.32 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.307 -1.114 . . . . 0.0 109.24 179.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -48.16 106.63 0.63 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.337 -0.852 . . . . 0.0 109.776 -179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.503 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 37.0 Cg_endo -80.74 42.23 1.29 Allowed 'Trans proline' 0 C--N 1.311 -1.42 0 C-N-CA 122.609 2.206 . . . . 0.0 110.477 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.503 ' CD2' ' O ' ' A' ' 24' ' ' PRO . 5.7 m-85 -159.83 69.53 0.42 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.09 -1.007 . . . . 0.0 109.584 -179.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.518 ' CE1' ' HA ' ' A' ' 6' ' ' ALA . 0.1 OUTLIER -84.61 112.86 20.82 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.214 -0.929 . . . . 0.0 109.215 179.865 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -79.74 135.39 36.5 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.291 -0.88 . . . . 0.0 109.77 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 14.3 mm -108.25 138.47 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.209 -0.932 . . . . 0.0 109.323 179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.425 HG13 HG23 ' A' ' 36' ' ' ILE . 75.8 t -131.92 103.83 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.385 -0.822 . . . . 0.0 109.459 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -85.43 88.65 7.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.183 -0.948 . . . . 0.0 109.539 -179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -82.83 141.73 32.06 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.316 -0.865 . . . . 0.0 109.386 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 4.9 tptt -117.58 -72.08 0.71 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.127 -0.983 . . . . 0.0 109.463 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 23.3 mttm -110.58 58.84 0.61 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.206 -0.934 . . . . 0.0 109.395 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 65.0 13.5 57.47 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.424 -1.47 . . . . 0.0 109.424 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 36' ' ' ILE . 25.0 t30 -132.74 105.87 7.42 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.293 -1.122 . . . . 0.0 109.403 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.47 ' H ' HD12 ' A' ' 36' ' ' ILE . 3.3 mp -42.97 114.25 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.311 -0.868 . . . . 0.0 109.577 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -96.76 -9.52 28.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 109.492 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -159.62 119.23 2.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.27 -0.894 . . . . 0.0 109.513 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 2.6 p -120.83 102.89 8.67 Favored 'General case' 0 N--CA 1.487 1.408 0 O-C-N 121.229 -0.919 . . . . 0.0 108.906 179.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -121.7 -176.45 3.32 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.371 -0.831 . . . . 0.0 109.859 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.8 p -151.98 130.4 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.408 -0.808 . . . . 0.0 109.309 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.42 ' O ' HG13 ' A' ' 42' ' ' ILE . 12.2 pt -114.12 131.22 66.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.189 -0.944 . . . . 0.0 109.671 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -97.73 150.42 21.23 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.285 -0.884 . . . . 0.0 109.429 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.471 ' HB2' ' HB3' ' A' ' 24' ' ' PRO . 55.6 m-20 -66.88 152.92 95.15 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.319 -0.863 . . . . 0.0 109.404 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.34 -78.71 0.01 OUTLIER 'Trans proline' 0 C--N 1.309 -1.521 0 C-N-CA 122.624 2.216 . . . . 0.0 110.402 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -123.34 74.6 1.25 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.303 -0.873 . . . . 0.0 109.351 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -75.43 -14.79 60.47 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.175 -0.953 . . . . 0.0 109.602 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.402 ' O ' ' HB2' ' A' ' 49' ' ' ALA . 0.5 OUTLIER -118.23 66.06 0.76 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.191 -0.943 . . . . 0.0 109.503 -179.955 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.402 ' HB2' ' O ' ' A' ' 48' ' ' SER . . . -179.79 -52.44 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.156 -0.965 . . . . 0.0 109.495 179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -55.23 170.74 0.19 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.252 -0.905 . . . . 0.0 109.471 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -100.35 134.31 11.64 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 50.1 84.28 0.02 OUTLIER Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -136.16 -150.28 0.36 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.228 -1.16 . . . . 0.0 109.483 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.724 ' O ' HG22 ' A' ' 57' ' ' THR . . . 82.85 -81.2 1.75 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.514 -1.435 . . . . 0.0 109.514 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.459 ' CD1' ' HA2' ' A' ' 21' ' ' GLY . 7.1 mm -74.82 -7.32 9.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.268 -1.136 . . . . 0.0 109.516 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.33 -23.07 60.2 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.237 -0.914 . . . . 0.0 109.23 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.724 HG22 ' O ' ' A' ' 54' ' ' GLY . 6.1 t -57.47 -22.77 45.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.39 -0.819 . . . . 0.0 109.468 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.83 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -53.71 -50.0 66.88 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.306 -0.871 . . . . 0.0 109.624 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -46.41 -41.24 13.41 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.91 . . . . 0.0 109.625 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 50.4 mt -71.51 -39.97 71.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.237 -0.914 . . . . 0.0 109.703 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.83 HD12 ' HA ' ' A' ' 58' ' ' ALA . 63.4 mt -56.11 -32.82 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.226 -0.922 . . . . 0.0 109.473 -179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.498 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -76.67 -31.19 57.13 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.285 -0.884 . . . . 0.0 109.477 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 27.7 t30 -72.71 -14.38 61.55 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -0.876 . . . . 0.0 109.639 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -90.08 -1.22 57.92 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.206 -0.934 . . . . 0.0 109.649 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.52 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 87.4 -6.37 83.49 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.5 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 96.0 t -48.09 92.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -1.103 . . . . 0.0 109.662 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.52 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.6 OUTLIER -79.5 -2.09 40.54 Favored 'General case' 0 C--N 1.304 -1.389 0 O-C-N 121.371 -0.83 . . . . 0.0 108.813 179.38 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.853 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -134.79 129.52 34.7 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.322 -0.861 . . . . 0.0 109.373 179.739 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 23.4 t -130.46 96.84 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.163 -0.96 . . . . 0.0 109.613 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.509 HD13 HD21 ' A' ' 100' ' ' ASN . 7.0 mt -91.22 109.73 21.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.213 -0.929 . . . . 0.0 109.288 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.695 ' HB1' ' CB ' ' A' ' 20' ' ' PHE . . . -144.08 176.94 8.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.248 -0.908 . . . . 0.0 109.778 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.635 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 75.1 m -133.38 41.6 3.07 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.527 -0.733 . . . . 0.0 109.435 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.423 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.8 OUTLIER -53.64 143.12 39.91 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.307 -0.871 . . . . 0.0 109.459 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 35.8 Cg_endo -79.03 88.04 1.5 Allowed 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 122.639 2.226 . . . . 0.0 110.601 -179.835 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . 122.5 162.6 11.6 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.404 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.3 Cg_endo -78.84 7.88 4.05 Favored 'Trans proline' 0 C--N 1.31 -1.494 0 C-N-CA 122.75 2.3 . . . . 0.0 110.591 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.472 ' O ' ' HB3' ' A' ' 80' ' ' GLU . 1.5 m120 -55.25 -65.66 0.55 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.226 -0.921 . . . . 0.0 109.583 -179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . . . . . . . . . . . -59.8 -51.93 67.64 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.906 . . . . 0.0 109.675 -179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 12.8 m-30 -57.76 -15.97 9.76 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.223 -0.923 . . . . 0.0 109.754 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.472 ' HB3' ' O ' ' A' ' 77' ' ' ASN . 54.0 tt0 -72.82 -50.34 24.77 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.197 -0.939 . . . . 0.0 109.302 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 82' ' ' LEU . 2.4 t -71.3 -53.16 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 O-C-N 121.289 -0.882 . . . . 0.0 109.258 179.677 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.519 ' HB3' ' CG1' ' A' ' 89' ' ' ILE . 4.4 mm? -45.75 -30.09 1.51 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.267 -0.895 . . . . 0.0 109.14 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -77.06 -47.75 19.71 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.336 -0.853 . . . . 0.0 109.346 179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 -68.02 -8.63 39.18 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.244 -0.91 . . . . 0.0 109.59 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 3.6 mp -86.48 -48.4 8.43 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.22 -0.925 . . . . 0.0 109.539 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 116.35 11.1 9.96 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.498 HD11 ' HB2' ' A' ' 62' ' ' ALA . 1.6 mt -91.69 172.37 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.24 -1.153 . . . . 0.0 109.419 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.477 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 0.1 OUTLIER -90.35 114.66 26.8 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.269 -0.894 . . . . 0.0 109.669 -179.926 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.519 ' CG1' ' HB3' ' A' ' 82' ' ' LEU . 5.9 mt -82.77 150.37 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.294 -0.879 . . . . 0.0 108.939 179.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.566 ' CE2' ' HB3' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -139.68 148.17 42.01 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.228 -0.92 . . . . 0.0 109.625 -179.95 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -106.42 140.2 39.7 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.315 -0.866 . . . . 0.0 109.614 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.635 ' HB3' ' OG ' ' A' ' 72' ' ' SER . . . -110.32 88.04 2.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.202 -0.936 . . . . 0.0 109.677 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.92 -40.32 42.98 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.258 -0.901 . . . . 0.0 109.29 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 128.3 116.43 1.95 Allowed Glycine 0 N--CA 1.489 2.221 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -164.38 -67.3 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.198 -1.178 . . . . 0.0 109.471 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.472 ' O ' ' HB2' ' A' ' 100' ' ' ASN . 0.1 OUTLIER 171.71 157.21 0.09 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.244 -179.965 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.63 HG13 HG21 ' A' ' 5' ' ' ILE . 1.8 t -74.28 -48.07 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.278 -0.889 . . . . 0.0 109.651 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -50.93 -50.16 58.29 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.276 -0.89 . . . . 0.0 109.846 -179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 31.0 mm-40 -70.55 -35.58 73.18 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.224 -0.923 . . . . 0.0 109.893 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.55 ' OD1' HD11 ' A' ' 109' ' ' LEU . 7.4 t30 -56.23 -39.08 71.96 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.165 -0.96 . . . . 0.0 109.735 -179.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 75.7 mt -57.77 -62.92 1.45 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.233 -0.917 . . . . 0.0 109.558 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 5.7 ttpt -62.52 -15.11 48.77 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.212 -0.93 . . . . 0.0 109.575 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.469 HD12 ' HA ' ' A' ' 103' ' ' LEU . 0.9 OUTLIER -77.09 -33.55 56.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.224 -0.922 . . . . 0.0 109.799 -179.791 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.746 ' CD2' HD11 ' A' ' 3' ' ' ILE . 79.3 t80 -74.2 -24.78 59.4 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.163 -0.961 . . . . 0.0 109.765 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 61.3 m -72.24 -22.91 61.17 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.227 -0.92 . . . . 0.0 109.674 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 67.4 mt-10 -103.79 4.95 35.67 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.229 -0.919 . . . . 0.0 109.597 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 55.95 40.54 82.17 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 9.9 t-20 -79.96 -51.45 9.06 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.192 -1.181 . . . . 0.0 109.558 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.55 HD11 ' OD1' ' A' ' 100' ' ' ASN . 13.8 mt -56.34 176.8 0.08 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.212 -0.93 . . . . 0.0 109.497 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.425 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 8.7 pt-20 -109.65 148.4 31.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.286 -0.884 . . . . 0.0 109.42 179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.566 ' HB3' ' CE2' ' A' ' 90' ' ' TYR . 6.1 pt-20 -134.25 155.68 49.75 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.232 -0.917 . . . . 0.0 109.656 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 67.5 mt -135.36 143.44 36.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.321 -0.862 . . . . 0.0 109.047 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -139.76 -172.41 3.38 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.112 -0.992 . . . . 0.0 109.909 -179.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 29.1 t -156.94 95.23 2.2 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.441 -0.787 . . . . 0.0 109.19 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.64 152.64 29.6 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 122.533 2.156 . . . . 0.0 110.584 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -128.89 18.79 5.59 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 2.6 p -132.22 60.89 1.67 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.351 -1.088 . . . . 0.0 109.369 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -120.07 169.25 13.89 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.701 -1.36 . . . . 0.0 109.701 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 49.33 88.68 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.338 -1.095 . . . . 0.0 109.66 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -76.71 105.5 2.03 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.22 77.57 1.41 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.162 -1.199 . . . . 0.0 109.728 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -83.35 149.71 26.56 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.161 -0.962 . . . . 0.0 109.303 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.505 ' O ' ' CG ' ' A' ' 124' ' ' ARG . 1.2 mtt180 -90.08 106.93 18.81 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.215 -0.928 . . . . 0.0 109.668 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.505 ' CG ' ' O ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.508 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.476 ' HA ' ' HB2' ' A' ' 67' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.456 ' HD2' ' O ' ' A' ' 65' ' ' GLY . 0.5 OUTLIER -89.29 147.4 24.13 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.223 -0.923 . . . . 0.0 109.474 -179.926 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.531 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 5.3 mt -115.08 119.86 62.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.212 -0.93 . . . . 0.0 109.701 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.567 ' CB ' HD13 ' A' ' 28' ' ' ILE . . . -112.87 111.45 22.22 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.279 -0.888 . . . . 0.0 109.073 179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.74 HG23 ' CG2' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -98.41 126.19 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.228 -0.92 . . . . 0.0 109.8 -179.487 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.49 134.27 42.28 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.302 -0.874 . . . . 0.0 109.153 179.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.414 ' OG ' ' HG3' ' A' ' 27' ' ' MET . 0.0 OUTLIER -144.45 156.08 44.03 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.067 -1.02 . . . . 0.0 109.768 -179.814 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.42 -26.56 11.4 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.345 -0.847 . . . . 0.0 109.427 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -87.63 -105.62 0.9 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -148.73 -45.05 0.15 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.155 -1.203 . . . . 0.0 109.407 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' A' ' 11' ' ' ASP . 2.3 t70 -154.47 -55.29 0.1 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -0.895 . . . . 0.0 109.367 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.2 tt -105.62 -37.69 6.68 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.18 -0.95 . . . . 0.0 109.337 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -57.71 -26.47 57.5 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.443 ' OG ' HG22 ' A' ' 97' ' ' VAL . 54.4 p -76.92 80.14 3.48 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.271 -1.135 . . . . 0.0 109.439 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.531 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.3 OUTLIER -76.88 82.0 3.45 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.261 -0.899 . . . . 0.0 109.575 -179.88 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.531 HG23 ' C ' ' A' ' 15' ' ' GLU . 3.0 t 73.16 19.64 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.255 -0.903 . . . . 0.0 109.651 179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 44.36 -163.56 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.209 -0.932 . . . . 0.0 109.422 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -126.32 -32.71 2.67 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.257 -0.902 . . . . 0.0 109.508 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -150.12 -179.83 7.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.141 -0.974 . . . . 0.0 109.666 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.452 ' CG ' ' HB1' ' A' ' 71' ' ' ALA . 21.7 t80 -121.77 83.78 2.14 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.356 -0.84 . . . . 0.0 109.404 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 147.1 -18.64 1.56 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.442 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 1.6 mtp180 -110.55 -29.41 8.07 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.257 -1.143 . . . . 0.0 109.373 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -56.37 110.61 2.47 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.917 . . . . 0.0 109.399 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.5 46.65 2.31 Favored 'Trans proline' 0 C--N 1.312 -1.369 0 C-N-CA 122.692 2.261 . . . . 0.0 110.948 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.472 ' CE2' ' OE2' ' A' ' 43' ' ' GLU . 11.3 m-85 -158.51 70.01 0.51 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.99 -1.068 . . . . 0.0 109.417 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.499 ' CD1' ' HB2' ' A' ' 44' ' ' ASN . 46.1 m-85 -81.4 153.53 26.9 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.2 -0.937 . . . . 0.0 109.737 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . 0.45 ' O ' ' HA ' ' A' ' 4' ' ' ALA . 37.9 mtp -120.3 114.16 21.47 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.34 -0.85 . . . . 0.0 109.041 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.567 HD13 ' CB ' ' A' ' 4' ' ' ALA . 26.6 mm -105.46 120.48 56.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.158 -0.964 . . . . 0.0 109.797 -179.566 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.707 HG11 HD12 ' A' ' 36' ' ' ILE . 44.2 t -122.74 116.03 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.362 -0.836 . . . . 0.0 109.301 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -89.73 86.84 6.78 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.25 -0.906 . . . . 0.0 109.615 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.748 ' HE1' HG23 ' A' ' 105' ' ' THR . 1.2 ttp -83.29 125.07 31.22 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.179 -0.951 . . . . 0.0 109.328 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -87.99 -91.3 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.229 -0.919 . . . . 0.0 109.765 -179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.431 ' O ' ' C ' ' A' ' 34' ' ' GLY . 3.6 tmtm? -98.52 85.39 3.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.16 -0.962 . . . . 0.0 109.743 -179.679 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 43.07 33.99 1.95 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -144.4 104.11 4.04 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.139 -1.212 . . . . 0.0 109.504 -179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.707 HD12 HG11 ' A' ' 29' ' ' VAL . 3.9 tt -53.57 118.63 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.29 -0.881 . . . . 0.0 109.232 179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -127.75 26.2 5.91 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.227 -0.92 . . . . 0.0 109.662 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.462 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 1.0 OUTLIER 176.25 128.2 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.233 -0.917 . . . . 0.0 109.629 179.96 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.657 ' OG ' HD11 ' A' ' 36' ' ' ILE . 5.5 m -156.19 112.4 3.06 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.242 -0.911 . . . . 0.0 109.304 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -130.11 139.0 50.97 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.184 -0.947 . . . . 0.0 109.707 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 61.3 t -92.36 154.49 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.3 -0.875 . . . . 0.0 109.086 179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.0 tt -147.47 142.53 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.125 -0.984 . . . . 0.0 109.822 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.472 ' OE2' ' CE2' ' A' ' 25' ' ' TYR . 1.9 mt-10 -88.55 79.31 7.63 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.319 -0.863 . . . . 0.0 109.177 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.499 ' HB2' ' CD1' ' A' ' 26' ' ' PHE . 1.4 m-80 -44.83 147.19 1.16 Allowed Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.2 -0.937 . . . . 0.0 109.521 -179.774 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.08 -167.01 0.44 Allowed 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 122.595 2.196 . . . . 0.0 110.43 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER 68.7 7.29 6.01 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.249 -0.907 . . . . 0.0 109.579 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -73.57 -41.15 63.29 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.221 -0.925 . . . . 0.0 109.318 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -140.49 57.28 1.58 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.359 -0.838 . . . . 0.0 109.311 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -103.27 61.33 0.77 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.363 -0.835 . . . . 0.0 109.301 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.405 ' O ' ' O ' ' A' ' 51' ' ' GLY . 1.7 t 50.58 52.07 15.61 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.288 -0.883 . . . . 0.0 109.428 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.405 ' O ' ' O ' ' A' ' 50' ' ' SER . . . 62.54 142.66 0.01 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -169.9 -172.01 36.0 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -107.0 144.68 33.28 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.294 -1.121 . . . . 0.0 109.523 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -102.78 -6.73 46.01 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.4 mm -72.95 -19.56 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.26 -1.141 . . . . 0.0 109.672 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 3.7 mtt-85 -74.98 -16.61 60.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.141 -0.974 . . . . 0.0 109.486 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.666 ' HA ' HD12 ' A' ' 60' ' ' ILE . 53.3 m -67.94 -24.9 65.23 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.271 -0.893 . . . . 0.0 109.418 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -51.9 -56.05 16.46 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.32 -0.862 . . . . 0.0 109.651 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -51.04 -36.42 39.61 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.275 -0.891 . . . . 0.0 109.777 -179.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.666 HD12 ' HA ' ' A' ' 57' ' ' THR . 76.9 mt -63.82 -63.5 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.177 -0.952 . . . . 0.0 109.838 -179.595 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.77 HG23 HG21 ' A' ' 66' ' ' VAL . 10.5 mt -53.67 -24.46 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.231 -0.918 . . . . 0.0 109.935 -179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.596 ' CB ' HD11 ' A' ' 87' ' ' ILE . . . -65.28 -46.73 79.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.131 -0.981 . . . . 0.0 109.8 -179.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 9.2 m-20 -77.65 6.85 6.51 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.275 -0.89 . . . . 0.0 110.293 -179.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.644 ' HB3' HG23 ' A' ' 66' ' ' VAL . 0.7 OUTLIER -96.1 7.56 46.08 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 120.997 -1.064 . . . . 0.0 109.835 -179.859 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.456 ' O ' ' HD2' ' A' ' 2' ' ' LYS . . . 73.07 8.81 75.02 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.77 HG21 HG23 ' A' ' 61' ' ' ILE . 17.6 t -68.61 97.5 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.301 -1.117 . . . . 0.0 109.574 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.525 ' O ' ' CB ' ' A' ' 88' ' ' LYS . 13.4 tttt -79.11 -3.92 47.75 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.225 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.647 ' O ' HG12 ' A' ' 66' ' ' VAL . . . -138.79 131.38 28.95 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.319 -0.863 . . . . 0.0 109.002 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 10.6 t -128.84 109.2 18.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.061 -1.024 . . . . 0.0 109.791 -179.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.74 ' CG2' HG23 ' A' ' 5' ' ' ILE . 2.1 mp -89.51 95.09 5.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.133 -0.98 . . . . 0.0 109.137 179.674 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.452 ' HB1' ' CG ' ' A' ' 20' ' ' PHE . . . -126.67 171.92 10.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 109.573 -179.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 47.6 p -130.52 29.67 4.79 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.282 -0.886 . . . . 0.0 109.498 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -49.22 151.06 2.67 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.279 -0.888 . . . . 0.0 109.636 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.29 -72.48 0.01 OUTLIER 'Trans proline' 0 C--N 1.309 -1.528 0 C-N-CA 122.705 2.27 . . . . 0.0 110.467 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.419 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -68.26 145.5 44.5 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.419 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.8 Cg_endo -78.69 6.29 4.98 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.653 2.236 . . . . 0.0 110.473 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -53.94 -57.43 11.02 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.281 -0.887 . . . . 0.0 109.511 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.691 ' O ' HD12 ' A' ' 82' ' ' LEU . . . -57.6 -45.0 85.86 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.23 -0.919 . . . . 0.0 109.5 -179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 18.4 m-30 -56.59 -27.39 57.91 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.178 -0.951 . . . . 0.0 109.343 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -72.48 -36.85 68.55 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.307 -0.87 . . . . 0.0 109.465 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 41.6 t -69.19 -46.19 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.492 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.691 HD12 ' O ' ' A' ' 78' ' ' ALA . 3.1 mp -53.18 -37.09 61.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.219 -0.925 . . . . 0.0 109.615 -179.822 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 13.5 t-20 -61.67 -40.81 96.28 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.287 -0.883 . . . . 0.0 109.622 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -76.6 -20.75 56.43 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.173 -0.955 . . . . 0.0 109.555 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.562 ' HB3' HD12 ' A' ' 87' ' ' ILE . 0.3 OUTLIER -87.13 -14.82 40.21 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.265 -0.897 . . . . 0.0 109.522 -179.995 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 86.93 11.71 69.77 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.596 HD11 ' CB ' ' A' ' 62' ' ' ALA . 9.3 mt -87.51 145.5 7.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.202 -1.176 . . . . 0.0 109.587 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.525 ' CB ' ' O ' ' A' ' 67' ' ' LYS . 6.1 ttmm -80.05 116.75 20.35 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.124 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.671 HD12 ' HA ' ' A' ' 113' ' ' ARG . 3.3 mt -80.93 106.42 12.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.274 -0.891 . . . . 0.0 109.602 -179.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.571 ' CD2' ' O ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -103.18 142.35 34.31 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.333 -0.855 . . . . 0.0 109.158 179.825 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.467 ' O ' ' HB3' ' A' ' 110' ' ' GLU . 20.6 ttt180 -106.02 145.76 30.97 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.182 -0.949 . . . . 0.0 109.606 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.98 92.13 8.93 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.327 -0.858 . . . . 0.0 109.277 179.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 58.9 m -107.46 -16.41 14.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.255 -0.903 . . . . 0.0 109.691 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -66.05 -128.71 0.02 OUTLIER Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.483 ' O ' HG23 ' A' ' 16' ' ' VAL . 9.8 t -142.13 -32.98 0.5 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.319 -1.107 . . . . 0.0 109.927 179.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -133.54 151.83 51.8 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.138 -0.976 . . . . 0.0 109.356 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.443 HG22 ' OG ' ' A' ' 14' ' ' SER . 35.1 m -71.06 -34.29 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.25 -0.906 . . . . 0.0 109.7 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.37 -47.91 83.64 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.245 -0.91 . . . . 0.0 109.803 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -71.75 -42.78 66.83 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.271 -0.893 . . . . 0.0 109.942 -179.559 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 48.3 t-20 -52.91 -33.98 52.93 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.201 -0.937 . . . . 0.0 109.669 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.561 HD11 HD12 ' A' ' 36' ' ' ILE . 1.7 tt -57.12 -42.93 81.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.248 -0.907 . . . . 0.0 109.841 -179.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.49 ' N ' HD23 ' A' ' 101' ' ' LEU . 0.5 OUTLIER -74.48 -33.36 62.85 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.117 -0.989 . . . . 0.0 110.039 -179.487 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -62.3 -39.81 94.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.107 -0.996 . . . . 0.0 109.826 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.526 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 6.4 t80 -70.15 -30.02 67.07 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.18 -0.95 . . . . 0.0 109.813 -179.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.748 HG23 ' HE1' ' A' ' 31' ' ' MET . 0.2 OUTLIER -67.21 -29.86 69.64 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.128 -0.982 . . . . 0.0 109.935 -179.615 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 9.0 mm-40 -99.31 13.06 34.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.139 -0.976 . . . . 0.0 109.606 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 52.17 57.72 12.51 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.069 -1.612 . . . . 0.0 109.069 -179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -81.87 -54.86 5.0 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.368 -1.078 . . . . 0.0 109.781 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.541 HD23 ' H ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER 178.04 -152.03 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.093 -1.004 . . . . 0.0 109.742 -179.835 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.571 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 13.8 mt-10 60.29 25.17 14.61 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.375 -0.828 . . . . 0.0 109.459 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.592 ' C ' HD12 ' A' ' 112' ' ' ILE . 7.5 pt-20 -103.94 135.95 44.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.343 -0.848 . . . . 0.0 109.358 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.592 HD12 ' C ' ' A' ' 111' ' ' GLU . 3.2 mp -153.15 135.06 5.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.3 -0.875 . . . . 0.0 109.421 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.671 ' HA ' HD12 ' A' ' 89' ' ' ILE . 26.4 ttp180 -134.26 -45.47 0.77 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.224 -0.922 . . . . 0.0 109.346 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.409 ' O ' ' OG ' ' A' ' 114' ' ' SER . 0.5 OUTLIER -127.15 81.08 70.61 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.267 -0.896 . . . . 0.0 109.36 179.872 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.418 ' O ' ' C ' ' A' ' 116' ' ' GLY . 35.9 Cg_endo -77.93 -168.61 0.63 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.604 2.203 . . . . 0.0 110.356 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.418 ' C ' ' O ' ' A' ' 115' ' ' PRO . . . 44.59 79.7 0.06 OUTLIER Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -112.17 -66.39 1.09 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.252 -1.146 . . . . 0.0 109.346 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 134.42 81.27 0.15 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -142.44 76.48 1.54 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.231 -1.158 . . . . 0.0 109.431 -179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 127.22 165.39 11.9 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.41 ' O ' ' C ' ' A' ' 122' ' ' ARG . 3.6 ttt180 -129.5 101.63 6.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.233 -1.157 . . . . 0.0 109.495 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.41 ' C ' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -44.54 141.96 1.8 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.308 -0.87 . . . . 0.0 109.485 179.958 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.2 tpp180 -95.27 140.56 30.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.261 -0.899 . . . . 0.0 109.442 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 10.5 mmm180 . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 117.98 -1.009 . . . . 0.0 109.363 179.99 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.7 mmm . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.479 ' HD3' ' O ' ' A' ' 65' ' ' GLY . 1.2 mttm -120.65 136.72 54.75 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.324 -0.86 . . . . 0.0 109.552 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.497 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 5.4 mt -114.44 108.43 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.318 -0.864 . . . . 0.0 109.399 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.7 ' HB1' ' CZ ' ' A' ' 26' ' ' PHE . . . -112.37 127.6 56.06 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.25 -0.906 . . . . 0.0 109.306 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.928 HG21 HG12 ' A' ' 97' ' ' VAL . 27.9 mt -102.88 139.71 23.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.276 -0.89 . . . . 0.0 109.555 -179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.3 170.07 17.2 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.384 -0.823 . . . . 0.0 109.421 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.465 ' O ' ' HB3' ' A' ' 8' ' ' SER . 54.3 p 46.32 -141.38 0.39 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.259 -0.901 . . . . 0.0 109.333 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.9 ' HB2' HG11 ' A' ' 97' ' ' VAL . 42.4 t 63.61 51.81 2.41 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.119 -0.988 . . . . 0.0 109.415 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.537 ' N ' ' HB3' ' A' ' 14' ' ' SER . . . -50.87 106.23 0.25 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.481 ' HG1' ' H ' ' A' ' 11' ' ' ASP . 3.2 p 49.01 -90.65 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.343 -1.092 . . . . 0.0 109.89 179.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.517 ' N ' ' O ' ' A' ' 9' ' ' GLY . 1.0 OUTLIER 173.15 -150.61 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.198 -0.939 . . . . 0.0 109.446 -179.687 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.461 ' HB3' ' O ' ' A' ' 11' ' ' ASP . 12.9 tp 70.25 13.2 7.66 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.257 -0.902 . . . . 0.0 109.362 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 145.77 -23.66 1.8 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.537 ' HB3' ' N ' ' A' ' 9' ' ' GLY . 43.4 m -77.2 82.51 3.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.193 -1.18 . . . . 0.0 109.64 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.467 ' HA ' HG22 ' A' ' 97' ' ' VAL . 0.2 OUTLIER -72.75 -114.2 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.202 -0.936 . . . . 0.0 109.456 -179.826 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.747 HG22 HG13 ' A' ' 97' ' ' VAL . 5.0 t -115.47 23.47 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 120.738 -1.227 . . . . 0.0 109.679 -179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.433 ' HB2' ' HB2' ' A' ' 7' ' ' SER . 4.3 t 47.06 -150.26 0.11 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.178 -0.951 . . . . 0.0 109.345 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.55 12.95 1.53 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.192 -0.943 . . . . 0.0 109.595 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.466 ' CD1' ' O ' ' A' ' 19' ' ' PHE . 28.1 p90 -153.8 144.52 22.56 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.223 -0.923 . . . . 0.0 109.66 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -123.82 89.88 3.17 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.313 -0.867 . . . . 0.0 109.218 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -145.26 -73.35 0.02 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.73 21.68 16.26 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -1.172 . . . . 0.0 109.675 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -58.33 113.25 6.18 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.243 -0.911 . . . . 0.0 109.23 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.474 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 36.8 Cg_endo -80.74 54.34 5.19 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.571 2.181 . . . . 0.0 110.867 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.474 ' CD2' ' O ' ' A' ' 24' ' ' PRO . 31.4 m-85 -160.41 70.92 0.43 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.992 -1.068 . . . . 0.0 109.214 179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.7 ' CZ ' ' HB1' ' A' ' 4' ' ' ALA . 40.1 t80 -79.92 104.58 10.59 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.429 -0.794 . . . . 0.0 109.732 -179.718 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . 0.727 ' CG ' HG12 ' A' ' 41' ' ' VAL . 0.2 OUTLIER -82.84 125.03 30.87 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.29 -0.881 . . . . 0.0 109.21 179.694 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.436 ' O ' HG23 ' A' ' 28' ' ' ILE . 1.4 tp -119.99 114.75 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.154 -0.966 . . . . 0.0 109.586 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 3.1 t -118.91 144.25 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.224 -0.922 . . . . 0.0 109.408 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -117.63 136.18 53.48 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.261 -0.9 . . . . 0.0 109.445 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 1.8 mtt -119.86 132.18 55.49 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.209 -0.932 . . . . 0.0 109.545 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 13.4 mmtt -81.99 -79.76 0.17 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.308 -0.87 . . . . 0.0 109.299 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -126.16 86.53 2.54 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.3 -0.875 . . . . 0.0 109.174 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 48.87 34.12 14.71 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.413 ' O ' ' C ' ' A' ' 36' ' ' ILE . 0.6 OUTLIER -149.12 100.56 3.06 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.345 -1.091 . . . . 0.0 109.461 -179.859 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.413 ' C ' ' O ' ' A' ' 35' ' ' ASN . 4.3 tt -45.2 134.27 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.234 -0.916 . . . . 0.0 109.35 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.407 ' O ' ' HB2' ' A' ' 38' ' ' SER . 0.5 OUTLIER -145.65 20.11 1.49 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.303 -0.873 . . . . 0.0 109.497 -179.959 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.407 ' HB2' ' O ' ' A' ' 37' ' ' GLU . 5.1 t -179.21 129.66 0.1 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.266 -0.896 . . . . 0.0 109.471 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 96.0 p -151.2 115.3 5.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.284 -0.885 . . . . 0.0 109.337 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -132.09 132.26 43.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.276 -0.89 . . . . 0.0 109.629 -179.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.727 HG12 ' CG ' ' A' ' 27' ' ' MET . 27.7 m -97.13 137.9 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.31 -0.869 . . . . 0.0 109.328 179.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 58.7 mt -123.79 145.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.257 -0.902 . . . . 0.0 109.558 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.442 ' HG2' ' CE1' ' A' ' 25' ' ' TYR . 2.8 mp0 -115.09 148.31 39.1 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.283 -0.886 . . . . 0.0 109.581 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 13.8 m-20 -134.82 79.99 50.67 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.273 -0.892 . . . . 0.0 109.314 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.494 ' O ' ' CB ' ' A' ' 46' ' ' SER . 35.5 Cg_endo -77.8 123.2 6.21 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 122.657 2.238 . . . . 0.0 110.512 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' A' ' 45' ' ' PRO . 0.1 OUTLIER 74.6 36.67 0.59 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.897 . . . . 0.0 109.47 179.921 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -54.49 -62.82 1.41 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.293 -0.879 . . . . 0.0 109.492 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.3 p -98.34 75.17 2.23 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.241 -0.912 . . . . 0.0 109.557 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -85.25 -21.86 28.87 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.248 -0.907 . . . . 0.0 109.398 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.1 m -100.91 58.93 0.91 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.28 -0.887 . . . . 0.0 109.417 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 116.72 162.2 12.71 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -79.01 157.98 43.87 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -140.5 -86.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.277 -1.131 . . . . 0.0 109.302 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 81.16 -95.79 1.68 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.628 HD12 ' HB2' ' A' ' 78' ' ' ALA . 34.2 mm -73.62 -16.46 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.253 -1.145 . . . . 0.0 109.825 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.18 -22.63 66.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.261 -0.899 . . . . 0.0 109.681 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 61.2 m -63.52 -21.58 66.41 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.241 -0.912 . . . . 0.0 109.673 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.412 ' O ' ' C ' ' A' ' 59' ' ' GLN . . . -52.99 -47.93 67.87 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.233 -0.917 . . . . 0.0 109.508 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.412 ' C ' ' O ' ' A' ' 58' ' ' ALA . 0.0 OUTLIER -44.09 -43.39 6.85 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.421 179.989 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 20.9 mm -73.15 -36.5 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.173 -0.954 . . . . 0.0 109.167 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 16.8 mm -50.68 -36.49 14.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 O-C-N 121.354 -0.842 . . . . 0.0 109.235 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.472 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -75.02 -33.39 61.78 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.277 -0.889 . . . . 0.0 109.686 -179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -61.5 -18.22 58.12 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.259 -0.9 . . . . 0.0 109.767 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.477 ' HB3' ' CG2' ' A' ' 66' ' ' VAL . 0.4 OUTLIER -90.68 27.36 1.78 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.082 -1.011 . . . . 0.0 109.653 -179.86 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.479 ' O ' ' HD3' ' A' ' 2' ' ' LYS . . . 43.96 40.47 5.56 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.493 HG12 ' O ' ' A' ' 68' ' ' ALA . 2.9 t -86.25 96.21 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.268 -1.136 . . . . 0.0 109.68 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 4.6 tptt -78.95 -11.32 60.0 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 179.046 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.497 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -136.58 125.29 23.86 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.444 -0.785 . . . . 0.0 108.964 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.426 ' O ' ' HB2' ' A' ' 90' ' ' TYR . 67.1 t -124.39 119.84 57.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.049 -1.032 . . . . 0.0 109.961 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.455 ' CD1' ' CG2' ' A' ' 3' ' ' ILE . 1.9 mp -102.1 114.19 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.359 -0.838 . . . . 0.0 108.98 179.606 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -151.87 172.87 15.53 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.214 -0.929 . . . . 0.0 109.865 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 11.9 p -135.5 55.69 1.87 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.378 -0.826 . . . . 0.0 109.245 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -55.53 152.82 16.5 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.295 -0.878 . . . . 0.0 109.645 -179.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.67 -13.65 14.55 Favored 'Trans proline' 0 C--N 1.31 -1.472 0 C-N-CA 122.757 2.305 . . . . 0.0 110.531 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -139.8 161.66 26.26 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.7 -5.67 14.86 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.698 2.265 . . . . 0.0 110.415 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 16.9 t30 -57.91 -33.25 68.57 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.262 -0.899 . . . . 0.0 109.649 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.628 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -71.94 -60.43 2.24 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.251 -0.906 . . . . 0.0 109.437 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.46 ' CD1' ' N ' ' A' ' 79' ' ' PHE . 3.5 m-85 -51.7 -22.09 3.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.231 -0.918 . . . . 0.0 109.115 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 13.9 tt0 -63.91 -46.95 82.54 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.283 -0.885 . . . . 0.0 109.265 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.4 ' O ' ' HB2' ' A' ' 85' ' ' LEU . 2.5 t -69.45 -43.66 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.246 -0.909 . . . . 0.0 109.194 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 1.8 mt -63.36 -21.62 66.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.328 -0.858 . . . . 0.0 109.516 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -77.1 -61.35 2.01 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.258 -0.901 . . . . 0.0 109.603 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -58.92 -21.56 58.1 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.22 -0.925 . . . . 0.0 109.667 -179.774 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.587 ' HB3' HD12 ' A' ' 87' ' ' ILE . 0.1 OUTLIER -73.14 -37.43 66.61 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.215 -0.928 . . . . 0.0 109.637 -179.9 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 108.77 21.83 7.29 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.587 HD12 ' HB3' ' A' ' 85' ' ' LEU . 5.5 mt -103.94 150.3 7.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -1.165 . . . . 0.0 109.51 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 8.2 mttt -80.03 125.84 30.29 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.233 -0.917 . . . . 0.0 109.361 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 3.3 mp -90.31 141.06 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.161 -0.962 . . . . 0.0 109.543 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.597 ' CE1' ' HB3' ' A' ' 111' ' ' GLU . 2.2 m-85 -127.99 127.35 43.08 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.211 -0.931 . . . . 0.0 109.529 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 73.5 mtt180 -87.46 122.77 31.61 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.465 -179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -89.67 122.83 33.16 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.236 -0.915 . . . . 0.0 109.471 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -64.95 -40.0 94.35 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.363 -0.836 . . . . 0.0 109.558 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 116.76 52.47 0.35 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 30.8 m -114.37 -82.72 0.61 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -1.119 . . . . 0.0 109.351 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -157.56 128.61 6.64 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.396 -0.815 . . . . 0.0 109.357 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.928 HG12 HG21 ' A' ' 5' ' ' ILE . 0.2 OUTLIER -51.12 -23.27 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.221 -0.924 . . . . 0.0 109.535 -179.943 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.82 -49.05 69.63 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.195 -0.941 . . . . 0.0 109.317 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.594 ' HG2' HD12 ' A' ' 103' ' ' LEU . 21.4 tt0 -70.88 -28.14 64.34 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.304 -0.873 . . . . 0.0 109.311 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -63.93 -49.46 72.52 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.322 -0.862 . . . . 0.0 109.42 179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 37.7 tp -57.56 -57.58 12.08 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.301 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 1.3 tmtt? -56.92 -25.62 57.7 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.135 -0.978 . . . . 0.0 109.257 179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.594 HD12 ' HG2' ' A' ' 99' ' ' GLU . 0.2 OUTLIER -71.14 -37.11 72.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.23 -0.919 . . . . 0.0 109.36 179.861 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -65.57 -22.99 66.75 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.198 -0.939 . . . . 0.0 109.175 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -57.34 -29.76 64.25 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.412 -0.805 . . . . 0.0 109.31 179.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 48.2 mm-40 -112.46 -2.69 14.63 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -0.881 . . . . 0.0 109.603 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 61.23 39.46 97.22 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . 0.499 ' HB3' HD23 ' A' ' 103' ' ' LEU . 24.4 t-20 -93.97 -17.92 22.44 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.103 -1.233 . . . . 0.0 109.395 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.458 ' HA ' HD23 ' A' ' 109' ' ' LEU . 5.4 mt -55.67 -168.44 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.24 -0.913 . . . . 0.0 109.334 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 90' ' ' TYR . 1.2 tt0 -103.42 106.91 17.55 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.256 -0.903 . . . . 0.0 109.303 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.597 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 4.1 pt-20 -101.7 156.69 17.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.264 -0.898 . . . . 0.0 109.764 -179.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.401 HG21 HD13 ' A' ' 112' ' ' ILE . 2.9 mt -142.8 126.11 14.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.275 -0.89 . . . . 0.0 109.314 179.768 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -147.85 93.61 2.22 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.293 -0.879 . . . . 0.0 109.441 -179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 1.1 p -104.13 155.3 37.36 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.204 -0.935 . . . . 0.0 109.565 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.17 -169.79 0.84 Allowed 'Trans proline' 0 C--N 1.309 -1.545 0 C-N-CA 122.671 2.247 . . . . 0.0 110.56 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' A' ' 117' ' ' SER . . . -89.63 140.78 15.78 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 179.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.465 ' O ' ' OG ' ' A' ' 117' ' ' SER . 0.0 OUTLIER 49.64 97.45 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.26 -1.141 . . . . 0.0 109.353 -179.957 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 164.89 43.0 0.02 OUTLIER Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -138.2 142.72 40.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.187 -1.184 . . . . 0.0 109.355 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 139.54 146.02 4.82 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 23.7 mtt180 -96.58 -47.34 5.97 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.281 -1.129 . . . . 0.0 109.513 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -91.32 142.11 28.05 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.275 -0.89 . . . . 0.0 109.359 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.64 -64.35 0.29 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.142 -0.974 . . . . 0.0 109.571 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.103 -0.951 . . . . 0.0 109.547 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.9 mmm . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.271 0.557 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.508 ' HB3' HG12 ' A' ' 66' ' ' VAL . 0.0 OUTLIER -154.03 160.05 41.85 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.289 -0.882 . . . . 0.0 109.118 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.583 HG12 ' CE2' ' A' ' 104' ' ' PHE . 6.4 mt -117.4 121.12 66.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.266 -0.896 . . . . 0.0 109.901 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.671 ' HB2' HG11 ' A' ' 66' ' ' VAL . . . -113.09 102.97 10.89 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.373 -0.83 . . . . 0.0 109.119 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -94.81 118.64 41.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -0.924 . . . . 0.0 109.742 -179.553 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.37 142.3 41.21 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.234 -0.916 . . . . 0.0 109.068 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.513 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 3.8 p -161.72 -159.92 0.66 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.119 -0.988 . . . . 0.0 109.518 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 6.9 m -149.06 57.09 1.02 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.287 -0.883 . . . . 0.0 109.537 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 167.08 164.5 22.85 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.435 ' O ' ' HB3' ' A' ' 11' ' ' ASP . 0.0 OUTLIER -85.02 -32.62 22.82 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.322 -1.105 . . . . 0.0 109.472 179.981 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 11' ' ' ASP . 18.7 p-10 171.84 172.16 0.09 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.229 -0.919 . . . . 0.0 109.374 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.515 ' HA ' HD12 ' A' ' 12' ' ' LEU . 8.1 tp 45.35 32.77 1.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.305 -0.872 . . . . 0.0 109.191 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -175.47 -32.88 0.04 OUTLIER Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 1.5 p -65.55 86.34 0.08 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.435 -1.038 . . . . 0.0 109.304 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.503 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 14.4 mt-10 -77.65 6.98 6.25 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.478 -0.764 . . . . 0.0 110.153 -179.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.503 ' HB ' ' O ' ' A' ' 15' ' ' GLU . 15.1 t 70.62 65.6 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.2 -0.937 . . . . 0.0 109.615 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.413 ' C ' ' O ' ' A' ' 16' ' ' VAL . 3.9 m -44.64 122.83 3.32 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.328 -0.858 . . . . 0.0 109.233 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.452 ' HG2' ' HB2' ' A' ' 72' ' ' SER . 1.4 ttm-85 -61.72 -18.7 60.76 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.25 -0.906 . . . . 0.0 109.721 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.492 ' CE2' ' HG3' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -84.91 108.16 17.41 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.12 -0.987 . . . . 0.0 109.63 -179.905 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.435 ' CB ' ' HB1' ' A' ' 71' ' ' ALA . 21.8 t80 -106.43 125.37 50.91 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.263 -0.898 . . . . 0.0 109.354 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.1 -36.6 0.76 Allowed Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.439 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 1.1 mpt_? -118.62 -22.27 7.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.343 -1.093 . . . . 0.0 109.256 179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.513 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -49.15 106.91 0.68 Allowed Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.304 -0.872 . . . . 0.0 109.436 179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.3 Cg_endo -79.95 62.56 8.55 Favored 'Trans proline' 0 C--N 1.313 -1.304 0 C-N-CA 122.561 2.174 . . . . 0.0 110.822 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.449 ' CE1' ' HB3' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -160.52 69.58 0.38 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.008 -1.058 . . . . 0.0 109.395 179.692 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -80.46 121.1 25.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.27 -0.894 . . . . 0.0 109.549 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . 0.434 ' O ' ' HA ' ' A' ' 4' ' ' ALA . 2.1 mmt -94.46 110.6 22.38 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.226 -0.921 . . . . 0.0 109.266 179.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.9 mm -104.02 117.99 50.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.904 . . . . 0.0 109.472 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.912 HG21 HD11 ' A' ' 101' ' ' LEU . 13.4 m -138.04 147.59 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.209 -0.932 . . . . 0.0 109.833 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -127.26 143.26 51.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 108.899 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.2 mtt -113.81 152.03 31.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.1 -1.0 . . . . 0.0 109.938 -179.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.35 -46.37 7.38 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.369 -0.832 . . . . 0.0 109.262 179.775 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -152.64 47.48 0.73 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.367 -0.833 . . . . 0.0 109.222 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.567 ' O ' HG23 ' A' ' 105' ' ' THR . . . 92.22 -1.43 73.38 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.423 ' O ' ' C ' ' A' ' 36' ' ' ILE . 5.6 p-10 -116.56 92.89 4.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.204 -1.174 . . . . 0.0 109.362 179.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.794 HD13 HD21 ' A' ' 101' ' ' LEU . 1.6 tt -43.95 118.61 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.261 -0.899 . . . . 0.0 109.497 -179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.46 ' O ' ' OE1' ' A' ' 37' ' ' GLU . 0.2 OUTLIER -123.08 20.78 9.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.329 -0.857 . . . . 0.0 109.441 179.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.413 ' O ' ' OG ' ' A' ' 38' ' ' SER . 12.0 p -170.82 107.46 0.29 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.325 -0.859 . . . . 0.0 109.263 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.761 ' HA ' HG12 ' A' ' 29' ' ' VAL . 5.8 p -135.35 105.72 6.38 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.228 -0.92 . . . . 0.0 109.914 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -109.18 143.8 38.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.389 -0.819 . . . . 0.0 109.268 179.598 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.413 HG13 ' SD ' ' A' ' 27' ' ' MET . 2.2 t -110.99 124.03 67.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.215 -0.928 . . . . 0.0 109.755 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 11.1 mt -121.57 119.43 58.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.262 -0.899 . . . . 0.0 109.268 179.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.449 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 4.1 pm0 -93.28 126.08 38.21 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.254 -0.904 . . . . 0.0 109.564 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.672 ' HB3' ' HB2' ' A' ' 47' ' ' ALA . 2.5 t-20 -55.91 115.82 10.65 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.317 -0.864 . . . . 0.0 109.548 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -78.05 -37.88 0.73 Allowed 'Trans proline' 0 C--N 1.311 -1.44 0 C-N-CA 122.458 2.105 . . . . 0.0 110.495 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 8.2 p -74.45 -11.98 60.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.268 -0.895 . . . . 0.0 109.536 -179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.672 ' HB2' ' HB3' ' A' ' 44' ' ' ASN . . . -46.06 -40.94 11.47 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 109.402 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.455 ' O ' ' HB2' ' A' ' 49' ' ' ALA . 0.6 OUTLIER -115.83 92.11 3.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.261 -0.899 . . . . 0.0 109.439 179.919 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.455 ' HB2' ' O ' ' A' ' 48' ' ' SER . . . 176.81 -57.84 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.315 -0.865 . . . . 0.0 109.37 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.0 t -115.01 88.52 2.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.28 -0.887 . . . . 0.0 109.333 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.79 173.39 41.52 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 132.52 -53.14 0.81 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -136.34 -165.9 1.8 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.291 -1.123 . . . . 0.0 109.274 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.409 ' O ' HG22 ' A' ' 57' ' ' THR . . . -175.77 -35.07 0.04 OUTLIER Glycine 0 N--CA 1.49 2.288 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.719 HD12 ' HB2' ' A' ' 78' ' ' ALA . 39.8 mm -76.72 0.03 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.136 -1.214 . . . . 0.0 109.85 -179.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.08 -10.96 59.83 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.192 -0.943 . . . . 0.0 109.558 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.439 ' O ' HG13 ' A' ' 61' ' ' ILE . 8.8 t -77.32 -25.86 51.59 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.257 -0.902 . . . . 0.0 109.667 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -48.77 -39.97 27.07 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.286 -0.884 . . . . 0.0 109.492 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 -60.4 -58.47 8.38 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.274 -0.891 . . . . 0.0 109.608 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.1 mt -53.82 -25.48 12.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.33 -0.856 . . . . 0.0 109.589 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.481 HG22 HG21 ' A' ' 66' ' ' VAL . 46.3 mt -72.96 -39.66 58.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.243 -0.911 . . . . 0.0 109.454 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.17 -30.65 70.67 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 109.552 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -67.93 -9.08 42.26 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.294 -0.878 . . . . 0.0 109.614 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 28.8 t-20 -85.9 -24.93 26.43 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.191 -0.943 . . . . 0.0 109.537 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.523 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 114.55 -26.0 9.91 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.671 HG11 ' HB2' ' A' ' 4' ' ' ALA . 4.6 m -43.44 94.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.271 -1.135 . . . . 0.0 109.559 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.523 ' N ' ' O ' ' A' ' 65' ' ' GLY . 7.0 mmtp -79.36 -4.27 50.16 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.357 -0.84 . . . . 0.0 108.758 179.291 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -122.82 129.33 51.55 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.385 -0.822 . . . . 0.0 109.274 179.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.639 HG21 ' CD2' ' A' ' 82' ' ' LEU . 97.8 t -123.45 107.83 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.111 -0.993 . . . . 0.0 109.544 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 53.1 mt -91.99 115.52 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.226 -0.921 . . . . 0.0 109.36 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.435 ' HB1' ' CB ' ' A' ' 20' ' ' PHE . . . -164.84 176.77 8.44 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.217 -0.927 . . . . 0.0 109.913 -179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.601 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 12.5 m -140.84 59.07 1.54 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.508 -0.745 . . . . 0.0 109.176 179.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.487 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 11.6 p -49.71 152.15 2.69 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.389 -0.819 . . . . 0.0 109.791 -179.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.492 ' HG3' ' CE2' ' A' ' 19' ' ' PHE . 35.1 Cg_endo -78.27 -22.65 9.51 Favored 'Trans proline' 0 C--N 1.31 -1.497 0 C-N-CA 122.631 2.221 . . . . 0.0 110.17 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -134.95 164.15 24.76 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -80.53 27.62 0.55 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 C-N-CA 122.771 2.314 . . . . 0.0 111.265 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.3 t-20 -74.73 -68.86 0.5 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.88 -1.137 . . . . 0.0 109.588 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.778 ' O ' HD12 ' A' ' 82' ' ' LEU . . . -62.03 -40.53 96.03 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.252 -0.905 . . . . 0.0 109.714 -179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.487 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 4.3 m-85 -52.95 -32.46 46.03 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.639 -179.879 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -75.61 -38.46 59.0 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.26 -0.9 . . . . 0.0 109.65 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 48.8 t -61.33 -53.46 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.307 -0.871 . . . . 0.0 109.743 -179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.778 HD12 ' O ' ' A' ' 78' ' ' ALA . 3.2 mp -59.06 -18.7 37.38 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.274 -0.891 . . . . 0.0 109.814 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -76.47 -48.42 19.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.18 -0.95 . . . . 0.0 109.695 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -64.38 -35.44 80.9 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.143 -0.973 . . . . 0.0 109.563 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.535 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 0.1 OUTLIER -68.17 -16.21 63.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.282 -0.886 . . . . 0.0 109.491 -179.919 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 81.59 24.68 55.72 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.538 HG22 ' N ' ' A' ' 88' ' ' LYS . 5.6 mt -87.47 161.5 2.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.252 -1.146 . . . . 0.0 109.558 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.538 ' N ' HG22 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -94.5 112.13 23.9 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 109.317 179.858 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.563 HG22 ' N ' ' A' ' 90' ' ' TYR . 14.1 mt -82.03 168.14 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.221 -0.924 . . . . 0.0 109.67 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.593 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 1.2 m-85 -153.09 129.98 10.97 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.304 -0.873 . . . . 0.0 109.246 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.511 ' NH1' ' HA ' ' A' ' 93' ' ' THR . 0.7 OUTLIER -80.12 135.81 36.39 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 109.447 -179.966 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.601 ' HB3' ' OG ' ' A' ' 72' ' ' SER . . . -86.64 149.79 24.66 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.216 -0.928 . . . . 0.0 109.627 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.511 ' HA ' ' NH1' ' A' ' 91' ' ' ARG . 73.4 p -86.0 -26.51 25.38 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.278 -0.889 . . . . 0.0 109.544 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.83 66.85 1.51 Allowed Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.19 -67.71 0.36 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.256 -1.143 . . . . 0.0 109.466 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -171.56 132.95 0.77 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.304 -0.872 . . . . 0.0 109.33 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.466 HG11 ' HB3' ' A' ' 7' ' ' SER . 16.8 m -54.86 -19.76 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.168 -0.958 . . . . 0.0 109.575 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -68.27 -52.57 32.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.762 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -69.78 -39.19 76.79 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.146 -0.971 . . . . 0.0 109.498 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.443 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 5.1 m-20 -59.28 -36.73 76.09 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.163 -0.96 . . . . 0.0 109.259 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.912 HD11 HG21 ' A' ' 29' ' ' VAL . 11.0 tp -59.22 -50.93 72.15 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.287 -0.883 . . . . 0.0 109.308 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -70.12 -15.76 63.01 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.371 -0.831 . . . . 0.0 109.232 179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.542 HD22 ' HG ' ' A' ' 109' ' ' LEU . 0.2 OUTLIER -72.6 -45.74 57.6 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.359 -0.838 . . . . 0.0 109.55 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.583 ' CE2' HG12 ' A' ' 3' ' ' ILE . 6.4 t80 -63.53 -17.23 62.58 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.315 -0.865 . . . . 0.0 109.758 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.567 HG23 ' O ' ' A' ' 34' ' ' GLY . 19.2 m -69.2 -33.47 73.39 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 109.572 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -95.57 -14.72 23.35 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.199 -0.938 . . . . 0.0 109.527 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 71.17 45.53 48.82 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . 0.415 ' HB3' HD23 ' A' ' 103' ' ' LEU . 10.1 t-20 -97.21 -29.31 13.65 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.289 -1.124 . . . . 0.0 109.544 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.542 ' HG ' HD22 ' A' ' 103' ' ' LEU . 0.6 OUTLIER -57.11 155.89 7.86 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 109.342 179.91 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.488 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 5.3 pt-20 -96.06 144.88 25.94 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.215 -0.928 . . . . 0.0 109.528 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.593 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 6.1 pm0 -114.61 165.87 12.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.227 -0.92 . . . . 0.0 109.501 179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.516 ' O ' HD12 ' A' ' 89' ' ' ILE . 83.0 mt -136.4 120.21 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.261 -0.899 . . . . 0.0 109.254 179.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -113.96 -21.69 10.47 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.339 -0.851 . . . . 0.0 109.332 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.416 ' HB2' ' HD2' ' A' ' 115' ' ' PRO . 68.3 p -139.74 157.98 68.81 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.237 -0.914 . . . . 0.0 109.554 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.416 ' HD2' ' HB2' ' A' ' 114' ' ' SER . 36.4 Cg_endo -78.68 178.72 7.23 Favored 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.585 2.19 . . . . 0.0 110.438 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 118.46 -179.68 16.97 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -170.37 -173.09 1.38 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.266 -1.138 . . . . 0.0 109.545 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -89.77 146.02 18.6 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 2.7 ttm-85 -53.57 145.63 14.66 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.235 -1.156 . . . . 0.0 109.365 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 123.39 175.05 14.38 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.471 ' HG2' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -118.02 138.39 52.24 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.159 -1.201 . . . . 0.0 109.676 -179.882 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.494 ' NE ' ' HA ' ' A' ' 122' ' ' ARG . 0.2 OUTLIER -117.99 105.12 11.56 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.314 -0.867 . . . . 0.0 109.181 179.818 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.24 -19.87 11.12 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.267 -0.896 . . . . 0.0 109.655 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 118.01 -0.995 . . . . 0.0 109.494 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.4 ttm . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.414 ' CG ' ' HG3' ' A' ' 30' ' ' GLU . 2.1 mppt? -114.61 164.01 14.62 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.187 -0.945 . . . . 0.0 109.594 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.479 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 11.0 mt -131.68 135.72 58.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.291 -0.881 . . . . 0.0 109.655 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.584 ' CB ' HG21 ' A' ' 66' ' ' VAL . . . -123.48 129.96 52.0 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.817 -0.808 . . . . 0.0 108.817 179.57 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 1.112 HG21 HG23 ' A' ' 97' ' ' VAL . 6.3 mt -111.1 120.79 62.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.179 -0.951 . . . . 0.0 109.881 -179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.39 165.19 25.53 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.277 -0.889 . . . . 0.0 109.36 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.518 ' O ' ' CB ' ' A' ' 8' ' ' SER . 0.8 OUTLIER 70.22 -144.67 0.08 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.227 -0.921 . . . . 0.0 109.485 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.518 ' CB ' ' O ' ' A' ' 7' ' ' SER . 0.2 OUTLIER 77.02 3.35 3.31 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.139 -0.976 . . . . 0.0 109.554 -179.908 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.471 ' O ' ' HB3' ' A' ' 25' ' ' TYR . . . 46.47 -113.6 1.18 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.87 -5.85 7.41 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.225 -1.162 . . . . 0.0 109.481 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -141.18 -142.15 0.14 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.481 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.4 mt -105.11 -18.28 14.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.108 -0.995 . . . . 0.0 109.745 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -47.76 -40.32 18.22 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.596 -1.402 . . . . 0.0 109.596 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.406 ' O ' ' O ' ' A' ' 15' ' ' GLU . 3.6 m -75.54 81.42 2.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.283 -1.128 . . . . 0.0 109.636 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.475 ' O ' ' HB ' ' A' ' 97' ' ' VAL . 0.1 OUTLIER -48.17 -93.18 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.261 -0.899 . . . . 0.0 109.552 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 18.9 m -131.11 52.95 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.062 -1.024 . . . . 0.0 109.718 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.512 ' O ' ' CB ' ' A' ' 18' ' ' ARG . 1.3 p -99.07 136.61 38.79 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.174 -0.954 . . . . 0.0 109.255 179.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.512 ' CB ' ' O ' ' A' ' 17' ' ' SER . 6.3 mtt-85 75.45 78.28 0.1 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.222 -0.924 . . . . 0.0 108.916 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.432 ' O ' ' C ' ' A' ' 20' ' ' PHE . 0.5 OUTLIER -79.65 -177.52 5.9 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.335 -0.853 . . . . 0.0 109.678 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.628 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 2.6 t80 -41.24 137.84 1.31 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.485 -0.76 . . . . 0.0 109.82 -179.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 151.14 -64.12 0.38 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.471 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 2.0 tpp180 -155.04 18.87 0.43 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.147 -1.208 . . . . 0.0 109.8 -179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.79 113.43 18.67 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.276 -0.89 . . . . 0.0 109.661 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.583 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.7 Cg_endo -82.08 53.9 4.77 Favored 'Trans proline' 0 C--N 1.311 -1.399 0 C-N-CA 122.61 2.207 . . . . 0.0 110.462 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.583 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 98.6 m-85 -159.8 70.82 0.46 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.163 -0.96 . . . . 0.0 109.503 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.48 ' CE1' ' OD1' ' A' ' 44' ' ' ASN . 23.7 m-85 -83.61 119.03 24.24 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.204 -0.935 . . . . 0.0 109.536 179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -93.56 122.45 36.01 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.234 -0.916 . . . . 0.0 109.67 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.515 HG12 HD12 ' A' ' 42' ' ' ILE . 15.1 mm -99.17 122.15 50.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.314 -0.866 . . . . 0.0 109.176 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 54.7 t -127.97 137.74 56.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.099 -1.0 . . . . 0.0 109.651 -179.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.444 ' HB3' ' OG ' ' A' ' 38' ' ' SER . 1.7 tt0 -124.61 137.82 54.36 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.3 -0.875 . . . . 0.0 109.379 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.411 ' HG3' ' HA ' ' A' ' 36' ' ' ILE . 7.9 ttm -116.06 145.18 43.22 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.189 -0.944 . . . . 0.0 109.647 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.61 -63.48 1.29 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 109.332 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.66 65.29 0.87 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.287 -0.883 . . . . 0.0 109.384 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.25 17.03 70.19 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 36' ' ' ILE . 3.0 t-20 -144.38 103.17 3.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.222 -1.164 . . . . 0.0 109.451 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.411 ' HA ' ' HG3' ' A' ' 31' ' ' MET . 2.6 mp -44.69 137.49 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.277 -0.89 . . . . 0.0 109.461 179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -144.01 16.36 1.74 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.193 -0.942 . . . . 0.0 109.48 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.444 ' OG ' ' HB3' ' A' ' 30' ' ' GLU . 0.2 OUTLIER -166.68 122.86 1.21 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.259 -0.901 . . . . 0.0 109.441 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.6 m -142.9 110.16 5.68 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.196 -0.94 . . . . 0.0 109.6 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.91 153.98 46.97 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.31 -0.869 . . . . 0.0 109.2 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 8.0 p -113.76 144.34 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.204 -0.935 . . . . 0.0 109.675 -179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.515 HD12 HG12 ' A' ' 28' ' ' ILE . 23.5 mt -136.42 132.7 49.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.341 -0.849 . . . . 0.0 109.37 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.443 ' O ' ' HD3' ' A' ' 45' ' ' PRO . 1.6 mp0 -106.59 131.38 53.81 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.241 -0.912 . . . . 0.0 109.692 -179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.48 ' OD1' ' CE1' ' A' ' 26' ' ' PHE . 2.7 m120 -55.61 109.93 1.94 Allowed Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.276 -0.89 . . . . 0.0 109.28 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 43' ' ' GLU . 35.4 Cg_endo -77.46 -75.63 0.01 OUTLIER 'Trans proline' 0 C--N 1.311 -1.446 0 C-N-CA 122.376 2.051 . . . . 0.0 110.578 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.6 m -99.55 68.96 1.61 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.182 -0.949 . . . . 0.0 109.614 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.434 ' HB2' ' HB3' ' A' ' 44' ' ' ASN . . . -77.26 -37.12 53.68 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.223 -0.923 . . . . 0.0 109.421 179.754 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -101.55 92.55 4.94 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.317 -0.865 . . . . 0.0 109.456 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -172.75 -47.97 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.301 -0.875 . . . . 0.0 109.357 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.84 94.51 4.38 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.332 -0.855 . . . . 0.0 109.208 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 113.08 -60.59 0.34 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 59.96 91.55 0.01 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -172.96 -47.89 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.181 -1.188 . . . . 0.0 109.538 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.527 ' O ' HG22 ' A' ' 57' ' ' THR . . . 111.34 -50.01 0.8 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.706 HD12 ' HB2' ' A' ' 78' ' ' ALA . 16.6 mm -70.4 -5.58 5.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.338 -1.095 . . . . 0.0 109.555 179.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.67 -25.28 53.55 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.195 -0.94 . . . . 0.0 109.553 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.527 HG22 ' O ' ' A' ' 54' ' ' GLY . 10.8 t -68.66 -7.9 37.49 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.201 -0.937 . . . . 0.0 109.556 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.425 ' O ' ' C ' ' A' ' 59' ' ' GLN . . . -61.67 -56.18 22.45 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.926 . . . . 0.0 109.249 179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 58' ' ' ALA . 1.6 tm0? -44.21 -29.26 0.61 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.337 -0.852 . . . . 0.0 109.286 179.808 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 73.1 mt -75.59 -46.66 36.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.295 -0.878 . . . . 0.0 109.179 179.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.484 HG23 HG11 ' A' ' 66' ' ' VAL . 37.8 mt -56.03 -25.24 19.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 109.36 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -68.66 -38.08 80.15 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.279 -0.888 . . . . 0.0 109.681 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 26.8 m-20 -72.75 -4.94 34.5 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.247 -0.908 . . . . 0.0 109.721 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -83.9 -16.1 45.57 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.188 -0.945 . . . . 0.0 109.572 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.06 -12.74 59.27 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.584 HG21 ' CB ' ' A' ' 4' ' ' ALA . 2.6 p -58.21 98.77 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.268 -1.136 . . . . 0.0 109.66 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.542 ' HA ' HG23 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -79.28 -6.36 56.5 Favored 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 179.234 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.536 ' HB2' ' CE2' ' A' ' 104' ' ' PHE . . . -113.67 120.66 41.63 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.284 -0.885 . . . . 0.0 109.119 179.627 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 70.6 t -108.43 112.04 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.165 -0.959 . . . . 0.0 109.852 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.407 ' N ' HD13 ' A' ' 70' ' ' ILE . 3.2 mm -99.79 97.53 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.155 -0.965 . . . . 0.0 109.136 179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.628 ' HB1' ' HB2' ' A' ' 20' ' ' PHE . . . -158.39 169.85 23.53 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.237 -0.914 . . . . 0.0 109.816 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.435 ' O ' ' C ' ' A' ' 73' ' ' SER . 9.1 t -133.33 50.65 2.21 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.364 -0.835 . . . . 0.0 109.048 179.79 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.463 ' HB3' ' HB3' ' A' ' 20' ' ' PHE . 60.5 p -41.26 149.55 0.36 Allowed Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.509 -0.745 . . . . 0.0 109.937 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.487 ' HD3' ' O ' ' A' ' 20' ' ' PHE . 36.2 Cg_endo -78.14 -35.26 1.35 Allowed 'Trans proline' 0 C--N 1.31 -1.483 0 C-N-CA 122.657 2.238 . . . . 0.0 110.051 179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -108.61 153.14 16.91 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.492 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 35.5 Cg_endo -77.72 1.15 9.13 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.537 2.158 . . . . 0.0 110.668 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.501 ' O ' HG23 ' A' ' 81' ' ' VAL . 5.4 t30 -59.93 -42.28 93.64 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.223 -0.923 . . . . 0.0 109.686 -179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.706 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -64.17 -67.59 0.42 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.231 -0.918 . . . . 0.0 109.681 -179.836 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.794 ' CD1' HG21 ' A' ' 89' ' ' ILE . 16.6 m-30 -53.06 -19.27 2.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.232 -0.917 . . . . 0.0 109.875 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.492 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 36.3 tt0 -70.73 -49.93 41.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.122 -0.986 . . . . 0.0 109.579 -179.907 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.501 HG23 ' O ' ' A' ' 77' ' ' ASN . 3.0 t -67.4 -48.19 78.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.147 -0.971 . . . . 0.0 109.665 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 36.1 mt -55.59 -29.32 58.88 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.114 -0.992 . . . . 0.0 109.508 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 64.0 t-20 -68.03 -38.89 83.07 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.265 -0.897 . . . . 0.0 109.383 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.14 -26.29 61.15 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.331 -0.856 . . . . 0.0 109.47 179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.673 HD13 HD11 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -71.87 -37.11 70.25 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.955 . . . . 0.0 109.551 -179.94 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 105.53 13.08 25.17 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.673 HD11 HD13 ' A' ' 85' ' ' LEU . 3.7 mt -85.38 169.54 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.278 -1.131 . . . . 0.0 109.623 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.512 ' N ' HG22 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -99.17 123.67 43.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.259 -0.901 . . . . 0.0 109.25 179.842 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.794 HG21 ' CD1' ' A' ' 79' ' ' PHE . 1.6 mt -95.16 161.84 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.19 -0.944 . . . . 0.0 109.757 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.532 ' CD1' ' O ' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -148.21 133.93 18.9 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.226 -0.921 . . . . 0.0 109.444 -179.862 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.421 ' HB2' ' HB2' ' A' ' 110' ' ' GLU . 0.0 OUTLIER -89.45 123.12 33.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.148 -0.97 . . . . 0.0 109.475 179.964 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.16 87.78 5.48 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.235 -0.916 . . . . 0.0 109.681 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.527 ' O ' HG22 ' A' ' 93' ' ' THR . 18.6 m -139.23 21.02 2.6 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.223 -0.923 . . . . 0.0 109.412 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -74.46 -77.8 0.64 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 92.8 m -159.81 -70.78 0.08 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.246 -1.15 . . . . 0.0 109.386 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.42 ' HA ' ' HB2' ' A' ' 15' ' ' GLU . 37.0 m -132.38 148.71 52.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.303 -0.873 . . . . 0.0 109.384 179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 1.112 HG23 HG21 ' A' ' 5' ' ' ILE . 12.1 p -44.36 -27.98 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.345 -0.847 . . . . 0.0 109.487 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -66.69 -52.81 40.53 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.337 -0.852 . . . . 0.0 109.734 -179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.434 ' O ' ' CG ' ' A' ' 103' ' ' LEU . 4.7 tt0 -71.02 -16.35 62.61 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.136 -0.977 . . . . 0.0 109.493 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.417 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 2.6 m120 -75.95 -40.76 53.37 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.218 -0.926 . . . . 0.0 109.397 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 30.9 tp -60.58 -47.69 85.07 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.336 -0.853 . . . . 0.0 109.433 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.87 -20.43 56.29 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.208 -0.932 . . . . 0.0 109.432 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.434 ' CG ' ' O ' ' A' ' 99' ' ' GLU . 6.4 mt -67.37 -43.5 81.26 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.312 -0.868 . . . . 0.0 109.676 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.541 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.1 t80 -61.28 -29.17 69.69 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.28 -0.888 . . . . 0.0 109.453 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 92.0 m -62.34 -40.59 96.88 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.211 -0.93 . . . . 0.0 109.563 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 107' ' ' GLY . 6.4 mm-40 -87.94 3.21 49.44 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.181 -0.949 . . . . 0.0 109.729 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.417 ' C ' ' O ' ' A' ' 106' ' ' GLU . . . 44.25 39.03 5.24 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -103.22 -10.94 18.35 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -1.162 . . . . 0.0 109.607 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.482 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 0.7 OUTLIER -74.05 -161.17 0.11 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.208 -0.932 . . . . 0.0 109.482 -179.989 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.532 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 7.0 mt-10 -95.07 113.88 25.63 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.304 -0.872 . . . . 0.0 109.418 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -103.18 142.8 33.54 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.35 -0.844 . . . . 0.0 109.599 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.465 ' O ' ' HB2' ' A' ' 113' ' ' ARG . 13.6 mm -129.84 117.53 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.272 -0.893 . . . . 0.0 109.302 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.465 ' HB2' ' O ' ' A' ' 112' ' ' ILE . 3.4 ttt-85 178.39 71.77 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.195 -0.94 . . . . 0.0 109.619 -179.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -134.58 89.24 26.84 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.235 -0.916 . . . . 0.0 109.555 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.468 ' O ' ' O ' ' A' ' 116' ' ' GLY . 35.7 Cg_endo -78.84 -44.6 0.13 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.635 2.224 . . . . 0.0 110.665 -179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 115' ' ' PRO . . . -60.59 -131.0 0.01 OUTLIER Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.824 -1.31 . . . . 0.0 109.824 -179.762 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 116' ' ' GLY . 57.9 p 52.69 82.98 0.07 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.299 -1.118 . . . . 0.0 109.654 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 77.84 48.6 7.69 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.744 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.6 ttt-85 -119.78 66.52 0.81 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.191 -1.182 . . . . 0.0 109.571 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 151.2 -70.44 0.3 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.773 -1.331 . . . . 0.0 109.773 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -175.15 95.56 0.07 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.23 -1.159 . . . . 0.0 109.582 -179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -80.44 84.36 6.08 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.245 -0.91 . . . . 0.0 109.366 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.437 ' O ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -52.58 128.76 27.12 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.249 -0.907 . . . . 0.0 109.582 -179.891 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.437 ' HB2' ' O ' ' A' ' 123' ' ' ARG . 2.8 tpp180 . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 117.99 -1.005 . . . . 0.0 109.436 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -92.09 155.77 17.84 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.202 -0.936 . . . . 0.0 109.309 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.486 ' HA ' ' O ' ' A' ' 68' ' ' ALA . 7.8 mt -120.31 117.41 53.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.277 -0.889 . . . . 0.0 110.052 -179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.992 ' HB2' HG11 ' A' ' 66' ' ' VAL . . . -112.51 116.92 31.02 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.317 -0.864 . . . . 0.0 108.672 179.275 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.842 HG23 ' HB ' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -102.98 135.23 41.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.128 -0.983 . . . . 0.0 109.926 -179.311 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.55 143.24 46.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.39 -0.819 . . . . 0.0 109.175 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.715 ' CB ' HG11 ' A' ' 97' ' ' VAL . 0.7 OUTLIER -151.39 157.96 43.11 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.208 -0.933 . . . . 0.0 109.683 -179.792 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 66.9 p -119.39 0.96 11.2 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.324 -0.86 . . . . 0.0 109.388 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.548 ' O ' ' CG ' ' A' ' 25' ' ' TYR . . . -125.62 -153.96 8.59 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.561 HG23 ' CE1' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -126.45 -30.52 2.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.183 -1.186 . . . . 0.0 109.664 -179.849 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 173.31 -43.8 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.122 -0.986 . . . . 0.0 109.528 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -80.66 5.15 16.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.299 -0.875 . . . . 0.0 109.629 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -166.31 31.43 0.21 Allowed Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.854 ' HB3' HG22 ' A' ' 97' ' ' VAL . 5.0 m -77.06 79.43 3.59 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.124 -1.221 . . . . 0.0 109.357 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.713 ' C ' HG23 ' A' ' 16' ' ' VAL . 9.2 mm-40 -76.91 1.57 17.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.302 -0.874 . . . . 0.0 109.576 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.713 HG23 ' C ' ' A' ' 15' ' ' GLU . 1.9 t 73.68 18.38 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.403 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.1 t 59.11 176.04 0.07 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.32 -0.863 . . . . 0.0 109.399 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -109.04 -36.25 6.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -131.79 123.18 27.09 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.299 -0.875 . . . . 0.0 109.363 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.714 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 2.5 t80 -62.23 96.72 0.08 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.251 -0.905 . . . . 0.0 109.497 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -136.76 -87.02 0.2 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.428 ' O ' ' C ' ' A' ' 23' ' ' ALA . 1.8 ptp85 -114.7 43.85 1.86 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.311 -1.111 . . . . 0.0 109.18 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.446 ' HB3' ' CE1' ' A' ' 26' ' ' PHE . . . -42.79 114.14 1.45 Allowed Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.406 -0.808 . . . . 0.0 109.405 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.58 21.14 0.88 Allowed 'Trans proline' 0 C--N 1.311 -1.412 0 C-N-CA 122.578 2.185 . . . . 0.0 110.947 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.561 ' CE1' HG23 ' A' ' 10' ' ' THR . 0.5 OUTLIER -159.51 70.78 0.47 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.949 -1.094 . . . . 0.0 109.301 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.446 ' CE1' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -79.52 126.27 30.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.284 -0.885 . . . . 0.0 109.441 -179.917 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -101.22 115.94 31.65 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.407 HD12 HG23 ' A' ' 28' ' ' ILE . 28.9 mm -96.78 131.43 43.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.3 -0.875 . . . . 0.0 109.661 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.405 ' CG1' HG23 ' A' ' 36' ' ' ILE . 4.5 t -130.25 137.09 57.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.295 -0.878 . . . . 0.0 109.117 179.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -118.17 95.99 5.13 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.095 -1.003 . . . . 0.0 109.816 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.408 ' HE2' ' HB2' ' A' ' 31' ' ' MET . 41.1 ttm -81.91 146.06 30.0 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.268 -0.895 . . . . 0.0 109.029 179.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -99.96 -70.01 0.75 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.113 -0.992 . . . . 0.0 110.002 -179.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 19.3 tttm -138.59 62.71 1.54 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.094 -1.004 . . . . 0.0 109.95 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 80.51 31.64 36.53 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.406 ' O ' ' C ' ' A' ' 36' ' ' ILE . 2.9 p30 -159.58 97.47 1.33 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.169 -1.195 . . . . 0.0 109.552 179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.545 HG12 HD21 ' A' ' 101' ' ' LEU . 2.9 mp -44.06 132.39 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.247 -0.908 . . . . 0.0 109.327 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -130.01 18.97 5.51 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.119 -0.988 . . . . 0.0 109.737 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 175.38 129.9 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.078 -1.014 . . . . 0.0 109.619 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.4 p -149.58 107.51 3.71 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.323 -0.86 . . . . 0.0 109.373 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.22 164.27 15.42 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.234 -0.916 . . . . 0.0 109.537 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 14.7 p -124.42 148.03 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.497 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.525 HD12 ' H ' ' A' ' 43' ' ' GLU . 2.6 tp -141.65 154.27 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.302 -0.874 . . . . 0.0 109.392 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.525 ' H ' HD12 ' A' ' 42' ' ' ILE . 26.7 mp0 -93.9 68.8 3.88 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.267 -0.895 . . . . 0.0 109.497 -179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.472 ' CG ' ' CB ' ' A' ' 47' ' ' ALA . 1.3 m-20 53.2 92.13 0.06 OUTLIER Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.307 -0.87 . . . . 0.0 109.727 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -77.46 111.32 3.14 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 C-N-CA 122.572 2.181 . . . . 0.0 110.392 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.5 t 53.25 20.26 1.81 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.275 -0.89 . . . . 0.0 109.531 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.472 ' CB ' ' CG ' ' A' ' 44' ' ' ASN . . . -66.47 -26.8 67.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.272 -0.893 . . . . 0.0 109.45 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 71.2 m -137.1 45.86 2.21 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.282 -0.886 . . . . 0.0 109.355 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -57.92 -44.99 87.2 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.317 -0.865 . . . . 0.0 109.719 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 92.4 p -115.79 28.41 8.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.233 -0.917 . . . . 0.0 109.664 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 79.71 -141.51 23.68 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 106.39 -128.0 9.13 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -151.1 -57.48 0.16 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.234 -1.156 . . . . 0.0 109.486 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 158.0 -21.29 0.37 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.446 HD12 ' HB2' ' A' ' 78' ' ' ALA . 46.6 mm -69.77 -45.82 76.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.127 -1.219 . . . . 0.0 109.479 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -63.17 -33.26 75.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.221 -0.924 . . . . 0.0 109.535 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 21.6 m -58.95 -23.9 62.01 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.18 -0.95 . . . . 0.0 109.634 -179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -53.51 -51.94 61.18 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.258 -0.901 . . . . 0.0 109.574 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.498 ' OE1' ' CG1' ' A' ' 81' ' ' VAL . 1.4 tp60 -46.06 -44.73 15.64 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.188 -0.945 . . . . 0.0 109.504 -179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 23.5 mt -62.63 -40.22 87.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.193 -0.942 . . . . 0.0 109.522 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 50.3 mt -66.61 -20.38 27.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.201 -0.937 . . . . 0.0 109.487 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.513 ' CB ' HD23 ' A' ' 85' ' ' LEU . . . -77.16 -36.23 55.33 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.256 -0.903 . . . . 0.0 109.687 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 52.2 m-20 -75.47 -0.15 19.13 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.258 -0.901 . . . . 0.0 109.694 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -82.9 -7.68 59.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.129 -0.982 . . . . 0.0 109.747 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.11 -23.98 32.14 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.992 HG11 ' HB2' ' A' ' 4' ' ' ALA . 19.2 m -59.51 93.9 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.242 -1.152 . . . . 0.0 109.688 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.419 ' O ' ' HD3' ' A' ' 88' ' ' LYS . 26.9 mtpt -79.49 -3.45 46.75 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.36 -0.838 . . . . 0.0 108.793 179.286 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' A' ' 3' ' ' ILE . . . -135.21 103.14 5.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.227 -0.921 . . . . 0.0 109.19 179.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.808 ' O ' HG23 ' A' ' 89' ' ' ILE . 55.1 t -110.93 129.99 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.023 -1.048 . . . . 0.0 109.999 -179.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.842 ' HB ' HG23 ' A' ' 5' ' ' ILE . 3.6 mp -92.68 119.38 40.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.286 -0.883 . . . . 0.0 109.078 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.714 ' HB1' ' HB2' ' A' ' 20' ' ' PHE . . . -157.3 176.97 12.0 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.169 -0.957 . . . . 0.0 109.693 -179.724 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.461 ' O ' ' O ' ' A' ' 73' ' ' SER . 3.1 p -152.64 51.89 0.76 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.48 -0.762 . . . . 0.0 109.494 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.563 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 0.1 OUTLIER -44.29 167.51 0.09 OUTLIER Pre-proline 0 N--CA 1.491 1.579 0 O-C-N 121.172 -0.955 . . . . 0.0 109.436 179.962 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.63 -1.92 12.02 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.613 2.209 . . . . 0.0 110.309 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -162.63 168.61 37.6 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.552 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.2 Cg_endo -79.17 7.9 4.14 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.671 2.248 . . . . 0.0 110.582 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 36.1 m120 -58.57 -44.54 89.77 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.178 -0.951 . . . . 0.0 109.649 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.446 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -77.04 -48.87 16.68 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.176 -0.952 . . . . 0.0 109.851 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.563 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 2.9 m-85 -55.06 -19.81 8.09 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.209 -0.932 . . . . 0.0 109.776 -179.695 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -76.68 -46.71 24.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.147 -0.97 . . . . 0.0 109.815 -179.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.498 ' CG1' ' OE1' ' A' ' 59' ' ' GLN . 22.2 t -64.49 -51.09 72.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.154 -0.966 . . . . 0.0 109.495 -179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.792 ' HB3' HD11 ' A' ' 89' ' ' ILE . 0.9 OUTLIER -55.03 -46.44 75.29 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.254 -0.903 . . . . 0.0 109.71 -179.88 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 53.6 t30 -57.81 -41.53 82.36 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.219 -0.925 . . . . 0.0 109.534 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.49 -50.39 71.89 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.266 -0.896 . . . . 0.0 109.497 -179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.549 ' HB3' ' CD1' ' A' ' 87' ' ' ILE . 2.4 mp -60.21 -28.1 67.71 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.175 -0.953 . . . . 0.0 109.477 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 112.43 10.24 17.77 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 179.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.644 HD12 ' N ' ' A' ' 87' ' ' ILE . 3.2 mp -94.38 147.71 5.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.115 -1.226 . . . . 0.0 109.439 179.888 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.419 ' HD3' ' O ' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -104.81 155.91 18.48 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.259 -0.901 . . . . 0.0 109.818 -179.835 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.808 HG23 ' O ' ' A' ' 69' ' ' VAL . 3.5 mp -136.6 140.21 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.254 -0.904 . . . . 0.0 109.507 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.556 ' CD2' ' O ' ' A' ' 109' ' ' LEU . 16.9 m-30 -102.82 167.7 9.7 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.313 -0.867 . . . . 0.0 109.53 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.558 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 0.0 OUTLIER -85.7 130.43 34.57 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.245 -0.909 . . . . 0.0 109.866 -179.615 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -87.76 116.89 26.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.422 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 63.4 p -61.77 -26.32 68.01 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.281 -0.887 . . . . 0.0 109.372 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.56 18.22 42.36 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 58.4 m -86.35 -74.88 0.41 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -1.134 . . . . 0.0 109.473 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 14' ' ' SER . 74.4 m -155.98 144.08 19.84 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.321 -0.862 . . . . 0.0 109.43 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.854 HG22 ' HB3' ' A' ' 14' ' ' SER . 28.8 m -68.94 -35.9 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -0.885 . . . . 0.0 109.698 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 13.7 tt0 -60.08 -38.06 81.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.135 -0.978 . . . . 0.0 109.323 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.402 ' OE1' ' HA ' ' A' ' 99' ' ' GLU . 0.0 OUTLIER -71.85 -50.69 27.32 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.335 -0.853 . . . . 0.0 109.433 179.881 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.506 ' HA ' HD12 ' A' ' 103' ' ' LEU . 42.2 m-20 -49.62 -34.44 18.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.271 -0.893 . . . . 0.0 109.551 -179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.545 HD21 HG12 ' A' ' 36' ' ' ILE . 12.3 tp -52.99 -55.86 20.35 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.247 -0.908 . . . . 0.0 109.725 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.49 -20.49 61.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.13 -0.982 . . . . 0.0 109.728 -179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.506 HD12 ' HA ' ' A' ' 100' ' ' ASN . 23.9 mt -71.74 -25.38 62.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.174 -0.954 . . . . 0.0 109.611 -179.782 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.447 ' HE2' ' HB1' ' A' ' 68' ' ' ALA . 41.3 t80 -70.0 -38.11 75.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.207 -0.933 . . . . 0.0 109.237 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 48.6 m -74.56 -24.39 58.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.33 -0.857 . . . . 0.0 109.504 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -80.81 -18.52 47.25 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.193 -0.942 . . . . 0.0 109.5 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 76.24 24.48 68.47 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -92.68 -37.92 12.13 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.14 -1.212 . . . . 0.0 109.534 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.556 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 0.0 OUTLIER -88.56 119.98 29.52 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.135 -0.978 . . . . 0.0 109.479 179.925 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.526 ' HA ' ' CG ' ' A' ' 90' ' ' TYR . 16.6 pt-20 -149.29 173.83 13.07 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.463 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.558 ' HB2' ' N ' ' A' ' 91' ' ' ARG . 8.1 tp10 -175.77 -111.24 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.318 -0.864 . . . . 0.0 109.84 179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.478 ' N ' ' HG3' ' A' ' 111' ' ' GLU . 19.8 tt -84.21 134.58 26.65 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 O-C-N 121.08 -1.012 . . . . 0.0 110.072 -179.222 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -132.59 -177.63 4.57 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.442 -0.786 . . . . 0.0 109.285 179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -73.69 154.72 89.37 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.145 -0.972 . . . . 0.0 109.64 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -77.52 -46.43 0.14 Allowed 'Trans proline' 0 C--N 1.309 -1.515 0 C-N-CA 122.651 2.234 . . . . 0.0 110.305 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.469 ' O ' ' HB2' ' A' ' 117' ' ' SER . . . -123.83 -122.93 2.74 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.469 ' HB2' ' O ' ' A' ' 116' ' ' GLY . 24.8 t 177.49 37.2 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.351 -1.088 . . . . 0.0 109.444 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 138.35 -111.11 0.78 Allowed Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -76.99 117.93 19.07 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.328 -1.101 . . . . 0.0 109.345 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -158.11 122.4 1.15 Allowed Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 41.4 mtm180 -97.82 137.57 36.48 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.326 -1.102 . . . . 0.0 109.155 179.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 -138.72 133.76 32.68 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.278 -0.889 . . . . 0.0 109.837 -179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 ttp180 -140.08 25.47 2.29 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.321 -0.862 . . . . 0.0 109.107 179.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 7.6 mtm180 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 117.905 -1.045 . . . . 0.0 109.419 -179.809 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.3 ptp . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.484 ' HG2' ' HG3' ' A' ' 30' ' ' GLU . 0.1 OUTLIER -131.67 144.29 50.91 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.245 -0.909 . . . . 0.0 109.583 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.569 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 5.3 mt -118.32 104.45 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.288 -0.883 . . . . 0.0 109.565 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -106.16 116.41 31.88 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.329 -0.857 . . . . 0.0 109.31 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.681 HG21 HG13 ' A' ' 97' ' ' VAL . 2.8 mp -94.61 120.8 44.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.15 -0.969 . . . . 0.0 109.467 -179.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.459 ' O ' ' O ' ' A' ' 7' ' ' SER . . . -61.91 150.43 37.61 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.278 -0.889 . . . . 0.0 109.46 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.507 ' O ' ' CB ' ' A' ' 8' ' ' SER . 0.0 OUTLIER 53.6 169.95 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.28 -0.887 . . . . 0.0 109.598 179.963 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.758 ' HB3' HG11 ' A' ' 97' ' ' VAL . 0.2 OUTLIER 162.52 -35.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.322 -0.862 . . . . 0.0 109.321 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.457 ' HA3' ' HB2' ' A' ' 14' ' ' SER . . . 75.91 9.56 85.16 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER 61.92 16.78 8.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.244 -1.151 . . . . 0.0 109.46 179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.0 t0 -173.17 -167.48 0.41 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.237 -0.915 . . . . 0.0 109.597 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.2 mt -79.85 -1.85 40.87 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.211 -0.93 . . . . 0.0 109.613 -179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.81 -61.62 7.01 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.457 ' HB2' ' HA3' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -77.31 83.23 3.76 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.198 -1.177 . . . . 0.0 109.505 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.404 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 7.2 mt-10 -72.22 83.1 1.02 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.34 -0.85 . . . . 0.0 109.176 179.724 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.417 ' O ' ' C ' ' A' ' 17' ' ' SER . 22.1 t 62.6 63.97 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.916 . . . . 0.0 109.308 -179.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.479 ' HB3' ' CB ' ' A' ' 7' ' ' SER . 8.2 t -43.77 159.01 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.311 -0.868 . . . . 0.0 109.426 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 22.3 mtp85 -95.67 30.62 2.26 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.26 -0.9 . . . . 0.0 109.376 179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -127.38 159.03 35.68 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.184 -0.948 . . . . 0.0 109.474 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -133.17 -32.51 1.19 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.186 -0.946 . . . . 0.0 109.903 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -101.5 -37.29 3.55 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.808 -1.317 . . . . 0.0 109.808 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.438 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -84.31 -25.9 28.91 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.131 -1.217 . . . . 0.0 109.775 -179.753 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.419 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -42.49 103.01 0.29 Allowed Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.335 -0.853 . . . . 0.0 109.7 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.482 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.7 Cg_endo -80.68 41.28 1.11 Allowed 'Trans proline' 0 C--N 1.311 -1.411 0 C-N-CA 122.602 2.202 . . . . 0.0 110.533 179.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.482 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 84.1 m-85 -158.19 68.5 0.49 Allowed 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.106 -0.996 . . . . 0.0 109.286 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.442 ' CE1' ' HA ' ' A' ' 6' ' ' ALA . 0.8 OUTLIER -83.02 116.49 22.3 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.271 -0.893 . . . . 0.0 109.585 -179.87 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 1.4 ttt -94.21 132.42 38.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.156 -0.965 . . . . 0.0 109.635 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.682 ' O ' HG23 ' A' ' 28' ' ' ILE . 5.1 tt -129.42 116.81 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.897 . . . . 0.0 109.401 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.868 HG13 ' O ' ' A' ' 38' ' ' SER . 94.6 t -125.11 129.7 73.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 109.388 -179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.484 ' HG3' ' HG2' ' A' ' 2' ' ' LYS . 26.9 tt0 -99.05 99.45 10.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.226 -0.921 . . . . 0.0 109.635 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 2.2 tpp -81.8 134.24 35.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.319 -0.863 . . . . 0.0 109.309 179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -99.0 -68.66 0.79 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.236 -0.915 . . . . 0.0 109.681 -179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -129.99 81.47 2.01 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.204 -0.935 . . . . 0.0 109.631 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 52.15 28.04 24.97 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.412 ' O ' ' N ' ' A' ' 37' ' ' GLU . 1.3 m-20 -147.73 108.49 4.18 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.173 -1.192 . . . . 0.0 109.536 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.726 HG23 ' CG1' ' A' ' 29' ' ' VAL . 72.6 mt -48.28 98.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.169 -0.957 . . . . 0.0 109.405 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.412 ' N ' ' O ' ' A' ' 35' ' ' ASN . 34.7 mt-10 -96.46 9.77 40.3 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.287 -0.883 . . . . 0.0 109.614 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.868 ' O ' HG13 ' A' ' 29' ' ' VAL . 0.5 OUTLIER -169.6 122.67 0.75 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.239 -0.913 . . . . 0.0 109.546 179.99 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.611 ' HA ' HG22 ' A' ' 29' ' ' VAL . 0.7 OUTLIER -141.03 107.95 5.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.281 -0.887 . . . . 0.0 109.541 179.986 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -132.38 138.59 47.77 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.197 -0.939 . . . . 0.0 109.437 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 11.9 t -98.63 154.72 3.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.269 -0.895 . . . . 0.0 109.547 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 6.6 mt -131.92 134.33 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 109.341 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.453 ' O ' ' HD3' ' A' ' 45' ' ' PRO . 53.7 mt-10 -91.06 85.92 6.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.297 -0.877 . . . . 0.0 109.527 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.445 ' C ' ' O ' ' A' ' 43' ' ' GLU . 1.0 OUTLIER -41.87 101.61 0.25 Allowed Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.371 -0.831 . . . . 0.0 109.473 179.977 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 43' ' ' GLU . 36.2 Cg_endo -78.56 -166.69 0.42 Allowed 'Trans proline' 0 C--N 1.31 -1.486 0 C-N-CA 122.529 2.152 . . . . 0.0 110.578 -179.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.1 m 56.49 36.34 27.41 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.893 . . . . 0.0 109.395 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -76.87 -39.89 49.48 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.327 -0.858 . . . . 0.0 109.506 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.21 -27.65 29.83 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.168 -0.957 . . . . 0.0 109.351 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -86.35 151.01 23.92 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.217 -0.927 . . . . 0.0 109.549 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.38 132.83 54.1 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.323 -0.86 . . . . 0.0 109.543 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -146.2 30.22 1.62 Allowed Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.651 ' O ' ' HB2' ' A' ' 53' ' ' ALA . . . 174.33 -82.77 0.08 OUTLIER Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.651 ' HB2' ' O ' ' A' ' 52' ' ' GLY . . . 167.24 -31.06 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.325 -1.103 . . . . 0.0 109.453 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 136.75 -49.19 0.88 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.583 HD12 ' HB2' ' A' ' 78' ' ' ALA . 51.0 mm -60.77 -14.08 8.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.258 -1.142 . . . . 0.0 109.63 -179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.403 ' O ' ' C ' ' A' ' 57' ' ' THR . 0.0 OUTLIER -65.01 -37.04 86.34 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.211 -0.93 . . . . 0.0 109.658 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.403 ' C ' ' O ' ' A' ' 56' ' ' ARG . 14.6 m -43.48 -33.88 1.21 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.202 -0.936 . . . . 0.0 109.723 -179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -51.29 -52.36 45.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -0.933 . . . . 0.0 109.771 -179.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.3 tt0 -54.54 -34.31 61.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 109.933 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.6 mt -69.39 -65.76 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.127 -0.983 . . . . 0.0 109.726 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 18.8 pt -51.71 -20.95 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.741 -179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.401 ' HB1' HD11 ' A' ' 87' ' ' ILE . . . -71.16 -47.31 58.46 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.212 -0.93 . . . . 0.0 109.621 -179.809 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 49.7 t30 -76.42 1.58 16.01 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.296 -0.877 . . . . 0.0 109.757 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -95.34 -2.11 49.87 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.088 -1.008 . . . . 0.0 109.772 -179.757 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 93.59 -14.41 65.36 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 31.8 t -49.66 91.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.298 -1.119 . . . . 0.0 109.632 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' GLY . 3.6 mmmp? -79.3 -7.39 58.27 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.338 -0.851 . . . . 0.0 108.811 179.371 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.569 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -131.26 123.44 28.41 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.287 -0.883 . . . . 0.0 109.199 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 57.0 t -121.34 106.69 18.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.161 -0.962 . . . . 0.0 109.853 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.71 HD13 ' HB2' ' A' ' 90' ' ' TYR . 13.4 mm -83.2 104.32 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.18 -0.95 . . . . 0.0 109.03 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -143.74 173.5 11.62 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.22 -0.925 . . . . 0.0 109.789 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 10.0 p -145.49 40.01 1.19 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.374 -0.829 . . . . 0.0 109.249 179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.421 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -45.05 149.76 0.83 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.355 -0.841 . . . . 0.0 109.669 -179.905 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.2 Cg_endo -78.61 4.97 5.92 Favored 'Trans proline' 0 C--N 1.309 -1.533 0 C-N-CA 122.737 2.291 . . . . 0.0 110.336 179.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.424 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -144.42 148.46 20.24 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.647 -1.381 . . . . 0.0 109.647 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.424 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 36.2 Cg_endo -79.38 11.16 2.75 Favored 'Trans proline' 0 C--N 1.31 -1.449 0 C-N-CA 122.716 2.277 . . . . 0.0 110.79 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -73.54 -36.07 65.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.077 -1.014 . . . . 0.0 109.691 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.583 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -68.21 -50.59 53.15 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.173 -0.954 . . . . 0.0 109.628 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.536 ' CD1' ' N ' ' A' ' 79' ' ' PHE . 1.4 m-85 -65.04 -18.31 65.19 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.133 -0.98 . . . . 0.0 109.519 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -67.53 -49.67 62.26 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.111 -0.993 . . . . 0.0 109.538 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.7 t -71.2 -43.88 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.194 -0.941 . . . . 0.0 109.609 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.461 ' HA ' HD23 ' A' ' 82' ' ' LEU . 20.1 mt -49.66 -49.36 47.66 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.173 -0.955 . . . . 0.0 109.446 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -61.35 -34.3 75.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.228 -0.92 . . . . 0.0 109.302 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -67.31 -25.65 66.12 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.434 -0.792 . . . . 0.0 109.6 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 4.5 mt -97.7 18.43 15.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.275 -0.891 . . . . 0.0 109.37 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 56.3 62.84 5.89 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.401 HD11 ' HB1' ' A' ' 62' ' ' ALA . 97.7 mt -132.38 144.9 35.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.287 -1.126 . . . . 0.0 109.306 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.482 ' HG3' ' O ' ' A' ' 67' ' ' LYS . 0.2 OUTLIER -82.77 124.64 30.45 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.296 -0.877 . . . . 0.0 109.423 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.535 HG21 ' CD1' ' A' ' 79' ' ' PHE . 3.7 mt -104.16 129.95 55.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.259 -0.901 . . . . 0.0 109.52 -179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.71 ' HB2' HD13 ' A' ' 70' ' ' ILE . 3.6 m-85 -116.46 157.57 24.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.405 -0.809 . . . . 0.0 109.249 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.407 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 1.2 ttt-85 -96.09 143.22 27.42 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.245 -0.909 . . . . 0.0 109.568 -179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -109.97 86.72 2.35 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 109.4 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.622 ' O ' HG22 ' A' ' 93' ' ' THR . 34.1 m -149.35 26.85 0.85 Allowed 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.192 -0.943 . . . . 0.0 109.421 -179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.17 -71.8 1.23 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 15.8 m -165.92 -46.17 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.205 -1.174 . . . . 0.0 109.727 -179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.77 162.9 38.84 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.23 -0.919 . . . . 0.0 109.79 -179.684 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.758 HG11 ' HB3' ' A' ' 8' ' ' SER . 47.4 t -77.08 -40.03 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.272 -0.893 . . . . 0.0 109.351 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -59.15 -50.06 75.49 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.273 -0.892 . . . . 0.0 109.803 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.428 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 1.2 tt0 -72.17 -33.0 67.36 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.12 -0.988 . . . . 0.0 109.645 -179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -57.2 -43.39 82.71 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.224 -0.922 . . . . 0.0 109.759 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.591 HD21 HG11 ' A' ' 29' ' ' VAL . 51.9 tp -51.39 -43.14 61.83 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.207 -0.933 . . . . 0.0 109.795 -179.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 7.6 tptm -75.18 -30.5 60.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.138 -0.977 . . . . 0.0 109.762 -179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.428 ' HG ' ' O ' ' A' ' 99' ' ' GLU . 48.6 mt -67.09 -23.96 65.9 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.165 -0.959 . . . . 0.0 109.608 -179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.419 ' CD1' ' C ' ' A' ' 104' ' ' PHE . 24.4 t80 -58.79 -48.07 82.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.198 -0.939 . . . . 0.0 109.357 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 55.4 m -65.28 -39.1 92.13 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.348 -0.845 . . . . 0.0 109.304 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -70.98 -6.81 41.68 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.234 -0.916 . . . . 0.0 109.505 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 56.16 30.65 58.15 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.306 -1.517 . . . . 0.0 109.306 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -83.66 -28.84 28.1 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.313 -1.11 . . . . 0.0 109.529 -179.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -138.6 138.48 37.94 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.073 -1.017 . . . . 0.0 109.763 -179.805 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.596 ' HA ' ' CD2' ' A' ' 90' ' ' TYR . 1.7 pt-20 -170.76 -151.54 0.08 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.324 -0.86 . . . . 0.0 109.449 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.501 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 0.7 OUTLIER -163.49 -112.16 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.257 -0.902 . . . . 0.0 109.623 -179.81 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.416 HD12 HD13 ' A' ' 89' ' ' ILE . 2.6 mt -83.33 90.34 2.42 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.761 0 O-C-N 121.154 -0.966 . . . . 0.0 109.489 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -64.58 -59.83 3.84 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.206 -0.934 . . . . 0.0 109.321 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.408 ' HA ' ' HD3' ' A' ' 115' ' ' PRO . 0.3 OUTLIER -177.32 146.3 0.63 Allowed Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 109.48 -179.978 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 114' ' ' SER . 34.8 Cg_endo -78.06 -179.31 5.32 Favored 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 122.638 2.225 . . . . 0.0 110.366 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 87.43 20.56 51.46 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 47.4 p -160.44 -38.51 0.05 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.198 -1.178 . . . . 0.0 109.565 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -100.43 19.48 52.47 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 3.2 ttp85 -63.15 136.81 57.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.288 -1.125 . . . . 0.0 109.595 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -84.79 -156.45 25.47 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 2.4 mtm180 -144.17 86.77 1.86 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.291 -1.123 . . . . 0.0 109.494 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.424 ' NH1' ' CG ' ' A' ' 122' ' ' ARG . 0.0 OUTLIER -92.88 173.84 7.55 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.316 -0.865 . . . . 0.0 109.211 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 62.5 mtt180 -121.89 86.0 2.5 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.171 -0.956 . . . . 0.0 109.498 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 118.008 -0.996 . . . . 0.0 109.505 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 65' ' ' GLY . 4.4 mtmt -118.25 145.97 44.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.308 -0.87 . . . . 0.0 109.293 179.902 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.632 HD11 ' CD1' ' A' ' 104' ' ' PHE . 5.3 mt -119.76 111.1 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.348 -0.845 . . . . 0.0 109.616 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.667 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -115.27 122.86 47.25 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.336 -0.852 . . . . 0.0 109.219 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.631 HG23 ' HB ' ' A' ' 70' ' ' ILE . 2.5 mp -98.4 142.61 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.233 -0.917 . . . . 0.0 109.543 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.498 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -81.49 155.84 25.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.358 -0.839 . . . . 0.0 109.755 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.467 ' HB2' ' HB3' ' A' ' 17' ' ' SER . 1.0 OUTLIER 52.83 -89.98 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.252 -0.905 . . . . 0.0 109.659 179.928 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.498 ' N ' ' O ' ' A' ' 6' ' ' ALA . 3.0 m 62.85 24.22 14.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.243 -0.911 . . . . 0.0 109.566 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 44.07 -107.46 0.13 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.81 -76.91 0.13 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.26 -1.141 . . . . 0.0 109.494 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -158.2 -43.71 0.06 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.232 -0.918 . . . . 0.0 109.614 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -92.59 -0.44 57.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.2 -0.938 . . . . 0.0 109.55 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -150.12 19.91 1.09 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 8' ' ' SER . 9.7 p -77.02 81.91 3.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.355 -1.085 . . . . 0.0 109.464 -179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.882 ' O ' HG22 ' A' ' 97' ' ' VAL . 2.7 mt-10 -77.22 -137.5 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.192 -0.943 . . . . 0.0 109.025 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.695 ' HA ' HG13 ' A' ' 97' ' ' VAL . 6.1 p -88.75 34.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.066 -1.021 . . . . 0.0 109.587 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.467 ' HB3' ' HB2' ' A' ' 7' ' ' SER . 0.5 OUTLIER 69.32 -157.7 0.17 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.349 -0.845 . . . . 0.0 109.479 179.921 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -154.4 -72.88 0.12 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.528 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -112.38 -164.54 0.92 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.189 -0.944 . . . . 0.0 109.611 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.487 ' CE1' ' HB2' ' A' ' 6' ' ' ALA . 24.8 t80 -158.05 48.98 0.39 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.333 -0.854 . . . . 0.0 109.499 179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -127.27 -68.44 0.15 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.424 ' O ' ' C ' ' A' ' 23' ' ' ALA . 55.1 mtt180 -112.49 16.76 19.72 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.311 -1.111 . . . . 0.0 109.398 179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.424 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -43.46 107.3 0.56 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.323 -0.861 . . . . 0.0 109.619 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -80.57 44.05 1.66 Allowed 'Trans proline' 0 C--N 1.314 -1.286 0 C-N-CA 122.601 2.2 . . . . 0.0 110.604 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.488 ' CE1' ' HG2' ' A' ' 43' ' ' GLU . 4.9 m-85 -158.02 70.09 0.55 Allowed 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.112 -0.993 . . . . 0.0 109.267 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.521 ' CE2' HD11 ' A' ' 61' ' ' ILE . 4.4 m-30 -79.44 121.96 25.82 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.36 -0.837 . . . . 0.0 109.492 -179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -102.9 117.67 35.11 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.241 -0.912 . . . . 0.0 109.325 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.422 HD13 ' HB1' ' A' ' 4' ' ' ALA . 39.7 mm -104.55 130.95 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.219 -0.926 . . . . 0.0 109.526 -179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.77 HG11 HD21 ' A' ' 101' ' ' LEU . 82.8 t -131.33 132.17 63.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.328 -0.857 . . . . 0.0 109.5 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.455 ' HB2' ' CB ' ' A' ' 38' ' ' SER . 7.8 mt-10 -106.64 163.71 12.67 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.322 -0.861 . . . . 0.0 109.376 179.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.54 ' HE3' ' CD1' ' A' ' 3' ' ' ILE . 41.9 ttm -147.74 139.05 23.63 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.174 -0.954 . . . . 0.0 109.538 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.05 -70.5 0.71 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.206 -0.934 . . . . 0.0 109.578 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 6.3 mtmt -136.17 73.99 1.48 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.25 -0.906 . . . . 0.0 109.447 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.617 ' HA2' HG23 ' A' ' 105' ' ' THR . . . 68.53 16.2 69.34 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 -179.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.46 103.21 6.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.316 -1.108 . . . . 0.0 109.456 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.413 HG13 ' CE ' ' A' ' 31' ' ' MET . 2.0 mt -66.68 115.53 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.238 -0.914 . . . . 0.0 109.579 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -130.97 33.63 4.16 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.219 -0.926 . . . . 0.0 109.237 179.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.455 ' CB ' ' HB2' ' A' ' 30' ' ' GLU . 0.6 OUTLIER -161.22 100.11 1.21 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.303 -0.873 . . . . 0.0 109.474 -179.87 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 56.4 m -129.01 104.84 7.81 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.161 -0.962 . . . . 0.0 109.087 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -126.05 125.46 42.66 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.334 -0.854 . . . . 0.0 109.83 -179.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 5.5 p -98.54 139.65 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.378 -0.826 . . . . 0.0 109.119 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 5.5 mt -139.81 142.68 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.177 -0.952 . . . . 0.0 109.727 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.488 ' HG2' ' CE1' ' A' ' 25' ' ' TYR . 12.4 mt-10 -94.9 142.15 27.81 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.298 -0.876 . . . . 0.0 109.531 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.501 ' ND2' ' O ' ' A' ' 44' ' ' ASN . 9.1 p-10 -140.48 75.04 27.64 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.231 -0.918 . . . . 0.0 109.365 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.64 2.14 8.12 Favored 'Trans proline' 0 C--N 1.308 -1.572 0 C-N-CA 122.585 2.19 . . . . 0.0 110.345 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 3.5 m -54.93 -27.73 45.57 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.261 -0.9 . . . . 0.0 109.273 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -71.84 -38.04 70.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.258 -0.901 . . . . 0.0 109.321 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.5 m -90.54 56.02 3.19 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.258 -0.901 . . . . 0.0 109.383 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -129.96 -50.52 1.13 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.299 -0.876 . . . . 0.0 109.534 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -143.74 148.64 35.96 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.146 -0.971 . . . . 0.0 109.541 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 61.08 162.34 0.15 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' A' ' 53' ' ' ALA . . . -86.89 -88.81 1.03 Allowed Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.455 ' O ' ' O ' ' A' ' 52' ' ' GLY . . . 47.87 -174.28 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.21 -1.171 . . . . 0.0 109.407 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.607 ' O ' HG22 ' A' ' 57' ' ' THR . . . 154.0 -54.13 0.44 Allowed Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.438 HD12 ' HB2' ' A' ' 78' ' ' ALA . 24.2 mm -67.87 -8.03 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -1.155 . . . . 0.0 109.646 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -69.24 -33.33 73.11 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.216 -0.927 . . . . 0.0 109.666 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.607 HG22 ' O ' ' A' ' 54' ' ' GLY . 13.2 t -58.82 -15.54 12.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.297 -0.877 . . . . 0.0 109.783 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.85 -46.02 85.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.231 -0.918 . . . . 0.0 109.804 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.722 ' HG3' HD11 ' A' ' 85' ' ' LEU . 52.6 tt0 -65.5 -28.59 69.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.269 -0.894 . . . . 0.0 109.805 -179.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.2 mm -75.9 -29.21 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.175 -0.953 . . . . 0.0 109.718 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.521 HD11 ' CE2' ' A' ' 26' ' ' PHE . 65.8 mt -75.27 -41.54 43.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.147 -0.971 . . . . 0.0 109.636 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -67.45 -26.29 66.32 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.154 -0.966 . . . . 0.0 109.627 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -76.68 -5.77 49.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.192 -0.943 . . . . 0.0 109.674 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -90.94 27.6 1.78 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.136 -0.977 . . . . 0.0 109.618 -179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 2' ' ' LYS . . . 66.72 11.84 58.22 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.667 HG11 ' HB3' ' A' ' 4' ' ' ALA . 96.0 t -87.06 91.81 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.2 -1.177 . . . . 0.0 109.386 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.483 ' O ' ' HB2' ' A' ' 88' ' ' LYS . 39.2 mmtt -79.43 -4.76 52.65 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.432 -0.792 . . . . 0.0 108.863 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.463 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -124.27 107.45 11.2 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.24 -0.913 . . . . 0.0 109.521 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 60.9 t -104.96 119.14 53.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.324 -0.86 . . . . 0.0 109.366 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.631 ' HB ' HG23 ' A' ' 5' ' ' ILE . 3.1 mm -99.24 108.19 21.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.347 -0.846 . . . . 0.0 109.397 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -153.37 173.79 15.18 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.255 -0.903 . . . . 0.0 109.557 -179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.33 49.32 1.43 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.444 -0.785 . . . . 0.0 109.224 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.402 ' OG ' ' HB3' ' A' ' 20' ' ' PHE . 1.0 OUTLIER -50.42 145.53 10.39 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.328 -0.858 . . . . 0.0 109.513 -179.864 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.05 -0.08 10.34 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 122.576 2.184 . . . . 0.0 110.477 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -141.76 154.67 24.95 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.47 -1.66 11.8 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.686 2.257 . . . . 0.0 110.574 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -53.66 -48.19 69.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.237 -0.914 . . . . 0.0 109.643 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.438 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -70.48 -59.29 2.94 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.279 -0.888 . . . . 0.0 109.881 -179.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.717 ' CD1' HG21 ' A' ' 89' ' ' ILE . 25.1 m-85 -46.98 -23.52 0.47 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.206 -0.934 . . . . 0.0 109.934 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 14.7 mm-40 -71.16 -53.05 15.85 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.096 -1.003 . . . . 0.0 109.566 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.429 ' H ' HG23 ' A' ' 81' ' ' VAL . 4.9 t -63.03 -46.46 96.18 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.162 -0.961 . . . . 0.0 109.432 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.522 HD22 HG12 ' A' ' 89' ' ' ILE . 0.0 OUTLIER -52.23 -56.26 15.83 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.287 -0.883 . . . . 0.0 109.399 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.2 m-20 -54.83 -33.41 61.63 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.337 -0.852 . . . . 0.0 109.503 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -63.03 -46.22 88.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.196 -0.94 . . . . 0.0 109.427 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.722 HD11 ' HG3' ' A' ' 59' ' ' GLN . 0.2 OUTLIER -64.62 -11.55 36.34 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.276 -0.89 . . . . 0.0 109.419 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 79.78 31.25 40.7 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.505 HG22 ' H ' ' A' ' 88' ' ' LYS . 5.3 mm -98.05 172.85 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.32 -1.106 . . . . 0.0 109.326 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.505 ' H ' HG22 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -97.82 114.41 26.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.21 -0.932 . . . . 0.0 109.631 -179.798 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.717 HG21 ' CD1' ' A' ' 79' ' ' PHE . 19.8 mt -85.6 149.02 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.38 -0.825 . . . . 0.0 109.181 179.722 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.522 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 0.4 OUTLIER -135.47 122.39 21.23 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.01 -1.056 . . . . 0.0 109.673 -179.987 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.13 121.98 31.16 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.259 -0.901 . . . . 0.0 109.599 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -86.99 106.79 18.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.263 -0.898 . . . . 0.0 109.547 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.429 ' O ' ' C ' ' A' ' 94' ' ' GLY . 6.7 t -122.17 -20.63 6.16 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.272 -0.892 . . . . 0.0 109.732 -179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.448 ' O ' ' HB ' ' A' ' 95' ' ' THR . . . -43.14 -88.11 0.01 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.563 HG23 ' N ' ' A' ' 96' ' ' SER . 5.2 t 176.51 -45.84 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.257 -1.143 . . . . 0.0 109.423 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.563 ' N ' HG23 ' A' ' 95' ' ' THR . 8.5 m -121.93 115.88 23.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.263 -0.898 . . . . 0.0 109.495 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.882 HG22 ' O ' ' A' ' 15' ' ' GLU . 6.4 m -47.14 -35.96 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.26 -0.9 . . . . 0.0 109.591 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 3.2 tt0 -48.19 -49.45 32.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.13 -0.981 . . . . 0.0 109.431 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -73.02 -45.36 58.18 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.26 -0.9 . . . . 0.0 109.642 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.499 ' HA ' HD12 ' A' ' 103' ' ' LEU . 10.4 m-20 -51.41 -24.18 4.61 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.24 -0.913 . . . . 0.0 109.686 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.77 HD21 HG11 ' A' ' 29' ' ' VAL . 19.2 tp -65.51 -66.33 0.56 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.179 -0.951 . . . . 0.0 109.327 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 13.5 ptmt -56.1 -21.09 20.21 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.225 -0.922 . . . . 0.0 109.348 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.986 ' HB3' HD12 ' A' ' 109' ' ' LEU . 10.2 mt -69.87 -45.22 68.17 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.336 -0.852 . . . . 0.0 109.54 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.632 ' CD1' HD11 ' A' ' 3' ' ' ILE . 21.2 t80 -55.54 -19.0 8.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.325 -0.859 . . . . 0.0 109.368 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.617 HG23 ' HA2' ' A' ' 34' ' ' GLY . 96.4 m -59.79 -51.2 70.75 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.27 -0.894 . . . . 0.0 109.483 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.46 ' OE2' HD23 ' A' ' 103' ' ' LEU . 13.6 pt-20 -83.4 -26.18 30.65 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.487 -179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.08 35.72 9.54 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 1.3 t30 -91.43 -6.33 52.95 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.247 -1.149 . . . . 0.0 109.577 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.986 HD12 ' HB3' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -76.63 -161.77 0.22 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.194 -0.942 . . . . 0.0 109.478 179.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 4.5 tt0 -99.26 106.46 18.6 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.162 -0.961 . . . . 0.0 109.663 -179.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.522 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 9.4 pt-20 -110.35 127.89 55.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.308 -0.87 . . . . 0.0 109.328 179.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 5.6 mt -127.83 132.19 69.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.188 -0.945 . . . . 0.0 109.582 -179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 1.1 ptm180 -142.18 177.47 8.21 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.283 -0.885 . . . . 0.0 109.264 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 3.4 m -117.72 158.65 44.94 Favored Pre-proline 0 N--CA 1.49 1.569 0 O-C-N 121.22 -0.925 . . . . 0.0 109.547 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.12 136.48 14.61 Favored 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.645 2.23 . . . . 0.0 110.382 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -148.04 -113.07 0.71 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.628 -1.389 . . . . 0.0 109.628 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -148.94 152.56 36.58 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -1.139 . . . . 0.0 109.487 -179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -65.43 159.27 45.18 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.72 154.82 48.58 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.268 -1.137 . . . . 0.0 109.424 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -177.55 157.43 21.99 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.429 -1.469 . . . . 0.0 109.429 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.457 ' O ' ' O ' ' A' ' 122' ' ' ARG . 0.1 OUTLIER -114.64 13.8 17.48 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.256 -1.143 . . . . 0.0 109.523 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.457 ' O ' ' O ' ' A' ' 121' ' ' ARG . 54.7 mtt-85 53.63 102.67 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.192 -0.943 . . . . 0.0 109.377 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -132.89 148.88 52.29 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.31 -0.869 . . . . 0.0 109.463 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 118.003 -0.998 . . . . 0.0 109.432 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 37.3 mtp . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.248 0.546 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -114.17 150.48 34.14 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.232 -0.917 . . . . 0.0 109.315 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.581 HG12 ' CE2' ' A' ' 104' ' ' PHE . 7.6 mt -120.89 101.82 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.279 -0.888 . . . . 0.0 109.892 -179.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -99.07 103.6 15.54 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.345 -0.847 . . . . 0.0 109.137 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.672 HG22 HG12 ' A' ' 97' ' ' VAL . 7.7 mt -88.13 122.19 39.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.249 -0.907 . . . . 0.0 109.807 -179.606 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.73 ' HB2' ' HE2' ' A' ' 20' ' ' PHE . . . -69.95 147.11 50.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 109.12 179.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.707 ' HB3' HG11 ' A' ' 97' ' ' VAL . 25.8 p -158.63 -178.68 7.44 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.165 -0.96 . . . . 0.0 109.788 -179.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -132.46 11.84 4.5 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.299 -0.876 . . . . 0.0 109.361 179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -150.2 175.37 29.3 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -73.49 -44.97 56.67 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.272 -1.134 . . . . 0.0 109.46 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.426 ' OD2' ' OE1' ' A' ' 98' ' ' GLU . 10.5 t0 -176.93 -51.81 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.17 -0.956 . . . . 0.0 109.436 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.407 HD23 ' C ' ' A' ' 12' ' ' LEU . 8.7 tt -57.06 -29.82 63.74 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.203 -0.936 . . . . 0.0 109.245 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -123.31 18.97 7.73 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.475 ' O ' ' HA ' ' A' ' 96' ' ' SER . 93.9 p -76.89 79.94 3.46 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.259 -1.142 . . . . 0.0 109.517 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.613 ' C ' HG23 ' A' ' 16' ' ' VAL . 4.7 tt0 -77.39 4.27 11.29 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -0.828 . . . . 0.0 109.766 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.774 HG22 HG13 ' A' ' 97' ' ' VAL . 2.5 t 74.91 12.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.131 -0.98 . . . . 0.0 109.241 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 60.4 163.83 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.327 -0.858 . . . . 0.0 109.672 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.21 -44.11 3.03 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.148 179.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.414 ' O ' ' C ' ' A' ' 20' ' ' PHE . 33.7 m-85 -108.28 78.67 1.19 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.319 -0.863 . . . . 0.0 109.235 179.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.73 ' HE2' ' HB2' ' A' ' 6' ' ' ALA . 26.4 t80 -42.73 125.84 3.51 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.272 -0.893 . . . . 0.0 109.565 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -179.69 -66.39 0.07 OUTLIER Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.426 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 7.1 mtt180 -116.71 15.92 15.39 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.211 -1.17 . . . . 0.0 109.654 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.425 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -44.55 104.8 0.4 Allowed Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.234 -0.917 . . . . 0.0 109.491 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.426 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.49 43.14 1.47 Allowed 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.692 2.261 . . . . 0.0 110.794 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 14.8 m-85 -159.91 70.45 0.44 Allowed 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.118 -0.989 . . . . 0.0 109.096 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.48 ' HB2' HG23 ' A' ' 42' ' ' ILE . 32.7 m-85 -79.72 129.35 34.4 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.253 -0.904 . . . . 0.0 109.781 -179.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 3.2 ttt -103.64 102.68 12.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.887 . . . . 0.0 109.162 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.1 mm -90.41 116.76 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.098 -1.001 . . . . 0.0 109.552 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.553 HG11 HD11 ' A' ' 101' ' ' LEU . 3.9 t -118.96 160.17 19.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.289 -0.882 . . . . 0.0 109.705 -179.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.506 ' HB3' ' CB ' ' A' ' 38' ' ' SER . 0.1 OUTLIER -139.18 84.6 2.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.314 -0.866 . . . . 0.0 109.337 -179.972 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.417 ' HB2' ' HE3' ' A' ' 31' ' ' MET . 22.2 ttm -93.58 140.32 29.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.24 -0.912 . . . . 0.0 109.539 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . 0.478 ' HG2' ' N ' ' A' ' 33' ' ' LYS . 14.7 ttpp -83.61 -84.98 0.13 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.304 -0.872 . . . . 0.0 109.495 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.478 ' N ' ' HG2' ' A' ' 32' ' ' LYS . 0.0 OUTLIER -131.38 40.31 3.44 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.265 -0.897 . . . . 0.0 109.622 -179.826 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 119.96 24.93 2.65 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 68.6 m-80 -150.05 105.97 3.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.282 -1.128 . . . . 0.0 109.349 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.416 HG23 ' CG1' ' A' ' 29' ' ' VAL . 1.4 mp -66.48 114.75 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.279 -0.888 . . . . 0.0 109.584 -179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.21 33.06 5.68 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.506 ' CB ' ' HB3' ' A' ' 30' ' ' GLU . 0.2 OUTLIER -179.71 110.84 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.368 -0.832 . . . . 0.0 109.363 179.996 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -138.24 108.84 6.57 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.546 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -126.26 134.12 51.26 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.386 -0.821 . . . . 0.0 109.478 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.8 t -102.21 137.71 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.294 -0.879 . . . . 0.0 109.294 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.614 ' O ' HG23 ' A' ' 42' ' ' ILE . 0.8 OUTLIER -136.81 107.53 5.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.272 -0.892 . . . . 0.0 109.468 -179.935 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.402 ' C ' ' HD3' ' A' ' 45' ' ' PRO . 1.9 mp0 -74.59 171.66 13.44 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.382 -0.824 . . . . 0.0 109.409 -179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.467 ' N ' ' HD3' ' A' ' 45' ' ' PRO . 1.0 OUTLIER -133.85 65.09 69.47 Favored Pre-proline 0 N--CA 1.49 1.531 0 O-C-N 121.29 -0.881 . . . . 0.0 109.556 179.921 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.467 ' HD3' ' N ' ' A' ' 44' ' ' ASN . 35.8 Cg_endo -78.12 172.01 16.18 Favored 'Trans proline' 0 C--N 1.309 -1.516 0 C-N-CA 122.679 2.253 . . . . 0.0 110.363 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . 0.419 ' C ' ' O ' ' A' ' 45' ' ' PRO . 0.5 OUTLIER 44.28 35.37 1.25 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.403 179.956 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -76.68 -18.41 58.56 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.245 -0.909 . . . . 0.0 109.462 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.512 ' O ' ' N ' ' A' ' 50' ' ' SER . 0.6 OUTLIER -87.97 -81.97 0.24 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.285 -0.885 . . . . 0.0 109.425 179.926 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.428 ' N ' ' OG ' ' A' ' 48' ' ' SER . . . 46.36 -93.43 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.237 -0.914 . . . . 0.0 109.525 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.512 ' N ' ' O ' ' A' ' 48' ' ' SER . 0.7 OUTLIER -130.44 112.18 13.0 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.16 -0.963 . . . . 0.0 109.443 -179.937 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 106.32 143.96 11.75 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -90.96 97.69 2.35 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -112.38 105.59 13.9 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.195 -1.179 . . . . 0.0 109.467 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.688 ' O ' HG22 ' A' ' 57' ' ' THR . . . -137.11 -75.15 0.07 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 1.101 HD11 ' HB2' ' A' ' 78' ' ' ALA . 0.9 OUTLIER -74.98 -14.64 15.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.274 -1.133 . . . . 0.0 109.365 179.871 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.73 -13.68 61.39 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.861 . . . . 0.0 109.296 179.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.688 HG22 ' O ' ' A' ' 54' ' ' GLY . 9.2 t -65.78 -25.04 67.07 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.263 -0.898 . . . . 0.0 109.199 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.691 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -53.8 -42.73 68.66 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.375 -0.828 . . . . 0.0 109.527 179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.9 mt-30 -58.98 -35.08 72.6 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.232 -0.918 . . . . 0.0 109.417 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 28.3 mt -72.79 -33.86 45.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.296 -0.877 . . . . 0.0 109.403 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.724 HG23 HG21 ' A' ' 66' ' ' VAL . 38.3 mt -63.19 -40.56 89.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.242 -0.911 . . . . 0.0 109.298 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -63.98 -23.86 67.5 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.207 -0.933 . . . . 0.0 109.37 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -75.15 -21.95 58.46 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.274 -0.891 . . . . 0.0 109.543 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.8 m-20 -80.16 -17.57 52.09 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.262 -0.899 . . . . 0.0 109.514 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.514 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 115.7 -15.28 17.03 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.724 HG21 HG23 ' A' ' 61' ' ' ILE . 57.3 t -44.4 93.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.399 -1.059 . . . . 0.0 109.806 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.514 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -79.5 -9.36 59.6 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.221 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -139.9 126.66 20.61 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.344 -0.847 . . . . 0.0 109.153 179.764 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.601 HG21 HD21 ' A' ' 82' ' ' LEU . 97.6 t -119.21 126.4 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.165 -0.96 . . . . 0.0 109.694 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.646 HD12 HG12 ' A' ' 5' ' ' ILE . 57.7 mt -100.33 117.47 45.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.354 -0.841 . . . . 0.0 109.349 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -148.25 174.51 11.93 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.232 -0.917 . . . . 0.0 109.706 -179.669 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.595 ' HB3' ' HB3' ' A' ' 92' ' ' ALA . 53.7 p -143.26 40.87 1.48 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.365 -0.835 . . . . 0.0 109.373 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.423 ' HB2' ' HD2' ' A' ' 74' ' ' PRO . 11.4 p -51.97 159.14 1.49 Allowed Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.279 -0.888 . . . . 0.0 109.606 -179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.423 ' HD2' ' HB2' ' A' ' 73' ' ' SER . 35.1 Cg_endo -77.57 -31.05 3.56 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.609 2.206 . . . . 0.0 110.541 179.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -118.06 163.71 12.87 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.571 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.5 Cg_endo -79.96 17.21 1.34 Allowed 'Trans proline' 0 C--N 1.31 -1.487 0 C-N-CA 122.831 2.354 . . . . 0.0 111.006 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.404 ' O ' HG23 ' A' ' 81' ' ' VAL . 2.9 m120 -63.1 -52.06 64.15 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.949 -1.095 . . . . 0.0 109.742 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 1.101 ' HB2' HD11 ' A' ' 55' ' ' ILE . . . -61.77 -37.63 85.03 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.308 -0.87 . . . . 0.0 109.774 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.571 ' CD2' ' HA ' ' A' ' 76' ' ' PRO . 4.0 m-30 -66.17 -29.03 69.23 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 109.606 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -71.83 -41.5 68.12 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.167 -0.958 . . . . 0.0 109.566 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.404 HG23 ' O ' ' A' ' 77' ' ' ASN . 3.6 t -66.78 -50.42 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.165 -0.959 . . . . 0.0 109.652 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.601 HD21 HG21 ' A' ' 69' ' ' VAL . 2.3 mp -66.77 -27.45 67.6 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.232 -0.917 . . . . 0.0 109.468 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -65.78 -47.32 75.58 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.216 -0.927 . . . . 0.0 109.245 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -68.25 -31.61 71.21 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.31 -0.869 . . . . 0.0 109.26 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.488 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.4 OUTLIER -66.92 -25.96 66.62 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.289 -0.882 . . . . 0.0 109.386 179.894 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 93.69 22.58 25.78 Favored Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.488 HG12 ' HB3' ' A' ' 85' ' ' LEU . 5.9 mm -101.34 163.0 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.238 -1.154 . . . . 0.0 109.456 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.412 ' CG ' ' O ' ' A' ' 113' ' ' ARG . 12.5 mttm -93.7 133.03 37.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -0.883 . . . . 0.0 109.401 179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.501 HG21 ' CD1' ' A' ' 79' ' ' PHE . 2.0 mt -113.49 135.83 51.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.19 -0.944 . . . . 0.0 109.546 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.505 ' HA ' ' HB3' ' A' ' 111' ' ' GLU . 21.5 m-85 -124.56 151.25 44.97 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.505 -0.747 . . . . 0.0 109.365 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.468 ' O ' ' HG ' ' A' ' 109' ' ' LEU . 6.9 ttt-85 -83.46 152.86 24.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.229 -0.919 . . . . 0.0 109.701 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.595 ' HB3' ' HB3' ' A' ' 72' ' ' SER . . . -106.04 158.91 16.46 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.235 -0.915 . . . . 0.0 109.305 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -96.63 7.35 46.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.167 -0.958 . . . . 0.0 109.589 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 47.96 72.01 0.49 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 17.6 m -150.64 -61.61 0.19 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.308 -1.113 . . . . 0.0 109.356 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.475 ' HA ' ' O ' ' A' ' 14' ' ' SER . 66.4 m -165.98 123.11 1.4 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.233 -0.917 . . . . 0.0 109.525 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.774 HG13 HG22 ' A' ' 16' ' ' VAL . 27.2 m -65.62 -43.92 93.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.237 -0.914 . . . . 0.0 109.378 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . 0.526 ' N ' HG23 ' A' ' 97' ' ' VAL . 0.2 OUTLIER -45.15 -44.06 10.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.229 -0.919 . . . . 0.0 109.406 179.941 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.561 ' HG3' HD13 ' A' ' 103' ' ' LEU . 38.7 tp10 -73.92 -46.83 41.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.275 -0.891 . . . . 0.0 109.477 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.453 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 2.2 m-80 -47.55 -26.21 1.36 Allowed 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.198 -0.938 . . . . 0.0 109.336 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.553 HD11 HG11 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -59.09 -57.03 14.88 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -0.919 . . . . 0.0 109.291 179.867 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.04 -27.61 68.92 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.238 -0.914 . . . . 0.0 109.327 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.561 HD13 ' HG3' ' A' ' 99' ' ' GLU . 0.8 OUTLIER -63.65 -35.08 79.34 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.372 -0.83 . . . . 0.0 109.534 179.984 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.581 ' CE2' HG12 ' A' ' 3' ' ' ILE . 6.1 t80 -63.79 -27.03 68.91 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.193 -0.942 . . . . 0.0 109.608 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 90.8 m -74.49 -19.93 60.18 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.189 -0.945 . . . . 0.0 109.484 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.9 mm-40 -106.17 8.19 31.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.202 -0.936 . . . . 0.0 109.515 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 52.53 40.73 55.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -83.59 -43.24 15.86 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.328 -1.101 . . . . 0.0 109.498 -179.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.529 HD21 ' HA ' ' A' ' 92' ' ' ALA . 1.5 tp -96.45 147.54 23.73 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.32 -0.863 . . . . 0.0 109.292 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.411 ' HG3' ' O ' ' A' ' 109' ' ' LEU . 3.4 mt-10 -176.52 -177.75 0.86 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.091 -1.005 . . . . 0.0 109.862 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.505 ' HB3' ' HA ' ' A' ' 90' ' ' TYR . 1.1 tp10 -177.35 -111.88 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.468 -0.77 . . . . 0.0 109.067 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.521 ' CD1' ' HB3' ' A' ' 79' ' ' PHE . 8.0 mt -79.74 121.53 33.21 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 O-C-N 121.177 -0.952 . . . . 0.0 109.367 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.412 ' O ' ' CG ' ' A' ' 88' ' ' LYS . 0.7 OUTLIER -90.53 -61.56 1.65 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.171 -0.955 . . . . 0.0 109.384 179.915 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 59.29 89.96 0.1 OUTLIER Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.307 -0.871 . . . . 0.0 109.536 179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.63 -167.53 0.49 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.701 2.267 . . . . 0.0 110.405 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -164.57 71.95 0.19 Allowed Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 -179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -143.81 105.19 4.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.191 -1.182 . . . . 0.0 109.41 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 95.38 -178.2 35.36 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -167.71 128.19 1.41 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.267 -1.137 . . . . 0.0 109.539 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 69.64 -140.75 33.87 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.421 ' HG3' ' HD3' ' A' ' 124' ' ' ARG . 0.0 OUTLIER 58.98 26.21 14.76 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.328 -1.101 . . . . 0.0 109.518 -179.964 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -83.93 -37.65 22.05 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.231 -0.918 . . . . 0.0 109.357 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 1.4 mpt_? -65.27 -60.5 2.92 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.275 -0.891 . . . . 0.0 109.436 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.421 ' HD3' ' HG3' ' A' ' 121' ' ' ARG . 10.3 ptm180 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.017 -0.992 . . . . 0.0 109.455 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.3 mmt . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.576 ' N ' ' CD ' ' A' ' 2' ' ' LYS . 0.0 OUTLIER -90.44 133.88 34.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.252 -0.905 . . . . 0.0 109.158 179.915 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.501 ' HB ' HG12 ' A' ' 29' ' ' VAL . 9.4 mm -101.29 104.33 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.338 -0.851 . . . . 0.0 110.207 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.864 ' HB2' HD12 ' A' ' 28' ' ' ILE . . . -110.23 88.46 2.77 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.662 HD12 HG21 ' A' ' 70' ' ' ILE . 9.5 tt -98.81 133.11 42.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.239 -0.913 . . . . 0.0 110.014 -179.142 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -57.72 156.64 8.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.354 -0.841 . . . . 0.0 109.081 179.51 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.698 ' HB3' HG11 ' A' ' 97' ' ' VAL . 0.0 OUTLIER -159.97 178.96 9.19 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.092 -1.005 . . . . 0.0 109.798 -179.873 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.538 ' C ' ' CD2' ' A' ' 25' ' ' TYR . 0.0 OUTLIER -126.73 23.49 6.71 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.386 -0.821 . . . . 0.0 109.189 179.921 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.464 ' HA2' ' CD1' ' A' ' 25' ' ' TYR . . . 153.08 -151.51 23.29 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.882 HG22 HG21 ' A' ' 41' ' ' VAL . 16.1 p -124.97 101.94 7.29 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.185 -1.185 . . . . 0.0 109.353 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 53.9 -154.03 0.26 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.282 -0.886 . . . . 0.0 109.327 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER 60.05 17.96 7.23 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.27 -0.894 . . . . 0.0 109.576 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 118.85 26.06 2.64 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 4.0 m -73.59 83.46 1.54 Allowed 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.301 -1.117 . . . . 0.0 109.281 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.436 ' O ' ' HB ' ' A' ' 16' ' ' VAL . 0.4 OUTLIER -79.4 38.81 0.38 Allowed 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.435 -0.79 . . . . 0.0 110.62 -179.967 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.541 HG12 ' O ' ' A' ' 16' ' ' VAL . 21.2 t 63.55 13.08 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 120.716 -1.24 . . . . 0.0 109.413 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 65.78 177.97 0.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.226 -0.921 . . . . 0.0 109.493 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 7.5 ttt180 -120.26 7.13 10.71 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.184 -0.947 . . . . 0.0 109.596 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 19.2 m-85 -144.02 165.9 26.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.204 -0.935 . . . . 0.0 109.42 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.87 ' CD2' ' HB1' ' A' ' 71' ' ' ALA . 2.3 t80 -132.68 88.81 2.56 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.278 -0.889 . . . . 0.0 109.392 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 158.85 -53.49 0.38 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.922 -1.271 . . . . 0.0 109.922 179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.442 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 5.6 mtp180 -93.58 -19.95 20.69 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.265 -1.138 . . . . 0.0 109.67 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.53 110.24 2.12 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.183 -0.948 . . . . 0.0 109.525 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.502 ' HA ' ' CB ' ' A' ' 44' ' ' ASN . 36.9 Cg_endo -81.29 51.56 3.95 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.614 2.21 . . . . 0.0 110.715 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.538 ' CD2' ' C ' ' A' ' 8' ' ' SER . 4.9 m-85 -159.1 68.91 0.45 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.99 -1.069 . . . . 0.0 109.555 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -84.31 127.05 33.74 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.243 -0.911 . . . . 0.0 109.189 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . 0.78 ' HG3' HG13 ' A' ' 41' ' ' VAL . 1.7 mtt -100.85 121.98 42.64 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.253 -0.904 . . . . 0.0 109.817 -179.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.864 HD12 ' HB2' ' A' ' 4' ' ' ALA . 1.1 tp -121.36 132.2 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.357 -0.839 . . . . 0.0 109.06 179.622 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.772 HG23 ' O ' ' A' ' 38' ' ' SER . 14.1 p -138.89 133.41 41.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.221 -0.924 . . . . 0.0 109.538 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.431 ' HG2' ' N ' ' A' ' 31' ' ' MET . 3.4 tt0 -103.41 138.69 39.81 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.246 -0.909 . . . . 0.0 109.461 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.431 ' N ' ' HG2' ' A' ' 30' ' ' GLU . 11.4 ptp -130.4 153.65 48.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 109.381 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.57 -76.88 0.44 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.235 -0.915 . . . . 0.0 109.688 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.34 -73.17 0.67 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.123 -0.985 . . . . 0.0 109.646 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . -142.68 26.6 2.24 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.62 -1.392 . . . . 0.0 109.62 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -140.36 99.52 3.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.229 -1.16 . . . . 0.0 109.571 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.705 HD13 HD21 ' A' ' 101' ' ' LEU . 7.2 pt -50.1 129.38 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.24 179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -113.43 0.38 14.72 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.159 -0.963 . . . . 0.0 109.817 -179.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.772 ' O ' HG23 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -156.41 110.34 2.73 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.031 -1.043 . . . . 0.0 110.007 -179.839 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -120.63 100.22 7.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.313 -0.867 . . . . 0.0 108.901 179.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -108.05 159.46 16.55 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.188 -0.945 . . . . 0.0 109.912 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.882 HG21 HG22 ' A' ' 10' ' ' THR . 2.8 t -129.29 122.48 56.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.373 -0.83 . . . . 0.0 109.141 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.3 mp -111.74 142.48 24.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.184 -0.947 . . . . 0.0 109.582 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -87.95 158.09 18.76 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.258 -0.901 . . . . 0.0 109.304 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.502 ' CB ' ' HA ' ' A' ' 24' ' ' PRO . 4.0 t-20 -118.99 102.61 48.96 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.217 -0.927 . . . . 0.0 109.506 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -77.1 -169.09 0.67 Allowed 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.407 2.071 . . . . 0.0 110.449 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 54.98 36.0 25.91 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.264 -0.898 . . . . 0.0 109.317 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -72.12 -55.89 6.53 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.437 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -128.37 71.44 1.39 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.128 -0.983 . . . . 0.0 109.58 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -145.74 -87.85 0.1 Allowed 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.225 -0.922 . . . . 0.0 109.492 179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 4.1 t -50.42 -39.23 46.8 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.301 -0.874 . . . . 0.0 109.414 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 172.89 -168.11 41.08 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -97.53 81.89 0.68 Allowed Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -79.87 128.74 33.82 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.32 -1.106 . . . . 0.0 109.729 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.855 ' O ' HG22 ' A' ' 57' ' ' THR . . . -141.82 -61.95 0.03 OUTLIER Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.641 HD12 ' HB2' ' A' ' 78' ' ' ALA . 30.2 mm -76.02 -17.97 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.287 -1.125 . . . . 0.0 109.328 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -76.39 -16.13 59.79 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.32 -0.862 . . . . 0.0 109.307 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.855 HG22 ' O ' ' A' ' 54' ' ' GLY . 11.9 t -72.61 -24.62 61.1 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.282 -0.887 . . . . 0.0 109.47 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -59.65 -36.62 76.76 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.115 -0.99 . . . . 0.0 109.268 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 -71.45 -23.01 61.76 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.294 -0.879 . . . . 0.0 109.523 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.7 mm -76.84 -54.65 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.268 -0.895 . . . . 0.0 109.476 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.607 ' O ' HG22 ' A' ' 66' ' ' VAL . 0.9 OUTLIER -66.79 -27.57 40.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.254 -0.904 . . . . 0.0 109.544 -179.955 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.619 ' HB1' HD22 ' A' ' 85' ' ' LEU . . . -65.98 -34.07 77.26 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.183 -0.948 . . . . 0.0 109.572 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 4.0 m-80 -77.03 -10.17 59.19 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.204 -0.935 . . . . 0.0 109.624 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.1 m-20 -83.61 -12.62 55.81 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.264 -0.898 . . . . 0.0 109.591 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.415 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 97.31 0.89 59.48 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.747 ' O ' HG23 ' A' ' 66' ' ' VAL . 32.8 m -48.03 98.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.181 -1.188 . . . . 0.0 109.761 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.415 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -78.53 -11.2 59.95 Favored 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 178.951 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -139.8 126.31 20.34 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 179.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 71.4 t -126.16 124.79 66.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 120.981 -1.074 . . . . 0.0 109.755 -179.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.662 HG21 HD12 ' A' ' 5' ' ' ILE . 4.2 mp -104.18 96.86 4.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.199 -0.938 . . . . 0.0 109.314 179.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.87 ' HB1' ' CD2' ' A' ' 20' ' ' PHE . . . -130.1 172.36 11.85 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.401 -0.812 . . . . 0.0 109.473 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.424 ' O ' ' C ' ' A' ' 73' ' ' SER . 0.2 OUTLIER -138.64 34.22 2.23 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.29 -0.881 . . . . 0.0 109.555 -179.881 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.424 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.3 OUTLIER -44.57 153.06 0.48 Allowed Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.221 -0.924 . . . . 0.0 109.315 179.914 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.23 -47.38 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.605 2.203 . . . . 0.0 110.335 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.419 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -84.67 141.55 19.62 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.419 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.6 Cg_endo -78.45 -0.68 10.93 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.501 2.134 . . . . 0.0 110.347 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -60.56 -32.51 71.57 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.308 -0.87 . . . . 0.0 109.522 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.641 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -70.04 -54.24 14.01 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.22 -0.925 . . . . 0.0 109.521 -179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.412 ' CD1' HG21 ' A' ' 89' ' ' ILE . 11.3 m-30 -54.64 -24.2 20.5 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.247 -0.908 . . . . 0.0 109.738 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.1 tm-20 -72.43 -37.34 68.63 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.156 -0.965 . . . . 0.0 109.723 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 75.4 t -76.1 -36.23 30.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.219 -0.926 . . . . 0.0 109.77 -179.726 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.56 HD12 ' O ' ' A' ' 78' ' ' ALA . 0.7 OUTLIER -62.01 -36.58 81.94 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.253 -0.904 . . . . 0.0 109.599 -179.85 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -73.51 -24.53 60.17 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.236 -0.915 . . . . 0.0 109.46 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -76.78 -33.41 58.04 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.233 -0.917 . . . . 0.0 109.526 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.619 HD22 ' HB1' ' A' ' 62' ' ' ALA . 0.5 OUTLIER -77.52 -23.65 50.14 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.135 -0.978 . . . . 0.0 109.564 -179.86 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.5 21.59 14.42 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.472 HG22 ' N ' ' A' ' 88' ' ' LYS . 7.7 mt -98.83 158.33 3.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.257 -1.143 . . . . 0.0 109.381 179.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.472 ' N ' HG22 ' A' ' 87' ' ' ILE . 0.2 OUTLIER -90.76 128.58 36.73 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.15 -0.969 . . . . 0.0 109.332 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.538 HG12 ' CB ' ' A' ' 82' ' ' LEU . 5.5 mt -98.91 151.22 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.17 -0.956 . . . . 0.0 109.29 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.573 ' CE1' ' HA ' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -138.54 141.15 39.3 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.321 -0.862 . . . . 0.0 109.225 -179.708 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.42 ' O ' ' HB3' ' A' ' 110' ' ' GLU . 1.5 tpp85 -92.6 128.56 38.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.198 -0.939 . . . . 0.0 109.782 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.44 121.46 25.75 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.326 -0.859 . . . . 0.0 109.486 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -74.12 -27.89 61.08 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.309 -0.87 . . . . 0.0 109.505 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 97.06 61.21 0.94 Allowed Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -130.51 -60.72 0.98 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.192 -1.181 . . . . 0.0 109.451 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 15' ' ' GLU . 0.3 OUTLIER -173.34 150.39 1.86 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.291 -0.881 . . . . 0.0 109.543 -179.878 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.698 HG11 ' HB3' ' A' ' 7' ' ' SER . 4.0 m -72.16 -34.17 49.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.582 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -65.39 -53.29 45.46 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.258 -0.901 . . . . 0.0 109.46 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.482 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 0.3 OUTLIER -58.3 -45.04 88.71 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.329 -0.857 . . . . 0.0 109.709 -179.921 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -61.18 -30.27 70.31 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.205 -0.934 . . . . 0.0 109.847 -179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.705 HD21 HD13 ' A' ' 36' ' ' ILE . 31.7 tp -63.07 -56.51 16.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.176 -0.953 . . . . 0.0 109.648 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.404 ' HG2' ' O ' ' A' ' 102' ' ' LYS . 0.0 OUTLIER -73.86 -11.91 60.51 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.146 -0.972 . . . . 0.0 109.5 -179.906 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.534 HD22 ' OE2' ' A' ' 110' ' ' GLU . 0.3 OUTLIER -76.17 -45.31 34.03 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.232 -0.917 . . . . 0.0 109.497 -179.91 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.551 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 3.5 t80 -76.57 -26.31 54.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.344 -0.847 . . . . 0.0 109.49 -179.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.425 HG23 ' SD ' ' A' ' 31' ' ' MET . 17.7 m -61.4 -33.59 73.94 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.229 -0.919 . . . . 0.0 109.676 -179.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -103.43 8.94 37.95 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.104 -0.997 . . . . 0.0 109.575 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.29 59.13 10.51 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.335 -1.506 . . . . 0.0 109.335 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . 0.565 ' O ' HD12 ' A' ' 109' ' ' LEU . 48.2 t-20 -81.18 -38.77 26.54 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.38 -1.071 . . . . 0.0 109.564 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.565 HD12 ' O ' ' A' ' 108' ' ' ASN . 0.0 OUTLIER 171.0 -156.77 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.162 -0.961 . . . . 0.0 109.735 -179.942 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.565 ' O ' ' CD2' ' A' ' 90' ' ' TYR . 23.2 mt-10 60.59 29.82 19.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.865 . . . . 0.0 109.259 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.573 ' HA ' ' CE1' ' A' ' 90' ' ' TYR . 1.0 OUTLIER -92.44 144.74 25.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.319 -0.863 . . . . 0.0 109.675 -179.823 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.464 HG12 ' O ' ' A' ' 111' ' ' GLU . 9.2 mm -155.67 125.62 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.477 -0.764 . . . . 0.0 109.15 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -129.38 9.86 5.65 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.255 -0.903 . . . . 0.0 109.353 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.43 ' N ' ' HD3' ' A' ' 115' ' ' PRO . 71.5 m 45.13 66.85 4.74 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.29 -0.881 . . . . 0.0 109.626 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.43 ' HD3' ' N ' ' A' ' 114' ' ' SER . 36.1 Cg_endo -78.51 -46.41 0.11 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.654 2.236 . . . . 0.0 110.405 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.05 119.96 0.79 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 3.8 m -101.73 20.58 16.0 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.259 -1.142 . . . . 0.0 109.479 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -81.99 117.77 4.48 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.85 -21.28 7.26 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.264 -1.139 . . . . 0.0 109.389 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 141.52 -158.77 26.65 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 2.2 mmt85 -126.23 175.45 7.79 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.388 -1.066 . . . . 0.0 109.383 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.468 ' HD3' ' N ' ' A' ' 122' ' ' ARG . 0.1 OUTLIER -101.78 -21.73 14.54 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.204 -0.935 . . . . 0.0 109.51 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 7.7 ttt180 -74.29 82.58 1.88 Allowed 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.19 -0.944 . . . . 0.0 109.511 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 1.1 ttt85 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.459 179.97 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.448 ' O ' ' HE3' ' A' ' 2' ' ' LYS . 21.0 ttm . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.357 0.599 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.448 ' HE3' ' O ' ' A' ' 1' ' ' MET . 0.1 OUTLIER -143.44 106.9 4.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.203 -0.935 . . . . 0.0 109.413 -179.996 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.752 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 2.3 mp -107.68 114.77 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.336 -0.853 . . . . 0.0 109.414 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.566 ' HB1' ' CZ ' ' A' ' 26' ' ' PHE . . . -113.24 122.07 46.36 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.235 -0.915 . . . . 0.0 109.347 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.477 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 2.8 mp -96.93 129.22 47.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.174 -0.954 . . . . 0.0 109.568 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.419 ' O ' ' HB3' ' A' ' 7' ' ' SER . . . -68.93 146.86 52.42 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.257 -0.902 . . . . 0.0 109.272 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.419 ' HB3' ' O ' ' A' ' 6' ' ' ALA . 13.3 t 60.05 -94.5 0.05 OUTLIER 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.179 -0.95 . . . . 0.0 109.426 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.621 ' OG ' HG11 ' A' ' 97' ' ' VAL . 8.7 t 63.45 31.42 14.99 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.161 -0.962 . . . . 0.0 109.772 179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 42.53 -105.57 0.07 OUTLIER Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.669 -1.372 . . . . 0.0 109.669 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -158.7 -46.44 0.06 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.251 -1.146 . . . . 0.0 109.411 179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.86 -72.89 0.35 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.185 -0.947 . . . . 0.0 109.637 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 31.6 mt -107.09 -14.7 14.86 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.202 -0.936 . . . . 0.0 109.572 -179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.21 6.12 64.73 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.476 ' HB3' ' O ' ' A' ' 8' ' ' SER . 93.9 p -77.68 77.16 4.2 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.267 -1.137 . . . . 0.0 109.673 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.598 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -77.81 78.49 4.31 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.235 -0.916 . . . . 0.0 109.456 179.881 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.598 HG12 ' O ' ' A' ' 15' ' ' GLU . 11.6 p 41.1 42.31 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.427 -0.795 . . . . 0.0 109.839 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.438 ' OG ' ' C ' ' A' ' 16' ' ' VAL . 0.0 OUTLIER 59.97 -163.54 0.24 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.249 -0.907 . . . . 0.0 109.486 -179.959 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -170.27 -36.32 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.258 -0.901 . . . . 0.0 109.373 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -148.16 140.06 23.94 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.33 -0.856 . . . . 0.0 109.471 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.428 ' CG ' ' O ' ' A' ' 20' ' ' PHE . 12.9 t80 -116.1 38.45 3.36 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.252 -0.905 . . . . 0.0 109.733 -179.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -93.94 -56.76 1.37 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.432 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 18.9 mtt180 -140.16 41.74 1.94 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.29 -1.124 . . . . 0.0 109.111 179.747 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -52.3 108.8 1.17 Allowed Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.41 -0.806 . . . . 0.0 109.744 -179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.482 ' O ' ' HB3' ' A' ' 43' ' ' GLU . 36.7 Cg_endo -80.83 40.9 1.05 Allowed 'Trans proline' 0 C--N 1.312 -1.374 0 C-N-CA 122.561 2.174 . . . . 0.0 110.434 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.422 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 6.2 m-85 -161.11 74.74 0.5 Allowed 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.143 -0.973 . . . . 0.0 108.909 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.566 ' CZ ' ' HB1' ' A' ' 4' ' ' ALA . 16.5 t80 -78.26 112.52 15.33 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.433 -0.792 . . . . 0.0 109.496 -179.439 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 1.6 ttm -94.12 114.48 26.63 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.455 -0.778 . . . . 0.0 109.31 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.405 HG23 ' O ' ' A' ' 28' ' ' ILE . 0.3 OUTLIER -106.62 123.88 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.283 -0.886 . . . . 0.0 109.488 -179.869 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.651 HG12 HG23 ' A' ' 36' ' ' ILE . 2.1 t -121.74 120.64 62.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.24 -0.912 . . . . 0.0 109.636 -179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -116.95 96.81 5.63 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.334 -0.854 . . . . 0.0 109.482 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 21.1 ptp -87.26 167.24 14.27 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.23 -0.919 . . . . 0.0 109.358 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -92.58 -93.62 0.15 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.259 -0.9 . . . . 0.0 109.552 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -112.62 35.59 3.78 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.232 -0.917 . . . . 0.0 109.485 -179.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 120.7 21.66 3.21 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 12.4 t30 -141.04 109.45 5.89 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.175 -1.191 . . . . 0.0 109.381 179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.651 HG23 HG12 ' A' ' 29' ' ' VAL . 4.5 mt -63.25 114.12 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.236 -0.915 . . . . 0.0 109.631 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -123.03 28.55 7.14 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.265 -0.897 . . . . 0.0 109.27 179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -172.96 96.12 0.12 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.324 -0.86 . . . . 0.0 109.434 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.1 m -125.99 103.5 7.78 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.276 -0.89 . . . . 0.0 109.147 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.0 mm-40 -114.52 142.58 46.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.255 -0.903 . . . . 0.0 110.046 -179.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.4 t -116.72 96.21 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.415 -0.803 . . . . 0.0 108.955 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 13.6 mt -121.21 126.8 75.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.148 -0.97 . . . . 0.0 109.812 -179.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.482 ' HB3' ' O ' ' A' ' 24' ' ' PRO . 0.0 OUTLIER -53.65 148.59 9.46 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.353 -0.842 . . . . 0.0 109.582 179.847 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -64.11 148.06 95.89 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.179 -0.951 . . . . 0.0 109.218 179.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -78.3 155.09 28.72 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.68 2.253 . . . . 0.0 110.76 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.8 p 58.31 18.02 5.17 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.347 -0.845 . . . . 0.0 109.902 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.63 -69.24 0.12 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.142 -0.974 . . . . 0.0 109.201 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.78 114.98 26.76 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.327 -0.858 . . . . 0.0 109.188 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -139.2 -172.18 3.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.219 -0.925 . . . . 0.0 109.722 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.6 m -92.61 24.0 3.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.329 -0.857 . . . . 0.0 109.495 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 167.35 76.01 0.03 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.559 -1.417 . . . . 0.0 109.559 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -125.98 164.82 19.41 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -121.36 -57.79 1.82 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.196 -1.179 . . . . 0.0 109.484 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.842 ' O ' HG22 ' A' ' 57' ' ' THR . . . 126.77 -47.99 0.99 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.568 HG23 ' HB2' ' A' ' 78' ' ' ALA . 22.9 mm -75.61 -20.05 15.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.252 -1.146 . . . . 0.0 109.6 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 17.6 tpp180 -69.87 -25.58 63.79 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.323 -0.861 . . . . 0.0 109.505 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.842 HG22 ' O ' ' A' ' 54' ' ' GLY . 11.2 t -56.48 -25.86 52.4 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.234 -0.916 . . . . 0.0 109.561 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.455 ' O ' ' HB ' ' A' ' 61' ' ' ILE . . . -45.27 -41.84 8.99 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.183 -0.948 . . . . 0.0 109.356 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.82 -56.12 15.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.307 -0.871 . . . . 0.0 109.552 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 44.6 mt -54.97 -33.74 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.231 -0.918 . . . . 0.0 109.38 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.455 ' HB ' ' O ' ' A' ' 58' ' ' ALA . 22.9 mm -59.73 -52.72 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.245 -0.909 . . . . 0.0 109.579 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -64.18 -21.52 66.59 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.277 -0.889 . . . . 0.0 109.739 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -75.96 -23.26 55.35 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.222 -0.924 . . . . 0.0 109.656 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -83.83 -16.91 42.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.125 -0.985 . . . . 0.0 109.703 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.469 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 98.37 -2.09 59.09 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.436 HG23 ' H ' ' A' ' 66' ' ' VAL . 3.7 t -42.37 97.87 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.315 -1.109 . . . . 0.0 109.773 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.469 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -79.22 -9.97 59.7 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.081 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.752 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -135.58 118.51 16.3 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.48 -0.763 . . . . 0.0 109.354 179.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.637 ' CG2' HD21 ' A' ' 82' ' ' LEU . 59.3 t -111.6 119.92 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.24 -0.913 . . . . 0.0 109.63 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.477 ' HB ' ' HA ' ' A' ' 5' ' ' ILE . 4.4 mm -102.69 117.12 47.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.149 -0.969 . . . . 0.0 109.551 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -160.03 171.77 18.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.312 -0.868 . . . . 0.0 109.745 -179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 37.4 t -133.71 42.98 2.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.354 -0.841 . . . . 0.0 109.278 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.437 ' OG ' ' HD2' ' A' ' 74' ' ' PRO . 0.2 OUTLIER -51.81 155.57 2.91 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.42 -0.8 . . . . 0.0 109.83 -179.731 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.437 ' HD2' ' OG ' ' A' ' 73' ' ' SER . 35.2 Cg_endo -78.17 -12.1 15.99 Favored 'Trans proline' 0 C--N 1.309 -1.517 0 C-N-CA 122.725 2.283 . . . . 0.0 110.642 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -148.89 154.23 25.69 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.533 ' HA ' ' CD2' ' A' ' 79' ' ' PHE . 36.4 Cg_endo -79.92 38.81 0.77 Allowed 'Trans proline' 0 C--N 1.31 -1.459 0 C-N-CA 122.862 2.375 . . . . 0.0 111.017 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.411 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 1.5 t-20 -77.25 -54.52 6.38 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.966 -1.084 . . . . 0.0 109.675 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.568 ' HB2' HG23 ' A' ' 55' ' ' ILE . . . -66.15 -38.39 88.0 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 109.644 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.598 ' CD1' ' N ' ' A' ' 79' ' ' PHE . 2.7 m-30 -55.41 -33.79 63.83 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.931 . . . . 0.0 109.475 -179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.411 ' HB2' ' O ' ' A' ' 77' ' ' ASN . 16.9 mt-10 -53.19 -55.79 21.52 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.932 . . . . 0.0 109.521 -179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.404 HG23 ' H ' ' A' ' 81' ' ' VAL . 2.4 t -60.89 -39.17 81.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.203 -0.936 . . . . 0.0 109.443 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.929 HD23 HG13 ' A' ' 89' ' ' ILE . 1.3 tp -52.23 -40.8 62.11 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.396 -0.815 . . . . 0.0 109.935 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -73.98 -36.98 64.6 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.128 -0.983 . . . . 0.0 109.81 -179.598 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -66.92 -20.04 65.83 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.268 -0.895 . . . . 0.0 109.822 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.492 ' HA ' HD22 ' A' ' 85' ' ' LEU . 0.2 OUTLIER -102.98 24.68 10.38 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.16 -0.963 . . . . 0.0 109.716 -179.81 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 51.94 65.2 3.37 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.401 HG22 ' N ' ' A' ' 88' ' ' LYS . 75.0 mt -141.03 155.55 21.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.225 -1.162 . . . . 0.0 109.299 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.401 ' N ' HG22 ' A' ' 87' ' ' ILE . 15.6 mttp -101.2 130.89 47.37 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.126 -0.984 . . . . 0.0 109.839 -179.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.929 HG13 HD23 ' A' ' 82' ' ' LEU . 2.2 mp -94.73 160.43 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.338 -0.851 . . . . 0.0 109.425 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.527 ' CE2' ' O ' ' A' ' 109' ' ' LEU . 0.2 OUTLIER -144.51 135.61 25.18 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.336 -0.852 . . . . 0.0 109.394 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -99.01 139.9 33.96 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.303 -0.873 . . . . 0.0 109.476 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.496 ' HB1' HG22 ' A' ' 16' ' ' VAL . . . -81.42 112.22 18.48 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -0.903 . . . . 0.0 109.434 -179.976 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -144.32 16.23 1.68 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.256 -0.902 . . . . 0.0 109.45 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -92.13 -130.45 5.11 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 51.9 m -122.91 -54.87 1.82 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.218 -1.166 . . . . 0.0 109.489 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 2.3 m -127.52 172.09 11.02 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.245 -0.909 . . . . 0.0 109.457 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.621 HG11 ' OG ' ' A' ' 8' ' ' SER . 49.4 t -77.33 -43.82 30.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.319 -0.863 . . . . 0.0 109.612 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -56.46 -34.79 67.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.26 -0.9 . . . . 0.0 109.551 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 48.9 tp10 -75.85 -59.52 2.72 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.252 -0.905 . . . . 0.0 109.518 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.4 HD22 HG21 ' A' ' 70' ' ' ILE . 47.1 t30 -51.02 -22.19 2.19 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.224 -0.923 . . . . 0.0 109.463 -179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 24.0 tp -64.18 -69.59 0.27 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.196 -0.94 . . . . 0.0 109.306 179.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.41 ' O ' ' HG2' ' A' ' 106' ' ' GLU . 0.6 OUTLIER -62.76 -14.82 49.33 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.335 -0.853 . . . . 0.0 109.458 179.97 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -77.0 -32.51 57.26 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 109.619 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.633 ' CE1' HD11 ' A' ' 3' ' ' ILE . 1.9 t80 -71.28 -31.08 67.04 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.277 -0.889 . . . . 0.0 109.59 -179.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 51.6 m -74.26 -21.08 59.92 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.045 -1.034 . . . . 0.0 109.99 -179.425 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.41 ' HG2' ' O ' ' A' ' 102' ' ' LYS . 30.1 mm-40 -92.07 11.86 23.95 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.064 -1.023 . . . . 0.0 109.514 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 53.06 53.68 32.83 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.3 -1.52 . . . . 0.0 109.3 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . 0.487 ' OD1' HD23 ' A' ' 109' ' ' LEU . 1.6 t-20 -79.88 -63.82 1.33 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.348 -1.089 . . . . 0.0 109.469 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.527 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.6 OUTLIER 177.87 -153.56 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.306 -0.871 . . . . 0.0 109.528 179.989 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.519 ' HG3' ' CD1' ' A' ' 109' ' ' LEU . 79.4 mt-10 62.15 27.9 16.78 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.208 -0.933 . . . . 0.0 109.287 -179.867 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.495 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 7.9 pt-20 -108.7 147.74 31.49 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.757 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.442 ' O ' HD12 ' A' ' 89' ' ' ILE . 14.4 mt -151.76 128.39 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.323 -0.861 . . . . 0.0 109.193 179.822 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.434 ' O ' ' O ' ' A' ' 114' ' ' SER . 0.0 OUTLIER -138.36 20.09 2.75 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.235 -0.916 . . . . 0.0 109.805 -179.741 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 113' ' ' ARG . 0.5 OUTLIER 59.62 154.33 0.1 OUTLIER Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.162 -0.961 . . . . 0.0 109.442 179.982 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.38 -28.84 4.25 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.566 2.177 . . . . 0.0 110.519 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 150.44 -118.55 0.93 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -151.92 26.04 0.64 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.205 -1.174 . . . . 0.0 109.561 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 160.1 149.9 5.7 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.35 139.11 24.13 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.185 -1.185 . . . . 0.0 109.499 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 144.49 86.78 0.08 OUTLIER Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.31 -43.51 41.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.332 -1.099 . . . . 0.0 109.396 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.05 141.42 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.273 -0.892 . . . . 0.0 109.596 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.51 ' O ' ' CB ' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -151.61 25.53 0.67 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.287 -0.883 . . . . 0.0 109.257 179.852 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.51 ' CB ' ' O ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 117.978 -1.01 . . . . 0.0 109.485 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.4 mtp . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.795 ' HD3' HG22 ' A' ' 28' ' ' ILE . 0.0 OUTLIER -139.42 140.56 37.4 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.195 -0.94 . . . . 0.0 109.667 -179.849 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.537 ' CG2' HD11 ' A' ' 70' ' ' ILE . 5.5 mt -110.41 99.67 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.46 -0.775 . . . . 0.0 109.824 -179.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.641 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -100.07 115.39 29.64 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.337 -0.852 . . . . 0.0 109.08 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.652 HG13 HD12 ' A' ' 70' ' ' ILE . 3.4 mp -92.04 142.47 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.217 -0.927 . . . . 0.0 109.756 -179.741 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.502 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -80.39 171.62 14.83 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.295 -0.878 . . . . 0.0 109.546 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.547 ' HA ' ' HB1' ' A' ' 23' ' ' ALA . 71.7 m 47.95 -93.02 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.251 -0.906 . . . . 0.0 109.522 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.502 ' N ' ' O ' ' A' ' 6' ' ' ALA . 41.0 t 52.9 25.39 3.91 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.083 -1.011 . . . . 0.0 109.528 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 8' ' ' SER . . . 44.38 -101.41 0.03 OUTLIER Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.59 -67.1 0.19 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.212 -1.17 . . . . 0.0 109.479 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.5 t0 -158.66 -79.41 0.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.156 -0.965 . . . . 0.0 109.592 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -60.17 -19.82 55.71 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.147 -0.971 . . . . 0.0 109.515 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -130.68 37.46 2.11 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 58.6 m -76.49 82.07 3.19 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.24 -1.153 . . . . 0.0 109.254 179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.49 ' HG3' ' N ' ' A' ' 16' ' ' VAL . 5.3 pt-20 -77.14 -134.38 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.266 -0.896 . . . . 0.0 109.054 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.775 HG13 ' O ' ' A' ' 16' ' ' VAL . 12.2 p -154.45 67.24 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 120.99 -1.069 . . . . 0.0 109.422 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.0 m -52.6 156.94 1.69 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.253 -0.904 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -102.53 12.85 35.86 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.287 -0.883 . . . . 0.0 109.447 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -107.49 103.54 12.89 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.274 -0.891 . . . . 0.0 109.451 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -101.79 127.51 48.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.162 -0.961 . . . . 0.0 109.435 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 150.29 -64.49 0.39 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.451 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 3.6 ttt180 -91.85 -12.44 33.64 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.229 -1.16 . . . . 0.0 109.362 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.573 ' O ' ' CE1' ' A' ' 26' ' ' PHE . . . -41.48 101.82 0.25 Allowed Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.528 -0.732 . . . . 0.0 109.752 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.491 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.8 Cg_endo -80.91 44.23 1.71 Allowed 'Trans proline' 0 C--N 1.311 -1.419 0 C-N-CA 122.653 2.236 . . . . 0.0 110.574 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.491 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 31.6 m-85 -160.07 70.21 0.43 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.015 -1.053 . . . . 0.0 109.641 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.573 ' CE1' ' O ' ' A' ' 23' ' ' ALA . 18.8 m-30 -80.35 111.5 16.8 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.178 -0.951 . . . . 0.0 109.377 179.704 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . 0.417 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 6.3 ttm -90.56 116.67 28.64 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.276 -0.89 . . . . 0.0 109.509 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.795 HG22 ' HD3' ' A' ' 2' ' ' LYS . 7.2 mm -101.99 108.36 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.272 -0.893 . . . . 0.0 109.437 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.676 ' CG1' HD12 ' A' ' 36' ' ' ILE . 96.8 t -104.47 142.34 18.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.264 -0.898 . . . . 0.0 109.553 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.457 ' O ' ' OG ' ' A' ' 38' ' ' SER . 32.5 tt0 -137.28 100.87 4.37 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.329 -0.857 . . . . 0.0 109.53 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.886 ' HB3' HD13 ' A' ' 36' ' ' ILE . 4.5 ptp -95.75 155.22 16.84 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.276 -0.89 . . . . 0.0 109.252 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 27.4 mmtm -102.26 -46.77 4.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.241 -0.912 . . . . 0.0 109.877 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.42 ' O ' ' C ' ' A' ' 34' ' ' GLY . 1.5 ttpp -146.27 92.62 2.2 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.21 -0.931 . . . . 0.0 109.639 -179.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 43.36 28.2 0.88 Allowed Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.1 m-20 -151.06 111.01 4.08 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.205 -1.173 . . . . 0.0 109.387 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.886 HD13 ' HB3' ' A' ' 31' ' ' MET . 49.1 mm -56.74 116.91 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.236 -0.915 . . . . 0.0 109.588 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -116.34 18.54 15.19 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.317 -0.864 . . . . 0.0 109.415 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' A' ' 30' ' ' GLU . 0.7 OUTLIER -174.94 127.52 0.29 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.317 -0.864 . . . . 0.0 109.527 -179.877 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.22 110.94 6.48 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.247 -0.908 . . . . 0.0 109.329 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -125.15 106.34 9.83 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.237 -0.914 . . . . 0.0 109.74 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.514 ' O ' HG13 ' A' ' 41' ' ' VAL . 14.9 p -97.15 124.49 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.24 -0.912 . . . . 0.0 109.247 179.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.0 pt -122.52 161.02 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.26 -0.9 . . . . 0.0 109.778 -179.656 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -104.0 159.81 15.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.346 -0.846 . . . . 0.0 109.379 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.9 m120 -137.15 81.95 31.01 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.297 -0.877 . . . . 0.0 109.238 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.37 -2.77 12.8 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 122.686 2.257 . . . . 0.0 110.682 -179.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 1.5 m -69.02 -18.08 63.99 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.177 -0.952 . . . . 0.0 109.531 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.33 -52.11 48.41 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.219 -0.926 . . . . 0.0 109.537 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 25.9 t -99.15 47.74 0.96 Allowed 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.246 -0.909 . . . . 0.0 109.567 -179.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . 0.414 ' O ' ' C ' ' A' ' 50' ' ' SER . . . -156.6 -65.44 0.1 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.236 -0.915 . . . . 0.0 109.482 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.414 ' C ' ' O ' ' A' ' 49' ' ' ALA . 15.8 m -43.85 -52.96 6.4 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.286 -0.884 . . . . 0.0 109.479 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 120.56 139.8 5.88 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 122.3 -133.84 9.47 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -111.46 -32.04 6.83 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.305 -1.114 . . . . 0.0 109.488 -179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.517 ' O ' HG22 ' A' ' 57' ' ' THR . . . 110.32 -33.07 6.19 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.61 -1.396 . . . . 0.0 109.61 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.513 HG21 ' HB2' ' A' ' 78' ' ' ALA . 23.8 mt -73.88 -9.18 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.303 -1.116 . . . . 0.0 109.47 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.466 ' NH1' ' HG3' ' A' ' 56' ' ' ARG . 0.0 OUTLIER -69.03 -23.44 64.07 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.211 -0.93 . . . . 0.0 109.532 179.978 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.708 ' HA ' HD12 ' A' ' 60' ' ' ILE . 13.0 t -64.29 -14.18 54.36 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.208 -0.933 . . . . 0.0 109.673 -179.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -54.25 -46.11 72.52 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.167 -0.958 . . . . 0.0 109.439 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -52.11 -36.77 52.06 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.141 -0.974 . . . . 0.0 109.472 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.708 HD12 ' HA ' ' A' ' 57' ' ' THR . 6.6 mt -74.81 -33.56 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.266 -0.896 . . . . 0.0 109.609 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 61.0 mt -61.39 -36.69 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.178 -0.951 . . . . 0.0 109.4 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -70.72 -21.68 62.52 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.281 -0.887 . . . . 0.0 109.61 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -75.09 -9.68 58.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.118 -0.989 . . . . 0.0 109.283 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -88.59 -21.83 23.84 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.245 -0.909 . . . . 0.0 109.476 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 120.02 17.66 4.49 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.641 HG11 ' HB3' ' A' ' 4' ' ' ALA . 17.9 t -87.16 89.9 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.222 -1.164 . . . . 0.0 109.483 179.883 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.627 ' HA ' HG23 ' A' ' 87' ' ' ILE . 4.3 tttp -79.54 -7.97 58.84 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.364 -0.835 . . . . 0.0 108.984 179.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 2' ' ' LYS . . . -130.83 113.96 14.73 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.112 -0.993 . . . . 0.0 109.319 179.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 93.4 t -112.02 123.84 68.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.106 -0.996 . . . . 0.0 109.705 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.754 ' CG2' ' HB2' ' A' ' 92' ' ' ALA . 80.9 mt -103.14 116.36 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.397 -0.814 . . . . 0.0 109.186 179.766 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -147.91 175.42 10.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.161 -0.962 . . . . 0.0 109.934 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.02 57.36 1.48 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.508 -0.745 . . . . 0.0 109.23 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 22.2 m -65.18 155.57 83.96 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.199 -0.938 . . . . 0.0 109.614 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.18 -18.8 12.49 Favored 'Trans proline' 0 C--N 1.309 -1.535 0 C-N-CA 122.752 2.301 . . . . 0.0 110.312 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -129.99 162.38 23.01 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.16 9.9 3.18 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 C-N-CA 122.814 2.343 . . . . 0.0 110.755 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -60.9 -55.03 37.82 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.065 -1.022 . . . . 0.0 109.655 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.513 ' HB2' HG21 ' A' ' 55' ' ' ILE . . . -56.06 -52.33 64.66 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.246 -0.909 . . . . 0.0 109.498 -179.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.702 ' CD1' HG21 ' A' ' 89' ' ' ILE . 12.9 m-30 -53.55 -30.1 40.25 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.226 -0.921 . . . . 0.0 109.628 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -68.79 -42.51 77.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.276 -0.89 . . . . 0.0 109.632 -179.836 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 47.3 t -65.36 -53.09 44.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.184 -0.947 . . . . 0.0 109.478 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 53.5 mt -59.66 -28.01 66.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.27 -0.894 . . . . 0.0 109.639 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.478 ' HB2' ' O ' ' A' ' 79' ' ' PHE . 1.4 t-20 -69.06 -44.81 71.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.197 -0.94 . . . . 0.0 109.268 179.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -68.85 -23.58 64.26 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.207 -0.933 . . . . 0.0 109.17 179.775 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.43 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.0 OUTLIER -75.21 -35.39 61.5 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.271 -0.893 . . . . 0.0 109.484 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 101.75 25.01 8.29 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.627 HG23 ' HA ' ' A' ' 67' ' ' LYS . 30.5 mm -105.49 169.9 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.253 -1.145 . . . . 0.0 109.592 -179.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.554 ' N ' HG22 ' A' ' 87' ' ' ILE . 5.4 mttt -93.71 134.91 35.54 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.285 -0.884 . . . . 0.0 109.536 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.702 HG21 ' CD1' ' A' ' 79' ' ' PHE . 4.3 mt -107.06 142.55 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.287 -0.883 . . . . 0.0 109.464 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.551 ' N ' ' CD1' ' A' ' 90' ' ' TYR . 4.5 m-85 -130.8 148.76 52.62 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.514 -0.741 . . . . 0.0 109.558 -179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.428 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 1.1 ttt180 -104.61 128.86 52.73 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.251 -0.906 . . . . 0.0 109.351 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.754 ' HB2' ' CG2' ' A' ' 70' ' ' ILE . . . -108.49 116.51 32.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.159 -0.963 . . . . 0.0 109.713 -179.778 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 4.4 m -145.59 21.3 1.49 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.348 -0.845 . . . . 0.0 109.37 179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.79 -111.63 0.03 OUTLIER Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 1.6 t -142.08 -40.39 0.36 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.236 -1.155 . . . . 0.0 109.803 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 3.1 m -142.6 131.23 22.58 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.21 -0.931 . . . . 0.0 109.615 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 15' ' ' GLU . 19.9 t -56.18 -19.99 8.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.308 -0.87 . . . . 0.0 109.307 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -60.37 -64.3 1.0 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.278 -0.889 . . . . 0.0 109.313 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.63 ' O ' HD12 ' A' ' 103' ' ' LEU . 4.6 mt-10 -67.21 -24.59 65.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.355 -0.84 . . . . 0.0 109.305 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.476 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 18.1 t-20 -68.19 -29.48 68.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.285 -0.885 . . . . 0.0 109.427 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.449 HD11 HG11 ' A' ' 29' ' ' VAL . 33.2 tp -62.66 -68.67 0.31 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.182 -0.949 . . . . 0.0 109.164 179.831 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 10.0 tttp -59.24 -21.94 60.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.204 -0.935 . . . . 0.0 109.149 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.63 HD12 ' O ' ' A' ' 99' ' ' GLU . 1.5 mt -68.73 -34.92 76.43 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.394 -0.817 . . . . 0.0 109.448 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.536 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.5 t80 -53.94 -30.71 47.8 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.203 -0.936 . . . . 0.0 109.254 179.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 34.9 m -64.19 -39.62 94.37 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.244 -0.91 . . . . 0.0 109.42 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.494 ' OE1' HD23 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -82.99 -11.85 57.77 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.297 -0.877 . . . . 0.0 109.338 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.489 ' HA2' ' OE2' ' A' ' 110' ' ' GLU . . . 65.08 40.31 96.89 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -80.9 -12.87 59.33 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -1.153 . . . . 0.0 109.407 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.43 ' C ' ' HG2' ' A' ' 110' ' ' GLU . 0.2 OUTLIER -152.6 111.37 3.78 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.261 -0.899 . . . . 0.0 109.259 179.867 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.489 ' OE2' ' HA2' ' A' ' 107' ' ' GLY . 5.9 mt-10 -140.97 -149.19 0.26 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.91 . . . . 0.0 109.819 -179.662 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.496 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 0.5 OUTLIER -168.63 -114.87 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.34 -0.85 . . . . 0.0 109.315 -179.794 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.3 mt -87.81 149.56 4.03 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.092 -1.005 . . . . 0.0 109.427 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.479 ' HA ' ' HG2' ' A' ' 88' ' ' LYS . 0.1 OUTLIER -114.05 -93.73 0.48 Allowed 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.218 -0.926 . . . . 0.0 109.692 -179.737 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.483 ' OG ' ' HD2' ' A' ' 115' ' ' PRO . 0.1 OUTLIER -125.6 166.0 23.51 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.197 -0.94 . . . . 0.0 109.689 -179.657 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.483 ' HD2' ' OG ' ' A' ' 114' ' ' SER . 36.1 Cg_endo -78.22 98.85 1.23 Allowed 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.702 2.268 . . . . 0.0 110.448 179.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.55 -52.55 2.29 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 93.4 p -128.15 24.2 5.98 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.327 -1.102 . . . . 0.0 109.432 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -114.2 -177.15 19.14 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.5 ptp180 -59.15 -173.34 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.208 -1.172 . . . . 0.0 109.432 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 117.66 -97.53 0.73 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.82 156.95 4.38 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.248 -1.148 . . . . 0.0 109.403 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -95.69 -148.33 0.29 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.279 -0.888 . . . . 0.0 109.465 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 40.5 mtm180 -81.16 149.08 29.27 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.219 -0.926 . . . . 0.0 109.413 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 15.4 mtm180 . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.585 -179.967 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.4 mtp . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.441 ' HG2' ' CG ' ' A' ' 30' ' ' GLU . 0.5 OUTLIER -91.2 142.4 27.76 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.293 -0.88 . . . . 0.0 109.494 179.994 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.622 ' CG2' HD11 ' A' ' 70' ' ' ILE . 4.9 mt -118.67 116.08 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.296 -0.877 . . . . 0.0 109.779 -179.773 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -114.91 119.73 37.53 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.344 -0.847 . . . . 0.0 109.03 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.931 HG12 HD13 ' A' ' 70' ' ' ILE . 8.6 mt -100.68 140.73 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.21 -0.931 . . . . 0.0 109.801 -179.56 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.502 ' HB2' ' CE2' ' A' ' 26' ' ' PHE . . . -106.73 138.49 42.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.279 -0.888 . . . . 0.0 109.141 179.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.512 ' HB3' HG11 ' A' ' 97' ' ' VAL . 39.4 p -163.3 -148.73 0.13 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.215 -0.928 . . . . 0.0 109.524 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.548 ' O ' ' CD2' ' A' ' 25' ' ' TYR . 20.3 t -122.35 -65.35 1.12 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.263 -0.898 . . . . 0.0 109.546 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -59.98 168.34 8.32 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 1.2 p -87.38 -42.27 12.98 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.209 -1.171 . . . . 0.0 109.512 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -173.81 -40.74 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.193 -0.942 . . . . 0.0 109.709 179.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.1 mt -84.19 -10.85 57.39 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.156 -0.965 . . . . 0.0 109.629 -179.824 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -137.91 8.31 3.58 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.456 ' OG ' HG22 ' A' ' 97' ' ' VAL . 79.9 p -77.11 80.17 3.63 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.184 -1.186 . . . . 0.0 109.467 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.466 ' C ' HG23 ' A' ' 16' ' ' VAL . 2.6 pt-20 -76.85 1.68 16.76 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.255 -0.903 . . . . 0.0 109.702 -179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.685 HG22 HG13 ' A' ' 97' ' ' VAL . 3.5 t 71.38 73.29 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.13 -0.981 . . . . 0.0 109.655 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.22 -164.46 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.297 -0.877 . . . . 0.0 109.46 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -118.98 26.74 9.31 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.214 -0.929 . . . . 0.0 109.617 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -117.23 115.31 25.05 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.237 -0.914 . . . . 0.0 109.604 -179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.589 ' CG ' ' O ' ' A' ' 20' ' ' PHE . 45.6 t80 -112.44 38.4 2.75 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.309 -0.869 . . . . 0.0 109.159 179.731 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -99.27 -84.37 1.79 Allowed Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.449 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.0 OUTLIER -90.21 67.46 6.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.255 -1.144 . . . . 0.0 109.485 -179.946 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -47.1 105.45 0.49 Allowed Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.356 -0.84 . . . . 0.0 109.567 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.549 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.0 Cg_endo -78.73 -3.37 13.22 Favored 'Trans proline' 0 C--N 1.31 -1.467 0 C-N-CA 122.461 2.107 . . . . 0.0 110.365 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.549 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 71.4 m-85 -160.52 72.67 0.48 Allowed 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.177 -0.952 . . . . 0.0 109.235 -179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.502 ' CE2' ' HB2' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -79.02 114.8 18.26 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.305 -0.872 . . . . 0.0 109.471 -179.768 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . 0.424 ' HG3' HG22 ' A' ' 41' ' ' VAL . 0.1 OUTLIER -87.57 114.15 23.91 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.339 -0.851 . . . . 0.0 109.39 -179.974 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.469 ' O ' HG23 ' A' ' 28' ' ' ILE . 0.5 OUTLIER -102.61 126.73 56.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.261 -0.899 . . . . 0.0 109.594 -179.934 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 69.4 t -124.01 138.44 53.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.289 -0.882 . . . . 0.0 109.293 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.441 ' CG ' ' HG2' ' A' ' 2' ' ' LYS . 0.5 OUTLIER -124.28 116.8 23.24 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.209 -0.932 . . . . 0.0 109.544 179.938 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.468 ' SD ' ' CD1' ' A' ' 3' ' ' ILE . 4.4 ptp -114.68 141.92 47.17 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.276 -0.89 . . . . 0.0 109.477 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 2.7 tttp -84.48 -80.83 0.19 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.285 -0.884 . . . . 0.0 109.455 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 12.4 tppt? -117.12 87.45 2.7 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.225 -0.922 . . . . 0.0 109.391 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 51.66 26.52 16.82 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -140.8 97.62 3.23 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.214 -1.168 . . . . 0.0 109.559 -179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.472 HD11 ' OG ' ' A' ' 39' ' ' SER . 6.6 tt -49.67 137.12 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.196 -0.94 . . . . 0.0 109.55 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.504 ' C ' ' HG ' ' A' ' 38' ' ' SER . 0.0 OUTLIER -135.54 18.79 3.33 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 109.526 179.939 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.504 ' HG ' ' C ' ' A' ' 37' ' ' GLU . 0.0 OUTLIER -178.05 128.79 0.13 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.17 -0.956 . . . . 0.0 109.6 -179.958 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.472 ' OG ' HD11 ' A' ' 36' ' ' ILE . 0.4 OUTLIER -143.39 111.46 6.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.291 -0.881 . . . . 0.0 109.151 179.696 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -131.01 162.93 28.69 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.242 -0.911 . . . . 0.0 109.799 -179.617 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.424 HG22 ' HG3' ' A' ' 27' ' ' MET . 21.8 t -120.45 148.61 23.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.371 -0.831 . . . . 0.0 109.184 179.789 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.409 ' O ' ' HA ' ' A' ' 25' ' ' TYR . 7.1 mt -123.07 129.92 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.154 -0.966 . . . . 0.0 109.792 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -108.88 100.12 9.37 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.307 -0.87 . . . . 0.0 109.211 179.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -47.28 144.3 4.47 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.273 -0.892 . . . . 0.0 109.617 -179.7 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.2 -45.0 0.12 Allowed 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.681 2.254 . . . . 0.0 110.596 -179.827 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -92.13 29.61 1.6 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.215 -0.928 . . . . 0.0 109.609 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -73.93 -13.26 60.87 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.245 -0.909 . . . . 0.0 109.348 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.8 m -104.3 8.08 35.92 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.372 -0.83 . . . . 0.0 109.497 179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -104.03 -176.53 3.11 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.187 -0.945 . . . . 0.0 109.493 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 8.6 t -54.59 143.86 23.33 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.222 -0.924 . . . . 0.0 109.528 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -104.62 87.65 0.56 Allowed Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -80.54 -116.72 0.34 Allowed Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -77.74 102.76 7.3 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.268 -1.136 . . . . 0.0 109.47 179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.77 -16.24 31.7 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 -179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.758 HD12 ' HB2' ' A' ' 78' ' ' ALA . 47.5 mm -66.15 -14.65 17.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -1.189 . . . . 0.0 109.525 -179.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.78 -22.87 60.77 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.256 -0.902 . . . . 0.0 109.433 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.462 ' O ' HG13 ' A' ' 61' ' ' ILE . 21.8 m -55.7 -25.32 39.37 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 109.533 179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -57.31 -55.65 32.07 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.233 -0.917 . . . . 0.0 109.641 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -51.69 -37.93 52.81 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.161 -0.962 . . . . 0.0 109.587 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 72.9 mt -64.28 -38.01 81.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.29 -0.882 . . . . 0.0 109.655 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.48 ' CG2' HG21 ' A' ' 66' ' ' VAL . 36.7 mt -72.95 -21.96 19.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.22 -0.925 . . . . 0.0 109.652 -179.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.418 ' HB1' HD22 ' A' ' 85' ' ' LEU . . . -71.46 -28.66 64.11 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.165 -0.959 . . . . 0.0 109.487 -179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -74.78 -2.72 27.83 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.347 -0.845 . . . . 0.0 109.687 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -98.61 -18.25 18.21 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.094 -1.004 . . . . 0.0 109.603 -179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.521 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 102.8 -9.51 55.33 Favored Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.48 HG21 ' CG2' ' A' ' 61' ' ' ILE . 94.0 t -42.61 94.99 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.327 -1.102 . . . . 0.0 109.702 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.521 ' N ' ' O ' ' A' ' 65' ' ' GLY . 24.0 mmtt -79.3 -3.81 47.83 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.379 -0.826 . . . . 0.0 108.863 179.398 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.487 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -139.67 132.29 28.84 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.274 -0.891 . . . . 0.0 109.449 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 89.8 t -128.66 122.19 56.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.182 -0.949 . . . . 0.0 109.752 -179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.931 HD13 HG12 ' A' ' 5' ' ' ILE . 2.1 mp -99.28 116.61 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.226 -0.921 . . . . 0.0 109.245 179.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -152.46 175.01 13.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.258 -0.901 . . . . 0.0 109.567 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.504 ' OG ' ' HB3' ' A' ' 92' ' ' ALA . 3.7 m -137.14 39.66 2.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.428 -0.795 . . . . 0.0 109.288 179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.422 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 7.4 m -50.1 134.64 22.64 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.242 -0.911 . . . . 0.0 109.41 -179.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.2 Cg_endo -79.66 -20.72 9.08 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.458 2.106 . . . . 0.0 110.456 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.4 ' HA2' ' HD3' ' A' ' 76' ' ' PRO . . . -104.69 149.43 16.91 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -179.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.4 ' HD3' ' HA2' ' A' ' 75' ' ' GLY . 35.6 Cg_endo -78.39 -0.33 10.61 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 C-N-CA 122.717 2.278 . . . . 0.0 110.287 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -67.56 -49.88 61.1 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.261 -0.899 . . . . 0.0 109.487 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.758 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -61.28 -53.4 57.21 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.329 -0.857 . . . . 0.0 109.458 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -56.39 -20.3 18.82 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.341 -0.85 . . . . 0.0 109.522 -179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.428 ' O ' ' HG3' ' A' ' 84' ' ' GLU . 1.2 tp10 -75.27 -45.88 37.13 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.228 -0.92 . . . . 0.0 109.557 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.448 ' HA ' ' HB2' ' A' ' 84' ' ' GLU . 6.3 t -67.58 -41.71 86.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.276 -0.89 . . . . 0.0 109.587 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.502 ' HA ' HD13 ' A' ' 82' ' ' LEU . 4.2 mm? -51.75 -56.93 10.93 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.127 -0.983 . . . . 0.0 109.48 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 1.2 t30 -65.15 -22.14 66.88 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.881 . . . . 0.0 109.444 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.448 ' HB2' ' HA ' ' A' ' 81' ' ' VAL . 5.1 mt-10 -74.17 -25.75 59.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.265 -0.897 . . . . 0.0 109.403 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.418 HD22 ' HB1' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -88.13 -30.85 19.52 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.224 -0.922 . . . . 0.0 109.488 -179.991 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 104.63 42.58 1.82 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 1.7 mt -122.66 155.98 27.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.275 -1.133 . . . . 0.0 109.375 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.522 ' HD2' ' N ' ' A' ' 88' ' ' LYS . 0.0 OUTLIER -81.66 138.22 35.32 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.167 -0.958 . . . . 0.0 109.521 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . . . . . . . . . 3.0 mt -106.98 155.42 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.208 -0.932 . . . . 0.0 109.539 -179.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.567 ' CZ ' ' CD2' ' A' ' 104' ' ' PHE . 1.0 OUTLIER -133.9 138.84 45.79 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.286 -0.884 . . . . 0.0 109.531 179.97 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.515 ' NE ' ' HA ' ' A' ' 110' ' ' GLU . 1.3 ptt-85 -97.76 113.4 25.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.289 -0.882 . . . . 0.0 109.291 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.504 ' HB3' ' OG ' ' A' ' 72' ' ' SER . . . -79.76 125.0 29.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.259 -0.9 . . . . 0.0 109.565 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 76.0 p -67.57 -42.12 83.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.259 -0.901 . . . . 0.0 109.433 179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 119.73 97.74 1.71 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -168.87 -69.87 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.2 -1.177 . . . . 0.0 109.474 179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -166.64 120.07 1.04 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.194 -0.941 . . . . 0.0 109.493 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.685 HG13 HG22 ' A' ' 16' ' ' VAL . 35.8 m -55.33 -21.47 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.207 -0.933 . . . . 0.0 109.589 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -61.48 -51.23 69.51 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.156 -0.965 . . . . 0.0 109.585 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.439 ' O ' HD12 ' A' ' 103' ' ' LEU . 4.9 mt-10 -77.19 -32.93 56.42 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -0.922 . . . . 0.0 109.768 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -60.21 -30.64 69.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.196 -0.94 . . . . 0.0 109.571 -179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 36.1 tp -68.25 -57.65 5.65 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.171 -0.955 . . . . 0.0 109.547 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.427 ' O ' ' CG ' ' A' ' 106' ' ' GLU . 0.0 OUTLIER -62.04 -20.54 64.06 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.224 -0.923 . . . . 0.0 109.518 -179.923 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.77 HD23 ' CB ' ' A' ' 108' ' ' ASN . 0.1 OUTLIER -76.96 -41.29 43.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.131 -0.981 . . . . 0.0 109.701 -179.876 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.567 ' CD2' ' CZ ' ' A' ' 90' ' ' TYR . 4.3 t80 -57.7 -53.8 54.08 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.197 -0.939 . . . . 0.0 109.312 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 9.7 m -67.87 -19.54 65.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.252 -0.905 . . . . 0.0 109.475 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.427 ' CG ' ' O ' ' A' ' 102' ' ' LYS . 4.4 mm-40 -83.44 9.27 11.52 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.337 -0.852 . . . . 0.0 109.302 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 51.66 45.13 54.78 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . 0.77 ' CB ' HD23 ' A' ' 103' ' ' LEU . 1.9 m120 -79.84 -66.32 0.89 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.306 -1.114 . . . . 0.0 109.498 -179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.58 HD12 ' HG3' ' A' ' 110' ' ' GLU . 0.7 OUTLIER 173.81 -159.83 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.301 -0.875 . . . . 0.0 109.372 -179.906 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.58 ' HG3' HD12 ' A' ' 109' ' ' LEU . 30.8 mt-10 73.29 30.03 1.6 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.282 -0.886 . . . . 0.0 109.482 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -104.44 147.12 27.92 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.239 -0.913 . . . . 0.0 109.536 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 7.8 mt -142.15 125.21 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.281 -0.887 . . . . 0.0 109.153 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.48 ' HG2' ' HE2' ' A' ' 88' ' ' LYS . 21.6 mtt180 -111.12 -58.02 2.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.347 -0.846 . . . . 0.0 109.846 -179.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.424 ' HA ' ' HD3' ' A' ' 115' ' ' PRO . 0.7 OUTLIER -153.92 145.57 16.74 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.07 -1.019 . . . . 0.0 109.782 -179.682 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 114' ' ' SER . 36.5 Cg_endo -78.88 107.28 2.22 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.668 2.245 . . . . 0.0 110.403 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.415 ' O ' ' CB ' ' A' ' 117' ' ' SER . . . 150.11 -124.81 1.83 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.415 ' CB ' ' O ' ' A' ' 116' ' ' GLY . 0.6 OUTLIER 170.13 122.77 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.239 -1.153 . . . . 0.0 109.569 179.994 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -126.92 -152.86 8.12 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 4.9 mtt85 -141.89 169.36 17.74 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.266 -1.138 . . . . 0.0 109.499 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -177.14 -112.75 0.33 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.25 98.03 3.14 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.273 -1.133 . . . . 0.0 109.509 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.48 52.86 2.15 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.292 -0.88 . . . . 0.0 109.436 179.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER 55.64 56.82 5.81 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.276 -0.89 . . . . 0.0 109.351 179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.404 ' HD2' ' OXT' ' A' ' 124' ' ' ARG . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.546 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.428 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 121.254 0.55 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.47 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 12.9 mttt -112.65 144.09 42.74 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.213 -0.93 . . . . 0.0 109.268 179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.555 HG23 ' CD1' ' A' ' 70' ' ' ILE . 3.7 mt -121.96 106.78 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.184 -0.948 . . . . 0.0 110.339 -179.404 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.653 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -106.02 111.54 24.21 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.302 -0.873 . . . . 0.0 108.706 179.064 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.924 HG23 ' HB ' ' A' ' 70' ' ' ILE . 1.0 OUTLIER -100.48 131.86 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.191 -0.943 . . . . 0.0 109.861 -179.379 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -63.56 139.16 58.74 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.303 -0.873 . . . . 0.0 109.113 179.549 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.446 ' HB3' ' O ' ' A' ' 25' ' ' TYR . 17.4 t -126.84 172.99 9.92 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.086 -1.009 . . . . 0.0 109.772 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -122.44 -32.61 3.59 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.408 -0.808 . . . . 0.0 109.266 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.637 ' O ' HG23 ' A' ' 10' ' ' THR . . . -113.98 -82.44 1.1 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.637 HG23 ' O ' ' A' ' 9' ' ' GLY . 0.1 OUTLIER -169.67 -62.14 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.288 -1.125 . . . . 0.0 109.589 179.962 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -145.33 -55.17 0.31 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.28 -0.888 . . . . 0.0 109.572 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.1 mt -75.93 -38.77 57.3 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.227 -0.921 . . . . 0.0 109.645 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.42 17.12 57.24 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.412 ' O ' ' HA ' ' A' ' 96' ' ' SER . 89.7 p -77.19 78.42 3.72 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.248 -1.148 . . . . 0.0 109.757 -179.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.595 ' C ' HG23 ' A' ' 16' ' ' VAL . 44.2 tt0 -77.25 -0.29 24.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.253 -0.904 . . . . 0.0 109.408 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.677 HG22 HG13 ' A' ' 97' ' ' VAL . 2.5 t 73.73 74.55 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.26 -0.9 . . . . 0.0 109.64 -179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -46.65 151.7 0.55 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.168 -0.957 . . . . 0.0 109.289 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.411 ' HG2' ' CD1' ' A' ' 19' ' ' PHE . 3.2 ptm180 -104.92 31.74 4.61 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.216 -0.927 . . . . 0.0 109.625 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.411 ' CD1' ' HG2' ' A' ' 18' ' ' ARG . 45.7 m-85 -119.2 115.58 24.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.225 -0.922 . . . . 0.0 109.518 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.443 ' HE2' ' HB2' ' A' ' 58' ' ' ALA . 25.9 t80 -91.34 78.02 5.79 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.23 -0.918 . . . . 0.0 109.352 179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.61 -20.98 0.71 Allowed Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.665 ' O ' ' HB1' ' A' ' 47' ' ' ALA . 3.4 ttm-85 -111.17 -40.31 4.49 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.368 -1.077 . . . . 0.0 109.28 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.442 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -41.78 101.98 0.26 Allowed Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.533 -0.729 . . . . 0.0 109.643 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.451 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.6 Cg_endo -80.01 41.04 1.05 Allowed 'Trans proline' 0 C--N 1.312 -1.395 0 C-N-CA 122.579 2.186 . . . . 0.0 110.89 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.539 ' CE2' ' O ' ' A' ' 9' ' ' GLY . 0.4 OUTLIER -160.39 71.07 0.43 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.98 -1.075 . . . . 0.0 109.448 179.952 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.551 ' CE2' HD12 ' A' ' 61' ' ' ILE . 0.1 OUTLIER -79.5 117.08 20.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.287 -0.883 . . . . 0.0 109.549 -179.939 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 3.2 ttt -95.62 104.26 16.16 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.216 -0.928 . . . . 0.0 109.297 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.498 HG23 ' HB2' ' A' ' 4' ' ' ALA . 27.2 mt -100.83 126.13 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.266 -0.896 . . . . 0.0 109.709 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.553 ' CG1' HG23 ' A' ' 36' ' ' ILE . 90.5 t -123.95 117.82 52.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.298 -0.876 . . . . 0.0 109.349 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.403 ' HG2' ' HD3' ' A' ' 2' ' ' LYS . 13.0 mt-10 -83.92 115.97 22.56 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.221 -0.925 . . . . 0.0 109.622 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.459 ' HG2' ' HA ' ' A' ' 36' ' ' ILE . 0.3 OUTLIER -96.88 138.76 33.94 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.268 -0.895 . . . . 0.0 109.514 179.897 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 1.2 tptp -96.76 -62.45 1.26 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.889 . . . . 0.0 109.326 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . 0.401 ' O ' ' C ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -139.88 89.45 2.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.283 -0.886 . . . . 0.0 109.161 179.725 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' A' ' 33' ' ' LYS . . . 45.66 30.41 3.34 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -150.52 114.42 5.03 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.285 -1.126 . . . . 0.0 109.555 -179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.553 HG23 ' CG1' ' A' ' 29' ' ' VAL . 2.1 mp -54.14 132.4 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.164 -0.96 . . . . 0.0 109.41 179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 3.0 tt0 -133.28 12.82 4.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.255 -0.903 . . . . 0.0 109.375 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.502 ' O ' HG13 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -174.28 116.87 0.21 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 109.502 -179.981 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.533 ' HA ' HG22 ' A' ' 29' ' ' VAL . 4.5 p -129.73 104.23 7.29 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.265 -0.897 . . . . 0.0 109.536 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -122.91 139.59 53.88 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.392 -0.818 . . . . 0.0 109.375 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 73.9 t -114.11 119.31 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.218 -0.926 . . . . 0.0 109.531 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 2.4 mt -118.28 143.03 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.364 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.414 ' O ' ' C ' ' A' ' 44' ' ' ASN . 29.6 mp0 -86.1 118.91 25.86 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.15 -0.969 . . . . 0.0 109.391 179.915 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.414 ' C ' ' O ' ' A' ' 43' ' ' GLU . 2.0 t30 -44.48 141.77 2.62 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.244 -0.91 . . . . 0.0 109.365 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -79.23 -25.4 5.86 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 122.569 2.18 . . . . 0.0 110.413 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.4 m -119.81 42.29 2.95 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.204 -0.935 . . . . 0.0 109.661 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.665 ' HB1' ' O ' ' A' ' 22' ' ' ARG . . . -58.29 -72.51 0.09 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 109.363 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -106.28 66.94 0.72 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.318 -0.864 . . . . 0.0 109.35 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -115.76 143.46 45.35 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.328 -0.857 . . . . 0.0 109.51 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 79.3 p -63.84 -179.04 0.36 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.124 -0.985 . . . . 0.0 109.412 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 106.14 -30.86 9.0 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 177.66 -168.7 40.39 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -75.72 -15.05 60.34 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.262 -1.14 . . . . 0.0 109.503 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.447 ' O ' HG22 ' A' ' 57' ' ' THR . . . 110.47 19.02 8.14 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.639 -1.384 . . . . 0.0 109.639 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.417 HD12 ' HB2' ' A' ' 78' ' ' ALA . 23.3 mm -76.58 -14.95 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.27 -1.135 . . . . 0.0 109.573 -179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -58.46 -17.63 22.42 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.227 -0.921 . . . . 0.0 109.662 -179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.447 HG22 ' O ' ' A' ' 54' ' ' GLY . 6.0 t -63.38 -37.74 88.43 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.171 -0.956 . . . . 0.0 109.812 -179.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.443 ' HB2' ' HE2' ' A' ' 20' ' ' PHE . . . -45.42 -34.51 3.15 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.176 -0.953 . . . . 0.0 109.817 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -61.29 -64.59 0.9 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.237 -0.914 . . . . 0.0 109.847 -179.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.439 HG22 ' O ' ' A' ' 57' ' ' THR . 0.9 OUTLIER -58.8 -18.41 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.245 -0.91 . . . . 0.0 109.926 -179.593 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.551 HD12 ' CE2' ' A' ' 26' ' ' PHE . 19.3 mm -75.56 -36.38 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.177 -0.952 . . . . 0.0 109.688 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.71 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -73.38 -28.37 61.98 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.225 -0.922 . . . . 0.0 109.757 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -77.25 -9.81 59.03 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.087 -1.008 . . . . 0.0 109.906 -179.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.481 ' HB2' HG23 ' A' ' 66' ' ' VAL . 57.9 m-20 -88.13 7.65 30.63 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.108 -0.995 . . . . 0.0 109.629 -179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 69.24 10.67 62.92 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.653 HG11 ' HB3' ' A' ' 4' ' ' ALA . 2.0 t -67.65 89.54 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.198 -1.178 . . . . 0.0 109.415 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.452 ' HG2' ' HE3' ' A' ' 88' ' ' LYS . 0.5 OUTLIER -79.6 -7.4 58.51 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.348 -0.845 . . . . 0.0 108.92 179.648 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.575 ' HB1' ' CE2' ' A' ' 104' ' ' PHE . . . -137.53 103.64 5.11 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.19 -0.944 . . . . 0.0 109.273 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.484 HG22 HG11 ' A' ' 66' ' ' VAL . 56.9 t -112.01 132.1 61.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.054 -1.029 . . . . 0.0 109.817 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.924 ' HB ' HG23 ' A' ' 5' ' ' ILE . 3.2 mp -104.61 112.76 39.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.352 -0.843 . . . . 0.0 109.199 179.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -149.61 -178.04 6.21 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.22 -0.925 . . . . 0.0 109.979 -179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.9 m -146.12 46.89 1.24 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.642 -0.661 . . . . 0.0 109.524 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.551 ' OG ' ' CE1' ' A' ' 79' ' ' PHE . 2.6 p -45.49 151.94 0.72 Allowed Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.224 -0.922 . . . . 0.0 109.624 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.84 -25.99 7.18 Favored 'Trans proline' 0 C--N 1.31 -1.484 0 C-N-CA 122.719 2.279 . . . . 0.0 110.615 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -121.73 152.22 16.86 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.17 -16.57 13.88 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 C-N-CA 122.602 2.202 . . . . 0.0 110.483 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -46.94 -47.06 21.81 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.226 -0.922 . . . . 0.0 109.619 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.636 ' O ' HD13 ' A' ' 82' ' ' LEU . . . -67.51 -34.98 78.22 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.256 -0.903 . . . . 0.0 109.628 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.551 ' CE1' ' OG ' ' A' ' 73' ' ' SER . 8.7 m-30 -71.59 -17.16 62.31 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.632 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.435 ' O ' ' OD1' ' A' ' 83' ' ' ASN . 4.3 mm-40 -73.24 -42.92 61.99 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.124 -0.985 . . . . 0.0 108.967 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.417 ' H ' HG23 ' A' ' 81' ' ' VAL . 2.3 t -76.63 -30.05 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.435 -0.79 . . . . 0.0 109.254 179.725 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.636 HD13 ' O ' ' A' ' 78' ' ' ALA . 4.8 mp -61.54 -56.29 21.59 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.354 -0.841 . . . . 0.0 109.575 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.435 ' OD1' ' O ' ' A' ' 80' ' ' GLU . 9.6 p-10 -69.64 -14.12 62.66 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.293 -0.879 . . . . 0.0 109.578 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -76.98 -36.34 56.52 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.284 -0.885 . . . . 0.0 109.606 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.429 ' HA ' HD23 ' A' ' 85' ' ' LEU . 73.8 mt -86.0 12.38 9.56 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.189 -0.945 . . . . 0.0 109.669 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 80.99 8.71 87.14 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.71 HD11 ' HB2' ' A' ' 62' ' ' ALA . 18.3 mt -81.19 144.72 10.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.191 -1.182 . . . . 0.0 109.604 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.452 ' HE3' ' HG2' ' A' ' 67' ' ' LYS . 20.1 mttt -92.55 128.67 38.49 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.209 -0.932 . . . . 0.0 109.226 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.488 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.5 mt -99.22 128.66 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.178 -0.951 . . . . 0.0 109.582 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.59 ' CE1' ' HB2' ' A' ' 110' ' ' GLU . 2.0 m-30 -117.95 152.21 35.9 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.462 -0.774 . . . . 0.0 109.12 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.545 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 7.5 tpt180 -98.66 120.23 38.72 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.153 -0.967 . . . . 0.0 109.71 -179.714 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.726 ' HB2' HG22 ' A' ' 70' ' ' ILE . . . -86.01 132.24 34.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -0.904 . . . . 0.0 109.495 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 3.7 m -71.9 -38.16 69.99 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.232 -0.918 . . . . 0.0 109.41 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 114.09 14.35 9.27 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -79.7 -68.74 0.64 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.246 -1.149 . . . . 0.0 109.244 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 14' ' ' SER . 0.2 OUTLIER -171.16 132.72 0.83 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.204 -0.935 . . . . 0.0 109.341 179.927 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.677 HG13 HG22 ' A' ' 16' ' ' VAL . 23.8 m -56.56 -23.61 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.917 . . . . 0.0 109.527 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 3.1 tt0 -68.81 -38.83 80.19 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.256 -0.902 . . . . 0.0 109.449 -179.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -77.27 -42.24 37.86 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.232 -0.917 . . . . 0.0 109.68 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -64.89 -27.75 69.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.247 -0.908 . . . . 0.0 109.692 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.458 HD22 HD11 ' A' ' 36' ' ' ILE . 0.6 OUTLIER -59.63 -61.56 2.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.185 -0.947 . . . . 0.0 109.634 -179.913 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.53 -28.54 69.71 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.228 -0.92 . . . . 0.0 109.426 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.497 HD23 ' HB2' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -66.92 -29.04 68.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.278 -0.889 . . . . 0.0 109.664 -179.934 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.575 ' CE2' ' HB1' ' A' ' 68' ' ' ALA . 9.3 t80 -75.5 -26.48 58.16 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.186 -0.946 . . . . 0.0 109.631 -179.883 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 14.6 m -63.1 -20.59 65.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.231 -0.918 . . . . 0.0 109.728 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -103.88 -30.46 10.33 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.179 -0.951 . . . . 0.0 109.455 179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.92 42.0 6.14 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 32.9 m-20 -95.61 -20.09 19.23 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -1.162 . . . . 0.0 109.318 179.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.497 ' HB2' HD23 ' A' ' 103' ' ' LEU . 0.2 OUTLIER -127.87 143.29 51.11 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.402 -0.811 . . . . 0.0 109.044 179.807 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.59 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 4.7 pt-20 -172.38 -157.28 0.1 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.149 -0.969 . . . . 0.0 109.888 -179.718 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.545 ' HB2' ' N ' ' A' ' 91' ' ' ARG . 3.0 tt0 -158.66 -104.21 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.368 -0.833 . . . . 0.0 109.365 -179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.472 ' HB ' ' HB ' ' A' ' 89' ' ' ILE . 46.8 mm -93.17 111.32 24.5 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 O-C-N 121.27 -0.894 . . . . 0.0 109.586 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.509 ' HG3' ' N ' ' A' ' 114' ' ' SER . 0.1 OUTLIER -129.49 -34.24 1.82 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.326 -0.858 . . . . 0.0 109.44 179.942 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.509 ' N ' ' HG3' ' A' ' 113' ' ' ARG . 0.9 OUTLIER 169.39 148.16 0.11 Allowed Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.227 -0.921 . . . . 0.0 109.474 179.917 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.57 -53.6 0.06 OUTLIER 'Trans proline' 0 C--N 1.309 -1.54 0 C-N-CA 122.729 2.286 . . . . 0.0 110.427 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 152.2 -46.5 0.58 Allowed Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.52 154.9 40.97 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.289 -1.124 . . . . 0.0 109.522 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -106.44 -90.62 2.17 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.582 -1.407 . . . . 0.0 109.582 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.62 -45.43 2.7 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.244 -1.15 . . . . 0.0 109.39 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 129.06 97.76 0.86 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.85 32.15 5.81 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.312 -1.111 . . . . 0.0 109.437 -179.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER 58.18 56.13 4.72 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.237 -0.914 . . . . 0.0 109.302 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 51.98 -173.59 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.323 -0.861 . . . . 0.0 109.391 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.416 ' NE ' ' HA ' ' A' ' 124' ' ' ARG . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 118.098 -0.953 . . . . 0.0 109.466 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.653 ' O ' ' HB3' ' A' ' 68' ' ' ALA . 0.5 OUTLIER -90.65 121.48 32.6 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.245 -0.909 . . . . 0.0 109.345 179.881 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.583 HG12 ' CD2' ' A' ' 104' ' ' PHE . 4.1 mt -100.26 111.7 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.291 -0.881 . . . . 0.0 109.853 -179.781 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.593 ' HB1' ' CE2' ' A' ' 26' ' ' PHE . . . -104.12 112.69 25.8 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.226 -0.921 . . . . 0.0 109.397 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.874 HG21 HG13 ' A' ' 97' ' ' VAL . 14.4 mm -87.78 117.62 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.226 -0.921 . . . . 0.0 109.525 -179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.448 ' O ' ' HB3' ' A' ' 7' ' ' SER . . . -62.64 153.78 31.23 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.289 -0.882 . . . . 0.0 109.608 -179.915 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 25' ' ' TYR . 2.4 t 61.62 -88.96 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.218 -0.926 . . . . 0.0 109.522 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.838 ' HA ' HG21 ' A' ' 97' ' ' VAL . 0.2 OUTLIER 57.95 22.62 8.96 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.193 -0.942 . . . . 0.0 109.457 -179.96 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 48.94 -102.12 0.05 OUTLIER Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -155.85 -47.05 0.08 Allowed 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.205 -1.173 . . . . 0.0 109.46 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.706 ' HB3' HD12 ' A' ' 12' ' ' LEU . 1.7 t70 -155.59 -62.05 0.11 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.239 -0.913 . . . . 0.0 109.448 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.706 HD12 ' HB3' ' A' ' 11' ' ' ASP . 5.9 mp -108.17 -15.81 14.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.204 -0.935 . . . . 0.0 109.529 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -94.19 27.49 13.19 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 89.6 p -78.28 74.34 4.82 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.391 -1.064 . . . . 0.0 109.695 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.583 ' C ' HG23 ' A' ' 16' ' ' VAL . 32.4 tt0 -78.33 5.55 10.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.023 -1.048 . . . . 0.0 109.815 179.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.633 HG22 ' N ' ' A' ' 97' ' ' VAL . 2.1 t 68.37 54.15 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.168 -0.957 . . . . 0.0 109.116 -179.559 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.433 ' C ' ' O ' ' A' ' 16' ' ' VAL . 1.0 OUTLIER -42.74 159.47 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.411 -0.806 . . . . 0.0 109.688 -179.844 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -111.32 39.08 2.39 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.265 -0.897 . . . . 0.0 109.428 -179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -129.22 103.49 6.98 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.255 -0.903 . . . . 0.0 109.508 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 23.5 t80 -102.41 142.01 34.31 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.516 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 114.25 -46.73 1.13 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.445 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 7.9 ttp180 -103.12 -37.36 7.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.371 -1.076 . . . . 0.0 109.141 179.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.436 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -41.47 102.0 0.26 Allowed Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.569 -0.707 . . . . 0.0 109.821 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.493 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 36.7 Cg_endo -81.21 54.73 5.33 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 122.652 2.235 . . . . 0.0 110.478 179.688 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.458 ' O ' ' O ' ' A' ' 7' ' ' SER . 68.5 m-85 -154.15 68.5 0.75 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.108 -0.995 . . . . 0.0 109.204 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.593 ' CE2' ' HB1' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -79.39 111.13 15.34 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.256 -0.903 . . . . 0.0 109.337 -179.907 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . 0.469 ' HB2' ' CB ' ' A' ' 8' ' ' SER . 7.2 ttm -88.76 102.09 14.66 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.3 -0.875 . . . . 0.0 109.559 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.612 ' O ' HG23 ' A' ' 28' ' ' ILE . 6.1 tp -83.61 114.67 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.294 -0.879 . . . . 0.0 109.363 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.662 HG22 ' HB3' ' A' ' 39' ' ' SER . 47.7 t -126.11 128.71 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.155 -0.966 . . . . 0.0 109.653 -179.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 -111.21 113.86 26.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.283 -0.886 . . . . 0.0 109.368 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.439 ' SD ' ' CA ' ' A' ' 34' ' ' GLY . 0.7 OUTLIER -112.53 132.65 54.99 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.229 -0.92 . . . . 0.0 109.6 -179.851 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 7.2 mmmt -87.67 -55.81 3.62 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.268 -0.895 . . . . 0.0 109.33 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.15 68.24 0.93 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.336 -0.853 . . . . 0.0 109.209 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.439 ' CA ' ' SD ' ' A' ' 31' ' ' MET . . . 75.92 8.6 84.9 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 -179.795 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -130.52 98.35 4.65 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.176 -1.19 . . . . 0.0 109.493 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.467 HD11 HD23 ' A' ' 101' ' ' LEU . 2.9 mt -57.43 127.49 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.251 -0.906 . . . . 0.0 109.658 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.443 ' O ' ' HB3' ' A' ' 38' ' ' SER . 0.5 OUTLIER -101.66 -2.3 30.65 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.401 179.68 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.443 ' HB3' ' O ' ' A' ' 37' ' ' GLU . 77.3 p 176.8 125.55 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.288 -0.882 . . . . 0.0 109.201 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.662 ' HB3' HG22 ' A' ' 29' ' ' VAL . 0.2 OUTLIER -136.85 106.97 6.33 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.208 -0.932 . . . . 0.0 109.644 -179.759 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.87 163.62 14.41 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.899 . . . . 0.0 109.439 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.658 ' O ' HG13 ' A' ' 41' ' ' VAL . 7.6 p -134.6 118.66 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.331 -0.855 . . . . 0.0 109.447 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.403 ' O ' HG13 ' A' ' 42' ' ' ILE . 21.5 pt -126.88 133.63 68.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.218 -0.926 . . . . 0.0 109.569 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.493 ' CG ' ' O ' ' A' ' 24' ' ' PRO . 1.3 mt-10 -74.46 146.61 42.67 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.369 179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.404 ' H ' ' HA ' ' A' ' 24' ' ' PRO . 12.2 m-20 -46.19 153.43 0.7 Allowed Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.242 -0.911 . . . . 0.0 109.318 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -78.4 -47.79 0.1 Allowed 'Trans proline' 0 C--N 1.309 -1.532 0 C-N-CA 122.639 2.226 . . . . 0.0 110.523 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.2 p -119.14 54.58 0.97 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.898 . . . . 0.0 109.56 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -58.56 -44.48 89.71 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.271 -0.893 . . . . 0.0 109.169 179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -159.94 96.35 1.22 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.367 -0.833 . . . . 0.0 109.331 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -174.19 -60.83 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.255 -0.903 . . . . 0.0 109.488 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 26.0 t -71.18 -14.52 62.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.301 -0.874 . . . . 0.0 109.48 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 97.45 88.19 1.86 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -151.72 157.65 27.34 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -76.37 -20.07 57.54 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.191 -1.182 . . . . 0.0 109.52 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.437 ' O ' HG22 ' A' ' 57' ' ' THR . . . 113.53 -37.1 3.73 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.601 HD12 ' HB2' ' A' ' 78' ' ' ALA . 47.2 mm -66.49 -14.15 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.279 -1.13 . . . . 0.0 109.484 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -8.9 38.79 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.29 -0.881 . . . . 0.0 109.496 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 54' ' ' GLY . 14.8 t -76.93 -16.04 59.49 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.191 -0.943 . . . . 0.0 109.529 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.419 ' HA ' HD12 ' A' ' 61' ' ' ILE . . . -57.28 -32.35 66.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 109.536 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 21.8 tt0 -65.11 -52.98 52.22 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.306 -0.871 . . . . 0.0 109.44 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.443 HD13 ' HA ' ' A' ' 60' ' ' ILE . 35.9 mm -62.72 -25.6 38.64 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.228 -0.92 . . . . 0.0 109.326 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.485 HD13 ' CZ ' ' A' ' 26' ' ' PHE . 45.5 mt -69.71 -39.28 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.234 -0.916 . . . . 0.0 109.276 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.797 ' HB2' HD11 ' A' ' 87' ' ' ILE . . . -74.6 -25.44 59.26 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.248 -0.908 . . . . 0.0 109.429 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.4 t30 -77.09 -5.15 47.83 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.237 -0.914 . . . . 0.0 109.51 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.49 ' HB2' HG23 ' A' ' 66' ' ' VAL . 6.8 m-20 -100.26 1.86 42.18 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.134 -0.979 . . . . 0.0 109.527 179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.499 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 90.89 -5.94 81.95 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.49 HG23 ' HB2' ' A' ' 64' ' ' ASN . 48.3 t -53.5 88.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.201 -1.176 . . . . 0.0 109.858 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.499 ' N ' ' O ' ' A' ' 65' ' ' GLY . 6.4 tttp -79.75 -12.46 59.79 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.119 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.653 ' HB3' ' O ' ' A' ' 2' ' ' LYS . . . -127.62 131.99 49.83 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.436 -0.79 . . . . 0.0 109.108 179.685 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.582 HG21 HD21 ' A' ' 82' ' ' LEU . 2.4 t -129.64 105.49 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.123 -0.985 . . . . 0.0 109.806 -179.643 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.622 HD12 ' CD1' ' A' ' 5' ' ' ILE . 23.3 mt -91.41 119.96 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.277 -0.89 . . . . 0.0 109.01 179.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -149.12 177.08 9.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.152 -0.967 . . . . 0.0 109.938 -179.512 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.04 35.38 3.73 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.535 -0.728 . . . . 0.0 109.14 179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.451 ' HB2' ' CE1' ' A' ' 79' ' ' PHE . 0.1 OUTLIER -44.87 134.23 4.99 Favored Pre-proline 0 N--CA 1.49 1.537 0 O-C-N 121.286 -0.884 . . . . 0.0 109.465 -179.807 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -78.75 -19.78 10.96 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.436 2.091 . . . . 0.0 110.351 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -114.15 148.31 18.77 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.83 9.16 3.38 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 C-N-CA 122.631 2.221 . . . . 0.0 110.706 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -74.44 -42.62 58.81 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.095 -1.003 . . . . 0.0 109.722 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.601 ' HB2' HD12 ' A' ' 55' ' ' ILE . . . -68.69 -50.78 48.22 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 109.588 -179.902 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.451 ' CE1' ' HB2' ' A' ' 73' ' ' SER . 11.3 m-30 -48.81 -38.43 22.12 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.264 -0.898 . . . . 0.0 109.652 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.484 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 0.6 OUTLIER -65.75 -47.4 75.37 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.188 -0.945 . . . . 0.0 109.71 -179.833 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 86.7 t -52.89 -50.85 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.182 -0.949 . . . . 0.0 109.466 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.582 HD21 HG21 ' A' ' 69' ' ' VAL . 1.9 mt -56.47 -31.15 63.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.226 -0.921 . . . . 0.0 109.549 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.484 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 3.2 m-20 -61.96 -51.26 68.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.163 -0.961 . . . . 0.0 109.301 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -62.81 -27.67 69.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.242 -0.911 . . . . 0.0 109.21 179.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 8.1 mt -72.03 -34.21 68.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.174 -0.954 . . . . 0.0 109.527 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 99.1 19.98 19.72 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.797 HD11 ' HB2' ' A' ' 62' ' ' ALA . 27.7 mt -103.83 163.03 4.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.289 -1.124 . . . . 0.0 109.617 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.437 ' N ' HG22 ' A' ' 87' ' ' ILE . 3.4 mptt -91.74 147.07 23.26 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.253 -0.904 . . . . 0.0 109.263 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.51 ' O ' ' HB3' ' A' ' 111' ' ' GLU . 3.3 mt -120.76 131.76 72.03 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.112 -0.992 . . . . 0.0 109.211 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.581 ' CE2' ' HB1' ' A' ' 68' ' ' ALA . 12.8 m-85 -119.47 161.26 20.85 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.476 -0.765 . . . . 0.0 109.547 -179.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.488 ' N ' ' HB2' ' A' ' 111' ' ' GLU . 0.1 OUTLIER -99.25 136.78 38.7 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.264 -0.897 . . . . 0.0 109.627 -179.909 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.64 129.33 34.38 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.259 -0.901 . . . . 0.0 109.443 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -62.35 -40.33 96.05 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.26 -0.9 . . . . 0.0 109.476 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 102.94 22.07 9.66 Favored Glycine 0 N--CA 1.491 2.335 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.73 -83.75 0.54 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.128 -1.219 . . . . 0.0 109.4 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.539 ' HA ' HG23 ' A' ' 16' ' ' VAL . 3.3 m -146.71 137.65 24.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.324 -0.86 . . . . 0.0 109.315 179.814 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.874 HG13 HG21 ' A' ' 5' ' ' ILE . 86.8 t -64.2 -31.18 52.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.289 -0.882 . . . . 0.0 109.609 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -56.58 -44.36 80.95 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.194 -0.941 . . . . 0.0 109.465 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 6.3 mm-40 -75.46 -35.8 60.82 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.254 -0.904 . . . . 0.0 109.47 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.475 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 15.1 m-20 -54.44 -37.71 65.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.224 -0.922 . . . . 0.0 109.669 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.572 HD21 HG11 ' A' ' 29' ' ' VAL . 0.4 OUTLIER -49.43 -53.48 22.58 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.283 -0.885 . . . . 0.0 109.651 -179.874 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 6.0 mmtm -69.64 -33.43 72.6 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.23 -0.919 . . . . 0.0 109.656 -179.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.501 ' CD1' ' HB3' ' A' ' 108' ' ' ASN . 2.2 mm? -57.94 -31.75 67.14 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.205 -0.934 . . . . 0.0 109.438 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.583 ' CD2' HG12 ' A' ' 3' ' ' ILE . 20.9 t80 -72.75 -38.61 67.31 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.384 -0.823 . . . . 0.0 109.779 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 17.6 m -70.56 -25.69 63.2 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.266 -0.896 . . . . 0.0 109.751 -179.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -88.1 -0.51 57.14 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.204 -0.935 . . . . 0.0 109.674 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.456 ' HA2' ' OE2' ' A' ' 110' ' ' GLU . . . 59.95 25.42 61.75 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . 0.501 ' HB3' ' CD1' ' A' ' 103' ' ' LEU . 1.2 m-20 -88.48 -53.28 4.74 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.204 -1.174 . . . . 0.0 109.424 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 11.9 tp -85.19 129.75 34.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.243 -0.911 . . . . 0.0 109.202 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.456 ' OE2' ' HA2' ' A' ' 107' ' ' GLY . 0.3 OUTLIER -165.68 -166.31 0.94 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.198 -0.939 . . . . 0.0 109.729 -179.818 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.51 ' HB3' ' O ' ' A' ' 89' ' ' ILE . 68.5 tt0 -172.68 -113.85 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.285 -0.885 . . . . 0.0 109.371 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.476 ' N ' ' HG2' ' A' ' 111' ' ' GLU . 5.3 mt -82.31 140.37 16.53 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 O-C-N 121.093 -1.005 . . . . 0.0 109.253 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.48 ' NH1' ' HG2' ' A' ' 113' ' ' ARG . 0.0 OUTLIER -140.65 157.84 44.86 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.203 -0.935 . . . . 0.0 109.623 -179.885 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -146.1 156.76 50.72 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.279 -0.888 . . . . 0.0 109.345 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.48 6.33 4.87 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 C-N-CA 122.696 2.264 . . . . 0.0 110.486 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 94.78 -23.95 30.4 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 4.8 t -169.59 112.0 0.48 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.214 -1.168 . . . . 0.0 109.41 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 139.44 132.8 2.95 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 1.3 ttp85 -173.17 -55.65 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.15 -1.206 . . . . 0.0 109.551 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -119.0 85.36 0.39 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 -179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.483 ' O ' ' CB ' ' A' ' 122' ' ' ARG . 1.0 OUTLIER -68.12 155.16 40.19 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.293 -1.122 . . . . 0.0 109.253 179.883 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.483 ' CB ' ' O ' ' A' ' 121' ' ' ARG . 0.1 OUTLIER 73.7 85.65 0.11 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.257 -0.902 . . . . 0.0 109.378 -179.97 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 8.1 ttt85 -148.98 150.3 32.62 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.209 -0.932 . . . . 0.0 109.506 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 117.978 -1.011 . . . . 0.0 109.463 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.461 ' HG3' ' HB2' ' A' ' 67' ' ' LYS . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 121.28 0.562 . . . . 0.0 109.514 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.93 139.68 36.98 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.219 -0.926 . . . . 0.0 109.201 179.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.493 HG23 HD11 ' A' ' 70' ' ' ILE . 4.8 mt -115.24 113.49 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.12 -0.987 . . . . 0.0 110.006 -179.609 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -108.03 119.55 39.78 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.507 -0.746 . . . . 0.0 109.024 179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.59 HG21 ' HB ' ' A' ' 97' ' ' VAL . 3.3 mp -98.15 136.94 27.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.128 -0.982 . . . . 0.0 109.879 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.49 ' HB2' ' CZ ' ' A' ' 26' ' ' PHE . . . -89.74 121.99 32.42 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.296 -0.877 . . . . 0.0 109.138 179.725 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.547 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -142.08 170.82 14.99 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.143 -0.973 . . . . 0.0 109.728 -179.832 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 51.5 p -116.32 25.31 10.73 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.316 -0.865 . . . . 0.0 109.299 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -162.64 -145.27 4.29 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.632 HG23 HG11 ' A' ' 41' ' ' VAL . 0.2 OUTLIER -147.17 22.56 1.2 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.243 -1.151 . . . . 0.0 109.521 -179.94 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -147.57 -178.68 6.38 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.199 -0.938 . . . . 0.0 109.602 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.525 ' O ' HD23 ' A' ' 12' ' ' LEU . 6.6 tt -64.39 -14.24 55.44 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.337 -0.852 . . . . 0.0 109.571 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -56.74 -52.4 50.87 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.709 -1.356 . . . . 0.0 109.709 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.08 86.57 0.06 Allowed 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.335 -1.097 . . . . 0.0 109.397 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -73.46 81.21 1.44 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.476 -0.765 . . . . 0.0 109.54 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.707 HG12 ' O ' ' A' ' 16' ' ' VAL . 59.3 t 54.54 30.45 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.238 -0.914 . . . . 0.0 109.665 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 26.6 p 46.14 -160.66 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.275 -0.891 . . . . 0.0 109.433 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 2.9 mtt-85 -98.2 -46.92 5.66 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.264 -0.898 . . . . 0.0 109.376 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -150.27 122.65 8.44 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.364 -0.835 . . . . 0.0 109.429 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.442 ' CD2' ' HB1' ' A' ' 71' ' ' ALA . 4.0 t80 -57.65 124.49 19.26 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.238 -0.914 . . . . 0.0 109.391 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -171.98 -49.37 0.04 OUTLIER Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.95 45.4 1.46 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.283 -1.128 . . . . 0.0 109.446 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.547 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -54.6 112.65 4.21 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.352 -0.842 . . . . 0.0 109.516 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.452 ' O ' ' CB ' ' A' ' 43' ' ' GLU . 36.6 Cg_endo -80.61 20.53 0.95 Allowed 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 122.606 2.204 . . . . 0.0 110.947 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 7.2 m-85 -154.8 69.79 0.75 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.036 -1.04 . . . . 0.0 108.942 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.49 ' CZ ' ' HB2' ' A' ' 6' ' ' ALA . 0.3 OUTLIER -79.1 125.21 29.11 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.348 -0.845 . . . . 0.0 109.722 -179.456 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 10.7 mtt -90.06 110.69 21.67 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.289 -0.882 . . . . 0.0 109.369 179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 31.6 mm -93.46 107.45 19.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.209 -0.932 . . . . 0.0 109.467 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.512 HG11 HD13 ' A' ' 36' ' ' ILE . 23.3 t -115.63 116.35 52.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.266 -0.896 . . . . 0.0 109.429 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -103.81 114.81 29.34 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.277 -0.889 . . . . 0.0 109.554 -179.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.418 ' HE2' HG13 ' A' ' 36' ' ' ILE . 12.6 ptp -116.3 160.33 20.63 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.241 -0.912 . . . . 0.0 109.419 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -109.71 -94.98 0.41 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.256 -0.903 . . . . 0.0 109.626 -179.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -89.5 62.35 5.92 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.116 -0.99 . . . . 0.0 109.348 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 63.13 35.58 92.28 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 109.246 -1.542 . . . . 0.0 109.246 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.4 ' O ' ' C ' ' A' ' 36' ' ' ILE . 44.9 t30 -138.96 84.26 2.0 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.302 -1.116 . . . . 0.0 109.462 -179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.526 HD13 HD21 ' A' ' 101' ' ' LEU . 50.6 mt -45.41 111.27 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.221 -0.924 . . . . 0.0 109.419 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -111.49 9.26 21.3 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.232 -0.917 . . . . 0.0 109.482 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -167.28 124.18 1.19 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.187 -0.946 . . . . 0.0 109.485 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 16.2 p -144.96 107.9 4.51 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.284 -0.885 . . . . 0.0 109.478 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -123.37 148.2 46.29 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.259 -0.901 . . . . 0.0 109.526 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.632 HG11 HG23 ' A' ' 10' ' ' THR . 61.4 t -103.99 137.82 31.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.87 . . . . 0.0 109.519 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -139.33 136.28 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.259 -0.9 . . . . 0.0 109.421 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.452 ' CB ' ' O ' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -96.85 120.66 37.6 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.225 -0.922 . . . . 0.0 109.429 179.915 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.441 ' CG ' ' HD2' ' A' ' 45' ' ' PRO . 0.8 OUTLIER -60.74 147.82 83.66 Favored Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.21 -0.931 . . . . 0.0 109.357 -179.911 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.441 ' HD2' ' CG ' ' A' ' 44' ' ' ASN . 35.9 Cg_endo -78.48 -34.0 1.62 Allowed 'Trans proline' 0 C--N 1.31 -1.48 0 C-N-CA 122.559 2.173 . . . . 0.0 110.454 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 9.9 m -49.26 -23.88 1.56 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.308 -0.87 . . . . 0.0 109.529 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -61.76 -48.44 80.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.15 -0.969 . . . . 0.0 109.469 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.75 -3.71 51.89 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.302 -0.874 . . . . 0.0 109.592 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -112.57 95.14 5.27 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.193 -0.942 . . . . 0.0 109.484 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 10.3 p -67.62 121.3 15.57 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.277 -0.89 . . . . 0.0 109.376 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 116.45 38.28 0.94 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.442 ' O ' ' HB3' ' A' ' 53' ' ' ALA . . . -124.53 9.42 8.21 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 -179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.442 ' HB3' ' O ' ' A' ' 52' ' ' GLY . . . 61.54 165.2 0.09 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.218 -1.166 . . . . 0.0 109.342 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -122.54 -36.89 0.66 Allowed Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.7 HG23 ' HB2' ' A' ' 78' ' ' ALA . 20.7 mm -71.85 -39.88 68.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.191 -1.182 . . . . 0.0 109.42 -179.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 7.3 mmm-85 -65.67 -11.13 42.37 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.223 -0.923 . . . . 0.0 109.557 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.786 ' O ' HG22 ' A' ' 60' ' ' ILE . 44.8 m -70.3 -33.47 71.58 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.2 -0.937 . . . . 0.0 109.312 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.684 ' HB1' HD21 ' A' ' 82' ' ' LEU . . . -50.83 -23.84 3.08 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.243 -0.91 . . . . 0.0 109.318 179.903 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tm0? -70.67 -51.58 26.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.247 -0.908 . . . . 0.0 109.485 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.786 HG22 ' O ' ' A' ' 57' ' ' THR . 0.3 OUTLIER -59.03 -33.43 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.229 -0.919 . . . . 0.0 109.412 -179.98 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 96.0 mt -67.38 -40.96 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.206 -0.934 . . . . 0.0 109.215 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -76.01 -18.64 59.18 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.338 -0.851 . . . . 0.0 109.461 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 7.7 t-20 -74.55 -17.63 60.71 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.21 -0.931 . . . . 0.0 109.399 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -86.77 11.75 12.43 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.28 -0.888 . . . . 0.0 109.56 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.454 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 88.6 -6.24 83.82 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.514 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 96.8 t -54.78 89.76 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.283 -1.128 . . . . 0.0 109.878 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.461 ' HB2' ' HG3' ' A' ' 1' ' ' MET . 16.5 mmtm -79.18 2.24 21.69 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.139 -0.975 . . . . 0.0 109.017 179.427 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.514 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -142.96 140.05 30.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.236 -0.915 . . . . 0.0 109.06 179.656 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.496 ' C ' HD13 ' A' ' 70' ' ' ILE . 42.2 t -139.76 131.15 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.077 -1.014 . . . . 0.0 110.049 -179.584 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.496 HD13 ' C ' ' A' ' 69' ' ' VAL . 1.3 mm -108.33 111.63 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.305 -0.872 . . . . 0.0 108.85 179.461 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.442 ' HB1' ' CD2' ' A' ' 20' ' ' PHE . . . -154.13 177.05 11.52 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.164 -0.96 . . . . 0.0 109.968 -179.627 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -141.5 44.87 1.73 Allowed 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.53 -0.731 . . . . 0.0 109.23 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -45.74 150.61 0.94 Allowed Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.333 -0.855 . . . . 0.0 109.533 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -77.83 -38.88 0.57 Allowed 'Trans proline' 0 C--N 1.309 -1.509 0 C-N-CA 122.677 2.251 . . . . 0.0 110.292 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -102.16 146.28 16.89 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -78.68 8.09 3.89 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 122.605 2.203 . . . . 0.0 110.663 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.487 ' O ' HG23 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -63.93 -46.39 84.99 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.151 -0.968 . . . . 0.0 109.612 -179.934 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.7 ' HB2' HG23 ' A' ' 55' ' ' ILE . . . -67.4 -50.24 60.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 109.557 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.865 ' CD1' HG21 ' A' ' 89' ' ' ILE . 12.8 m-85 -52.08 -33.16 38.16 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.642 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.466 ' O ' ' HB2' ' A' ' 83' ' ' ASN . 0.0 OUTLIER -67.01 -41.81 86.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.251 -0.905 . . . . 0.0 109.736 -179.732 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 77' ' ' ASN . 2.7 t -63.21 -53.77 41.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.167 -0.958 . . . . 0.0 109.751 -179.793 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.684 HD21 ' HB1' ' A' ' 58' ' ' ALA . 25.0 mt -60.38 -18.38 50.07 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.27 -0.894 . . . . 0.0 109.719 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.466 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 6.9 m-20 -69.61 -56.37 7.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.275 -0.891 . . . . 0.0 109.716 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -66.12 -34.81 78.89 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.145 -0.972 . . . . 0.0 109.676 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.401 ' CB ' HG12 ' A' ' 87' ' ' ILE . 6.8 mt -61.5 -13.41 20.72 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.237 -0.914 . . . . 0.0 109.416 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 77.61 24.06 65.99 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.401 HG12 ' CB ' ' A' ' 85' ' ' LEU . 5.2 mm -92.32 144.34 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.239 -1.154 . . . . 0.0 109.4 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -79.87 110.37 15.18 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.249 -0.907 . . . . 0.0 109.442 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.865 HG21 ' CD1' ' A' ' 79' ' ' PHE . 13.0 mt -86.76 151.48 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.344 -0.848 . . . . 0.0 109.655 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.568 ' CZ ' ' HB3' ' A' ' 111' ' ' GLU . 1.1 m-85 -134.87 134.02 40.3 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.304 -0.873 . . . . 0.0 109.453 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.96 132.72 35.19 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.225 -0.922 . . . . 0.0 109.405 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.51 ' HB1' HG21 ' A' ' 16' ' ' VAL . . . -84.6 66.0 9.31 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.226 -0.921 . . . . 0.0 109.614 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 9.5 t -74.2 -28.14 61.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.158 -0.964 . . . . 0.0 109.463 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.401 ' O ' ' HB ' ' A' ' 95' ' ' THR . . . -59.1 -106.21 0.01 OUTLIER Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.514 HG23 ' N ' ' A' ' 96' ' ' SER . 4.0 t 178.31 -44.09 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.217 -1.166 . . . . 0.0 109.592 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.514 ' N ' HG23 ' A' ' 95' ' ' THR . 7.2 m -95.66 125.52 40.3 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.231 -0.918 . . . . 0.0 109.444 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.59 ' HB ' HG21 ' A' ' 5' ' ' ILE . 5.5 m -63.46 -34.99 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.238 -0.914 . . . . 0.0 109.402 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -64.42 -35.27 80.36 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.198 -0.939 . . . . 0.0 109.29 179.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.676 ' O ' HD23 ' A' ' 103' ' ' LEU . 20.7 tt0 -73.32 -36.78 66.28 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.334 -0.854 . . . . 0.0 109.403 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.494 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 98.9 m-20 -67.74 -27.79 67.09 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.171 -0.955 . . . . 0.0 109.424 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.526 HD21 HD13 ' A' ' 36' ' ' ILE . 24.9 tp -58.28 -62.24 1.98 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.358 -0.839 . . . . 0.0 109.674 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -68.19 -24.97 65.02 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.153 -0.967 . . . . 0.0 109.443 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.676 HD23 ' O ' ' A' ' 99' ' ' GLU . 0.9 OUTLIER -65.0 -29.58 70.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.305 -0.872 . . . . 0.0 109.482 179.929 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.528 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 9.8 t80 -64.12 -43.89 93.92 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.156 -0.965 . . . . 0.0 109.501 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 86.4 m -57.31 -31.36 65.58 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.934 . . . . 0.0 109.753 -179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -87.64 -22.78 24.52 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.242 -0.911 . . . . 0.0 109.578 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 77.02 24.36 66.73 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . 0.635 ' HB3' HD12 ' A' ' 103' ' ' LEU . 2.4 t30 -80.31 -32.52 37.99 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.179 -1.189 . . . . 0.0 109.367 179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.479 ' HA ' HD12 ' A' ' 109' ' ' LEU . 3.4 tp -66.59 -163.89 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.274 -0.891 . . . . 0.0 109.519 179.958 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -110.58 137.54 48.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.337 -0.852 . . . . 0.0 109.263 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.568 ' HB3' ' CZ ' ' A' ' 90' ' ' TYR . 20.8 pt-20 -127.58 165.08 20.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.236 -0.915 . . . . 0.0 109.69 -179.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 10.3 mt -151.54 104.26 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.264 -0.897 . . . . 0.0 109.147 179.746 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -122.5 5.87 9.56 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.236 -0.915 . . . . 0.0 109.838 -179.496 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 3.3 m -137.2 156.25 75.52 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.086 -1.009 . . . . 0.0 109.783 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -78.13 170.11 19.23 Favored 'Trans proline' 0 C--N 1.31 -1.489 0 C-N-CA 122.622 2.214 . . . . 0.0 110.076 179.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 122.78 163.8 11.93 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 28.0 m 57.07 -173.88 0.07 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.291 -1.123 . . . . 0.0 109.502 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . 108.97 60.32 0.53 Allowed Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.25 159.59 16.82 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.223 -1.163 . . . . 0.0 109.608 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -146.44 148.14 19.59 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.8 70.61 0.76 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.248 -1.148 . . . . 0.0 109.559 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 1.8 mpp_? -60.17 -87.47 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.148 -0.97 . . . . 0.0 109.45 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.2 mtm105 -99.24 143.21 29.77 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.238 -0.914 . . . . 0.0 109.472 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.424 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -111.14 137.26 49.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.25 -0.906 . . . . 0.0 109.449 179.867 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.594 HG12 ' CZ ' ' A' ' 104' ' ' PHE . 4.9 mt -102.84 101.89 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.377 -0.827 . . . . 0.0 109.72 -179.76 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.424 ' HB3' HG11 ' A' ' 66' ' ' VAL . . . -103.66 101.22 11.06 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.318 -0.864 . . . . 0.0 109.147 179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.66 ' HB ' HD12 ' A' ' 70' ' ' ILE . 14.7 tt -98.25 130.19 47.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.256 -0.902 . . . . 0.0 109.592 -179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -59.26 146.09 40.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -0.9 . . . . 0.0 109.406 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.494 ' HB3' ' CB ' ' A' ' 14' ' ' SER . 0.8 OUTLIER -135.85 162.12 33.71 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.921 . . . . 0.0 109.594 -179.863 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.82 -20.43 12.78 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.306 -0.872 . . . . 0.0 109.34 179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.571 ' O ' ' CD1' ' A' ' 25' ' ' TYR . . . -119.81 -124.66 3.24 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.78 -37.21 1.03 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.19 -1.182 . . . . 0.0 109.544 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -144.92 -73.11 0.25 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.234 -0.916 . . . . 0.0 109.704 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -89.58 -29.76 18.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.254 -0.904 . . . . 0.0 109.514 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.19 -15.12 72.0 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.532 ' OG ' HG21 ' A' ' 97' ' ' VAL . 0.8 OUTLIER -77.39 82.62 3.84 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.196 -1.179 . . . . 0.0 109.479 179.976 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.487 ' HG2' ' O ' ' A' ' 95' ' ' THR . 13.2 tt0 -77.34 3.66 12.58 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.279 -0.888 . . . . 0.0 109.837 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.576 HG22 HG13 ' A' ' 97' ' ' VAL . 9.7 t 66.62 65.96 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.16 -0.962 . . . . 0.0 109.227 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.448 ' O ' ' O ' ' A' ' 16' ' ' VAL . 60.2 p -57.65 -159.35 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.258 -0.901 . . . . 0.0 109.703 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.45 54.18 1.93 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.297 -0.877 . . . . 0.0 109.47 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -136.95 71.41 1.41 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.211 -0.931 . . . . 0.0 109.438 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.547 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . 5.7 t80 -65.58 100.93 0.55 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.29 -0.881 . . . . 0.0 109.61 -179.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 151.91 -42.97 0.69 Allowed Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.468 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 5.5 ttt85 -104.51 -33.9 8.41 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.203 -1.175 . . . . 0.0 109.783 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.457 ' C ' ' O ' ' A' ' 22' ' ' ARG . . . -39.22 99.02 0.19 Allowed Pre-proline 0 N--CA 1.495 1.809 0 O-C-N 121.543 -0.723 . . . . 0.0 109.78 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.484 ' O ' ' HG2' ' A' ' 43' ' ' GLU . 36.5 Cg_endo -81.03 45.39 1.98 Allowed 'Trans proline' 0 C--N 1.312 -1.359 0 C-N-CA 122.716 2.277 . . . . 0.0 110.927 -179.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.571 ' CD1' ' O ' ' A' ' 9' ' ' GLY . 1.9 m-85 -161.05 72.34 0.43 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.946 -1.096 . . . . 0.0 109.627 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -79.7 150.01 31.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.305 -0.872 . . . . 0.0 109.438 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . 0.431 ' HB2' ' OG ' ' A' ' 7' ' ' SER . 5.2 ttt -123.54 122.1 37.33 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.198 -0.939 . . . . 0.0 109.402 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 28.3 mt -114.08 129.34 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.262 -0.899 . . . . 0.0 109.547 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.414 ' CG1' HG23 ' A' ' 36' ' ' ILE . 73.6 t -138.69 136.18 43.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.218 -0.926 . . . . 0.0 109.532 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -120.73 94.66 4.43 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.193 -0.942 . . . . 0.0 109.444 179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.497 ' SD ' ' CD1' ' A' ' 3' ' ' ILE . 0.0 OUTLIER -83.44 152.31 25.05 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.241 -0.912 . . . . 0.0 109.385 179.919 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 5.8 mtpm? -96.73 -94.02 0.21 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.189 -0.944 . . . . 0.0 109.492 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -101.43 65.22 1.04 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.133 -0.979 . . . . 0.0 109.299 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 70.25 37.59 71.48 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -150.41 116.15 5.54 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.316 -1.108 . . . . 0.0 109.308 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.441 ' N ' HD13 ' A' ' 36' ' ' ILE . 5.9 mm -64.12 122.81 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.29 -0.881 . . . . 0.0 109.593 -179.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 2.3 tm-20 -130.77 16.61 5.26 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.188 -0.945 . . . . 0.0 109.318 179.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 17.1 m -173.51 101.29 0.12 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.382 -0.824 . . . . 0.0 109.245 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -123.55 101.06 7.12 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.258 -0.901 . . . . 0.0 109.577 -179.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -107.94 155.91 19.78 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.336 -0.853 . . . . 0.0 109.418 179.852 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 3.1 t -125.99 129.6 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.205 -0.935 . . . . 0.0 109.337 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 92.8 mt -110.32 143.05 21.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.264 -0.897 . . . . 0.0 109.853 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.488 ' O ' ' HD3' ' A' ' 45' ' ' PRO . 0.4 OUTLIER -109.73 128.94 55.61 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.314 -0.866 . . . . 0.0 109.281 179.852 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . 0.437 ' HB3' ' HB2' ' A' ' 47' ' ' ALA . 0.7 OUTLIER -115.58 82.72 10.26 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.199 -0.938 . . . . 0.0 109.407 -179.95 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.488 ' HD3' ' O ' ' A' ' 43' ' ' GLU . 36.2 Cg_endo -78.61 -22.59 9.08 Favored 'Trans proline' 0 C--N 1.309 -1.52 0 C-N-CA 122.671 2.247 . . . . 0.0 110.427 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -108.33 18.31 21.17 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.265 -0.897 . . . . 0.0 109.618 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . 0.437 ' HB2' ' HB3' ' A' ' 44' ' ' ASN . . . -47.75 -66.85 0.34 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.265 -0.897 . . . . 0.0 109.417 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.465 ' HB3' ' CA ' ' A' ' 54' ' ' GLY . 79.0 p -129.05 -58.22 1.15 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.232 -0.917 . . . . 0.0 109.472 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 56.97 42.12 26.69 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.296 -0.878 . . . . 0.0 109.499 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 11.3 t -145.63 -53.9 0.28 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.273 -0.892 . . . . 0.0 109.435 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 128.57 76.17 0.19 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 135.38 -72.12 0.47 Allowed Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.68 175.97 0.32 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.288 -1.125 . . . . 0.0 109.313 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.465 ' CA ' ' HB3' ' A' ' 48' ' ' SER . . . 128.1 -19.73 5.72 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 -179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.772 HG21 ' HB2' ' A' ' 78' ' ' ALA . 22.2 mt -76.08 0.1 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.254 -1.144 . . . . 0.0 109.619 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.17 -9.57 58.67 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.199 -0.938 . . . . 0.0 109.553 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.417 HG22 ' O ' ' A' ' 54' ' ' GLY . 7.2 t -76.96 -19.0 57.88 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.276 -0.89 . . . . 0.0 109.583 -179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -56.55 -38.45 71.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.289 -0.882 . . . . 0.0 109.581 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -56.46 -39.31 72.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.271 -0.893 . . . . 0.0 109.68 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 3.4 mt -75.6 -35.44 31.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.247 -0.908 . . . . 0.0 109.648 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.412 HG21 HD13 ' A' ' 61' ' ' ILE . 48.8 mt -62.1 -29.05 45.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.54 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.669 ' HB1' HD11 ' A' ' 87' ' ' ILE . . . -71.82 -34.89 69.71 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.251 -0.905 . . . . 0.0 109.7 -179.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -76.8 -0.42 23.84 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.173 -0.954 . . . . 0.0 109.687 -179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -94.27 8.34 42.15 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.213 -0.929 . . . . 0.0 109.586 -179.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 87.34 -11.21 66.3 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.454 ' CG1' ' O ' ' A' ' 68' ' ' ALA . 70.0 t -58.44 91.62 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.226 -1.161 . . . . 0.0 109.489 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.53 -7.34 58.41 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.372 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.454 ' O ' ' CG1' ' A' ' 66' ' ' VAL . . . -132.98 137.63 46.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.252 -0.905 . . . . 0.0 109.273 179.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . . . . . . . . . 32.3 t -134.28 111.86 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.15 -0.969 . . . . 0.0 109.646 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.733 HG22 ' HB2' ' A' ' 92' ' ' ALA . 11.7 mt -95.71 116.9 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.289 -0.882 . . . . 0.0 109.261 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.547 ' HB1' ' HB2' ' A' ' 20' ' ' PHE . . . -148.78 173.83 12.84 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.156 -0.965 . . . . 0.0 109.684 -179.696 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -127.73 38.89 3.96 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.393 -0.817 . . . . 0.0 109.422 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.401 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 0.1 OUTLIER -50.17 141.25 15.74 Favored Pre-proline 0 N--CA 1.489 1.496 0 O-C-N 121.264 -0.898 . . . . 0.0 109.406 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 36.1 Cg_endo -78.59 -62.95 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.593 2.195 . . . . 0.0 110.474 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -74.28 155.78 49.31 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.45 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.3 Cg_endo -78.6 4.7 6.15 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 C-N-CA 122.702 2.268 . . . . 0.0 110.535 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -62.4 -56.86 14.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.207 -0.933 . . . . 0.0 109.512 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.772 ' HB2' HG21 ' A' ' 55' ' ' ILE . . . -57.26 -54.41 47.08 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.164 -0.96 . . . . 0.0 109.536 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -55.64 -22.25 21.82 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.3 -0.875 . . . . 0.0 109.523 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.45 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.2 OUTLIER -74.84 -37.01 62.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.162 -0.961 . . . . 0.0 109.467 -179.982 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 3.3 t -73.12 -50.68 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.242 -0.911 . . . . 0.0 109.377 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.657 ' HB2' HD11 ' A' ' 89' ' ' ILE . 14.9 mt -50.1 -50.69 47.51 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.333 -0.854 . . . . 0.0 109.396 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -65.2 -33.36 75.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.242 -0.911 . . . . 0.0 109.431 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -58.37 -35.26 71.69 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.246 -0.909 . . . . 0.0 109.507 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -82.36 -37.39 25.72 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.341 -0.849 . . . . 0.0 109.379 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 110.36 22.1 6.61 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.669 HD11 ' HB1' ' A' ' 62' ' ' ALA . 6.0 mt -88.46 160.18 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.222 -1.163 . . . . 0.0 109.495 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.472 ' N ' HG22 ' A' ' 87' ' ' ILE . 2.1 mttt -86.15 113.31 22.09 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.26 -0.9 . . . . 0.0 109.768 -179.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.657 HD11 ' HB2' ' A' ' 82' ' ' LEU . 43.5 mt -88.38 161.92 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.267 -0.895 . . . . 0.0 108.938 179.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.581 ' CE1' ' HB3' ' A' ' 109' ' ' LEU . 2.6 m-85 -139.9 137.68 35.03 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.966 -1.084 . . . . 0.0 109.702 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 17.6 mmm180 -87.99 119.42 28.34 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.409 -0.807 . . . . 0.0 109.558 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.733 ' HB2' HG22 ' A' ' 70' ' ' ILE . . . -98.41 108.04 20.64 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.301 -0.875 . . . . 0.0 109.387 179.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.598 HG23 ' N ' ' A' ' 94' ' ' GLY . 8.1 t -53.86 -47.19 71.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.326 -0.859 . . . . 0.0 109.477 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.598 ' N ' HG23 ' A' ' 93' ' ' THR . . . 125.31 83.47 0.53 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.665 HG22 ' N ' ' A' ' 96' ' ' SER . 17.5 m -137.65 -92.8 0.22 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.236 -1.155 . . . . 0.0 109.459 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.665 ' N ' HG22 ' A' ' 95' ' ' THR . 0.2 OUTLIER -153.01 130.74 11.6 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.157 -0.965 . . . . 0.0 109.399 -179.942 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.576 HG13 HG22 ' A' ' 16' ' ' VAL . 22.2 m -52.05 -20.9 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 109.676 -179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -66.62 -57.97 6.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.238 -0.914 . . . . 0.0 109.522 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 32.3 mm-40 -66.0 -29.49 69.88 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.277 -0.889 . . . . 0.0 109.524 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.541 ' OD1' HG21 ' A' ' 16' ' ' VAL . 33.2 m120 -60.9 -46.16 91.76 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.132 -0.98 . . . . 0.0 109.34 179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -58.51 -37.04 74.76 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.216 -0.927 . . . . 0.0 109.148 179.781 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.417 ' HE2' ' HB2' ' A' ' 102' ' ' LYS . 0.3 OUTLIER -73.9 -22.06 59.84 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.287 -0.883 . . . . 0.0 109.311 179.822 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.464 ' HA ' HD22 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -76.54 -38.06 55.67 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.255 -0.903 . . . . 0.0 109.247 179.82 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.594 ' CZ ' HG12 ' A' ' 3' ' ' ILE . 0.5 OUTLIER -70.39 -6.64 36.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.3 -0.875 . . . . 0.0 109.551 -179.984 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.421 HG22 ' OE1' ' A' ' 106' ' ' GLU . 51.6 m -73.34 -39.09 65.49 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.189 -0.945 . . . . 0.0 109.682 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . 0.421 ' OE1' HG22 ' A' ' 105' ' ' THR . 2.8 mm-40 -94.19 -41.87 9.26 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.32 -0.862 . . . . 0.0 109.505 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 110.78 25.78 5.01 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.446 -1.462 . . . . 0.0 109.446 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -79.93 -21.6 43.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.278 -1.131 . . . . 0.0 109.374 179.97 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.581 ' HB3' ' CE1' ' A' ' 90' ' ' TYR . 2.8 mt -59.41 144.99 45.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.373 -0.829 . . . . 0.0 109.421 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.512 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 1.4 pt-20 -94.72 145.62 24.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.182 -0.949 . . . . 0.0 109.303 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.547 ' HG2' ' CZ ' ' A' ' 90' ' ' TYR . 0.4 OUTLIER -139.32 -178.58 5.43 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.161 -0.962 . . . . 0.0 109.816 -179.603 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.9 mp -138.34 134.26 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.406 -0.809 . . . . 0.0 109.294 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . . . . . . . . . 3.1 ptp180 -131.23 177.3 7.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.213 -0.929 . . . . 0.0 109.544 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 3.0 p -174.95 152.07 1.47 Allowed Pre-proline 0 N--CA 1.488 1.474 0 O-C-N 121.246 -0.909 . . . . 0.0 109.242 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.6 Cg_endo -77.81 -17.81 13.72 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 C-N-CA 122.556 2.17 . . . . 0.0 110.302 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 135.68 119.41 1.9 Allowed Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 1.6 t -154.19 125.16 7.24 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.266 -1.138 . . . . 0.0 109.523 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -163.26 83.91 0.11 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -100.64 135.95 41.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.305 -1.115 . . . . 0.0 109.297 179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -167.22 121.84 1.0 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 6.6 mtt180 -127.09 -176.79 3.82 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.296 -1.12 . . . . 0.0 109.448 179.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.95 12.8 2.45 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.205 -0.934 . . . . 0.0 109.711 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.445 ' O ' ' CB ' ' A' ' 124' ' ' ARG . 0.6 OUTLIER -160.51 -171.53 3.18 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.118 -0.989 . . . . 0.0 109.606 179.992 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.445 ' CB ' ' O ' ' A' ' 123' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.49 0 CA-C-O 118.009 -0.995 . . . . 0.0 109.523 -179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.462 ' HG3' ' O ' ' A' ' 1' ' ' MET . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.495 ' CE ' ' OE1' ' A' ' 30' ' ' GLU . 17.2 mttp -102.71 146.67 27.87 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.259 -0.901 . . . . 0.0 109.366 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.795 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 6.8 mt -113.27 131.5 64.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.3 -0.875 . . . . 0.0 109.918 -179.692 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -125.74 146.56 49.7 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.415 -0.803 . . . . 0.0 108.855 179.518 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.493 HG23 ' CG2' ' A' ' 70' ' ' ILE . 1.6 mp -132.35 127.52 57.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 109.718 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -63.5 148.64 48.12 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.351 -0.843 . . . . 0.0 109.403 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.861 ' O ' ' HB1' ' A' ' 23' ' ' ALA . 0.4 OUTLIER -143.91 164.99 28.99 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.138 -0.976 . . . . 0.0 109.549 -179.95 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -101.96 -6.46 23.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.319 -0.863 . . . . 0.0 109.597 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.556 ' O ' ' CG ' ' A' ' 25' ' ' TYR . . . -148.15 -145.37 4.15 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.724 HG22 ' O ' ' A' ' 10' ' ' THR . 96.7 m -135.6 18.56 3.32 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.241 -1.152 . . . . 0.0 109.433 179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -141.6 -174.47 4.06 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.222 -0.924 . . . . 0.0 109.529 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -66.61 -22.22 66.12 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.22 -0.925 . . . . 0.0 109.482 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -54.73 -50.44 57.84 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 15' ' ' GLU . 81.4 p -76.81 84.39 3.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.294 -1.121 . . . . 0.0 109.244 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.706 ' O ' HG13 ' A' ' 97' ' ' VAL . 18.6 mt-10 -46.89 -98.11 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.398 -0.814 . . . . 0.0 109.859 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.809 HG11 ' HB1' ' A' ' 92' ' ' ALA . 4.2 t -123.06 33.76 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.939 -1.101 . . . . 0.0 109.782 -179.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.401 ' C ' ' O ' ' A' ' 16' ' ' VAL . 7.2 p 43.93 -162.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.288 -0.883 . . . . 0.0 109.533 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.546 ' O ' ' CD1' ' A' ' 19' ' ' PHE . 0.0 OUTLIER -140.34 11.91 2.35 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.338 -0.851 . . . . 0.0 109.388 179.908 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.546 ' CD1' ' O ' ' A' ' 18' ' ' ARG . 32.6 m-85 -142.64 -165.3 2.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.283 -0.886 . . . . 0.0 109.52 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 7.3 t80 -133.88 -61.81 0.79 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.316 -0.865 . . . . 0.0 109.355 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -79.81 2.28 74.83 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.419 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.1 OUTLIER -103.91 -64.51 1.09 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.183 -1.187 . . . . 0.0 109.489 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.861 ' HB1' ' O ' ' A' ' 7' ' ' SER . . . -44.24 104.58 0.39 Allowed Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.287 -0.883 . . . . 0.0 109.404 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.515 ' O ' ' CG ' ' A' ' 25' ' ' TYR . 36.6 Cg_endo -79.94 61.49 8.21 Favored 'Trans proline' 0 C--N 1.312 -1.348 0 C-N-CA 122.656 2.237 . . . . 0.0 110.927 -179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.556 ' CG ' ' O ' ' A' ' 9' ' ' GLY . 51.1 m-85 -160.54 70.45 0.41 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.04 -1.037 . . . . 0.0 109.325 179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 48.5 m-85 -79.85 109.22 14.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.206 -0.934 . . . . 0.0 109.321 -179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . 0.473 ' HA ' ' HA ' ' A' ' 41' ' ' VAL . 0.0 OUTLIER -79.6 141.37 36.61 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.332 -0.855 . . . . 0.0 109.742 -179.65 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.482 HG12 HG12 ' A' ' 42' ' ' ILE . 7.8 mm -125.04 139.32 51.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.32 -0.863 . . . . 0.0 109.235 179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.439 HG21 ' CD1' ' A' ' 101' ' ' LEU . 10.6 t -140.63 144.64 26.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.273 -0.892 . . . . 0.0 109.499 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.495 ' OE1' ' CE ' ' A' ' 2' ' ' LYS . 6.2 mt-10 -125.33 107.95 11.21 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.237 -0.914 . . . . 0.0 109.545 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 3.1 mtt -81.56 149.82 28.47 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.204 -0.935 . . . . 0.0 109.382 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -107.04 -51.79 2.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.184 -0.948 . . . . 0.0 109.587 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -156.02 53.25 0.57 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.498 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.4 21.83 55.61 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.403 ' O ' ' C ' ' A' ' 36' ' ' ILE . 1.6 t30 -148.13 95.43 2.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.254 -1.145 . . . . 0.0 109.477 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.435 ' O ' HG13 ' A' ' 36' ' ' ILE . 9.5 pt -45.47 114.16 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.168 -0.957 . . . . 0.0 109.295 179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -113.68 9.4 17.78 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.207 -0.933 . . . . 0.0 109.411 179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 53.5 p -163.46 113.4 1.32 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.286 -0.884 . . . . 0.0 109.36 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -135.03 104.6 6.01 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.288 -0.883 . . . . 0.0 109.493 -179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -120.96 -174.58 2.86 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.309 -0.869 . . . . 0.0 109.245 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.588 HG11 HG23 ' A' ' 10' ' ' THR . 14.8 p -131.93 166.65 28.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.074 -1.016 . . . . 0.0 109.648 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.587 ' N ' HG22 ' A' ' 41' ' ' VAL . 7.4 mm -129.97 99.37 4.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.35 -0.844 . . . . 0.0 109.501 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.526 ' HG3' ' CE1' ' A' ' 25' ' ' TYR . 31.8 tt0 -77.88 126.3 30.64 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.275 -0.891 . . . . 0.0 109.299 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 1.8 m120 -126.84 80.38 70.97 Favored Pre-proline 0 N--CA 1.491 1.592 0 O-C-N 121.214 -0.929 . . . . 0.0 109.647 -179.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -77.99 88.07 1.46 Allowed 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.684 2.256 . . . . 0.0 110.353 179.759 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 2.3 p -176.75 -55.54 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.159 -0.963 . . . . 0.0 109.514 -179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -49.86 -37.6 31.62 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.177 -0.952 . . . . 0.0 109.373 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -113.68 47.91 1.12 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.256 -0.902 . . . . 0.0 109.354 179.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -147.7 -46.77 0.17 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.308 -0.87 . . . . 0.0 109.513 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -135.73 24.81 3.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.2 -0.937 . . . . 0.0 109.478 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 76.79 29.16 57.85 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -58.08 -172.42 0.32 Allowed Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.602 -1.399 . . . . 0.0 109.602 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.462 ' HB1' ' HB2' ' A' ' 56' ' ' ARG . . . -97.92 116.75 30.77 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.251 -1.147 . . . . 0.0 109.481 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.957 ' O ' HG22 ' A' ' 57' ' ' THR . . . -111.66 -39.27 1.34 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 33.6 mm -76.76 -28.87 17.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.259 -1.142 . . . . 0.0 109.499 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . 0.462 ' HB2' ' HB1' ' A' ' 53' ' ' ALA . 8.0 mmm180 -76.69 -34.11 58.2 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.183 -0.948 . . . . 0.0 109.594 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.957 HG22 ' O ' ' A' ' 54' ' ' GLY . 14.8 t -49.11 -23.63 1.31 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.255 -0.903 . . . . 0.0 109.737 -179.832 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . . . . . . . . . . . -45.25 -47.25 12.82 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.272 -0.892 . . . . 0.0 109.9 -179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -53.83 -48.43 69.93 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.195 -0.941 . . . . 0.0 109.92 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 80.2 mt -60.91 -36.73 73.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.213 -0.929 . . . . 0.0 110.115 -179.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 32.7 mt -62.94 -40.95 90.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.249 -0.907 . . . . 0.0 109.947 -179.582 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -71.38 -28.73 64.24 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.149 -0.969 . . . . 0.0 109.791 -179.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -77.32 4.39 10.86 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.213 -0.929 . . . . 0.0 109.947 -179.796 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -106.6 2.54 26.1 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.018 -1.051 . . . . 0.0 109.661 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.03 -11.21 62.2 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.453 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 81.8 t -62.61 88.27 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.253 -1.146 . . . . 0.0 109.61 179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.66 -2.74 44.12 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.291 -0.88 . . . . 0.0 108.986 179.467 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.795 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -127.8 127.54 43.72 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.34 -0.85 . . . . 0.0 109.172 179.849 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.6 HG21 HD22 ' A' ' 82' ' ' LEU . 74.8 t -125.57 112.43 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.17 -0.956 . . . . 0.0 109.78 -179.667 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.493 ' CG2' HG23 ' A' ' 5' ' ' ILE . 3.5 mt -99.33 124.31 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.192 -0.942 . . . . 0.0 109.129 179.549 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -158.52 172.81 17.63 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.175 -0.953 . . . . 0.0 109.766 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -130.15 49.18 2.31 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.367 -0.833 . . . . 0.0 109.514 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.86 160.11 22.38 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.201 -0.937 . . . . 0.0 109.407 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -77.85 -89.9 0.0 OUTLIER 'Trans proline' 0 C--N 1.309 -1.544 0 C-N-CA 122.557 2.172 . . . . 0.0 110.296 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -64.6 162.96 36.91 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.48 ' O ' ' HB2' ' A' ' 80' ' ' GLU . 36.7 Cg_endo -80.29 27.74 0.55 Allowed 'Trans proline' 0 C--N 1.309 -1.538 0 C-N-CA 122.825 2.35 . . . . 0.0 111.17 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.73 ' O ' HG23 ' A' ' 81' ' ' VAL . 0.9 OUTLIER -76.7 -59.84 2.6 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.879 -1.138 . . . . 0.0 109.423 179.961 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.419 ' O ' ' HB ' ' A' ' 81' ' ' VAL . . . -55.61 -43.51 76.15 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.266 -0.896 . . . . 0.0 109.389 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.632 ' O ' HD11 ' A' ' 89' ' ' ILE . 3.8 m-30 -60.2 -49.17 78.7 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.264 -0.898 . . . . 0.0 109.498 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.48 ' HB2' ' O ' ' A' ' 76' ' ' PRO . 0.3 OUTLIER -61.36 -21.03 63.67 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.238 -0.914 . . . . 0.0 109.331 179.798 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 77' ' ' ASN . 95.5 t -73.28 -63.12 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.217 -0.927 . . . . 0.0 109.373 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.714 ' HA ' HD12 ' A' ' 85' ' ' LEU . 1.5 mt -57.74 -27.09 62.7 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.179 -0.951 . . . . 0.0 109.302 179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 9.9 t30 -62.06 -51.32 68.44 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.322 -0.861 . . . . 0.0 109.332 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -77.01 -12.28 59.92 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.262 -0.899 . . . . 0.0 109.362 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.714 HD12 ' HA ' ' A' ' 82' ' ' LEU . 55.5 mt -77.49 -23.63 50.28 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.227 -0.921 . . . . 0.0 109.365 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . 0.456 ' C ' HD12 ' A' ' 87' ' ' ILE . . . 100.86 41.42 2.67 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.505 HD12 ' N ' ' A' ' 87' ' ' ILE . 5.3 mp -137.7 161.87 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.234 -1.156 . . . . 0.0 109.512 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.5 ' N ' HG22 ' A' ' 87' ' ' ILE . 4.6 mmtm -92.56 131.5 37.63 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.258 -0.901 . . . . 0.0 109.627 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.632 HD11 ' O ' ' A' ' 79' ' ' PHE . 50.9 mt -92.29 157.35 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.251 -0.906 . . . . 0.0 109.51 179.963 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.529 ' CE2' ' HB3' ' A' ' 111' ' ' GLU . 0.3 OUTLIER -142.33 143.12 32.61 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.336 -0.852 . . . . 0.0 109.44 -179.898 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.707 ' O ' HD22 ' A' ' 109' ' ' LEU . 12.4 mmt180 -100.15 125.28 46.25 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.245 -0.909 . . . . 0.0 109.428 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . 0.809 ' HB1' HG11 ' A' ' 16' ' ' VAL . . . -82.97 113.84 20.83 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.217 -0.927 . . . . 0.0 109.473 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 3.8 m -144.98 13.03 1.45 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.233 -0.917 . . . . 0.0 109.518 -179.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -79.02 -121.68 0.31 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.47 HG22 ' OG ' ' A' ' 96' ' ' SER . 17.3 m -129.59 -54.5 1.16 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.356 -1.085 . . . . 0.0 109.385 -179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.49 ' CB ' ' HG2' ' A' ' 15' ' ' GLU . 0.8 OUTLIER -139.19 143.53 38.13 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 121.275 -0.891 . . . . 0.0 109.367 179.993 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.706 HG13 ' O ' ' A' ' 15' ' ' GLU . 15.0 m -44.1 -26.72 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.26 -0.9 . . . . 0.0 109.295 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . 0.407 ' N ' ' O ' ' A' ' 96' ' ' SER . 3.3 tp10 -64.27 -51.76 61.96 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.264 -0.897 . . . . 0.0 109.246 179.702 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.436 ' O ' ' HB2' ' A' ' 103' ' ' LEU . 3.0 tp10 -64.15 -37.46 87.52 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.297 -0.877 . . . . 0.0 109.068 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 5.0 m-20 -63.89 -30.73 71.79 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.331 -0.856 . . . . 0.0 109.218 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.439 ' CD1' HG21 ' A' ' 29' ' ' VAL . 6.4 tp -55.98 -55.85 27.76 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.363 -0.835 . . . . 0.0 109.219 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 44.4 mttt -76.82 -13.94 59.96 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.25 179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.51 HD12 ' HA ' ' A' ' 103' ' ' LEU . 6.1 tp -77.16 -23.39 51.63 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.245 -0.909 . . . . 0.0 109.579 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.591 ' CD1' ' CD1' ' A' ' 3' ' ' ILE . 32.2 t80 -75.58 -23.75 56.53 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.234 -0.916 . . . . 0.0 109.106 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 1.6 m -74.57 -34.05 62.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.319 -0.863 . . . . 0.0 109.259 179.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -90.73 -0.28 57.65 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.287 -0.883 . . . . 0.0 109.487 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 54.73 37.87 62.7 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -82.74 -23.1 34.16 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.217 -1.167 . . . . 0.0 109.473 -179.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.707 HD22 ' O ' ' A' ' 91' ' ' ARG . 0.8 OUTLIER -83.69 162.03 20.85 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.235 -0.916 . . . . 0.0 109.289 179.958 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.4 ' HG2' ' N ' ' A' ' 111' ' ' GLU . 34.3 tt0 -87.63 146.95 25.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.184 -0.947 . . . . 0.0 109.91 -179.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.529 ' HB3' ' CE2' ' A' ' 90' ' ' TYR . 9.2 pt-20 -135.79 179.8 6.12 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.43 -0.794 . . . . 0.0 109.077 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 6.8 mt -149.84 127.13 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.708 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.414 ' CD ' ' N ' ' A' ' 113' ' ' ARG . 0.0 OUTLIER -118.99 -69.87 0.82 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.37 -0.831 . . . . 0.0 109.356 179.854 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 46.6 t -166.47 69.69 1.1 Allowed Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.25 -0.906 . . . . 0.0 109.379 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -79.13 9.47 3.34 Favored 'Trans proline' 0 C--N 1.31 -1.457 0 C-N-CA 122.656 2.238 . . . . 0.0 110.785 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 164.19 158.33 10.07 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 2.4 t -49.73 -61.77 1.94 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.29 -1.124 . . . . 0.0 109.459 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.414 ' O ' ' C ' ' A' ' 119' ' ' ARG . . . 132.24 -118.14 2.19 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.414 ' C ' ' O ' ' A' ' 118' ' ' GLY . 0.3 OUTLIER -44.24 145.88 0.73 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.33 -1.1 . . . . 0.0 109.591 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -152.85 -163.37 11.63 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.36 117.63 21.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.203 -1.175 . . . . 0.0 109.44 -179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -162.79 -163.29 0.86 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.289 -0.882 . . . . 0.0 109.457 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.65 138.98 38.32 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.198 -0.938 . . . . 0.0 109.529 -179.816 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 5.1 ttp180 . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 117.967 -1.016 . . . . 0.0 109.44 179.947 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.464 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 36.7 mttt -147.01 126.73 13.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.269 -0.895 . . . . 0.0 109.221 179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.951 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 4.3 mt -111.16 116.44 52.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.248 -0.908 . . . . 0.0 109.832 -179.582 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.697 ' C ' HD13 ' A' ' 5' ' ' ILE . . . -108.28 146.57 32.7 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.248 -0.908 . . . . 0.0 109.394 179.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.697 HD13 ' C ' ' A' ' 4' ' ' ALA . 5.4 mm -114.73 121.12 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.206 -0.934 . . . . 0.0 109.53 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.486 ' O ' ' N ' ' A' ' 8' ' ' SER . . . -47.63 144.79 3.0 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.192 -0.943 . . . . 0.0 109.362 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 25' ' ' TYR . 11.3 t 49.99 -93.19 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.234 -0.916 . . . . 0.0 109.458 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.955 ' HA ' HG11 ' A' ' 97' ' ' VAL . 0.5 OUTLIER 66.81 8.68 6.18 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.169 -0.957 . . . . 0.0 109.518 -179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . 0.544 ' N ' ' HB2' ' A' ' 14' ' ' SER . . . 44.06 -128.13 6.53 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.474 -1.451 . . . . 0.0 109.474 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.07 -13.59 11.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.304 -1.115 . . . . 0.0 109.546 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -171.32 -70.61 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.195 -0.941 . . . . 0.0 109.921 -179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.421 ' O ' ' C ' ' A' ' 13' ' ' GLY . 0.3 OUTLIER -122.37 -22.54 5.48 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.129 -0.982 . . . . 0.0 110.022 -179.619 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 12' ' ' LEU . . . -42.19 -42.34 4.18 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.835 -1.306 . . . . 0.0 109.835 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.544 ' HB2' ' N ' ' A' ' 9' ' ' GLY . 27.3 t -77.87 85.28 4.14 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.272 -1.134 . . . . 0.0 109.674 179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.693 ' C ' HG23 ' A' ' 16' ' ' VAL . 1.7 mt-10 -67.96 85.32 0.23 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.413 -0.805 . . . . 0.0 109.214 179.802 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.693 HG23 ' C ' ' A' ' 15' ' ' GLU . 1.5 t 70.58 30.98 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.451 -0.781 . . . . 0.0 109.265 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.474 ' HA ' ' OG ' ' A' ' 14' ' ' SER . 4.3 p 62.45 -160.99 0.3 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.339 -0.851 . . . . 0.0 109.543 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 8.0 ttm180 -154.8 -46.43 0.09 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.399 -0.813 . . . . 0.0 109.053 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -145.72 147.8 32.32 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.369 -0.832 . . . . 0.0 109.095 179.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.48 ' CG ' ' HB1' ' A' ' 71' ' ' ALA . 85.1 t80 -118.32 138.19 52.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.161 -0.962 . . . . 0.0 109.578 -179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.475 ' O ' ' HA2' ' A' ' 54' ' ' GLY . . . 139.84 -59.12 0.59 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.47 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.1 OUTLIER -116.98 13.45 14.87 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.2 -1.177 . . . . 0.0 109.774 -179.753 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.96 109.53 1.71 Allowed Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.233 -0.917 . . . . 0.0 109.884 -179.839 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.9 Cg_endo -81.17 41.37 1.13 Allowed 'Trans proline' 0 C--N 1.312 -1.351 0 C-N-CA 122.548 2.165 . . . . 0.0 110.485 179.699 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.418 ' O ' ' O ' ' A' ' 7' ' ' SER . 0.4 OUTLIER -158.74 69.82 0.49 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.09 -1.006 . . . . 0.0 109.314 -179.911 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.538 ' CZ ' HD13 ' A' ' 61' ' ' ILE . 0.3 OUTLIER -82.27 112.69 19.5 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.62 -179.854 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . 0.965 ' HG3' HG12 ' A' ' 41' ' ' VAL . 0.0 OUTLIER -85.15 144.69 28.03 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.296 -0.877 . . . . 0.0 109.308 -179.996 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 39.4 mt -139.76 126.18 22.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.228 -0.92 . . . . 0.0 109.518 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.556 HG13 ' O ' ' A' ' 38' ' ' SER . 34.8 t -124.09 128.67 74.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.35 -0.844 . . . . 0.0 109.471 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 33.0 mt-10 -98.88 167.22 10.89 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.368 -0.833 . . . . 0.0 109.237 179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . 0.52 ' HE3' HG22 ' A' ' 36' ' ' ILE . 29.9 mtt -133.19 138.91 46.75 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.932 . . . . 0.0 109.448 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 6.7 ttmm -98.93 -48.06 5.04 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.239 -0.913 . . . . 0.0 109.464 179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 15.8 mtmm -148.81 66.59 1.05 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.341 -0.849 . . . . 0.0 109.218 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 62.77 12.59 42.46 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.419 ' O ' ' C ' ' A' ' 36' ' ' ILE . 8.2 t-20 -130.83 94.36 3.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.211 -1.17 . . . . 0.0 109.462 179.889 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.52 HG22 ' HE3' ' A' ' 31' ' ' MET . 26.3 pt -43.64 126.07 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.258 -0.901 . . . . 0.0 109.702 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -137.06 16.53 3.02 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.232 -0.918 . . . . 0.0 109.344 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.556 ' O ' HG13 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -154.94 117.12 4.2 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.343 -0.848 . . . . 0.0 109.14 -179.98 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 80.9 p -143.77 112.45 6.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.532 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -124.91 171.95 9.77 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.272 -0.893 . . . . 0.0 109.373 -179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.965 HG12 ' HG3' ' A' ' 27' ' ' MET . 20.8 m -131.73 115.87 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.274 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 3.2 tp -105.06 152.6 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.245 -0.909 . . . . 0.0 109.413 -179.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 33.6 mt-10 -105.1 145.12 30.96 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.223 -0.923 . . . . 0.0 109.399 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -56.68 151.45 31.03 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.278 -0.889 . . . . 0.0 109.558 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -78.22 -59.12 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.622 2.215 . . . . 0.0 110.081 179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 4.1 m -132.61 72.21 1.49 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.363 -0.836 . . . . 0.0 109.111 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -62.21 -19.79 63.52 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.342 -0.848 . . . . 0.0 109.811 -179.566 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.4 m -138.32 -85.08 0.28 Allowed 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.088 -1.007 . . . . 0.0 109.693 -179.845 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . 53.39 -166.59 0.07 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.246 -0.909 . . . . 0.0 109.337 -179.72 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.92 111.45 18.8 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.222 -0.924 . . . . 0.0 109.443 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 149.09 -58.61 0.46 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.524 -1.431 . . . . 0.0 109.524 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 90.27 115.15 1.67 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.566 -1.414 . . . . 0.0 109.566 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -162.85 -165.02 1.05 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.26 -1.141 . . . . 0.0 109.535 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 21' ' ' GLY . . . 165.46 -54.95 0.26 Allowed Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.488 HG23 ' HA ' ' A' ' 78' ' ' ALA . 42.9 mm -68.55 -11.55 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.157 -1.202 . . . . 0.0 109.376 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 9.5 ttt180 -76.36 -16.32 59.77 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.327 -0.858 . . . . 0.0 109.6 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 10.6 t -63.34 -25.94 68.53 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.253 -0.904 . . . . 0.0 109.252 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.487 ' O ' HG13 ' A' ' 61' ' ' ILE . . . -54.36 -36.17 63.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.335 -0.853 . . . . 0.0 109.588 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -74.01 -32.55 63.43 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.141 -0.974 . . . . 0.0 109.425 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 81.9 mt -65.96 -40.7 88.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.267 -0.896 . . . . 0.0 109.541 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.538 HD13 ' CZ ' ' A' ' 26' ' ' PHE . 8.6 pt -76.69 -29.23 17.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.576 -179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -62.57 -39.26 93.1 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.187 -0.946 . . . . 0.0 109.711 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -68.98 -12.68 61.89 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.237 -0.914 . . . . 0.0 109.831 -179.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -89.15 -7.84 54.88 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.182 -0.949 . . . . 0.0 109.542 -179.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.522 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 100.8 -12.04 59.26 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.464 ' HA ' ' HB2' ' A' ' 2' ' ' LYS . 16.4 t -51.81 89.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.375 -1.073 . . . . 0.0 109.489 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.522 ' N ' ' O ' ' A' ' 65' ' ' GLY . 0.0 OUTLIER -80.91 -5.66 57.7 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.307 -0.871 . . . . 0.0 109.099 179.568 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.951 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -125.2 134.84 52.21 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.211 -0.931 . . . . 0.0 109.523 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.416 ' C ' HD12 ' A' ' 70' ' ' ILE . 86.4 t -137.27 111.93 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.162 -0.961 . . . . 0.0 109.919 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.631 HD12 ' N ' ' A' ' 70' ' ' ILE . 1.7 mp -94.88 106.11 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.313 -0.867 . . . . 0.0 108.979 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.48 ' HB1' ' CG ' ' A' ' 20' ' ' PHE . . . -135.78 173.57 11.57 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.129 -0.982 . . . . 0.0 109.86 -179.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -137.26 40.54 2.46 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.428 -0.795 . . . . 0.0 109.44 179.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . 0.414 ' HA ' ' HD3' ' A' ' 74' ' ' PRO . 1.4 t -45.98 146.67 1.98 Allowed Pre-proline 0 N--CA 1.49 1.557 0 O-C-N 121.207 -0.933 . . . . 0.0 109.41 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 73' ' ' SER . 35.9 Cg_endo -77.98 -17.92 13.36 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 122.642 2.228 . . . . 0.0 110.492 -179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -127.02 164.76 20.48 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.515 -1.434 . . . . 0.0 109.515 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -77.87 4.65 5.92 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.626 2.217 . . . . 0.0 110.431 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.48 ' O ' ' HB3' ' A' ' 80' ' ' GLU . 2.9 t-20 -62.3 -43.16 99.47 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.314 -0.866 . . . . 0.0 109.545 179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.488 ' HA ' HG23 ' A' ' 55' ' ' ILE . . . -64.13 -57.71 8.78 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.283 -0.886 . . . . 0.0 109.53 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.695 ' CD1' HG21 ' A' ' 89' ' ' ILE . 9.2 m-85 -58.21 -21.42 47.81 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.258 -0.901 . . . . 0.0 109.58 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.48 ' HB3' ' O ' ' A' ' 77' ' ' ASN . 29.7 tt0 -62.17 -59.6 4.81 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.197 -0.939 . . . . 0.0 109.393 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 20.4 t -61.22 -44.88 99.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.235 -0.916 . . . . 0.0 109.203 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 1.008 HD23 HD12 ' A' ' 87' ' ' ILE . 14.3 mt -50.35 -37.94 39.63 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.248 -0.907 . . . . 0.0 109.307 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -64.31 -42.87 96.13 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.344 -0.848 . . . . 0.0 109.363 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.2 tm-20 -69.98 -15.69 63.07 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.328 -0.858 . . . . 0.0 109.338 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.476 ' HB3' HG13 ' A' ' 87' ' ' ILE . 17.9 mt -95.6 -8.1 35.9 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.181 -0.95 . . . . 0.0 109.517 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 63.03 32.83 85.46 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 1.008 HD12 HD23 ' A' ' 82' ' ' LEU . 13.1 mt -96.22 171.4 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.234 -1.157 . . . . 0.0 109.511 179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.524 ' H ' HG22 ' A' ' 87' ' ' ILE . 8.0 mttt -91.86 117.08 29.45 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.253 -0.904 . . . . 0.0 109.646 -179.767 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.695 HG21 ' CD1' ' A' ' 79' ' ' PHE . 10.5 mt -94.29 128.18 45.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.346 -0.846 . . . . 0.0 109.388 179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.551 ' CE2' ' O ' ' A' ' 109' ' ' LEU . 2.2 m-85 -123.21 144.01 49.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.278 -0.889 . . . . 0.0 109.334 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . 0.501 ' HG2' ' CG ' ' A' ' 111' ' ' GLU . 0.0 OUTLIER -91.21 132.05 36.35 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.158 -0.964 . . . . 0.0 109.653 -179.921 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -91.02 94.3 9.57 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.239 -0.913 . . . . 0.0 109.409 179.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -135.46 23.14 3.43 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.125 -0.984 . . . . 0.0 109.624 -179.808 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -86.69 -134.26 3.84 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.669 -1.373 . . . . 0.0 109.669 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.443 HG23 ' N ' ' A' ' 96' ' ' SER . 5.2 t -136.14 -38.35 0.7 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.267 -1.137 . . . . 0.0 109.447 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.443 ' N ' HG23 ' A' ' 95' ' ' THR . 29.0 t -125.77 137.08 53.78 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.314 -0.866 . . . . 0.0 109.502 179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.955 HG11 ' HA ' ' A' ' 8' ' ' SER . 0.3 OUTLIER -55.03 -35.59 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.328 -0.858 . . . . 0.0 109.406 179.916 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -69.2 -51.83 33.95 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.247 -0.908 . . . . 0.0 109.233 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.548 ' O ' HD13 ' A' ' 103' ' ' LEU . 3.2 tt0 -52.18 -31.67 32.71 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.244 -0.91 . . . . 0.0 109.166 179.826 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -72.39 -49.73 31.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.342 -0.848 . . . . 0.0 109.152 179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.465 HD21 HG11 ' A' ' 29' ' ' VAL . 27.1 tp -50.4 -51.31 47.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.284 -0.885 . . . . 0.0 109.513 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . . . . . . . . . 12.4 tptt -65.77 -35.4 80.61 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.205 -0.935 . . . . 0.0 109.492 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.548 HD13 ' O ' ' A' ' 99' ' ' GLU . 0.7 OUTLIER -71.71 -11.17 60.7 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.269 -0.895 . . . . 0.0 109.537 179.947 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.504 ' C ' ' CD1' ' A' ' 104' ' ' PHE . 7.8 t80 -76.93 -38.3 53.68 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.263 -0.898 . . . . 0.0 109.453 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . 0.421 ' O ' HG22 ' A' ' 105' ' ' THR . 28.8 m -72.09 -13.78 61.67 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.19 -0.944 . . . . 0.0 109.464 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -96.45 -17.23 20.71 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.182 -0.949 . . . . 0.0 109.49 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 74.43 29.45 61.89 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . 0.462 ' HB3' HD23 ' A' ' 103' ' ' LEU . 0.4 OUTLIER -79.96 -44.11 20.86 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.297 -1.119 . . . . 0.0 109.693 -179.882 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.551 ' O ' ' CE2' ' A' ' 90' ' ' TYR . 0.4 OUTLIER -123.28 146.62 47.73 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.235 -0.916 . . . . 0.0 109.463 -179.949 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.528 ' HA ' ' CG ' ' A' ' 90' ' ' TYR . 1.1 pm0 -171.66 -156.79 0.11 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.253 -0.904 . . . . 0.0 109.458 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.564 ' OE1' ' CE2' ' A' ' 79' ' ' PHE . 0.0 OUTLIER -146.29 -87.19 0.1 Allowed 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.27 -0.894 . . . . 0.0 109.678 179.951 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 7.0 mt -131.37 151.37 35.51 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.192 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.435 ' HG2' ' HG2' ' A' ' 88' ' ' LYS . 0.0 OUTLIER -120.89 -62.02 1.49 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.34 -0.85 . . . . 0.0 109.382 179.931 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.489 ' N ' ' HD3' ' A' ' 115' ' ' PRO . 94.9 p -179.8 63.96 0.13 Allowed Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.203 -0.936 . . . . 0.0 109.573 179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.489 ' HD3' ' N ' ' A' ' 114' ' ' SER . 35.6 Cg_endo -78.2 177.56 8.62 Favored 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.65 2.234 . . . . 0.0 110.319 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.442 ' O ' ' N ' ' A' ' 118' ' ' GLY . . . 72.99 56.25 5.9 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.434 -1.467 . . . . 0.0 109.434 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 116' ' ' GLY . 0.4 OUTLIER -43.96 99.73 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.308 -1.113 . . . . 0.0 109.37 -179.967 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 116' ' ' GLY . . . -102.34 72.86 0.32 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.01 -45.97 0.2 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.242 -1.152 . . . . 0.0 109.672 -179.919 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 98.27 116.0 3.56 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -179.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.73 -70.4 0.79 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.26 -1.141 . . . . 0.0 109.505 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -122.8 1.56 9.38 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.293 -0.879 . . . . 0.0 109.548 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . 0.508 ' NH1' ' HG3' ' A' ' 123' ' ' ARG . 0.4 OUTLIER -95.85 81.58 3.46 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.246 -0.909 . . . . 0.0 109.589 -179.895 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.487 0 CA-C-O 118.072 -0.966 . . . . 0.0 109.393 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.42 ' O ' ' HG2' ' A' ' 1' ' ' MET . 5.1 ttt . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.455 ' HB2' ' HA ' ' A' ' 66' ' ' VAL . 0.1 OUTLIER -131.18 156.05 45.99 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.218 -0.926 . . . . 0.0 109.521 -179.967 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.63 ' HA ' ' HB3' ' A' ' 68' ' ' ALA . 7.0 mt -116.01 107.47 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.866 . . . . 0.0 109.552 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.697 ' HB2' HD12 ' A' ' 28' ' ' ILE . . . -97.18 170.85 8.83 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.326 -0.859 . . . . 0.0 109.13 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.732 HG21 ' HB ' ' A' ' 97' ' ' VAL . 98.1 mt -148.13 119.93 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.172 -0.955 . . . . 0.0 109.889 -179.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.538 ' HB1' ' HD1' ' A' ' 20' ' ' PHE . . . -87.14 143.95 27.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.249 -0.907 . . . . 0.0 108.949 179.565 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.426 ' HB2' ' O ' ' A' ' 6' ' ' ALA . 1.2 m 61.77 81.74 0.19 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.055 -1.028 . . . . 0.0 109.129 -179.723 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.646 ' HB2' HG21 ' A' ' 97' ' ' VAL . 0.0 OUTLIER -136.32 -37.63 0.7 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.29 -0.881 . . . . 0.0 109.308 -179.788 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.49 -171.95 27.05 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.494 -1.443 . . . . 0.0 109.494 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -86.05 9.99 15.57 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.175 -1.191 . . . . 0.0 109.454 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 47.5 p-10 -170.25 -174.14 1.65 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.263 -0.898 . . . . 0.0 109.483 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.627 ' H ' HD23 ' A' ' 12' ' ' LEU . 0.7 OUTLIER -75.66 -20.97 58.09 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.21 -0.932 . . . . 0.0 109.456 179.941 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.496 ' N ' ' HG ' ' A' ' 12' ' ' LEU . . . -46.38 -45.5 16.45 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.499 ' CB ' ' O ' ' A' ' 8' ' ' SER . 0.6 OUTLIER -76.15 81.43 2.97 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.278 -1.131 . . . . 0.0 109.429 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLU . . . . . 0.66 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -73.27 83.06 1.38 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.339 -0.851 . . . . 0.0 109.359 179.874 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.885 HG21 ' HA2' ' A' ' 94' ' ' GLY . 2.6 t 78.01 77.56 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.485 -0.759 . . . . 0.0 109.478 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.428 ' C ' ' O ' ' A' ' 16' ' ' VAL . 0.1 OUTLIER -43.59 -73.92 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.238 -0.914 . . . . 0.0 109.594 -179.93 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.2 mmt180 -140.33 -82.06 0.25 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.23 -0.919 . . . . 0.0 109.542 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 24.2 m-85 -146.29 -144.71 0.16 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.29 -0.882 . . . . 0.0 109.332 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.538 ' HD1' ' HB1' ' A' ' 6' ' ' ALA . 16.6 t80 -121.5 27.5 8.23 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.172 -0.955 . . . . 0.0 109.497 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -83.07 -74.7 1.2 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.427 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 0.5 OUTLIER -123.0 27.98 7.41 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.277 -1.131 . . . . 0.0 109.349 179.929 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -50.91 108.46 1.05 Allowed Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 121.371 -0.83 . . . . 0.0 109.34 179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 22' ' ' ARG . 36.3 Cg_endo -79.57 39.27 0.81 Allowed 'Trans proline' 0 C--N 1.311 -1.425 0 C-N-CA 122.566 2.178 . . . . 0.0 111.077 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.542 ' CD1' ' HG2' ' A' ' 43' ' ' GLU . 48.1 m-85 -155.55 67.16 0.63 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.98 -1.075 . . . . 0.0 109.065 179.813 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.647 ' CZ ' ' HB1' ' A' ' 4' ' ' ALA . 9.2 t80 -81.88 120.25 24.96 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.436 -0.79 . . . . 0.0 109.592 -179.694 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' MET . . . . . . . . . . . . . 4.5 ttm -103.45 159.99 15.1 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.277 -0.889 . . . . 0.0 109.558 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.756 HD11 HG22 ' A' ' 66' ' ' VAL . 1.1 tp -148.53 133.01 9.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.268 -0.895 . . . . 0.0 109.54 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.591 HG11 HD11 ' A' ' 101' ' ' LEU . 39.5 t -143.11 124.83 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.242 -0.911 . . . . 0.0 109.592 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -99.09 171.4 8.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.235 -0.916 . . . . 0.0 109.317 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' MET . . . . . . . . . . . . . 13.6 ttm -139.66 138.93 36.49 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.271 -0.893 . . . . 0.0 109.583 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.74 -47.82 6.02 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.21 -0.931 . . . . 0.0 109.522 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 13.1 mttp -153.27 41.09 0.55 Allowed 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.235 -0.916 . . . . 0.0 109.463 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 101.99 -8.53 55.92 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.483 ' O ' ' HG2' ' A' ' 37' ' ' GLU . 6.9 m-20 -117.02 97.18 5.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.234 -1.157 . . . . 0.0 109.356 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.486 ' O ' HG13 ' A' ' 36' ' ' ILE . 5.6 pt -47.25 113.02 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.412 -0.805 . . . . 0.0 109.586 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.483 ' HG2' ' O ' ' A' ' 35' ' ' ASN . 14.9 mm-40 -109.72 19.26 19.36 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.233 -0.917 . . . . 0.0 109.664 -179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 2.1 p -163.53 120.78 1.82 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.244 -0.91 . . . . 0.0 109.319 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.441 ' CB ' HG22 ' A' ' 29' ' ' VAL . 5.7 p -149.28 107.53 3.76 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.172 -0.955 . . . . 0.0 109.539 -179.804 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -117.3 156.27 28.09 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.171 -0.955 . . . . 0.0 109.516 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 2.2 p -126.19 138.71 53.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.257 -0.902 . . . . 0.0 109.402 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.566 HD12 ' HD3' ' A' ' 45' ' ' PRO . 40.8 pt -135.71 146.43 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.351 -0.843 . . . . 0.0 109.614 -179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.542 ' HG2' ' CD1' ' A' ' 25' ' ' TYR . 42.0 mt-10 -98.25 55.61 1.14 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.231 -0.918 . . . . 0.0 109.13 179.7 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 49.77 89.08 0.1 OUTLIER Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.323 -0.86 . . . . 0.0 109.372 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' PRO . . . . . 0.566 ' HD3' HD12 ' A' ' 42' ' ' ILE . 34.8 Cg_endo -77.65 -8.47 17.02 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.643 2.228 . . . . 0.0 110.366 -179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.45 41.09 1.04 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.313 -0.867 . . . . 0.0 109.377 179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ALA . . . . . . . . . . . . . . . -51.03 -38.5 51.76 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.199 -0.938 . . . . 0.0 109.546 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 28.9 t -113.17 84.81 2.06 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.239 -0.913 . . . . 0.0 109.571 -179.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ALA . . . . . . . . . . . . . . . -145.76 158.39 43.86 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.272 -0.892 . . . . 0.0 109.485 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -58.07 175.03 0.23 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.234 -0.916 . . . . 0.0 109.488 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.519 ' O ' HD11 ' A' ' 60' ' ' ILE . . . 48.38 37.53 18.7 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -174.21 140.08 5.26 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -150.8 32.23 0.62 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.27 -1.135 . . . . 0.0 109.488 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 93.97 -91.51 1.47 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.809 HG23 ' HB2' ' A' ' 78' ' ' ALA . 34.6 mm -65.35 -33.24 62.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.319 -1.106 . . . . 0.0 109.648 -179.806 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.74 -14.77 62.11 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.208 -0.932 . . . . 0.0 109.717 -179.826 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.448 ' HA ' HD12 ' A' ' 60' ' ' ILE . 85.7 m -67.53 -18.02 64.88 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.114 -0.991 . . . . 0.0 109.744 -179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ALA . . . . . 0.431 ' HB2' ' HE2' ' A' ' 20' ' ' PHE . . . -60.28 -28.16 67.86 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.235 -0.916 . . . . 0.0 109.654 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -62.67 -49.75 73.88 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.295 -0.878 . . . . 0.0 109.687 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.519 HD11 ' O ' ' A' ' 51' ' ' GLY . 3.7 mt -64.04 -45.67 96.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.892 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 41.6 mt -52.2 -48.0 43.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.237 -0.914 . . . . 0.0 109.957 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -66.74 -37.45 84.67 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.171 -0.955 . . . . 0.0 109.998 -179.524 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ASN . . . . . . . . . . . . . 5.2 m120 -66.25 -11.1 48.15 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.097 -1.002 . . . . 0.0 109.851 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -88.99 16.75 6.54 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.117 -0.989 . . . . 0.0 109.556 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.453 ' O ' ' N ' ' A' ' 67' ' ' LYS . . . 95.31 -20.75 47.89 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . 0.756 HG22 HD11 ' A' ' 28' ' ' ILE . 97.1 t -57.06 88.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.312 -1.111 . . . . 0.0 109.506 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.453 ' N ' ' O ' ' A' ' 65' ' ' GLY . 14.0 mttt -79.91 -8.45 59.33 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.329 -0.857 . . . . 0.0 108.777 179.331 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.63 ' HB3' ' HA ' ' A' ' 3' ' ' ILE . . . -128.05 138.61 52.64 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' VAL . . . . . 0.433 ' C ' HD12 ' A' ' 70' ' ' ILE . 95.3 t -141.37 122.08 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.112 -0.993 . . . . 0.0 109.821 -179.794 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.582 HD12 ' N ' ' A' ' 70' ' ' ILE . 1.3 mp -93.43 144.5 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.345 -0.847 . . . . 0.0 108.804 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . . . . . . . . . . . -176.81 175.94 1.56 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.127 -0.983 . . . . 0.0 109.755 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -153.04 66.51 0.79 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.412 -0.805 . . . . 0.0 109.347 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -73.02 158.92 86.43 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.238 -0.914 . . . . 0.0 109.568 -179.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -78.55 -39.2 0.42 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.658 2.239 . . . . 0.0 110.764 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . . . . . . . . . . . -121.22 178.45 16.38 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.751 -1.34 . . . . 0.0 109.751 -179.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' PRO . . . . . 0.428 ' HA ' ' HB2' ' A' ' 79' ' ' PHE . 36.6 Cg_endo -80.28 40.67 1.0 Allowed 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.853 2.369 . . . . 0.0 110.753 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 52.5 m-20 -76.1 -67.54 0.67 Allowed 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.085 -1.01 . . . . 0.0 109.314 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ALA . . . . . 0.809 ' HB2' HG23 ' A' ' 55' ' ' ILE . . . -74.66 -25.91 59.51 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.247 -0.908 . . . . 0.0 109.32 179.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' PHE . . . . . 0.428 ' HB2' ' HA ' ' A' ' 76' ' ' PRO . 3.1 m-85 -66.23 -21.11 66.29 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.373 -0.829 . . . . 0.0 109.398 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.417 ' O ' ' HB2' ' A' ' 84' ' ' GLU . 11.8 mt-10 -77.4 -46.84 21.44 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.233 -0.917 . . . . 0.0 109.833 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 2.4 t -68.65 -36.13 73.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.132 -0.98 . . . . 0.0 109.824 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.498 ' HB3' ' CG1' ' A' ' 89' ' ' ILE . 8.7 mt -73.75 -57.61 3.87 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.268 -0.895 . . . . 0.0 109.707 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.425 ' N ' HD11 ' A' ' 89' ' ' ILE . 8.2 t-20 -49.53 -37.78 28.21 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.212 -0.93 . . . . 0.0 109.6 -179.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.417 ' HB2' ' O ' ' A' ' 80' ' ' GLU . 0.3 OUTLIER -73.02 -39.34 66.08 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.217 -0.927 . . . . 0.0 109.403 -179.947 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' LEU . . . . . 0.424 ' HB3' HG12 ' A' ' 87' ' ' ILE . 0.3 OUTLIER -64.54 -13.12 51.06 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.134 -0.979 . . . . 0.0 109.475 -179.943 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . 75.13 26.57 66.05 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . 0.521 HG22 ' N ' ' A' ' 88' ' ' LYS . 23.1 mm -91.91 160.85 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.345 -1.091 . . . . 0.0 109.423 -180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' LYS . . . . . 0.521 ' N ' HG22 ' A' ' 87' ' ' ILE . 7.8 mtpt -83.01 105.14 13.76 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.169 -0.957 . . . . 0.0 109.309 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ILE . . . . . 0.511 ' O ' ' CB ' ' A' ' 111' ' ' GLU . 3.1 mt -90.75 152.33 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.182 -0.949 . . . . 0.0 109.513 -179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' TYR . . . . . 0.484 ' CD1' ' O ' ' A' ' 110' ' ' GLU . 1.1 m-85 -136.63 141.27 43.22 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.299 -0.875 . . . . 0.0 109.404 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.25 149.19 22.85 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.255 -0.903 . . . . 0.0 109.537 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -106.86 141.04 38.72 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.277 -0.889 . . . . 0.0 109.365 179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -92.98 -17.28 24.12 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.237 -0.914 . . . . 0.0 109.541 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.885 ' HA2' HG21 ' A' ' 16' ' ' VAL . . . 101.94 13.55 31.4 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.575 -1.41 . . . . 0.0 109.575 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 52.0 m -81.19 -55.3 4.83 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.227 -1.16 . . . . 0.0 109.459 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER 173.16 130.19 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.321 -0.862 . . . . 0.0 109.572 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.732 ' HB ' HG21 ' A' ' 5' ' ' ILE . 33.6 m -65.02 -23.79 34.14 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.167 -0.958 . . . . 0.0 109.374 179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . 0.54 ' HB2' ' CB ' ' A' ' 12' ' ' LEU . 1.5 tt0 -65.89 -60.05 3.24 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.236 -0.915 . . . . 0.0 109.277 179.75 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.882 ' O ' HD12 ' A' ' 103' ' ' LEU . 36.1 mm-40 -60.38 -28.66 68.39 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.291 -0.881 . . . . 0.0 109.33 179.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ASN . . . . . 0.439 ' HA ' ' HB2' ' A' ' 103' ' ' LEU . 6.4 m-20 -69.68 -30.58 68.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.286 -0.884 . . . . 0.0 109.409 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' LEU . . . . . 0.711 HD23 ' N ' ' A' ' 102' ' ' LYS . 6.8 tt -59.87 -60.08 4.41 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.27 -0.894 . . . . 0.0 109.404 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' LYS . . . . . 0.711 ' N ' HD23 ' A' ' 101' ' ' LEU . 0.2 OUTLIER -64.94 -29.07 69.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.319 -0.863 . . . . 0.0 109.38 179.922 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.882 HD12 ' O ' ' A' ' 99' ' ' GLU . 0.4 OUTLIER -65.46 -30.69 71.5 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.239 -0.913 . . . . 0.0 109.627 -179.935 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' PHE . . . . . 0.434 ' CD1' HD11 ' A' ' 3' ' ' ILE . 23.4 t80 -59.75 -32.1 70.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.192 -0.942 . . . . 0.0 109.589 -179.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' THR . . . . . . . . . . . . . 28.3 m -67.19 -40.92 86.59 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.28 -0.887 . . . . 0.0 109.73 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 6.5 mm-40 -79.8 4.99 14.76 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.276 -0.89 . . . . 0.0 109.553 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 46.09 28.98 3.23 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -80.01 -33.2 39.48 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.193 -1.181 . . . . 0.0 109.379 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.433 ' HB2' ' CE1' ' A' ' 90' ' ' TYR . 45.5 mt -65.84 -176.93 0.42 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.313 -0.867 . . . . 0.0 109.306 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.484 ' O ' ' CD1' ' A' ' 90' ' ' TYR . 11.3 pt-20 -108.48 143.59 37.24 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 109.572 -179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' GLU . . . . . 0.511 ' CB ' ' O ' ' A' ' 89' ' ' ILE . 0.0 OUTLIER -137.06 -174.01 3.62 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.276 -0.89 . . . . 0.0 109.298 179.863 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.444 HG13 ' O ' ' A' ' 111' ' ' GLU . 2.3 mp -147.99 147.48 17.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.18 -0.95 . . . . 0.0 109.493 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ARG . . . . . 0.435 ' HB2' ' O ' ' A' ' 112' ' ' ILE . 0.0 OUTLIER 179.1 -65.66 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.331 -0.855 . . . . 0.0 109.417 179.945 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -166.07 85.68 0.94 Allowed Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.241 -0.912 . . . . 0.0 109.258 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.63 12.79 2.28 Favored 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.811 2.341 . . . . 0.0 110.999 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -145.23 161.52 28.16 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' SER . . . . . . . . . . . . . 37.8 t -114.83 -10.08 12.41 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.196 -1.179 . . . . 0.0 109.479 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -67.49 -36.05 87.91 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -46.35 160.06 0.08 Allowed 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.265 -1.138 . . . . 0.0 109.501 -179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.517 ' O ' ' CG ' ' A' ' 121' ' ' ARG . . . 157.72 96.81 0.12 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 -179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.517 ' CG ' ' O ' ' A' ' 120' ' ' GLY . 0.0 OUTLIER -179.8 58.84 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.222 -1.164 . . . . 0.0 109.385 -179.983 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 3.6 mtp180 -65.41 109.75 2.41 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.258 -0.901 . . . . 0.0 109.489 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -167.69 120.61 0.91 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.174 -0.954 . . . . 0.0 109.61 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 117.955 -1.022 . . . . 0.0 109.474 179.96 . . . . . . . . 1 1 . 1 stop_ save_